-DOCSTART- -X- O O

Problem-based JJ N
learning NN N
: : N
is VBZ N
anatomy IN N
a DT N
casualty NN N
? . N
INTRODUCTION NNP N
The DT N
teaching NN N
of IN N
medical JJ N
anatomy NN N
is VBZ N
changing VBG N
. . N

Medical JJ N
schools NNS N
worldwide WDT N
are VBP N
moving VBG N
away RB N
from IN N
dissection NN N
and CC N
lectures VBZ N
to TO N
a DT N
more RBR N
integrated JJ N
course NN N
, , N
where WRB N
basic JJ N
science NN N
and CC N
clinical JJ N
skills NNS N
are VBP N
taught JJ N
simultaneously RB N
. . N

Medical JJ N
students NNS N
on IN N
these DT N
integrated VBN N
courses NNS N
have VBP N
reported VBN N
a DT N
lack NN N
of IN N
confidence NN N
in IN N
their PRP$ N
basic JJ N
science NN N
knowledge NN N
, , N
especially RB N
concerning VBG N
anatomy NN N
. . N

Our PRP$ N
aim NN N
was VBD N
to TO N
perform VB N
a DT N
randomised JJ N
controlled VBN N
trial NN N
( ( N
RCT NNP N
) ) N
to TO N
compare VB N
anatomical JJ N
knowledge NN N
of IN N
two CD N
groups NNS N
of IN N
second-year JJ N
medical JJ N
students NNS N
, , N
the DT N
first JJ N
group NN N
taught NN N
on IN N
a DT N
traditional JJ N
course NN N
, , N
the DT N
second JJ N
on IN N
an DT N
integrated JJ N
course NN N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
Testing NNP N
was VBD N
done VBN N
using VBG N
a DT N
Questionnaire NN N
in IN N
a DT N
True/False NNP N
format NN N
. . N

There EX N
were VBD N
80 CD 3_p
students NNS N
in IN N
each DT N
group NN N
. . N

There EX N
was VBD N
no DT N
penalty NN N
for IN N
an DT N
incorrect JJ N
answer NN N
. . N

The DT N
test NN N
was VBD N
performed VBN N
under IN N
examination NN N
conditions NNS N
. . N

Papers NNS N
were VBD N
marked VBN N
under IN N
blind JJ N
conditions NNS N
. . N

Results NNS N
were VBD N
analysed VBN N
using VBG N
a DT N
Student NN N
's POS N
t JJ N
test NN N
analysis NN N
. . N

RESULTS NNP N
Those DT N
students NNS N
taught VBP N
on IN N
a DT N
traditional JJ N
course NN N
exhibited VBD N
a DT N
significantly RB N
higher JJR N
level NN N
of IN N
basic JJ N
anatomical JJ N
knowledge NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
than IN N
those DT N
taught VBN N
on IN N
an DT N
integrated JJ N
course NN N
. . N

The DT N
students NNS N
taught VBD N
on IN N
an DT N
integrated JJ N
course NN N
showed VBD N
a DT N
much RB N
greater JJR N
range NN N
of IN N
results NNS N
. . N

CONCLUSIONS JJ N
Students NNS N
taught VBD N
on IN N
a DT N
traditional JJ N
course NN N
have VBP N
a DT N
higher JJR N
level NN N
of IN N
anatomical JJ N
knowledge NN N
than IN N
those DT N
taught VBN N
on IN N
an DT N
integrated JJ N
course NN N
. . N

Our PRP$ N
results NNS N
differ VBP N
from IN N
previous JJ N
studies NNS N
done VBN N
in IN N
Europe NNP N
which WDT N
show VBP N
no DT N
difference NN N
between IN N
the DT N
courses NNS N
. . N

-DOCSTART- -X- O O

Transurethral JJ 4_p
prostate NN 4_p
resection NN 4_p
and CC N
bleeding NN N
: : N
a DT N
randomized JJ N
, , N
placebo NN N
controlled VBD N
trial NN N
of IN N
role NN N
of IN N
finasteride NN N
for IN N
decreasing VBG N
operative JJ N
blood NN N
loss NN N
. . N

PURPOSE NNP N
Bleeding NNP N
associated VBN N
with IN N
transurethral JJ N
prostate NN N
resection NN N
can MD N
often RB N
be VB N
significant JJ N
and CC N
lead JJ N
to TO N
increased VBN N
morbidity NN N
and CC N
occasionally RB N
mortality NN N
. . N

It PRP N
has VBZ N
been VBN N
shown VBN N
that IN N
finasteride NN N
decreases VBZ N
bleeding VBG N
in IN N
patients NNS N
with IN N
hematuria NNS 4_p
of IN N
prostatic JJ N
origin NN N
. . N

We PRP N
hypothesized VBD N
that IN N
bleeding VBG N
in IN N
patients NNS N
undergoing JJ N
transurethral JJ 4_p
prostate NN 4_p
resection NN 4_p
could MD N
be VB N
decreased VBN N
by IN N
giving VBG N
finasteride NN N
for IN N
2 CD N
weeks NNS N
before RB N
surgery NN N
. . N

MATERIALS NNP N
AND NNP N
METHODS NNP N
A NNP N
total JJ N
70 CD 3_p
patients NNS N
scheduled VBN N
to TO N
undergo VB N
elective JJ 4_p
transurethral JJ 4_p
prostate NN 4_p
resection NN 4_p
were VBD N
randomized VBN N
to TO N
receive VB N
5 CD N
mg. NNS N
finasteride JJ N
daily RB N
or CC N
placebo VB N
for IN N
2 CD N
weeks NNS N
before RB N
surgery NN N
. . N

Serum NNP N
hemoglobin NN N
was VBD N
measured VBN N
before IN N
and CC N
after IN N
surgery NN N
, , N
and CC N
the DT N
following JJ N
day NN N
. . N

The DT N
volume NN N
of IN N
irrigation NN N
fluid NN N
used VBN N
and CC N
its PRP$ N
hemoglobin JJ N
concentration NN N
as RB N
well RB N
as IN N
resected VBN N
prostate NN N
weight NN N
were VBD N
recorded VBN N
. . N

RESULTS NNP N
Of IN N
the DT N
68 CD 3_p
patients NNS N
who WP N
underwent JJ N
transurethral JJ 4_p
prostate NN 4_p
resection NN 4_p
2 CD N
were VBD N
withdrawn VBN N
before RB N
surgery NN N
, , N
and CC N
so RB N
32 CD N
received VBD N
finasteride NN N
and CC N
36 CD N
received VBD N
placebo NN N
. . N

There EX N
was VBD N
significantly RB N
less JJR N
mean JJ N
blood NN N
loss NN N
in IN N
irrigation NN N
fluid NN N
in IN N
the DT N
finasteride NN N
group NN N
than IN N
in IN N
the DT N
control NN N
group NN N
( ( N
43.6 CD N
versus NN N
69.3 CD N
gm NN N
. . N

hemoglobin NN N
, , N
p NN N
= NNP N
0.011 CD N
) ) N
. . N

The DT N
mean JJ N
difference NN N
was VBD N
more RBR N
significant JJ N
when WRB N
blood NN N
loss NN N
per IN N
gm NN N
. . N

resected JJ N
prostate NN N
was VBD N
calculated VBN N
( ( N
2.65 CD N
versus NN N
4.65 CD N
gm NN N
. . N

hemoglobin NN N
per IN N
gm NN N
. . N

prostate NN N
, , N
p NN N
< NNP N
0.01 CD N
) ) N
. . N

CONCLUSIONS VB N
This DT N
study NN N
shows VBZ N
that IN N
finasteride NN N
given VBN N
for IN N
2 CD N
weeks NNS N
preoperatively RB N
decreases VBZ N
bleeding VBG N
in IN N
patients NNS N
undergoing JJ N
transurethral JJ 4_p
prostate NN 4_p
resection NN 4_p
. . N

Further NNP N
study NN N
is VBZ N
required VBN N
to TO N
determine VB N
the DT N
optimal JJ N
timing NN N
and CC N
dose JJ N
duration NN N
to TO N
minimize VB N
blood NN N
loss NN N
and CC N
identify VB N
how WRB N
relevant JJ N
such JJ N
a DT N
decrease NN N
in IN N
bleeding NN N
is VBZ N
in IN N
clinical JJ N
practice NN N
. . N

-DOCSTART- -X- O O

The DT N
effect NN N
of IN N
person-centred JJ N
dementia NN N
care NN N
to TO N
prevent VB N
agitation NN N
and CC N
other JJ N
neuropsychiatric JJ N
symptoms NNS N
and CC N
enhance JJ N
quality NN N
of IN N
life NN N
in IN N
nursing NN 4_p
home NN 4_p
patients NNS 4_p
: : N
a DT N
10-month JJ N
randomized NN N
controlled VBD N
trial NN N
. . N

AIMS IN N
We PRP N
examined VBD N
whether IN N
Dementia NNP N
Care NNP N
Mapping NNP N
( ( N
DCM NNP N
) ) N
or CC N
the DT N
VIPS NNP N
practice NN N
model NN N
( ( N
VPM NNP N
) ) N
is VBZ N
more RBR N
effective JJ N
than IN N
education NN N
of IN N
the DT N
nursing NN N
home NN N
staff NN N
about IN N
dementia NN N
( ( N
control VB N
group NN N
) ) N
in IN N
reducing VBG N
agitation NN N
and CC N
other JJ N
neuropsychiatric JJ N
symptoms NNS N
as RB N
well RB N
as IN N
in IN N
enhancing VBG N
the DT N
quality NN N
of IN N
life NN N
among IN N
nursing JJ N
home NN N
patients NNS N
. . N

METHODS VB N
A DT N
10-month JJ N
three-armed JJ N
cluster-randomized JJ N
controlled VBN N
trial NN N
compared VBN N
DCM NNP N
and CC N
VPM NNP N
with IN N
control NN N
. . N

Of IN N
624 CD 3_p
nursing NN N
home NN N
patients NNS N
with IN N
dementia NN 4_p
, , N
446 CD 3_p
completed VBD N
follow-up JJ N
assessments NNS N
. . N

The DT N
primary JJ N
outcome NN N
was VBD N
the DT N
change NN N
on IN N
the DT N
Brief JJ N
Agitation NNP N
Rating NNP N
Scale NNP N
( ( N
BARS NNP N
) ) N
. . N

Secondary JJ N
outcomes NNS N
were VBD N
changes NNS N
on IN N
the DT N
10-item JJ N
version NN N
of IN N
the DT N
Neuropsychiatric NNP N
Inventory NNP N
Questionnaire NNP N
( ( N
NPI-Q NNP N
) ) N
, , N
the DT N
Cornell NNP N
Scale NNP N
for IN N
Depression NNP N
in IN N
Dementia NNP N
( ( N
CSDD NNP N
) ) N
and CC N
the DT N
Quality NN N
of IN N
Life NNP N
in IN N
Late-Stage NNP N
Dementia NNP N
( ( N
QUALID NNP N
) ) N
scale NN N
. . N

RESULTS NNP N
Changes NNP N
in IN N
the DT N
BARS NNP N
score NN N
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
the DT N
DCM NNP N
and CC N
the DT N
control NN N
group NN N
or CC N
between IN N
the DT N
VPM NNP N
and CC N
the DT N
control NN N
group NN N
after IN N
10 CD N
months NNS N
. . N

Positive JJ N
differences NNS N
were VBD N
found VBN N
for IN N
changes NNS N
in IN N
the DT N
secondary JJ N
outcomes NNS N
: : N
the DT N
NPI-Q NNP N
sum NN N
score NN N
as RB N
well RB N
as IN N
the DT N
subscales NNS N
NPI-Q NNP N
agitation NN N
and CC N
NPI-Q JJ N
psychosis NN N
were VBD N
in IN N
favour NN N
of IN N
both DT N
interventions NNS N
versus VBP N
control NN N
, , N
the DT N
QUALID NNP N
score NN N
was VBD N
in IN N
favour NN N
of IN N
DCM NNP N
versus NN N
control NN N
and CC N
the DT N
CSDD NNP N
score NN N
was VBD N
in IN N
favour NN N
of IN N
VPM NNP N
versus NN N
control NN N
. . N

CONCLUSIONS NNP N
This DT N
study NN N
failed VBD N
to TO N
find VB N
a DT N
significant JJ N
effect NN N
of IN N
both DT N
interventions NNS N
on IN N
the DT N
primary JJ N
outcome NN N
. . N

Positive JJ N
effects NNS N
on IN N
the DT N
secondary JJ N
outcomes NNS N
indicate VBP N
that IN N
the DT N
methods NNS N
merit VBP N
further JJ N
investigation NN N
. . N

-DOCSTART- -X- O O

Acute JJ N
effects NNS N
of IN N
decaffeinated JJ N
coffee NN N
and CC N
the DT N
major JJ N
coffee NN N
components NNS N
chlorogenic JJ N
acid NN N
and CC N
trigonelline NN N
on IN N
glucose JJ 4_p
tolerance NN 4_p
. . N

OBJECTIVE NNP N
Coffee NNP N
consumption NN N
has VBZ N
been VBN N
associated VBN N
with IN N
lower JJR N
risk NN N
of IN N
type NN 4_p
2 CD 4_p
diabetes NNS 4_p
. . N

We PRP N
evaluated VBD N
the DT N
acute JJ N
effects NNS N
of IN N
decaffeinated JJ N
coffee NN N
and CC N
the DT N
major JJ N
coffee NN N
components NNS N
chlorogenic JJ N
acid NN N
and CC N
trigonelline NN N
on IN N
glucose JJ N
tolerance NN N
. . N

RESEARCH NNP N
DESIGN NNP N
AND NNP N
METHODS NNP N
We PRP N
conducted VBD N
a DT N
randomized VBN N
crossover NN N
trial NN N
of IN N
the DT N
effects NNS N
of IN N
12 CD N
g NN N
decaffeinated VBD N
coffee NN N
, , N
1 CD N
g NN N
chlorogenic JJ N
acid NN N
, , N
500 CD N
mg NN N
trigonelline NN N
, , N
and CC N
placebo NN N
( ( N
1 CD N
g NN N
mannitol NN N
) ) N
on IN N
glucose NN N
and CC N
insulin NN N
concentrations NNS N
during IN N
a DT N
2-h JJ N
oral JJ N
glucose NN N
tolerance NN N
test NN N
( ( N
OGTT NNP N
) ) N
in IN N
15 CD 3_p
overweight JJ 4_p
men NNS 2_p
. . N

RESULTS NNP N
Chlorogenic NNP N
acid NN N
and CC N
trigonelline NN N
ingestion NN N
significantly RB N
reduced VBN N
glucose NN N
( ( N
-0.7 JJ N
mmol/l NN N
, , N
P NNP N
= NNP N
0.007 CD N
, , N
and CC N
-0.5 NNP N
mmol/l NN N
, , N
P NNP N
= NNP N
0.024 CD N
, , N
respectively RB N
) ) N
and CC N
insulin NN N
( ( N
-73 JJ N
pmol/l NN N
, , N
P NNP N
= NNP N
0.038 CD N
, , N
and CC N
-117 NNP N
pmol/l NN N
, , N
P NNP N
= NNP N
0.007 CD N
) ) N
concentrations NNS N
15 CD N
min NN N
following VBG N
an DT N
OGTT NNP N
compared VBN N
with IN N
placebo NN N
. . N

None NN N
of IN N
the DT N
treatments NNS N
affected VBD N
insulin NN N
or CC N
glucose JJ N
area NN N
under IN N
the DT N
curve NN N
values NNS N
during IN N
the DT N
OGTT NNP N
compared VBN N
with IN N
placebo NN N
. . N

CONCLUSIONS NNP N
Chlorogenic NNP N
acid NN N
and CC N
trigonelline NN N
reduced VBD N
early JJ N
glucose NN N
and CC N
insulin NN N
responses NNS N
during IN N
an DT N
OGTT NNP N
. . N

-DOCSTART- -X- O O

An DT N
evaluation NN N
of IN N
chemical JJ N
arthrodesis NN N
of IN N
the DT N
proximal JJ 4_p
interphalangeal NN 4_p
joint NN 4_p
in IN N
the DT N
horse NN N
by IN N
using VBG N
monoiodoacetate NN N
. . N

The DT N
use NN N
of IN N
monoiodoacetate NN N
( ( N
MIA NNP N
) ) N
for IN N
arthrodesis NN N
of IN N
the DT N
proximal JJ N
interphalangeal NN N
joint NN N
( ( N
PIJ NNP N
) ) N
and CC N
the DT N
effect NN N
of IN N
exercise NN N
on IN N
the DT N
degree NN N
of IN N
fusion NN N
were VBD N
investigated VBN N
. . N

Eight JJ 3_p
horses NNS N
received VBD N
3 CD N
injections NNS N
( ( N
Weeks NNP N
0 CD N
, , N
3 CD N
, , N
6 CD N
) ) N
of IN N
MIA NNP N
( ( N
2 CD N
mL NN N
; : N
60 CD N
mg/mL NN N
) ) N
into IN N
the DT N
right NN N
or CC N
left VBD N
front JJ N
PIJ NNP N
. . N

Peri-operatively RB N
, , N
the DT N
horses NNS N
received VBD N
phenylbutazone NN N
, , N
butorphanol NN N
, , N
and CC N
abaxial JJ N
sesamoidean NN N
nerve NN N
blocks NNS N
to TO N
relieve VB N
pain NN N
. . N

During IN N
the DT N
study NN N
, , N
the DT N
horses NNS N
were VBD N
monitored VBN N
for IN N
general JJ N
health NN N
, , N
lameness NN N
, , N
and CC N
swelling VBG N
around IN N
the DT N
injection NN N
area NN N
. . N

Radiographs NNP N
were VBD N
taken VBN N
biweekly RB N
to TO N
evaluate VB N
bony NN N
fusion NN N
. . N

Horses NNS N
were VBD N
randomly RB N
divided VBN N
into IN N
non-exercised JJ N
and CC N
exercised JJ N
groups NNS N
. . N

Exercise NNP N
consisted VBD N
of IN N
20 CD N
minutes NNS N
of IN N
trotting VBG N
on IN N
a DT N
treadmill NN N
( ( N
4 CD N
m/s NN N
) ) N
, , N
3 CD N
days NNS N
per IN N
week NN N
for IN N
13 CD N
weeks NNS N
. . N

The DT N
horses NNS N
were VBD N
euthanized VBN N
at IN N
24 CD N
weeks NNS N
. . N

Slab NNP N
sections NNS N
of IN N
the DT N
PIJ NNP N
were VBD N
evaluated VBN N
grossly RB N
and CC N
radiographically RB N
for IN N
bony NN N
fusion NN N
. . N

Histologic JJ N
examinations NNS N
were VBD N
performed VBN N
to TO N
evaluate VB N
articular JJ N
cartilage NN N
. . N

Three CD N
horses NNS N
were VBD N
excluded VBN N
from IN N
the DT N
study NN N
after IN N
developing VBG N
soft JJ N
tissue NN N
necrosis NN N
around IN N
the DT N
injection NN N
site NN N
, , N
septic JJ N
arthritis NN N
, , N
and CC N
necrotic JJ N
tendinitis NN N
. . N

The DT N
remaining VBG N
horses NNS N
remained VBD N
healthy JJ N
, , N
developed VBD N
a DT N
grade NN N
1 CD N
to TO N
4 CD N
lameness NN N
with IN N
minimal JJ N
to TO N
severe VB N
swelling VBG N
in IN N
the DT N
PIJ NNP N
region NN N
. . N

All DT N
5 CD N
horses NNS N
showed VBD N
radiographic JJ N
evidence NN N
of IN N
bony NN N
fusion NN N
, , N
however RB N
, , N
no DT N
fusion NN N
was VBD N
present JJ N
when WRB N
injected JJ N
joints NNS N
were VBD N
examined VBN N
on IN N
postmortem NN N
examination NN N
. . N

Histologic NNP N
examination NN N
revealed VBD N
thinning NN N
of IN N
the DT N
cartilage NN N
, , N
diffuse VBP N
necrosis NN N
of IN N
chondrocytes NNS N
, , N
with IN N
the DT N
calcified JJ N
zone NN N
intact JJ N
. . N

Subjectively RB N
, , N
exercise NN N
did VBD N
not RB N
influence VB N
the DT N
degree NN N
of IN N
cartilage NN N
destruction NN N
. . N

Based VBN N
on IN N
this DT N
study NN N
, , N
chemical JJ N
arthrodesis NN N
can MD N
not RB N
be VB N
advocated VBN N
in IN N
clinical JJ N
cases NNS N
because IN N
of IN N
the DT N
high JJ N
complication NN N
rate NN N
and CC N
lack NN N
of IN N
bony NN N
fusion NN N
. . N

-DOCSTART- -X- O O

Impact NN N
of IN N
a DT N
single JJ N
intravenous JJ N
administration NN N
of IN N
nicorandil JJ N
before IN N
reperfusion NN N
in IN N
patients NNS N
with IN N
ST-segment-elevation NNP 4_p
myocardial JJ 4_p
infarction NN 4_p
. . N

BACKGROUND NNP N
Intravenous NNP N
nicorandil NN N
, , N
a DT N
hybrid JJ N
compound NN N
of IN N
ATP-sensitive JJ N
potassium NN N
channel NN N
opener NN N
and CC N
nitric JJ N
oxide NN N
donor NN N
, , N
has VBZ N
been VBN N
reported VBN N
to TO N
ameliorate VB N
early JJ N
functional NN N
and CC N
clinical JJ N
problems NNS N
in IN N
patients NNS N
with IN N
acute JJ N
myocardial JJ N
infarction NN N
. . N

However RB N
, , N
its PRP$ N
effects NNS N
on IN N
the DT N
late JJ N
phase NN N
remain VBP N
unclear JJ N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
This DT N
follow-up JJ N
study NN N
to TO N
5 CD N
years NNS N
of IN N
a DT N
randomized JJ N
, , N
double-blinded JJ N
trial NN N
was VBD N
conducted VBN N
among IN N
368 CD 3_p
patients NNS N
with IN N
first JJ N
ST-segment-elevation NNP N
myocardial JJ N
infarction NN N
undergoing VBG N
percutaneous JJ 4_p
coronary JJ 4_p
intervention NN 4_p
( ( N
PCI NNP 4_p
) ) N
. . N

They PRP N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
12 CD N
mg NN N
of IN N
nicorandil NN N
or CC N
a DT N
placebo NN N
intravenously RB N
just RB N
before IN N
reperfusion NN N
. . N

We PRP N
analyzed VBD N
incidence NN N
of IN N
cardiovascular JJ N
death NN N
or CC N
rehospitalization NN N
for IN N
congestive JJ N
heart NN N
failure NN N
after IN N
PCI NNP N
as RB N
well RB N
as IN N
various JJ N
aspects NNS N
of IN N
epicardial JJ N
flow NN N
and CC N
microvascular JJ N
function NN N
. . N

Mean JJ N
follow-up NN N
was VBD N
2.4 CD N
years NNS N
( ( N
SD NNP N
, , N
1.4 CD N
) ) N
. . N

A DT N
total NN N
of IN N
12 CD N
( ( N
6.5 CD N
% NN N
) ) N
patients NNS N
receiving VBG N
nicorandil JJ N
and CC N
30 CD N
( ( N
16.4 CD N
% NN N
) ) N
receiving NN N
placebo NN N
had VBD N
cardiovascular JJ N
death NN N
or CC N
hospital NN N
admission NN N
for IN N
congestive JJ N
heart NN N
failure NN N
( ( N
hazard JJ N
ratio NN N
, , N
0.39 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.20 CD N
to TO N
0.76 CD N
; : N
P=0.0058 NNP N
) ) N
. . N

Postprocedural NNP N
TIMI NNP N
3 CD N
flow NN N
was VBD N
obtained VBN N
in IN N
89.7 CD N
% NN N
of IN N
the DT N
nicorandil JJ N
group NN N
and CC N
in IN N
81.4 CD N
% NN N
of IN N
the DT N
placebo NN N
( ( N
hazard JJ N
ratio NN N
, , N
1.99 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
1.09 CD N
to TO N
3.65 CD N
; : N
P=0.025 NNP N
) ) N
. . N

Corrected VBN N
TIMI NNP N
frame NN N
count NN N
was VBD N
furthermore RB N
lower JJR N
in IN N
the DT N
nicorandil NN N
group NN N
( ( N
21.0+/-9.1 JJ N
versus NN N
25.1+/-14.1 CD N
; : N
P=0.0009 NNP N
) ) N
. . N

ST-segment JJ N
resolution NN N
> VBD N
50 CD N
% NN N
was VBD N
observed VBN N
in IN N
79.5 CD N
% NN N
and CC N
61.2 CD N
% NN N
of IN N
the DT N
nicorandil NN N
and CC N
placebo NN N
groups NNS N
, , N
respectively RB N
( ( N
hazard JJ N
ratio NN N
, , N
2.45 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
1.54 CD N
to TO N
3.90 CD N
; : N
P=0.0002 NNP N
) ) N
. . N

CONCLUSIONS VB N
The DT N
addition NN N
of IN N
intravenous JJ N
nicorandil NNS N
to TO N
PCI NNP N
leads VBZ N
to TO N
beneficial JJ N
clinical JJ N
outcomes NNS N
and CC N
prevents NNS N
cardiovascular JJ N
events NNS N
of IN N
long JJ N
duration NN N
and CC N
death NN N
in IN N
patients NNS N
with IN N
ST-segment-elevation NNP N
myocardial JJ N
infarction NN N
. . N

-DOCSTART- -X- O O

Efficacy NN N
of IN N
physiotherapy JJ N
management NN N
of IN N
knee NN 4_p
joint JJ 4_p
osteoarthritis NN 4_p
: : N
a DT N
randomised JJ N
, , N
double JJ N
blind NN N
, , N
placebo NN N
controlled VBD N
trial NN N
. . N

OBJECTIVE NN N
To TO N
determine VB N
whether IN N
a DT N
multimodal JJ N
physiotherapy NN N
programme NN N
including VBG N
taping VBG N
, , N
exercises NNS N
, , N
and CC N
massage NN N
is VBZ N
effective JJ N
for IN N
knee NN 4_p
osteoarthritis NN 4_p
, , N
and CC N
if IN N
benefits NNS N
can MD N
be VB N
maintained VBN N
with IN N
self JJ N
management NN N
. . N

METHODS NNP N
Randomised VBD N
, , N
double JJ N
blind NN N
, , N
placebo NN N
controlled VBD N
trial NN N
; : N
140 CD 3_p
community NN N
volunteers NNS N
with IN N
knee NN 4_p
osteoarthritis NN 4_p
participated VBD N
and CC N
119 CD 3_p
completed VBD N
the DT N
trial NN N
. . N

Physiotherapy NNP N
and CC N
placebo JJ N
interventions NNS N
were VBD N
applied VBN N
by IN N
10 CD N
physiotherapists NNS N
in IN N
private JJ N
practices NNS N
for IN N
12 CD N
weeks NNS N
. . N

Physiotherapy NNP N
included VBD N
exercise NN N
, , N
massage NN N
, , N
taping VBG N
, , N
and CC N
mobilisation NN N
, , N
followed VBN N
by IN N
12 CD N
weeks NNS N
of IN N
self JJ N
management NN N
. . N

Placebo NNP N
was VBD N
sham VBN N
ultrasound JJ N
and CC N
light JJ N
application NN N
of IN N
a DT N
non-therapeutic JJ N
gel NN N
, , N
followed VBN N
by IN N
no DT N
treatment NN N
. . N

Primary JJ N
outcomes NNS N
were VBD N
pain RB N
measured VBN N
by IN N
visual JJ N
analogue NN N
scale NN N
and CC N
patient JJ N
global JJ N
change NN N
. . N

Secondary JJ N
measures NNS N
included VBD N
WOMAC NNP N
, , N
knee NN N
pain NN N
scale NN N
, , N
SF-36 NNP N
, , N
assessment NN N
of IN N
quality NN N
of IN N
life NN N
index NN N
, , N
quadriceps JJ N
strength NN N
, , N
and CC N
balance NN N
test NN N
. . N

RESULTS NNP N
Using VBG N
an DT N
intention NN N
to TO N
treat VB N
analysis NN N
, , N
physiotherapy NN N
and CC N
placebo NN N
groups NNS N
showed VBD N
similar JJ N
pain NN N
reductions NNS N
at IN N
12 CD N
weeks NNS N
: : N
-2.2 NN N
cm NN N
( ( N
95 CD N
% NN N
CI NNP N
, , N
-2.6 NNP N
to TO N
-1.7 VB N
) ) N
and CC N
-2.0 $ N
cm NN N
( ( N
-2.5 UH N
to TO N
-1.5 VB N
) ) N
, , N
respectively RB N
. . N

At IN N
24 CD N
weeks NNS N
, , N
pain NN N
remained VBD N
reduced VBN N
from IN N
baseline NN N
in IN N
both DT N
groups NNS N
: : N
-2.1 NN N
( ( N
-2.6 UH N
to TO N
-1.6 VB N
) ) N
and CC N
-1.6 NNP N
( ( N
-2.2 UH N
to TO N
-1.0 VB N
) ) N
, , N
respectively RB N
. . N

Global JJ N
improvement NN N
was VBD N
reported VBN N
by IN N
70 CD N
% NN N
of IN N
physiotherapy NN N
participants NNS N
( ( N
51/73 CD N
) ) N
at IN N
12 CD N
weeks NNS N
and CC N
by IN N
59 CD N
% NN N
( ( N
43/73 CD N
) ) N
at IN N
24 CD N
weeks NNS N
. . N

Similarly RB N
, , N
global JJ N
improvement NN N
was VBD N
reported VBN N
by IN N
72 CD N
% NN N
of IN N
placebo NN N
participants NNS N
( ( N
48/67 CD N
) ) N
at IN N
12 CD N
weeks NNS N
and CC N
by IN N
49 CD N
% NN N
( ( N
33/67 CD N
) ) N
at IN N
24 CD N
weeks NNS N
( ( N
all DT N
p VBP N
> $ N
0.05 CD N
) ) N
. . N

CONCLUSIONS VB N
The DT N
physiotherapy NN N
programme NN N
tested VBN N
in IN N
this DT N
trial NN N
was VBD N
no DT N
more RBR N
effective JJ N
than IN N
regular JJ N
contact NN N
with IN N
a DT N
therapist NN N
at IN N
reducing VBG N
pain NN N
and CC N
disability NN N
. . N

-DOCSTART- -X- O O

Prophylactic JJ N
vs NN N
therapeutic JJ N
blood NN N
patch NN N
for IN N
obstetric JJ 4_p
patients NNS N
with IN N
accidental JJ 4_p
dural JJ 4_p
puncture NN 4_p
-- : N
a DT N
randomised JJ N
controlled VBN N
trial NN N
. . N

Epidural JJ N
blood NN N
patch NN N
is VBZ N
a DT N
standard JJ N
treatment NN N
for IN N
obstetric JJ 4_p
patients NNS N
experiencing VBG N
a DT N
severe JJ 4_p
post-dural JJ 4_p
puncture NN 4_p
headache NN 4_p
. . N

Patients NNS N
who WP N
sustained VBD N
an DT N
accidental JJ 4_p
dural JJ 4_p
puncture NN 4_p
during IN N
establishment NN N
of IN N
epidural JJ 4_p
analgesia NN 4_p
during IN N
labour NN 4_p
or CC N
at IN N
caesarean JJ 4_p
delivery NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
a DT N
prophylactic JJ N
epidural JJ N
blood NN N
patch NN N
or CC N
conservative JJ N
treatment NN N
with IN N
a DT N
therapeutic JJ N
epidural JJ N
blood NN N
patch NN N
if IN N
required VBN N
. . N

Eleven NNP 3_p
of IN N
60 CD 3_p
( ( N
18.3 CD N
% NN N
) ) N
patients NNS N
in IN N
the DT N
prophylactic JJ N
epidural JJ N
blood NN N
patch NN N
group NN N
developed VBD N
a DT N
post-dural JJ N
puncture NN N
headache NN N
compared VBN N
with IN N
39 CD 3_p
of IN N
49 CD 3_p
( ( N
79.6 CD N
% NN N
) ) N
in IN N
the DT N
therapeutic JJ N
epidural JJ N
blood NN N
patch NN N
group NN N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
. . N

A DT N
blood NN N
patch NN N
was VBD N
performed VBN N
in IN N
36 CD N
( ( N
73.4 CD N
% NN N
) ) N
of IN N
patients NNS N
in IN N
the DT N
therapeutic JJ N
group NN N
. . N

The DT N
number NN N
of IN N
patients NNS N
who WP N
needed VBD N
a DT N
second JJ N
blood NN N
patch NN N
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
the DT N
two CD N
groups NNS N
: : N
6 CD N
( ( N
10.0 CD N
% NN N
) ) N
for IN N
prophylactic JJ N
epidural JJ N
blood NN N
patch NN N
and CC N
4 CD N
( ( N
11.1 CD N
% NN N
) ) N
for IN N
therapeutic JJ N
epidural JJ N
blood NN N
patch NN N
. . N

We PRP N
conclude VBP N
that IN N
prophylactic JJ N
epidural JJ N
blood NN N
patch NN N
is VBZ N
an DT N
effective JJ N
method NN N
to TO N
reduce VB N
the DT N
development NN N
of IN N
post-dural JJ N
puncture NN N
headache NN N
in IN N
obstetric JJ 4_p
patients NNS N
. . N

-DOCSTART- -X- O O

Behavioral JJ N
effects NNS N
of IN N
Org NNP N
2766 CD N
, , N
a DT N
synthetic JJ N
analog NN N
of IN N
the DT N
adrenocorticotrophic JJ N
hormone NN N
( ( N
4-9 JJ N
) ) N
, , N
in IN N
14 CD 3_p
outpatient JJ N
autistic JJ 4_p
children NNS 1_p
. . N

Fourteen NNP 3_p
children NNS 1_p
( ( N
12 CD 3_p
infantile NN 4_p
autism NN 4_p
full JJ N
syndrome NN N
present NN N
, , N
2 CD 3_p
atypical JJ 4_p
pervasive JJ 4_p
developmental JJ 4_p
disorder NN 4_p
) ) N
between IN N
5 CD 1_p
and CC 1_p
13 CD 1_p
years NNS N
of IN N
age NN N
participated VBN N
in IN N
a DT N
double-blind JJ N
placebo-controlled JJ N
cross-over JJ N
trial NN N
. . N

Each DT N
child NN N
received VBD N
20 CD N
mg NNS N
Org JJ N
2766 CD N
( ( N
synthetic JJ N
analog NN N
of IN N
ACTH NNP N
4-9 JJ N
) ) N
/day NN N
during IN N
4 CD N
weeks NNS N
, , N
or CC N
placebo NN N
in IN N
a DT N
randomly NN N
assigned VBN N
sequence NN N
. . N

Drug JJ N
effects NNS N
were VBD N
monitored VBN N
by IN N
ethological JJ N
playroom NN N
observation NN N
and CC N
by IN N
Aberrant NNP N
Behavior NNP N
Checklist NNP N
ratings NNS N
by IN N
parents NNS N
and CC N
teachers NNS N
. . N

Data NNP N
of IN N
the DT N
playroom NN N
observation NN N
pointed VBD N
to TO N
an DT N
activating VBG N
influence NN N
of IN N
Org NNP N
2766 CD N
, , N
as IN N
revealed VBN N
by IN N
a DT N
significant JJ N
decrease NN N
of IN N
stereotypic NN N
behavior NN N
and CC N
significant JJ N
increases NNS N
in IN N
change NN N
toys NNS N
, , N
locomote NN N
, , N
and CC N
talk NN N
. . N

Checklist JJ N
ratings NNS N
did VBD N
not RB N
show VB N
significant JJ N
changes NNS N
. . N

The DT N
clinical JJ N
implications NNS N
of IN N
these DT N
findings NNS N
are VBP N
discussed VBN N
. . N

-DOCSTART- -X- O O

Psychoeducational NNP N
group NN N
intervention NN N
for IN N
wives NNS 2_p
of IN N
men NNS 2_p
with IN N
prostate NN 4_p
cancer NN 4_p
. . N

OBJECTIVE CC N
The DT N
effects NNS N
of IN N
a DT N
6-week JJ N
psychoeducational JJ N
group NN N
intervention NN N
on IN N
the DT N
distress NN N
, , N
coping NN N
, , N
personal JJ N
growth NN N
, , N
and CC N
marital JJ N
communication NN N
of IN N
wives NNS 2_p
of IN N
men NNS 2_p
diagnosed VBN N
with IN N
prostate JJ 4_p
cancer NN 4_p
were VBD N
evaluated VBN N
using VBG N
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

METHODS NNP N
Sixty NNP 3_p
wives NNS 2_p
completed VBD N
measures NNS N
prior RB N
to TO N
random VB N
assignment NN N
to TO N
either VB N
the DT N
psychoeducational JJ N
group NN N
intervention NN N
or CC N
a DT N
no-treatment JJ N
control NN N
group NN N
, , N
and CC N
1 CD N
month NN N
after IN N
completion NN N
of IN N
the DT N
group NN N
. . N

RESULTS NNP N
No NNP N
differences NNS N
with IN N
regard NN N
to TO N
wives NNS N
' POS N
general JJ N
distress NN N
or CC N
cancer-specific JJ N
distress NN N
were VBD N
noted VBN N
. . N

In IN N
comparison NN N
with IN N
the DT N
control NN N
group NN N
, , N
participants NNS N
receiving VBG N
the DT N
intervention NN N
perceived VBD N
that IN N
having VBG N
a DT N
spouse NN N
with IN N
prostate NN N
cancer NN N
had VBD N
made VBN N
positive JJ N
contributions NNS N
to TO N
their PRP$ N
lives NNS N
, , N
reported VBD N
gains NNS N
in IN N
the DT N
use NN N
of IN N
positive JJ N
reappraisal NN N
coping VBG N
and CC N
reductions NNS N
in IN N
denial JJ N
coping NN N
. . N

CONCLUSION NNP N
Although IN N
the DT N
psychoeducational JJ N
intervention NN N
did VBD N
not RB N
result VB N
in IN N
changes NNS N
in IN N
psychological JJ N
distress NN N
, , N
improvements NNS N
in IN N
adaptive JJ N
coping NN N
and CC N
indicators NNS N
of IN N
psychological JJ N
growth NN N
were VBD N
found VBN N
. . N

The DT N
utility NN N
of IN N
group NN N
interventions NNS N
for IN N
spouses NNS 2_p
of IN N
men NNS 2_p
with IN N
prostate NN 4_p
cancer NN 4_p
is VBZ N
discussed VBN N
. . N

-DOCSTART- -X- O O

The DT N
evaluation NN N
of IN N
pulmonary JJ N
hypertension NN N
using VBG N
right JJ N
ventricular JJ N
myocardial JJ N
isovolumic JJ N
relaxation NN N
time NN N
. . N

Right JJ N
ventricular NN N
( ( N
RV NNP N
) ) N
blood VBD N
pool-derived JJ N
isovolumic JJ N
relaxation NN N
time NN N
( ( N
IVRT NNP N
) ) N
correlates VBZ N
well RB N
with IN N
systolic JJ N
pulmonary JJ N
arterial JJ N
pressure NN N
( ( N
PAP NNP N
) ) N
. . N

However RB N
, , N
because IN N
of IN N
complex JJ N
parameter NN N
derivation NN N
, , N
the DT N
method NN N
is VBZ N
rarely RB N
used VBN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
validate VB N
the DT N
measurement NN N
of IN N
myocardial JJ N
velocity NN N
imaging-derived JJ N
RV NNP N
IVRT NNP N
( ( N
IVRT NNP N
' POS N
) ) N
against IN N
invasively RB N
measured VBN N
PAP NNP N
. . N

Transthoracic NNP N
echocardiography NN N
with IN N
myocardial JJ N
velocity NN N
imaging NN N
and CC N
right JJ N
heart NN N
catheterization NN N
were VBD N
performed VBN N
in IN N
33 CD 3_p
patients NNS N
with IN N
pulmonary JJ 4_p
hypertension NN 4_p
. . N

Blood NNP N
pool NN N
IVRT NNP N
and CC N
myocardial JJ N
IVRTs NNP N
for IN N
the DT N
tricuspid JJ N
valve NN N
annulus NN N
ring NN N
, , N
basal NN N
and CC N
apical JJ N
RV NNP N
free JJ N
wall NN N
segments NNS N
were VBD N
measured VBN N
and CC N
compared VBN N
with IN N
data NNS N
from IN N
33 CD 3_p
age- JJ N
and CC N
sex-matched JJ N
control NN N
subjects NNS N
. . N

Measured VBN N
IVRTs NNP N
were VBD N
significantly RB N
longer RBR N
in IN N
patients NNS N
with IN N
pulmonary JJ N
hypertension NN N
than IN N
in IN N
control NN N
subjects NNS N
. . N

The DT N
strongest JJS N
correlation NN N
( ( N
R NNP N
= NNP N
0.74 CD N
, , N
P NNP N
< NNP N
.0001 NNP N
) ) N
was VBD N
found VBN N
between IN N
systolic JJ N
PAP NNP N
and CC N
the DT N
heart NN N
rate-corrected JJ N
IVRT NNP N
' POS N
derived VBN N
from IN N
the DT N
basal NN N
RV NNP N
free JJ N
wall NN N
segment NN N
. . N

The DT N
basal NN N
segment NN N
IVRT NNP N
' POS N
corrected VBN N
for IN N
heart NN N
rate NN N
correlates NNS N
well RB N
with IN N
the DT N
invasive JJ N
PAP NNP N
measurement NN N
and CC N
, , N
therefore RB N
, , N
can MD N
be VB N
used VBN N
to TO N
predict VB N
systolic JJ N
PAP NNP N
. . N

It PRP N
can MD N
even RB N
be VB N
considered VBN N
as IN N
an DT N
alternative NN N
to TO N
tricuspid VB N
regurgitation-derived JJ N
PAP NNP N
systolic NN N
when WRB N
tricuspid JJ N
regurgitation NN N
is VBZ N
nonrecordable JJ N
. . N

A DT N
proposed VBN N
method NN N
to TO N
derive VB N
systolic JJ N
PAP NNP N
should MD N
be VB N
used VBN N
while IN N
screening VBG N
the DT N
patients NNS N
at IN N
risk NN N
for IN N
pulmonary JJ N
hypertension NN N
, , N
monitoring VBG N
the DT N
disease NN N
progression NN N
and CC N
the DT N
effect NN N
of IN N
treatment NN N
. . N

-DOCSTART- -X- O O

The DT N
effect NN N
of IN N
acupressure NN N
at IN N
the DT N
extra JJ N
1 CD N
point NN N
on IN N
subjective JJ N
and CC N
autonomic JJ N
responses NNS N
to TO N
needle VB N
insertion NN N
. . N

BACKGROUND NNP N
Premedication NNP N
with IN N
sedatives NNS N
can MD N
decrease VB N
the DT N
discomfort NN N
associated VBN N
with IN N
invasive JJ N
anesthetic JJ N
procedures NNS N
. . N

Some DT N
researchers NNS N
have VBP N
shown VBN N
that IN N
acupressure NN N
on IN N
the DT N
acupuncture NN N
extra JJ N
1 CD N
point NN N
is VBZ N
effective JJ N
for IN N
sedation NN N
. . N

We PRP N
investigated VBD N
whether IN N
acupressure NN N
on IN N
the DT N
extra JJ N
1 CD N
point NN N
could MD N
alleviate VB N
the DT N
pain NN N
of IN N
needle JJ N
insertion NN N
. . N

METHODS NNP N
We PRP N
investigated VBD N
the DT N
effect NN N
of IN N
acupressure NN N
at IN N
the DT N
extra JJ N
1 CD N
point NN N
or CC N
a DT N
sham JJ N
point NN N
on IN N
needle JJ N
insertion NN N
using VBG N
verbal JJ N
rating NN N
scale NN N
( ( N
VRS NNP N
) ) N
pain NN N
scores NNS N
and CC N
heart NN N
rate NN N
variability NN N
( ( N
HRV NNP N
) ) N
. . N

Twenty-two NNP 3_p
healthy JJ 4_p
female NN 2_p
volunteers NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
two CD N
groups NNS N
: : N
the DT N
extra JJ N
1 CD N
group NN N
received VBD N
acupressure NN N
at IN N
the DT N
extra JJ N
1 CD N
point NN N
, , N
and CC N
the DT N
sham NN N
group NN N
received VBD N
acupressure NN N
at IN N
a DT N
sham JJ N
point NN N
. . N

After IN N
starting VBG N
the DT N
electrocardiogram NN N
record NN N
, , N
a DT N
27-gauge JJ N
needle NN N
was VBD N
inserted VBN N
into IN N
the DT N
skin NN N
of IN N
a DT N
forearm NN N
. . N

Thereafter NNP N
, , N
another DT N
needle NN N
was VBD N
inserted VBN N
into IN N
the DT N
skin NN N
of IN N
the DT N
other JJ N
forearm NN N
during IN N
acupressure NN N
. . N

RESULTS JJ N
Acupressure NN N
at IN N
the DT N
extra JJ N
1 CD N
point NN N
significantly RB N
reduced VBD N
the DT N
VRS NNP N
, , N
but CC N
acupressure NN N
at IN N
the DT N
sham NN N
increased VBD N
the DT N
VRS NNP N
. . N

Acupressure NN N
at IN N
the DT N
extra JJ N
1 CD N
significantly RB N
reduced VBD N
the DT N
low JJ N
frequency/high JJ N
frequency NN N
ratio NN N
of IN N
HRV NNP N
responding VBG N
to TO N
needle DT N
insertion NN N
. . N

CONCLUSIONS JJ N
Acupressure NN N
at IN N
the DT N
extra JJ N
1 CD N
point NN N
significantly RB N
reduced VBD N
needle JJ N
insertion NN N
pain NN N
compared VBN N
with IN N
acupressure NN N
at IN N
the DT N
sham NN N
point NN N
. . N

Also RB N
, , N
acupressure NN N
at IN N
the DT N
extra JJ N
1 CD N
point NN N
significantly RB N
reduced VBD N
the DT N
low JJ N
frequency/high JJ N
frequency NN N
ratio NN N
of IN N
HRV NNP N
responding VBG N
to TO N
needle VB N
insertion NN N
, , N
which WDT N
implies VBZ N
a DT N
reduction NN N
in IN N
sympathetic JJ N
nervous JJ N
system NN N
activity NN N
. . N

-DOCSTART- -X- O O

Physostigmine JJ N
reverses VBZ N
propofol-induced JJ N
unconsciousness NN N
and CC N
attenuation NN N
of IN N
the DT N
auditory NN N
steady JJ N
state NN N
response NN N
and CC N
bispectral JJ N
index NN N
in IN N
human JJ N
volunteers NNS N
. . N

BACKGROUND IN N
It PRP N
is VBZ N
postulated VBN N
that IN N
alteration NN N
of IN N
central JJ N
cholinergic JJ N
transmission NN N
plays VBZ N
an DT N
important JJ N
role NN N
in IN N
the DT N
mechanism NN N
by IN N
which WDT N
anesthetics NNS N
produce VBP N
unconsciousness JJ N
. . N

The DT N
authors NNS N
investigated VBD N
the DT N
effect NN N
of IN N
altering VBG N
central JJ N
cholinergic JJ N
transmission NN N
, , N
by IN N
physostigmine NN N
and CC N
scopolamine NN N
, , N
on IN N
unconsciousness NN N
produced VBN N
by IN N
propofol NN N
. . N

METHODS NNP N
Propofol NNP N
was VBD N
administered VBN N
to TO N
American NNP N
Society NNP N
of IN N
Anesthesiologists NNP N
physical JJ 4_p
status NN 4_p
1 CD 4_p
( ( N
n JJ N
= NNP N
17 CD 3_p
) ) N
volunteers NNS N
with IN N
use NN N
of IN N
a DT N
computer-controlled JJ N
infusion NN N
pump NN N
at IN N
increasing VBG N
concentrations NNS N
until IN N
unconsciousness JJ N
resulted VBD N
( ( N
inability NN N
to TO N
respond VB N
to TO N
verbal VB N
commands NNS N
, , N
abolition NN N
of IN N
spontaneous JJ N
movement NN N
) ) N
. . N

Central NNP N
nervous JJ N
system NN N
function NN N
was VBD N
assessed VBN N
by IN N
use NN N
of IN N
the DT N
Auditory NNP N
Steady NNP N
State NNP N
Response NNP N
( ( N
ASSR NNP N
) ) N
and CC N
Bispectral NNP N
Index NNP N
( ( N
BIS NNP N
) ) N
analysis NN N
of IN N
electrooculogram NN N
. . N

During IN N
continuous JJ N
administration NN N
of IN N
propofol NN N
, , N
reversal NN N
of IN N
unconsciousness NN N
produced VBN N
by IN N
physostigmine NN N
( ( N
28 CD N
microgram/kg NN N
) ) N
and CC N
block NN N
of IN N
this DT N
reversal NN N
by IN N
scopolamine NN N
( ( N
8.6 CD N
microgram/kg NN N
) ) N
were VBD N
evaluated VBN N
. . N

RESULTS NNP N
Propofol NNP N
produced VBD N
unconsciousness JJ N
at IN N
a DT N
plasma JJ N
concentration NN N
of IN N
3.2 CD N
+/- JJ N
0.8 CD N
( ( N
+/- JJ N
SD NNP N
) ) N
microgram/ml NN N
( ( N
n JJ N
= NNP N
17 CD N
) ) N
. . N

Unconsciousness NN N
was VBD N
associated VBN N
with IN N
reductions NNS N
in IN N
ASSR NNP N
( ( N
0.10 CD N
+/- JJ N
0.08 CD N
microV NN N
[ NNP N
awake VBP N
baseline JJ N
0.32 CD N
+/- JJ N
0.18 CD N
microV NN N
] NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
BIS NNP N
( ( N
55.7 CD N
+/- JJ N
8.8 CD N
[ JJ N
awake NN N
baseline NN N
92.4 CD N
+/- JJ N
3.9 CD N
] NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Physostigmine NNP N
restored VBD N
consciousness NN N
in IN N
9 CD N
of IN N
11 CD N
subjects NNS N
, , N
with IN N
concomitant JJ N
increases NNS N
in IN N
ASSR NNP N
( ( N
0.38 CD N
+/- JJ N
0.17 CD N
microV NN N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
BIS NNP N
( ( N
75.3 CD N
+/- JJ N
8.3 CD N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

In IN N
all DT N
subjects NNS N
( ( N
n JJ N
= NNP N
6 CD N
) ) N
scopolamine NN N
blocked VBD N
the DT N
physostigmine-induced JJ N
reversal NN N
of IN N
unconsciousness NN N
and CC N
the DT N
increase NN N
of IN N
the DT N
ASSR NNP N
and CC N
BIS NNP N
( ( N
ASSR NNP N
and CC N
BIS NNP N
during IN N
propofol-induced JJ N
unconsciousness NN N
: : N
0.09 CD N
+/- JJ N
0.09 CD N
microV NN N
and CC N
58.2 CD N
+/- JJ N
7.5 CD N
, , N
respectively RB N
; : N
ASSR NNP N
and CC N
BIS NNP N
after IN N
physostigmine JJ N
administration NN N
: : N
0.08 CD N
+/- JJ N
0.06 CD N
microV NN N
and CC N
56.8 CD N
+/- JJ N
6.7 CD N
, , N
respectively RB N
, , N
NS NNP N
) ) N
. . N

CONCLUSIONS NNP N
These DT N
findings NNS N
suggest VBP N
that IN N
the DT N
unconsciousness NN N
produced VBN N
by IN N
propofol NN N
is VBZ N
mediated VBN N
at IN N
least JJS N
in IN N
part NN N
via IN N
interruption NN N
of IN N
central JJ N
cholinergic NN N
muscarinic JJ N
transmission NN N
. . N

-DOCSTART- -X- O O

The DT N
effect NN N
of IN N
magnesium NN N
added VBN N
to TO N
levobupivacaine VB N
for IN N
femoral JJ N
nerve NN N
block NN N
on IN N
postoperative JJ N
analgesia NN N
in IN N
patients NNS N
undergoing VBG N
ACL NNP 4_p
reconstruction NN 4_p
. . N

PURPOSE VB N
The DT N
aim NN N
of IN N
this DT N
prospective JJ N
randomised VBD N
double-blind NN N
study NN N
is VBZ N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
magnesium NN N
added VBN N
to TO N
local JJ N
anaesthetics NNS N
on IN N
postoperative JJ N
VAS NNP N
scores NNS N
, , N
total JJ N
opioid JJ N
consumption NN N
, , N
time NN N
to TO N
first JJ N
mobilisation NN N
, , N
patient JJ N
satisfaction NN N
and CC N
rescue NN N
analgesic JJ N
requirements NNS N
in IN N
arthroscopic JJ N
ACL NNP N
reconstruction NN N
surgery NN N
. . N

METHODS NNP N
A NNP N
total NN N
of IN N
107 CD 3_p
American JJ N
Society NNP N
of IN N
Anaesthesiologists NNP N
physical JJ N
status NN N
grade NN N
I PRP N
and CC N
II NNP N
patients NNS N
between IN N
18 CD 1_p
and CC 1_p
65 CD 1_p
years NNS N
of IN N
age NN N
who WP N
were VBD N
scheduled VBN N
to TO N
undergo VB N
elective JJ 4_p
anterior JJ 4_p
crucial JJ 4_p
ligament NN 4_p
( ( 4_p
ACL NNP 4_p
) ) 4_p
reconstruction NN 4_p
with IN N
hamstring VBG N
autografts NNS N
were VBD N
enrolled VBN N
in IN N
the DT N
study NN N
. . N

The DT N
patients NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
Groups NNP N
L NNP N
( ( N
n JJ N
= NNP N
51 CD N
) ) N
and CC N
LM NNP N
( ( N
n JJ N
= NNP N
56 CD N
) ) N
using VBG N
the DT N
closed-envelope NN N
method NN N
. . N

Group NNP N
LM NNP N
was VBD N
administered VBN N
19 CD N
ml NN N
of IN N
0.25 CD N
% NN N
levobupivacaine NN N
and CC N
1 CD N
ml NN N
of IN N
15 CD N
% NN N
magnesium NN N
sulphate NN N
, , N
while IN N
Group NNP N
L NNP N
was VBD N
administered VBN N
20 CD N
ml NN N
of IN N
0.25 CD N
% NN N
levobupivacaine NN N
for IN N
femoral JJ N
blockade NN N
. . N

General NNP N
anaesthesia NN N
was VBD N
administered VBN N
using VBG N
laryngeal JJ N
airway RB N
masks NNS N
following VBG N
neural JJ N
blockade NN N
in IN N
both DT N
groups NNS N
. . N

The DT N
patients NNS N
were VBD N
evaluated VBN N
for IN N
heart NN N
rate NN N
and CC N
mean VB N
arterial JJ N
pressure NN N
, , N
oxygen NN N
saturation NN N
, , N
visual JJ N
analogue NN N
score NN N
( ( N
VAS NNP N
) ) N
, , N
verbal JJ N
rating NN N
scale NN N
( ( N
VRS NNP N
) ) N
, , N
rescue NN N
analgesic JJ N
requirements NNS N
, , N
total JJ N
opioid JJ N
consumption NN N
, , N
side NN N
effects NNS N
and CC N
time NN N
to TO N
first JJ N
mobilisation NN N
at IN N
the DT N
1st CD N
, , N
2nd CD N
, , N
4th CD N
, , N
6th CD N
, , N
12th CD N
and CC N
24th CD N
hours NNS N
postoperatively RB N
. . N

RESULTS NNP N
There EX N
was VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
in IN N
terms NNS N
of IN N
demographic JJ N
data NNS N
, , N
mean JJ N
arterial JJ N
pressure NN N
, , N
heart NN N
rate NN N
or CC N
oxygen NN N
saturation NN N
between IN N
groups NNS N
. . N

The DT N
area NN N
under IN N
the DT N
curve NN N
VAS NNP N
and CC N
VRS NNP N
scores NNS N
were VBD N
lower JJR N
at IN N
4 CD N
, , N
6 CD N
, , N
12 CD N
and CC N
24 CD N
h NN N
in IN N
Group NNP N
LM NNP N
( ( N
p JJ N
= NN N
0.001 CD N
, , N
p NN N
= VBD N
0.016 CD N
, , N
respectively RB N
) ) N
. . N

The DT N
rescue NN N
analgesic JJ N
requirement NN N
and CC N
the DT N
total JJ N
opioid JJ N
consumption NN N
were VBD N
significantly RB N
lower JJR N
in IN N
Group NNP N
LM NNP N
( ( N
p JJ N
= NN N
0.015 CD N
, , N
p NN N
= VBD N
0.019 CD N
, , N
respectively RB N
) ) N
. . N

The DT N
time NN N
to TO N
first JJ N
mobilisation NN N
and CC N
the DT N
Likert NNP N
score NN N
( ( N
completely RB N
comfortable JJ N
; : N
quite RB N
comfortable JJ N
; : N
slight JJ N
discomfort NN N
; : N
painful JJ N
; : N
very RB N
painful JJ N
) ) N
were VBD N
higher JJR N
, , N
and CC N
the DT N
block NN N
onset VBD N
time NN N
was VBD N
lower JJR N
in IN N
Group NNP N
LM NNP N
( ( N
p JJ N
= NN N
0.014 CD N
and CC N
p VB N
= JJ N
0.012 CD N
, , N
respectively RB N
) ) N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
terms NNS N
of IN N
side NN N
effects NNS N
. . N

CONCLUSIONS VB N
The DT N
addition NN N
of IN N
magnesium NN N
to TO N
levobupivacaine VB N
prolongs NNS N
the DT N
sensory NN N
and CC N
motor NN N
block NN N
duration NN N
without IN N
increasing VBG N
side NN N
effects NNS N
, , N
enhances VBZ N
the DT N
quality NN N
of IN N
postoperative JJ N
analgesia NN N
and CC N
increases VBZ N
patient JJ N
satisfaction NN N
; : N
however RB N
, , N
the DT N
addition NN N
of IN N
magnesium NN N
delays VBZ N
the DT N
time NN N
to TO N
first JJ N
mobilisation NN N
and CC N
decreases VBZ N
rescue NN N
analgesic JJ N
requirements NNS N
. . N

-DOCSTART- -X- O O

Warfarin NNP N
for IN N
atrial JJ 4_p
fibrillation NN 4_p
. . N

The DT N
patient NN N
's POS N
perspective NN N
. . N

OBJECTIVE UH N
To TO N
determine VB N
the DT N
minimal JJ N
clinically RB N
important JJ N
difference NN N
( ( N
MCID NNP N
) ) N
of IN N
warfarin NN N
therapy NN N
for IN N
the DT N
treatment NN N
of IN N
nonvalvular JJ 4_p
atrial JJ 4_p
fibrillation NN 4_p
from IN N
the DT N
perspective NN N
of IN N
patients NNS N
using VBG N
2 CD N
different JJ N
elicitation NN N
methods NNS N
. . N

DESIGN NNP N
All DT N
patients NNS N
completed VBD N
2 CD N
face-to-face JJ N
interviews NNS N
, , N
which WDT N
were VBD N
2 CD N
weeks NNS N
apart RB N
. . N

For IN N
each DT N
interview NN N
, , N
they PRP N
were VBD N
randomized VBN N
to TO N
receive VB N
1 CD N
of IN N
2 CD N
elicitation NN N
methods NNS N
: : N
ping-ponging NN N
or CC N
starting VBG N
at IN N
the DT N
known JJ N
efficacy NN N
. . N

SETTING CC N
The DT N
practices NNS N
of IN N
2 CD N
university-affiliated JJ N
family NN N
medicine NN N
centers NNS N
( ( N
8 CD N
physicians NNS N
each DT N
) ) N
, , N
14 CD N
community-based JJ N
family NN N
physicians NNS N
, , N
and CC N
2 CD N
cardiologists NNS N
. . N

PATIENTS VB N
Sixty-four JJ 3_p
patients NNS N
with IN N
nonvalvular JJ 4_p
atrial JJ 4_p
fibrillation NN 4_p
who WP N
were VBD N
initiated VBN N
with IN N
warfarin JJ N
therapy NN N
at IN N
least JJS N
3 CD N
months NNS N
before IN N
the DT N
study NN N
. . N

INTERVENTION NNP N
During IN N
each DT N
interview NN N
, , N
the DT N
patients NNS N
' POS N
MCIDs NNP N
were VBD N
determined VBN N
by IN N
using VBG N
( ( N
1 CD N
) ) N
a DT N
pictorial JJ N
flip NN N
chart NN N
to TO N
describe VB N
atrial JJ N
fibrillation NN N
; : N
the DT N
consequences NNS N
of IN N
a DT N
minor JJ N
stroke NN N
, , N
a DT N
major JJ N
stroke NN N
, , N
and CC N
a DT N
major JJ N
bleeding NN N
episode NN N
; : N
the DT N
chance NN N
of IN N
stroke NN N
if IN N
not RB N
taking VBG N
warfarin NN N
; : N
the DT N
chance NN N
of IN N
a DT N
major JJ N
bleeding NN N
episode NN N
if IN N
taking VBG N
warfarin NN N
; : N
examples NNS N
of IN N
the DT N
inconvenience NN N
, , N
minor JJ N
side NN N
effects NNS N
, , N
and CC N
costs NNS N
of IN N
warfarin JJ N
therapy NN N
; : N
and CC N
then RB N
( ( N
2 CD N
) ) N
1 CD N
of IN N
the DT N
2 CD N
elicitation NN N
methods NNS N
to TO N
determine VB N
their PRP$ N
MCIDs NNP N
( ( N
the DT N
smallest JJS N
reduction NN N
in IN N
stroke NN N
risk NN N
at IN N
which WDT N
the DT N
patients NNS N
were VBD N
willing JJ N
to TO N
take VB N
warfarin NN N
) ) N
. . N

Patients NNS N
' POS N
knowledge NN N
of IN N
their PRP$ N
stroke NN N
risk NN N
, , N
acceptability NN N
of IN N
the DT N
interview NN N
process NN N
, , N
and CC N
factors NNS N
determining VBG N
their PRP$ N
preferences NNS N
were VBD N
also RB N
assessed VBN N
. . N

MAIN NNP N
RESULTS NNP N
Given NNP N
a DT N
baseline NN N
risk NN N
of IN N
having VBG N
a DT N
stroke NN N
in IN N
the DT N
next JJ N
2 CD N
years NNS N
, , N
if IN N
not RB N
taking VBG N
warfarin NN N
, , N
of IN N
10 CD N
of IN N
100 CD N
, , N
the DT N
mean JJ N
MCID NNP N
was VBD N
2.01 CD N
of IN N
100 CD N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
1.60-2.42 JJ N
) ) N
. . N

Fifty-two JJ N
percent NN N
of IN N
the DT N
patients NNS N
would MD N
take VB N
warfarin NN N
for IN N
an DT N
absolute JJ N
decrease NN N
in IN N
stroke NN N
risk NN N
of IN N
1 CD N
% NN N
over IN N
2 CD N
years NNS N
. . N

Before IN N
eliciting VBG N
their PRP$ N
MCIDs NNP N
, , N
patients NNS N
showed VBD N
poor JJ N
knowledge NN N
of IN N
their PRP$ N
stroke NN N
risk NN N
, , N
which WDT N
improved VBD N
afterward RB N
. . N

The DT N
interview NN N
process NN N
was VBD N
well RB N
accepted VBN N
by IN N
the DT N
patients NNS N
. . N

The DT N
MCID NNP N
using VBG N
the DT N
ping-ponging JJ N
elicitation NN N
method NN N
was VBD N
1.015 CD N
of IN N
100 CD N
smaller JJR N
compared VBN N
with IN N
use NN N
of IN N
the DT N
starting NN N
at IN N
the DT N
known JJ N
efficacy NN N
method NN N
( ( N
P NNP N
= NNP N
.01 NNP N
) ) N
. . N

CONCLUSIONS NN N
We PRP N
were VBD N
able JJ N
to TO N
determine VB N
the DT N
MCID NNP N
of IN N
warfarin NN N
therapy NN N
for IN N
the DT N
prevention NN N
of IN N
stroke NN N
from IN N
the DT N
perspective NN N
of IN N
patients NNS N
with IN N
nonvalvular JJ 4_p
atrial JJ 4_p
fibrillation NN 4_p
. . N

Their PRP$ N
MCIDs NNPS N
were VBD N
much RB N
smaller JJR N
than IN N
those DT N
that WDT N
have VBP N
been VBN N
implied VBN N
by IN N
some DT N
experts NNS N
and CC N
clinicians NNS N
. . N

The DT N
interview NN N
process NN N
, , N
using VBG N
the DT N
flip JJ N
chart NN N
approach NN N
, , N
appeared VBD N
to TO N
improve VB N
the DT N
patients NNS N
' POS N
knowledge NN N
of IN N
their PRP$ N
disease NN N
and CC N
its PRP$ N
consequences NNS N
and CC N
treatment NN N
. . N

The DT N
method NN N
used VBN N
to TO N
elicit VB N
the DT N
patients NNS N
' POS N
MCIDs NNP N
can MD N
have VB N
a DT N
clinically RB N
important JJ N
effect NN N
on IN N
patient NN N
responses NNS N
. . N

The DT N
method NN N
used VBN N
in IN N
our PRP$ N
study NN N
can MD N
be VB N
generalized VBN N
to TO N
other JJ N
conditions NNS N
and CC N
, , N
thus RB N
, , N
could MD N
be VB N
helpful JJ N
in IN N
3 CD N
ways NNS N
: : N
( ( N
1 CD N
) ) N
from IN N
a DT N
clinical JJ N
decision-making NN N
perspective NN N
, , N
it PRP N
could MD N
facilitate VB N
patient-physician JJ N
communication NN N
; : N
( ( N
2 CD N
) ) N
it PRP N
could MD N
clarify VB N
the DT N
patient NN N
perspective NN N
when WRB N
interpreting VBG N
the DT N
results NNS N
of IN N
previously RB N
completed VBN N
trials NNS N
; : N
and CC N
( ( N
3 CD N
) ) N
it PRP N
could MD N
be VB N
used VBN N
to TO N
derive VB N
more RBR N
clinically RB N
relevant JJ N
sample NN N
sizes NNS N
for IN N
randomized JJ N
treatment NN N
trials NNS N
. . N

-DOCSTART- -X- O O

Effectiveness NN N
and CC N
safety NN N
of IN N
the DT N
Levitan NNP N
FPS NNP N
Scope? NNP N
for IN N
tracheal JJ N
intubation NN N
under IN N
general JJ N
anesthesia NN N
with IN N
a DT N
simulated JJ N
difficult JJ N
airway NN N
. . N

PURPOSE NNP N
Studies NNP N
show VBP N
that IN N
the DT N
Levitan NNP N
FPS NNP N
( ( N
first JJ N
pass NN N
success NN N
) ) N
Scope? NNP N
( ( N
LFS NNP N
) ) N
is VBZ N
analogous JJ N
to TO N
a DT N
bougie NN N
in IN N
simulated JJ N
difficult JJ N
airways NNS N
with IN N
comparable JJ N
tracheal JJ N
intubation NN N
success NN N
rates NNS N
. . N

In IN N
this DT N
study NN N
, , N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
tracheal JJ N
intubation NN N
with IN N
the DT N
LFS NNP N
was VBD N
compared VBN N
with IN N
that DT N
of IN N
the DT N
Macintosh NNP N
laryngoscope NN N
utilizing VBG N
manual JJ N
in-line JJ N
stabilization NN N
( ( N
MILS NNP N
) ) N
to TO N
simulate VB N
difficult JJ N
airways NNS N
. . N

METHODS NNP N
Ninety-four JJ N
subjects NNS N
successfully RB N
completed VBD N
the DT N
trial NN N
. . N

Manual JJ N
in-line JJ N
stabilization NN N
of IN N
the DT N
cervical JJ N
spine NN N
was VBD N
applied VBN N
and CC N
the DT N
initial JJ N
laryngoscopy NN N
was VBD N
performed VBN N
using VBG N
either CC N
the DT N
Macintosh NNP N
or CC N
the DT N
LFS NNP N
in IN N
conjunction NN N
with IN N
the DT N
Macintosh NNP N
. . N

Following VBG N
the DT N
initial JJ N
grading NN N
, , N
a DT N
second JJ N
laryngoscopy NN N
was VBD N
repeated VBN N
using VBG N
the DT N
second JJ N
randomized JJ N
technique NN N
. . N

Cormack-Lehane NNP N
grades NNS N
, , N
percentage NN N
of IN N
glottic JJ N
opening NN N
( ( N
POGO NNP N
) ) N
scores VBZ N
, , N
time NN N
to TO N
intubate VB N
, , N
number NN N
of IN N
intubation NN N
attempts NNS N
, , N
and CC N
the DT N
use NN N
of IN N
alternate NN N
techniques NNS N
were VBD N
recorded VBN N
. . N

The DT N
anesthesiologist NN N
rated VBD N
the DT N
subjective JJ N
difficulty NN N
in IN N
using VBG N
each DT N
technique NN N
with IN N
a DT N
numeric JJ N
rating NN N
scale NN N
and CC N
a DT N
visual JJ N
rating NN N
scale NN N
. . N

RESULTS NNP N
There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
primary JJ N
outcome NN N
good JJ N
laryngoscopic NN N
views NNS N
( ( N
Cormack-Lehane NNP N
grade VBD N
1 CD N
and CC N
2 CD N
) ) N
compared VBN N
with IN N
poor JJ N
laryngoscopic JJ N
views NNS N
( ( N
Cormack-Lehane NNP N
grade VBD N
3 CD N
and CC N
4 CD N
) ) N
between IN N
the DT N
LFS NNP N
and CC N
the DT N
Macintosh NNP N
. . N

There EX N
were VBD N
higher JJR N
POGO NNP N
scores NNS N
with IN N
the DT N
LFS NNP N
compared VBN N
with IN N
the DT N
Macintosh NNP N
( ( N
80 CD N
% NN N
vs JJ N
20 CD N
% NN N
, , N
respectively RB N
; : N
P NNP N
< NNP N
0.0001 CD N
) ) N
, , N
but CC N
this DT N
did VBD N
not RB N
translate VB N
to TO N
easier JJR N
intubations NNS N
, , N
as IN N
documented VBN N
by IN N
the DT N
need NN N
for IN N
an DT N
alternate JJ N
intubation NN N
technique NN N
or CC N
time NN N
to TO N
intubate VB N
( ( N
< JJ N
30 CD N
and CC N
< $ N
60 CD N
sec NN N
, , N
respectively RB N
) ) N
. . N

The DT N
incidence NN N
of IN N
mucosal NN N
trauma NN N
, , N
sore RB N
throat NN N
, , N
and CC N
hemodynamic JJ N
responses NNS N
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
the DT N
two CD N
techniques NNS N
. . N

CONCLUSION VB N
The DT N
LFS NNP N
in IN N
conjunction NN N
with IN N
the DT N
Macintosh NNP N
laryngoscope NN N
does VBZ N
not RB N
improve VB N
the DT N
efficacy NN N
or CC N
safety NN N
of IN N
tracheal JJ N
intubation NN N
in IN N
a DT N
simulated JJ N
difficult JJ N
airway NN N
. . N

-DOCSTART- -X- O O

Clinical JJ N
trial NN N
: : N
exposure NN N
to TO N
ribavirin VB N
predicts NNS N
EVR NNP N
and CC N
SVR NNP N
in IN N
patients NNS N
with IN N
HCV NNP 4_p
genotype NN 4_p
1 CD 4_p
infection NN N
treated VBN N
with IN N
peginterferon NN N
alpha-2a JJ N
plus CC N
ribavirin JJ N
. . N

BACKGROUND VB N
The DT N
impact NN N
of IN N
reduced JJ N
drug NN N
exposure NN N
on IN N
outcomes NNS N
in IN N
patients NNS N
with IN N
chronic JJ 4_p
hepatitis NN 4_p
C NNP 4_p
has VBZ N
not RB N
been VBN N
determined VBN N
in IN N
routine JJ N
clinical JJ N
practice NN N
. . N

AIM NNP N
To TO N
examine VB N
the DT N
impact NN N
of IN N
exposure NN N
to TO N
peginterferon VB N
alpha-2a JJ N
and CC N
ribavirin VB N
on IN N
early JJ N
virological JJ N
response NN N
( ( N
EVR NNP N
) ) N
and CC N
sustained VBD N
virological JJ N
response NN N
( ( N
SVR NNP N
) ) N
in IN N
treatment-naive JJ N
patients NNS N
with IN N
HCV NNP N
genotype NN N
1 CD N
infection NN N
enrolled VBN N
in IN N
a DT N
large JJ N
expanded JJ N
access NN N
programme NN N
. . N

METHODS NNP N
Eight NNP 3_p
hundred VBD 3_p
and CC 3_p
ninety-one JJ 3_p
patients NNS N
treated VBD N
for IN N
48 CD N
weeks NNS N
with IN N
an DT N
initial JJ N
ribavirin NN N
dose NN N
of IN N
800 CD N
or CC N
1000/1200 CD N
mg/day NNS N
were VBD N
evaluated VBN N
. . N

Ribavirin JJ N
1000 CD N
mg/day NN N
( ( N
< JJ N
75 CD N
kg NN N
) ) N
or CC N
1200 CD N
mg/day NN N
( ( N
> JJ N
or=75 RB N
kg NN N
) ) N
and CC N
peginterferon VB N
alpha-2a JJ N
180 CD N
microg/week NN N
were VBD N
considered VBN N
optimal JJ N
. . N

The DT N
impact NN N
of IN N
reduced JJ N
drug NN N
exposure NN N
( ( N
expressed VBN N
as IN N
a DT N
percentage NN N
of IN N
optimal NN N
) ) N
on IN N
EVR NNP N
and CC N
SVR NNP N
was VBD N
evaluated VBN N
. . N

RESULTS JJ N
Mean NNP N
ribavirin NN N
exposure NN N
in IN N
week NN N
0-12 NN N
was VBD N
70 CD N
% NN N
and CC N
96 CD N
% NN N
in IN N
patients NNS N
assigned VBN N
to TO N
ribavirin VB N
800 CD N
and CC N
1000/1200 CD N
mg/day NN N
, , N
respectively RB N
. . N

EVR NNP N
and CC N
SVR NNP N
rates NNS N
were VBD N
lower JJR N
in IN N
patients NNS N
assigned VBN N
to TO N
ribavirin VB N
800 CD N
than IN N
1000/1200 CD N
mg/day NN N
( ( N
EVR NNP N
, , N
75 CD N
% NN N
vs. FW N
84 CD N
% NN N
, , N
respectively RB N
, , N
P NNP N
< NNP N
0.001 CD N
; : N
SVR NNP N
, , N
45 CD N
% NN N
vs. FW N
54 CD N
% NN N
, , N
respectively RB N
, , N
P NNP N
= NNP N
0.011 CD N
) ) N
. . N

Furthermore RB N
, , N
there EX N
was VBD N
a DT N
strong JJ N
correlation NN N
between IN N
achievement NN N
of IN N
EVR NNP N
and CC N
SVR NNP N
and CC N
ribavirin VB N
dose NN N
over IN N
the DT N
first JJ N
12 CD N
weeks NNS N
expressed VBD N
either CC N
as IN N
absolute JJ N
dose NN N
or CC N
proportion NN N
of IN N
optimal JJ N
dose NN N
received VBD N
( ( N
P NNP N
< VBZ N
0.001 CD N
for IN N
both DT N
) ) N
. . N

CONCLUSIONS NNP N
Ribavirin NNP N
exposure NN N
to TO N
week NN N
12 CD N
is VBZ N
significantly RB N
associated VBN N
with IN N
EVR NNP N
and CC N
SVR NNP N
in IN N
genotype JJ N
1 CD N
patients NNS N
. . N

Maintenance NNP N
of IN N
an DT N
optimal JJ N
ribavirin NN N
dose NN N
is VBZ N
the DT N
most RBS N
important JJ N
modifiable JJ N
factor NN N
during IN N
combination NN N
therapy NN N
for IN N
chronic JJ N
hepatitis NN N
C NNP N
. . N

-DOCSTART- -X- O O

Computer-navigated JJ N
versus NN N
conventional JJ N
total JJ N
knee NN N
arthroplasty IN N
a DT N
prospective JJ N
randomized VBN N
trial NN N
. . N

BACKGROUND VB N
The DT N
literature NN N
lacks VBZ N
studies NNS N
that IN N
confirm VBP N
whether IN N
the DT N
improved JJ N
radiographic JJ N
alignment NN N
that WDT N
can MD N
be VB N
achieved VBN N
with IN N
computer-navigated JJ N
total JJ N
knee NN N
arthroplasty NN N
improves VBZ N
patients? JJ N
activities NNS N
of IN N
daily JJ N
living NN N
or CC N
the DT N
durability NN N
of IN N
total JJ N
knee NN N
prostheses NNS N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
whether IN N
computer-navigated JJ N
total JJ N
knee NN N
arthroplasty NN N
improves VBZ N
the DT N
clinical JJ N
function NN N
, , N
alignment NN N
, , N
and CC N
survivorship NN N
of IN N
the DT N
components NNS N
. . N

METHODS NNP N
We PRP N
prospectively RB N
compared VBN N
the DT N
results NNS N
of IN N
520 CD N
patients NNS N
with IN N
osteoarthritis NN N
who WP N
underwent VBD N
computer-navigated JJ N
total JJ N
knee NN N
arthroplasty NN N
for IN N
one CD N
knee NN N
and CC N
conventional JJ N
total JJ N
knee NN N
arthroplasty NN N
for IN N
the DT N
other JJ N
. . N

The DT N
assignment NN N
of IN N
the DT N
knee NN N
to TO N
navigation NN N
or CC N
not RB N
was VBD N
done VBN N
randomly RB N
. . N

There EX N
were VBD N
452 CD N
women NNS N
( ( N
904 CD N
knees NNS N
) ) N
and CC N
sixty-eight JJ N
men NNS N
( ( N
136 CD N
knees NNS N
) ) N
with IN N
a DT N
mean JJ N
age NN N
of IN N
sixty-eight JJ N
years NNS N
( ( N
range NN N
, , N
forty-nine JJ N
to TO N
eighty-eight JJ N
years NNS N
) ) N
at IN N
the DT N
time NN N
of IN N
the DT N
index NN N
arthroplasty NN N
. . N

The DT N
mean JJ N
follow-up JJ N
period NN N
was VBD N
10.8 CD N
years NNS N
( ( N
range NN N
, , N
ten VB N
to TO N
twelve VB N
years NNS N
) ) N
. . N

The DT N
patients NNS N
were VBD N
assessed VBN N
clinically RB N
and CC N
radiographically RB N
with IN N
the DT N
rating NN N
system NN N
of IN N
the DT N
Knee NNP N
Society NNP N
and CC N
with IN N
the DT N
Western NNP N
Ontario NNP N
and CC N
McMaster NNP N
Universities NNP N
Osteoarthritis NNP N
Index NNP N
( ( N
WOMAC NNP N
) ) N
score NN N
at IN N
three CD N
months NNS N
, , N
one CD N
year NN N
, , N
and CC N
annually RB N
thereafter RB N
. . N

RESULTS NNP N
Total JJ N
knee NN N
scores NNS N
, , N
knee NN N
function NN N
scores NNS N
, , N
pain NN N
scores NNS N
, , N
WOMAC NNP N
scores VBZ N
, , N
knee VB N
motion NN N
, , N
and CC N
activity NN N
scores NNS N
did VBD N
not RB N
show VB N
statistically RB N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
preoperatively RB N
or CC N
at IN N
the DT N
time NN N
of IN N
the DT N
final JJ N
follow-up NN N
. . N

Alignment NNP N
and CC N
the DT N
survivorship NN N
of IN N
the DT N
components NNS N
were VBD N
not RB N
significantly RB N
different JJ N
between IN N
the DT N
two CD N
groups NNS N
. . N

The DT N
Kaplan-Meier NNP N
survivorship NN N
with IN N
revision NN N
as IN N
the DT N
end NN N
point NN N
at IN N
10.8 CD N
years NNS N
was VBD N
98.8 CD N
% NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
0.96 CD N
to TO N
1.00 CD N
) ) N
in IN N
the DT N
computernavigated JJ N
total JJ N
knee NN N
arthroplasty NN N
group NN N
and CC N
99.2 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.96 CD N
to TO N
1.00 CD N
) ) N
in IN N
the DT N
conventional JJ N
total JJ N
knee NN N
arthroplasty NN N
group NN N
. . N

CONCLUSIONS NNP N
Our PRP$ N
data NNS N
demonstrated VBD N
no DT N
difference NN N
in IN N
clinical JJ N
function NN N
or CC N
alignment NN N
and CC N
survivorship NN N
of IN N
the DT N
components NNS N
between IN N
the DT N
knees NNS N
that WDT N
underwent VBD N
computer-navigated JJ N
total JJ N
knee NN N
arthroplasty NN N
and CC N
those DT N
that WDT N
underwent JJ N
conventional JJ N
total JJ N
knee NN N
arthroplasty NN N
. . N

-DOCSTART- -X- O O

B-domain NNP N
deleted VBD N
recombinant JJ N
factor NN N
VIII NNP N
preparations NNS N
are VBP N
bioequivalent JJ N
to TO N
a DT N
monoclonal JJ N
antibody NN N
purified VBD N
plasma-derived JJ N
factor NN N
VIII NNP N
concentrate NN N
: : N
a DT N
randomized JJ N
, , N
three-way JJ N
crossover NN N
study NN N
. . N

BACKGROUND NNP N
Deletion NNP N
of IN N
the DT N
B-domain NNP N
of IN N
recombinant JJ N
blood NN N
coagulation NN N
factor NN N
VIII NNP N
( ( N
BDDrFVIII NNP N
) ) N
increases VBZ N
the DT N
manufacturing VBG N
yield NN N
of IN N
the DT N
product NN N
but CC N
does VBZ N
not RB N
impair VB N
in IN N
vitro NN N
or CC N
in IN N
vivo JJ N
functionality NN N
. . N

BDDrFVIII NNP N
( ( N
ReFacto NNP N
) ) N
has VBZ N
been VBN N
developed VBN N
with IN N
the DT N
additional JJ N
benefit NN N
of IN N
being VBG N
formulated VBN N
without IN N
human JJ N
albumin NN N
. . N

OBJECTIVE CC N
The DT N
primary JJ N
objective NN N
of IN N
this DT N
three-way JJ N
crossover-design NN N
study NN N
was VBD N
to TO N
compare VB N
the DT N
pharmacokinetic JJ N
( ( N
PK NNP N
) ) N
parameters NNS N
of IN N
two CD N
BDDrFVIII NNP N
formulations NNS N
( ( N
one CD N
reconstituted VBN N
with IN N
5 CD N
mL NNS N
of IN N
sterile JJ N
water NN N
, , N
the DT N
other JJ N
reconstituted VBD N
with IN N
4 CD N
mL NNS N
sodium JJ N
chloride RB N
0.9 CD N
% NN N
USP NNP N
) ) N
with IN N
those DT N
of IN N
a DT N
plasma-derived JJ N
, , N
full-length JJ N
FVIII NNP N
preparation NN N
( ( N
Hemofil NNP N
M NNP N
) ) N
in IN N
patients NNS N
with IN N
haemophilia PDT 4_p
A DT 4_p
to TO N
determine VB N
bioequivalence NN N
. . N

METHODS VB N
A NNP N
series NN N
of IN N
blood NN N
samples NNS N
were VBD N
collected VBN N
over IN N
a DT N
period NN N
of IN N
48 CD N
h NN N
after IN N
i.v NN N
. . N

administration NN N
of IN N
each DT N
of IN N
the DT N
FVIII NNP N
preparations NNS N
. . N

Plasma NNP N
FVIII NNP N
activity NN N
was VBD N
determined VBN N
using VBG N
a DT N
validated JJ N
chromogenic JJ N
substrate NN N
assay NN N
. . N

Plasma NNP N
FVIII NNP N
activity NN N
vs. FW N
time NN N
curves NNS N
was VBD N
characterized VBN N
for IN N
a DT N
standard JJ N
set NN N
of IN N
PK NNP N
parameter NN N
estimates NNS N
. . N

Two CD N
parameter NN N
estimates NNS N
, , N
the DT N
maximum JJ N
plasma JJ N
concentration NN N
( ( N
Cmax NNP N
) ) N
and CC N
the DT N
area NN N
under IN N
plasma JJ N
concentration NN N
vs. FW N
time NN N
curves NNS N
( ( N
AUCs NNP N
) ) N
, , N
were VBD N
used VBN N
to TO N
evaluate VB N
bioequivalence NN N
. . N

The DT N
two CD N
preparations NNS N
were VBD N
considered VBN N
bioequivalent NN N
if IN N
the DT N
90 CD N
% NN N
confidence NN N
intervals NNS N
for IN N
the DT N
ratio NN N
of IN N
geometric JJ N
means NNS N
for IN N
Cmax NNP N
and CC N
AUCs NNP N
fell VBD N
within IN N
the DT N
bioequivalence NN N
window NN N
of IN N
80 CD N
% NN N
to TO N
125 CD N
% NN N
. . N

RESULTS/CONCLUSION NNP N
Results NNP N
show VBP N
that IN N
each DT N
BDDrFVIII NNP N
formulation NN N
is VBZ N
bioequivalent JJ N
to TO N
Hemofil NNP N
M NNP N
and CC N
the DT N
two CD N
formulations NNS N
of IN N
BDDrFVIII NNP N
are VBP N
bioequivalent JJ N
to TO N
each DT N
other JJ N
. . N

-DOCSTART- -X- O O

QT/QTc NNP N
study NN N
conducted VBD N
in IN N
Japanese JJ N
adult NN 1_p
healthy JJ 4_p
subjects NNS N
: : N
a DT N
novel JJ N
xanthine NN N
oxidase NN N
inhibitor NN N
topiroxostat NN N
was VBD N
not RB N
associated VBN N
with IN N
QT NNP N
prolongation NN N
. . N

A DT N
QT/QTc NNP N
study NN N
was VBD N
conducted VBN N
in IN N
compliance NN N
with IN N
ICH NNP N
E14 NNP N
guideline NN N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
a DT N
new JJ N
xanthine JJ N
oxidase NN N
inhibitor NN N
topiroxostat NN N
in IN N
Japanese JJ N
healthy JJ 4_p
subjects NNS 4_p
. . N

Forty-eight JJ 3_p
Japanese JJ N
healthy JJ 4_p
subjects NNS 4_p
( ( N
males NNS 2_p
24 CD 3_p
; : N
females NNS 2_p
24 CD 3_p
) ) N
received VBD N
a DT N
single JJ N
oral JJ N
dose NN N
of IN N
topiroxostat NN N
( ( N
60 CD N
or CC N
180 CD N
mg NN N
) ) N
, , N
moxifloxacin FW N
( ( N
400 CD N
mg NN N
) ) N
or CC N
placebo NN N
in IN N
a DT N
single-center JJ N
, , N
double-blind JJ N
, , N
four-period JJ N
crossover NN N
design NN N
. . N

Fridericia NNP N
's POS N
formula NN N
( ( N
QTcF NNP N
= NNP N
QT/RR NNP N
( ( N
0.33 CD N
) ) N
) ) N
was VBD N
used VBN N
as IN N
a DT N
primary JJ N
method NN N
for IN N
QT-interval JJ N
correction NN N
. . N

The DT N
mean JJ N
QTcF NNP N
was VBD N
prolonged VBN N
by IN N
moxifloxacin NN N
, , N
of IN N
which WDT N
largest JJS N
time-matched JJ N
difference NN N
from IN N
placebo JJ N
administration NN N
was VBD N
13.6 CD N
milliseconds NNS N
with IN N
90 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
of IN N
11.2 CD N
and CC N
15.9 CD N
milliseconds NNS N
at IN N
4 CD N
hours NNS N
post-dose JJ N
. . N

The DT N
mean JJ N
QTcF NNP N
was VBD N
hardly RB N
affected VBN N
by IN N
either DT N
dose NN N
of IN N
topiroxostat NN N
, , N
of IN N
which WDT N
largest JJS N
time-matched JJ N
difference NN N
from IN N
placebo JJ N
administration NN N
was VBD N
2.9 CD N
milliseconds NNS N
with IN N
90 CD N
% NN N
CI NNP N
of IN N
0.6 CD N
and CC N
5.3 CD N
milliseconds NNS N
at IN N
4 CD N
hours NNS N
post-dose JJ N
for IN N
60 CD N
mg NN N
, , N
and CC N
2.3 CD N
milliseconds NNS N
with IN N
90 CD N
% NN N
CI NNP N
of IN N
0 CD N
and CC N
4.7 CD N
milliseconds NNS N
at IN N
1 CD N
hour NN N
post-dose NN N
for IN N
180 CD N
mg NN N
. . N

The DT N
results NNS N
were VBD N
essentially RB N
the DT N
same JJ N
in IN N
the DT N
sex NN N
subgroup NN N
analysis NN N
. . N

Moxifloxacin NNP N
can MD N
be VB N
used VBN N
as IN N
a DT N
positive JJ N
control NN N
for IN N
QT/QTc NNP N
studies NNS N
in IN N
Japanese JJ N
subjects NNS N
; : N
and CC N
topiroxostat VB N
may MD N
not RB N
cause VB N
QT-interval JJ N
prolongation NN N
in IN N
males NNS N
as RB N
well RB N
as IN N
females NNS N
. . N

-DOCSTART- -X- O O

Lactobacillus NNP N
plantarum NN N
CECT7315 NNP N
and CC N
CECT7316 NNP N
stimulate VBP N
immunoglobulin NN N
production NN N
after IN N
influenza JJ 4_p
vaccination NN 4_p
in IN N
elderly JJ 1_p
. . N

OBJECTIVE IN N
The DT N
effectiveness NN N
of IN N
influenza JJ N
vaccination NN N
in IN N
preventing VBG N
illness NN N
is VBZ N
lower RBR N
in IN N
the DT N
elderly JJ N
; : N
this DT N
is VBZ N
why WRB N
the DT N
ability NN N
of IN N
Lactobacillus NNP N
plantarum NN N
CECT NNP N
7315/7316 CD N
to TO N
stimulate VB N
the DT N
response NN N
to TO N
influenza VB 4_p
vaccination NN 4_p
in IN N
elderly JJ 1_p
was VBD N
evaluated VBN N
. . N

RESEARCH NNP N
METHODS NNP N
AND NNP N
PROCEDURES NNP N
A NNP N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
human JJ N
trial NN N
including VBG N
60 CD 3_p
institutionalized JJ N
volunteers NNS N
aged VBN N
65-85 CD 1_p
years NNS N
was VBD N
performed VBN N
. . N

All PDT N
the DT N
volunteers NNS N
were VBD N
vaccinated VBN N
with IN N
a DT N
trivalent JJ N
influenza NN N
vaccine NN N
( ( N
A/Wisconsin/67/2005 NNP N
NYMC NNP N
X-161B NNP N
( ( N
H3N2 NNP N
) ) N
, , N
A/Solomon NNP N
Islands/3/2006 NNP N
( ( N
H1N1 NNP N
) ) N
and CC N
B/Malaysia/2506/2004 NNP N
) ) N
for IN N
the DT N
Spanish JJ N
vaccine NN N
campaign NN N
2006/2007 CD N
. . N

The DT N
consumption NN N
of IN N
the DT N
probiotic JJ N
began VBD N
between IN N
three CD N
and CC N
four CD N
months NNS N
after IN N
the DT N
vaccination NN N
. . N

Volunteers NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
three CD N
following VBG N
groups NNS N
: : N
group NN N
A NNP N
( ( N
receiving VBG N
5*10 CD N
( ( N
9 CD N
) ) N
cfu/day NN N
of IN N
L. NNP N
plantarum NN N
CECT NNP N
7315/7316 CD N
in IN N
20 CD N
g NN N
powdered VBD N
skim JJ N
milk NN N
) ) N
, , N
group NN N
B NNP N
( ( N
receiving VBG N
5*10 CD N
( ( N
8 CD N
) ) N
cfu/day NN N
of IN N
L. NNP N
plantarum NN N
CECT NNP N
7315/7316 CD N
in IN N
20 CD N
g NN N
powdered VBD N
skim JJ N
milk NN N
) ) N
and CC N
group NN N
C NNP N
or CC N
placebo NN N
( ( N
20 CD N
g NN N
powered VBN N
skim JJ N
milk NN N
) ) N
. . N

The DT N
participants NNS N
consumed VBD N
the DT N
probiotic JJ N
during IN N
3 CD N
months NNS N
. . N

RESULTS VB N
The DT N
consumption NN N
of IN N
L. NNP N
plantarum NN N
CECT NNP N
7315/7316 CD N
during IN N
3 CD N
months NNS N
after IN N
influenza JJ N
vaccination NN N
increased VBD N
the DT N
levels NNS N
of IN N
influenza-specific JJ N
IgA NNP N
and CC N
IgG NNP N
antibodies NNS N
. . N

Moreover RB N
, , N
a DT N
trend NN N
towards IN N
an DT N
increase NN N
in IN N
influenza-specific JJ N
IgM NNP N
antibodies NNS N
was VBD N
also RB N
observed VBN N
. . N

CONCLUSION NNP N
L. NNP N
plantarum NN N
CECT7315/7316 NNP N
has VBZ N
an DT N
immunostimulating JJ N
effect NN N
and CC N
could MD N
be VB N
used VBN N
to TO N
improve VB N
the DT N
response NN N
to TO N
influenza VB N
vaccination NN N
in IN N
elderly JJ N
. . N

-DOCSTART- -X- O O

Multiple JJ N
courses NNS N
of IN N
rituximab NN N
produce NN N
sustained VBD N
clinical JJ N
and CC N
radiographic JJ N
efficacy NN N
and CC N
safety NN N
in IN N
patients NNS N
with IN N
rheumatoid JJ 4_p
arthritis NN 4_p
and CC N
an DT N
inadequate JJ N
response NN N
to TO N
1 CD N
or CC N
more JJR N
tumor JJ N
necrosis NN N
factor NN N
inhibitors NNS N
: : N
5-year JJ N
data NNS N
from IN N
the DT N
REFLEX NNP N
study NN N
. . N

OBJECTIVE VB N
This DT N
5-year JJ N
observational JJ N
posthoc NN N
analysis NN N
of IN N
the DT N
REFLEX NNP N
study NN N
and CC N
its PRP$ N
open-label JJ N
extension NN N
assessed VBD N
clinical JJ N
efficacy NN N
, , N
radiographic JJ N
response NN N
, , N
and CC N
safety NN N
of IN N
rituximab NN N
( ( N
RTX NNP N
) ) N
in IN N
patients NNS N
with IN N
rheumatoid JJ N
arthritis NN N
( ( N
RA NNP 4_p
) ) N
who WP N
had VBD N
an DT N
inadequate JJ N
response NN N
to TO N
tumor VB N
necrosis NN N
factor NN N
( ( N
TNF NNP N
) ) N
inhibitors NNS N
. . N

METHODS NNP N
Patients NNPS N
in IN N
REFLEX NNP N
were VBD N
originally RB N
randomized VBN N
to TO N
placebo VB N
( ( N
PBO NNP N
) ) N
+ NN N
methotrexate NN N
( ( N
MTX NNP N
; : N
PBO-randomized NNP N
) ) N
or CC N
RTX NNP N
+ NNP N
MTX NNP N
( ( N
RTX-randomized NNP N
) ) N
. . N

PBO-randomized JJ N
patients NNS N
were VBD N
rescued VBN N
with IN N
RTX NNP N
as IN N
appropriate JJ N
. . N

Patients NNS N
responding VBG N
to TO N
initial JJ N
RTX NNP N
treatment NN N
could MD N
receive VB N
further JJ N
RTX NNP N
courses NNS N
. . N

For IN N
clinical JJ N
efficacy NN N
and CC N
safety NN N
analyses NNS N
, , N
PBO-randomized JJ N
patients NNS N
were VBD N
re-baselined JJ N
prior NN N
to TO N
first JJ N
RTX NNP N
treatment NN N
and CC N
the DT N
data NNS N
were VBD N
pooled VBN N
with IN N
RTX-randomized JJ N
patient NN N
data NNS N
. . N

Efficacy NNP N
outcomes RB N
24 CD N
weeks NNS N
after IN N
each DT N
course NN N
were VBD N
calculated VBN N
relative JJ N
to TO N
first JJ N
RTX NNP N
pretreatment NN N
baseline NN N
. . N

Radiographic JJ N
outcomes NNS N
were VBD N
assessed VBN N
relative JJ N
to TO N
randomization VB N
baseline NN N
for IN N
both DT N
PBO-randomized NNP N
and CC N
RTX-randomized NNP N
groups NNS N
. . N

RESULTS VB N
A DT N
total NN N
of IN N
480 CD N
patients NNS N
received VBN N
? . N
1 CD N
RTX NNP N
course NN N
. . N

At IN N
24 CD N
weeks NNS N
, , N
American NNP N
College NNP N
of IN N
Rheumatology NNP N
20/50/70 CD N
responses NNS N
were VBD N
62.0 CD N
% NN N
, , N
30.8 CD N
% NN N
, , N
and CC N
13.0 CD N
% NN N
, , N
respectively RB N
at IN N
course NN N
1 CD N
( ( N
n JJ N
= NNP N
400 CD N
) ) N
and CC N
70.3 CD N
% NN N
, , N
41.8 CD N
% NN N
, , N
and CC N
22.0 CD N
% NN N
at IN N
course NN N
5 CD N
( ( N
n JJ N
= NNP N
91 CD N
) ) N
. . N

European JJ N
League NNP N
Against NNP N
Rheumatism NNP N
good/moderate NN N
responses NNS N
were VBD N
77.2 CD N
% NN N
and CC N
84.4 CD N
% NN N
at IN N
courses NNS N
1 CD N
( ( N
n JJ N
= NNP N
390 CD N
) ) N
and CC N
5 CD N
( ( N
n JJ N
= NNP N
90 CD N
) ) N
. . N

Rates NNS N
of IN N
adverse JJ N
events NNS N
( ( N
AE NNP N
) ) N
, , N
serious JJ N
AE NNP N
, , N
and CC N
infections NNS N
generally RB N
remained VBD N
stable JJ N
. . N

Rate NNP N
of IN N
progressive JJ N
joint JJ N
damage NN N
( ( N
PJD NNP N
; : N
change NN N
in IN N
mean JJ N
Total NNP N
Sharp NNP N
Score NNP N
) ) N
decreased VBD N
over RP N
time NN N
in IN N
both DT N
PBO-randomized NNP N
( ( N
n JJ N
= NNP N
79 CD N
) ) N
and CC N
RTX-randomized NNP N
( ( N
n JJ N
= NNP N
105 CD N
) ) N
groups NNS N
. . N

Mean JJ N
change NN N
from IN N
baseline NN N
in IN N
PJD NNP N
over IN N
5 CD N
years NNS N
was VBD N
greater JJR N
in IN N
PBO-randomized NNP N
versus NN N
RTX-randomized JJ N
patients NNS N
( ( N
5.51 CD N
vs RB N
3.21 CD N
) ) N
. . N

CONCLUSION NNP N
RTX NNP N
re-treatment NN N
over IN N
5 CD N
years NNS N
is VBZ N
associated VBN N
with IN N
maintained VBN N
or CC N
improved VBN N
efficacy NN N
, , N
continued VBD N
inhibition NN N
of IN N
PJD NNP N
, , N
and CC N
a DT N
safety NN N
profile NN N
consistent JJ N
with IN N
that DT N
previously RB N
reported VBN N
. . N

A DT N
delay NN N
in IN N
initiating VBG N
RTX NNP N
treatment NN N
may MD N
result VB N
in IN N
increased JJ N
PJD NNP N
. . N

-DOCSTART- -X- O O

Gefitinib NNP N
plus CC N
best JJS N
supportive JJ N
care NN N
in IN N
previously RB N
treated VBN N
patients NNS N
with IN N
refractory JJ 4_p
advanced JJ 4_p
non-small-cell JJ 4_p
lung NN 4_p
cancer NN 4_p
: : N
results NNS N
from IN N
a DT N
randomised VBN N
, , N
placebo-controlled JJ N
, , N
multicentre JJ N
study NN N
( ( N
Iressa NNP N
Survival NNP N
Evaluation NNP N
in IN N
Lung NNP N
Cancer NNP N
) ) N
. . N

BACKGROUND VB N
This DT N
placebo-controlled JJ N
phase NN N
III NNP N
study NN N
investigated VBD N
the DT N
effect NN N
on IN N
survival NN N
of IN N
gefitinib NN N
as IN N
second-line JJ N
or CC N
third-line JJ N
treatment NN N
for IN N
patients NNS N
with IN N
locally RB 4_p
advanced JJ 4_p
or CC 4_p
metastatic JJ 4_p
non-small-cell JJ 4_p
lung NN 4_p
cancer NN 4_p
. . N

METHODS NNP N
1692 CD 3_p
patients NNS N
who WP N
were VBD N
refractory JJ 4_p
to TO 4_p
or CC 4_p
intolerant VB 4_p
of IN N
their PRP$ N
latest JJS 4_p
chemotherapy NN 4_p
regimen NNS N
were VBD N
randomly RB N
assigned VBN N
in IN N
a DT N
ratio NN N
of IN N
two CD N
to TO N
one CD N
either DT N
gefitinib NN N
( ( N
250 CD N
mg/day NN N
) ) N
or CC N
placebo NN N
, , N
plus CC N
best JJS N
supportive JJ N
care NN N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
survival VBN N
in IN N
the DT N
overall JJ N
population NN N
of IN N
patients NNS N
and CC N
those DT N
with IN N
adenocarcinoma NN N
. . N

The DT N
primary JJ N
analysis NN N
of IN N
the DT N
population NN N
for IN N
survival NN N
was VBD N
by IN N
intention NN N
to TO N
treat VB N
. . N

This DT N
study NN N
has VBZ N
been VBN N
submitted VBN N
for IN N
registration NN N
with IN N
ClinicalTrials.gov NNP N
, , N
number NN N
1839IL/709 CD N
. . N

FINDINGS JJ N
1129 CD 3_p
patients NNS N
were VBD N
assigned VBN N
gefitinib NNS N
and CC N
563 CD 3_p
placebo NN N
. . N

At IN N
median JJ N
follow-up NN N
of IN N
7.2 CD N
months NNS N
, , N
median JJ N
survival NN N
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
the DT N
groups NNS N
in IN N
the DT N
overall JJ N
population NN N
( ( N
5.6 CD N
months NNS N
for IN N
gefitinib NN N
and CC N
5.1 CD N
months NNS N
for IN N
placebo NN N
; : N
hazard CC N
ratio VB N
0.89 CD N
[ JJ N
95 CD N
% NN N
CI NNP N
0.77-1.02 CD N
] NNP N
, , N
p=0.087 NN N
) ) N
or CC N
among IN N
the DT N
812 CD 3_p
patients NNS N
with IN N
adenocarcinoma NN 4_p
( ( N
6.3 CD N
months NNS N
vs RB N
5.4 CD N
months NNS N
; : N
0.84 CD N
[ IN N
0.68-1.03 JJ N
] NN N
, , N
p=0.089 NN N
) ) N
. . N

Preplanned VBN N
subgroup NN N
analyses VBZ N
showed VBN N
significantly RB N
longer RBR N
survival NN N
in IN N
the DT N
gefitinib NN N
group NN N
than IN N
the DT N
placebo NN N
group NN N
for IN N
never-smokers NNS N
( ( N
n=375 NN N
; : N
0.67 CD N
[ IN N
0.49-0.92 JJ N
] NN N
, , N
p=0.012 NN N
; : N
median JJ N
survival NN N
8.9 CD N
vs NN N
6.1 CD N
months NNS N
) ) N
and CC N
patients NNS N
of IN N
Asian JJ N
origin NN N
( ( N
n=342 JJ N
; : N
0.66 CD N
[ IN N
0.48-0.91 JJ N
] NN N
, , N
p=0.01 NN N
; : N
median JJ N
survival NN N
9.5 CD N
vs NN N
5.5 CD N
months NNS N
) ) N
. . N

Gefitinib NNP N
was VBD N
well RB N
tolerated VBN N
, , N
as IN N
in IN N
previous JJ N
studies NNS N
. . N

INTERPRETATION NNP N
Treatment NNP N
with IN N
gefitinib NN N
was VBD N
not RB N
associated VBN N
with IN N
significant JJ N
improvement NN N
in IN N
survival NN N
in IN N
either DT N
coprimary JJ N
population NN N
. . N

There EX N
was VBD N
pronounced JJ N
heterogeneity NN N
in IN N
survival JJ N
outcomes NNS N
between IN N
groups NNS N
of IN N
patients NNS N
, , N
with IN N
some DT N
evidence NN N
of IN N
benefit NN N
among IN N
never-smokers NNS N
and CC N
patients NNS N
of IN N
Asian JJ N
origin NN N
. . N

-DOCSTART- -X- O O

Human NNP N
recombinant JJ N
GM-CSF NNP N
in IN N
allogeneic JJ N
bone NN N
marrow NN N
transplantation NN N
for IN N
leukaemia NN N
: : N
double-blind JJ N
placebo NN N
controlled VBN N
trial NN N
. . N

A DT N
double-blind NN N
randomised VBN N
trial NN N
compared VBN N
20 CD 3_p
patients NNS N
with IN N
leukaemia JJ 4_p
receiving VBG N
human JJ N
recombinant JJ N
granulocyte NN N
macrophage NN N
colony NN N
stimulating VBG N
factor NN N
( ( N
GM NNP N
CSF NNP N
) ) N
, , N
with IN N
20 CD 3_p
patients NNS N
receiving VBG N
placebo NN N
for IN N
14 CD N
days NNS N
after IN N
allogeneic JJ N
matched VBD N
sibling VBG N
bone NN N
marrow NN N
transplantation NN N
. . N

The DT N
median JJ N
neutrophil NN N
count NN N
at IN N
14 CD N
days NNS N
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
GM NNP N
CSF NNP N
group NN N
( ( N
1.90 CD N
vs. FW N
0.46 CD N
x $ N
10 CD N
( ( N
9 CD N
) ) N
/l NN N
) ) N
. . N

The DT N
duration NN N
of IN N
hospital NN N
stay NN N
, , N
the DT N
number NN N
of IN N
antibiotic JJ N
days NNS N
, , N
and CC N
the DT N
number NN N
of IN N
fever JJ N
days NNS N
was VBD N
the DT N
same JJ N
for IN N
both DT N
patient JJ N
groups NNS N
. . N

The DT N
lymphocyte NN N
count NN N
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
GM-CSF NNP N
group NN N
than IN N
in IN N
the DT N
placebo NN N
group NN N
between IN N
days NNS N
10 CD N
and CC N
15 CD N
after IN N
transplantation NN N
. . N

The DT N
GM-CSF NNP N
group NN N
had VBD N
lower JJR N
haemoglobin NN N
concentrations NNS N
and CC N
platelets NNS N
counts NNS N
, , N
and CC N
higher JJR N
plasma NN N
urea JJ N
creatinine NN N
and CC N
bilirubin NN N
, , N
than IN N
the DT N
placebo NN N
group NN N
. . N

There EX N
was VBD N
no DT N
evidence NN N
that IN N
GM NNP N
CSF NNP N
was VBD N
associated VBN N
with IN N
a DT N
greater JJR N
incidence NN N
of IN N
leukaemic JJ N
relapse NN N
. . N

-DOCSTART- -X- O O

Olanzapine NNP N
versus NN N
haloperidol NN N
in IN N
children NNS 1_p
with IN N
autistic JJ 4_p
disorder NN 4_p
: : N
an DT N
open JJ N
pilot NN N
study NN N
. . N

OBJECTIVES NNP N
Conventional NNP N
neuroleptics NNS N
ameliorate VBP N
symptoms NNS N
in IN N
children NNS 1_p
with IN N
autistic JJ 4_p
disorder NN 4_p
; : N
however RB N
, , N
they PRP N
are VBP N
known VBN N
to TO N
cause VB N
dyskinesias NN N
. . N

Atypical JJ N
neuroleptics NNS N
, , N
including VBG N
olanzapine NN N
, , N
may MD N
have VB N
less JJR N
risk NN N
for IN N
dyskinesia NN N
, , N
but CC N
their PRP$ N
efficacy NN N
in IN N
autistic JJ N
disorder NN N
is VBZ N
not RB N
established VBN N
. . N

This DT N
study NN N
was VBD N
designed VBN N
to TO N
investigate VB N
the DT N
safety NN N
and CC N
effectiveness NN N
of IN N
open-label JJ N
olanzapine NN N
as IN N
a DT N
treatment NN N
for IN N
children NNS 1_p
with IN N
autistic JJ 4_p
disorder NN 4_p
by IN N
using VBG N
haloperidol NN N
as IN N
a DT N
standard JJ N
comparator NN N
treatment NN N
. . N

METHOD NNP N
In IN N
a DT N
parallel JJ N
groups NNS N
design NN N
, , N
12 CD 3_p
children NNS 1_p
with IN N
DSM-IV NNP 4_p
autistic JJ 4_p
disorder NN 4_p
( ( N
mean JJ N
age NN N
7.8+/-2.1 CD 1_p
years NNS N
) ) N
were VBD N
randomized VBN N
to TO N
6 CD N
weeks NNS N
of IN N
open JJ N
treatment NN N
with IN N
olanzapine NN N
or CC N
haloperidol NN N
. . N

Mean NNP N
final JJ N
dosages NNS N
were VBD N
7.9+/-2.5 JJ N
mg/day NN N
for IN N
olanzapine NN N
and CC N
1.4+/-0.7 JJ N
mg/day NN N
for IN N
haloperidol NN N
. . N

Outcome NNP N
measures NNS N
included VBD N
the DT N
Clinical NNP N
Global NNP N
Impressions NNP N
( ( N
CGI NNP N
) ) N
and CC N
the DT N
Children NNP N
's POS N
Psychiatric NNP N
Rating NNP N
Scale NNP N
( ( N
CPRS NNP N
) ) N
. . N

RESULTS NNP N
Both NNP N
groups NNS N
had VBD N
symptom VBN N
reduction NN N
. . N

Five CD N
of IN N
six CD N
in IN N
the DT N
olanzapine NN N
group NN N
and CC N
three CD N
of IN N
six CD N
in IN N
the DT N
haloperidol NN N
group NN N
were VBD N
rated VBN N
as IN N
responders NNS N
according VBG N
to TO N
the DT N
CGI NNP N
Improvement NNP N
item NN N
. . N

Subjects NNS N
showed VBD N
improvement NN N
on IN N
the DT N
CPRS NNP N
Autism NNP N
Factor NNP N
( ( N
F1,9 NNP N
= NNP N
24.4 CD N
, , N
p NN N
= NNP N
.0008 NNP N
) ) N
. . N

Side JJ N
effects NNS N
included VBD N
drowsiness NN N
and CC N
weight JJ N
gain NN N
. . N

CONCLUSIONS VB N
The DT N
findings NNS N
suggest VBP N
that IN N
olanzapine NN N
is VBZ N
a DT N
promising JJ N
treatment NN N
for IN N
children NNS 1_p
with IN N
autistic JJ 4_p
disorder NN 4_p
. . N

Further JJ N
placebo-controlled JJ N
and CC N
long-term JJ N
studies NNS N
of IN N
olanzapine NN N
in IN N
autistic JJ N
disorder NN N
are VBP N
required VBN N
. . N

-DOCSTART- -X- O O

Evaluation NN N
of IN N
reducing VBG N
postoperative JJ N
hip NN N
precautions NNS N
in IN N
total JJ 4_p
hip JJ 4_p
replacement NN 4_p
: : N
a DT N
randomized JJ N
prospective JJ N
study NN N
. . N

Currently NNP N
, , N
many JJ N
rehabilitation NN N
protocols NNS N
for IN N
total JJ N
hip NN N
replacements NNS N
( ( N
THRs NNP N
) ) N
include VBP N
activity NN N
restrictions NNS N
to TO N
prevent VB N
postoperative JJ N
dislocation NN N
. . N

There EX N
is VBZ N
increasing VBG N
demand NN N
for IN N
more RBR N
efficient JJ N
and CC N
safe JJ N
rehabilitation NN N
protocols NNS N
. . N

This DT N
randomized JJ N
prospective JJ N
study NN N
evaluates VBZ N
the DT N
need NN N
for IN N
hip NN N
restrictions NNS N
following VBG N
a DT N
modified JJ N
anterolateral JJ N
procedure NN N
. . N

From IN N
2004 CD N
to TO N
2008 CD N
, , N
81 CD 3_p
patients NNS N
seeking VBG N
elective JJ N
THRs NNP N
were VBD N
randomly RB N
assigned VBN N
into IN N
a DT N
standard JJ N
rehabilitation NN N
group NN N
or CC N
an DT N
early JJ N
rehabilitation NN N
group NN N
. . N

The DT N
standard JJ N
group NN N
included VBD N
restrictions NNS N
to TO N
avoid VB N
hip NN N
flexion NN N
> VBD N
90 CD N
degrees NNS N
and CC N
avoidance NN N
of IN N
riding VBG N
in IN N
a DT N
car NN N
for IN N
the DT N
first JJ N
postoperative JJ N
month NN N
. . N

The DT N
early JJ N
group NN N
had VBD N
no DT N
flexion NN N
or CC N
car NN N
riding NN N
restrictions NNS N
. . N

Forty-three JJ 3_p
patients NNS N
were VBD N
in IN N
the DT N
standard JJ N
group NN N
and CC N
38 CD 3_p
patients NNS N
were VBD N
in IN N
the DT N
early JJ N
group NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
demographic JJ N
differences NNS N
between IN N
the DT N
2 CD N
groups NNS N
. . N

All DT N
patients NNS N
completed VBD N
the DT N
Short JJ N
Form NNP N
12-question JJ N
Health NNP N
Survey NNP N
and CC N
Harris NNP N
Hip NNP N
Score NNP N
preoperatively RB N
and CC N
at IN N
4 CD N
weeks NNS N
, , N
1 CD N
month NN N
, , N
3 CD N
months NNS N
, , N
and CC N
1 CD N
year NN N
postoperatively RB N
. . N

The DT N
time-points NNS N
at IN N
which WDT N
the DT N
patient NN N
first RB N
drove VBD N
and CC N
ambulated VBD N
with IN N
a DT N
cane NN N
, , N
without IN N
a DT N
cane NN N
, , N
and CC N
without IN N
a DT N
limp NN N
were VBD N
also RB N
collected VBN N
. . N

No DT N
incidents NNS N
of IN N
dislocation NN N
occurred VBD N
. . N

Patients NNS N
in IN N
the DT N
early JJ N
group NN N
were VBD N
faster JJR N
to TO N
ambulate VB N
with IN N
only RB N
a DT N
cane NN N
( ( N
P=.03 NNP N
) ) N
, , N
without IN N
a DT N
cane NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
and CC N
without IN N
a DT N
limp NN N
( ( N
P=.003 NNP N
) ) N
. . N

They PRP N
also RB N
drove VBD N
earlier RBR N
( ( N
P=.02 NNP N
) ) N
. . N

Pace NN N
of IN N
recovery NN N
was VBD N
the DT N
only JJ N
significant JJ N
difference NN N
between IN N
the DT N
2 CD N
groups NNS N
. . N

The DT N
early JJ N
rehabilitation NN N
protocol NN N
increases VBZ N
the DT N
pace NN N
of IN N
recovery NN N
compared VBN N
to TO N
a DT N
pathway NN N
with IN N
hip NN N
precautions NNS N
without IN N
increasing VBG N
complications NNS N
. . N

-DOCSTART- -X- O O

Use NNP N
and CC N
limitations NNS N
of IN N
Holter NNP N
electrocardiography NN N
in IN N
assessing VBG N
drug NN N
therapy NN N
of IN N
myocardial JJ 4_p
ischemia NN 4_p
during IN N
the DT N
peri-PTCA JJ 4_p
period NN N
. . N

Incidence NN N
and CC N
pattern NN N
of IN N
myocardial JJ N
ischemia NN N
during IN N
the DT N
peri-PTCA JJ 4_p
( ( N
percutaneous JJ 4_p
transluminal JJ 4_p
coronary JJ 4_p
angioplasty NN 4_p
) ) N
period NN N
and CC N
the DT N
possible JJ N
role NN N
of IN N
continuous JJ N
intravenous JJ N
isosorbide NN N
dinitrate NN N
in IN N
its PRP$ N
prevention NN N
were VBD N
examined VBN N
prospectively RB N
in IN N
30 CD 3_p
patients NNS N
. . N

Holter NNP N
electrocardiographic JJ N
monitoring NN N
was VBD N
performed VBN N
for IN N
21 CD N
+/- JJ N
3 CD N
h NN N
before IN N
PTCA NNP N
and CC N
continued VBN N
during IN N
and CC N
for IN N
41 CD N
+/- JJ N
8 CD N
h NN N
after IN N
the DT N
procedure NN N
. . N

Before IN N
PTCA NNP N
, , N
19 CD N
ischemic JJ N
episodes NNS N
were VBD N
present JJ N
in IN N
10 CD N
( ( N
33 CD N
% NN N
) ) N
of IN N
30 CD 3_p
patients NNS N
. . N

PTCA NNP N
produced VBD N
an DT N
abrupt JJ N
decrease NN N
in IN N
number NN N
( ( N
p JJ N
= NNP N
0.015 CD N
) ) N
and CC N
duration NN N
( ( N
p JJ N
= NNP N
0.03 CD N
) ) N
of IN N
spontaneous JJ N
ischemic JJ N
episodes NNS N
. . N

The DT N
rarity NN N
of IN N
recurrent JJ N
myocardial JJ N
ischemic JJ N
events NNS N
by IN N
Holter NNP N
monitoring NN N
after IN N
PTCA NNP N
negated VBD N
any DT N
attempt NN N
at IN N
assessing VBG N
the DT N
efficacy NN N
of IN N
intravenous JJ N
isosorbide JJ N
dinitrate NN N
in IN N
their PRP$ N
prevention NN N
. . N

Holter NNP N
monitoring NN N
could MD N
not RB N
be VB N
used VBN N
as IN N
an DT N
early JJ N
predictor NN N
of IN N
late JJ N
coronary JJ N
restenosis NN N
. . N

-DOCSTART- -X- O O

Simvastatin NNP N
reduces VBZ N
sympathetic JJ N
outflow NN N
and CC N
augments NNS N
endothelium-independent JJ N
dilation NN N
in IN N
non-hyperlipidaemic JJ 4_p
primary JJ 4_p
hypertension NN 4_p
. . N

OBJECTIVES NNP N
Previous JJ N
reports NNS N
, , N
involving VBG N
hypercholesterolaemic JJ N
hypertensive JJ N
subjects NNS N
, , N
that IN N
statins VBZ N
reduce VB N
muscle NN N
sympathetic JJ N
nerve NN N
activity NN N
( ( N
MSNA NNP N
) ) N
did VBD N
not RB N
investigate VB N
potential JJ N
neural JJ N
sites NNS N
of IN N
such JJ N
sympathoinhibition NN N
or CC N
determine VB N
its PRP$ N
consequences NNS N
for IN N
endothelial JJ N
function NN N
or CC N
insulin NN N
resistance NN N
. . N

This DT N
study NN N
of IN N
hypertensive JJ 4_p
subjects NNS 4_p
with IN 4_p
lower JJR 4_p
plasma NN 4_p
cholesterol NN 4_p
tested VBD N
the DT N
hypotheses NNS N
that WDT N
lipophilic JJ N
simvastatin NN N
would MD N
attenuate VB N
resting VBG N
sympathoexcitation NN N
and CC N
augment NN N
baroreflex JJ N
modulation NN N
of IN N
MSNA NNP N
and CC N
heart NN N
rate NN N
( ( N
HR NNP N
) ) N
, , N
flow-mediated JJ N
vasodilation NN N
and CC N
insulin NN N
sensitivity NN N
. . N

DESIGN NNP N
Prospective NNP N
, , N
randomised VBD N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
crossover NN N
study NN N
. . N

SETTING NNP N
Academic NNP N
hospital-based JJ N
study NN N
. . N

PATIENTS NNP N
Fourteen JJ N
non-hyperlipidaemic JJ N
primary JJ N
hypertensive JJ N
subjects NNS N
( ( N
10 CD N
men NNS N
; : N
overall JJ N
mean?SD NN N
age NN N
58?12 CD N
years NNS N
) ) N
. . N

INTERVENTIONS NNP N
Four NNP N
weeks NNS N
of IN N
simvastatin NN N
( ( N
80 CD N
mg/day NN N
) ) N
or CC N
placebo NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Resting NNP N
blood NN N
pressure NN N
( ( N
BP NNP N
) ) N
, , N
HR NNP N
, , N
MSNA NNP N
, , N
spontaneous JJ N
arterial JJ N
baroreflex NN N
MSNA NNP N
and CC N
HR NNP N
modulation NN N
, , N
endothelium-dependent JJ N
and CC N
endothelium-independent JJ N
vasodilation NN N
, , N
and CC N
the DT N
homoeostatic JJ N
model NN N
assessment NN N
of IN N
insulin NN N
resistance NN N
( ( N
HOMA-IR NNP N
) ) N
. . N

RESULTS NNP N
Simvastatin NNP N
lowered VBD N
MSNA NNP N
burst JJ N
frequency NN N
( ( N
from IN N
32?12 CD N
to TO N
25?9 CD N
bursts/min NN N
) ) N
and CC N
MSNA NNP N
burst NN N
incidence NN N
( ( N
from IN N
55?23 CD N
% NN N
to TO N
43?17 CD N
% NN N
; : N
all DT N
p VBP N
< $ N
0.01 CD N
) ) N
without IN N
affecting VBG N
BP NNP N
, , N
HR NNP N
, , N
baroreflex JJ N
modulation NN N
of IN N
either DT N
MSNA NNP N
or CC N
HR NNP N
, , N
or CC N
HR NNP N
variability NN N
( ( N
all DT N
p VBP N
> $ N
0.05 CD N
) ) N
. . N

Plasma NNP N
glucose NN N
, , N
insulin NN N
, , N
HOMA-IR NNP N
and CC N
endothelium-dependent JJ N
vasodilation NN N
( ( N
all DT N
p VBP N
> $ N
0.05 CD N
) ) N
were VBD N
unchanged JJ N
, , N
whereas JJ N
endothelium-independent JJ N
vasodilation NN N
increased VBD N
( ( N
7.1?3.8 CD N
% NN N
to TO N
9.7?3.9 CD N
% NN N
, , N
n=13 RB N
; : N
p VB N
< $ N
0.01 CD N
) ) N
. . N

The DT N
fall NN N
in IN N
MSNA NNP N
was VBD N
unrelated JJ N
to TO N
the DT N
decrease NN N
in IN N
low-density NN N
lipoprotein NN N
cholesterol NN N
( ( N
r=0.41 NN N
, , N
p=0.14 NN N
) ) N
. . N

CONCLUSIONS NNP N
These DT N
findings NNS N
are VBP N
consistent JJ N
with IN N
the DT N
concept NN N
that IN N
, , N
in IN N
non-hyperlipidaemic JJ N
subjects NNS N
with IN N
primary JJ N
hypertension NN N
, , N
simvastatin JJ N
causes VBZ N
a DT N
cholesterol-independent JJ N
reduction NN N
in IN N
an DT N
elevated JJ N
central JJ N
set-point NN N
for IN N
MSNA NNP N
, , N
without IN N
affecting VBG N
arterial JJ N
baroreflex JJ N
modulation NN N
of IN N
either DT N
MSNA NNP N
or CC N
HR NNP N
. . N

There EX N
may MD N
be VB N
less JJR N
neurogenic JJ N
constraint NN N
on IN N
endothelium-independent JJ N
vasodilation NN N
as IN N
a DT N
consequence NN N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
a DT N
leisure NN N
programme NN N
on IN N
quality NN N
of IN N
life NN N
and CC N
stress NN N
of IN N
individuals NNS N
with IN N
ASD NNP 4_p
. . N

BACKGROUND NNP N
Even RB N
though IN N
there EX N
is VBZ N
research NN N
demonstrating VBG N
a DT N
positive JJ N
relationship NN N
between IN N
leisure NN N
participation NN N
and CC N
the DT N
two CD N
constructs NNS N
of IN N
quality NN N
of IN N
life NN N
and CC N
stress NN N
reduction NN N
, , N
current JJ N
conceptualisation NN N
of IN N
leisure NN N
as IN N
a DT N
contributor NN N
to TO N
quality NN N
of IN N
life NN N
is VBZ N
limited VBN N
. . N

In IN N
addition NN N
, , N
in IN N
spite NN N
of IN N
improvements NNS N
in IN N
accurate JJ N
diagnosis NN N
of IN N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
( ( N
ASD NNP N
) ) N
at IN N
increasingly RB N
earlier JJR N
ages NNS N
and CC N
proliferation NN N
of IN N
interventions NNS N
, , N
research NN N
associated VBN N
with IN N
leisure NN N
and CC N
quality NN N
of IN N
life NN N
for IN N
people NNS N
with IN N
ASD NNP N
is VBZ N
lacking VBG N
. . N

METHODS NNP N
Therefore NNP N
, , N
a DT N
study NN N
using VBG N
a DT N
repeated JJ N
measures NNS N
design NN N
was VBD N
used VBN N
to TO N
measure VB N
effects NNS N
of IN N
a DT N
1-year JJ N
group NN N
leisure NN N
programme NN N
intended VBN N
to TO N
facilitate VB N
interaction NN N
with IN N
media NNS N
, , N
engagement NN N
in IN N
exercise NN N
, , N
playing VBG N
games NNS N
and CC N
doing VBG N
crafts NNS N
, , N
attending VBG N
events NNS N
, , N
and CC N
participating VBG N
in IN N
other JJ N
recreation NN N
activities NNS N
on IN N
quality NN N
of IN N
life NN N
and CC N
stress NN N
of IN N
37 CD 3_p
participants NNS N
( ( N
22 CD 3_p
male NN 2_p
, , N
15 CD 3_p
female NN 2_p
) ) N
, , N
ages VBZ N
17-39 JJ 1_p
( ( N
M NNP N
= NNP N
31.49 CD 1_p
) ) N
years NNS N
at IN N
the DT N
beginning NN N
of IN N
the DT N
programme NN N
) ) N
diagnosed VBD N
with IN N
an DT N
ASD NNP N
and CC N
a DT N
group NN N
of IN N
34 CD 3_p
adults NNS N
with IN N
ASD NNP N
as IN N
control NN N
group NN N
( ( N
waiting VBG N
list NN N
) ) N
( ( N
19 CD 3_p
male NN 2_p
, , N
15 CD 3_p
female NN 2_p
) ) N
, , N
ages VBZ N
24-38 JJ 1_p
( ( N
M NNP N
= VBZ N
30 CD 1_p
at IN N
programme JJ N
initiation NN N
) ) N
years NNS N
. . N

RESULTS NNP N
There EX N
was VBD N
a DT N
significant JJ N
decrease NN N
in IN N
overall JJ N
scores NNS N
of IN N
stress NN N
levels NNS N
for IN N
participants NNS N
over IN N
the DT N
course NN N
of IN N
the DT N
study NN N
and CC N
there EX N
was VBD N
a DT N
significant JJ N
increase NN N
in IN N
the DT N
four CD N
factors NNS N
of IN N
quality NN N
of IN N
life NN N
that WDT N
were VBD N
measured VBN N
( ( N
satisfaction NN N
, , N
independence NN N
, , N
competence NN N
and CC N
social JJ N
interaction NN N
) ) N
as RB N
well RB N
as IN N
the DT N
total JJ N
score NN N
for IN N
quality NN N
of IN N
life NN N
from IN N
baseline NN N
to TO N
the DT N
end NN N
of IN N
the DT N
intervention NN N
12 CD N
months NNS N
later RB N
. . N

In IN N
contrast NN N
, , N
the DT N
control NN N
group NN N
demonstrated VBD N
no DT N
significant JJ N
improvements NNS N
related VBN N
to TO N
stress VB N
or CC N
quality NN N
of IN N
life NN N
. . N

Implications NNS N
of IN N
these DT N
findings NNS N
to TO N
leisure VB N
services NNS N
and CC N
the DT N
quality NN N
of IN N
life NN N
of IN N
individuals NNS N
with IN N
ASD NNP N
are VBP N
discussed VBN N
. . N

CONCLUSION NNP N
Findings NNP N
support NN N
the DT N
contention NN N
that WDT N
participation NN N
in IN N
recreation NN N
activities NNS N
positively RB N
influenced VBD N
the DT N
stress NN N
and CC N
quality NN N
of IN N
life NN N
of IN N
adults NNS 1_p
with IN N
ASD NNP N
. . N

-DOCSTART- -X- O O

Margarines NNS N
fortified VBN N
with IN N
?-linolenic JJ N
acid NN N
, , N
eicosapentaenoic JJ N
acid NN N
, , N
or CC N
docosahexaenoic JJ N
acid NN N
alter IN N
the DT N
fatty JJ N
acid JJ N
composition NN N
of IN N
erythrocytes NNS N
but CC N
do VBP N
not RB N
affect VB N
the DT N
antioxidant JJ N
status NN N
of IN N
healthy JJ N
adults NNS N
. . N

We PRP N
aimed VBD N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
increased JJ N
intake NN N
of IN N
?-linolenic JJ N
acid NN N
( ( N
ALA NNP N
) ) N
, , N
EPA NNP N
, , N
or CC N
DHA NNP N
incorporated VBN N
into IN N
a DT N
food NN N
matrix NN N
on IN N
the DT N
fatty JJ N
acid JJ N
composition NN N
of IN N
erythrocytes NNS N
and CC N
on IN N
biomarkers NNS N
of IN N
oxidant/antioxidant JJ N
status NN N
. . N

To TO N
this DT N
end NN N
, , N
a DT N
controlled VBN N
dietary NN N
study NN N
was VBD N
conducted VBN N
in IN N
74 CD N
healthy JJ N
men NNS N
and CC N
women NNS N
. . N

The DT N
participants NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
1 CD N
of IN N
3 CD N
interventions NNS N
in IN N
which WDT N
margarines NNS N
fortified VBD N
with IN N
either DT N
10 CD N
weight NN N
percent NN N
ALA NNP N
, , N
EPA NNP N
, , N
or CC N
DHA NNP N
ethyl VBP N
esters NNS N
replaced VBD N
their PRP$ N
normal JJ N
spread NN N
for IN N
6 CD N
wk NN N
. . N

The DT N
total JJ N
intakes NNS N
of IN N
ALA NNP N
, , N
EPA NNP N
, , N
and CC N
DHA NNP N
were VBD N
4.4 CD N
, , N
2.2 CD N
, , N
and CC N
2.3 CD N
g/d NN N
, , N
respectively RB N
. . N

Consuming VBG N
EPA NNP N
increased VBD N
the DT N
erythrocyte JJ N
proportion NN N
of IN N
EPA NNP N
( ( N
394 CD N
% NN N
) ) N
and CC N
the DT N
omega-3 JJ N
index NN N
( ( N
sum NN N
of IN N
EPA NNP N
and CC N
DHA NNP N
, , N
38 CD N
% NN N
) ) N
. . N

Consumption NN N
of IN N
DHA NNP N
increased VBD N
erythrocyte JJ N
DHA NNP N
( ( N
91 CD N
% NN N
) ) N
, , N
the DT N
omega-3 JJ N
index NN N
( ( N
98 CD N
% NN N
) ) N
, , N
and CC N
EPA NNP N
( ( N
137 CD N
% NN N
) ) N
. . N

The DT N
omega-3 JJ N
index NN N
increased VBD N
to TO N
a DT N
significantly RB N
greater JJR N
extent NN N
in IN N
the DT N
DHA NNP N
group NN N
than IN N
in IN N
the DT N
EPA NNP N
group NN N
. . N

ALA NNP N
did VBD N
not RB N
increase VB N
erythrocyte NN N
EPA NNP N
or CC N
the DT N
omega-3 JJ N
index NN N
. . N

We PRP N
found VBD N
no DT N
change NN N
in IN N
plasma NN N
uric JJ N
acid NN N
or CC N
antioxidant JJ N
capacity NN N
in IN N
any DT N
of IN N
the DT N
groups NNS N
. . N

Plasma NNP N
malondialdehyde NN N
( ( N
MDA NNP N
) ) N
increased VBD N
with IN N
the DT N
EPA NNP N
and CC N
DHA NNP N
interventions NNS N
. . N

All DT N
3 CD N
interventions NNS N
decreased VBD N
erythrocyte JJ N
linoleic NN N
acid NN N
hydroperoxides NNS N
but CC N
did VBD N
not RB N
affect VB N
their PRP$ N
MDA NNP N
concentrations NNS N
. . N

In IN N
conclusion NN N
, , N
the DT N
intake NN N
of IN N
both DT N
isolated JJ N
EPA NNP N
and CC N
DHA NNP N
incorporated VBD N
into IN N
margarine NN N
resulted VBN N
in IN N
an DT N
enhanced JJ N
incorporation NN N
of IN N
EPA NNP N
and CC N
DHA NNP N
into IN N
erythrocytes NNS N
. . N

Our PRP$ N
findings NNS N
indicate VBP N
that IN N
DHA NNP N
is VBZ N
quantitatively RB N
superior JJ N
to TO N
EPA NNP N
in IN N
view NN N
of IN N
the DT N
EPA+DHA NNP N
tissue NN N
incorporation NN N
and CC N
also RB N
that IN N
4 CD N
g/d NN N
ALA NNP N
is VBZ N
not RB N
sufficient JJ N
to TO N
increase VB N
the DT N
omega-3 JJ N
index NN N
over IN N
a DT N
6-wk JJ N
period NN N
. . N

-DOCSTART- -X- O O

A DT N
comparative JJ N
study NN N
of IN N
methyldopa NN N
and CC N
labetalol NN N
in IN N
the DT N
treatment NN N
of IN N
hypertension NN 4_p
. . N

1 CD N
Twenty CD 3_p
patients NNS N
with IN N
essential JJ 4_p
hypertension NN 4_p
completed VBD N
a DT N
double-blind JJ N
, , N
dose-tritrated JJ N
, , N
cross-over JJ N
comparison NN N
of IN N
methyldopa NN N
and CC N
labetalol NN N
. . N

2 CD N
Average JJ N
lying VBG N
BPs NNP N
( ( N
systolic/diastolic JJ N
) ) N
were VBD N
reduced VBN N
by IN N
28/15 CD N
mmHg NNS N
with IN N
methyldopa NN N
and CC N
by IN N
23/15 CD N
mmHg NNS N
with IN N
labetalol NN N
. . N

3 CD N
Average JJ N
standing VBG N
BPs NNP N
( ( N
systolic/diastolic JJ N
) ) N
were VBD N
reduced VBN N
by IN N
29/14 CD N
mmHg NNS N
with IN N
methyldopa NN N
and CC N
by IN N
29/15 CD N
mmHg NNS N
with IN N
labetalol NN N
. . N

4 CD N
Both DT N
lying NN N
and CC N
standing VBG N
heart NN N
rates NNS N
were VBD N
reduced VBN N
with IN N
labetalol NN N
. . N

5 CD N
It PRP N
is VBZ N
concluded VBN N
that IN N
the DT N
antihypertensive JJ N
properties NNS N
of IN N
labetalol NN N
and CC N
methyldopa NN N
are VBP N
similar JJ N
but CC N
that IN N
larger JJR N
patient NN N
populations NNS N
are VBP N
needed VBN N
to TO N
study VB N
the DT N
relative JJ N
incidence NN N
of IN N
subjective JJ N
adverse JJ N
effects NNS N
. . N

-DOCSTART- -X- O O

Intravenous JJ N
or CC N
intramuscular JJ N
teicoplanin NN N
once RB N
daily JJ N
for IN N
skin NN 4_p
and CC 4_p
soft-tissue JJ 4_p
infections NNS 4_p
. . N

Teicoplanin NNP N
is VBZ N
a DT N
new JJ N
glycopeptide NN N
antibiotic JJ N
with IN N
potent JJ N
activity NN N
against IN N
gram-positive JJ N
bacteria NNS N
and CC N
pharmacokinetics NNS N
that WDT N
allow VBP N
once RB N
daily JJ N
administration NN N
. . N

To TO N
study VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
teicoplanin NN N
for IN N
skin NN N
and CC N
soft-tissue NN N
infections NNS N
, , N
75 CD 3_p
patients NNS N
received VBD N
teicoplanin JJ N
intravenously RB N
( ( N
38 CD 3_p
) ) N
or CC N
intramuscularly RB N
( ( N
37 CD 3_p
, , N
of IN N
which WDT N
16 CD 3_p
were VBD N
outpatients NNS N
) ) N
. . N

Of IN N
62 CD 3_p
clinically RB N
evaluable JJ N
patients NNS N
, , N
97 CD N
percent NN N
of IN N
teicoplanin NN N
iv NN N
and CC N
93 CD N
percent NN N
of IN N
teicoplanin NN N
im NN N
patients NNS N
were VBD N
cured VBN N
or CC N
improved VBN N
. . N

All DT N
teicoplanin JJ N
iv NN N
patients NNS N
and CC N
64 CD N
percent NN N
of IN N
teicoplanin NN N
im NN N
patients NNS N
were VBD N
cured VBN N
microbiologically RB N
at IN N
24-48 JJ N
hours NNS N
posttherapy NN N
. . N

Persistence NN N
of IN N
organisms NNS N
frequently RB N
was VBD N
associated VBN N
with IN N
skin JJ N
ulcers NNS N
or CC N
abscess JJ N
cavities NNS N
and CC N
usually RB N
had VBD N
no DT N
bearing NN N
on IN N
clinical JJ N
outcome NN N
. . N

Possible JJ N
adverse JJ N
clinical JJ N
and CC N
laboratory JJ N
reactions NNS N
caused VBN N
by IN N
teicoplanin NN N
occurred VBD N
in IN N
4 CD N
of IN N
38 CD N
teicoplanin JJ N
iv NN N
patients NNS N
( ( N
11 CD N
percent NN N
) ) N
and CC N
in IN N
8 CD N
of IN N
37 CD N
teicoplanin JJ N
im NN N
patients NNS N
( ( N
22 CD N
percent NN N
) ) N
. . N

Reactions NNPS N
were VBD N
mild JJ N
and CC N
resolved VBN N
with IN N
discontinuation NN N
of IN N
teicoplanin NN N
in IN N
most JJS N
cases NNS N
. . N

In IN N
this DT N
study NN N
, , N
teicoplanin NN N
appeared VBD N
to TO N
be VB N
safe JJ N
, , N
efficacious JJ N
, , N
and CC N
convenient NN N
for IN N
both DT N
hospital JJ N
staff NN N
and CC N
patients NNS N
, , N
and CC N
potentially RB N
cost-effective JJ N
for IN N
the DT N
treatment NN N
of IN N
skin NN N
and CC N
soft-tissue JJ N
infections NNS N
. . N

In IN N
particular JJ N
, , N
teicoplanin JJ N
appears VBZ N
to TO N
be VB N
appropriate JJ N
for IN N
outpatient JJ N
parenteral JJ N
therapy NN N
. . N

-DOCSTART- -X- O O

Efficacy NN N
of IN N
nebulized JJ N
flunisolide NN N
combined VBN N
with IN N
salbutamol NN N
and CC N
ipratropium NN N
bromide NN N
in IN N
stable JJ N
patients NNS N
with IN N
moderate-to-severe JJ N
chronic JJ 4_p
obstructive JJ 4_p
pulmonary JJ 4_p
disease NN 4_p
. . N

BACKGROUND IN N
The DT N
efficacy NN N
of IN N
nebulized JJ N
corticosteroids NNS N
in IN N
the DT N
prevention NN N
of IN N
exacerbation NN N
of IN N
chronic JJ N
obstructive JJ N
pulmonary JJ N
disease NN N
( ( N
COPD NNP 4_p
) ) N
has VBZ N
been VBN N
poorly RB N
studied VBN N
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
efficacy NN N
and CC N
tolerability NN N
of IN N
nebulized JJ N
flunisolide NN N
( ( N
1 CD N
mg NN N
) ) N
+ VBZ N
salbutamol/ipratropium JJ N
bromide NN N
( ( N
1,875/375 CD N
microg NN N
) ) N
b.i.d NN N
. . N

in IN N
comparison NN N
with IN N
placebo NN N
+ NNP N
salbutamol/ipratropium NN N
bromide NN N
. . N

METHODS NNP N
This DT N
was VBD N
a DT N
randomized JJ N
, , N
parallel-group JJ N
, , N
double-blind JJ N
study NN N
on IN N
114 CD 3_p
patients NNS N
with IN N
COPD NNP 4_p
of IN N
moderate-to-severe JJ N
degree NN N
. . N

The DT N
main JJ N
outcome NN N
was VBD N
the DT N
frequency NN N
of IN N
severe JJ N
exacerbations NNS N
over IN N
a DT N
6-month JJ N
period NN N
. . N

Before IN N
and CC N
after IN N
treatment NN N
, , N
respiratory NN N
symptoms NNS N
, , N
forced VBD N
expiratory JJ N
volume NN N
in IN N
1 CD N
s NN N
( ( N
FEV NNP N
( ( N
1 CD N
) ) N
) ) N
, , N
shuttle JJ N
walking VBG N
test NN N
distance NN N
and CC N
St. NNP N
George NNP N
's POS N
Respiratory NNP N
Questionnaire NNP N
scores NNS N
were VBD N
evaluated VBN N
. . N

RESULTS VB N
The DT N
total JJ N
number NN N
of IN N
exacerbations NNS N
was VBD N
slightly RB N
lower JJR N
in IN N
the DT N
flunisolide NN N
group NN N
compared VBN N
to TO N
the DT N
placebo NN N
group NN N
( ( N
19 CD N
vs. FW N
34 CD N
, , N
p NN N
= NNP N
0.054 CD N
) ) N
; : N
the DT N
number NN N
of IN N
patients NNS N
experiencing VBG N
at IN N
least JJS N
one CD N
exacerbation NN N
during IN N
the DT N
study NN N
was VBD N
also RB N
decreased VBN N
( ( N
16 CD N
vs. FW N
26 CD N
, , N
p NN N
= NNP N
0.059 CD N
) ) N
. . N

In IN N
particular JJ N
, , N
type JJ N
3 CD N
Anthonisens NNP N
's POS N
exacerbations NNS N
were VBD N
significantly RB N
reduced VBN N
by IN N
flunisolide NN N
( ( N
p JJ N
= NNP N
0.044 CD N
) ) N
. . N

In IN N
the DT N
placebo NN N
group NN N
, , N
scores NNS N
were VBD N
higher JJR N
than IN N
in IN N
the DT N
flunisolide JJ N
group NN N
but CC N
nonsignificant NN N
for IN N
dyspnea NN N
, , N
cough NN N
, , N
sputum NN N
amount NN N
and CC N
purulence NN N
. . N

FEV NNP N
( ( N
1 CD N
) ) N
was VBD N
significantly RB N
increased VBN N
compared VBN N
to TO N
baseline VB N
in IN N
both DT N
groups NNS N
, , N
and CC N
the DT N
area NN N
under IN N
the DT N
FEV NNP N
( ( N
1 CD N
) ) N
-time NN N
curve NN N
during IN N
the DT N
6-month JJ N
period NN N
was VBD N
significantly RB N
greater JJR N
in IN N
the DT N
flunisolide NN N
group NN N
( ( N
5.2 CD N
+/- JJ N
10.6 CD N
vs. FW N
2.1 CD N
+/- JJ N
5.0 CD N
, , N
flunisolide RB N
vs. FW N
placebo NN N
, , N
respectively RB N
; : N
p VB N
= $ N
0.047 CD N
) ) N
. . N

For IN N
shuttle JJ N
walking VBG N
test NN N
distance NN N
and CC N
scores NNS N
of IN N
the DT N
St. NNP N
George NNP N
's POS N
Respiratory NNP N
Questionnaire NNP N
, , N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
baseline NN N
evaluation NN N
and CC N
the DT N
end NN N
of IN N
the DT N
study NN N
was VBD N
observed VBN N
in IN N
both DT N
groups NNS N
. . N

CONCLUSIONS NNP N
Nebulized NNP N
flunisolide NN N
is VBZ N
a DT N
good JJ N
alternative NN N
to TO N
other JJ N
inhaled JJ N
corticosteroids NNS N
when WRB N
added VBN N
to TO N
nebulized JJ N
salbutamol/ipratropium NN N
bromide NN N
in IN N
the DT N
long-term JJ N
treatment NN N
of IN N
moderate-to-severe JJ 4_p
COPD NNP 4_p
patients NNS N
. . N

-DOCSTART- -X- O O

Comparison NNP N
of IN N
thiopentone/guaifenesin NN N
, , N
ketamine/guaifenesin NN N
and CC N
ketamine/midazolam NN N
for IN N
the DT N
induction NN N
of IN N
horses NNS N
to TO N
be VB N
anaesthetised VBN 4_p
with IN N
isoflurane NN N
. . N

Forty-eight JJ 3_p
horses NNS N
subjected VBN N
to TO N
elective VB 4_p
surgery NN 4_p
were VBD N
randomly RB N
assigned VBN N
to TO N
three CD 3_p
groups NNS N
of IN N
16 CD 3_p
horses NNS N
. . N

After IN N
premedication NN N
with IN N
0.1 CD N
mg/kg NNS N
acepromazine VBP N
intramuscularly RB N
and CC N
0.6 CD N
mg/kg NNS N
xylazine JJ N
intravenously RB N
, , N
anaesthesia NN N
was VBD N
induced VBN N
either RB N
with IN N
2 CD N
g NNS N
thiopentone NN N
in IN N
500 CD N
ml NN N
of IN N
a DT N
10 CD N
per IN N
cent NN N
guaifenesin NN N
solution NN N
, , N
given VBN N
intravenously RB N
at IN N
a DT N
dose NN N
of IN N
1 CD N
ml/kg NNS N
( ( N
group NN N
TG NNP N
) ) N
, , N
or CC N
with IN N
100 CD N
mg/kg NNS N
guaifenesin NN N
and CC N
2.2 CD N
mg/kg NN N
ketamine NN N
given VBN N
intravenously RB N
( ( N
group NN N
KG NNP N
) ) N
, , N
or CC N
with IN N
0.06 CD N
mg/kg NNS N
midazolam NN N
, , N
and CC N
2.2 CD N
mg/kg NN N
ketamine NN N
given VBN N
intravenously RB N
( ( N
group NN N
KM NNP N
) ) N
. . N

Anaesthesia NNP N
was VBD N
maintained VBN N
with IN N
isoflurane NN N
. . N

The DT N
mean NN N
( ( N
sd NN N
) ) N
end NN N
tidal JJ N
isoflurane NN N
concentration NN N
( ( N
per IN N
cent NN N
) ) N
needed VBD N
to TO N
maintain VB N
a DT N
light JJ N
surgical JJ N
anaesthesia NN N
( ( N
stage NN N
III NNP N
, , N
plane NN N
2 CD N
) ) N
was VBD N
significantly RB N
lower JJR N
in IN N
group NN N
KM NNP N
( ( N
0.91 CD N
[ RB N
0.03 CD N
] NN N
) ) N
than IN N
in IN N
groups NNS N
TG NNP N
( ( N
1.11 CD N
[ RB N
0.03 CD N
] NN N
) ) N
and CC N
KG NNP N
( ( N
1.14 CD N
[ RB N
0.03 CD N
] NN N
) ) N
. . N

The DT N
mean NN N
( ( N
sd NN N
) ) N
arterial JJ N
pressure NN N
( ( N
mmHg NN N
) ) N
was VBD N
significantly RB N
lower JJR N
in IN N
group NN N
KG NNP N
( ( N
67.4 CD N
[ RB N
2.07 CD N
] NN N
) ) N
than IN N
in IN N
groups NNS N
TC NNP N
( ( N
75.6 CD N
[ RB N
2.23 CD N
] NN N
) ) N
and CC N
KM NNP N
( ( N
81.0 CD N
[ RB N
2.16 CD N
] NN N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
logarithm NN N
of IN N
the DT N
heart NN N
rate NN N
, , N
recovery NN N
time NN N
or CC N
quality NN N
of IN N
recovery NN N
between IN N
the DT N
three CD N
induction NN N
groups NNS N
. . N

However RB N
, , N
pronounced VBD N
ataxia NN N
was VBD N
observed VBN N
in IN N
the DT N
horses NNS N
of IN N
group NN N
KM NNP N
, , N
especially RB N
after IN N
periods NNS N
of IN N
anaesthesia NN N
lasting VBG N
less JJR N
than IN N
75 CD N
minutes NNS N
. . N

-DOCSTART- -X- O O

Similar JJ N
effects NNS N
of IN N
rofecoxib NN N
and CC N
indomethacin NN N
on IN N
the DT N
incidence NN N
of IN N
heterotopic NN N
ossification NN N
after IN N
hip NN 4_p
arthroplasty NN 4_p
. . N

BACKGROUND NNP N
Although IN N
indomethacin NN N
is VBZ N
effective JJ N
in IN N
preventing VBG N
heterotopic NN N
ossification NN N
( ( N
HO NNP N
) ) N
after IN N
primary JJ 4_p
total JJ 4_p
hip NN 4_p
arthroplasty NN 4_p
, , N
side NN N
effects NNS N
are VBP N
frequently RB N
observed VBN N
. . N

In IN N
the DT N
last JJ N
decade NN N
a DT N
new JJ N
class NN N
of IN N
drugs NNS N
-- : N
the DT N
COX-2 NNP N
selective JJ N
nonsteroidal JJ N
anti-inflammatory JJ N
drugs NNS N
-- : N
has VBZ N
been VBN N
developed VBN N
. . N

To TO N
investigate VB N
the DT N
effect NN N
of IN N
these DT N
COX-2 NNP N
selective NN N
NSAIDs NNP N
on IN N
heterotopic NN N
ossification NN N
( ( N
HO NNP N
) ) N
after IN N
primary JJ N
total JJ N
hip NN N
arthroplasty NN N
( ( N
THA NNP N
) ) N
, , N
we PRP N
conducted VBD N
a DT N
randomized VBN N
controlled VBN N
trial NN N
using VBG N
either CC N
indomethacin NN N
or CC N
rofecoxib NN N
for IN N
7 CD N
days NNS N
. . N

METHODS NNP N
186 CD 3_p
patients NNS N
received VBD N
either RB N
indomethacin JJ N
3 CD N
times NNS N
daily RB N
, , N
or CC N
rofecoxib VB N
twice RB N
, , N
and CC N
1 CD N
placebo NN N
, , N
daily RB N
for IN N
7 CD N
days NNS N
. . N

HO NNP N
was VBD N
graded VBN N
according VBG N
to TO N
the DT N
1-year JJ N
postoperative NN N
radiographs NN N
according VBG N
to TO N
the DT N
Brooker NNP N
classification NN N
. . N

RESULTS NNP N
12 CD N
of IN N
the DT N
186 CD N
patients NNS N
included VBD N
discontinued VBN N
their PRP$ N
medication NN N
before IN N
the DT N
end NN N
of IN N
the DT N
trial NN N
due JJ N
to TO N
side VB N
effects NNS N
. . N

The DT N
remaining VBG N
174 CD 3_p
patients NNS N
were VBD N
included VBN N
in IN N
the DT N
analysis NN N
. . N

In IN N
the DT N
indomethacin NN N
group NN N
( ( N
n JJ N
= NNP N
89 CD 3_p
) ) N
, , N
77 CD N
patients NNS N
( ( N
87 CD N
% NN N
) ) N
showed VBD N
no DT N
HO NNP N
, , N
9 CD N
showed VBD N
HO NNP N
of IN N
grade NN N
1 CD N
and CC N
3 CD N
showed VBD N
HO NNP N
of IN N
grade NN N
2 CD N
according VBG N
to TO N
the DT N
Brooker NNP N
classification NN N
. . N

In IN N
the DT N
rofecoxib NN N
group NN N
( ( N
n JJ N
= NNP N
85 CD 3_p
) ) N
73 CD N
patients NNS N
( ( N
86 CD N
% NN N
) ) N
showed VBD N
no DT N
ossification NN N
, , N
9 CD N
showed VBD N
grade NN N
1 CD N
, , N
and CC N
3 CD N
showed VBD N
grade JJ N
2 CD N
. . N

INTERPRETATION VB N
The DT N
prophylactic JJ N
effect NN N
of IN N
rofecoxib NN N
for IN N
7 CD N
days NNS N
in IN N
preventing VBG N
heterotopic NN N
ossification NN N
after IN N
primary JJ N
total JJ N
hip NN N
arthroplasty NN N
is VBZ N
comparable JJ N
to TO N
the DT N
effect NN N
of IN N
indomethacin NN N
given VBN N
for IN N
7 CD N
days NNS N
. . N

These DT N
results NNS N
indicate VBP N
that IN N
the DT N
development NN N
of IN N
HO NNP N
follows VBZ N
a DT N
COX-2 JJ N
pathway NN N
. . N

-DOCSTART- -X- O O

Pre-bent JJ N
instruments NNS N
used VBN N
in IN N
single-port JJ N
laparoscopic NN N
surgery NN N
versus IN N
conventional JJ N
laparoscopic NN N
surgery NN N
: : N
comparative JJ N
study NN N
of IN N
performance NN N
in IN N
a DT N
dry JJ N
lab NN N
. . N

BACKGROUND NNP N
Different NNP N
types NNS N
of IN N
single-incision NN N
laparoscopic NN N
surgery NN N
( ( N
SILS NNP N
) ) N
have VBP N
become VBN N
increasingly RB N
popular JJ N
. . N

Although IN N
SILS NNP N
is VBZ N
technically RB N
even RB N
more RBR N
challenging JJ N
than IN N
conventional JJ N
laparoscopy NN N
, , N
published VBN N
data NNS N
of IN N
first JJ N
clinical JJ N
series NN N
seem VBP N
to TO N
demonstrate VB N
the DT N
feasibility NN N
of IN N
these DT N
approaches NNS N
. . N

Various JJ N
attempts NNS N
have VBP N
been VBN N
made VBN N
to TO N
overcome VB N
restrictions NNS N
due JJ N
to TO N
loss NN N
of IN N
triangulation NN N
in IN N
SILS NNP N
by IN N
specially RB N
designed VBN N
SILS-specific JJ N
instruments NNS N
. . N

This DT N
study NN N
involving VBG N
novices NNS N
in IN N
a DT N
dry JJ N
lab NN N
compared VBN N
task NN N
performances NNS N
between IN N
conventional JJ N
laparoscopic NN N
surgery NN N
( ( N
CLS NNP N
) ) N
and CC N
single-port JJ N
laparoscopic NN N
surgery NN N
( ( N
SPLS NNP N
) ) N
using VBG N
newly RB N
designed VBN N
pre-bent JJ N
instruments NNS N
. . N

METHODS NNP N
In IN N
this DT N
study NN N
, , N
90 CD 3_p
medical JJ 4_p
students NNS N
without IN N
previous JJ N
experience NN N
in IN N
laparoscopic NN N
techniques NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
undergo VB N
one CD N
of IN N
three CD N
procedures NNS N
: : N
CLS NNP N
, , N
SPLS NNP N
using VBG N
two CD N
pre-bent JJ N
instruments NNS N
( ( N
SPLS-pp NNP N
) ) N
, , N
or CC N
SPLS NNP N
using VBG N
one CD N
pre-bent NN N
and CC N
one CD N
straight NN N
laparoscopic NN N
instrument NN N
( ( N
SPLS-ps NNP N
) ) N
. . N

In IN N
the DT N
dry JJ N
lab NN N
, , N
the DT N
participants NNS N
performed VBD N
four CD N
typical JJ N
laparoscopic NN N
tasks NNS N
of IN N
increasing VBG N
difficulty NN N
. . N

Evaluation NNP N
included VBD N
performance NN N
times NNS N
or CC N
number NN N
of IN N
completed VBN N
tasks NNS N
within IN N
a DT N
given VBN N
time NN N
frame NN N
. . N

All DT N
performances NNS N
were VBD N
videotaped VBN N
and CC N
evaluated VBN N
for IN N
unsuccessful JJ N
attempts NNS N
and CC N
unwanted JJ N
interactions NNS N
of IN N
instruments NNS N
. . N

Using VBG N
subjective JJ N
questionnaires NNS N
, , N
the DT N
participants NNS N
rated VBN N
difficulties NNS N
with IN N
two-dimensional JJ N
vision NN N
and CC N
coordination NN N
of IN N
instruments NNS N
. . N

RESULTS NNP N
Task NNP N
performances NNS N
were VBD N
significantly RB N
better RBR N
in IN N
the DT N
CLS NNP N
group NN N
than IN N
in IN N
either DT N
SPLS NNP N
group NN N
. . N

The DT N
SPLS-ps NNP N
group NN N
showed VBD N
a DT N
tendency NN N
toward IN N
better JJR N
performances NNS N
than IN N
the DT N
SPLS-pp NNP N
group NN N
, , N
but CC N
the DT N
difference NN N
was VBD N
not RB N
significant JJ N
. . N

Video NNP N
sequences NNS N
and CC N
participants` NN N
questionnaires NNS N
showed VBD N
instrument JJ N
interaction NN N
as IN N
the DT N
major JJ N
problem NN N
in IN N
the DT N
single-incision NN N
surgery NN N
groups NNS N
. . N

CONCLUSIONS NNP N
Although IN N
SILS NNP N
is VBZ N
feasible JJ N
, , N
as IN N
shown VBN N
in IN N
clinical JJ N
series NN N
published VBN N
by IN N
laparoscopically RB N
experienced JJ N
experts NNS N
, , N
SILS NNP N
techniques NNS N
are VBP N
demanding VBG N
due JJ N
to TO N
restrictions NNS N
that IN N
come VBP N
with IN N
the DT N
loss NN N
of IN N
triangulation NN N
. . N

These DT N
can MD N
be VB N
compensated VBN N
only RB N
partially RB N
by IN N
currently RB N
available JJ N
SILS-designed JJ N
instruments NNS N
. . N

The DT N
future NN N
of IN N
SILS NNP N
depends VBZ N
on IN N
further JJ N
improvements NNS N
in IN N
the DT N
available JJ N
equipment NN N
or CC N
the DT N
development NN N
of IN N
new JJ N
approaches NNS N
such JJ N
as IN N
needlescopically RB N
assisted VBN N
or CC N
robotically RB N
assisted JJ N
procedures NNS N
. . N

-DOCSTART- -X- O O

Phytase NNP N
and CC N
1alpha-hydroxycholecalciferol JJ N
supplementation NN N
of IN N
broiler NN 4_p
chickens NNS 4_p
during IN N
the DT N
starting NN N
and CC N
growing/finishing NN N
phases NNS N
. . N

Supplemental JJ N
1alpha-hydroxycholecalciferol JJ N
( ( N
1alpha-OHD3 JJ N
) ) N
has VBZ N
been VBN N
shown VBN N
to TO N
have VB N
qualitatively RB N
similar JJ N
and CC N
quantitatively RB N
additive JJ N
effects NNS N
to TO N
exogenous JJ N
phytase NN N
. . N

Two CD N
experiments NNS N
were VBD N
conducted VBN N
from IN N
0 CD N
to TO N
35 CD N
d NN N
in IN N
floor NN N
pens NNS N
to TO N
determine VB N
the DT N
additive JJ N
effect NN N
of IN N
phytase NN N
and CC N
1alpha-OHD3 JJ N
when WRB N
supplemented VBN N
to TO N
Ca- NNP N
and CC N
P-deficient NNP N
diets NNS N
. . N

In IN N
both DT N
experiments NNS N
, , N
at IN N
least JJS N
4 CD N
replicates NNS N
per IN N
treatment NN N
( ( N
50 CD 3_p
chicks NNS N
per IN N
replicate NN N
) ) N
were VBD N
used VBN N
. . N

Corn-soybean-meal-and JJ N
soybean-oil-based JJ N
diets NNS N
were VBD N
fed VBN N
and CC N
birds NNS N
were VBD N
raised VBN N
in IN N
a DT N
house NN N
impervious JJ N
to TO N
ultraviolet VB N
light NN N
. . N

During IN N
the DT N
starter JJ N
phase NN N
( ( N
ST NNP N
) ) N
, , N
from IN N
0 CD N
to TO N
18 CD N
d NN N
, , N
chicks NNS N
were VBD N
fed VBN N
a DT N
23 CD N
% NN N
CP NNP N
diet JJ N
containing VBG N
0.60 CD N
% NN N
Ca NNP N
and CC N
0.47 CD N
% NN N
total JJ N
P NNP N
( ( N
tP NN N
) ) N
. . N

During IN N
the DT N
grower/finisher NN N
phase NN N
( ( N
GF NNP N
) ) N
, , N
from IN N
19 CD N
to TO N
35 CD N
d NN N
, , N
birds NNS N
were VBD N
fed VBN N
a DT N
19 CD N
% NN N
CP NNP N
diet JJ N
containing VBG N
0.30 CD N
% NN N
Ca NNP N
and CC N
0.37 CD N
% NN N
tP NN N
. . N

A DT N
combination NN N
of IN N
1,000 CD N
phytase NN N
units/kg NN N
of IN N
Natuphos NNP N
phytase NN N
and CC N
5 CD N
microg/kg NN N
of IN N
1alpha-OHD3 JJ N
( ( N
P+1A NNP N
) ) N
was VBD N
supplemented VBN N
to TO N
some DT N
of IN N
the DT N
feed NN N
during IN N
the DT N
ST NNP N
and CC N
GF NNP N
. . N

Diets NNS N
containing VBG N
adequate NN N
Ca NNP N
and CC N
P NNP N
were VBD N
also RB N
fed VBN N
during IN N
the DT N
ST NNP N
( ( N
0.90 CD N
% NN N
Ca NNP N
, , N
0.68 CD N
% NN N
tP NN N
) ) N
and CC N
GF NNP N
( ( N
0.80 CD N
% NN N
Ca NNP N
, , N
0.67 CD N
% NN N
tP NN N
) ) N
. . N

Performance NN N
characteristics NNS N
and CC N
the DT N
incidence NN N
of IN N
rickets NNS N
and CC N
tibial JJ N
dyschondroplasia NN N
were VBD N
measured VBN N
at IN N
18 CD N
and CC N
35 CD N
d. NN N
In IN N
experiment JJ N
1 CD N
, , N
unsupplemented JJ N
chicks NNS N
performed VBN N
well RB N
but CC N
had VBD N
considerable JJ N
leg JJ N
problems NNS N
. . N

Chicks NNP N
fed VBD N
P+1A NNP N
during IN N
the DT N
ST NNP N
or CC N
GF NNP N
did VBD N
not RB N
perform VB N
as RB N
well RB N
as IN N
birds NNS N
fed VBN N
P+1A NNP N
throughout IN N
. . N

Birds NNS N
fed VBD N
P+1A NNP N
throughout IN N
performed VBN N
as IN N
well RB N
birds NNS N
fed VBD N
the DT N
adequate JJ N
diets NNS N
without IN N
any DT N
indication NN N
of IN N
leg NN N
problems NNS N
. . N

In IN N
experiment JJ N
2 CD N
, , N
unsupplemented JJ N
birds NNS N
performed VBD N
similarly RB N
to TO N
unsupplemented JJ N
birds NNS N
in IN N
experiment JJ N
1 CD N
. . N

However RB N
, , N
chicks NNS N
fed VBP N
the DT N
supplements NNS N
or CC N
the DT N
control JJ N
diets NNS N
did VBD N
not RB N
perform VB N
as RB N
well RB N
or CC N
accumulate VB N
as IN N
much JJ N
bone NN N
ash NN N
as IN N
birds NNS N
in IN N
experiment JJ N
1 CD N
, , N
although IN N
the DT N
diets NNS N
were VBD N
formulated VBN N
identically RB N
in IN N
both DT N
experiments NNS N
. . N

Diets NNS N
with IN N
as RB N
little JJ N
as IN N
0.30 CD N
% NN N
Ca NNP N
and CC N
0.37 CD N
% NN N
tP NN N
appear VBP N
to TO N
be VB N
adequate JJ N
for IN N
broilers NNS N
older JJR N
than IN N
18 CD N
d NN N
if IN N
supplemented VBN N
with IN N
the DT N
correct JJ N
amounts NNS N
of IN N
phytase NN N
and CC N
1alpha-OHD3 JJ N
. . N

However RB N
, , N
there EX N
are VBP N
unknown JJ N
variables NNS N
that WDT N
may MD N
limit VB N
the DT N
potential NN N
of IN N
broilers NNS N
in IN N
terms NNS N
of IN N
bone NN N
mineralization NN N
and CC N
bone NN N
pathology NN N
, , N
even RB N
when WRB N
adequate JJ N
diets NNS N
are VBP N
fed VBN N
. . N

-DOCSTART- -X- O O

Family RB N
education NN N
for IN N
people NNS N
with IN N
schizophrenia NN 4_p
in IN N
Beijing NNP N
, , N
China NNP N
: : N
randomised VBD N
controlled JJ N
trial NN N
. . N

BACKGROUND NNP N
Much NNP N
of IN N
China NNP N
lacks VBZ N
well-developed JJ N
services NNS N
for IN N
people NNS N
with IN N
schizophrenia NN N
and CC N
their PRP$ N
families NNS N
, , N
and CC N
most JJS N
of IN N
the DT N
existing VBG N
services NNS N
focus NN N
on IN N
hospitals NNS N
. . N

There EX N
is VBZ N
a DT N
need NN N
for IN N
culturally RB N
sensitive JJ N
family NN N
treatments NNS N
offered VBN N
by IN N
nurses NNS N
. . N

AIMS NNP N
To TO N
conduct VB N
a DT N
longitudinal JJ N
experimental NN N
study NN N
examining VBG N
the DT N
effect NN N
of IN N
patient NN N
and CC N
family NN N
education NN N
in IN N
a DT N
sample NN N
of IN N
Chinese JJ N
people NNS N
with IN N
schizophrenia NN N
. . N

METHOD NNP N
A NNP N
randomised VBD N
controlled VBN N
trial NN N
was VBD N
conducted VBN N
in IN N
a DT N
large JJ N
hospital NN N
with IN N
a DT N
was VBD N
conducted VBN N
in IN N
a DT N
large JJ N
hospital NN N
with IN N
a DT N
sample NN N
of IN N
101 CD 3_p
patients NNS N
with IN N
schizophrenia NN N
and CC N
their PRP$ N
families NNS N
. . N

Data NNS N
were VBD N
collected VBN N
at IN N
admission NN N
and CC N
at IN N
discharge NN N
, , N
and CC N
then RB N
at IN N
3 CD N
and CC N
9 CD N
months NNS N
after IN N
discharge NN N
. . N

The DT N
intervention NN N
group NN N
received VBD N
family NN N
education NN N
, , N
and CC N
data NNS N
on IN N
their PRP$ N
knowledge NN N
about IN N
schizophrenia NN N
, , N
symptoms NNS N
, , N
functioning VBG N
, , N
psychosocial JJ N
behaviour NN N
, , N
relapse NN N
and CC N
medication NN N
adherence NN N
were VBD N
collected VBN N
and CC N
compared VBN N
with IN N
the DT N
control NN N
group NN N
. . N

RESULTS NNP N
There EX N
was VBD N
a DT N
significant JJ N
improvement NN N
in IN N
knowledge NN N
about IN N
schizophrenia NN N
in IN N
the DT N
experimental JJ N
group NN N
and CC N
a DT N
significant JJ N
difference NN N
in IN N
symptom JJ N
scores NNS N
and CC N
functioning VBG N
at IN N
9 CD N
months NNS N
after IN N
discharge NN N
. . N

Patients NNS N
who WP N
were VBD N
nonadherent JJ N
to TO N
medication NN N
regimens NNS N
were VBD N
more RBR N
likely JJ N
to TO N
relapse VB N
. . N

CONCLUSIONS NNP N
Family NNP N
education NN N
on IN N
schizophrenia NN N
by IN N
nurses NNS N
in IN N
China NNP N
was VBD N
effective JJ N
in IN N
improving VBG N
knowledge NN N
and CC N
promoting VBG N
improvement NN N
in IN N
patients NNS N
' POS N
symptoms NNS N
. . N

-DOCSTART- -X- O O

Laser NNP N
conization NN N
versus NN N
cold JJ N
knife NN N
conization NN N
. . N

This DT N
prospective JJ N
, , N
randomized VBN N
study NN N
compares VBZ N
, , N
for IN N
the DT N
first JJ N
time NN N
, , N
measured VBN N
blood NN N
loss NN N
at IN N
conization NN N
and CC N
within IN N
24 CD N
hours NNS N
after IN N
using VBG N
either CC N
the DT N
cold JJ N
knife NN N
technique NN N
or CC N
the DT N
carbon NN N
dioxide NN N
laser NN N
scalpel NN N
. . N

One CD 3_p
hundred CD 3_p
and CC 3_p
ten VB 3_p
consecutive JJ N
patients NNS N
were VBD N
evaluated VBN N
. . N

The DT N
median JJ N
blood NN N
loss NN N
in IN N
the DT N
laser NN N
group NN N
of IN N
55 CD N
patients NNS N
was VBD N
4.6 CD N
milliliters NNS N
at IN N
, , N
and CC N
within IN N
, , N
24 CD N
hours NNS N
after IN N
operation NN N
compared VBN N
with IN N
30.1 CD N
milliliters NNS N
in IN N
the DT N
cold JJ N
knife NN N
group NN N
of IN N
55 CD N
patients NNS N
. . N

More RBR N
important JJ N
, , N
however RB N
, , N
is VBZ N
that IN N
the DT N
corresponding JJ N
figures NNS N
for IN N
the DT N
range NN N
of IN N
bleeding VBG N
were VBD N
0.4 CD N
to TO N
155.4 CD N
milliliters NNS N
and CC N
5.6 CD N
to TO N
1,570.9 CD N
milliliters NNS N
, , N
respectively RB N
. . N

The DT N
incidence NN N
rate NN N
for IN N
bleeding VBG N
complications NNS N
requiring VBG N
surgical JJ N
intervention NN N
was VBD N
1.8 CD N
per IN N
cet NN N
for IN N
the DT N
laser NN N
group NN N
and CC N
14.6 CD N
per IN N
cent NN N
for IN N
the DT N
cold JJ N
knife NN N
group NN N
. . N

This DT N
difference NN N
was VBD N
statistically RB N
significant JJ N
, , N
p RB N
less JJR N
than IN N
0.015 CD N
-- : N
Fischer NNP N
's POS N
exact JJ N
test NN N
. . N

Conization NN N
for IN N
treatment NN N
of IN N
premalignant JJ 4_p
changes NNS 4_p
of IN 4_p
the DT 4_p
cervix NN 4_p
uteri NN 4_p
will MD N
probably RB N
remain VB N
the DT N
treatment NN N
of IN N
choice NN N
for IN N
some DT N
time NN N
to TO N
come VB N
. . N

It PRP N
is VBZ N
our PRP$ N
opinion NN N
that IN N
, , N
in IN N
the DT N
future NN N
, , N
laser JJR N
conization NN N
will MD N
replace VB N
cold JJ N
knife NN N
conization NN N
. . N

-DOCSTART- -X- O O

[ JJ N
Dose-reduced NNP N
antihypertensive JJ N
agents NNS N
-- : N
use NN N
in IN N
complex JJ N
nonmedicamentous JJ N
therapy NN N
of IN N
hypertension NN N
] NNP N
. . N

In IN N
order NN N
to TO N
estimate VB N
the DT N
influence NN N
of IN N
a DT N
non-medicamentous JJ N
therapy NN N
( ( N
CNT NNP N
) ) N
on IN N
the DT N
consumption NN N
of IN N
medicaments NNS N
and CC N
coronary JJ N
risk NN N
in IN N
high JJ N
blood NN N
pressure NN N
73 CD 3_p
hypertensives NNS 4_p
of IN N
a DT N
medicamentously RB N
stabilized VBN N
CNT-group NNP N
were VBD N
examined VBN N
in IN N
comparison NN N
to TO N
a DT N
group NN N
of IN N
the DT N
same JJ N
size NN N
of IN N
patients NNS N
with IN N
hypertension NN 4_p
who WP N
were VBD N
managed VBN N
exclusively RB N
medicamentously RB N
for IN N
behaviour NN N
of IN N
blood NN N
pressure NN N
, , N
need NN N
of IN N
antihypertensive JJ N
drugs NNS N
and CC N
changes NNS N
of IN N
hypertension-associated JJ N
risk NN N
factors NNS N
. . N

After IN N
an DT N
exactly RB N
controlled VBN N
6-month JJ N
treatment NN N
hypertensives NNS 4_p
with IN N
additionally RB N
recommended VBN N
far-reaching NN N
CNT NNP N
showed VBD N
an DT N
economization NN N
of IN N
medicaments NNS N
by IN N
scarcely RB N
the DT N
half NN N
in IN N
comparison NN N
to TO N
the DT N
reference NN N
group NN N
. . N

By IN N
means NNS N
of IN N
suitable JJ N
control NN N
methods VBZ N
a DT N
causal JJ N
non-medicamentously RB N
conditioned JJ N
decrease NN N
of IN N
blood NN N
pressure NN N
could MD N
be VB N
excluded VBN N
. . N

A DT N
different JJ N
need NN N
of IN N
antihypertensive JJ N
drugs NNS N
was VBD N
simulated VBN N
by IN N
the DT N
exacter JJ N
intake NN N
of IN N
medicaments NNS N
in IN N
the DT N
index-patients NNS N
. . N

Notwithstanding VBG N
the DT N
metabolic JJ N
effects NNS N
of IN N
the DT N
additional JJ N
therapy NN N
have VBP N
induced VBN N
a DT N
positive JJ N
change NN N
of IN N
atherogenic JJ N
lipids NNS N
. . N

The DT N
examinations NNS N
indicate VBP N
in IN N
general JJ N
the DT N
difficulty NN N
of IN N
the DT N
judgement NN N
of IN N
efficacy NN N
of IN N
non-medicamentous JJ N
therapeutic JJ N
measures NNS N
in IN N
connection NN N
with IN N
a DT N
rational JJ N
dose-reduced JJ N
long-term JJ N
therapy NN N
with IN N
antihypertensive JJ N
drugs NNS N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
alfuzosin NN N
10 CD N
mg NN N
once RB N
daily RB N
on IN N
sexual JJ N
function NN N
in IN N
men NNS 2_p
treated VBN N
for IN N
symptomatic JJ 4_p
benign NN 4_p
prostatic JJ 4_p
hyperplasia NN 4_p
. . N

We PRP N
evaluated VBD N
the DT N
effects NNS N
of IN N
extended-release JJ N
alfuzosin NN N
HCl NNP N
10 CD N
mg NN N
once RB N
daily JJ N
( ( N
q.d JJ N
. . N

) ) N
on IN N
sexual JJ N
function NN N
in IN N
men NNS N
with IN N
lower JJR 4_p
urinary JJ 4_p
tract NN 4_p
symptoms NNS 4_p
associated VBN N
with IN N
benign JJ 4_p
prostatic JJ 4_p
hyperplasia NN 4_p
( ( N
BPH NNP 4_p
) ) N
. . N

In IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
of IN N
men NNS N
aged VBN N
> NN 1_p
or CC 1_p
= $ 1_p
50 CD 1_p
years NNS N
, , N
after IN N
a DT N
28-day JJ N
placebo NN N
run-in JJ N
period NN N
, , N
patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
alfuzosin NN N
10 CD N
mg NN N
q.d NN N
. . N

or CC N
matching VBG N
placebo NN N
for IN N
28 CD N
days NNS N
. . N

The DT N
mean JJ N
change NN N
from IN N
baseline NN N
( ( N
day NN N
1 CD N
) ) N
in IN N
sexual JJ N
function NN N
on IN N
day NN N
29 CD N
was VBD N
assessed VBN N
using VBG N
the DT N
Danish JJ N
Prostate NNP N
Symptom NNP N
Score NNP N
Sex NNP N
( ( N
DAN-PSSsex NNP N
) ) N
questionnaire NN N
. . N

A DT N
total NN N
of IN N
372 CD 3_p
patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
alfuzosin NN N
( ( N
n=186 JJ N
) ) N
or CC N
placebo NN N
( ( N
n=186 JJ N
) ) N
, , N
with IN N
355 CD 3_p
completing VBG N
the DT N
study NN N
. . N

At IN N
baseline NN N
, , N
64 CD N
% NN N
of IN N
the DT N
patients NNS N
reported VBD N
erectile JJ 4_p
dysfunction NN 4_p
( ( N
ED NNP 4_p
) ) N
and CC N
63 CD N
% NN N
reported VBD N
ejaculatory JJ 4_p
dysfunction NN 4_p
( ( N
EjD NNP 4_p
) ) N
. . N

For IN N
the DT N
320 CD N
patients NNS N
who WP N
completed VBD N
the DT N
DAN-PSSsex NNP N
, , N
alfuzosin NN N
treatment NN N
was VBD N
associated VBN N
with IN N
a DT N
significant JJ N
improvement NN N
in IN N
the DT N
mean JJ N
change NN N
from IN N
baseline NN N
in IN N
erectile JJ N
function NN N
on IN N
day NN N
29 CD N
compared VBN N
with IN N
placebo NN N
( ( N
P=0.02 NNP N
) ) N
. . N

No DT N
significant JJ N
difference NN N
was VBD N
observed VBN N
between IN N
the DT N
two CD N
treatment NN N
groups NNS N
in IN N
the DT N
mean JJ N
change NN N
from IN N
baseline NN N
in IN N
ejaculatory JJ N
function NN N
on IN N
day NN N
29 CD N
. . N

For IN N
patients NNS N
with IN N
ED NNP N
at IN N
baseline NN N
, , N
a DT N
marginal JJ N
improvement NN N
in IN N
erectile JJ N
function NN N
was VBD N
demonstrated VBN N
with IN N
alfuzosin NN N
treatment NN N
( ( N
P=0.09 NNP N
vs NNP N
placebo NN N
) ) N
. . N

For IN N
patients NNS N
with IN N
EjD NNP N
at IN N
baseline NN N
, , N
the DT N
mean JJ N
change NN N
from IN N
baseline NN N
in IN N
ejaculatory JJ N
function NN N
with IN N
alfuzosin NN N
was VBD N
comparable JJ N
to TO N
that DT N
with IN N
placebo NN N
. . N

Dizziness NNP N
was VBD N
the DT N
most RBS N
common JJ N
adverse JJ N
event NN N
with IN N
alfuzosin NN N
treatment NN N
( ( N
5 CD N
vs RB N
0 CD N
% NN N
with IN N
placebo NN N
) ) N
, , N
with IN N
other JJ N
adverse JJ N
events NNS N
reported VBN N
with IN N
comparable JJ N
frequency NN N
in IN N
both DT N
treatment NN N
groups NNS N
. . N

After IN N
1 CD N
month NN N
of IN N
treatment NN N
, , N
alfuzosin RB N
10 CD N
mg NN N
q.d NN N
. . N

significantly RB N
improved VBN N
erectile JJ N
function NN N
in IN N
men NNS N
with IN N
lower JJR N
urinary JJ N
tract NN N
symptoms/ NN N
benign JJ N
prostatic JJ N
hypertrophy NN N
and CC N
had VBD N
no DT N
adverse JJ N
effect NN N
on IN N
ejaculatory NN N
function NN N
. . N

-DOCSTART- -X- O O

Moist NN N
Exposed VBD N
Burn NNP N
Ointment NNP N
( ( N
MEBO NNP N
) ) N
in IN N
partial JJ 4_p
thickness NN 4_p
burns NNS 4_p
- : N
a DT N
randomized JJ N
, , N
comparative JJ N
open JJ N
mono-center NN N
study NN N
on IN N
the DT N
efficacy NN N
of IN N
dermaheal NN N
( ( N
MEBO NNP N
) ) N
ointment NN N
on IN N
thermal JJ 4_p
2nd CD 4_p
degree NN 4_p
burns NNS 4_p
compared VBN N
to TO N
conventional JJ N
therapy NN N
. . N

OBJECTIVE NNP N
Wound NNP N
healing NN N
in IN N
burn NN N
wounds NNS N
presents VBZ N
a DT N
challenge NN N
in IN N
healthcare NN N
, , N
and CC N
there EX N
is VBZ N
still RB N
a DT N
lack NN N
of IN N
alternatives NNS N
in IN N
topical JJ N
burn NN N
wound NN N
treatments NNS N
. . N

- : N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
a DT N
new JJ N
therapeutic JJ N
ointment NN N
( ( N
MEBO NNP N
) ) N
in IN N
the DT N
treatment NN N
of IN N
partial JJ 4_p
thickness NN 4_p
burns NNS 4_p
. . N

METHODS NNP N
40 CD 3_p
patients NNS N
received VBD N
either RB N
topical JJ N
treatment NN N
with IN N
Moist NNP N
Exposed VBD N
Burn NNP N
Ointment NNP N
( ( N
MEBO NNP N
) ) N
or CC N
standard JJ N
Flammazine NNP N
treatment NN N
. . N

All DT N
patients NNS N
suffered VBD N
from IN N
partial-thickness JJ N
burn NN N
injuries NNS N
( ( N
< VB N
20 CD N
% NN N
TBSA NNP N
) ) N
. . N

Wounds NNS N
were VBD N
evaluated VBN N
for IN N
60 CD N
up RB N
to TO N
days NNS N
regarding VBG N
wound NN N
healing NN N
, , N
water NN N
loss NN N
, , N
inflammation NN N
, , N
and CC N
pain NN N
alleviation NN N
. . N

RESULTS NNP N
For IN N
transepidermal JJ N
water NN N
loss NN N
, , N
there EX N
was VBD N
a DT N
difference NN N
of IN N
2.3 CD N
gr/m2/h NN N
between IN N
MEBO NNP N
, , N
and CC N
Flammazine NNP N
, , N
favoring VBG N
MEBO NNP N
. . N

However RB N
, , N
this DT N
difference NN N
was VBD N
not RB N
statistically RB N
significant JJ N
( ( N
p=0.78 NN N
) ) N
. . N

For IN N
all DT N
secondary JJ N
efficacy NN N
parameter NN N
results NNS N
were VBD N
similar JJ N
. . N

- : N
CONCLUSIONS NN N
This DT N
study NN N
showed VBD N
that IN N
MEBO NNP N
ointment NN N
for IN N
topical JJ N
treatment NN N
of IN N
burn NN N
injuries NNS N
presents VBZ N
an DT N
attractive JJ N
alternative NN N
for IN N
the DT N
topical JJ N
treatment NN N
of IN N
limited JJ 4_p
partial JJ 4_p
thickness NN 4_p
thermal JJ 4_p
burns NNS 4_p
. . N

-DOCSTART- -X- O O

Propofol NNP N
sedation NN N
with IN N
bispectral JJ N
index NN N
monitoring NN N
is VBZ N
useful JJ N
for IN N
endoscopic NN N
submucosal JJ N
dissection NN N
: : N
a DT N
randomized JJ N
prospective JJ N
phase NN N
II NNP N
clinical JJ N
trial NN N
. . N

BACKGROUND NNP N
AND NNP N
STUDY NNP N
AIMS NNP N
Endoscopic NNP N
submucosal NN N
dissection NN N
( ( N
ESD NNP N
) ) N
has VBZ N
become VBN N
a DT N
standard JJ N
treatment NN N
. . N

However RB N
, , N
the DT N
treatment NN N
time NN N
tends VBZ N
to TO N
be VB N
relatively RB N
long JJ N
and CC N
insufflation NN N
and CC N
manipulation NN N
of IN N
the DT N
endoscope NN N
can MD N
increase VB N
pain NN N
and CC N
discomfort NN N
. . N

We PRP N
aimed VBD N
to TO N
find VB N
an DT N
optimal JJ N
method NN N
for IN N
sedation NN N
during IN N
ESD NNP N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Patients NNP N
scheduled VBD N
to TO N
undergo VB N
ESD NNP N
for IN N
early JJ 4_p
gastric JJ 4_p
cancer NN 4_p
or CC 4_p
adenoma NN 4_p
were VBD N
randomly RB N
assigned VBN N
to TO N
sedation NN N
with IN N
midazolam NN N
or CC N
propofol NN N
, , N
and CC N
consciousness JJ N
level NN N
was VBD N
evaluated VBN N
by IN N
bispectral JJ N
index NN N
( ( N
BIS NNP N
) ) N
monitoring NN N
. . N

Primary JJ N
end NN N
points NNS N
of IN N
effectiveness NN N
( ( N
three CD N
parameters NNS N
) ) N
and CC N
secondary JJ N
end NN N
points NNS N
of IN N
safety NN N
during IN N
ESD NNP N
and CC N
after IN N
return NN N
to TO N
the DT N
ward NN N
were VBD N
compared VBN N
between IN N
the DT N
groups NNS N
. . N

Study NNP N
registration NN N
was VBD N
in IN N
the DT N
UMIN NNP N
Clinical NNP N
Trial NNP N
Registry NNP N
( ( N
UMIN NNP N
000001497 CD N
) ) N
, , N
and CC N
the DT N
institutional JJ N
trial NN N
number NN N
was VBD N
KDOG NNP N
0801 CD N
. . N

RESULTS VBN N
From IN N
June NNP N
2008 CD N
through IN N
June NNP N
2009 CD N
, , N
we PRP N
enrolled VBD N
178 CD 3_p
patients NNS N
( ( N
90 CD N
midazolam NN N
, , N
88 CD N
propofol NN N
) ) N
. . N

Regarding VBG N
safety NN N
after IN N
ESD NNP N
, , N
recovery NN N
was VBD N
significantly RB N
better RBR N
in IN N
the DT N
propofol NN N
group NN N
immediately RB N
after IN N
and CC N
at IN N
1 CD N
hour NN N
and CC N
2 CD N
hours NNS N
after IN N
return NN N
to TO N
the DT N
ward NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
number NN N
of IN N
patients NNS N
who WP N
required VBD N
a DT N
continuous JJ N
supply NN N
of IN N
oxygen NN N
2 CD N
hours NNS N
after IN N
returning VBG N
to TO N
the DT N
ward NN N
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
propofol NN N
group NN N
( ( N
midazolam JJ N
18 CD N
; : N
propofol CC N
6 CD N
; : N
P NNP N
= NNP N
0.010 CD N
) ) N
. . N

Though IN N
propofol NN N
seemed VBD N
to TO N
be VB N
better JJR N
for IN N
effectiveness NN N
and CC N
safety NN N
, , N
there EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
for IN N
all DT N
three CD N
primary JJ N
end NN N
points NNS N
and CC N
the DT N
safety NN N
parameters NNS N
( ( N
hypotension NN N
, , N
hypoxia NN N
, , N
bradycardia NN N
) ) N
. . N

CONCLUSIONS NNP N
Propofol NNP N
with IN N
BIS NNP N
monitoring VBG N
improved JJ N
recovery NN N
of IN N
patients NNS N
after IN N
ESD NNP N
, , N
though IN N
this DT N
study NN N
was VBD N
underpowered VBN N
to TO N
prove VB N
the DT N
effectiveness NN N
and CC N
safety NN N
of IN N
propofol NN N
. . N

-DOCSTART- -X- O O

Utility NN N
of IN N
the DT N
bladder NN N
flap NN N
at IN N
cesarean JJ 4_p
delivery NN 4_p
: : N
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

OBJECTIVE UH N
To TO N
test VB N
the DT N
hypothesis NN N
that IN N
omission NN N
of IN N
the DT N
bladder NN N
flap NN N
in IN N
primary JJ 4_p
and CC N
repeat JJ 4_p
cesarean JJ 4_p
deliveries NNS 4_p
shortens VBZ N
operating VBG N
time NN N
without IN N
increasing VBG N
intraoperative JJ N
and CC N
postoperative JJ N
complications NNS N
. . N

METHODS NNP N
We PRP N
randomized VBD N
258 CD 3_p
women NNS 2_p
undergoing VBG N
primary JJ N
and CC N
repeat JJ N
cesarean JJ N
deliveries NNS N
at IN N
32 CD N
weeks NNS N
of IN N
gestation NN N
or CC N
more JJR N
to TO N
creation NN N
( ( N
n=131 JJ 3_p
) ) N
or CC N
omission NN N
( ( N
n=127 JJ 3_p
) ) N
of IN N
the DT N
bladder NN N
flap NN N
. . N

Emergency NNP N
cesarean JJ N
deliveries NNS N
, , N
planned VBD N
vertical JJ N
uterine NN N
incisions NNS N
, , N
and CC N
previous JJ N
abdominal JJ N
surgeries NNS N
besides IN N
cesarean JJ N
deliveries NNS N
were VBD N
excluded VBN N
. . N

The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
total JJ N
operating NN N
time NN N
. . N

Secondary JJ N
outcomes NNS N
were VBD N
bladder JJ N
injury NN N
, , N
incision-to-delivery JJ N
time NN N
, , N
incision-to-fascial JJ N
closure NN N
time NN N
, , N
estimated VBN N
blood NN N
loss NN N
, , N
postoperative JJ N
microhematuria NN N
, , N
postoperative JJ N
pain NN N
, , N
hospital NN N
days NNS N
, , N
endometritis NN N
, , N
and CC N
urinary JJ N
tract NN N
infection NN N
. . N

Analysis NN N
followed VBD N
the DT N
intention-to-treat JJ N
principle NN N
. . N

RESULTS VB N
The DT N
median JJ N
skin NN N
incision NN N
to TO N
delivery NN N
interval NN N
was VBD N
shorter JJR N
with IN N
omission NN N
of IN N
the DT N
bladder NN N
flap NN N
( ( N
9 CD N
[ NN N
range NN N
1-43 JJ N
] NNS N
compared VBN N
with IN N
10 CD N
[ JJ N
range NN N
2-70 JJ N
] NNP N
minutes NNS N
; : N
P=.04 NNP N
) ) N
, , N
but CC N
there EX N
was VBD N
no DT N
difference NN N
in IN N
total JJ N
operating NN N
time NN N
( ( N
51 CD N
[ NN N
range NN N
18-124 JJ N
] NNP N
minutes NNS N
compared VBN N
with IN N
51 CD N
[ JJ N
range NN N
16-178 JJ N
] NN N
; : N
P=.10 NNP N
) ) N
. . N

No DT N
bladder NN N
injuries NNS N
occurred VBD N
in IN N
either DT N
group NN N
and CC N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
estimated VBN N
blood NN N
loss NN N
, , N
change NN N
in IN N
hemoglobin JJ N
level NN N
, , N
postoperative JJ N
microhematuria NN N
, , N
postoperative JJ N
pain NN N
, , N
hospital NN N
days NNS N
, , N
endometritis NN N
, , N
or CC N
urinary JJ N
tract NN N
infection NN N
. . N

CONCLUSION NNP N
Omission NNP N
of IN N
the DT N
bladder NN N
flap NN N
at IN N
primary JJ N
and CC N
repeat JJ N
cesarean JJ N
deliveries NNS N
does VBZ N
not RB N
increase VB N
intraoperative JJ N
or CC N
postoperative JJ N
complications NNS N
. . N

Incision-to-delivery JJ N
time NN N
is VBZ N
shortened VBN N
but CC N
total JJ N
operating NN N
time NN N
appears VBZ N
unchanged JJ N
. . N

CLINICAL JJ N
TRIAL NNP N
REGISTRATION NNP N
ClinicalTrials.gov NNP N
, , N
www.ClinicalTrials.gov NN N
, , N
NCT00918996 NNP N
. . N

LEVEL NNP N
OF IN N
EVIDENCE NNP N
I PRP N
. . N

-DOCSTART- -X- O O

Role NNP N
of IN N
posterior JJ N
tibial JJ N
nerve NN N
stimulation NN N
in IN N
the DT N
treatment NN N
of IN N
refractory JJ N
monosymptomatic JJ N
nocturnal JJ N
enuresis NN N
: : N
a DT N
pilot NN N
study NN N
. . N

PURPOSE NNP N
We PRP N
evaluated VBD N
the DT N
early JJ N
clinical JJ N
and CC N
urodynamic JJ N
results NNS N
of IN N
posterior JJ N
tibial JJ N
nerve NN N
stimulation NN N
in IN N
patients NNS N
with IN N
refractory JJ 4_p
monosymptomatic JJ 4_p
nocturnal JJ 4_p
enuresis NN 4_p
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
We PRP N
randomly VBP N
assigned VBD N
28 CD 3_p
patients NNS N
with IN N
refractory JJ N
monosymptomatic JJ N
nocturnal JJ N
enuresis NN N
to TO N
2 CD N
equal JJ N
groups NNS N
. . N

Group NNP N
1 CD N
received VBD N
a DT N
weekly JJ N
session NN N
of IN N
posterior JJ N
tibial JJ N
nerve NN N
stimulation NN N
for IN N
12 CD N
weeks NNS N
and CC N
group NN N
2 CD N
was VBD N
the DT N
placebo NN N
group NN N
. . N

Evaluation NN N
was VBD N
performed VBN N
in IN N
each DT N
group NN N
at IN N
baseline NN N
and CC N
after IN N
posterior JJ N
tibial JJ N
nerve NN N
stimulation NN N
to TO N
compare VB N
clinical JJ N
and CC N
urodynamic JJ N
findings NNS N
. . N

Another DT N
clinical JJ N
assessment NN N
was VBD N
done VBN N
3 CD N
months NNS N
after IN N
the DT N
first JJ N
followup NN N
. . N

RESULTS VB N
The DT N
2 CD N
groups NNS N
were VBD N
comparable JJ N
in IN N
baseline JJ N
clinical JJ N
and CC N
urodynamic JJ N
data NNS N
. . N

Overall NNP N
, , N
13 CD N
patients NNS N
( ( N
46.4 CD N
% NN N
) ) N
had VBD N
detrusor VBN N
overactivity NN N
and CC N
14 CD N
( ( N
50 CD N
% NN N
) ) N
had VBD N
decreased VBN N
bladder NN N
capacity NN N
. . N

After IN N
treatment NN N
11 CD N
group NN N
1 CD N
patients NNS N
( ( N
78.6 CD N
% NN N
) ) N
had VBD N
a DT N
partial JJ N
or CC N
full JJ N
response NN N
to TO N
posterior VB N
tibial JJ N
nerve NN N
stimulation NN N
but CC N
only RB N
2 CD N
( ( N
14.3 CD N
% NN N
) ) N
in IN N
group NN N
2 CD N
had VBD N
a DT N
partial JJ N
response NN N
( ( N
p JJ N
= NNP N
0.002 CD N
) ) N
. . N

Also RB N
, , N
the DT N
average JJ N
number NN N
of IN N
wet JJ N
nights NNS N
in IN N
group NN N
1 CD N
was VBD N
significantly RB N
lower JJR N
than IN N
at IN N
baseline NN N
( ( N
p JJ N
= NNP N
0.002 CD N
) ) N
. . N

All DT N
urodynamic JJ N
parameters NNS N
significantly RB N
improved VBN N
in IN N
group NN N
1 CD N
. . N

In IN N
contrast NN N
, , N
the DT N
number NN N
of IN N
wet JJ N
nights NNS N
and CC N
urodynamic JJ N
parameters NNS N
did VBD N
not RB N
change VB N
significantly RB N
in IN N
group NN N
2 CD N
. . N

At IN N
3-month JJ N
followup NN N
the DT N
number NN N
of IN N
patients NNS N
with IN N
a DT N
partial JJ N
or CC N
full JJ N
response NN N
in IN N
group NN N
1 CD N
had VBD N
decreased VBN N
from IN N
11 CD N
( ( N
78.6 CD N
% NN N
) ) N
to TO N
6 CD N
( ( N
42.9 CD N
% NN N
) ) N
. . N

No DT N
change NN N
was VBD N
evident JJ N
in IN N
group NN N
2 CD N
. . N

CONCLUSIONS NNP N
Posterior NNP N
tibial JJ N
nerve NN N
stimulation NN N
can MD N
be VB N
a DT N
viable JJ N
treatment NN N
option NN N
in IN N
some DT N
patients NNS N
with IN N
refractory JJ N
monosymptomatic JJ N
nocturnal JJ N
enuresis NN N
. . N

However RB N
, , N
deterioration NN N
in IN N
some DT N
responders NNS N
with IN N
time NN N
suggests VBZ N
the DT N
need NN N
for IN N
maintenance NN N
protocols NNS N
. . N

-DOCSTART- -X- O O

Does VBZ N
the DT N
result NN N
of IN N
completion NN N
axillary JJ N
lymph NN N
node NN N
dissection NN N
influence NN N
the DT N
recommendation NN N
for IN N
adjuvant JJ N
treatment NN N
in IN N
sentinel JJ 4_p
lymph JJ 4_p
node-positive JJ 4_p
patients NNS N
? . N
OBJECTIVE IN N
The DT N
Hungarian NNP N
National NNP N
Institute NNP N
of IN N
Oncology NNP N
has VBZ N
just RB N
closed VBN N
a DT N
single-center JJ N
randomized JJ N
clinical JJ N
study NN N
. . N

The DT N
Optimal NNP N
Treatment NNP N
of IN N
the DT N
Axilla-Surgery NNP N
or CC N
Radiotherapy NNP N
( ( N
OTOASOR NNP N
) ) N
trial NN N
compares VBZ N
completion NN N
axillary JJ N
lymph NN N
node NN N
dissection NN N
( ( N
cALND NN N
) ) N
with IN N
regional JJ N
nodal JJ N
irradiation NN N
( ( N
RNI NNP N
) ) N
in IN N
patients NNS N
with IN N
sentinel JJ 4_p
lymph JJ 4_p
node-positive JJ 4_p
( ( 4_p
SLN+ NNP 4_p
) ) 4_p
primary VBP 4_p
invasive JJ 4_p
breast NN 4_p
cancer NN 4_p
. . N

In IN N
the DT N
investigational JJ N
treatment NN N
arm NN N
, , N
patients NNS N
received VBD N
50 CD N
Gy NNP N
RNI NNP N
instead RB N
of IN N
cALND NN N
. . N

In IN N
these DT N
patients NNS N
we PRP N
had VBD N
information NN N
only RB N
about IN N
the DT N
sentinel NN N
lymph NN N
node NN N
( ( N
SLN NNP N
) ) N
status NN N
, , N
but CC N
the DT N
further JJ N
axillary JJ N
nodal JJ N
involvement NN N
remained VBD N
unknown JJ N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
whether IN N
the DT N
result NN N
of IN N
cALND NN N
influenced VBD N
the DT N
recommendation NN N
for IN N
adjuvant JJ N
treatment NN N
in IN N
patients NNS N
with IN N
SLN+ NNP 4_p
breast NN 4_p
cancer NN 4_p
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Patients NNPS N
with IN N
SLN+ NNP 4_p
primary JJ 4_p
breast NN 4_p
cancer NN 4_p
were VBD N
randomized VBN N
for IN N
cALND NN N
( ( N
arm NN N
A NNP N
, , N
standard JJ N
treatment NN N
) ) N
or CC N
RNI NNP N
( ( N
arm NN N
B NNP N
, , N
investigational JJ N
treatment NN N
) ) N
. . N

Adjuvant JJ N
systemic JJ N
treatments NNS N
were VBD N
given VBN N
according VBG N
to TO N
the DT N
standard JJ N
institutional JJ N
protocol NN N
, , N
and CC N
patients NNS N
were VBD N
followed VBN N
according VBG N
to TO N
the DT N
actual JJ N
institutional JJ N
guidelines NNS N
. . N

RESULTS NNP N
Between NNP N
August NNP N
2002 CD N
and CC N
June NNP N
2009 CD N
, , N
474 CD 3_p
SLN+ NN 4_p
patients NNS N
were VBD N
randomized VBN N
to TO N
cALND VB N
( ( N
arm NN N
A NNP N
, , N
standard JJ N
treatment NN N
= JJ N
244 CD N
patients NNS N
) ) N
or CC N
RNI NNP N
( ( N
arm NN N
B NNP N
, , N
investigational JJ N
treatment NN N
= VBD N
230 CD N
patients NNS N
) ) N
. . N

The DT N
2 CD N
arms NNS N
were VBD N
well RB N
balanced VBN N
according VBG N
to TO N
the DT N
majority NN N
of IN N
main JJ N
prognostic JJ N
factors NNS N
. . N

However RB N
, , N
more JJR N
patients NNS N
were VBD N
premenopausal JJ 4_p
( ( N
34 CD N
% NN N
vs. FW N
27 CD N
% NN N
; : N
P NNP N
= NNP N
.095 NNP N
) ) N
and CC N
had VBD N
pT2-3 NN N
tumors NNS N
( ( N
57 CD N
% NN N
vs. FW N
40 CD N
% NN N
; : N
P NNP N
= NNP N
.003 NNP N
) ) N
in IN N
the DT N
completion NN N
axillary JJ N
lymph NN N
node NN N
dissection NN N
( ( N
ALND NNP N
) ) N
arm NN N
. . N

On IN N
the DT N
other JJ N
hand NN N
, , N
there EX N
were VBD N
more JJR N
patients NNS N
with IN N
known JJ N
human JJ N
epidermal JJ N
growth NN N
factor NN N
receptor NN N
type VBD N
2 CD N
positive JJ N
tumor NN N
( ( N
12 CD N
% NN N
vs. FW N
17 CD N
% NN N
, , N
P NNP N
= NNP N
.066 NNP N
) ) N
in IN N
the DT N
RNI NNP N
arm NN N
. . N

In IN N
the DT N
ALND NNP N
and CC N
RNI NNP N
arms NNS N
, , N
78 CD N
% NN N
( ( N
190/244 CD N
) ) N
and CC N
69 CD N
% NN N
( ( N
159/230 CD N
) ) N
, , N
respectively RB N
, , N
received VBD N
chemotherapy NN N
( ( N
P NNP N
= NNP N
.020 NNP N
) ) N
. . N

Endocrine NNP N
therapy NN N
was VBD N
administered VBN N
in IN N
87 CD N
% NN N
( ( N
213/244 CD N
) ) N
of IN N
the DT N
patients NNS N
in IN N
the DT N
ALND NNP N
arm NN N
and CC N
89 CD N
% NN N
( ( N
204/230 CD N
) ) N
of IN N
the DT N
patients NNS N
in IN N
the DT N
RNI NNP N
arm NN N
( ( N
P NNP N
= NNP N
.372 NNP N
) ) N
. . N

Six CD N
patients NNS N
( ( N
2.5 CD N
% NN N
) ) N
on IN N
arm NN N
A NN N
and CC N
13 CD N
patients NNS N
( ( N
5.7 CD N
% NN N
) ) N
on IN N
arm NN N
B NNP N
received VBD N
adjuvant JJ N
trastuzumab NN N
treatment NN N
( ( N
P NNP N
= NNP N
not RB N
significant JJ N
) ) N
. . N

Subgroup NNP N
analyses VBZ N
explored VBD N
that IN N
more RBR N
frequent JJ N
administration NN N
of IN N
adjuvant JJ N
chemotherapy NN N
in IN N
arm NN N
A NN N
was VBD N
associated VBN N
with IN N
the DT N
higher JJR N
percentage NN N
of IN N
premenopausal NN N
patients NNS N
and CC N
patients NNS N
with IN N
larger JJR N
( ( 4_p
pT2-3 NN 4_p
) ) 4_p
tumors NNS 4_p
. . N

CONCLUSIONS VB N
The DT N
result NN N
of IN N
cALND NN N
after IN N
positive JJ N
SLN NNP N
biopsy NN N
seems VBZ N
to TO N
have VB N
no DT N
major JJ N
impact NN N
on IN N
the DT N
administration NN N
of IN N
adjuvant JJ N
systemic JJ N
therapy NN N
. . N

-DOCSTART- -X- O O

The DT N
effectiveness NN N
of IN N
physical JJ N
activity NN N
monitoring NN N
and CC N
distance NN N
counselling NN N
in IN N
an DT N
occupational JJ N
health NN N
setting NN N
-- : N
a DT N
research NN N
protocol NN N
for IN N
a DT N
randomised JJ N
controlled VBN N
trial NN N
( ( N
CoAct NNP N
) ) N
. . N

BACKGROUND IN N
The DT N
CoAct NNP N
( ( N
Cocreating NNP N
Activity NNP N
) ) N
study NN N
is VBZ N
investigating VBG N
a DT N
novel JJ N
lifestyle JJ N
intervention NN N
, , N
aimed VBN N
at IN N
the DT N
working VBG 4_p
population NN 4_p
, , N
with IN N
daily JJ N
activity NN N
monitoring NN N
and CC N
distance NN N
counselling NN N
via IN N
telephone NN N
and CC N
secure NN N
web NN N
messages NNS N
. . N

The DT N
main JJ N
purpose NN N
of IN N
this DT N
study NN N
is VBZ N
to TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
lifestyle JJ N
counselling VBG N
on IN N
the DT N
level NN N
of IN N
physical JJ N
activity NN N
in IN N
an DT N
occupational JJ N
health NN N
setting NN N
. . N

The DT N
purposes NNS N
include VBP N
also RB N
analysing VBG N
the DT N
potential JJ N
effects NNS N
of IN N
changes NNS N
in IN N
physical JJ N
activity NN N
on IN N
productivity NN N
at IN N
work NN N
and CC N
sickness JJ N
absence NN N
, , N
and CC N
healthcare NN N
costs NNS N
. . N

This DT N
article NN N
describes VBZ N
the DT N
design NN N
of IN N
the DT N
study NN N
and CC N
the DT N
participant NN N
flow NN N
until IN N
and CC N
including VBG N
randomization NN N
. . N

METHODS/DESIGN NNP N
CoAct NNP N
is VBZ N
a DT N
randomised JJ N
controlled VBN N
trial NN N
with IN N
two CD N
arms NNS N
: : N
a DT N
control NN N
group NN N
and CC N
intervention NN N
group NN N
with IN N
daily JJ N
activity NN N
monitoring NN N
and CC N
distance NN N
counselling NN N
. . N

The DT N
intervention NN N
focuses VBZ N
on IN N
lifestyle JJ N
modification NN N
and CC N
takes VBZ N
12 CD N
months NNS N
. . N

The DT N
study NN N
population NN N
consists VBZ N
of IN N
volunteers NNS N
from IN N
1100 CD 3_p
eligible JJ N
employees NNS N
of IN N
a DT N
Finnish JJ N
insurance NN N
company NN N
. . N

The DT N
primary JJ N
outcomes NNS N
of IN N
this DT N
study NN N
are VBP N
change NN N
in IN N
physical JJ N
activity NN N
measured VBN N
in IN N
MET NNP N
minutes NNS N
per IN N
week NN N
, , N
work NN N
productivity NN N
and CC N
sickness NN N
absence NN N
, , N
and CC N
healthcare JJ N
utilisation NN N
. . N

Secondary JJ N
outcomes NNS N
include VBP N
various JJ N
physiological JJ N
measures NNS N
. . N

Cost-effectiveness JJ N
analysis NN N
will MD N
also RB N
be VB N
performed VBN N
. . N

The DT N
outcomes NNS N
will MD N
be VB N
measured VBN N
by IN N
questionnaires NNS N
at IN N
baseline NN N
, , N
after IN N
6 CD N
, , N
12 CD N
, , N
and CC N
24 CD N
months NNS N
, , N
and CC N
sickness JJ N
absence NN N
will MD N
be VB N
obtained VBN N
from IN N
the DT N
employer NN N
's POS N
registers NNS N
. . N

DISCUSSION NNP N
No NNP N
trials NNS N
are VBP N
yet RB N
available JJ N
that WDT N
have VBP N
evaluated VBN N
the DT N
effectiveness NN N
of IN N
daily JJ N
physical JJ N
activity NN N
monitoring NN N
and CC N
distance NN N
counselling NN N
in IN N
an DT N
occupational JJ N
health NN N
setting NN N
over IN N
a DT N
12 CD N
month NN N
period NN N
and CC N
no DT N
data NN N
on IN N
cost-effectiveness NN N
of IN N
such JJ N
intervention NN N
are VBP N
available JJ N
. . N

TRIAL NNP N
REGISTRATION NNP N
ClinicalTrials.gov NNP N
identifier NN N
: : N
NCT00994565 NNP N
. . N

-DOCSTART- -X- O O

Sunbathing VBG N
and CC N
sunbed VBN N
use NN N
related VBN N
to TO N
self-image NN N
in IN N
a DT N
randomized JJ N
sample NN N
of IN N
Swedish JJ N
adolescents NNS 1_p
. . N

In IN N
1996 CD N
a DT N
randomized JJ N
sample NN N
of IN N
4,020 CD 3_p
Swedish JJ N
adolescents NNS 1_p
from IN N
three CD N
birth NN N
cohorts NNS N
were VBD N
sent VBN N
a DT N
questionnaire NN N
consisting NN N
of IN N
50 CD N
items NNS N
concerning VBG N
habitual JJ N
sun-related JJ N
behaviours NNS N
and CC N
attitudes NNS N
, , N
knowledge NN N
about IN N
melanoma NN N
, , N
risk NN N
perception NN N
and CC N
self-image NN N
. . N

A DT N
total NN N
of IN N
2,615 CD 3_p
questionnaires NNS N
were VBD N
returned VBN N
. . N

Girls NNP 2_p
sunbathed VBD N
and CC N
used VBD N
sunbeds NNS N
more RBR N
than IN N
boys NNS 2_p
at IN N
all DT N
ages NNS N
. . N

Sunbathing VBG N
and CC N
sunbed VBN N
use NN N
increased VBN N
with IN N
age NN N
. . N

Boys NNS N
who WP N
were VBD N
most RBS N
satisfied JJ N
and CC N
girls NNS N
least JJS N
satisfied JJ N
with IN N
themselves PRP N
sunbathed VBD N
most JJS N
. . N

Those DT N
who WP N
were VBD N
least JJS N
satisfied JJ N
with IN N
themselves PRP N
used VBD N
sunbeds NNS N
most RBS N
frequently RB N
. . N

Girls NNP N
reported VBD N
a DT N
higher JJR N
perceived JJ N
susceptibility NN N
to TO N
melanoma VB N
than IN N
did VBD N
boys VB N
. . N

The DT N
perception NN N
of IN N
susceptibility NN N
increased VBN N
with IN N
age NN N
. . N

Those DT N
who WP N
were VBD N
least JJS N
satisfied JJ N
with IN N
themselves PRP N
reported VBD N
feeling VBG N
most RBS N
susceptible JJ N
. . N

The DT N
overall JJ N
main JJ N
reason NN N
for IN N
sunbathing NN N
was VBD N
appearance NN N
, , N
both DT N
for IN N
own JJ N
sunbathing NN N
, , N
and CC N
to TO N
an DT N
even RB N
higher JJR N
degree NN N
, , N
as IN N
a DT N
supposed JJ N
reason NN N
for IN N
other JJ N
adolescents NNS N
' POS N
behaviour NN N
, , N
and CC N
was VBD N
reported VBN N
most JJS N
frequently RB N
by IN N
girls NNS N
and CC N
the DT N
older JJR N
age NN N
groups NNS N
. . N

The DT N
second JJ N
most RBS N
'important JJ N
' POS N
reason NN N
for IN N
sunbathing NN N
was VBD N
'feeling VBG N
warm JJ N
and CC N
comfortable JJ N
' '' N
. . N

Preventive JJ N
programmes NNS N
aimed VBN N
at IN N
a DT N
change NN N
of IN N
sun NN N
related VBN N
behaviours NNS N
among IN N
Swedish JJ N
adolescents NNS N
have VBP N
to TO N
be VB N
tailored VBN N
to TO N
the DT N
climate NN N
and CC N
cultural JJ N
conditions NNS N
and CC N
must MD N
take VB N
into IN N
account NN N
that IN N
having VBG N
a DT N
tan NN N
, , N
and CC N
the DT N
warmth NN N
of IN N
the DT N
sun NN N
, , N
are VBP N
highly RB N
valued VBN N
by IN N
most JJS N
adolescents NNS N
. . N

-DOCSTART- -X- O O

Comparison NNP N
of IN N
the DT N
in IN N
vitro NN N
and CC N
in IN N
vivo JJ N
release NN N
of IN N
digoxin NN N
from IN N
four CD N
different JJ N
soft JJ N
gelatin NN N
capsule NN N
formulations NNS N
. . N

A DT N
blinded JJ N
, , N
four-treatment JJ N
crossover NN N
study NN N
in IN N
16 CD 3_p
normal JJ N
adult NN 1_p
male NN 2_p
volunteers NNS N
compared VBN N
plasma JJ N
concentrations NNS N
and CC N
urinary JJ N
excretion NN N
of IN N
digoxin NN N
, , N
measured VBN N
by IN N
radioimmunoassay NN N
, , N
after IN N
oral JJ N
administration NN N
of IN N
soft JJ N
gelatin NN N
capsule NN N
formulations NNS N
of IN N
digoxin NN N
. . N

Four CD N
0.4-mg JJ N
formulations NNS N
with IN N
different JJ N
in IN N
vitro NN N
burst NN N
times NNS N
and CC N
dissolution NN N
rates NNS N
were VBD N
administered VBN N
, , N
with IN N
2-week JJ N
intervals NNS N
between IN N
treatments NNS N
. . N

The DT N
two CD N
capsules NNS N
with IN N
lowest JJS N
in IN N
vitro NN N
burst NN N
times NNS N
( ( N
2.9 CD N
and CC N
16 CD N
min NN N
) ) N
gave VBD N
comparable JJ N
in IN N
vivo JJ N
results NNS N
. . N

The DT N
other JJ N
two CD N
capsules NNS N
, , N
with IN N
in IN N
vitro NN N
burst NN N
times NNS N
of IN N
62 CD N
and CC N
229 CD N
min NN N
, , N
produced VBD N
significant JJ N
delays NNS N
in IN N
digoxin NN N
absorption NN N
. . N

In IN N
vitro-in JJ N
vivo NN N
correlations NNS N
were VBD N
obtained VBN N
by IN N
comparing VBG N
the DT N
logarithm NN N
of IN N
the DT N
in IN N
vitro JJ N
burst NN N
time NN N
with IN N
time NN N
to TO N
peak VB N
plasma JJ N
level NN N
and CC N
the DT N
time NN N
to TO N
the DT N
first JJ N
measurable JJ N
plasma NN N
level NN N
( ( N
> CD N
or CC N
= VB N
0 CD N
. . N

05 CD N
ng/ml NN N
) ) N
. . N

Also RB N
, , N
the DT N
mean JJ N
time NN N
to TO N
peak VB N
plasma JJ N
level NN N
correlated VBN N
with IN N
the DT N
logarithm NN N
of IN N
the DT N
time NN N
required VBN N
to TO N
release VB N
either RB N
50 CD N
% NN N
or CC N
85 CD N
% NN N
of IN N
the DT N
digoxin NN N
in IN N
vitro NN N
. . N

No DT N
significant JJ N
changes NNS N
were VBD N
found VBN N
in IN N
the DT N
amount NN N
of IN N
digoxin NN N
absorbed VBN N
from IN N
each DT N
capsule NN N
as IN N
determined VBN N
by IN N
urinary JJ N
excretion NN N
or CC N
AUC0-infinity NN N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
upper JJ N
arm NN N
brachial NN N
basilic NN N
and CC N
prosthetic JJ N
forearm NN N
arteriovenous JJ N
fistula NN N
on IN N
left JJ N
ventricular JJ N
hypertrophy NN N
. . N

BACKGROUND NNP N
Creation NNP N
of IN N
an DT N
arteriovenous JJ N
fistula NN N
( ( N
AVF NNP N
) ) N
may MD N
increase VB N
left VBD N
ventricular JJ N
hypertrophy NN N
in IN N
the DT N
hemodialysis NN 4_p
population NN N
. . N

Aim NNP N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
effects NNS N
of IN N
a DT N
brachial-basilic JJ N
( ( N
BB NNP N
) ) N
AVF NNP N
and CC N
the DT N
prosthetic JJ N
brachial-antecubital JJ N
forearm NN N
loop NN N
access NN N
( ( N
PTFE NNP N
) ) N
on IN N
cardiac JJ N
performance NN N
. . N

METHODS JJ N
Patients NNPS N
were VBD N
randomized VBN N
to TO N
receive VB N
BB-AVF NNP N
or CC N
prosthetic JJ N
brachial-antecubital JJ N
forearm NN N
loop NN N
access NN N
. . N

Before IN N
and CC N
three CD N
months NNS N
after IN N
AVF NNP N
creation NN N
patients NNS N
underwent VBD N
an DT N
echocardiographic JJ N
examination NN N
. . N

Mann-Whitney JJ N
U-test NNP N
was VBD N
used VBN N
to TO N
compare VB N
relative JJ N
increase NN N
between IN N
the DT N
measured JJ N
cardiac JJ N
parameters NNS N
for IN N
the DT N
two CD N
groups NNS N
. . N

RESULTS NNP N
Twenty-seven JJ 3_p
patients NNS N
participated VBN N
in IN N
the DT N
study NN N
. . N

The DT N
relative JJ N
increase NN N
in IN N
left JJ N
ventricular JJ N
parameters NNS N
was VBD N
not RB N
significantly RB N
different JJ N
between IN N
the DT N
two CD N
groups NNS N
. . N

Only RB N
left VBD N
ventricular JJ N
end-diastolic JJ N
diameter NN N
tended VBD N
to TO N
be VB N
of IN N
significance NN N
. . N

Mean NNP N
blood NN N
flow NN N
through IN N
the DT N
brachial JJ N
artery NN N
was VBD N
1680+/-156 JJ N
and CC N
1450+/-221 JJ N
mL/min NNS N
three CD N
months NNS N
after IN N
surgery NN N
for IN N
the DT N
PTFE NNP N
and CC N
the DT N
BB-AVF NNP N
group NN N
, , N
respectively RB N
. . N

CONCLUSION NN N
After IN N
three CD N
months NNS N
of IN N
follow-up NN N
, , N
changes NNS N
in IN N
cardiac JJ N
structure NN N
were VBD N
comparable JJ N
between IN N
patients NNS N
with IN N
BB NNP 4_p
and CC N
PTFE NNP 4_p
AVFs NNP 4_p
. . N

Also RB N
access NN N
flow NN N
was VBD N
comparable JJ N
at IN N
this DT N
time NN N
. . N

In IN N
general JJ N
, , N
the DT N
effects NNS N
of IN N
creation NN N
of IN N
a DT N
fistula NN N
on IN N
LV NNP N
structure NN N
were VBD N
limited VBN N
. . N

Longer RBR N
follow VB N
up RP N
time NN N
may MD N
be VB N
needed VBN N
to TO N
explore VB N
the DT N
long JJ N
term NN N
effects NNS N
of IN N
different JJ N
vascular JJ N
accesses NNS N
on IN N
cardiac JJ N
function NN N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
a DT N
multi-faceted JJ N
intervention NN N
on IN N
gingival JJ N
health NN N
among IN N
adults NNS 1_p
with IN N
systemic JJ 4_p
sclerosis NN 4_p
. . N

OBJECTIVES NNP N
To TO N
evaluate VB N
the DT N
effect NN N
of IN N
adaptive JJ N
oral JJ N
hygiene NN N
devices NNS N
and CC N
orofacial JJ N
exercise NN N
to TO N
improve VB N
gingival JJ N
health NN N
among IN N
adults NNS 1_p
with IN N
systemic JJ 4_p
sclerosis NN 4_p
( ( N
SSc NNP 4_p
) ) N
. . N

METHODS NNP N
Forty-eight JJ 3_p
patients NNS N
with IN N
SSc NNP 4_p
were VBD N
assigned VBN N
randomly RB N
to TO N
the DT N
multifaceted VBN N
oral JJ N
health NN N
intervention NN N
or CC N
usual JJ N
dental JJ N
care NN N
control NN N
group NN N
. . N

Participants NNS N
in IN N
the DT N
intervention NN N
group NN N
received VBD N
a DT N
rechargeable JJ N
, , N
powered JJ N
Oral-B? NNP N
oscillating-rotating-pulsating NN N
toothbrush NN N
and CC N
a DT N
Reach? NNP N
Access? NNP N
Flosser NNP N
that WDT N
has VBZ N
a DT N
toothbrush-like JJ N
handle NN N
. . N

For IN N
those DT N
with IN N
an DT N
oral JJ N
aperture NN N
of IN N
less JJR N
than IN N
40 CD N
mm NN N
, , N
orofacial JJ N
exercises NNS N
were VBD N
taught VBN N
. . N

Participants NNS N
in IN N
the DT N
control NN N
group NN N
were VBD N
each DT N
given VBN N
a DT N
manual JJ N
toothbrush NN N
and CC N
dental JJ N
floss NN N
. . N

Participants NNS N
in IN N
both DT N
groups NNS N
received VBD N
instructions NNS N
and CC N
demonstration NN N
on IN N
the DT N
use NN N
of IN N
the DT N
devices NNS N
, , N
and CC N
were VBD N
requested VBN N
to TO N
perform VB N
the DT N
respective JJ N
intervention NN N
twice RB N
a DT N
day NN N
for IN N
6 CD N
months NNS N
. . N

Evaluations NNS N
were VBD N
at IN N
baseline NN N
, , N
3- JJ N
, , N
and CC N
6-months NNS N
. . N

The DT N
main JJ N
outcome NN N
was VBD N
gingival JJ N
index NN N
( ( N
GI NNP N
) ) N
, , N
an DT N
indicator NN N
of IN N
gingival JJ N
inflammation NN N
. . N

RESULTS NNP N
Both NNP N
groups NNS N
showed VBD N
significant JJ N
reduction NN N
in IN N
GI NNP N
scores NNS N
at IN N
6 CD N
months NNS N
( ( N
ps JJ N
< NNP N
0.005 CD N
) ) N
. . N

Reduction NN N
in IN N
GI NNP N
scores NNS N
of IN N
the DT N
intervention NN N
group NN N
at IN N
6 CD N
months NNS N
was VBD N
20.8 CD N
% NN N
which WDT N
is VBZ N
considered VBN N
to TO N
be VB N
clinically RB N
significant JJ N
. . N

Compared VBN N
to TO N
the DT N
control NN N
group NN N
, , N
the DT N
intervention NN N
group NN N
showed VBD N
a DT N
significant JJ N
and CC N
larger JJR N
reduction NN N
in IN N
GI NNP N
score NN N
by IN N
8 CD N
% NN N
at IN N
6 CD N
months NNS N
( ( N
p=0.0007 NN N
) ) N
. . N

CONCLUSIONS JJ N
Results NNP N
support NN N
the DT N
use NN N
of IN N
adaptive JJ N
devices NNS N
and CC N
orofacial JJ N
exercise NN N
to TO N
improve VB N
gingival NN N
health NN N
in IN N
adults NNS N
with IN N
SSc NNP N
when WRB N
compared VBN N
to TO N
use VB N
of IN N
manual JJ N
toothbrushing NN N
and CC N
finger-held JJ N
flossing NN N
. . N

Recommending VBG N
and CC N
educating VBG N
patients NNS N
with IN N
SSc NNP N
to TO N
use VB N
adaptive JJ N
devices NNS N
to TO N
clean VB N
the DT N
tooth NN N
surfaces NNS N
looks VBZ N
promising VBG N
for IN N
long-term JJ N
oral JJ N
health NN N
improvement NN N
. . N

-DOCSTART- -X- O O

Immunological JJ N
changes NNS N
after IN N
minimally RB N
invasive JJ N
or CC N
conventional JJ N
esophageal JJ N
resection NN N
for IN N
cancer NN 4_p
: : N
a DT N
randomized JJ N
trial NN N
. . N

BACKGROUND VB N
This DT N
study NN N
was VBD N
performed VBN N
as IN N
a DT N
substudy NN N
analysis NN N
of IN N
a DT N
randomized JJ N
trial NN N
comparing VBG N
conventional JJ N
open JJ N
esophagectomy NN N
[ NNP N
open JJ N
surgical JJ N
technique NN N
( ( N
OE NNP N
) ) N
] NN N
by IN N
thoracotomy NN N
and CC N
laparotomy NN N
with IN N
minimally RB N
invasive JJ N
esophagectomy NN N
[ NNP N
minimally RB N
invasive JJ N
procedure NN N
( ( N
MIE NNP N
) ) N
] NN N
by IN N
thoracoscopy NN N
and CC N
laparoscopy NN N
. . N

This DT N
additional JJ N
analysis NN N
focuses VBZ N
on IN N
the DT N
immunological JJ N
changes NNS N
and CC N
surgical JJ N
stress NN N
response NN N
in IN N
these DT N
two CD N
randomized VBD N
groups NNS N
of IN N
a DT N
single JJ N
center NN N
. . N

METHODS NNP N
Patients NNPS N
with IN N
a DT N
resectable JJ 4_p
esophageal NN 4_p
cancer NN 4_p
were VBD N
randomized VBN N
to TO N
OE NNP N
( ( N
n JJ N
= NNP N
13 CD 3_p
) ) N
or CC N
MIE NNP N
( ( N
n JJ N
= NNP N
14 CD 3_p
) ) N
. . N

All DT N
patients NNS N
received VBD N
neoadjuvant JJ N
chemoradiotherapy NN N
. . N

The DT N
immunological JJ N
response NN N
was VBD N
measured VBN N
by IN N
means NNS N
of IN N
leukocyte NN N
counts NNS N
, , N
HLA-DR NNP N
expression NN N
on IN N
monocytes NNS N
, , N
the DT N
acute-phase JJ N
response NN N
by IN N
means NNS N
of IN N
C-reactive JJ N
protein NN N
( ( N
CRP NNP N
) ) N
, , N
interleukin-6 JJ N
( ( N
IL-6 NNP N
) ) N
, , N
and CC N
interleukin-8 JJ N
( ( N
IL-8 NNP N
) ) N
, , N
and CC N
the DT N
stress NN N
response NN N
was VBD N
measured VBN N
by IN N
cortisol NN N
, , N
growth NN N
hormone NN N
, , N
and CC N
prolactin NN N
. . N

All DT N
parameters NNS N
were VBD N
determined VBN N
at IN N
baseline NN N
( ( N
preoperatively RB N
) ) N
and CC N
24 CD N
, , N
72 CD N
, , N
96 CD N
, , N
and CC N
168 CD N
h NN N
postoperatively RB N
. . N

RESULTS NNP N
Significant JJ N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
were VBD N
seen VBN N
in IN N
favor NN N
of IN N
the DT N
MIE NNP N
group NN N
with IN N
regard NN N
to TO N
leukocyte VB N
counts NNS N
, , N
IL-8 NNP N
, , N
and CC N
prolactin NN N
at IN N
168 CD N
h NN N
( ( N
1 CD N
week NN N
) ) N
postoperatively RB N
. . N

For IN N
HLA-DR NNP N
expression NN N
, , N
IL-6 NNP N
, , N
and CC N
CRP NNP N
levels NNS N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
, , N
although IN N
there EX N
was VBD N
a DT N
clear JJ N
rise NN N
in IN N
levels NNS N
upon IN N
operation NN N
in IN N
both DT N
groups NNS N
. . N

CONCLUSION NNP N
In IN N
this DT N
substudy NN N
of IN N
a DT N
randomized JJ N
trial NN N
comparing VBG N
minimally RB N
invasive JJ N
and CC N
conventional JJ N
open JJ N
esophagectomies NNS N
for IN N
cancer NN N
, , N
significantly RB N
better RBR N
preserved VBN N
leukocyte JJ N
counts NNS N
and CC N
IL-8 JJ N
levels NNS N
were VBD N
observed VBN N
in IN N
the DT N
MIE NNP N
group NN N
compared VBN N
to TO N
the DT N
open JJ N
group NN N
. . N

Both DT N
findings NNS N
can MD N
be VB N
related VBN N
to TO N
fewer JJR N
respiratory NN N
infections NNS N
found VBD N
postoperatively RB N
in IN N
the DT N
MIE NNP N
group NN N
. . N

Moreover RB N
, , N
significant JJ N
differences NNS N
in IN N
the DT N
prolactin NN N
levels NNS N
at IN N
168 CD N
h NN N
after IN N
surgery NN N
imply NN N
that IN N
the DT N
stress NN N
response NN N
is VBZ N
better RBR N
preserved VBN N
in IN N
the DT N
MIE NNP N
group NN N
. . N

These DT N
findings NNS N
indicate VBP N
that IN N
less JJR N
surgical JJ N
trauma NN N
could MD N
lead VB N
to TO N
better JJR N
preserved VBN N
acute-phase NN N
and CC N
stress NN N
responses NNS N
and CC N
fewer JJR N
clinical JJ N
manifestations NNS N
of IN N
respiratory JJ N
infections NNS N
. . N

-DOCSTART- -X- O O

The DT N
dipeptidyl JJ N
peptidase-4 JJ N
inhibitor NN N
PHX1149 NNP N
improves VBZ N
blood NN N
glucose NN N
control NN N
in IN N
patients NNS N
with IN N
type JJ 4_p
2 CD 4_p
diabetes NNS 4_p
mellitus RB 4_p
. . N

AIM NNP N
To TO N
determine VB N
the DT N
efficacy NN N
and CC N
tolerability NN N
of IN N
PHX1149 NNP N
, , N
a DT N
novel JJ N
dipeptidyl NN N
peptidase-4 NN N
( ( N
DPP4 NNP N
) ) N
inhibitor NN N
, , N
in IN N
patients NNS N
with IN N
type JJ 4_p
2 CD 4_p
diabetes NNS 4_p
. . N

METHODS NNP N
This DT N
is VBZ N
a DT N
multicentre NN N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
4-week JJ N
study NN N
in IN N
patients NNS N
with IN N
type JJ N
2 CD N
diabetes NNS N
with IN N
suboptimal JJ N
metabolic JJ N
control NN N
. . N

Patients NNS N
with IN N
a DT N
baseline NN N
haemoglobin NN N
A NNP N
( ( N
1c CD N
) ) N
( ( N
HbA NNP N
( ( N
1c CD N
) ) N
) ) N
of IN N
7.3 CD N
to TO N
11.0 CD N
% NN N
were VBD N
randomized VBN N
1 CD N
: : N
1 CD N
: : N
1 CD N
: : N
1 CD N
to TO N
receive VB N
once-daily JJ N
oral JJ N
therapy NN N
with IN N
either DT N
PHX1149 NNP N
( ( N
100 CD N
, , N
200 CD N
or CC N
400 CD N
mg NN N
) ) N
or CC N
placebo NN N
; : N
patients NNS N
were VBD N
on IN N
a DT N
constant JJ N
background NN N
therapy NN N
of IN N
either DT N
metformin NN N
alone RB N
or CC N
metformin JJ N
plus CC N
a DT N
glitazone NN N
. . N

RESULTS NNP N
Treatment NNP N
with IN N
100 CD N
, , N
200 CD N
or CC N
400 CD N
mg NN N
of IN N
PHX1149 NNP N
significantly RB N
decreased VBD N
postprandial JJ N
glucose JJ N
area NN N
under IN N
the DT N
curve NN N
AUC NNP N
( ( N
0-2 JJ N
h NN N
) ) N
by IN N
approximately RB N
20 CD N
% NN N
( ( N
+0.11 JJ N
+/- JJ N
0.50 CD N
, , N
-2.08 VBD N
+/- JJ N
0.51 CD N
, , N
-1.73 VBD N
+/- JJ N
0.49 CD N
and CC N
-1.88 VB N
+/- JJ N
0.48 CD N
mmol/l NN N
x NN N
h NN N
, , N
respectively RB N
, , N
for IN N
placebo NN N
and CC N
100 CD N
, , N
200 CD N
and CC N
400 CD N
mg NN N
( ( N
p JJ N
= NN N
0.002 CD N
, , N
0.008 CD N
and CC N
0.004 CD N
vs. FW N
placebo NN N
) ) N
. . N

Postprandial JJ N
AUC NNP N
( ( N
0-2 JJ N
h NN N
) ) N
of IN N
intact JJ N
glucagon-like JJ N
peptide-1 NN N
, , N
the DT N
principal JJ N
mediator NN N
of IN N
the DT N
biological JJ N
effects NNS N
of IN N
DPP4 NNP N
inhibitors NNS N
, , N
was VBD N
increased VBN N
by IN N
3.90 CD N
+/- JJ N
2.83 CD N
, , N
11.63 CD N
+/- JJ N
2.86 CD N
, , N
16.42 CD N
+/- JJ N
2.72 CD N
and CC N
15.75 CD N
+/- JJ N
2.71 CD N
pmol/l NN N
x NN N
h NN N
, , N
respectively RB N
, , N
for IN N
placebo NN N
and CC N
100 CD N
, , N
200 CD N
and CC N
400 CD N
mg NN N
( ( N
p JJ N
= NN N
0.053 CD N
, , N
0.001 CD N
and CC N
0.002 CD N
vs. FW N
placebo NN N
) ) N
. . N

Mean JJ N
HbA NNP N
( ( N
1c CD N
) ) N
was VBD N
lower JJR N
in IN N
all DT N
dose JJ N
groups NNS N
; : N
the DT N
placebo-corrected JJ N
change NN N
in IN N
the DT N
groups NNS N
receiving VBG N
400 CD N
mg JJ N
PHX1149 NNP N
was VBD N
-0.28 VBN N
% NN N
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
. . N

DPP4 NNP N
inhibition NN N
on IN N
day NN N
28 CD N
was VBD N
53 CD N
, , N
73 CD N
and CC N
78 CD N
% NN N
at IN N
24 CD N
h NN N
postdose NN N
in IN N
the DT N
groups NNS N
receiving VBG N
100 CD N
, , N
200 CD N
and CC N
400 CD N
mg NN N
PHX1149 NNP N
, , N
respectively RB N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
adverse JJ N
events NNS N
between IN N
PHX1149-treated NNP N
and CC N
placebo JJ N
subjects NNS N
. . N

CONCLUSIONS NNP N
Addition NNP N
of IN N
the DT N
DPP4 NNP N
inhibitor NN N
PHX1149 NNP N
to TO N
a DT N
stable JJ N
regimen NN N
of IN N
metformin NN N
or CC N
metformin NN N
plus CC N
a DT N
glitazone NN N
in IN N
patients NNS N
with IN N
type JJ N
2 CD N
diabetes NNS N
was VBD N
well RB N
tolerated VBN N
and CC N
improved VBN N
blood NN N
glucose NN N
control NN N
. . N

-DOCSTART- -X- O O

The DT N
costs NNS N
and CC N
effects NNS N
of IN N
a DT N
nutritional JJ N
education NN N
program NN N
following VBG N
work-site JJ N
cholesterol NN N
screening NN N
. . N

OBJECTIVES CC N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
assess VB N
the DT N
costs NNS N
and CC N
impact NN N
of IN N
a DT N
nutrition JJ N
education NN N
program NN N
following VBG N
a DT N
cholesterol NN N
screening NN N
. . N

METHODS NNP N
Forty NNP 3_p
work-sites NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
two CD N
educational JJ N
interventions NNS N
: : N
a DT N
usual JJ N
intervention NN N
of IN N
5 CD N
minutes NNS N
of IN N
counseling NN N
, , N
or CC N
a DT N
special JJ N
intervention NN N
of IN N
2 CD N
hours NNS N
of IN N
behaviorally RB N
based VBN N
education NN N
on IN N
dietary JJ N
changes NNS N
to TO N
lower VB N
serum NN N
cholesterol NN N
. . N

Costs NNS N
were VBD N
monitored VBN N
, , N
and CC N
cholesterol NN N
levels NNS N
were VBD N
retested VBN N
6 CD N
and CC N
12 CD N
months NNS N
later RB N
. . N

RESULTS VB N
The DT N
total JJ N
per-person JJ N
cost NN N
for IN N
screening VBG N
and CC N
the DT N
educational JJ N
intervention NN N
was VBD N
about IN N
$ $ N
50 CD N
. . N

Cholesterol NN N
levels NNS N
differed VBD N
little RB N
between IN N
the DT N
two CD N
intervention NN N
groups NNS N
6 CD N
months NNS N
after IN N
screening VBG N
, , N
but CC N
after IN N
12 CD N
months NNS N
those DT N
in IN N
the DT N
special JJ N
intervention NN N
worksites NNS N
showed VBD N
a DT N
6.5 CD N
% NN N
drop NN N
in IN N
cholesterol NN N
, , N
whereas IN N
those DT N
at IN N
the DT N
usual JJ N
intervention NN N
worksites NNS N
showed VBD N
a DT N
drop NN N
of IN N
only RB N
3.0 CD N
% NN N
. . N

Hence NNP N
a DT N
3.5 CD N
% NN N
cholesterol NN N
reduction NN N
was VBD N
attributable JJ N
to TO N
the DT N
special JJ N
intervention NN N
. . N

CONCLUSIONS VB N
A NNP N
behaviorally RB N
based VBN N
nutrition JJ N
education NN N
program NN N
following VBG N
cholesterol NN N
screening VBG N
can MD N
have VB N
a DT N
meaningful JJ N
impact NN N
on IN N
long-term JJ N
cholesterol NN N
levels NNS N
at IN N
a DT N
low JJ N
cost NN N
. . N

Nutrition NNP N
education NN N
in IN N
work-sites NNS N
may MD N
therefore RB N
be VB N
a DT N
useful JJ N
way NN N
to TO N
lower VB N
the DT N
risk NN N
of IN N
heart NN N
disease NN N
in IN N
communities NNS N
. . N

-DOCSTART- -X- O O

Double-blind NNP N
randomized JJ N
evaluation NN N
of IN N
intercostal JJ N
nerve NN N
blocks NNS N
as IN N
an DT N
adjuvant NN N
to TO N
subarachnoid VB N
administered JJ N
morphine NN N
for IN N
post-thoracotomy JJ 4_p
analgesia NN 4_p
. . N

BACKGROUND NNP N
AND NNP N
OBJECTIVES NNP N
Thoracotomy NNP N
is VBZ N
associated VBN N
with IN N
pain NN N
and CC N
compromised VBD N
pulmonary JJ N
function NN N
. . N

Intercostal NNP N
nerve NN N
blocks NNS N
( ( N
INB NNP N
) ) N
and CC N
subarachnoid JJ N
morphine NN N
( ( N
SM NNP N
) ) N
act NN N
on IN N
different JJ N
portions NNS N
of IN N
the DT N
pain NN N
pathway RB N
. . N

Each DT N
is VBZ N
effective JJ N
for IN N
post-thoracotomy JJ N
pain NN N
relief NN N
. . N

The DT N
combination NN N
of IN N
these DT N
two CD N
modalities NNS N
in IN N
relieving VBG N
post-thoracotomy JJ N
pain NN N
and CC N
improving VBG N
postoperative JJ N
pulmonary JJ N
function NN N
has VBZ N
not RB N
been VBN N
investigated VBN N
. . N

METHODS NNP N
In IN N
a DT N
double-blind NN N
study NN N
, , N
20 CD 3_p
patients NNS N
undergoing JJ N
lateral JJ 4_p
thoracotomy NN 4_p
for IN N
lung NN 4_p
resection NN 4_p
were VBD N
randomized VBN N
to TO N
receive VB N
0.5 CD N
mg NN N
SM NNP N
preoperatively RB N
and CC N
INB NNP N
with IN N
bupivacaine NN N
( ( N
INB+ NNP N
) ) N
prior RB N
to TO N
wound VB N
closure NN N
or CC N
0.5 CD N
mg NNS N
SM NNP N
with IN N
INB NNP N
using VBG N
saline NN N
( ( N
INB- NNP N
) ) N
. . N

Visual JJ N
analog NN N
scale NN N
pain NN N
scores NNS N
at IN N
rest NN N
, , N
with IN N
cough NN N
, , N
and CC N
with IN N
movement NN N
of IN N
the DT N
ipsilateral JJ N
arm NN N
, , N
forced VBD N
expiratory JJ N
volume NN N
in IN N
1 CD N
second JJ N
( ( N
FEV1 NNP N
) ) N
, , N
and CC N
forced VBD N
vital JJ N
capacity NN N
( ( N
FVC NNP N
) ) N
were VBD N
measured VBN N
at IN N
4 CD N
, , N
24 CD N
, , N
48 CD N
, , N
and CC N
72 CD N
hours NNS N
after IN N
the DT N
operation NN N
. . N

Opioid NNP N
use NN N
was VBD N
measured VBN N
during IN N
the DT N
initial JJ N
24 CD N
hours NNS N
after IN N
the DT N
operation NN N
. . N

RESULTS NNP N
At IN N
4 CD N
hours NNS N
, , N
the DT N
INB+ NNP N
group NN N
demonstrated VBD N
better JJR N
FEV1 NNP N
( ( N
56.6 CD N
% NN N
vs. FW N
40.4 CD N
% NN N
of IN N
baseline NN N
, , N
P NNP N
< NNP N
.05 NNP N
) ) N
and CC N
FVC NNP N
values NNS N
( ( N
54.6 CD N
% NN N
vs. FW N
39.6 CD N
% NN N
of IN N
baseline NN N
, , N
P NNP N
< NNP N
.05 NNP N
) ) N
and CC N
less RBR N
resting VBG N
and CC N
cough JJ N
pain NN N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

However RB N
, , N
FEV1 NNP N
continued VBD N
to TO N
decline VB N
in IN N
the DT N
INB+ NNP N
group NN N
at IN N
24 CD N
hours NNS N
to TO N
lower JJR N
than IN N
the DT N
INB- NNP N
group NN N
although IN N
pain NN N
scores NNS N
were VBD N
similar JJ N
beyond IN N
4 CD N
hours NNS N
. . N

Opioid JJ N
usage NN N
during IN N
the DT N
first JJ N
24 CD N
hours NNS N
was VBD N
similar JJ N
( ( N
INB- NNP N
, , N
16.7 CD N
mg NN N
vs. FW N
INB+ NNP N
, , N
13.2 CD N
mg NN N
, , N
P NNP N
= NNP N
.7 NNP N
) ) N
. . N

CONCLUSIONS NNP N
Although IN N
postoperative JJ N
INB NNP N
provided VBD N
modest JJ N
improvements NNS N
in IN N
pain NN N
and CC N
pulmonary JJ N
function NN N
when WRB N
used VBN N
as IN N
an DT N
adjuvant NN N
to TO N
0.5 CD N
mg NNS N
SM NNP N
for IN N
post-thoracotomy JJ N
analgesia NN N
, , N
the DT N
benefits NNS N
were VBD N
transient JJ N
. . N

The DT N
authors NNS N
do VBP N
not RB N
recommend VB N
adding VBG N
INB NNP N
for IN N
patients NNS N
undergoing JJ N
lateral JJ N
thoracotomy NN N
who WP N
receive VBP N
0.5 CD N
mg NN N
SM NNP N
. . N

-DOCSTART- -X- O O

Dose NNP N
response NN N
effect NN N
of IN N
cyclical JJ N
medroxyprogesterone NN N
on IN N
blood NN N
pressure NN N
in IN N
postmenopausal JJ 4_p
women NNS 2_p
. . N

OBJECTIVE VB N
This DT N
study NN N
was VBD N
designed VBN N
to TO N
compare VB N
with IN N
placebo PDT N
the DT N
dose-response JJ N
effect NN N
of IN N
cyclical JJ N
doses NNS N
of IN N
the DT N
C21 NNP N
progestogen NN N
, , N
medroxyprogesterone NN N
acetate NN N
( ( N
MPA NNP N
) ) N
on IN N
blood NN N
pressure NN N
( ( N
BP NNP N
) ) N
when WRB N
administered VBN N
to TO N
normotensive JJ 4_p
postmenopausal NN 4_p
women NNS 2_p
receiving VBG N
a DT N
fixed JJ N
mid-range JJ N
daily JJ N
dose NN N
of IN N
conjugated JJ N
equine NN N
oestrogen NN N
( ( N
CEE NNP N
) ) N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
Twenty NNP 3_p
normotensive JJ 4_p
postmenopausal NN 4_p
women NNS 2_p
( ( N
median JJ N
age NN N
53 CD 1_p
years NNS N
) ) N
participated VBD N
in IN N
the DT N
study NN N
which WDT N
used VBD N
a DT N
double-blind JJ N
crossover NN N
design NN N
. . N

There EX N
were VBD N
four CD N
randomised VBN N
treatment NN N
phases NNS N
, , N
each DT N
of IN N
4 CD N
weeks NNS N
duration NN N
. . N

The DT N
four CD N
blinded VBD N
treatments NNS N
were VBD N
MPA NNP N
2.5 CD N
mg NN N
, , N
MPA NNP N
5 CD N
mg NN N
, , N
MPA NNP N
10 CD N
mg NN N
and CC N
matching VBG N
placebo NN N
, , N
taken VBN N
for IN N
the DT N
last JJ N
14 CD N
days NNS N
of IN N
each DT N
28 CD N
day NN N
treatment NN N
cycle NN N
. . N

CEE NNP N
0.625 CD N
mg NN N
was VBD N
also RB N
administered VBN N
once RB N
daily JJ N
as IN N
open JJ N
labelled VBD N
tablets NNS N
to TO N
all DT N
subjects NNS N
throughout IN N
the DT N
study NN N
. . N

Clinic NNP N
BP NNP N
was VBD N
measured VBN N
weekly RB N
with IN N
the DT N
mean JJ N
values NNS N
of IN N
weeks NNS N
3 CD N
and CC N
4 CD N
of IN N
each DT N
phase NN N
used VBN N
for IN N
analysis NN N
. . N

Ambulatory NNP N
BP NNP N
was VBD N
performed VBN N
in IN N
the DT N
final JJ N
week NN N
of IN N
each DT N
phase NN N
. . N

RESULTS NNP N
Compared VBD N
with IN N
the DT N
placebo NN N
phase NN N
, , N
end NN N
of IN N
phase NN N
clinic JJ N
BP NNP N
was VBD N
unchanged JJ N
by IN N
any DT N
of IN N
the DT N
progestogen NN N
treatments NNS N
. . N

There EX N
was VBD N
a DT N
dose-dependent JJ N
decrease NN N
in IN N
ambulatory JJ N
daytime JJ N
diastolic NN N
and CC N
mean JJ N
arterial JJ N
BP NNP N
with IN N
the DT N
progestogen NN N
treatments NNS N
compared VBN N
with IN N
placebo NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
In IN N
a DT N
regimen NN N
of IN N
postmenopausal NN N
hormone NN N
replacement NN N
therapy NN N
with IN N
a DT N
fixed JJ N
mid-range JJ N
daily JJ N
dose NN N
of IN N
CEE NNP N
combined VBD N
with IN N
a DT N
cyclical JJ N
regimen NN N
of IN N
a DT N
C21 NNP N
progestogen NN N
spanning VBG N
the DT N
current JJ N
clinical JJ N
dose NN N
range NN N
, , N
the DT N
progestogen NN N
has VBZ N
either CC N
no DT N
effect NN N
or CC N
a DT N
small JJ N
dose-dependent JJ N
reduction NN N
in IN N
clinic NN N
and CC N
ambulatory JJ N
BPs NNP N
over IN N
one CD N
treatment NN N
cycle NN N
. . N

-DOCSTART- -X- O O

Contingency NNP N
management NN N
for IN N
the DT N
treatment NN N
of IN N
antipsychotic-induced JJ N
weight JJ N
gain NN N
: : N
a DT N
randomized VBN N
controlled VBN N
pilot NN N
study NN N
. . N

OBJECTIVE NNP N
Weight NNP N
gain NN N
is VBZ N
common JJ N
for IN N
individuals NNS N
with IN N
serious JJ 4_p
mental JJ 4_p
illness NN 4_p
( ( N
SMI NNP 4_p
) ) N
receiving VBG N
antipsychotic JJ N
drug NN N
therapy NN N
. . N

Contingency NNP N
management NN N
( ( N
CM NNP N
) ) N
is VBZ N
a DT N
behavioral JJ N
intervention NN N
that IN N
rewards NNS N
positive JJ N
performance NN N
and CC N
has VBZ N
demonstrated VBN N
effectiveness NN N
in IN N
reducing VBG N
drug NN N
use NN N
in IN N
SMI NNP N
populations NNS N
. . N

This DT N
study NN N
evaluated VBD N
the DT N
feasibility NN N
of IN N
using VBG N
CM NNP N
to TO N
promote VB N
weight JJ N
loss NN N
in IN N
individuals NNS N
with IN N
SMI NNP N
over IN N
8 CD N
weeks NNS N
. . N

METHOD NNP N
30 CD N
individuals NNS N
( ( N
BMI NNP N
? . N
28 CD N
kg/m NN N
( ( N
2 CD N
) ) N
) ) N
were VBD N
randomized VBN N
to TO N
one CD N
of IN N
three CD N
conditions NNS N
: : N
i NN N
) ) N
The DT N
combination NN N
of IN N
a DT N
standardized JJ N
lifestyle NN N
modification NN N
( ( N
LM NNP N
) ) N
program NN N
for IN N
individuals NNS N
with IN N
SMI NNP N
and CC N
payment NN N
for IN N
group NN N
attendance NN N
( ( N
CM NNP N
( ( N
attendance NN N
) ) N
) ) N
, , N
ii NN N
) ) N
The DT N
combination NN N
of IN N
LM NNP N
and CC N
payment NN N
for IN N
weight JJ N
loss NN N
( ( N
CM NNP N
( ( N
weight NN N
) ) N
) ) N
, , N
and CC N
iii NN N
) ) N
waitlist NN N
control NN N
( ( N
CON NNP N
) ) N
. . N

After IN N
the DT N
waitlist JJ N
period NN N
, , N
those DT N
participants NNS N
joined VBD N
a DT N
LM NNP N
group NN N
and CC N
received VBD N
payment NN N
for IN N
behavioral JJ N
change NN N
( ( N
CM NNP N
( ( N
behavior NN N
) ) N
) ) N
. . N

RESULTS JJ N
Subjects NNPS N
in IN N
the DT N
CM NNP N
( ( N
attendance NN N
) ) N
and CC N
in IN N
the DT N
CM NNP N
( ( N
weight NN N
) ) N
group NN N
lost VBD N
a DT N
mean NN N
of IN N
1.16 CD N
kg NNS N
and CC N
1.23 CD N
kg NN N
, , N
respectively RB N
, , N
while IN N
subjects NNS N
in IN N
the DT N
CON NNP N
gained VBD N
a DT N
mean NN N
of IN N
0.68 CD N
kg NNS N
. . N

Subjects NNS N
receiving VBG N
CM NNP N
( ( N
behavior NN N
) ) N
, , N
lost VBD N
a DT N
mean NN N
of IN N
2.54 CD N
kg NNS N
, , N
which WDT N
was VBD N
a DT N
significant JJ N
weight NN N
loss NN N
compared VBN N
to TO N
the DT N
control NN N
period NN N
. . N

CONCLUSION NNP N
LM NNP N
supplemented VBD N
with IN N
CM NNP N
may MD N
facilitate VB N
weight NN N
loss NN N
in IN N
patients NNS N
taking VBG N
antipsychotic JJ N
medications NNS N
; : N
financial JJ N
reimbursement NN N
for IN N
behavioral JJ N
change NN N
may MD N
be VB N
particularly RB N
effective JJ N
in IN N
this DT N
population NN N
. . N

-DOCSTART- -X- O O

Coagulation NNP N
factor NN N
concentrate NN N
in IN N
the DT N
treatment NN N
of IN N
the DT N
haemorrhagic JJ 4_p
diathesis NN 4_p
of IN N
fulminant JJ 4_p
hepatic JJ 4_p
failure NN 4_p
. . N

To TO N
assess VB N
the DT N
value NN N
of IN N
clotting VBG N
factor NN N
concentrate NN N
infusions NNS N
in IN N
fulminant JJ 4_p
hepatic JJ 4_p
failure NN 4_p
, , N
a DT N
controlled JJ N
trial NN N
was VBD N
performed VBN N
in IN N
which WDT N
nine CD 3_p
patients NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
treatment NN N
with IN N
either DT N
concentrate NN N
alone RB N
or CC N
concentrate VB N
plus CC N
heparin VB N
. . N

The DT N
five CD N
patients NNS N
receiving VBG N
concentrate VB N
alone RB N
all DT N
died VBD N
, , N
with IN N
major JJ N
bleeding VBG N
as IN N
the DT N
direct JJ N
cause NN N
of IN N
death NN N
in IN N
three CD N
, , N
whereas NNS N
in IN N
the DT N
four CD N
receiving VBG N
heparin NN N
as RB N
well RB N
there EX N
was VBD N
only RB N
one CD N
instance NN N
of IN N
bleeding NN N
and CC N
one CD N
patient NN N
survived VBD N
. . N

Clinical JJ N
evidence NN N
of IN N
intravascular JJ N
coagulation NN N
appeared VBD N
in IN N
two CD N
patients NNS N
treated VBD N
with IN N
concentrate NN N
alone RB N
and CC N
the DT N
laboratory JJ N
evidence NN N
of IN N
this DT N
progressed VBN N
during IN N
the DT N
period NN N
of IN N
infusions NNS N
in IN N
all DT N
patients NNS N
in IN N
both DT N
treatment NN N
groups NNS N
, , N
although IN N
to TO N
a DT N
lesser JJR N
extent NN N
in IN N
those DT N
receiving VBG N
heparin NN N
. . N

Additional JJ N
evidence NN N
for IN N
intravascular JJ N
coagulation NN N
came VBD N
from IN N
the DT N
changes NNS N
observed VBN N
in IN N
factor NN N
VIII NNP N
levels NNS N
which WDT N
, , N
although IN N
initially RB N
high JJ N
in IN N
all DT N
patients NNS N
, , N
fell VBD N
subsequently RB N
, , N
particularly RB N
in IN N
those DT N
given VBN N
concentrate VBP N
alone RB N
. . N

There EX N
was VBD N
some DT N
improvement NN N
in IN N
the DT N
prothrombin NN N
ratio NN N
in IN N
both DT N
groups NNS N
of IN N
patients NNS N
but CC N
not RB N
complete JJ N
correction NN N
, , N
and CC N
serial JJ N
assays NNS N
of IN N
clotting VBG N
factors NNS N
showed VBD N
that IN N
although IN N
factor NN N
II NNP N
rose VBD N
to TO N
high JJ N
levels NNS N
during IN N
treatment NN N
, , N
factors NNS N
IX NNP N
and CC N
X NNP N
showed VBD N
little JJ N
response NN N
. . N

Thus RB N
, , N
the DT N
use NN N
of IN N
concentrate NN N
of IN N
factor NN N
IX NNP N
in IN N
this DT N
trial NN N
, , N
as RB N
well RB N
as IN N
potentiating VBG N
intravascular JJ N
coagulation NN N
, , N
was VBD N
inadequate JJ N
as IN N
replacement NN N
for IN N
the DT N
clotting NN N
factor NN N
deficiencies NNS N
. . N

-DOCSTART- -X- O O

Immunogenicity NN N
and CC N
safety NN N
of IN N
a DT N
plasma-derived JJ N
heat-inactivated JJ N
hepatitis NN N
B NNP N
vaccine NN N
( ( N
CLB NNP N
) ) N
. . N

Studies NNPS N
in IN N
volunteers NNS N
at IN N
a DT N
low JJ 4_p
risk NN 4_p
of IN N
infection NN N
with IN N
hepatitis NN 4_p
B NNP 4_p
virus NN 4_p
. . N

The DT N
safety NN N
and CC N
immunogenicity NN N
of IN N
a DT N
plasma-derived JJ N
heat-inactivated JJ N
hepatitis NN N
B NNP N
vaccine NN N
( ( N
CLB NNP N
) ) N
were VBD N
evaluated VBN N
in IN N
471 CD 3_p
healthy JJ 4_p
human JJ N
volunteers NNS N
, , N
who WP N
, , N
both DT N
in IN N
their PRP$ N
occupations NNS N
and CC N
in IN N
their PRP$ N
private JJ N
lives NNS N
, , N
had VBD N
been VBN N
at IN N
minimal JJ 4_p
risk NN 4_p
of IN N
being VBG N
infected VBN N
with IN N
hepatitis NN 4_p
B NNP 4_p
virus NN 4_p
. . N

The DT N
first JJ N
202 JJ N
individuals NNS N
received VBD N
three CD N
3-micrograms JJ N
doses NNS N
of IN N
heat-inactivated JJ N
hepatitis NN N
B NNP N
surface NN N
antigen NN N
( ( N
HBsAg NNP N
) ) N
at IN N
one-month JJ N
intervals NNS N
( ( N
trial NN N
A DT N
) ) N
. . N

A DT N
total NN N
of IN N
42 CD N
% NN N
one CD N
month NN N
after IN N
the DT N
first JJ N
injection NN N
, , N
84 CD N
% NN N
after IN N
two CD N
months NNS N
, , N
and CC N
93 CD N
% NN N
after IN N
five CD N
months NNS N
had VBD N
become VBN N
anti-HBs JJ N
( ( N
antibody NN N
to TO N
hepatitis VB N
B NNP N
surface NN N
antigen NN N
) ) N
positive JJ N
. . N

In IN N
a DT N
second JJ N
randomized VBN N
study NN N
( ( N
trial NN N
B NNP N
) ) N
, , N
the DT N
immunogenicity NN N
of IN N
five CD N
different JJ N
dosages NNS N
of IN N
the DT N
vaccine NN N
was VBD N
compared VBN N
in IN N
269 CD N
volunteers NNS N
. . N

When WRB N
the DT N
dose NN N
of IN N
HBsAg NNP N
was VBD N
diminished VBN N
from IN N
3 CD N
micrograms NNS N
to TO N
1.5 CD N
, , N
0.6 CD N
, , N
and CC N
0.25 CD N
microgram NN N
, , N
no DT N
decrease NN N
of IN N
the DT N
anti-HBs JJ N
response NN N
was VBD N
observed VBN N
. . N

However RB N
, , N
when WRB N
the DT N
dose NN N
was VBD N
diminished VBN N
to TO N
0.1 CD N
microgram NN N
of IN N
HBsAg NNP N
, , N
the DT N
anti-HBs JJ N
response NN N
dropped VBD N
significantly RB N
to TO N
63 CD N
% NN N
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
. . N

In IN N
the DT N
recipients NNS N
of IN N
all DT N
five CD N
vaccine NN N
dosages NNS N
, , N
no DT N
influence NN N
of IN N
sex NN N
and CC N
age NN N
was VBD N
found VBN N
on IN N
the DT N
anti-HBs JJ N
conversion NN N
rates NNS N
. . N

During IN N
the DT N
eight-month JJ N
observation NN N
period NN N
, , N
none NN N
of IN N
the DT N
vaccinees NNS N
became VBD N
HBsAg NNP N
and/or IN N
anti-HBc JJ N
( ( N
antibody NN N
to TO N
hepatitis VB N
B NNP N
core NN N
antigen NN N
) ) N
positive JJ N
, , N
and CC N
none NN N
developed VBD N
antibodies NNS N
associated VBN N
with IN N
autoimmune JJ N
liver NN N
disease NN N
. . N

No DT N
serious JJ N
side NN N
effects NNS N
were VBD N
observed VBN N
. . N

-DOCSTART- -X- O O

Effectiveness NN N
of IN N
Dader NNP N
Method NNP N
for IN N
pharmaceutical JJ N
care NN N
on IN N
control NN N
of IN N
blood NN N
pressure NN N
and CC N
total JJ N
cholesterol NN N
in IN N
outpatients NNS N
with IN N
cardiovascular JJ 4_p
disease NN 4_p
or CC N
cardiovascular JJ 4_p
risk NN 4_p
: : N
EMDADER-CV JJ N
randomized NNS N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Although IN N
some DT N
studies NNS N
have VBP N
demonstrated VBN N
that IN N
pharmacist JJ N
intervention NN N
can MD N
improve VB N
drug NN N
therapy NN N
among IN N
patients NNS N
with IN N
cardiovascular JJ 4_p
disease NN 4_p
( ( N
CVD NNP 4_p
) ) N
, , N
more JJR N
evidence NN N
derived VBN N
from IN N
randomized VBN N
controlled VBN N
trials NNS N
( ( N
RCTs NNP N
) ) N
is VBZ N
needed VBN N
, , N
including VBG N
assessment NN N
of IN N
the DT N
effect NN N
of IN N
community NN N
pharmacist NN N
interventions NNS N
in IN N
patients NNS N
with IN N
CVD NNP 4_p
. . N

OBJECTIVE NNP N
To TO N
assess VB N
the DT N
effectiveness NN N
of IN N
the DT N
Dader NNP N
Method NNP N
for IN N
pharmaceutical JJ N
care NN N
on IN N
achieving VBG N
therapeutic JJ N
goals NNS N
for IN N
blood NN N
pressure NN N
( ( N
BP NNP N
) ) N
, , N
total JJ N
cholesterol NN N
( ( N
TC NNP N
) ) N
, , N
and CC N
both DT N
BP NNP N
and CC N
TC NNP N
( ( N
BP/TC NNP N
) ) N
in IN N
patients NNS N
with IN N
CVD NNP N
and/or VBP N
high JJ 4_p
or CC 4_p
intermediate JJ 4_p
cardiovascular NN 4_p
( ( 4_p
CV NNP 4_p
) ) 4_p
risk NN 4_p
attending VBG N
community NN N
pharmacies NNS N
in IN N
Spain NNP N
. . N

METHODS NNP N
Patients NNPS N
aged VBD N
25 CD 1_p
to TO 1_p
74 CD 1_p
years NNS N
attending VBG N
community NN N
pharmacies NNS N
with IN N
a DT N
prescription NN N
for IN N
at IN N
least JJS N
1 CD N
drug NN N
indicated VBN N
for IN N
CVD NNP N
or CC N
CV NNP 4_p
risk NN N
factors NNS N
were VBD N
randomized VBN N
to TO N
2 CD N
groups NNS N
: : N
an DT N
intervention NN N
group NN N
that WDT N
received VBD N
pharmaceutical JJ N
care NN N
, , N
which WDT N
was VBD N
provided VBN N
by IN N
specially RB N
trained JJ N
pharmacists NNS N
working VBG N
in IN N
collaboration NN N
with IN N
physicians NNS N
, , N
and CC N
a DT N
control NN N
group NN N
that WDT N
received VBD N
usual JJ N
care NN N
( ( N
routine JJ N
dispensing VBG N
counseling NN N
) ) N
and CC N
verbal JJ N
and CC N
written VBN N
counseling VBG N
regarding VBG N
CVD NNP N
prevention NN N
. . N

Patients NNS N
were VBD N
recruited VBN N
from IN N
December NNP N
2005 CD N
to TO N
September NNP N
2006 CD N
, , N
and CC N
both DT N
groups NNS N
were VBD N
followed VBN N
for IN N
8 CD N
months NNS N
. . N

Study NNP N
outcomes NNS N
were VBD N
assessed VBN N
at IN N
baseline NN N
and CC N
at IN N
16 CD N
and CC N
32 CD N
weeks NNS N
after IN N
randomization NN N
. . N

The DT N
primary JJ N
outcome NN N
measures NNS N
were VBD N
the DT N
proportions NNS N
of IN N
patients NNS N
achieving VBG N
BP NNP N
, , N
TC NNP N
, , N
and CC N
BP/TC NNP N
therapeutic JJ N
goals NNS N
( ( N
BP NNP N
lower JJR N
than IN N
140/90 CD N
mm NNS N
Hg NNP N
for IN N
patients NNS N
with IN N
uncomplicated JJ N
hypertension NN N
and CC N
lower JJR N
than IN N
130/80 CD N
mm NNS N
Hg NNP N
for IN N
patients NNS N
with IN N
diabetes NNS N
, , N
chronic JJ N
kidney NN N
disease NN N
, , N
or CC N
history NN N
of IN N
myocardial JJ N
infarction NN N
or CC N
stroke NN N
; : N
TC NNP N
lower JJR N
than IN N
200 CD N
mg NNS N
per IN N
dL NN N
for IN N
patients NNS N
without IN N
CVD NNP N
and CC N
lower JJR N
than IN N
175 CD N
mg NNS N
per IN N
dL NN N
for IN N
patients NNS N
with IN N
CVD NNP N
) ) N
. . N

Secondary JJ N
outcomes NNS N
were VBD N
mean JJ N
BP NNP N
and CC N
TC NNP N
values NNS N
. . N

BP NNP N
was VBD N
assessed VBN N
manually RB N
by IN N
the DT N
pharmacist NN N
after IN N
a DT N
10-minute JJ N
rest NN N
in IN N
the DT N
supine JJ N
position NN N
. . N

This DT N
measurement NN N
was VBD N
performed VBN N
twice RB N
for IN N
every DT N
participant NN N
, , N
and CC N
the DT N
average NN N
of IN N
the DT N
2 CD N
measurements NNS N
was VBD N
calculated VBN N
. . N

TC NNP N
was VBD N
measured VBN N
by IN N
the DT N
pharmacist NN N
during IN N
the DT N
study NN N
visit NN N
using VBG N
the DT N
enzymatic JJ N
dry JJ N
method NN N
. . N

Statistical JJ N
analyses NNS N
were VBD N
performed VBN N
using VBG N
2-tailed JJ N
McNemar NNP N
tests NNS N
, , N
Pearson NNP N
chi-square NN N
tests NNS N
, , N
and CC N
Student NNP N
's POS N
t-tests NNS N
; : N
P NNP N
< VBD N
0.05 CD N
was VBD N
considered VBN N
statistically RB N
significant JJ N
. . N

RESULTS VB N
714 CD 3_p
patients NNS N
were VBD N
included VBN N
in IN N
the DT N
study NN N
( ( N
356 CD N
intervention NN N
, , N
358 CD N
control NN N
) ) N
, , N
and CC N
the DT N
mean JJ N
[ NNP N
SD NNP N
] NNP N
age NN N
was VBD N
62.8 CD 1_p
[ JJ N
8.1 CD N
] JJ N
years NNS N
. . N

The DT N
2 CD N
groups NNS N
were VBD N
similar JJ N
at IN N
baseline NN N
in IN N
clinical JJ N
and CC N
demographic JJ N
characteristics NNS N
, , N
including VBG N
the DT N
proportion NN N
of IN N
patients NNS N
at IN N
therapeutic JJ N
goals NNS N
for IN N
BP NNP N
, , N
TC NNP N
, , N
and CC N
BP/TC NNP N
. . N

After IN N
8 CD N
months NNS N
of IN N
follow-up NN N
, , N
there EX N
were VBD N
statistically RB N
significant JJ N
differences NNS N
in IN N
favor NN N
of IN N
pharmaceutical JJ N
care NN N
in IN N
the DT N
proportions NNS N
of IN N
patients NNS N
who WP N
achieved VBD N
therapeutic JJ N
goals NNS N
for IN N
BP NNP N
( ( N
52.5 CD N
% NN N
vs. FW N
43.0 CD N
% NN N
, , N
P=0.017 NNP N
) ) N
, , N
TC NNP N
( ( N
56.5 CD N
% NN N
vs. FW N
44.1 CD N
% NN N
, , N
P=0.001 NNP N
) ) N
, , N
and CC N
BP/TC NNP N
( ( N
37.1 CD N
% NN N
vs. FW N
21.8 CD N
% NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

CONCLUSION NNP N
Compared NNP N
with IN N
usual JJ N
care NN N
plus CC N
written VBN N
education NN N
, , N
pharmaceutical JJ N
care NN N
focused VBN N
on IN N
patient JJ N
evaluation NN N
and CC N
follow-up NN N
in IN N
collaboration NN N
with IN N
physicians NNS N
improved VBN N
the DT N
achievement NN N
of IN N
BP NNP N
, , N
TC NNP N
, , N
and CC N
BP/TC NNP N
treatment NN N
goals NNS N
in IN N
patients NNS N
with IN N
CVD NNP N
and/or VBP N
high JJ N
or CC N
intermediate JJ N
CV NNP N
risk NN N
attending VBG N
community NN N
pharmacies NNS N
in IN N
Spain NNP N
. . N

-DOCSTART- -X- O O

Efficacy NN N
and CC N
safety NN N
of IN N
transient JJ N
ulnar JJ N
artery NN N
compression NN N
to TO N
recanalize VB N
acute JJ N
radial JJ N
artery NN N
occlusion NN N
after IN N
transradial JJ N
catheterization NN N
. . N

Radial JJ N
artery NN N
occlusion NN N
( ( N
RAO NNP N
) ) N
can MD N
result VB N
from IN N
transradial JJ N
catheterization NN N
. . N

We PRP N
compared VBN N
the DT N
incidence NN N
of IN N
RAO NNP N
with IN N
2 CD N
heparin JJ N
dosage NN N
regimens NNS N
after IN N
transradial JJ N
coronary JJ N
angiography NN N
, , N
and CC N
we PRP N
evaluated VBD N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
transient JJ N
homolateral JJ N
ulnar JJ N
artery NN N
compression NN N
to TO N
achieve VB N
acute JJ N
radial JJ N
artery NN N
recanalization NN N
. . N

Patients NNS N
referred VBD N
for IN N
coronary JJ 4_p
angiography NN 4_p
were VBD N
randomized VBN N
to TO N
very-low-dose JJ N
heparin NN N
( ( N
2,000 CD N
IU NNP N
) ) N
or CC N
low-dose JJ N
heparin NN N
( ( N
5,000 CD N
IU NNP N
) ) N
. . N

On IN N
sheath NN N
removal NN N
, , N
hemostasis NN N
was VBD N
obtained VBN N
using VBG N
the DT N
TR NNP N
band NN N
with IN N
a DT N
plethysmography-guided JJ N
patent NN N
hemostasis NN N
technique NN N
. . N

In IN N
the DT N
case NN N
of IN N
RAO NNP N
as IN N
assessed VBN N
by IN N
duplex JJ N
ultrasonography NN N
3 CD N
to TO N
4 CD N
hours NNS N
after IN N
hemostasis NN N
, , N
immediate JJ N
1-hour JJ N
ulnar JJ N
artery NN N
compression NN N
was VBD N
applied VBN N
. . N

Hematomas NNP N
> VBD N
15 CD N
cm NN N
( ( N
2 CD N
) ) N
were VBD N
also RB N
assessed VBN N
. . N

We PRP N
randomized VBD N
465 CD 3_p
patients NNS N
, , N
222 CD N
in IN N
the DT N
2,000-IU JJ N
group NN N
and CC N
243 CD N
in IN N
the DT N
5,000-IU JJ N
group NN N
. . N

The DT N
baseline NN N
and CC N
procedural JJ N
characteristics NNS N
were VBD N
comparable JJ N
in IN N
both DT N
groups NNS N
. . N

The DT N
incidence NN N
of IN N
initial JJ N
RAO NNP N
was VBD N
5.9 CD N
% NN N
in IN N
the DT N
2,000-IU JJ N
group NN N
and CC N
2.9 CD N
% NN N
in IN N
the DT N
5,000-IU JJ N
group NN N
( ( N
p JJ N
= NNP N
0.17 CD N
) ) N
, , N
with IN N
a DT N
compression NN N
time NN N
of IN N
2.10 CD N
? . N
0.78 CD N
hours NNS N
and CC N
2.25 CD N
? . N
0.82 CD N
hours NNS N
, , N
respectively RB N
( ( N
p JJ N
= NNP N
0.051 CD N
) ) N
. . N

After IN N
ulnar JJ N
artery NN N
compression NN N
, , N
the DT N
final JJ N
incidence NN N
of IN N
RAO NNP N
was VBD N
4.1 CD N
% NN N
in IN N
the DT N
2,000-IU JJ N
group NN N
and CC N
0.8 CD N
% NN N
in IN N
the DT N
5,000-IU JJ N
group NN N
( ( N
p JJ N
= NNP N
0.03 CD N
) ) N
. . N

The DT N
incidence NN N
of IN N
local JJ N
hematoma NN N
was VBD N
2.3 CD N
% NN N
and CC N
3.7 CD N
% NN N
in IN N
the DT N
2,000- JJ N
and CC N
5,000-IU JJ N
groups NNS N
, , N
respectively RB N
( ( N
p JJ N
= NNP N
0.42 CD N
) ) N
. . N

In IN N
conclusion NN N
, , N
acute JJ N
RAO NNP N
after IN N
transradial JJ N
catheterization NN N
can MD N
be VB N
recanalized VBN N
by IN N
early JJ N
1-hour JJ N
homolateral JJ N
ulnar JJ N
artery NN N
compression NN N
. . N

This DT N
simple JJ N
nonpharmacologic JJ N
method NN N
was VBD N
effective JJ N
and CC N
safe JJ N
in IN N
patients NNS N
with IN N
very-low- JJ N
and CC N
low-dose JJ N
heparin NN N
. . N

Nevertheless NNP N
, , N
the DT N
incidence NN N
of IN N
final JJ N
RAO NNP N
remained VBD N
significantly RB N
lower JJR N
after IN N
a DT N
higher JJR N
anticoagulation NN N
level NN N
. . N

-DOCSTART- -X- O O

Take VB N
a DT N
walk NN N
in IN N
the DT N
park NN N
? . N
A DT N
cross-over NN N
pilot NN N
trial NN N
comparing VBG N
brisk JJ N
walking VBG N
in IN N
two CD N
different JJ N
environments NNS N
: : N
park NN N
and CC N
urban JJ N
. . N

OBJECTIVE CC N
The DT N
objective NN N
of IN N
the DT N
present JJ N
study NN N
is VBZ N
to TO N
investigate VB N
whether IN N
differences NNS N
exist VBP N
between IN N
a DT N
30 CD N
minute NN N
brisk NN N
walk VBP N
taken VBN N
in IN N
two CD N
different JJ N
environments NNS N
in IN N
order NN N
to TO N
determine VB N
which WDT N
environment NN N
best JJS N
facilitates NNS N
current JJ N
physical JJ N
activity NN N
guidelines NNS N
: : N
park NN N
or CC N
urban JJ N
. . N

METHODS NNP N
In IN N
this DT N
randomised JJ N
cross-over NN N
pilot NN N
study NN N
, , N
participants NNS N
performed VBD N
a DT N
self-timed JJ N
30 CD N
minute NN N
brisk NN 4_p
walk VBP 4_p
in IN N
two CD N
different JJ N
environments NNS N
, , N
park NN N
and CC N
urban JJ N
, , N
in IN N
Glasgow NNP N
, , N
Scotland NNP N
( ( N
October NNP N
2009 CD N
to TO N
January NNP N
2010 CD N
) ) N
. . N

Cadence NN N
, , N
recorded VBD N
using VBG N
the DT N
activPAL? NN N
activity NN N
monitor NN N
, , N
was VBD N
used VBN N
to TO N
measure VB N
intensity NN N
. . N

Outcome CC N
measures NNS N
were VBD N
: : N
mean JJ N
cadence NN N
; : N
moderate-to-vigorous JJ N
physical JJ N
activity NN N
time NN N
accumulated VBN N
in IN N
bouts NNS N
lasting VBG N
? . N
10 CD N
min NN N
; : N
number NN N
of IN N
walking VBG N
breaks NNS N
; : N
and CC N
duration NN N
. . N

RESULTS VB N
A DT N
convenience NN N
sample NN N
of IN N
40 CD N
healthy JJ N
adults NNS N
was VBD N
recruited VBN N
: : N
16 CD N
males NNS N
, , N
24 CD N
females NNS N
, , N
mean JJ N
age NN N
22.9 CD N
( ( N
5.5 CD N
) ) N
years NNS N
. . N

The DT N
mean JJ N
cadence NN N
for IN N
the DT N
whole JJ N
walk NN N
was VBD N
higher RBR N
in IN N
the DT N
park NN N
: : N
119.3 CD N
( ( N
8.3 CD N
) ) N
vs. FW N
110.9 CD N
( ( N
8.9 CD N
) ) N
steps/min NN N
. . N

Participants NNS N
accumulated VBD N
more RBR N
moderate-to-vigorous JJ N
physical JJ N
activity NN N
in IN N
? . N
10 CD N
minute NN N
bouts NNS N
during IN N
park JJ N
walks NNS N
: : N
25.5 CD N
( ( N
9.6 CD N
) ) N
[ NN N
median JJ N
( ( N
interquartile JJ N
range NN N
) ) N
] VBZ N
vs. FW N
14.0 CD N
( ( N
20.3 CD N
) ) N
min NN N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
self-timed JJ N
duration NN N
between IN N
locations NNS N
. . N

CONCLUSION NNP N
Participants NNPS N
accumulated VBD N
more RBR N
moderate-to-vigorous JJ N
physical JJ N
activity NN N
in IN N
bouts NNS N
? . N
10 CD N
min NN N
in IN N
duration NN N
on IN N
park NN N
walks NNS N
due JJ N
to TO N
the DT N
lack NN N
of IN N
interruptions NNS N
in IN N
walking VBG N
. . N

Hence NNP N
the DT N
park NN N
environment NN N
better RBR N
facilitated VBD N
the DT N
achievement NN N
of IN N
current JJ N
physical JJ N
activity NN N
guidelines NNS N
. . N

Further JJ N
research NN N
involving VBG N
a DT N
larger JJR N
, , N
more RBR N
heterogeneous JJ N
sample NN N
is VBZ N
recommended VBN N
. . N

-DOCSTART- -X- O O

The DT N
acute JJ N
effects NNS N
of IN N
fluid JJ N
intake NN N
on IN N
urine JJ N
specific JJ N
gravity NN N
and CC N
fluid JJ N
retention NN N
in IN N
a DT N
mildly RB 4_p
dehydrated JJ 4_p
state NN 4_p
. . N

Many JJ N
athletes NNS N
arrive VBP N
at IN N
training NN N
sessions NNS N
and CC N
competitions NNS N
in IN N
a DT N
mildly RB N
hypohydrated VBN N
( ( N
HYPO NNP 4_p
) ) N
state NN N
and CC N
are VBP N
instructed VBN N
to TO N
drink VB N
fluids NNS N
before IN N
exercise NN N
to TO N
reach VB N
a DT N
euhydrated JJ N
( ( N
HYD NNP N
) ) N
state NN N
. . N

Ten CD N
recreational JJ N
athletes NNS N
( ( N
6 CD N
women NNS N
, , N
4 CD N
men NNS N
; : N
71.9 CD N
? . N
4.6 CD N
kg NN N
, , N
25.2 CD N
? . N
0.9 CD N
years NNS N
) ) N
participated VBD N
in IN N
the DT N
studies NNS N
to TO N
examine VB N
( ( N
a DT N
) ) N
the DT N
day-to-day JJ N
variability NN N
of IN N
morning NN N
urine NN N
specific JJ N
gravity NN N
( ( N
USG NNP N
) ) N
, , N
( ( N
b NN N
) ) N
the DT N
effects NNS N
of IN N
consuming VBG N
600 CD N
ml NN N
of IN N
water NN N
on IN N
the DT N
hydration NN N
status NN N
of IN N
HYD NNP N
and CC N
HYPO NNP N
( ( N
USG NNP N
> NNP N
1.020 CD N
) ) N
subjects NNS N
, , N
and CC N
( ( N
c NN N
) ) N
the DT N
effects NNS N
of IN N
consuming VBG N
water NN N
( ( N
W NNP N
) ) N
, , N
salt-water JJ N
( ( N
SW NNP N
, , N
40 CD N
mM NN N
Na NNP N
) ) N
, , N
a DT N
carbohydrate-electrolyte JJ N
solution NN N
with IN N
3 CD N
% NN N
or CC N
light JJ N
carbohydrate NN N
( ( N
CES-L NNP N
, , N
20 CD N
mM NN N
Na NNP N
) ) N
or CC N
a DT N
CES NN N
with IN N
6 CD N
% NN N
carbohydrate NN N
( ( N
CES NNP N
, , N
20 CD N
mM NN N
Na NNP N
) ) N
on IN N
the DT N
hydration NN N
status NN N
of IN N
HYPO NNP N
subjects NNS N
. . N

The DT N
hydration NN N
status NN N
was VBD N
assessed VBN N
with IN N
USG NNP N
and CC N
body NN N
mass NN N
measures NNS N
and CC N
urine JJ N
volume NN N
collections NNS N
. . N

The DT N
day-to-day JJ N
variability NN N
in IN N
morning NN N
USG NNP N
( ( N
coefficient NN N
of IN N
variation NN N
= FW N
0.2 CD N
? . N
0.1 CD N
% NN N
) ) N
was VBD N
low JJ N
and CC N
the DT N
responses NNS N
to TO N
600 CD N
ml NN N
of IN N
W NNP N
ingestion NN N
were VBD N
repeatable JJ N
. . N

Pretrial JJ N
USG NNP N
was VBD N
1.022 CD N
? . N
0.001 CD N
in IN N
the DT N
HYPO NNP N
trial NN N
and CC N
decreased VBD N
< NNS N
1.020 CD N
by IN N
45 CD N
minutes NNS N
( ( N
1.013 CD N
? . N
0.003 CD N
) ) N
. . N

In IN N
the DT N
CES NNP N
study NN N
, , N
HYPO NNP N
subjects VBZ N
reached VBN N
HYD NNP N
status NN N
at IN N
45 CD N
minutes NNS N
in IN N
all DT N
conditions NNS N
( ( N
W NNP N
1.013 CD N
? . N
0.003 CD N
, , N
SW NNP N
1.013 CD N
? . N
0.003 CD N
, , N
CES-L NNP N
1.011 CD N
? . N
0.003 CD N
, , N
CES NNP N
1.017 CD N
? . N
0.004 CD N
) ) N
because IN N
salt NN N
or CC N
CES NNP N
ingestion NN N
did VBD N
not RB N
affect VB N
fluid NN N
retention NN N
( ( N
W NNP N
68 CD N
% NN N
, , N
SW NNP N
72 CD N
% NN N
, , N
CES-L JJ N
68 CD N
% NN N
, , N
CES NNP N
76 CD N
% NN N
) ) N
. . N

This DT N
study NN N
demonstrated VBD N
that IN N
mildly RB N
HYPO NNP N
subjects NNS N
could MD N
reach VB N
euhydration NN N
within IN N
45 CD N
minutes NNS N
of IN N
the DT N
ingestion NN N
of IN N
600 CD N
ml NN N
of IN N
W NNP N
or CC N
a DT N
combination NN N
of IN N
salt NN N
and CC N
CES NNP N
solutions NNS N
. . N

Following VBG N
this DT N
practice NN N
will MD N
minimize VB N
the DT N
incidence NN N
of IN N
starting VBG N
a DT N
practice NN N
or CC N
competition NN N
hypohydrated VBN N
. . N

-DOCSTART- -X- O O

Hip NNP N
protectors NNS N
improve VBP N
falls VBZ N
self-efficacy NN N
. . N

OBJECTIVES NNP N
To TO N
investigate VB N
the DT N
effect NN N
of IN N
use NN N
of IN N
external JJ N
hip NN N
protectors NNS N
on IN N
subjects NNS N
' POS N
fear NN N
of IN N
falling VBG N
and CC N
falls VBZ N
self-efficacy NN N
( ( N
belief NN N
in IN N
their PRP$ N
own JJ N
ability NN N
to TO N
avoid VB N
falling VBG N
) ) N
. . N

DESIGN NNP N
Randomized NNP N
controlled VBD N
trial NN N
. . N

SETTING CC N
Aged-care JJ 1_p
health NN N
services NNS N
in IN N
Sydney NNP N
, , N
Australia NNP N
. . N

PARTICIPANTS NNP N
131 CD 3_p
women NNS 2_p
aged VBN N
75 CD 1_p
years NNS 1_p
or CC 1_p
older JJR 1_p
, , N
who WP N
had VBD N
two CD N
or CC N
more JJR N
falls NNS 4_p
or CC N
one CD N
fall NN 4_p
requiring VBG 4_p
hospital JJ 4_p
admission NN 4_p
in IN N
the DT N
previous JJ N
year NN N
and CC N
who WP N
live VBP N
at IN N
home NN N
. . N

Sixty-one JJ 3_p
subjects NNS N
were VBD N
in IN N
the DT N
intervention NN N
group NN N
and CC N
70 CD 3_p
in IN N
the DT N
control NN N
group NN N
. . N

INTERVENTION NNP N
Use NNP N
of IN N
external JJ N
hip NN N
protectors NNS N
and CC N
encouragement NN N
to TO N
use VB N
the DT N
protectors NNS N
by IN N
an DT N
adherence NN N
nurse NN N
. . N

MEASUREMENTS CC N
At IN N
the DT N
time NN N
of IN N
enrolment NN N
into IN N
a DT N
wider NN N
study NN N
examining VBG N
the DT N
effect NN N
of IN N
hip NN N
protectors NNS N
on IN N
hip NN N
fractures NNS N
, , N
participants NNS N
recruited VBD N
at IN N
home NN N
completed VBD N
an DT N
assessment NN N
of IN N
fear NN N
of IN N
falling VBG N
and CC N
falls VBZ N
efficacy NN N
as IN N
measured VBN N
by IN N
the DT N
Falls NNP N
Efficacy NNP N
Scale NNP N
and CC N
the DT N
Modified NNP N
Falls NNP N
Efficacy NNP N
Scale NNP N
. . N

At IN N
4-month JJ N
follow-up NN N
, , N
these DT N
scales NNS N
were VBD N
readministered VBN N
by IN N
an DT N
observer NN N
who WP N
was VBD N
not RB N
aware JJ N
of IN N
the DT N
allocation NN N
of IN N
the DT N
participant NN N
to TO N
intervention NN N
or CC N
control NN N
groups NNS N
. . N

RESULTS NNP N
Fear NNP N
of IN N
falling VBG N
and CC N
falls VBZ N
self-efficacy NN N
, , N
as IN N
measured VBN N
by IN N
the DT N
Falls NNP N
Efficacy NNP N
and CC N
Modified NNP N
Falls NNP N
Efficacy NNP N
Scales NNP N
, , N
were VBD N
similar JJ N
at IN N
baseline NN N
in IN N
both DT N
groups NNS N
. . N

Fear NN N
of IN N
falling VBG N
was VBD N
present JJ N
at IN N
follow-up NN N
in IN N
43 CD N
% NN N
of IN N
subjects NNS N
using VBG N
hip NN N
protectors NNS N
and CC N
57 CD N
% NN N
of IN N
the DT N
control NN N
group NN N
( ( N
chi2 JJ N
= NN N
2.58 CD N
, , N
P NNP N
= NNP N
0.11 CD N
) ) N
. . N

Hip NNP N
protector NN N
users NNS N
had VBD N
greater JJR N
improvement NN N
in IN N
falls VBZ N
self-efficacy NN N
at IN N
follow-up JJ N
as IN N
measured VBN N
by IN N
the DT N
Falls NNP N
Efficacy NNP N
Scale NNP N
( ( N
t JJ N
= NN N
2.44 CD N
, , N
P NNP N
= NNP N
0.016 CD N
) ) N
and CC N
the DT N
Modified NNP N
Falls NNP N
Efficacy NNP N
Scale NNP N
( ( N
t JJ N
= NN N
2.08 CD N
, , N
P NNP N
= NNP N
0.039 CD N
) ) N
. . N

CONCLUSION NNP N
Hip NNP N
protectors NNS N
improve VBP N
falls VBZ N
self-efficacy NN N
. . N

As IN N
users NNS N
of IN N
hip NN N
protectors NNS N
feel VBP N
more RBR N
confident JJ N
that IN N
they PRP N
can MD N
complete VB N
tasks NNS N
safely RB N
, , N
they PRP N
may MD N
become VB N
more RBR N
physically RB N
active JJ N
and CC N
require VB N
less JJR N
assistance NN N
with IN N
activities NNS N
of IN N
daily JJ N
living NN N
. . N

-DOCSTART- -X- O O

Comparative JJ N
efficacy NN N
and CC N
safety NN N
of IN N
twice JJ N
daily JJ N
fluticasone NN N
propionate NN N
powder NN N
versus NN N
placebo NN N
in IN N
the DT N
treatment NN N
of IN N
moderate JJ 4_p
asthma NN 4_p
. . N

BACKGROUND NNP N
Fluticasone NNP N
propionate NN N
, , N
an DT N
inhaled JJ N
corticosteroid NN N
with IN N
negligible JJ N
systemic JJ N
bioavailability NN N
via IN N
the DT N
oral JJ N
route NN N
, , N
is VBZ N
efficacious JJ N
in IN N
the DT N
treatment NN N
of IN N
asthma NN 4_p
when WRB N
administered VBN N
via IN N
metered-dose JJ N
inhaler NN N
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
inhaled JJ N
fluticasone NN N
propionate NN N
powder NN N
in IN N
patients NNS N
with IN N
moderate JJ 4_p
asthma NNS 4_p
previously RB N
treated VBN N
with IN N
an DT N
inhaled JJ N
corticosteroid NN N
. . N

METHODS NNP N
This DT N
was VBD N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
parallel-group JJ N
, , N
multicenter NN N
study NN N
of IN N
342 CD 3_p
adolescent NN 1_p
and CC N
adult NN 1_p
patients NNS N
with IN N
moderate JJ 4_p
asthma NNS 4_p
[ RB N
forced VBD N
expiratory JJ N
volume NN N
in IN N
1 CD N
second JJ N
( ( N
FEV1 NNP N
) ) N
between IN N
50 CD N
% NN N
and CC N
80 CD N
% NN N
of IN N
predicted JJ N
] NNP N
treated VBD N
previously RB N
by IN N
beclomethasone NN N
dipropionate NN N
or CC N
triamcinolone NN N
acetonide RB N
. . N

Patients NNS N
received VBD N
fluticasone JJ N
propionate NN N
powder NN N
50 CD N
micrograms NNS N
, , N
100 CD N
micrograms NNS N
, , N
250 CD N
micrograms NNS N
, , N
or CC N
placebo NN N
via IN N
a DT N
breath-actuated JJ N
inhalation NN N
device NN N
, , N
the DT N
Diskhaler NNP N
, , N
twice RB N
daily RB N
for IN N
12 CD N
weeks NNS N
. . N

RESULTS JJ N
Patients NNPS N
in IN N
the DT N
fluticasone NN N
propionate NN N
groups NNS N
experienced VBD N
a DT N
mean JJ N
increase NN N
from IN N
baseline NN N
to TO N
endpoint VB N
in IN N
FEV1 NNP N
ranging VBG N
from IN N
0.43 CD N
L NNP N
to TO N
0.47 CD N
L. NNP N
Patients NNPS N
in IN N
the DT N
placebo NN N
group NN N
experienced VBD N
a DT N
mean JJ N
decrease NN N
from IN N
baseline NN N
of IN N
0.22 CD N
L NNP N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

The DT N
probability NN N
of IN N
patients NNS N
remaining VBG N
in IN N
the DT N
study NN N
over IN N
time NN N
without IN N
developing VBG N
signs NNS N
of IN N
exacerbating VBG N
asthma NN N
was VBD N
significantly RB N
greater JJR N
in IN N
the DT N
fluticasone NN N
propionate NN N
groups NNS N
than IN N
in IN N
the DT N
placebo NN N
group NN N
( ( N
P NNP N
= NNP N
.001 NNP N
) ) N
. . N

Asthma NNP N
symptom NN N
scores NNS N
, , N
supplemental JJ N
rescue NN N
albuterol NN N
use NN N
, , N
and CC N
number NN N
of IN N
nighttime JJ N
awakenings NNS N
due JJ N
to TO N
asthma VB N
requiring VBG N
treatment NN N
also RB N
improved VBN N
significantly RB N
with IN N
all DT N
fluticasone NN N
propionate NN N
treatment NN N
regimens NNS N
compared VBN N
with IN N
placebo NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
at IN N
endpoint NN N
among IN N
the DT N
three CD N
fluticasone NN N
propionate NN N
groups NNS N
. . N

No DT N
serious JJ N
drug-related JJ N
adverse JJ N
events NNS N
occurred VBD N
. . N

CONCLUSIONS NNP N
Fluticasone NNP N
propionate NN N
powder NN N
( ( N
50 CD N
, , N
100 CD N
, , N
and CC N
250 CD N
micrograms NNS N
) ) N
was VBD N
well-tolerated JJ N
and CC N
significantly RB N
improved VBN N
lung NN N
function NN N
in IN N
patients NNS N
with IN N
moderate JJ 4_p
asthma NNS 4_p
. . N

-DOCSTART- -X- O O

Anti-angiogenic JJ N
effects NNS N
of IN N
epigallocatechin-3-gallate NN N
in IN N
human JJ N
skin NN N
. . N

Epigallocatechin-3-gallate NNP N
( ( N
EGCG NNP N
) ) N
is VBZ N
the DT N
main JJ N
polyphenol JJ N
component NN N
of IN N
green JJ N
tea NN N
. . N

This DT N
compound NN N
exhibits VBZ N
antioxidant JJ N
, , N
immunomodulatory JJ N
, , N
photoprotective JJ N
, , N
anti-angiogenic JJ N
, , N
and CC N
anti-inflammatory JJ N
properties NNS N
. . N

We PRP N
conducted VBD N
a DT N
small JJ N
randomized NN N
, , N
double JJ N
blind NN N
, , N
split VBD N
face NN N
trial NN N
using VBG N
a DT N
cream NN N
containing VBG N
2.5 CD N
% NN N
w/w NN N
of IN N
EGCG NNP N
. . N

Four CD 3_p
healthy JJ 4_p
volunteers NNS N
with IN N
significant JJ N
erythema NN 4_p
and CC N
telangiectasia NN 4_p
on IN 4_p
the DT 4_p
face NN 4_p
applied VBD N
EGCG NNP N
cream NN N
to TO N
one CD N
side NN N
of IN N
the DT N
face NN N
, , N
and CC N
vehicle NN N
control NN N
cream NN N
to TO N
the DT N
other JJ N
, , N
twice JJ N
daily RB N
for IN N
six CD N
weeks NNS N
. . N

After IN N
six CD N
weeks NNS N
, , N
biopsies NNS N
were VBD N
taken VBN N
from IN N
EGCG NNP N
and CC N
vehicle NN N
treated VBN N
sites NNS N
. . N

Immunohistochemistry NN N
was VBD N
used VBN N
to TO N
measure VB N
VEGF NNP N
and CC N
HIF-1 NNP N
?. NNP N
HIF-1 NNP N
? . N
expression NN N
was VBD N
decreased VBN N
in IN N
EGCG NNP N
treated VBD N
sites NNS N
, , N
such JJ N
that IN N
28.4 CD N
% NN N
of IN N
the DT N
epidermis NN N
showed VBD N
positive JJ N
staining NN N
in IN N
vehicle NN N
treated VBD N
vs. FW N
13.8 CD N
% NN N
in IN N
EGCG NNP N
treated VBD N
sites NNS N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

A DT N
similar JJ N
decrease NN N
in IN N
VEGF NNP N
expression NN N
was VBD N
found VBN N
( ( N
6.7 CD N
% NN N
in IN N
EGCG NNP N
vs. FW N
11.0 CD N
% NN N
in IN N
in IN N
vehicle-treated JJ N
skin NN N
( ( N
p JJ N
< NNP N
0.005 CD N
) ) N
. . N

EGCG NNP N
topical JJ N
treatments NNS N
influence VB N
HIF-1 NNP N
? . N
induction NN N
and CC N
VEGF NNP N
expression NN N
and CC N
may MD N
serve VB N
as IN N
a DT N
potential JJ N
agent NN N
in IN N
the DT N
prevention NN N
of IN N
telangiectasias NN N
. . N

-DOCSTART- -X- O O

Randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
trial NN N
of IN N
oral JJ N
sirolimus NN N
for IN N
restenosis NN N
prevention NN N
in IN N
patients NNS N
with IN N
in-stent JJ 4_p
restenosis NN 4_p
: : N
the DT N
Oral NNP N
Sirolimus NNP N
to TO N
Inhibit NNP N
Recurrent NNP N
In-stent JJ N
Stenosis NNP N
( ( N
OSIRIS NNP N
) ) N
trial NN N
. . N

BACKGROUND NNP N
Despite IN N
recent JJ N
advances NNS N
in IN N
interventional JJ N
cardiology NN N
, , N
including VBG N
the DT N
introduction NN N
of IN N
drug-eluting JJ N
stents NNS N
for IN N
de FW N
novo FW N
coronary JJ N
lesions NNS N
, , N
the DT N
treatment NN N
of IN N
in-stent JJ N
restenosis NN N
( ( N
ISR NNP N
) ) N
remains VBZ N
a DT N
challenging JJ N
clinical JJ N
issue NN N
. . N

Given VBN N
the DT N
efficacy NN N
of IN N
systemic JJ N
sirolimus JJ N
administration NN N
to TO N
prevent VB N
neointimal JJ N
hyperplasia NN N
in IN N
animal JJ N
models NNS N
and CC N
to TO N
halt VB N
and CC N
even RB N
reverse VB N
the DT N
progression NN N
of IN N
allograft NN N
vasculopathy NN N
, , N
the DT N
aim NN N
of IN N
the DT N
present JJ N
double-blind NN N
, , N
placebo-controlled JJ N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
a DT N
10-day JJ N
oral JJ N
sirolimus NN N
treatment NN N
with IN N
2 CD N
different JJ N
loading VBG N
regimens NNS N
for IN N
the DT N
prevention NN N
of IN N
recurrent JJ N
restenosis NN N
in IN N
patients NNS N
with IN N
ISR NNP 4_p
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
Three NNP 3_p
hundred VBD 3_p
symptomatic JJ 4_p
patients NNS N
with IN N
ISR NNP 4_p
were VBD N
randomly RB N
assigned VBN N
to TO N
1 CD N
of IN N
3 CD N
treatment NN N
arms NNS N
: : N
placebo NN N
or CC N
usual-dose JJ N
or CC N
high-dose JJ N
sirolimus NN N
. . N

Patients NNS N
received VBD N
a DT N
cumulative JJ N
loading NN N
dose NN N
of IN N
0 CD N
, , N
8 CD N
, , N
or CC N
24 CD N
mg NN N
of IN N
sirolimus JJ N
2 CD N
days NNS N
before IN N
and CC N
the DT N
day NN N
of IN N
repeat NN N
intervention NN N
followed VBN N
by IN N
maintenance NN N
therapy NN N
of IN N
2 CD N
mg/d NN N
for IN N
7 CD N
days NNS N
. . N

Angiographic JJ N
restenosis NN N
at IN N
6-month JJ N
angiography NN N
was VBD N
the DT N
primary JJ N
end NN N
point NN N
of IN N
the DT N
study NN N
. . N

Restenosis NNP N
was VBD N
significantly RB N
reduced VBN N
from IN N
42.2 CD N
% NN N
to TO N
38.6 CD N
% NN N
and CC N
to TO N
22.1 CD N
% NN N
in IN N
the DT N
placebo NN N
, , N
usual-dose JJ N
, , N
and CC N
high-dose JJ N
sirolimus NN N
groups NNS N
, , N
respectively RB N
( ( N
P=0.005 NNP N
) ) N
. . N

Similarly RB N
, , N
the DT N
need NN N
for IN N
target NN N
vessel JJ N
revascularization NN N
was VBD N
reduced VBN N
from IN N
25.5 CD N
% NN N
to TO N
24.2 CD N
% NN N
and CC N
to TO N
15.2 CD N
% NN N
in IN N
the DT N
placebo NN N
, , N
usual-dose JJ N
, , N
and CC N
high-dose JJ N
groups NNS N
, , N
respectively RB N
( ( N
P=0.08 NNP N
) ) N
. . N

The DT N
sirolimus JJ N
blood NN N
concentration NN N
on IN N
the DT N
day NN N
of IN N
the DT N
procedure NN N
correlated VBD N
significantly RB N
with IN N
the DT N
late JJ N
lumen NNS N
loss NN N
at IN N
follow-up JJ N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

CONCLUSIONS NNP N
In IN N
patients NNS N
with IN N
ISR NNP N
, , N
an DT N
oral JJ N
adjunctive JJ N
sirolimus NN N
treatment NN N
with IN N
an DT N
intensified JJ N
loading NN N
regimen NNS N
before IN N
coronary JJ N
intervention NN N
resulted VBD N
in IN N
a DT N
significant JJ N
improvement NN N
in IN N
the DT N
angiographic JJ N
parameters NNS N
of IN N
restenosis NN N
. . N

-DOCSTART- -X- O O

Glibenclamide NNP N
vs NN N
gliclazide NN N
in IN N
reducing VBG N
oxidative JJ N
stress NN N
in IN N
patients NNS N
of IN N
noninsulin JJ 4_p
dependent JJ 4_p
diabetes VBZ 4_p
mellitus NN 4_p
-- : N
a DT N
double JJ N
blind NN N
randomized VBN N
study NN N
. . N

OBJECTIVE NNP N
Parameters NNPS N
of IN N
oxidative JJ N
stress NN N
were VBD N
quantitated VBN N
in IN N
50 CD 3_p
patients NNS N
with IN N
type JJ 4_p
2 CD 4_p
diabetes NNS 4_p
mellitus VBP 4_p
in IN 4_p
uncontrolled JJ 4_p
state NN 4_p
and CC N
after IN N
control NN N
using VBG N
oral JJ N
glibenclamide NN N
or CC N
gliclazide NN N
. . N

The DT N
estimates NNS N
were VBD N
further RB N
compared VBN N
between IN N
the DT N
two CD N
groups NNS N
irrespective JJ N
of IN N
drug NN N
used VBN N
to TO N
evaluate VB N
the DT N
difference NN N
, , N
if IN N
any DT N
. . N

METHODS NNP N
The DT N
study NN N
was VBD N
a DT N
double JJ N
blind NN N
, , N
uncontrolled JJ N
, , N
noncrossover RB N
and CC N
randomized JJ N
trial NN N
. . N

Fifty JJ 3_p
patients NNS N
of IN N
uncontrolled JJ 4_p
type NN 4_p
2 CD 4_p
diabetes NNS 4_p
were VBD N
divided VBN N
in IN N
to TO N
two CD N
groups NNS N
. . N

Group NNP N
I PRP N
( ( N
25 CD N
patients NNS N
) ) N
received VBD N
capsule NN N
A NNP N
( ( N
glibenclamide NN N
) ) N
while IN N
Group NNP N
II NNP N
( ( N
25 CD N
patients NNS N
) ) N
received VBD N
capsule NN N
B NNP N
( ( N
gliclazide NN N
) ) N
. . N

The DT N
parameters NNS N
studied VBN N
were VBD N
Superoxide NNP N
dismutase NN N
( ( N
SOD NNP N
) ) N
, , N
malonyl-dialdehyde JJ N
( ( N
MDA NNP N
) ) N
and CC N
reduced VBN N
glutathione NN N
( ( N
GSH NNP N
) ) N
. . N

They PRP N
were VBD N
done VBN N
at IN N
( ( N
a DT N
) ) N
uncontrolled JJ N
stage NN N
( ( N
FBS NNP N
-- : N
165 CD N
+/- JJ N
16.7 CD N
mg/dl NN N
, , N
PP NNP N
-- : N
240 CD N
+/- JJ N
30.1 CD N
mg/dl NN N
and CC N
HbA1 NNP N
-- : N
10.5 CD N
+/- JJ N
0.9 CD N
% NN N
in IN N
group NN N
I PRP N
and CC N
FBS NNP N
-- : N
150 CD N
+/- JJ N
15.8 CD N
mg/dl NN N
, , N
PP NNP N
-- : N
246 CD N
+/- JJ N
29.1 CD N
mg/dl NN N
HbA1 NNP N
10.6 CD N
+/- JJ N
0.8 CD N
% NN N
in IN N
group NN N
II NNP N
) ) N
and CC N
during IN N
controlled VBN N
stage NN N
at IN N
12 CD N
weeks NNS N
( ( N
FBS NNP N
-- : N
120 CD N
+/- JJ N
18.5 CD N
mg/dl NN N
, , N
PP NNP N
-- : N
180 CD N
+/- JJ N
19.1 CD N
mg/dl NN N
and CC N
HbA1 NNP N
-- : N
8.4 CD N
+/- JJ N
0.29 CD N
% NN N
in IN N
group NN N
I PRP N
and CC N
FBS NNP N
-- : N
118 CD N
+/- JJ N
17.6 CD N
mg/dl NN N
, , N
PP NNP N
-- : N
176 CD N
+/- JJ N
20.1 CD N
mg/dl NN N
and CC N
HbA1 NNP N
-- : N
8.5 CD N
+/- JJ N
0.39 CD N
% NN N
in IN N
group NN N
II NNP N
patients NNS N
) ) N
. . N

RESULTS VB N
The DT N
significantly RB N
raised VBN N
levels NNS N
of IN N
MDA NNP N
and CC N
SOD NNP N
, , N
and CC N
decreased JJ N
levels NNS N
of IN N
reduced VBN N
glutathione NN N
( ( N
GSH NNP N
) ) N
during IN N
uncontrolled JJ N
stage NN N
of IN N
diabetes NNS N
indicated VBD N
free JJ N
radical JJ N
stress NN N
induced VBD N
lipid JJ N
peroxidation NN N
. . N

The DT N
significant JJ N
fall NN N
of IN N
MDA NNP N
and CC N
SOD NNP N
and CC N
increased VBD N
levels NNS N
of IN N
GSH NNP N
in IN N
blood NN N
in IN N
both DT N
groups NNS N
after IN N
control NN N
revealed VBD N
beneficial JJ N
effects NNS N
of IN N
glycemic JJ N
control NN N
on IN N
oxidative JJ N
stress NN N
. . N

The DT N
levels NNS N
were VBD N
not RB N
normalized VBN N
and CC N
stayed VBD N
higher JJR N
than IN N
those DT N
in IN N
controls NNS N
. . N

On IN N
intergroup JJ N
comparison NN N
; : N
the DT N
control NN N
of IN N
diabetes NNS N
with IN N
gliclazide NN N
( ( N
group NN N
II NNP N
) ) N
showed VBD N
improvement NN N
in IN N
oxidative JJ N
stress NN N
( ( N
MDA NNP N
, , N
GSH NNP N
) ) N
better JJR N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
than IN N
glibenclamide NN N
( ( N
group NN N
I PRP N
) ) N
. . N

CONCLUSION NNP N
Oxidative NNP N
stress NN N
in IN N
uncontrolled JJ N
diabetes NNS N
is VBZ N
decreased VBN N
with IN N
glycemic JJ N
control NN N
. . N

The DT N
control NN N
of IN N
diabetes NNS N
with IN N
gliclazide NN N
reduced VBN N
oxidative JJ N
stress NN N
more JJR N
than IN N
glibenclamide NN N
, , N
indicating VBG N
higher JJR N
antioxidant JJ N
properties NNS N
of IN N
gliclazide NN N
. . N

Normalization NN N
of IN N
oxidative JJ N
stress NN N
was VBD N
not RB N
achieved VBN N
. . N

Further JJ N
studies NNS N
are VBP N
required VBN N
to TO N
see VB N
long-term JJ N
effect NN N
of IN N
drug NN N
therapy NN N
in IN N
combating VBG N
oxidative JJ N
stress NN N
after IN N
achieving VBG N
acceptable JJ N
control NN N
of IN N
diabetes NNS N
. . N

-DOCSTART- -X- O O

Measurement NN N
of IN N
transfer NN N
factor NN N
during IN N
constant JJ N
exhalation NN N
. . N

BACKGROUND NNP N
Transfer NNP N
factor NN N
of IN N
the DT N
lung NN N
for IN N
carbon NN N
monoxide NN N
( ( N
TLCO NNP N
) ) N
was VBD N
measured VBN N
by IN N
a DT N
new JJ N
method NN N
based VBN N
on IN N
analysis NN N
of IN N
the DT N
ratio NN N
of IN N
the DT N
concentrations NNS N
of IN N
carbon NN N
monoxide NN N
to TO N
an DT N
inert NN N
gas NN N
( ( N
methane NN N
) ) N
relative NN N
to TO N
lung NN N
volume NN N
during IN N
a DT N
constant JJ N
exhalation NN N
. . N

Since IN N
this DT N
new JJ N
technique NN N
is VBZ N
based VBN N
solely RB N
upon JJ N
exhalation NN N
, , N
anomalies NNS N
associated VBN N
with IN N
inspiration NN N
and CC N
breath NN N
holding VBG N
do VBP N
not RB N
affect VB N
results NNS N
. . N

Additionally RB N
, , N
because IN N
prolonged JJ N
breath NN N
holding NN N
is VBZ N
not RB N
required VBN N
, , N
measurements NNS N
can MD N
readily RB N
be VB N
made VBN N
in IN N
dyspnoeic JJ 4_p
patients NNS N
. . N

METHODS NNP N
Exhalation NNP N
TLCO NNP N
( ( N
TLCO NNP N
, , N
ex NN N
) ) N
was VBD N
compared VBN N
with IN N
the DT N
standard NN N
( ( N
Jones NNP N
and CC N
Meade NNP N
) ) N
10 CD N
second JJ N
breath NN N
holding VBG N
TLCO NNP N
( ( N
TLCO NNP N
, , N
bh NN N
) ) N
in IN N
100 CD 3_p
consecutive JJ N
patients NNS N
. . N

Patients NNS N
did VBD N
not RB N
practise VB N
the DT N
exhalation NN N
manoeuvre NN N
prior RB N
to TO N
testing VBG N
. . N

RESULTS VB N
The DT N
comparative JJ N
results NNS N
were VBD N
very RB N
close RB N
; : N
mean JJ N
difference NN N
( ( N
bias JJ N
) ) N
+/- JJ N
standard JJ N
deviation NN N
( ( N
precision NN N
) ) N
was VBD N
0.05 CD N
( ( N
0.84 CD N
) ) N
mmol/min/kPa NN N
. . N

The DT N
relation NN N
was VBD N
equally RB N
strong JJ N
in IN N
patients NNS N
with IN N
severe JJ 4_p
pulmonary JJ 4_p
disease NN 4_p
; : N
for IN N
patients NNS N
with IN N
FEV1 NNP N
< $ N
1.51 CD N
the DT N
mean NN N
difference NN N
was VBD N
0.21 CD N
( ( N
0.80 CD N
) ) N
mmol/min/kPa NN N
. . N

CONCLUSIONS NNP N
Since IN N
the DT N
results NNS N
were VBD N
essentially RB N
identical JJ N
between IN N
the DT N
techniques NNS N
, , N
it PRP N
seems VBZ N
that IN N
comparable JJ N
pathophysiological JJ N
factors NNS N
affect VBP N
TLCO NNP N
during IN N
breath NN N
holding NN N
and CC N
constant JJ N
exhalation NN N
. . N

Constant JJ N
exhalation NN N
may MD N
therefore RB N
be VB N
a DT N
useful JJ N
alternative NN N
to TO N
the DT N
breath NN N
holding NN N
technique NN N
for IN N
clinical JJ N
measurement NN N
of IN N
TLCO NNP N
. . N

-DOCSTART- -X- O O

A DT N
comparison NN N
of IN N
intermittent JJ N
vaginal JJ N
administration NN N
of IN N
misoprostol NN N
with IN N
continuous JJ N
dinoprostone NN N
for IN N
cervical JJ N
ripening NN N
and CC N
labor NN N
induction NN N
. . N

OBJECTIVE CC N
Our PRP$ N
purpose NN N
was VBD N
to TO N
compare VB N
the DT N
effect NN N
of IN N
vaginal JJ N
administration NN N
of IN N
misoprostol NN N
( ( N
Cytotec NNP N
) ) N
with IN N
that DT N
of IN N
dinoprostone NN N
( ( N
Cervidil NNP N
) ) N
on IN N
cervical JJ N
ripening NN N
and CC N
labor NN N
induction NN N
. . N

STUDY NNP N
DESIGN NNP N
Two CD 3_p
hundred VBD 3_p
patients NNS N
with IN N
indications NNS N
for IN N
induction NN 4_p
of IN 4_p
labor NN 4_p
and CC N
unfavorable JJ 4_p
cervical JJ 4_p
examinations NNS 4_p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
vaginally RB N
administered VBN N
misoprostol NN N
( ( N
prostaglandin JJ N
E1 NNP N
) ) N
or CC N
the DT N
dinoprostone NN N
( ( N
prostaglandin JJ N
E2 NNP N
) ) N
vaginal NN N
insert NN N
. . N

Twenty-five JJ N
microgram JJ N
tablets NNS N
of IN N
misoprostol NN N
were VBD N
placed VBN N
in IN N
the DT N
posterior JJ N
vaginal JJ N
fornix NN N
every DT N
4 CD N
hours NNS N
for IN N
a DT N
maximum NN N
of IN N
six CD N
doses NNS N
. . N

Additional NNP N
misoprostol NN N
was VBD N
not RB N
given VBN N
after IN N
either DT N
spontaneous JJ N
rupture NN N
of IN N
membranes NNS N
, , N
adequate JJ N
cervical JJ N
ripening NN N
( ( N
Bishop NNP N
score NN N
of IN N
> NN N
or CC N
= VB N
8 CD N
or CC N
cervical JJ N
dilatation NN N
of IN N
> NN N
or CC N
= $ N
3 CD N
cm NN N
) ) N
, , N
or CC N
beginning NN N
of IN N
active JJ N
labor NN N
. . N

The DT N
vaginal JJ N
insert NN N
, , N
Cervidil NNP N
, , N
containing VBG N
10 CD N
mg NN N
of IN N
dinoprostone NN N
in IN N
a DT N
timed-release JJ N
preparation NN N
was VBD N
placed VBN N
in IN N
the DT N
posterior JJ N
vaginal JJ N
formix NN N
for IN N
a DT N
maximum JJ N
period NN N
of IN N
24 CD N
hours NNS N
. . N

The DT N
vaginal JJ N
insert NN N
was VBD N
removed VBN N
for IN N
spontaneous JJ N
rupture NN N
of IN N
membranes NNS N
, , N
entry NN N
into IN N
active JJ N
labor NN N
, , N
adequate JJ N
cervical JJ N
ripening NN N
, , N
or CC N
abnormality NN N
of IN N
uterine JJ N
contractile NN N
pattern NN N
or CC N
fetal JJ N
cardiac JJ N
activity NN N
. . N

RESULTS NN N
Of IN N
the DT N
200 CD 3_p
patients NNS N
enrolled VBD N
, , N
99 CD 3_p
were VBD N
randomized VBN N
to TO N
misoprostol VB N
and CC N
101 CD 3_p
to TO N
dinoprostone VB N
. . N

The DT N
average JJ N
interval NN N
from IN N
start NN N
of IN N
induction NN N
to TO N
vaginal JJ N
delivery NN N
was VBD N
1 CD N
hour NN N
shorter NN N
in IN N
the DT N
misoprostol NN N
group NN N
( ( N
1296.7 CD N
+/- JJ N
722.1 CD N
minutes NNS N
) ) N
than IN N
in IN N
the DT N
dinoprostone NN N
group NN N
( ( N
1360.0 CD N
+/- JJ N
792.0 CD N
minutes NNS N
) ) N
, , N
but CC N
this DT N
difference NN N
was VBD N
not RB N
statistically RB N
significant JJ N
( ( N
p JJ N
= NNP N
0.97 CD N
) ) N
. . N

Oxytocin NNP N
augmentation NN N
of IN N
labor NN N
was VBD N
used VBN N
in IN N
50 CD N
( ( N
50.5 CD N
% NN N
) ) N
misoprostol-treated JJ N
patients NNS N
and CC N
43 CD N
( ( N
43.5 CD N
% NN N
) ) N
dinoprostone-treated JJ N
patients NNS N
( ( N
relative JJ N
risk NN N
1.14 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
0.86 CD N
to TO N
1.51 CD N
, , N
p NN N
= NNP N
0.35 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
routes NNS N
of IN N
delivery NN N
with IN N
misoprostol NN N
or CC N
dinoprostone NN N
. . N

Overall NNP N
, , N
38 CD 3_p
patients NNS N
( ( N
19.3 CD N
% NN N
) ) N
had VBD N
cesarean JJ N
deliveries NNS N
. . N

There EX N
was VBD N
a DT N
significantly RB N
lower JJR N
prevalence NN N
of IN N
tachysystole NN N
( ( N
six CD N
or CC N
more JJR N
uterine JJ N
contractions NNS N
in IN N
a DT N
10-minute JJ N
window NN N
for IN N
two CD N
consecutive JJ N
10-minute JJ N
periods NNS N
) ) N
in IN N
the DT N
misoprostol NN N
group NN N
( ( N
7.1 CD N
% NN N
) ) N
than IN N
in IN N
the DT N
dinoprostone NN N
group NN N
( ( N
18.4 CD N
% NN N
) ) N
( ( N
relative JJ N
risk NN N
0.52 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
0.31 CD N
to TO N
0.89 CD N
, , N
p NN N
= NNP N
0.02 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
frequency NN N
of IN N
uterine JJ N
hyperstimulation NN N
or CC N
hypertonus NN N
. . N

Abnormal NNP N
fetal JJ N
heart NN N
rate NN N
tracings NNS N
were VBD N
found VBN N
in IN N
23 CD N
( ( N
23.2 CD N
% NN N
) ) N
of IN N
misoprostol-treated JJ N
patients NNS N
and CC N
35 CD N
( ( N
35.7 CD N
% NN N
) ) N
of IN N
dinoprostone-treated JJ N
patients NNS N
( ( N
relative JJ N
risk NN N
0.73 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
0.52 CD N
to TO N
1.01 CD N
, , N
p NN N
= NNP N
0.0546 CD N
) ) N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
in IN N
meconium NN N
passage NN N
, , N
1- JJ N
or CC N
5-minute JJ N
Apgar NNP N
scores NNS N
< VBP N
7 CD N
, , N
neonatal JJ N
resuscitations NNS N
, , N
or CC N
admissions NNS N
to TO N
the DT N
neonatal JJ N
intensive JJ N
care NN N
unit NN N
between IN N
the DT N
two CD N
groups NNS N
. . N

CONCLUSIONS NNP N
Vaginally NNP N
administered VBD N
misoprostol NN N
is VBZ N
as RB N
effective JJ N
as IN N
dinoprostone NN N
for IN N
cervical JJ N
ripening NN N
and CC N
the DT N
induction NN N
of IN N
labor NN N
. . N

Mean JJ N
time NN N
intervals NNS N
to TO N
delivery NN N
, , N
need NN N
for IN N
oxytocin JJ N
augmentation NN N
, , N
and CC N
routes NNS N
of IN N
delivery NN N
were VBD N
similar JJ N
between IN N
the DT N
two CD N
groups NNS N
. . N

Incidence NN N
of IN N
uterine JJ N
tachysystole NN N
with IN N
misoprostol NN N
every DT N
4 CD N
hours NNS N
was VBD N
significantly RB N
less JJR N
than IN N
with IN N
dinoprostone NN N
. . N

-DOCSTART- -X- O O

The DT N
effect NN N
of IN N
a DT N
parent-implemented JJ N
imitation NN N
intervention NN N
on IN N
spontaneous JJ N
imitation NN N
skills NNS N
in IN N
young JJ 1_p
children NNS 1_p
with IN N
autism NN 4_p
. . N

Children NNP N
with IN N
autism NN N
exhibit NN N
significant JJ N
deficits NNS N
in IN N
their PRP$ N
ability NN N
to TO N
spontaneously RB N
imitate VB N
the DT N
play NN N
actions NNS N
and CC N
descriptive JJ N
gestures NNS N
of IN N
others NNS N
. . N

Reciprocal JJ N
imitation NN N
training NN N
( ( N
RIT NNP N
) ) N
is VBZ N
a DT N
naturalistic JJ N
imitation NN N
intervention NN N
designed VBN N
to TO N
teach VB N
spontaneous JJ N
imitation NN N
skills NNS N
during IN N
play NN N
. . N

This DT N
study NN N
assessed VBD N
the DT N
effectiveness NN N
of IN N
parent-implemented JJ N
RIT NNP N
using VBG N
a DT N
multiple-baseline JJ N
design NN N
across IN N
three CD 3_p
young JJ N
children NNS N
with IN N
autism NN N
and CC N
their PRP$ N
mothers NNS N
. . N

After IN N
an DT N
initial JJ N
baseline NN N
, , N
mothers NNS N
were VBD N
taught VBN N
to TO N
implement VB N
RIT NNP N
techniques NNS N
with IN N
their PRP$ N
child NN N
twice RB N
a DT N
week NN N
for IN N
10 CD N
weeks NNS N
in IN N
a DT N
clinic JJ N
setting NN N
. . N

Two CD N
mothers NNS N
were VBD N
taught VBN N
to TO N
use VB N
RIT NNP N
to TO N
teach VB N
object JJ N
imitation NN N
. . N

The DT N
third JJ N
mother NN N
was VBD N
taught VBN N
to TO N
use VB N
RIT NNP N
to TO N
target VB N
both DT N
object JJ N
and CC N
gesture JJ N
imitation NN N
in IN N
a DT N
multiple-baseline JJ N
design NN N
across IN N
behaviors NNS N
. . N

Generalization NNP N
was VBD N
assessed VBN N
in IN N
the DT N
families NNS N
' POS N
homes NNS N
at IN N
the DT N
end NN N
of IN N
treatment NN N
and CC N
a DT N
1-month JJ N
follow-up NN N
. . N

Parents NNS N
learned VBD N
to TO N
use VB N
the DT N
intervention NN N
strategies NNS N
and CC N
their PRP$ N
children NNS N
exhibited VBN N
increases NNS N
in IN N
spontaneous JJ N
imitation NN N
. . N

These DT N
findings NNS N
replicate VBP N
the DT N
results NNS N
from IN N
previous JJ N
studies NNS N
, , N
indicating VBG N
that IN N
RIT NNP N
is VBZ N
effective JJ N
for IN N
teaching VBG N
imitation NN N
skills NNS N
to TO N
young JJ N
children NNS N
with IN N
autism NN N
in IN N
a DT N
naturalistic JJ N
setting NN N
and CC N
extend VB N
the DT N
findings NNS N
to TO N
parents NNS N
. . N

-DOCSTART- -X- O O

Atrial NNP N
natriuretic JJ N
factor NN N
inhibits NNS N
metoclopramide RB N
stimulated VBD N
aldosterone JJ N
release NN N
in IN N
man NN 2_p
. . N

1 CD N
. . N

Atrial NNP N
natriuretic JJ N
factor NN N
( ( N
ANF NNP N
) ) N
has VBZ N
an DT N
inhibitory JJ N
effect NN N
on IN N
angiotensin NN N
II NNP N
and CC N
ACTH NNP N
stimulated VBD N
aldosterone CD N
secretion NN N
in IN N
man NN N
. . N

The DT N
selectivity NN N
of IN N
this DT N
aldosterone NN N
suppressing VBG N
effect NN N
of IN N
ANF NNP N
is VBZ N
unclear JJ N
in IN N
man NN N
. . N

The DT N
present JJ N
study NN N
investigated VBD N
the DT N
effect NN N
of IN N
ANF NNP N
on IN N
the DT N
increase NN N
in IN N
plasma JJ N
aldosterone NN N
due JJ N
to TO N
metoclopramide VB N
in IN N
man NN 2_p
. . N

2 CD N
. . N

Eight NNP 3_p
normal JJ 4_p
male NN 2_p
volunteers NNS N
were VBD N
studied VBN N
on IN N
three CD N
occasions NNS N
. . N

Metoclopramide NNP N
( ( N
10 CD N
mg RB N
slow JJ N
i.v NN N
. . N

) ) N
was VBD N
given VBN N
on IN N
all DT N
study NN N
days NNS N
and CC N
each DT N
volunteer NN N
was VBD N
randomised VBN N
to TO N
receive VB N
45 CD N
min JJ N
infusion NN N
of IN N
either DT N
5 CD N
% NN N
D-glucose NNP N
( ( N
placebo NN N
) ) N
or CC N
ANF NNP N
( ( N
99-126 CD N
) ) N
3 CD N
or CC N
15 CD N
pmol JJ N
kg-1 JJ N
min-1 NN N
. . N

3 CD N
. . N

Metoclopramide NNP N
increased VBD N
plasma RB N
aldosterone NN N
to TO N
approximately RB N
170 CD N
% NN N
of IN N
baseline NN N
levels NNS N
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

Concomitant JJ N
infusion NN N
of IN N
ANF NNP N
3 CD N
pmol JJ N
kg-1 JJ N
min-1 NN N
and CC N
15 CD N
pmol JJ N
kg-1 JJ N
min-1 NN N
significantly RB N
attenuated VBD N
this DT N
rise NN N
in IN N
plasma NN N
aldosterone NN N
to TO N
approximately RB N
130 CD N
% NN N
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
and CC N
110 CD N
% NN N
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
of IN N
baseline NN N
values NNS N
respectively RB N
. . N

4 CD N
. . N

It PRP N
is VBZ N
suggested VBN N
, , N
in IN N
the DT N
light NN N
of IN N
previous JJ N
findings NNS N
, , N
that IN N
the DT N
inhibitory JJ N
effect NN N
of IN N
ANF NNP N
represents VBZ N
a DT N
non-selective JJ N
action NN N
of IN N
ANF NNP N
on IN N
aldosterone NN N
release NN N
. . N

-DOCSTART- -X- O O

Brief JJ N
report NN N
: : N
imitation NN N
effects NNS N
on IN N
children NNS 1_p
with IN N
autism NN 4_p
. . N

Twenty NNP 3_p
children NNS 1_p
with IN N
autism NN 4_p
( ( N
mean JJ N
age NN N
, , N
5 CD 1_p
years NNS 1_p
) ) N
were VBD N
recruited VBN N
for IN N
the DT N
study NN N
from IN N
a DT N
school NN N
for IN N
children NNS 1_p
with IN N
autism NN 4_p
. . N

The DT N
children NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
an DT N
imitation NN N
( ( N
n JJ N
= NNP N
10 CD 3_p
) ) N
or CC N
contingently RB N
responsive JJ N
( ( N
n JJ N
= NNP N
10 CD 3_p
) ) N
interaction NN N
group NN N
based VBN N
on IN N
a DT N
stratification NN N
table NN N
for IN N
gender NN N
and CC N
developmental NN N
and CC N
chronological JJ N
age NN N
. . N

The DT N
sessions NNS N
consisted VBD N
of IN N
four CD N
phases NNS N
, , N
with IN N
each DT N
phase NN N
lasting VBG N
3 CD N
minutes NNS N
. . N

In IN N
the DT N
first JJ N
phase NN N
, , N
the DT N
child NN N
walked VBD N
into IN N
a DT N
room NN N
that WDT N
was VBD N
furnished VBN N
with IN N
a DT N
sofa NN N
, , N
a DT N
table NN N
, , N
chairs NNS N
, , N
and CC N
two CD N
sets NNS N
of IN N
identical JJ N
toys NN N
. . N

An DT N
adult NN N
was VBD N
in IN N
the DT N
room NN N
sitting VBG N
very RB N
still RB N
like IN N
a DT N
statue NN N
( ( N
first JJ N
still-face JJ N
condition NN N
) ) N
. . N

In IN N
the DT N
second JJ N
phase NN N
, , N
the DT N
adult NN N
either RB N
imitated VBD N
the DT N
child NN N
or CC N
was VBD N
contingently RB N
responsive JJ N
to TO N
the DT N
child NN N
. . N

In IN N
the DT N
third JJ N
phase NN N
, , N
the DT N
adult NN N
sat VBD N
still RB N
again RB N
( ( N
second JJ N
still-face JJ N
condition NN N
) ) N
, , N
and CC N
in IN N
the DT N
fourth JJ N
phase NN N
, , N
the DT N
adult NN N
engaged VBN N
in IN N
a DT N
spontaneous JJ N
interaction NN N
. . N

During IN N
the DT N
third JJ N
phase NN N
( ( N
the DT N
second JJ N
still-face JJ N
condition NN N
) ) N
, , N
the DT N
children NNS N
in IN N
the DT N
imitation NN N
group NN N
spent VBD N
less JJR N
time NN N
in IN N
gross JJ N
motor NN N
activity NN N
and CC N
more JJR N
time NN N
touching VBG N
the DT N
adult NN N
, , N
as IN N
if IN N
attempting VBG N
to TO N
initiate VB N
an DT N
interaction NN N
. . N

The DT N
contingency NN N
condition NN N
appeared VBD N
to TO N
be VB N
a DT N
more RBR N
effective JJ N
way NN N
to TO N
facilitate VB N
a DT N
distal JJ N
social JJ N
behavior NN N
( ( N
attention NN N
) ) N
, , N
whereas IN N
the DT N
imitative JJ N
condition NN N
was VBD N
a DT N
more RBR N
effective JJ N
way NN N
to TO N
facilitate VB N
a DT N
proximal JJ N
social JJ N
behavior NN N
( ( N
touching VBG N
) ) N
. . N

-DOCSTART- -X- O O

Social JJ N
support NN N
and CC N
abstinence NN N
from IN N
opiates NNS N
and CC N
cocaine NN N
during IN N
opioid JJ 4_p
maintenance NN 4_p
treatment NN 4_p
. . N

Social NNP N
support NN N
may MD N
play VB N
an DT N
important JJ N
role NN N
in IN N
helping VBG N
drug NN 4_p
users NNS 4_p
achieve VBP N
abstinence NN N
; : N
however RB N
these DT N
benefits NNS N
may MD N
depend VB N
on IN N
the DT N
type NN N
of IN N
support NN N
experienced VBN N
. . N

In IN N
this DT N
prospective JJ N
observational NN N
study NN N
, , N
we PRP N
examined VBD N
the DT N
extent NN N
to TO N
which WDT N
general JJ N
and CC N
abstinence-specific JJ N
support NN N
, , N
both DT N
structural JJ N
and CC N
functional JJ N
, , N
predicted JJ N
opiate NN N
and CC N
cocaine NN N
abstinence NN N
in IN N
128 CD 3_p
opioid JJ 4_p
maintenance NN 4_p
patients NNS 4_p
receiving VBG N
either CC N
methadone NN N
or CC N
LAAM NNP N
. . N

A DT N
new JJ N
multidimensional JJ N
self-report NN N
instrument NN N
assessing VBG N
abstinence-specific JJ N
functional JJ N
support NN N
was VBD N
developed VBN N
for IN N
the DT N
study NN N
. . N

Previously RB N
validated VBN N
measures NNS N
were VBD N
used VBN N
to TO N
assess VB N
the DT N
remaining VBG N
types NNS N
of IN N
support NN N
. . N

With IN N
baseline JJ N
abstinence NN N
and CC N
other JJ N
statistically RB N
important JJ N
covariates NNS N
adjusted VBN N
, , N
hierarchical JJ N
logistic JJ N
regression NN N
analyses NNS N
demonstrated VBD N
that IN N
the DT N
associations NNS N
between IN N
social JJ N
support NN N
at IN N
study NN N
baseline NN N
and CC N
biochemically RB N
confirmed VBN N
abstinence NN N
3 CD N
months NNS N
later RB N
varied VBN N
by IN N
type NN N
of IN N
support NN N
and CC N
by IN N
drug NN N
. . N

Greater NNP N
abstinence-specific JJ N
structural JJ N
support NN N
( ( N
operationalized VBN N
as IN N
fewer JJR N
drug NN N
users NNS N
in IN N
the DT N
social JJ N
network NN N
) ) N
and CC N
decreases VBZ N
in IN N
three CD N
types NNS N
of IN N
negative JJ N
abstinence-specific JJ N
functional JJ N
support NN N
( ( N
Complaints NNS N
about IN N
Drug NNP N
Use NNP N
, , N
Drug NNP N
Exposure NNP N
, , N
and CC N
Demoralization NNP N
) ) N
predicted VBD N
cocaine NN N
, , N
but CC N
not RB N
opiate JJ N
abstinence NN N
. . N

There EX N
were VBD N
no DT N
effects NNS N
for IN N
general JJ N
support NN N
, , N
whether IN N
structural JJ N
or CC N
functional JJ N
, , N
on IN N
abstinence NN N
from IN N
either DT N
drug NN N
. . N

Interventions NNS N
that WDT N
focus VBP N
on IN N
modifying VBG N
patients NNS N
' POS N
abstinence-specific JJ N
support NN N
may MD N
be VB N
helpful JJ N
in IN N
reducing VBG N
the DT N
high JJ N
rates NNS N
of IN N
cocaine NN 4_p
use NN 4_p
disorders NNS 4_p
in IN N
this DT N
population NN N
. . N

-DOCSTART- -X- O O

Action NNP N
observation NN N
treatment NN N
improves VBZ N
recovery NN N
of IN N
postsurgical JJ 4_p
orthopedic JJ 4_p
patients NNS 4_p
: : N
evidence NN N
for IN N
a DT N
top-down JJ N
effect NN N
? . N
OBJECTIVE UH N
To TO N
assess VB N
whether IN N
action NN N
observation NN N
treatment NN N
( ( N
AOT NNP N
) ) N
may MD N
also RB N
improve VB N
motor NN N
recovery NN N
in IN N
postsurgical JJ 4_p
orthopedic JJ 4_p
patients NNS N
, , N
in IN N
addition NN N
to TO N
conventional JJ N
physiotherapy NN N
. . N

DESIGN NNP N
Randomized NNP N
controlled VBD N
trial NN N
. . N

SETTING NNP N
Department NNP N
of IN N
rehabilitation NN N
. . N

PARTICIPANTS JJ N
Patients NNPS N
( ( N
N=60 NNP 3_p
) ) N
admitted VBD N
to TO N
our PRP$ N
department NN N
postorthopedic NN N
surgery NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
either VB N
a DT N
case NN N
( ( N
n=30 NN N
) ) N
or CC N
control NN N
( ( N
n=30 JJ N
) ) N
group NN N
. . N

Exclusion NN N
criteria NNS N
were VBD N
age NN N
18 CD 1_p
years NNS 1_p
or CC 1_p
younger JJR 1_p
and CC 1_p
90 CD 1_p
years NNS 1_p
or CC 1_p
older JJR 1_p
, , N
Mini-Mental JJ N
State NNP N
Examination NNP N
score NN N
of IN N
21 CD N
of IN N
30 CD N
or CC N
lower JJR N
, , N
no DT N
ambulating VBG N
order NN N
, , N
advanced JJ N
vision NN N
impairment NN N
, , N
malignancy NN N
, , N
pneumonia NN N
, , N
or CC N
heart NN N
failure NN N
. . N

INTERVENTIONS NNP N
All NNP N
participants NNS N
underwent JJ N
conventional JJ N
physiotherapy NN N
. . N

In IN N
addition NN N
, , N
patients NNS N
in IN N
the DT N
case NN N
group NN N
were VBD N
asked VBN N
to TO N
observe VB N
video JJ N
clips NNS N
showing VBG N
daily JJ N
actions NNS N
and CC N
to TO N
imitate VB N
them PRP N
afterward RB N
. . N

Patients NNS N
in IN N
the DT N
control NN N
group NN N
were VBD N
asked VBN N
to TO N
observe VB N
video JJ N
clips NNS N
with IN N
no DT N
motor NN N
content NN N
and CC N
to TO N
execute VB N
the DT N
same JJ N
actions NNS N
as IN N
patients NNS N
in IN N
the DT N
case NN N
group NN N
afterward RB N
. . N

Participants NNS N
were VBD N
scored VBN N
on IN N
functional JJ N
scales NNS N
at IN N
baseline NN N
and CC N
after IN N
treatment NN N
by IN N
a DT N
physician NN N
blinded VBD N
to TO N
group NN N
assignment NN N
. . N

MAIN NNP N
OUTCOMES NNP N
MEASURES NNP N
Changes NNP N
in IN N
FIM NNP N
and CC N
Tinetti NNP N
scale NN N
scores NNS N
, , N
and CC N
dependence NN N
on IN N
walking VBG N
aids NNS N
. . N

RESULTS NNP N
At IN N
baseline NN N
, , N
groups NNS N
did VBD N
not RB N
differ VB N
in IN N
clinical JJ N
and CC N
functional JJ N
scale NN N
scores NNS N
. . N

After IN N
treatment NN N
, , N
patients NNS N
in IN N
the DT N
case NN N
group NN N
scored VBD N
better JJR N
than IN N
patients NNS N
in IN N
the DT N
control NN N
group NN N
( ( N
FIM NNP N
total NN N
score NN N
, , N
P=.02 NNP N
; : N
FIM NNP N
motor NN N
subscore NN N
, , N
P=.001 NNP N
; : N
Tinetti NNP N
scale NN N
score NN N
, , N
P=.04 NNP N
) ) N
; : N
patients NNS N
in IN N
the DT N
case NN N
group NN N
were VBD N
assigned VBN N
more RBR N
frequently RB N
to TO N
1 CD N
crutch NN N
( ( N
P=.01 NNP N
) ) N
. . N

CONCLUSIONS NNP N
In IN N
addition NN N
to TO N
conventional JJ N
physiotherapy NN N
, , N
AOT NNP N
is VBZ N
effective JJ N
in IN N
the DT N
rehabilitation NN N
of IN N
postsurgical JJ N
orthopedic JJ N
patients NNS N
. . N

The DT N
present JJ N
results NNS N
strongly RB N
support VB N
top-down JJ N
effects NNS N
of IN N
this DT N
treatment NN N
in IN N
motor NN N
recovery NN N
, , N
even RB N
in IN N
nonneurologic JJ N
patients NNS N
. . N

-DOCSTART- -X- O O

Mechanisms NNP N
underlying VBG N
the DT N
lack NN N
of IN N
effect NN N
of IN N
implantable JJ N
cardioverter-defibrillator JJ N
therapy NN N
on IN N
mortality NN N
in IN N
high-risk JJ N
patients NNS N
with IN N
recent JJ N
myocardial JJ 4_p
infarction NN 4_p
: : N
insights NNS N
from IN N
the DT N
Defibrillation NNP N
in IN N
Acute NNP N
Myocardial NNP N
Infarction NNP N
Trial NNP N
( ( N
DINAMIT NNP N
) ) N
. . N

BACKGROUND NNP N
although IN N
implantable JJ N
cardioverter-defibrillators NNS N
( ( N
ICDs NNP N
) ) N
lower JJR N
mortality NN N
in IN N
stable JJ N
patients NNS N
with IN N
low JJ 4_p
ejection NN 4_p
fraction NN 4_p
late RB N
after IN N
myocardial JJ N
infarction NN N
, , N
randomized VBN N
trials NNS N
of IN N
ICD NNP N
versus FW N
control NN N
subjects NNS N
implanted VBD N
early RB N
after IN N
myocardial JJ N
infarction NN N
do VBP N
not RB N
show VB N
mortality NN N
benefit NN N
. . N

Our PRP$ N
objective NN N
was VBD N
to TO N
investigate VB N
possible JJ N
mechanisms NNS N
underlying VBG N
the DT N
lack NN N
of IN N
mortality NN N
benefit NN N
in IN N
the DT N
Defibrillation NNP N
in IN N
Acute NNP N
Myocardial NNP N
Infarction NNP N
Trial NNP N
( ( N
DINAMIT NNP N
) ) N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
this DT N
is VBZ N
a DT N
secondary JJ N
analysis NN N
of IN N
the DT N
prospective JJ N
randomized JJ N
clinical JJ N
trial NN N
. . N

Outpatients NNS N
with IN N
recent JJ N
( ( N
6 CD N
to TO N
40 CD N
days NNS N
) ) N
acute VBP 4_p
myocardial JJ 4_p
infarction NN 4_p
, , N
left VBD 4_p
ventricular JJ 4_p
dysfunction NN 4_p
( ( 4_p
ejection JJ 4_p
fraction NN 4_p
< VBD 4_p
35 CD 4_p
% NN 4_p
) ) N
, , N
and CC N
low JJ 4_p
heart NN 4_p
rate NN 4_p
variability NN 4_p
were VBD N
randomized VBN N
to TO N
ICD NNP N
( ( N
n=311 NN N
) ) N
or CC N
to TO N
standard VB N
medical JJ N
therapy NN N
( ( N
n=342 JJ N
) ) N
. . N

In IN N
a DT N
competing-risks JJ N
analysis NN N
, , N
those DT N
factors NNS N
that WDT N
increased VBD N
the DT N
risk NN N
of IN N
arrhythmic JJ N
death NN N
also RB N
increased VBD N
the DT N
risk NN N
of IN N
nonarrhythmic JJ N
deaths NNS N
. . N

After IN N
adjustment NN N
for IN N
these DT N
factors NNS N
, , N
receiving VBG N
an DT N
ICD NNP N
was VBD N
associated VBN N
with IN N
a DT N
decreased JJ N
risk NN N
of IN N
arrhythmic JJ N
death NN N
( ( N
hazard JJ N
ratio NN N
, , N
0.33 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
0.15 CD N
to TO N
0.71 CD N
) ) N
but CC N
an DT N
increase NN N
in IN N
nonarrhythmic JJ N
death NN N
( ( N
hazard JJ N
ratio NN N
, , N
1.70 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
1.00 CD N
to TO N
2.80 CD N
) ) N
. . N

In IN N
an DT N
adjusted JJ N
time-dependent JJ N
analysis NN N
, , N
patients NNS N
receiving VBG N
an DT N
ICD NNP N
and CC N
having VBG N
appropriate JJ N
ICD NNP N
therapy NN N
had VBD N
a DT N
15.1 CD N
% NN N
yearly RB N
hazard NN N
of IN N
mortality NN N
compared VBN N
with IN N
5.2 CD N
% NN N
in IN N
ICD NNP 4_p
patients NNS N
with IN N
no DT N
appropriate JJ N
therapy NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
reduction NN N
in IN N
sudden JJ N
death NN N
in IN N
ICD NNP 4_p
patients NNS N
was VBD N
completely RB N
offset VBN N
by IN N
increased JJ N
nonarrhythmic JJ N
deaths NNS N
, , N
which WDT N
were VBD N
greatest JJS N
in IN N
patients NNS N
receiving VBG N
ICD NNP N
shock NN N
therapy NN N
( ( N
hazard JJ N
ratio NN N
, , N
6.0 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
2.8 CD N
to TO N
12.7 CD N
) ) N
. . N

CONCLUSIONS NNP N
in IN N
patients NNS N
receiving VBG N
ICDs NNP 4_p
early RB N
after IN N
myocardial JJ 4_p
infarction NN 4_p
, , N
those DT N
factors NNS N
that WDT N
are VBP N
associated VBN N
with IN N
arrhythmia NN N
requiring VBG N
ICD NNP N
therapy NN N
are VBP N
also RB N
associated VBN N
with IN N
a DT N
high JJ N
risk NN N
of IN N
nonsudden JJ N
death NN N
, , N
negating VBG N
the DT N
benefit NN N
of IN N
ICDs NNP N
in IN N
this DT N
setting NN N
. . N

-DOCSTART- -X- O O

Enhanced NNP N
small JJ N
group NN N
instruction NN N
using VBG N
choral JJ N
responding NN N
and CC N
student NN N
interaction NN N
for IN N
children NNS N
with IN N
autism NN 4_p
and CC N
developmental JJ 4_p
disabilities NNS 4_p
. . N

The DT N
use NN N
of IN N
effective JJ N
instructional JJ N
strategies NNS N
in IN N
small JJ N
groups NNS N
was VBD N
investigated VBN N
to TO N
determine VB N
learning JJ N
effects NNS N
for IN N
24 CD 3_p
elementary JJ 1_p
age NN 1_p
students NNS N
with IN N
autism NN 4_p
and CC N
developmental JJ 4_p
disabilities NNS 4_p
. . N

Effective JJ N
strategies NNS N
included VBD N
( ( N
a DT N
) ) N
the DT N
use NN N
of IN N
choral JJ N
responding NN N
; : N
( ( N
b NN N
) ) N
the DT N
use NN N
of IN N
student-to-student JJ N
responding NN N
; : N
( ( N
c NN N
) ) N
the DT N
rotation NN N
of IN N
materials NNS N
every DT N
5 CD N
minutes NNS N
during IN N
the DT N
30-minute JJ N
group NN N
while IN N
teaching VBG N
2 CD N
to TO N
3 CD N
concepts NNS N
; : N
and CC N
( ( N
d NN N
) ) N
the DT N
use NN N
of IN N
random NN N
, , N
unpredictable JJ N
trials NNS N
for IN N
student NN N
responding VBG N
. . N

Thirty-minute JJ N
language NN N
groups NNS N
were VBD N
targeted VBN N
to TO N
teach VB N
receptive JJ N
and CC N
expressive JJ N
skills NNS N
using VBG N
pictures NNS N
and CC N
common JJ N
objects NNS N
across IN N
five CD N
categories NNS N
( ( N
e.g. NN N
, , N
household NN N
items NNS N
, , N
foods NNS N
) ) N
. . N

Results JJ N
showed VBD N
increased JJ N
opportunities NNS N
to TO N
respond VB N
, , N
increased JJ N
levels NNS N
of IN N
responding VBG N
and CC N
academic JJ N
engagement NN N
, , N
higher JJR N
gains NNS N
on IN N
weekly JJ N
criterion-referenced JJ N
pre- NN N
and CC N
posttests NNS N
, , N
and CC N
decreased VBD N
passive JJ N
and CC N
inappropriate JJ N
student NN N
behavior NN N
during IN N
interventions NNS N
. . N

-DOCSTART- -X- O O

Relation NN N
of IN N
total JJ N
homocysteine NN N
and CC N
lipid JJ N
levels NNS N
in IN N
children NNS 1_p
to TO N
premature VB N
cardiovascular JJ N
death NN N
in IN N
male JJ 2_p
relatives NNS N
. . N

We PRP N
assessed VBD N
the DT N
relative JJ N
importance NN N
of IN N
lipid JJ N
, , N
apo JJ N
B NNP N
, , N
lipoprotein NN N
( ( N
a DT N
) ) N
[ NN N
Lp NNP N
( ( N
a DT N
) ) N
] NN N
, , N
and CC N
total JJ N
homocysteine NN N
( ( N
tHcy NN N
) ) N
levels NNS N
in IN N
children NNS 1_p
in IN N
relation NN N
to TO N
premature VB N
cardiovascular JJ N
disease NN N
in IN N
family NN N
members NNS N
. . N

Parents NNS N
of IN N
381 CD 3_p
girls NNS 2_p
and CC N
375 CD 3_p
boys NNS 2_p
age NN N
8-12 JJ 1_p
y NN N
completed VBN N
family NN N
history NN N
questionnaires NNS N
. . N

Nonfasting VBG N
serum JJ N
lipid JJ N
and CC N
lipoproteins NNS N
and CC N
plasma NN N
tHcy NN N
and CC N
cysteine NN N
levels NNS N
were VBD N
measured VBN N
in IN N
the DT N
children NNS N
. . N

Serum NNP N
folate NN N
and CC N
vitamin NN N
B12 NNP N
levels NNS N
were VBD N
determined VBN N
in IN N
a DT N
random JJ N
subsample NN N
of IN N
23 CD N
% NN N
of IN N
the DT N
children NNS N
, , N
who WP N
participated VBD N
in IN N
a DT N
food NN N
frequency NN N
interview NN N
. . N

Children NNP N
whose WP$ N
parents NNS N
reported VBD N
hypercholesterolemia NN N
had VBD N
higher JJR N
total JJ N
and CC N
non-HDL JJ N
cholesterol NN N
and CC N
apo NN N
B NNP N
levels NNS N
than IN N
the DT N
rest NN N
, , N
but CC N
these DT N
levels NNS N
were VBD N
not RB N
associated VBN N
with IN N
cardiovascular JJ N
disease NN N
. . N

tHcy NN N
levels NNS N
were VBD N
similar JJ N
in IN N
girls NNS N
and CC N
boys NNS N
. . N

tHcy NN N
was VBD N
higher RBR N
in IN N
children NNS 1_p
whose WP$ N
father NN N
, , N
grandfather NN N
, , N
or CC N
uncle NN N
died VBN N
at IN N
age NN N
< NN N
or CC N
= $ N
55 CD N
y NN N
of IN N
myocardial JJ N
infarction NN N
or CC N
sudden JJ N
cardiac JJ N
arrest NN N
( ( N
n JJ N
= NNP N
42 CD N
) ) N
than IN N
in IN N
control NN N
children NNS N
[ VBP N
5.92 CD N
mumol/L NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
of IN N
5.47-6.36 NNP N
) ) N
versus NN N
5.25 CD N
mumol/L NN N
( ( N
95 CD N
% NN N
CI NNP N
, , N
5.16-5.34 JJ N
) ) N
] NN N
, , N
also RB N
after IN N
adjustment NN N
for IN N
socioeconomic JJ N
group NN N
. . N

Intake NNP N
and CC N
serum NN N
levels NNS N
of IN N
vitamin NN N
B12 NNP N
and CC N
folate NN N
were VBD N
within IN N
recommended VBN N
or CC N
reference NN N
ranges NNS N
. . N

In IN N
a DT N
stepwise NN N
multiple JJ N
regression NN N
analysis NN N
, , N
serum NN N
folate NN N
( ( N
negative JJ N
correlation NN N
) ) N
, , N
plasma JJ N
creatinine NN N
, , N
and CC N
sugar RB N
intake VB N
as IN N
percent NN N
of IN N
dietary JJ N
energy NN N
( ( N
positive JJ N
correlations NNS N
) ) N
were VBD N
significantly RB N
associated VBN N
with IN N
tHcy NN N
( ( N
multiple JJ N
r NN N
= NN N
0.44 CD N
, , N
adjusted VBN N
r2 NN N
= VBZ N
18 CD N
% NN N
; : N
95 CD N
% NN N
CI NNP N
, , N
5-30 JJ N
% NN N
) ) N
. . N

Our PRP$ N
data NNS N
show VBP N
that IN N
a DT N
modest JJ N
elevation NN N
in IN N
tHcy NN N
in IN N
children NNS N
was VBD N
related VBN N
to TO N
premature VB N
cardiovascular JJ N
death NN N
in IN N
their PRP$ N
male NN N
relatives NNS N
and CC N
may MD N
partly RB N
account VB N
for IN N
the DT N
contribution NN N
of IN N
family NN N
history NN N
to TO N
risk NN N
of IN N
cardiovascular JJ N
disease NN N
. . N

tHcy NN N
may MD N
be VB N
modifiable JJ N
through IN N
the DT N
diet NN N
, , N
even RB N
in IN N
children NNS N
with IN N
apparently RB N
adequate JJ N
vitamin JJ N
nutriture NN N
. . N

-DOCSTART- -X- O O

Efficacy NN N
of IN N
amantadine NN N
on IN N
quality NN N
of IN N
life NN N
in IN N
patients NNS N
with IN N
chronic JJ 4_p
hepatitis NN 4_p
C NNP 4_p
treated VBD N
with IN N
interferon-alpha JJ N
and CC N
ribavirin NN N
: : N
results NNS N
from IN N
a DT N
randomized VBN N
, , N
placebo-controlled JJ N
, , N
double-blind JJ N
trial NN N
. . N

AIM VB N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
whether IN N
amantadine JJ N
reduces NNS N
deterioration NN N
of IN N
quality NN N
of IN N
life NN N
in IN N
patients NNS N
with IN N
chronic JJ N
hepatitis NN N
C NNP N
during IN N
and CC N
after IN N
treatment NN N
with IN N
interferon-alpha JJ N
( ( N
IFN-alpha NNP N
) ) N
and CC N
ribavirin NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
In IN N
this DT N
randomized VBN N
, , N
prospective JJ N
, , N
placebo-controlled JJ N
, , N
multicenter JJ N
trial NN N
, , N
previously RB N
untreated JJ N
patients NNS N
with IN N
chronic JJ 4_p
hepatitis NN 4_p
C NNP 4_p
were VBD N
treated VBN N
with IN N
IFN-alpha NNP N
plus CC N
ribavirin JJ N
[ NN N
17 CD N
] NN N
and CC N
randomized VBN N
for IN N
treatment NN N
with IN N
amantadine NN N
( ( N
200 CD N
mg/day NN N
, , N
orally RB N
, , N
n=136 NN N
) ) N
or CC N
placebo NN N
( ( N
n=131 JJ N
) ) N
. . N

Quality NN N
of IN N
life NN N
was VBD N
assessed VBN N
with IN N
the DT N
'Profile NN N
of IN N
Mood NNP N
States NNPS N
' POS N
scale NN N
and CC N
the DT N
'Everyday JJ N
Life NNP N
' POS N
questionnaire NN N
at IN N
baseline NN N
, , N
treatment NN N
week NN N
( ( N
TW NNP N
) ) N
8 CD N
, , N
TW24 NNP N
, , N
TW48 NNP N
, , N
and CC N
at IN N
follow-up JJ N
. . N

RESULTS VB N
Early JJ N
during IN N
treatment NN N
at IN N
TW8 NNP N
, , N
quality NN N
of IN N
life NN N
was VBD N
not RB N
different JJ N
between IN N
patients NNS N
in IN N
the DT N
control NN N
and CC N
the DT N
amantadine NN N
group NN N
. . N

At IN N
TW24 NNP N
, , N
the DT N
control NN N
group NN N
but CC N
not RB N
the DT N
amantadine NN N
group NN N
, , N
however RB N
, , N
showed VBD N
significant JJ N
deterioration NN N
of IN N
the DT N
modalities NNS N
depression NN N
, , N
fatigue NN N
, , N
and CC N
vigor NN N
compared VBN N
with IN N
baseline NN N
. . N

Especially RB N
, , N
nonresponders NNS N
in IN N
the DT N
amantadine NN N
group NN N
showed VBD N
significantly RB N
lower JJR N
deterioration NN N
of IN N
depression NN N
, , N
anger NN N
, , N
mind NN N
function NN N
, , N
everyday JJ N
life NN N
, , N
and CC N
zest JJS N
for IN N
life NN N
than IN N
those DT N
in IN N
the DT N
placebo NN N
group NN N
. . N

After IN N
treatment NN N
, , N
the DT N
beneficial JJ N
effects NNS N
of IN N
amantadine NN N
disappeared VBN N
. . N

CONCLUSION VB N
The DT N
addition NN N
of IN N
amantadine NN N
to TO N
IFN-alpha NNP N
plus CC N
ribavirin JJ N
combination NN N
therapy NN N
may MD N
reduce VB N
deterioration NN N
of IN N
depression NN N
, , N
fatigue NN N
, , N
and CC N
vigor NN N
during IN N
treatment NN N
but CC N
does VBZ N
not RB N
affect JJ N
quality NN N
of IN N
life NN N
after IN N
treatment NN N
. . N

-DOCSTART- -X- O O

Psychological JJ N
well-being NN N
correlates NNS N
with IN N
free JJ N
thyroxine NN N
but CC N
not RB N
free JJ N
3,5,3'-triiodothyronine JJ N
levels NNS N
in IN N
patients NNS N
on IN N
thyroid JJ 4_p
hormone NN 4_p
replacement NN 4_p
. . N

CONTEXT NNP N
AND NNP N
OBJECTIVE NNP N
An DT N
association NN N
between IN N
mood NN N
disorders NNS N
and CC N
overt JJ N
thyroid JJ N
dysfunction NN N
is VBZ N
well RB N
established VBN N
, , N
but CC N
there EX N
are VBP N
few JJ N
data NNS N
on IN N
the DT N
potential NN N
for IN N
thyroid JJ N
hormone NN N
levels NNS N
closer RBR N
to TO N
the DT N
reference NN N
range NN N
to TO N
correlate VB N
with IN N
psychological JJ N
well-being NN N
. . N

DESIGN NNP N
, , N
SETTING NNP N
, , N
AND NNP N
PATIENTS NNP N
We PRP N
analyzed VBD N
the DT N
relationship NN N
between IN N
psychological JJ N
well-being NN N
and CC N
free JJ N
T NNP N
( ( N
4 CD N
) ) N
( ( N
fT4 NN N
) ) N
, , N
free JJ N
T NNP N
( ( N
3 CD N
) ) N
( ( N
fT3 NN N
) ) N
, , N
TSH NNP N
, , N
and CC N
total JJ N
rT NN N
( ( N
3 CD N
) ) N
in IN N
697 CD 3_p
patients NNS N
on IN N
thyroid JJ N
hormone NN N
replacement NN N
therapy NN N
at IN N
entry NN N
to TO N
a DT N
randomized VBN N
, , N
controlled VBD N
trial NN N
of IN N
combined JJ N
T NNP N
( ( N
4 CD N
) ) N
and CC N
T NNP N
( ( N
3 CD N
) ) N
replacement NN N
therapy NN N
. . N

All DT N
patients NNS N
were VBD N
on IN N
100 CD N
mug NN N
or CC N
more JJR N
T NNP N
( ( N
4 CD N
) ) N
. . N

INTERVENTIONS NNP N
AND CC N
MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Psychological NNP N
well-being NN N
was VBD N
assessed VBN N
with IN N
General NNP N
Health NNP N
Questionnaire-12 NNP N
( ( N
GHQ-12 NNP N
) ) N
, , N
Thyroid NNP N
Symptom NNP N
Questionnaire NNP N
, , N
and CC N
Hospital NNP N
Anxiety NNP N
and CC N
Depression NNP N
Scale NNP N
. . N

RESULTS NNP N
fT NN N
( ( N
4 CD N
) ) N
and CC N
TSH NNP N
showed VBD N
a DT N
strong JJ N
correlation NN N
with IN N
GHQ-12 NNP N
scores NNS N
( ( N
fT4 SYM N
- : N
b NN N
: : N
-0.16 NN N
, , N
P NNP N
= NNP N
0.005 CD N
; : N
TSH NNP N
- : N
b NN N
: : N
0.663 CD N
, , N
P NNP N
= NNP N
0.04 CD N
) ) N
. . N

No UH N
correlations NNS N
were VBD N
seen VBN N
between IN N
the DT N
GHQ NNP N
scores NNS N
and CC N
fT3 NN N
( ( N
b NN N
: : N
0.318 CD N
, , N
P NNP N
= NNP N
0.275 CD N
) ) N
, , N
rT NN N
( ( N
3 CD N
) ) N
( ( N
b NN N
: : N
0.095 CD N
, , N
P NNP N
= NNP N
0.95 CD N
) ) N
, , N
rT NN N
( ( N
3 CD N
) ) N
to TO N
fT4 VB N
ratio NN N
( ( N
b NN N
: : N
71.83 CD N
, , N
P NNP N
= NNP N
0.09 CD N
) ) N
or CC N
fT3 VBN N
to TO N
rT VB N
( ( N
3 CD N
) ) N
ratio NN N
( ( N
b NN N
: : N
0.05 CD N
, , N
P NNP N
= NNP N
0.32 CD N
) ) N
. . N

The DT N
correlations NNS N
remained VBD N
when WRB N
the DT N
data NN N
set NN N
was VBD N
limited VBN N
to TO N
patients NNS N
with IN N
TSH NNP N
in IN N
the DT N
range NN N
0.3-4.0 JJ N
mIU/liter NN N
. . N

Similar JJ N
correlations NNS N
were VBD N
seen VBN N
with IN N
the DT N
Thyroid NNP N
Symptom NNP N
Questionnaire NNP N
, , N
although IN N
not RB N
with IN N
the DT N
Hospital NNP N
Anxiety NNP N
and CC N
Depression NNP N
Scale NNP N
scores NNS N
. . N

CONCLUSIONS NNP N
Differences NNPS N
in IN N
fT4 NN N
and CC N
TSH NNP N
concentration NN N
, , N
even RB N
within IN N
the DT N
reference NN N
range NN N
, , N
may MD N
be VB N
a DT N
determinant NN N
of IN N
psychological JJ N
well-being NN N
in IN N
treated JJ N
hypothyroid NN 4_p
patients NNS N
although IN N
not RB N
necessarily RB N
with IN N
symptoms NNS N
typical JJ N
of IN N
anxiety NN N
or CC N
depression NN N
. . N

-DOCSTART- -X- O O

The DT N
influence NN N
of IN N
rTMS NN N
over IN N
the DT N
left JJ N
dorsolateral JJ N
prefrontal JJ N
cortex NN N
on IN N
Stroop NNP N
task NN N
performance NN N
. . N

Several JJ N
studies NNS N
have VBP N
demonstrated VBN N
that IN N
repetitive JJ N
transcranial JJ N
magnetic JJ N
stimulation NN N
( ( N
rTMS NN N
) ) N
can MD N
improve VB N
cognitive JJ N
processing NN N
. . N

Neuroimaging VBG N
studies NNS N
have VBP N
shown VBN N
the DT N
engagement NN N
of IN N
the DT N
left JJ N
dorsolateral JJ N
prefrontal NN N
cortex NN N
( ( N
DLPFC NNP N
) ) N
in IN N
executive NN N
functioning NN N
, , N
and CC N
more RBR N
specifically RB N
during IN N
selective JJ N
attention NN N
. . N

In IN N
the DT N
present JJ N
study NN N
, , N
the DT N
influence NN N
of IN N
high-frequency NN N
rTMS NN N
over IN N
the DT N
left JJ N
DLPFC NNP N
on IN N
Stroop NNP N
task NN N
performance NN N
in IN N
healthy JJ 4_p
female NN 2_p
volunteers NNS N
was VBD N
investigated VBN N
. . N

As IN N
expected VBN N
, , N
reaction NN N
time NN N
on IN N
both CC N
the DT N
incongruent NN N
and CC N
congruent NN N
trials NNS N
decreased VBD N
significantly RB N
after IN N
stimulation NN N
, , N
and CC N
there EX N
was VBD N
no DT N
difference NN N
with IN N
regard NN N
to TO N
the DT N
Stroop NNP N
interference NN N
effect NN N
. . N

Mood NNP N
remained VBD N
unchanged JJ N
after IN N
rTMS NN N
. . N

Such PDT N
a DT N
pattern NN N
is VBZ N
consistent JJ N
with IN N
the DT N
role NN N
of IN N
the DT N
left NN N
DLPFC NNP N
in IN N
implementing VBG N
top-down JJ N
attentional JJ N
control NN N
. . N

-DOCSTART- -X- O O

Validity NNP N
and CC N
reliability NN N
assessment NN N
of IN N
the DT N
Siriraj NNP N
Asthma NNP 4_p
Control NNP N
Questionnaire NNP N
. . N

OBJECTIVE CC N
The DT N
present JJ N
study NN N
assessed VBD N
the DT N
validity NN N
and CC N
reliability NN N
of IN N
the DT N
Siriraj NNP N
Asthma NNP N
Control NNP N
Questionnaire NNP N
in IN N
Asthma NNP N
Clinic NNP N
, , N
Siriraj NNP N
Hospital NNP N
. . N

MATERIAL NNP N
AND CC N
METHOD NNP N
The DT N
data NN N
of IN N
the DT N
questionnaire NN N
responses NNS N
and CC N
spirometric JJ N
results NNS N
from IN N
20 CD 3_p
randomized JJ N
asthmatic JJ 4_p
patients NNS N
in IN N
the DT N
clinic NN N
including VBG N
the DT N
record NN N
of IN N
3 CD N
visits NNS N
for IN N
each DT N
subject NN N
. . N

The DT N
validation NN N
was VBD N
performed VBN N
by IN N
Kruskal-Wallis NNP N
test NN N
comparing VBG N
the DT N
scores NNS N
with IN N
the DT N
level NN N
of IN N
asthma NNS N
control NN N
determined VBN N
by IN N
physicians NNS N
according VBG N
to TO N
GINA NNP N
guideline NN N
. . N

Internal NNP N
consistency NN N
reliability NN N
was VBD N
analyzed VBN N
by IN N
Cronbach NNP N
's POS N
alpha NN N
. . N

RESULTS NNP N
Sixty NNP N
questionnaires VBZ N
from IN N
20 CD N
patients NNS N
with IN N
age NN N
29-73 CD 1_p
years NNS N
were VBD N
analyzed VBN N
. . N

There EX N
were VBD N
40 CD N
controlled VBN N
, , N
7 CD N
partly RB N
controlled VBN N
and CC N
13 CD N
uncontrolled JJ N
visits NNS N
. . N

The DT N
scores NNS N
from IN N
5-items JJ N
questionnaires NNS N
and CC N
6-items JJ N
clinical JJ N
score NN N
were VBD N
significantly RB N
associated VBN N
with IN N
the DT N
physician-diagnosed JJ N
groups NNS N
( ( N
i.e. FW N
, , N
controlled VBD N
, , N
partly RB N
controlled VBN N
and CC N
uncontrolled JJ N
groups NNS N
) ) N
. . N

Median JJ N
scores NNS N
( ( N
min NN N
, , N
max NN N
) ) N
were VBD N
0 CD N
( ( N
0 CD N
, , N
5 CD N
) ) N
, , N
2 CD N
( ( N
0 CD N
, , N
6 CD N
) ) N
, , N
4 CD N
( ( N
0 CD N
, , N
12 CD N
) ) N
respectively RB N
, , N
( ( N
5-items CD N
, , N
p VBZ N
< NNP N
0.001 CD N
) ) N
and CC N
2 CD N
( ( N
0 CD N
, , N
7 CD N
) ) N
, , N
3 CD N
( ( N
1 CD N
, , N
7 CD N
) ) N
, , N
6 CD N
( ( N
2,15 CD N
) ) N
respectively RB N
, , N
( ( N
6-items CD N
, , N
p VBZ N
< NNP N
0.001 CD N
) ) N
. . N

Internal NNP N
consistency NN N
reliability NN N
of IN N
both DT N
5-items JJ N
questionnaire NN N
and CC N
6-items JJ N
clinical JJ N
score NN N
were VBD N
within IN N
the DT N
acceptable JJ N
range NN N
( ( N
0.829 CD N
and CC N
0.708 CD N
respectively RB N
) ) N
. . N

5-items JJ N
questionnaire NN N
is VBZ N
more RBR N
associated JJ N
with IN N
the DT N
physician NN N
diagnosed VBN N
group NN N
and CC N
more JJR N
consistent JJ N
than IN N
6-items JJ N
clinical JJ N
score NN N
. . N

Further JJ N
analysis NN N
revealed VBD N
cutoff NN N
point NN N
at IN N
2.5 CD N
to TO N
separate VB N
uncontrolled JJ N
from IN N
controlled VBN N
or CC N
partly RB N
controlled VBN N
patient NN N
with IN N
sensitivity NN N
76.9 CD N
% NN N
and CC N
specificity NN N
89.4 CD N
% NN N
and CC N
cutoff NN N
point NN N
at IN N
1.5 CD N
to TO N
separate VB N
uncontrolled JJ N
or CC N
partly RB N
controlled VBN N
from IN N
controlled VBN N
patient NN N
with IN N
sensitivity NN N
70.0 CD N
% NN N
and CC N
specificity NN N
85.0 CD N
% NN N
. . N

CONCLUSION NNP N
The DT N
validity NN N
and CC N
reliability NN N
of IN N
Siriraj NNP N
Asthma NNP N
Control NNP N
Questionnaire NNP N
is VBZ N
acceptable JJ N
and CC N
might MD N
be VB N
used VBN N
in IN N
the DT N
clinical JJ N
practice NN N
and CC N
research NN N
in IN N
Thai NNP N
asthmatic JJ 4_p
patients NNS N
. . N

-DOCSTART- -X- O O

Pilot NNP N
study NN N
of IN N
Panax NNP N
quinquefolius NN N
( ( N
American NNP N
ginseng NN N
) ) N
to TO N
improve VB N
cancer-related JJ 4_p
fatigue NN 4_p
: : N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
dose-finding JJ N
evaluation NN N
: : N
NCCTG NNP N
trial NN N
N03CA NNP N
. . N

PURPOSE NNP N
This DT N
pilot NN N
trial NN N
sought VBD N
to TO N
investigate VB N
whether IN N
any DT N
of IN N
three CD N
doses NNS N
of IN N
American JJ N
ginseng NN N
( ( N
Panax NNP N
quinquefolius RB N
) ) N
might MD N
help VB N
cancer-related JJ 4_p
fatigue NN 4_p
. . N

A DT N
secondary JJ N
aim NN N
was VBD N
to TO N
evaluate VB N
toxicity NN N
. . N

METHODS NNP N
Eligible JJ N
adults NNS 1_p
with IN N
cancer NN 4_p
were VBD N
randomized VBN N
in IN N
a DT N
double-blind JJ N
manner NN N
, , N
to TO N
receive VB N
American JJ N
ginseng NN N
in IN N
doses NNS N
of IN N
750 CD N
, , N
1,000 CD N
, , N
or CC N
2,000 CD N
mg/day NN N
or CC N
placebo VB N
given VBN N
in IN N
twice JJ N
daily JJ N
dosing NN N
over IN N
8 CD N
weeks NNS N
. . N

Outcome NNP N
measures NNS N
included VBD N
the DT N
Brief NNP N
Fatigue NNP N
Inventory NNP N
, , N
vitality NN N
subscale NN N
of IN N
the DT N
Medical NNP N
Outcome NNP N
Scale NNP N
Short NNP N
Form-36 NNP N
( ( N
SF-36 NNP N
) ) N
, , N
and CC N
the DT N
Global NNP N
Impression NNP N
of IN N
Benefit NNP N
Scale NNP N
at IN N
4 CD N
and CC N
8 CD N
weeks NNS N
. . N

RESULTS NNP N
Two CD 3_p
hundred VBD 3_p
ninety NN 3_p
patients NNS N
were VBD N
accrued VBN N
to TO N
this DT N
trial NN N
. . N

Nonsignificant JJ N
trends NNS N
for IN N
all DT N
outcomes NNS N
were VBD N
seen VBN N
in IN N
favor NN N
of IN N
the DT N
1,000- JJ N
and CC N
2,000-mg/day JJ N
doses NNS N
of IN N
American JJ N
ginseng NN N
. . N

Area NNP N
under IN N
the DT N
curve NN N
analysis NN N
of IN N
activity NN N
interference NN N
from IN N
the DT N
Brief NNP N
Fatigue NNP N
Inventory NNP N
was VBD N
460-467 JJ N
in IN N
the DT N
placebo NN N
group NN N
and CC N
750 CD N
mg/day NN N
group NN N
versus VBD N
480-551 CD N
in IN N
the DT N
1,000- JJ N
and CC N
2,000-mg/day JJ N
arms NNS N
, , N
respectively RB N
. . N

Change NN N
from IN N
baseline NN N
in IN N
the DT N
vitality NN N
subscale NN N
of IN N
the DT N
SF-36 NNP N
was VBD N
7.3-7.8 JJ N
in IN N
the DT N
placebo NN N
and CC N
the DT N
750-mg/day JJ N
arm NN N
, , N
versus NN N
10.5-14.6 JJ N
in IN N
the DT N
1,000- JJ N
and CC N
2,000-mg/day JJ N
arms NNS N
. . N

Over NNP N
twice RB N
as RB N
many JJ N
patients NNS N
on IN N
ginseng NN N
perceived VBD N
a DT N
benefit NN N
and CC N
were VBD N
satisfied VBN N
with IN N
treatment NN N
over IN N
those DT N
on IN N
placebo NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
any DT N
measured JJ N
toxicities NNS N
between IN N
any DT N
of IN N
the DT N
arms NNS N
. . N

CONCLUSION NN N
There EX N
appears VBZ N
to TO N
be VB N
some DT N
activity NN N
and CC N
tolerable JJ N
toxicity NN N
at IN N
1,000-2,000 CD N
mg/day JJ N
doses NNS N
of IN N
American JJ N
ginseng NN N
with IN N
regard NN N
to TO N
cancer-related JJ N
fatigue NN N
. . N

Thus NNP N
, , N
further JJ N
study NN N
of IN N
American NNP N
ginseng NN N
is VBZ N
warranted VBN N
. . N

-DOCSTART- -X- O O

Smoking VBG N
cessation NN N
with IN N
smokeless JJ N
tobacco NN N
and CC N
group NN N
therapy NN N
: : N
an DT N
open JJ N
, , N
randomized VBN N
, , N
controlled VBN N
trial NN N
. . N

Smokeless NNP N
tobacco NN N
might MD N
be VB N
effective JJ N
as IN N
an DT N
adjunct NN N
for IN N
smoking VBG N
cessation NN N
. . N

We PRP N
evaluated VBD N
the DT N
efficacy NN N
of IN N
smokeless NN N
tobacco NN N
and CC N
group NN N
support NN N
for IN N
smoking VBG N
cessation NN N
in IN N
an DT N
open JJ N
, , N
randomized VBN N
study NN N
that WDT N
compared VBN N
smokeless NN N
tobacco NN N
plus CC N
group NN N
support NN N
versus NN N
group NN N
support NN N
only RB N
. . N

The DT N
study NN N
enrolled VBD N
263 CD 3_p
healthy JJ 4_p
smokers NNS 4_p
( ( N
M NNP N
( ( N
age NN N
) ) N
= VBZ N
49 CD 1_p
years NNS 1_p
) ) N
who WP N
smoked VBD 4_p
a DT N
mean NN N
of IN N
24 CD 4_p
cigarettes/day NN 4_p
, , N
with IN N
a DT N
mean NN N
of IN N
31 CD 4_p
pack-years NNS 4_p
. . N

Smokeless NNP N
tobacco NN N
was VBD N
provided VBN N
for IN N
7 CD N
weeks NNS N
( ( N
or CC N
up RB N
to TO N
12 CD N
) ) N
, , N
combined VBN N
with IN N
eight CD N
group NN N
support NN N
visits NNS N
provided VBN N
by IN N
nurses NNS N
. . N

The DT N
control NN N
group NN N
received VBD N
group NN N
support NN N
only RB N
. . N

Smoking VBG N
cessation NN N
rates NNS N
were VBD N
statistically RB N
significantly RB N
better RBR N
in IN N
the DT N
smokeless NN N
tobacco NN N
group NN N
than IN N
in IN N
the DT N
control NN N
group NN N
during IN N
the DT N
first JJ N
7 CD N
weeks NNS N
. . N

Point-prevalence NN N
abstinence NN N
rates NNS N
at IN N
7 CD N
weeks NNS N
were VBD N
36.4 CD N
% NN N
versus IN N
20.8 CD N
% NN N
( ( N
OR NNP N
= VBZ N
2.52 CD N
, , N
p NN N
= NNP N
.001 NNP N
) ) N
, , N
respectively RB N
; : N
and CC N
continuous JJ N
abstinence NN N
rates NNS N
from IN N
weeks NNS N
4 CD N
to TO N
7 CD N
were VBD N
31.5 CD N
% NN N
versus IN N
19.2 CD N
% NN N
( ( N
OR NNP N
= VBZ N
1.94 CD N
, , N
p NN N
= NNP N
.023 NNP N
) ) N
, , N
respectively RB N
. . N

The DT N
primary JJ N
outcomes NNS N
( ( N
i.e. JJ N
, , N
6-month JJ N
point NN N
prevalence NN N
) ) N
were VBD N
23.1 CD N
% NN N
versus IN N
20.8 CD N
% NN N
, , N
respectively RB N
( ( N
OR NNP N
= VBZ N
1.31 CD N
, , N
ns NN N
) ) N
. . N

Smokeless NNP N
tobacco NN N
was VBD N
relatively RB N
well RB N
tolerated VBN N
, , N
although IN N
15 CD N
subjects NNS N
( ( N
11.2 CD N
% NN N
) ) N
stopped VBD N
use NN N
due JJ N
to TO N
adverse JJ N
events NNS N
. . N

A DT N
total NN N
of IN N
25 CD N
subjects NNS N
( ( N
17.5 CD N
% NN N
) ) N
were VBD N
still RB N
using VBG N
smokeless JJ N
tobacco NN N
after IN N
6 CD N
months NNS N
. . N

This DT N
trial NN N
demonstrated VBD N
short-term JJ N
efficacy NN N
of IN N
smokeless JJ N
tobacco NN N
in IN N
combination NN N
with IN N
group NN N
support NN N
for IN N
smoking VBG N
cessation NN N
but CC N
no DT N
long-term JJ N
efficacy NN N
. . N

-DOCSTART- -X- O O

Norfloxacin NNP N
modulates VBZ N
the DT N
inflammatory JJ N
response NN N
and CC N
directly RB N
affects VBZ N
neutrophils NNS N
in IN N
patients NNS N
with IN N
decompensated JJ 4_p
cirrhosis NN 4_p
. . N

BACKGROUND NNP N
& CC N
AIMS NNP N
Patients NNPS N
with IN N
cirrhosis NN 4_p
undergoing VBG N
selective JJ N
intestinal JJ N
decontamination NN N
with IN N
norfloxacin JJ N
show NN N
a DT N
reduction NN N
in IN N
serum JJ N
cytokine NN N
levels NNS N
, , N
probably RB N
because IN N
of IN N
a DT N
combined JJ N
effect NN N
of IN N
norfloxacin NN N
on IN N
bowel NN N
flora NNS N
and CC N
neutrophils NNS N
. . N

METHODS NNP N
Thirty-one CD 3_p
patients NNS N
with IN N
cirrhosis NN N
receiving VBG N
norfloxacin NN N
( ( N
400 CD N
mg/day NN N
) ) N
were VBD N
included VBN N
. . N

Blood NNP N
samples NNS N
were VBD N
collected VBN N
at IN N
0.5-4 JJ N
hours NNS N
( ( N
peak JJ N
samples NNS N
group NN N
, , N
n RB N
= VBZ N
47 CD N
) ) N
and CC N
at IN N
22-24 JJ N
hours NNS N
( ( N
trough IN N
samples NNS N
group NN N
, , N
n RB N
= VBZ N
84 CD N
) ) N
after IN N
dose NN N
. . N

Fifty-nine JJ N
ascitic JJ N
fluid NN N
samples NNS N
were VBD N
obtained VBN N
. . N

Single NNP N
doses NNS N
of IN N
norfloxacin NN N
and CC N
trimethoprim/sulfamethoxazole NN N
were VBD N
administered VBN N
to TO N
13 CD N
and CC N
5 CD N
patients NNS N
, , N
respectively RB N
, , N
( ( N
temporal JJ N
profile NN N
group NN N
) ) N
and CC N
samples NNS N
were VBD N
collected VBN N
at IN N
0 CD N
, , N
0.5 CD N
, , N
1 CD N
, , N
1.5 CD N
, , N
2 CD N
, , N
4 CD N
, , N
and CC N
24 CD N
hours NNS N
. . N

Norfloxacin NNP N
, , N
trimethoprim/sulfamethoxazole NN N
, , N
cytokines NNS N
, , N
nitric JJ N
oxide NN N
, , N
expression NN N
levels NNS N
of IN N
nuclear JJ N
factor NN N
( ( N
NF NNP N
) ) N
-kappaB NN N
and CC N
inhibitor NN N
of IN N
NF-kappaB NNP N
( ( N
IkB-alpha NNP N
) ) N
, , N
neutrophil JJ N
oxidative JJ N
burst NN N
, , N
and CC N
rate NN N
of IN N
apoptotic JJ N
events NNS N
were VBD N
determined VBN N
. . N

RESULTS NNP N
All NNP N
samples NNS N
were VBD N
bacterial JJ N
DNA NNP N
negative NN N
and CC N
had VBD N
no DT N
significant JJ N
levels NNS N
of IN N
lipopolysaccharide NN N
. . N

Serum NNP N
and CC N
ascitic JJ N
levels NNS N
of IN N
tumor NN N
necrosis NN N
factor-alpha JJ N
, , N
interferon-gamma JJ N
, , N
interleukin-12 JJ N
, , N
and CC N
nitric JJ N
oxide NN N
were VBD N
significantly RB N
lower JJR N
in IN N
peak NN N
than IN N
in IN N
trough JJ N
samples NNS N
. . N

A DT N
correlation NN N
was VBD N
present JJ N
between IN N
serum NN N
norfloxacins NNS N
concentrations NNS N
and CC N
tumor NN N
necrosis NN N
factor-alpha NN N
( ( N
r JJ N
= NNP N
-0.68 NNP N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
interferon-gamma JJ N
( ( N
r JJ N
= NNP N
-0.66 NNP N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
interleukin-12 JJ N
( ( N
r JJ N
= NNP N
-0.66 NNP N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
and CC N
nitric JJ N
oxide NN N
( ( N
r JJ N
= NNP N
-0.68 NNP N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

Serum NNP N
norfloxacin NN N
's POS N
highest JJS N
concentrations NNS N
( ( N
1 CD N
+/- JJ N
0.5 CD N
microg/mL NN N
) ) N
were VBD N
achieved VBN N
at IN N
1-2 JJ N
hours NNS N
and CC N
concurred VBN N
in IN N
time NN N
with IN N
the DT N
lower JJR N
levels NNS N
of IN N
cytokines NNS N
and CC N
nitric JJ N
oxide NN N
. . N

Intracellular NNP N
norfloxacin NN N
's POS N
highest JJS N
levels NNS N
( ( N
2 CD N
+/- JJ N
1 CD N
microg/mL/10 NN N
( ( N
7 CD N
) ) N
cells NNS N
) ) N
were VBD N
observed VBN N
at IN N
2 CD N
hours NNS N
and CC N
concurred VBN N
with IN N
a DT N
lower JJR N
NF-kappaB JJ N
expression NN N
, , N
a DT N
reduced JJ N
anion NN N
superoxide NN N
generation NN N
, , N
and CC N
apoptotic JJ N
rate NN N
in IN N
response NN N
to TO N
phorbol VB N
myristate JJ N
acetate NN N
. . N

Trimethoprim/sulfamethoxazole NNP N
did VBD N
not RB N
significantly RB N
modulate VB N
cytokine JJ N
expression NN N
. . N

CONCLUSIONS NNP N
Norfloxacin NNP N
but CC N
not RB N
trimethoprim/sulfamethoxazole JJ N
modulates NNS N
inflammatory JJ N
response NN N
and CC N
directly RB N
affects VBZ N
neutrophils NNS N
in IN N
patients NNS N
with IN N
cirrhosis NN 4_p
. . N

-DOCSTART- -X- O O

Treatment NN N
with IN N
metformin NN N
of IN N
non-diabetic JJ 4_p
men NNS 2_p
with IN N
hypertension NN 4_p
, , N
hypertriglyceridaemia NN 4_p
and CC N
central JJ 4_p
fat JJ 4_p
distribution NN 4_p
: : N
the DT N
BIGPRO NNP N
1.2 CD N
trial NN N
. . N

BACKGROUND NNP N
In IN N
the DT N
BIGPRO NNP N
1 CD N
trial NN N
, , N
one CD N
year NN N
of IN N
treatment NN N
with IN N
metformin NN N
in IN N
non-diabetic JJ 4_p
obese JJ 4_p
subjects NNS N
with IN N
a DT N
central JJ 4_p
fat JJ 4_p
distribution NN 4_p
had VBD N
no DT N
significant JJ N
effect NN N
on IN N
fasting VBG N
plasma JJ N
triglyceride JJ N
concentration NN N
or CC N
on IN N
blood NN N
pressure NN N
despite IN N
a DT N
decrease NN N
in IN N
weight NN N
, , N
fasting VBG N
plasma JJ N
insulin NN N
and CC N
glucose JJ N
concentrations NNS N
. . N

To TO N
re-evaluate VB N
the DT N
effect NN N
of IN N
metformin NN N
on IN N
fasting VBG N
triglyceride JJ N
concentration NN N
and CC N
on IN N
blood NN N
pressure NN N
, , N
the DT N
BIGPRO NNP N
1.2 CD N
trial NN N
included VBD N
non-diabetic JJ 4_p
men NNS 2_p
( ( N
n=168 NN 3_p
) ) N
with IN N
a DT N
fasting VBG N
plasma NN N
triglyceride JJ N
concentration NN N
> NN 4_p
or CC 4_p
=1.7 NN 4_p
and CC 4_p
< NN 4_p
or CC 4_p
=6.5 NN 4_p
mmol/l NN 4_p
, , N
high JJ 4_p
blood NN 4_p
pressure NN 4_p
( ( N
systolic JJ N
> NN N
or CC N
=140 NN N
and CC N
< NN N
or CC N
=180 VB N
and/or JJ N
diastolic JJ N
> NN N
or CC N
=90 NN N
and CC N
< NN N
or CC N
=105 NN N
mmHg NN N
, , N
or CC N
treatment NN N
for IN N
hypertension NN 4_p
) ) N
and CC N
a DT N
waist-to-hip JJ 4_p
ratio NN 4_p
> NN 4_p
or CC 4_p
=0.95 NN 4_p
. . 4_p

METHODS NNP N
A DT N
randomised JJ N
double-blind JJ N
trial NN N
comparing VBG N
metformin NN N
treatment NN N
( ( N
850 CD N
mg RB N
bid NN N
) ) N
with IN N
placebo NN N
. . N

RESULTS NNP N
Metformin NNP N
had VBD N
no DT N
significant JJ N
effect NN N
either DT N
on IN N
blood NN N
pressure NN N
or CC N
plasma NN N
triglyceride JJ N
concentration NN N
. . N

In IN N
comparison NN N
with IN N
the DT N
placebo NN N
group NN N
, , N
fasting VBG N
plasma JJ N
insulin NN N
( ( N
p JJ N
< NNP N
0.04 CD N
) ) N
, , N
total JJ N
cholesterol NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
and CC N
Apo NNP N
B NNP N
( ( N
p JJ N
< NNP N
0.008 CD N
) ) N
concentrations NNS N
decreased VBD N
more RBR N
in IN N
the DT N
metformin NN N
group NN N
in IN N
the DT N
BIGPRO NNP N
1 CD N
. . N

2 CD N
trial NN N
, , N
confirming VBG N
most JJS N
of IN N
the DT N
previous JJ N
results NNS N
of IN N
the DT N
BIGPRO NNP N
1 CD N
trial NN N
. . N

Tissue NNP N
plasminogen NN N
activator NN N
antigen NN N
concentration NN N
decreased VBN N
significantly RB N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
only RB N
in IN N
the DT N
metformin NN N
group NN N
, , N
but CC N
this DT N
was VBD N
not RB N
significantly RB N
different JJ N
from IN N
the DT N
placebo NN N
group NN N
( ( N
p JJ N
< NNP N
0.12 CD N
) ) N
; : N
further RB N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
change NN N
in IN N
plasminogen NN N
activator NN N
inhibitor NN N
1 CD N
. . N

CONCLUSIONS VB N
The DT N
consistency NN N
of IN N
the DT N
two CD N
BIGPRO NNP N
trials NNS N
supports VBZ N
the DT N
conclusion NN N
that IN N
metformin VBZ N
affects NNS N
several JJ N
cardiovascular JJ N
risk NN N
factors NNS N
favourably RB N
in IN N
non-diabetic JJ 4_p
subjects NNS N
with IN N
a DT N
central JJ 4_p
fat JJ 4_p
distribution NN 4_p
. . N

-DOCSTART- -X- O O

The DT N
influence NN N
of IN N
breast NN N
size NN N
on IN N
late JJ N
radiation NN N
effects NNS N
and CC N
association NN N
with IN N
radiotherapy NN N
dose JJ N
inhomogeneity NN N
. . N

A DT N
prospective JJ N
assessment NN N
of IN N
late JJ N
changes NNS N
in IN N
breast NN N
appearance NN N
in IN N
559 CD 3_p
patients NNS N
after IN N
tumour JJ 4_p
excision NN 4_p
and CC N
radiotherapy NN 4_p
for IN N
early JJ 4_p
breast NN 4_p
cancer NN 4_p
noted VBD N
a DT N
strong JJ N
association NN N
with IN N
breast NN N
size NN N
. . N

Only RB N
3/48 CD N
( ( N
6 CD N
% NN N
) ) N
patients NNS N
with IN N
small JJ N
breasts NNS N
developed VBD N
moderate JJ N
or CC N
severe JJ N
late JJ N
changes NNS N
compared VBN N
with IN N
94/423 CD N
( ( N
22 CD N
% NN N
) ) N
with IN N
medium NN N
sized VBN N
breasts NNS N
and CC N
34/88 CD N
( ( N
39 CD N
% NN N
) ) N
patients NNS N
with IN N
large JJ N
breasts NNS N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

One CD N
possibility NN N
is VBZ N
that IN N
greater JJR N
radiation NN N
changes NNS N
are VBP N
related VBN N
to TO N
greater JJR N
dose JJ N
inhomogeneity NN N
in IN N
women NNS N
with IN N
large JJ N
breasts NNS N
. . N

To TO N
explore VB N
this DT N
hypothesis NN N
, , N
radiation NN N
dose JJ N
distributions NNS N
were VBD N
assessed VBN N
in IN N
a DT N
separate JJ N
group NN N
of IN N
37 CD N
women NNS N
in IN N
whom WP N
three-level JJ N
transverse NN N
computer NN N
tomographic JJ N
images NNS N
of IN N
the DT N
breast NN N
in IN N
the DT N
treatment NN N
position NN N
were VBD N
available JJ N
. . N

A DT N
significant JJ N
correlation NN N
was VBD N
found VBN N
between IN N
breast NN N
size NN N
and CC N
dose NN N
inhomogeneity NN N
which WDT N
may MD N
account VB N
for IN N
the DT N
marked JJ N
changes NNS N
in IN N
breast NN N
appearance NN N
reported VBD N
in IN N
women NNS N
with IN N
large JJ N
breasts NNS N
. . N

-DOCSTART- -X- O O

Intra-articular JJ N
hyaluronic JJ N
acid NN N
compared VBN N
to TO N
exercise VB N
therapy NN N
in IN N
osteoarthritis NN 4_p
of IN N
the DT N
ankle NN 4_p
. . N

A DT N
prospective JJ N
randomized VBN N
trial NN N
with IN N
long-term JJ N
follow-up NN N
. . N

OBJECTIVE CC N
The DT N
goal NN N
of IN N
this DT N
study NN N
has VBZ N
been VBN N
to TO N
determine VB N
whether IN N
hyaluronic JJ N
acid NN N
( ( N
HA NNP N
) ) N
or CC N
exercise NN N
therapy NN N
can MD N
improve VB N
functional JJ N
parameters NNS N
in IN N
patients NNS N
with IN N
osteoarthritis NN N
( ( N
OA NNP 4_p
) ) N
of IN N
the DT N
ankle NN N
. . N

METHODS NNP N
In IN N
a DT N
prospective JJ N
clinical JJ N
trial NN N
, , N
43 CD N
ankles NNS N
( ( N
30 CD 3_p
patients NNS N
) ) N
with IN N
radiographic JJ N
Kellgren NNP N
Lawrence NNP N
grade VBD N
III NNP N
OA NNP N
were VBD N
randomized VBN N
to TO N
receive VB N
three CD N
intra-articular JJ N
HA NNP N
injections NNS N
, , N
with IN N
one-week JJ N
interval NN N
of IN N
or CC N
exercise NN N
therapy NN N
for IN N
six CD N
weeks NNS N
. . N

Patients NNS N
were VBD N
evaluated VBN N
by IN N
the DT N
American JJ N
Orthopaedic NNP N
Foot NNP N
and CC N
Ankle NNP N
Society NNP N
( ( N
AOFAS NNP N
) ) N
Ankle-Hindfoot NNP N
Scale NNP N
and CC N
followed-up NN N
after IN N
12 CD N
months NNS N
. . N

RESULTS NNP N
Total JJ N
AOFAS NNP N
Ankle-Hindfoot NNP N
score NN N
of IN N
OA NNP N
patients NNS N
has VBZ N
improved VBN N
in IN N
both DT N
groups NNS N
, , N
varying VBG N
from IN N
61.6+/-16.8 JJ N
to TO N
90.1+/-9.7 JJ N
with IN N
HA NNP N
treatment NN N
and CC N
from IN N
72.1+/-16.6 JJ N
to TO N
87.5+/-17.5 JJ N
using VBG N
exercise NN N
therapy NN N
at IN N
the DT N
end NN N
of IN N
the DT N
trial NN N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
between IN N
the DT N
groups NNS N
. . N

CONCLUSION NNP N
This DT N
prospective JJ N
randomized VBN N
trial NN N
confirmed VBD N
that IN N
, , N
both DT N
HA NNP N
injections NNS N
and CC N
exercise NN N
therapy NN N
provide VBP N
functional JJ N
improvement NN N
. . N

However RB N
, , N
larger JJR N
trials NNS N
with IN N
longer JJR N
follow-up NN N
are VBP N
necessary JJ N
for IN N
more RBR N
definite JJ N
conclusions NNS N
. . N

-DOCSTART- -X- O O

A DT N
pilot NN N
study NN N
of IN N
extended JJ N
duration NN N
peginterferon NN N
alfa-2a NN N
for IN N
patients NNS N
with IN N
hepatitis NN 4_p
B NNP 4_p
e VBZ 4_p
antigen-negative JJ 4_p
chronic JJ 4_p
hepatitis NN 4_p
B NNP 4_p
. . N

OBJECTIVES NNP N
Forty-eight JJ N
weeks NNS N
of IN N
peginterferon NN N
alfa-2a NN N
is VBZ N
the DT N
approved JJ N
regimen NNS N
for IN N
chronic JJ 4_p
hepatitis NN 4_p
B NNP 4_p
( ( N
CHB NNP 4_p
) ) N
. . N

Standard NNP N
interferon NN N
is VBZ N
more RBR N
effective JJ N
for IN N
hepatitis NN N
B NNP N
e NN N
antigen NN N
( ( N
HBeAg NNP N
) ) N
-negative VBP N
CHB NNP N
when WRB N
given VBN N
for IN N
longer JJR N
than IN N
1 CD N
yr NN N
. . N

This DT N
study NN N
evaluated VBD N
peginterferon JJ N
alfa-2a NN N
for IN N
60 CD N
wk NN N
, , N
alone RB N
or CC N
in IN N
combination NN N
with IN N
lamivudine NN N
. . N

METHODS NNP N
Thirteen NNP 3_p
patients NNS N
with IN N
HBeAg-negative JJ N
CHB NNP N
received VBD N
peginterferon JJ N
alfa-2a JJ N
( ( N
180 CD N
microg/week NN N
) ) N
for IN N
60 CD N
wk NN N
or CC N
peginterferon VB N
alfa-2a JJ N
( ( N
180 CD N
microg/week NN N
) ) N
for IN N
12 CD N
wk NN N
followed VBN N
by IN N
48 CD N
wk NN N
of IN N
peginterferon NN N
alfa-2a JJ N
plus CC N
lamivudine JJ N
. . N

The DT N
primary JJ N
end NN N
point NN N
, , N
sustained VBD N
virologic JJ N
response NN N
( ( N
SVR NNP N
) ) N
, , N
was VBD N
defined VBN N
as IN N
a DT N
reduction NN N
in IN N
hepatitis NN N
B NNP N
virus NN N
deoxyribonucleic NN N
acid NN N
( ( N
HBV NNP N
DNA NNP N
) ) N
of IN N
> NNP N
or=2 FW N
log10 NN N
copies/mL NN N
and CC N
HBV NNP N
DNA NNP N
< VBD N
20,000 CD N
copies/mL NN N
at IN N
24 CD N
wk NN N
of IN N
follow-up NN N
( ( N
week NN N
84 CD N
) ) N
. . N

Hepatitis $ N
B NNP N
surface NN N
antigen NN N
( ( N
HBsAg NNP N
) ) N
concentrations NNS N
were VBD N
analyzed VBN N
and CC N
compared VBN N
to TO N
changes NNS N
in IN N
HBV NNP N
DNA NNP N
. . N

RESULTS NNP N
SVR NNP N
was VBD N
achieved VBN N
by IN N
9/13 CD N
patients NNS N
( ( N
69 CD N
% NN N
) ) N
. . N

At IN N
week NN N
84 CD N
, , N
HBV NNP N
DNA NNP N
was VBD N
undetectable JJ N
by IN N
polymerase NN N
chain NN N
reaction NN N
in IN N
5/13 CD N
( ( N
38 CD N
% NN N
) ) N
patients NNS N
, , N
and CC N
3 CD N
additional JJ N
patients NNS N
had VBD N
a DT N
sustained VBN N
2-3 CD N
log NN N
reduction NN N
in IN N
HBV NNP N
DNA NNP N
. . N

Five CD N
patients NNS N
demonstrated VBD N
a DT N
> JJ N
90 CD N
% NN N
decrease NN N
in IN N
HBsAg NNP N
concentration NN N
at IN N
week NN N
60 CD N
, , N
including VBG N
3 CD N
with IN N
undetectable JJ N
HBV NNP N
DNA NNP N
at IN N
week NN N
84 CD N
and CC N
a DT N
fourth JJ N
who WP N
met VBD N
criteria NNS N
for IN N
SVR NNP N
. . N

CONCLUSIONS NNP N
Sixty NNP N
weeks NNS N
of IN N
peginterferon NN N
alfa-2a NN N
with IN N
or CC N
without IN N
lamivudine JJ N
resulted VBN N
in IN N
a DT N
higher JJR N
rate NN N
of IN N
SVR NNP N
compared VBN N
to TO N
historical JJ N
controls NNS N
with IN N
HBeAg-negative JJ 4_p
CHB NNP 4_p
treated VBD N
with IN N
48 CD N
wk NN N
of IN N
pegylated JJ N
interferon NN N
. . N

Larger JJR N
studies NNS N
are VBP N
necessary JJ N
to TO N
assess VB N
if IN N
longer JJR N
duration NN N
therapy NN N
is VBZ N
more RBR N
effective JJ N
than IN N
the DT N
standard JJ N
regimen NNS N
and CC N
results NNS N
in IN N
a DT N
greater JJR N
decline NN N
in IN N
HBsAg NNP N
concentration NN N
. . N

-DOCSTART- -X- O O

[ JJ N
Observation NNP N
of IN N
curative JJ N
effect NN N
on IN N
fixed-point NN N
spin NN N
reduction NN N
of IN N
spinal JJ N
manipulation NN N
therapy NN N
for IN N
cervical JJ 4_p
vertigo NN 4_p
] NN N
. . N

OBJECTIVE UH N
To TO N
explore VB N
the DT N
role NN N
of IN N
fixed-point JJ N
spin JJ N
reduction NN N
of IN N
spinal JJ N
manipulation NN N
therapy NN N
in IN N
the DT N
treatment NN N
of IN N
cervical JJ 4_p
vertigo NN 4_p
and CC N
its PRP$ N
effect NN N
on IN N
cervical JJ N
artery NN N
spasm NN N
index NN N
( ( N
RI NNP N
) ) N
and CC N
atlantoaxial JJ N
displacement NN N
index NN N
( ( N
ADI NNP N
) ) N
. . N

METHODS NN N
From IN N
January NNP N
2002 CD N
to TO N
May NNP N
2008 CD N
, , N
168 CD 3_p
patients NNS N
with IN N
cervical JJ N
vertigo NNS N
were VBD N
randomly RB N
divided VBN N
into IN N
treatment NN N
group NN N
( ( N
84 CD 3_p
cases NNS N
) ) N
and CC N
the DT N
control NN N
group NN N
( ( N
84 CD 3_p
cases NNS N
) ) N
, , N
22 CD 3_p
males NNS 2_p
and CC N
62 CD 3_p
females NNS 2_p
in IN N
treatment NN N
group NN N
; : N
24 CD 3_p
males NNS 2_p
and CC N
60 CD 3_p
females NNS 2_p
in IN N
control NN N
group NN N
. . N

The DT N
patients NNS N
of IN N
treatment NN N
group NN N
and CC N
control NN N
group NN N
were VBD N
respectively RB N
treated VBN N
with IN N
fixed-point JJ N
spin NN N
reduction NN N
of IN N
spinal JJ N
manipulation NN N
therapy NN N
and CC N
dialectical JJ N
prescription NN N
. . N

The DT N
score NN N
of IN N
symptoms NNS N
and CC N
signs NNS N
, , N
RI NNP N
, , N
ADI NNP N
were VBD N
observed VBN N
and CC N
compared VBN N
between IN N
two CD N
groups NNS N
. . N

RESULTS VB N
The DT N
score NN N
of IN N
symptoms NNS N
and CC N
signs NNS N
markedly RB N
decreased VBD N
after IN N
treatment NN N
, , N
in IN N
treatment NN N
group NN N
: : N
vertigo NN N
had VBD N
( ( N
2.75 CD N
+/- JJ N
1.01 CD N
) ) N
scores NNS N
, , N
neck-shoulder JJ N
pain NN N
( ( N
1.58 CD N
+/- JJ N
0.36 CD N
) ) N
, , N
headache NN N
( ( N
0.39 CD N
+/- JJ N
0.09 CD N
) ) N
, , N
nausea-vomiting JJ N
( ( N
1.58 CD N
+/- JJ N
1.30 CD N
) ) N
, , N
ear JJ N
noises NNS N
( ( N
0.48 CD N
+/- JJ N
0.32 CD N
) ) N
, , N
positive JJ N
neck NN N
rotation NN N
test NN N
( ( N
0.59 CD N
+/- JJ N
0.21 CD N
) ) N
; : N
and CC N
in IN N
control NN N
group NN N
: : N
vertigo NN N
had VBD N
( ( N
5.68 CD N
+/- JJ N
2.02 CD N
) ) N
scores NNS N
, , N
neck-shoulder JJ N
pain NN N
( ( N
3.12 CD N
+/- JJ N
1.82 CD N
) ) N
, , N
headache NN N
( ( N
1.86 CD N
+/- JJ N
0.65 CD N
) ) N
, , N
nausea-vomiting JJ N
( ( N
3.25 CD N
+/- JJ N
0.69 CD N
) ) N
, , N
ear JJ N
noises NNS N
( ( N
1.64 CD N
+/- JJ N
0.61 CD N
) ) N
, , N
positive JJ N
neck NN N
rotation NN N
test NN N
( ( N
1.79 CD N
+/- JJ N
0.67 CD N
) ) N
. . N

Cervical JJ N
artery NN N
spasm NN N
index NN N
and CC N
atlantoaxial JJ N
displacement NN N
index NN N
had VBD N
been VBN N
significantly RB N
improved VBN N
, , N
cervical JJ N
artery NN N
spasm NN N
index NN N
was VBD N
respectively RB N
0.54 CD N
+/- JJ N
0.07 CD N
and CC N
0.52 CD N
+/- JJ N
0.13 CD N
, , N
atlantoaxial JJ N
displacement NN N
index NN N
was VBD N
respectively RB N
2.92 CD N
+/- JJ N
0.82 CD N
and CC N
4.50 CD N
+/- JJ N
1.32 CD N
between IN N
treatment NN N
group NN N
and CC N
control NN N
group NN N
. . N

CONCLUSION NNP N
Fixed-point NNP N
spin NN N
reduction NN N
of IN N
spinal JJ N
manipulation NN N
therapy NN N
for IN N
cervical JJ N
vertigo NN N
can MD N
accurately RB N
correct VB N
single JJ N
or CC N
multiple JJ N
vertebral JJ 4_p
body NN 4_p
displacement NN 4_p
, , N
restore VB N
normal JJ N
spinal JJ N
position NN N
, , N
reduce VB N
the DT N
oppression NN N
and CC N
stimulus NN N
of IN N
the DT N
vertebral JJ N
artery NN N
, , N
release NN N
ischemia NN N
of IN N
vestibular JJ N
labyrinth NN N
, , N
eliminate VB N
symptoms NNS N
of IN N
vertigo NN N
. . N

-DOCSTART- -X- O O

Double-blind NNP N
, , N
placebo-controlled JJ N
trial NN N
of IN N
risperidone NN N
plus CC N
amantadine NN N
in IN N
children NNS 1_p
with IN N
autism NN 4_p
: : N
a DT N
10-week JJ N
randomized NN N
study NN N
. . N

OBJECTIVE NNP N
This DT N
study NN N
aimed VBD N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
adding VBG N
amantadine NN N
to TO N
risperidone VB N
for IN N
treatment NN N
of IN N
autism NN N
. . N

METHODS NNP N
Forty NNP 3_p
outpatients NNS N
aged VBD N
4 CD 1_p
to12 NN 1_p
years NNS N
, , N
who WP N
were VBD N
diagnosed VBN N
with IN N
autism NN 4_p
spectrum NN 4_p
disorders NNS 4_p
based VBN N
on IN N
the DT N
Diagnostic NNP N
and CC N
Statistical NNP N
Manual NNP N
of IN N
Mental NNP N
Disorders NNP N
, , N
Fourth NNP N
Edition NNP N
, , N
Text NNP N
Revision NNP N
criteria NNS N
, , N
were VBD N
assigned VBN N
to TO N
this DT N
double-blind JJ N
clinical JJ N
trial NN N
. . N

The DT N
subjects NNS N
were VBD N
divided VBN N
randomly RB N
into IN N
2 CD N
groups NNS N
. . N

One CD N
group NN N
received VBD N
risperidone JJ N
plus CC N
amantadine JJ N
, , N
and CC N
the DT N
other JJ N
group NN N
received VBD N
risperidone JJ N
plus CC N
placebo NN N
. . N

The DT N
dose NN N
of IN N
risperidone NN N
was VBD N
titrated VBN N
between IN N
1 CD N
and CC N
2.0 CD N
mg/d NN N
, , N
and CC N
the DT N
dose NN N
of IN N
amantadine NN N
was VBD N
100 CD N
or CC N
150 CD N
mg/d NNS N
for IN N
patients NNS N
less JJR N
than IN N
30 CD N
kg NN N
or CC N
more JJR N
than IN N
30 CD N
kg NNS N
, , N
respectively RB N
. . N

The DT N
patients NNS N
were VBD N
assessed VBN N
using VBG N
the DT N
Aberrant NNP N
Behavioral NNP N
Checklist-Community NNP N
( ( N
ABC-C NNP N
) ) N
and CC N
adverse JJ N
effects NNS N
checklist NN N
as RB N
well RB N
as IN N
clinical JJ N
global JJ N
impression-improvement NN N
( ( N
CGI-I NNP N
) ) N
at2 VBZ N
checkpoints NNS N
of IN N
5-week JJ N
intervals NNS N
after IN N
the DT N
baseline NN N
. . N

Informed NNP N
consentwas NN N
obtained VBN N
from IN N
the DT N
parents NNS N
of IN N
each DT N
participant NN N
. . N

RESULTS NNP N
Among IN N
ABC-C NNP N
subscales NNS N
, , N
Hyperactivity NNP N
and CC N
Irritability NNP N
showed VBD N
significantly RB N
greater JJR N
reduction NN N
in IN N
the DT N
amantadine NN N
group NN N
than IN N
the DT N
placebo NN N
group NN N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
adverse JJ N
effects NNS N
between IN N
the DT N
2 CD N
groups NNS N
. . N

The DT N
CGI-I JJ N
scores NNS N
show VBP N
significant JJ N
improvement NN N
in IN N
the DT N
amantadine NN N
group NN N
compared VBN N
to TO N
the DT N
placebo NN N
group NN N
. . N

CONCLUSIONS VB N
The DT N
present JJ N
study NN N
suggests VBZ N
that IN N
amantadine NN N
may MD N
be VB N
a DT N
potential JJ N
adjunctive JJ N
treatment NN N
strategy NN N
for IN N
autism NN N
and CC N
it PRP N
was VBD N
generally RB N
well RB N
tolerated VBN N
. . N

-DOCSTART- -X- O O

Diode NNP N
laser NN N
photocoagulation NN N
for IN N
threshold JJ N
retinopathy NN 4_p
of IN 4_p
prematurity NN 4_p
. . N

A DT N
randomized JJ N
study NN N
. . N

BACKGROUND NNP N
Although IN N
peripheral JJ N
cryotherapy NN N
decreases VBZ N
the DT N
incidence NN N
of IN N
unfavorable JJ N
anatomic JJ N
outcomes NNS N
in IN N
threshold JJ N
retinopathy NN 4_p
of IN 4_p
prematurity NN 4_p
( ( N
ROP NNP 4_p
) ) N
, , N
apnea RB N
, , N
bradycardia NN N
, , N
and CC N
lid JJ N
edema NN N
can MD N
occur VB N
. . N

Argon NNP N
laser NN N
indirect JJ N
ophthalmoscope NN N
photocoagulation NN N
has VBZ N
been VBN N
used VBN N
as IN N
an DT N
alternative NN N
to TO N
cryotherapy VB N
, , N
with IN N
fewer JJR N
adverse JJ N
effects NNS N
. . N

Retinal JJ N
lesions NNS N
placed VBN N
with IN N
diode NN N
lasers NNS N
are VBP N
deeper JJR N
than IN N
similar JJ N
argon NN N
laser NN N
lesions NNS N
, , N
and CC N
it PRP N
is VBZ N
not RB N
known VBN N
whether IN N
this DT N
difference NN N
could MD N
influence VB N
the DT N
response NN N
to TO N
ablative JJ N
therapy NN N
. . N

METHODS JJ N
Patients NNPS N
were VBD N
enrolled VBN N
under IN N
a DT N
prospective JJ N
, , N
randomized VBN N
protocol NN N
. . N

One CD N
eye NN N
of IN N
each DT N
patient NN N
with IN N
symmetric JJ N
, , N
threshold JJ N
ROP NNP N
was VBD N
treated VBN N
with IN N
an DT N
814/815 CD N
nm JJ N
diode NN N
laser NN N
, , N
while IN N
the DT N
other JJ N
eye NN N
was VBD N
treated VBN N
with IN N
cryotherapy NN N
. . N

Patients NNS N
with IN N
asymmetric JJ N
diseases NNS N
also RB N
were VBD N
randomized VBN N
for IN N
treatment NN N
in IN N
the DT N
threshold NN N
eye NN N
. . N

RESULTS NNP N
Nineteen JJ 3_p
infants NNS N
( ( N
33 CD 3_p
eyes NNS N
) ) N
were VBD N
treated VBN N
, , N
ranging VBG N
from IN N
485 CD N
to TO N
863 CD N
g NNS N
birth JJ N
weight NN N
( ( N
23 CD N
to TO N
27 CD N
weeks NNS N
gestational JJ N
age NN N
) ) N
; : N
18 CD 3_p
patients NNS N
( ( N
32 CD 3_p
eyes NNS N
) ) N
were VBD N
followed VBN N
for IN N
3 CD N
months NNS N
or CC N
longer JJR N
. . N

Four CD 3_p
patients NNS N
( ( N
8 CD 3_p
eyes NNS N
) ) N
had VBD N
bilateral JJ N
zone CD N
1 CD N
disease NN N
. . N

Postconceptional JJ N
age NN N
was VBD N
36 CD 1_p
to TO 1_p
45 CD 1_p
weeks NNS N
at IN N
the DT N
time NN N
of IN N
treatment NN N
. . N

The DT N
diode NN N
laser NN N
treatment NN N
was VBD N
better RBR N
tolerated VBN N
than IN N
cryotherapy NN N
, , N
and CC N
the DT N
treatment NN N
apparatus NN N
was VBD N
more RBR N
easily RB N
transported VBN N
. . N

Apneic NNP N
episodes VBZ N
requiring VBG N
intubation NN N
resulted VBD N
from IN N
two CD N
cryotherapy NN N
sessions NNS N
but CC N
no DT N
diode NN N
laser NN N
sessions NNS N
. . N

Five CD N
cryotherapy-treated JJ N
eyes NNS N
required VBN N
retreatment NN N
because IN N
of IN N
persistent JJ N
disease NN N
with IN N
adjacent JJ N
skip NN N
areas NNS N
. . N

In IN N
the DT N
group NN N
followed VBD N
for IN N
3 CD N
to TO N
15 CD N
months NNS N
, , N
1 CD N
cryotherapy-treated JJ N
eye NN N
and CC N
1 CD N
diode NN N
laser-treated JJ N
eye NN N
progressed VBD N
to TO N
stage VB N
5 CD N
retinal JJ N
detachment NN N
. . N

CONCLUSION NNP N
Compared NNP N
with IN N
cryotherapy NN N
, , N
the DT N
diode NN N
laser NN N
was VBD N
more RBR N
convenient JJ N
, , N
technically RB N
easier JJR N
to TO N
administer VB N
, , N
and CC N
better RB N
tolerated VBN N
by IN N
the DT N
patient NN N
. . N

Although IN N
the DT N
number NN N
of IN N
patients NNS N
was VBD N
too RB N
small JJ N
for IN N
meaningful JJ N
statistical JJ N
analysis NN N
of IN N
outcome NN N
, , N
diode VB N
laser RBR N
peripheral JJ N
retinal JJ N
ablation NN N
appeared VBD N
to TO N
be VB N
as RB N
effective JJ N
as IN N
cryotherapy NN N
for IN N
the DT N
treatment NN N
of IN N
threshold JJ N
ROP NNP N
. . N

-DOCSTART- -X- O O

[ JJ N
Effect NNP N
of IN N
Yufeining VBG N
on IN N
induced JJ N
sputum JJ N
interleukin-8 NN N
in IN N
patients NNS N
with IN N
chronic JJ 4_p
obstructive JJ 4_p
pulmonary JJ 4_p
disease NN 4_p
at IN N
the DT N
stable JJ N
phase NN N
] NNP N
. . N

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
effect NN N
of IN N
Yufeining NNP N
, , N
a DT N
traditional JJ N
Chinese JJ N
medicine NN N
, , N
on IN N
induced JJ N
sputum NN N
interleukin-8 JJ N
( ( N
IL-8 NNP N
) ) N
in IN N
patients NNS N
with IN N
chronic JJ N
obstructive JJ N
pulmonary JJ N
disease NN N
( ( N
COPD NNP 4_p
) ) N
at IN N
the DT N
stable JJ 4_p
phase NN 4_p
. . N

METHODS NNP N
Thirty-six JJ 3_p
patients NNS N
with IN N
COPD NNP 4_p
were VBD N
divided VBN N
into IN N
trial NN N
group NN N
( ( N
18 CD N
cases NNS N
) ) N
and CC N
control NN N
group NN N
( ( N
18 CD N
cases NNS N
) ) N
randomly RB N
. . N

The DT N
trial NN N
group NN N
was VBD N
treated VBN N
with IN N
Yufeining VBG N
pills NNS N
taken VBN N
orally RB N
for IN N
half PDT N
a DT N
year NN N
; : N
the DT N
control NN N
group NN N
was VBD N
not RB N
given VBN N
any DT N
medicine NN N
. . N

Routine NNP N
lung NN N
function NN N
was VBD N
recorded VBN N
before IN N
and CC N
after IN N
treatment NN N
. . N

Total JJ N
cell NN N
count NN N
( ( N
TCC NNP N
) ) N
, , N
differential JJ N
cell NN N
counts NNS N
( ( N
DCCs NNP N
) ) N
and CC N
IL-8 NNP N
in IN N
induced JJ N
sputum NN N
were VBD N
determined VBN N
at IN N
the DT N
baseline NN N
and CC N
6 CD N
months NNS N
later RB N
. . N

RESULTS VB N
The DT N
indices NNS N
of IN N
lung NN N
function NN N
improved VBD N
significantly RB N
after IN N
6 CD N
months NNS N
' POS N
treatment NN N
in IN N
trial NN N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
; : N
TCC NNP N
and CC N
absolute JJ N
neutrophil NN N
count NN N
decreased VBD N
significantly RB N
compared VBN N
with IN N
baseline NN N
in IN N
the DT N
trial NN N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
; : N
Sputum NNP N
IL-8 NNP N
concentration NN N
dropped VBD N
significantly RB N
after IN N
6 CD N
months NNS N
' POS N
treatment NN N
, , N
from IN N
a DT N
mean NN N
of IN N
5.216 CD N
+/- JJ N
2.914 CD N
microg/L NN N
to TO N
4.222 CD N
+/- JJ N
2.140 CD N
microg/L NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

There EX N
were VBD N
insignificant JJ N
changes NNS N
in IN N
the DT N
parameters NNS N
in IN N
the DT N
control NN N
group NN N
between IN N
baseline NN N
and CC N
6 CD N
months NNS N
later RB N
. . N

CONCLUSION NNP N
Yufeining NNP N
could MD N
improve VB N
lung NN N
function NN N
, , N
decrease NN N
sputum NN N
TCC NNP N
, , N
absolute JJ N
neutrophil NN N
count NN N
and CC N
IL-8 NNP N
concentration NN N
, , N
and CC N
relieve VB N
airway NN N
inflammation NN N
in IN N
patients NNS N
with IN N
COPD NNP N
in IN N
the DT N
stable JJ N
phase NN N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
motivational JJ N
music NN N
on IN N
lactate NN N
levels NNS N
during IN N
recovery NN N
from IN N
intense JJ N
exercise NN N
. . N

The DT N
effects NNS N
of IN N
music NN N
played VBN N
during IN N
an DT N
exercise NN N
task NN N
on IN N
athletic JJ N
performance NN N
have VBP N
been VBN N
previously RB N
studied VBN N
. . N

Yet CC N
, , N
these DT N
results NNS N
are VBP N
not RB N
applicable JJ N
for IN N
competitive JJ N
athletes NNS N
, , N
who WP N
can MD N
use VB N
music NN N
only RB N
during IN N
warm-up NN N
or CC N
recovery NN N
from IN N
exercise NN N
. . N

Therefore RB N
, , N
the DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
effect NN N
of IN N
motivational JJ N
music NN N
( ( N
music NN N
that WDT N
stimulates VBZ N
or CC N
inspires VBZ N
physical JJ N
activity NN N
) ) N
during IN N
recovery NN N
from IN N
intense JJ N
exercise NN N
, , N
on IN N
activity NN N
pattern NN N
, , N
rate NN N
of IN N
perceived VBN N
exertion NN N
( ( N
RPE NNP N
) ) N
, , N
and CC N
blood NN N
lactate NN N
concentration NN N
. . N

Twenty NNP N
young JJ N
, , N
active JJ N
men NNS N
( ( N
mean JJ N
age NN N
26.2 CD N
? . N
2.1 CD N
years NNS N
) ) N
performed VBD N
a DT N
6-minute JJ N
run NN N
at IN N
peak NN N
oxygen NN N
consumption NN N
speed NN N
( ( N
predetermined VBN N
from IN N
the DT N
VO NNP N
( ( N
2 CD N
) ) N
max FW N
test NN N
) ) N
. . N

The DT N
mean JJ N
heart NN N
rate NN N
( ( N
HR NNP N
) ) N
, , N
RPE NNP N
, , N
number NN N
of IN N
steps NNS N
( ( N
determined VBN N
by IN N
step NN N
counter NN N
) ) N
, , N
and CC N
blood NN N
lactate NN N
concentrations NNS N
were VBD N
determined VBN N
at IN N
3 CD N
, , N
6 CD N
, , N
9 CD N
, , N
12 CD N
, , N
and CC N
15 CD N
minutes NNS N
during IN N
the DT N
recovery NN N
from IN N
the DT N
exercise NN N
, , N
with IN N
and CC N
without IN N
motivational JJ N
music NN N
( ( N
2 CD N
separate JJ N
sessions NNS N
, , N
at IN N
random JJ N
order NN N
) ) N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
mean JJ N
HR NNP N
during IN N
the DT N
recovery NN N
with IN N
and CC N
without IN N
music NN N
. . N

Listening VBG N
to TO N
motivational JJ N
music NN N
during IN N
the DT N
recovery NN N
was VBD N
associated VBN N
with IN N
increased JJ N
voluntary JJ N
activity NN N
of IN N
the DT N
participants NNS N
, , N
determined VBN N
by IN N
increased JJ N
number NN N
of IN N
steps NNS N
( ( N
499.4 CD N
? . N
220.1 CD N
vs. IN N
413.2 CD N
? . N
150.6 CD N
steps NNS N
, , N
with IN N
and CC N
without IN N
music NN N
, , N
respectively RB N
; : N
p VB N
? . N
0.05 CD N
) ) N
. . N

The DT N
increased JJ N
number NN N
of IN N
steps NNS N
during IN N
the DT N
recovery NN N
was VBD N
accompanied VBN N
by IN N
a DT N
significantly RB N
greater JJR N
decrease NN N
in IN N
blood NN N
lactate NN N
concentration NN N
percentage NN N
( ( N
28.1 CD N
? . N
12.2 CD N
vs. IN N
22.8 CD N
? . N
10.9 CD N
% NN N
, , N
with IN N
and CC N
without IN N
music NN N
, , N
respectively RB N
, , N
p VB N
? . N
0.05 CD N
) ) N
. . N

This DT N
was VBD N
associated VBN N
with IN N
a DT N
greater JJR N
decrease NN N
in IN N
RPE NNP N
( ( N
77.7 CD N
? . N
14.4 CD N
vs. IN N
73.1 CD N
? . N
14.7 CD N
% NN N
with IN N
and CC N
without IN N
music NN N
, , N
respectively RB N
; : N
p VB N
? . N
0.05 CD N
) ) N
. . N

Our PRP$ N
results NNS N
suggest VBP N
that IN N
listening VBG N
to TO N
motivational JJ N
music NN N
during IN N
nonstructured JJ N
recovery NN N
from IN N
intense JJ N
exercise NN N
leads VBZ N
to TO N
increased VBN N
activity NN N
, , N
faster JJR N
lactate JJ N
clearance NN N
, , N
and CC N
reduced VBD N
RPE NNP N
and CC N
therefore RB N
may MD N
be VB N
used VBN N
by IN N
athletes NNS N
in IN N
their PRP$ N
effort NN N
to TO N
enhance VB N
recovery NN N
. . N

-DOCSTART- -X- O O

Efficacy NN N
and CC N
safety NN N
of IN N
routine JJ N
blood NN N
pressure NN N
lowering VBG N
in IN N
older JJR N
patients NNS N
with IN N
diabetes NNS 4_p
: : N
results NNS N
from IN N
the DT N
ADVANCE NNP N
trial NN N
. . N

OBJECTIVE CC N
The DT N
efficacy NN N
and CC N
safety NN N
of IN N
blood NN N
pressure NN N
lowering VBG N
in IN N
elderly JJ 1_p
patients NNS N
have VBP N
not RB N
been VBN N
sufficiently RB N
investigated VBN N
in IN N
patients NNS N
with IN N
diabetes NNS 4_p
. . N

Using VBG N
data NNS N
from IN N
the DT N
Action NNP N
in IN N
Diabetes NNP N
and CC N
Vascular NNP N
disease NN N
: : N
preterAx NN N
and CC N
diamicroN-MR NN N
Controlled NNP N
Evaluation NNP N
study NN N
, , N
we PRP N
assessed VBD N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
routine JJ N
blood NN N
pressure NN N
lowering VBG N
to TO N
prevent VB N
major JJ N
clinical JJ N
outcomes NNS N
in IN N
elderly JJ N
patients NNS N
with IN N
type JJ 4_p
2 CD 4_p
diabetes NNS 4_p
. . N

METHODS NNP N
Eleven NNP 3_p
thousand VBP 3_p
one CD 3_p
hundred CD 3_p
and CC 3_p
forty JJ 3_p
patients NNS N
aged VBN N
at IN N
least JJS N
55 CD 1_p
years NNS N
with IN N
type NN N
2 CD N
diabetes NNS N
( ( N
mean JJ N
66+/-6 CD 1_p
years NNS N
) ) N
were VBD N
randomly RB N
assigned VBN N
to TO N
perindopril-indapamide JJ N
or CC N
placebo NN N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
a DT N
composite NN N
of IN N
major JJ N
macrovascular NN N
and CC N
microvascular JJ N
disease NN N
. . N

The DT N
effects NNS N
of IN N
active JJ N
treatment NN N
on IN N
outcomes NNS N
were VBD N
estimated VBN N
in IN N
subgroups NNS N
according VBG N
to TO N
age NN N
: : N
below IN 1_p
65 CD 1_p
, , N
65-74 JJ 1_p
and CC N
at IN 1_p
least JJS 1_p
75 CD 1_p
years NNS 1_p
. . N

RESULTS NNP N
During IN N
a DT N
mean JJ N
4.3-year JJ N
follow-up NN N
, , N
1799 CD N
( ( N
16.1 CD N
% NN N
) ) N
patients NNS N
experienced VBD N
a DT N
major JJ N
event NN N
. . N

Active JJ N
treatment NN N
produced VBD N
similar JJ N
relative JJ N
risk NN N
reductions NNS N
for IN N
the DT N
primary JJ N
outcome NN N
, , N
major JJ N
macrovascular JJ N
disease NN N
, , N
death NN N
and CC N
renal JJ N
events NNS N
across IN N
age NN N
groups NNS N
( ( N
all DT N
P NNP N
heterogeneity NN N
> NNP N
0.3 CD N
) ) N
. . N

Over IN N
5 CD N
years NNS N
, , N
active JJ N
treatment NN N
was VBD N
estimated VBN N
to TO N
prevent VB N
one CD N
primary JJ N
outcome NN N
in IN N
every DT N
21 CD N
, , N
71 CD N
and CC N
118 CD N
patients NNS N
of IN N
at IN N
least JJS N
75 CD N
, , N
65-74 JJ N
and CC N
below IN N
65 CD N
years NNS N
, , N
respectively RB N
. . N

Similar JJ N
patterns NNS N
of IN N
benefits NNS N
were VBD N
observed VBN N
for IN N
secondary JJ N
outcomes NNS N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
the DT N
tolerability NN N
between IN N
randomized VBN N
allocations NNS N
across IN N
age NN N
groups NNS N
( ( N
all DT N
P NNP N
heterogeneity NN N
> NNP N
0.6 CD N
) ) N
CONCLUSION NNP N
Routine NNP N
administration NN N
of IN N
perindopril-indapamide JJ N
lowers NNS N
blood NN N
pressure NN N
safely RB N
and CC N
reduces VBZ N
the DT N
risk NN N
of IN N
major JJ N
clinical JJ N
outcomes NNS N
in IN N
patients NNS N
of IN N
at IN N
least JJS N
75 CD N
years NNS N
with IN N
type NN N
2 CD N
diabetes NNS N
. . N

The DT N
greater JJR N
absolute JJ N
benefits NNS N
in IN N
older JJR N
patients NNS N
in IN N
this DT N
age NN N
group NN N
were VBD N
not RB N
offset VBN N
by IN N
an DT N
increased VBN N
risk NN N
of IN N
side NN N
effects NNS N
. . N

-DOCSTART- -X- O O

Differential JJ N
effects NNS N
of IN N
amino NN N
acid NN N
and CC N
ketoacid VB N
on IN N
protein NN N
metabolism NN N
in IN N
humans NNS N
. . N

We PRP N
examined VBD N
the DT N
effects NNS N
of IN N
insulin NN N
, , N
amino JJ N
acid NN N
( ( N
AA NNP N
) ) N
, , N
and CC N
branched-chain JJ N
ketoacid NN N
( ( N
KA NNP N
) ) N
availability NN N
on IN N
leucine JJ N
kinetics NNS N
in IN N
eight CD 3_p
healthy JJ 4_p
volunteers NNS N
( ( N
age NN N
= VBZ N
22 CD 1_p
+/- JJ 1_p
2 CD 1_p
y NN N
, , N
body NN N
mass NN N
index NN N
= VBD N
24 CD 4_p
+/- JJ 4_p
1 CD 4_p
kg NN 4_p
) ) N
by IN N
using VBG N
the DT N
euglycemic JJ N
insulin NN N
clamp NN N
and CC N
[ JJ N
1-14C JJ N
] NNP N
leucine NN N
turnover NN N
techniques NNS N
. . N

Four CD N
experimental JJ N
conditions NNS N
were VBD N
studied VBN N
: : N
study NN N
I PRP N
, , N
hyperinsulinemia NN N
; : N
study NN N
II NNP N
, , N
hyperinsulinemia NN N
with IN N
maintenance NN N
of IN N
basal NN N
plasma NN N
AA NNP N
and CC N
branched-chain JJ N
KA NNP N
concentrations NNS N
; : N
study NN N
III NNP N
, , N
hyperinsulinemia NN N
with IN N
hyperaminoacidemia NN N
and CC N
basal NN N
plasma VBP N
branched-chain NN N
KA NNP N
concentrations NNS N
; : N
and CC N
study VB N
IV NNP N
, , N
hyperinsulinemia NN N
plus CC N
basal NN N
plasma VBP N
AA NNP N
concentrations NNS N
and CC N
elevated VBD N
branched-chain NN N
KA NNP N
levels NNS N
. . N

Basal NNP N
endogenous JJ N
leucine NN N
flux NN N
( ( N
ELF NNP N
) ) N
averaged VBD N
1.20 CD N
+/- JJ N
0.05 CD N
( ( N
mumol.kg-1.min-1 NN N
, , N
mean JJ N
+/- JJ N
SE NNP N
) ) N
; : N
basal CC N
leucine JJ N
oxidation NN N
( ( N
LOX NNP N
) ) N
was VBD N
0.25 CD N
+/- JJ N
0.01 CD N
; : N
and CC N
basal VB N
non-oxidative JJ N
leucine NN N
disposal NN N
( ( N
NOLD NNP N
) ) N
was VBD N
0.95 CD N
+/- JJ N
0.04 CD N
. . N

ELF NNP N
significantly RB N
decreased VBD N
in IN N
study NN N
I PRP N
( ( N
0.77 CD N
+/- JJ N
0.06 CD N
mumol.kg-1.min-1 NN N
, , N
P NNP N
< VBZ N
0.01 CD N
versus NN N
basal NN N
) ) N
. . N

When WRB N
plasma NN N
AA NNP N
and CC N
branched-chain JJ N
KA NNP N
were VBD N
either RB N
maintained VBN N
at IN N
their PRP$ N
basal NN N
levels NNS N
( ( N
study VB N
II NNP N
) ) N
or CC N
increased VBN N
above IN N
baseline NN N
values NNS N
( ( N
studies NNS N
III NNP N
and CC N
IV NNP N
) ) N
, , N
ELF NNP N
declined VBD N
further RBR N
( ( N
0.64 CD N
+/- JJ N
0.05 CD N
, , N
0.66 CD N
+/- JJ N
0.02 CD N
, , N
and CC N
0.66 CD N
+/- JJ N
0.03 CD N
mumol.kg-1.min-1 NN N
, , N
respectively RB N
; : N
all DT N
Ps NNP N
< NNP N
0.01 CD N
versus NN N
basal NN N
and CC N
P NNP N
< NNP N
0.01 CD N
versus NN N
study NN N
I PRP N
) ) N
. . N

LOX NNP N
declined VBD N
in IN N
study NN N
I PRP N
( ( N
0.12 CD N
+/- JJ N
0.02 CD N
mumol.kg-1.min-1 NN N
, , N
P NNP N
< VBZ N
0.01 CD N
versus NN N
basal NN N
) ) N
but CC N
increased VBD N
significantly RB N
in IN N
studies NNS N
II NNP N
, , N
III NNP N
, , N
and CC N
IV NNP N
( ( N
0.31 CD N
+/- JJ N
0.04 CD N
, , N
0.37 CD N
+/- JJ N
0.03 CD N
, , N
and CC N
0.40 CD N
+/- JJ N
0.03 CD N
mumol.kg-1.min-1 NN N
, , N
respectively RB N
, , N
all DT N
Ps NNP N
< NNP N
0.01 CD N
versus NN N
basal NN N
, , N
P NNP N
< NNP N
0.05 CD N
study NN N
IV NNP N
versus NN N
study NN N
II NNP N
, , N
and CC N
P NNP N
< NNP N
0.05 CD N
study NN N
III NNP N
versus NN N
study NN N
II NNP N
) ) N
. . N

NOLD NNP N
declined VBD N
in IN N
study NN N
I PRP N
( ( N
0.65 CD N
+/- JJ N
0.05 CD N
mumol/kg.min NN N
, , N
P NNP N
< VBZ N
0.01 CD N
versus NN N
basal NN N
) ) N
, , N
whereas IN N
neither CC N
the DT N
maintenance NN N
of IN N
basal NN N
plasma IN N
AA/branched-chain NNP N
KA NNP N
levels NNS N
( ( N
study NN N
II NNP N
; : N
0.89 CD N
+/- JJ N
0.2 CD N
mumol.kg-1.min-1 NN N
) ) N
nor CC N
the DT N
elevation NN N
of IN N
plasma JJ N
branched-chain JJ N
KA NNP N
concentration NN N
( ( N
study JJ N
IV NNP N
; : N
0.96 CD N
+/- JJ N
0.1 CD N
mumol.kg-1.min-1 NN N
) ) N
increased VBD N
NOLD NNP N
above IN N
baseline NN N
level NN N
. . N

A DT N
stimulation NN N
of IN N
NOLD NNP N
was VBD N
observed VBN N
only RB N
when WRB N
plasma JJ N
AA NNP N
levels NNS N
were VBD N
increased VBN N
( ( N
study NN N
III NNP N
; : N
1.23 CD N
+/- JJ N
0.03 CD N
mumol/kg.min NN N
, , N
P NNP N
< VBZ N
0.01 CD N
versus NN N
basal NN N
) ) N
. . N

In IN N
conclusion NN N
, , N
the DT N
present JJ N
data NNS N
do VBP N
not RB N
support VB N
the DT N
concept NN N
of IN N
a DT N
direct JJ N
anabolic JJ N
action NN N
of IN N
ketoanalogs NNS N
but CC N
do VBP N
provide VB N
additional JJ N
evidence NN N
for IN N
the DT N
pivotal JJ N
role NN N
of IN N
AA NNP N
availability NN N
in IN N
the DT N
stimulation NN N
of IN N
whole-body NN N
protein NN N
synthesis NN N
. . N

-DOCSTART- -X- O O

The DT N
effects NNS N
of IN N
physical JJ N
and CC N
emotional JJ N
status NN N
on IN N
adherence NN N
to TO N
a DT N
low-fat JJ N
dietary JJ N
pattern NN N
in IN N
the DT N
Women NNP N
's POS N
Health NNP N
Initiative NNP N
. . N

OBJECTIVE NNP N
To TO N
examine VB N
whether IN N
the DT N
effects NNS N
of IN N
physical JJ N
and CC N
emotional JJ N
status NN N
on IN N
adherance NN N
to TO N
a DT N
low-fat JJ N
( ( N
20 CD N
% NN N
energy NN N
) ) N
dietary JJ N
pattern NN N
are VBP N
mediated VBN N
by IN N
participation NN N
in IN N
an DT N
intervention NN N
program NN N
( ( N
attending VBG N
sessions NNS N
and CC N
self-monitoring NN N
) ) N
. . N

DESIGN VB N
The DT N
Baron NNP N
and CC N
Kenny NNP N
mediator NN N
model NN N
, , N
a DT N
series NN N
of IN N
4 CD N
regression NN N
analyses NNS N
, , N
was VBD N
used VBN N
to TO N
evaluate VB N
whether IN N
: : N
a DT N
) ) N
physical JJ N
and CC N
emotional JJ N
status NN N
predicted VBD N
program NN N
participation NN N
, , N
b NN N
) ) N
program NN N
participation NN N
predicted VBD N
dietary JJ N
adherence NN N
, , N
c NN N
) ) N
physical JJ N
and CC N
emotional JJ N
status NN N
factors NNS N
predicted VBD N
dietary JJ N
adherence NN N
, , N
and CC N
, , N
ultimately RB N
d NN N
) ) N
the DT N
effects NNS N
of IN N
physical JJ N
and CC N
emotional JJ N
status NN N
on IN N
dietary JJ N
adherence NN N
were VBD N
mediated VBN N
by IN N
program NN N
participation NN N
. . N

SUBJECTS/SETTING NNP N
Data NNP N
from IN N
13,277 CD 3_p
postmenopausal JJ 4_p
women NNS 2_p
randomly RB N
assigned VBN N
to TO N
the DT N
low-fat JJ N
intervention NN N
arm NN N
of IN N
the DT N
Women NNP N
's POS N
Health NNP N
Initiative NNP N
Dietary NNP N
Modification NNP N
Trial NNP N
. . N

INTERVENTION NNP N
The DT N
nutrition NN N
goals NNS N
for IN N
women NNS N
randomly RB N
assigned VBN N
to TO N
the DT N
low-fat JJ N
intervention NN N
were VBD N
to TO N
reduce VB N
total JJ N
fat JJ N
intake NN N
to TO N
20 CD N
% NN N
or CC N
less JJR N
of IN N
energy NN N
from IN N
fat JJ N
and CC N
to TO N
consume VB N
5 CD N
or CC N
more JJR N
fruit/vegetable JJ N
servings NNS N
daily RB N
and CC N
6 CD N
or CC N
more JJR N
grain JJ N
servings NNS N
daily RB N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Year NNP N
1 CD N
program NN N
participation NN N
( ( N
degree NN N
of IN N
attending VBG N
group NN N
sessions NNS N
and CC N
submitting VBG N
fat JJ N
scores NNS N
) ) N
and CC N
adherence NN N
to TO N
the DT N
low-fat JJ N
dietary JJ N
pattern NN N
( ( N
percent JJ N
energy NN N
from IN N
fat NN N
) ) N
as IN N
predicted VBN N
by IN N
baseline JJ N
physical JJ N
and CC N
emotional JJ N
status NN N
( ( N
eight CD N
SF-36 NNP N
Health NNP N
Survey NNP N
subscales VBZ N
) ) N
. . N

RESULTS NNP N
Participating VBG N
in IN N
the DT N
dietary JJ N
intervention NN N
program NN N
reduced VBN N
( ( N
mediated VBN N
) ) N
the DT N
negative JJ N
effect NN N
of IN N
poorer JJR N
mental JJ N
health NN N
on IN N
dietary JJ N
adherence NN N
by IN N
15 CD N
% NN N
. . N

Additional JJ N
findings NNS N
included VBD N
that IN N
a DT N
10 CD N
% NN N
increase NN N
in IN N
physical JJ N
functioning NN N
increased VBD N
session NN N
attendance NN N
by IN N
0.4 CD N
% NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
and CC N
a DT N
10 CD N
% NN N
increase NN N
in IN N
mental JJ N
health NN N
predicted VBD N
a DT N
decrease NN N
in IN N
percent NN N
energy NN N
from IN N
fat NN N
of IN N
0.3 CD N
% NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

Program NNP N
participation NN N
had VBD N
a DT N
marked JJ N
effect NN N
on IN N
dietary JJ N
adherence NN N
: : N
a DT N
10 CD N
% NN N
increase NN N
in IN N
session NN N
attendance NN N
predicted VBD N
a DT N
1.2 CD N
% NN N
decrease NN N
in IN N
percent NN N
energy NN N
from IN N
fat JJ N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

APPLICATIONS/CONCLUSIONS NNP N
Understanding NNP N
and CC N
using VBG N
instruments NNS N
to TO N
assess VB N
the DT N
physical JJ N
and CC N
emotional JJ N
status NN N
of IN N
a DT N
target NN N
population NN N
will MD N
help VB N
dietetic JJ N
professionals NNS N
promote VBP N
healthful JJ N
dietary JJ N
change NN N
and CC N
maintenance NN N
. . N

-DOCSTART- -X- O O

Study NN N
of IN N
the DT N
vaginal JJ N
tolerance NN N
to TO N
Acidform NNP N
, , N
an DT N
acid-buffering JJ N
, , N
bioadhesive JJ N
gel NN N
. . N

Vaginal JJ N
tolerance NN N
tests NNS N
were VBD N
performed VBN N
with IN N
a DT N
new JJ N
potential JJ N
microbicidal NN N
and CC N
spermicidal JJ N
product NN N
, , N
an DT N
acid-buffering JJ N
vaginal JJ N
gel NN N
( ( N
Acidform NNP N
) ) N
without IN N
or CC N
with IN N
nonoxynol-9 JJ N
( ( N
N-9 NNP N
) ) N
. . N

The DT N
potential JJ N
advantages NNS N
over IN N
other JJ N
vaginal JJ N
products NNS N
include VBP N
keeping VBG N
a DT N
low JJ N
pH NN N
, , N
decrease NN N
of IN N
the DT N
irritating VBG N
effect NN N
of IN N
N-9 NNP N
on IN N
the DT N
cervix NN N
or CC N
vaginal JJ N
mucosa NN N
associated VBN N
with IN N
greater JJR N
retention NN N
of IN N
the DT N
product NN N
after IN N
application NN N
, , N
and CC N
decreasing VBG N
messiness NN N
as IN N
compared VBN N
to TO N
other JJ N
vaginal JJ N
products NNS N
. . N

Three CD N
groups NNS N
of IN N
six CD 3_p
women NNS 2_p
were VBD N
admitted VBN N
and CC N
randomly RB N
assigned VBN N
to TO N
use VB N
Acidform NNP N
with IN N
0 CD N
% NN N
, , N
2.5 CD N
% NN N
, , N
and CC N
5 CD N
% NN N
N-9 NNP N
. . N

Colposcopic NNP N
evaluation NN N
for IN N
vulvar NN N
, , N
vaginal JJ N
, , N
and CC N
cervical JJ N
signs NNS N
of IN N
irritation NN N
was VBD N
performed VBN N
and CC N
photographs NNS N
were VBD N
taken VBN N
, , N
following VBG N
a DT N
specific JJ N
World NNP N
Health NNP N
Organization NNP N
protocol NN N
, , N
at IN N
time NN N
0 CD N
, , N
and CC N
after IN N
24 CD N
h NN N
and CC N
6 CD N
days NNS N
of IN N
application NN N
of IN N
the DT N
gel NN N
. . N

No DT N
irritation NN N
or CC N
symptom NN N
was VBD N
reported VBN N
by IN N
users NNS N
of IN N
Acidform NNP N
without IN N
N-9 NNP N
. . N

A NNP N
generalized JJ N
and CC N
intense JJ N
erythema NN N
in IN N
cervix NN N
was VBD N
observed VBN N
in IN N
10 CD N
of IN N
12 CD N
Acidform/N-9 JJ N
users NNS N
and CC N
abrasion NN N
occurred VBD N
in IN N
nine CD N
of IN N
them PRP N
. . N

Vulvar NNP N
irritation NN N
was VBD N
seen VBN N
in IN N
seven CD N
of IN N
these DT N
10 CD 3_p
volunteers NNS N
. . N

N-9 JJ N
concentration NN N
in IN N
the DT N
gel NN N
( ( N
2.5 CD N
% NN N
or CC N
5.0 CD N
% NN N
) ) N
was VBD N
not RB N
related VBN N
to TO N
the DT N
findings NNS N
. . N

No DT N
ulcer NN N
, , N
exulceration NN N
, , N
or CC N
de-epithelialization NN N
was VBD N
observed VBN N
. . N

Acidform VB N
without IN N
N-9 NNP N
was VBD N
well RB N
tolerated VBN N
by IN N
volunteers NNS N
, , N
but CC N
it PRP N
was VBD N
unable JJ N
to TO N
protect VB N
the DT N
cervix NN N
, , N
vagina NN N
, , N
and CC N
vulva NN N
from IN N
the DT N
N-9 JJ N
effects NNS N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
tonabersat NN N
on IN N
migraine NN 4_p
with IN 4_p
aura NN 4_p
: : N
a DT N
randomised JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
crossover NN N
study NN N
. . N

BACKGROUND NNP N
Migraine NNP N
with IN N
aura NN N
is VBZ N
thought VBN N
likely RB N
to TO N
be VB N
caused VBN N
by IN N
cortical JJ N
spreading VBG N
depression NN N
( ( N
CSD NNP N
) ) N
. . N

Tonabersat NNP N
inhibits VBZ N
CSD NNP N
, , N
and CC N
we PRP N
therefore RB N
investigated VBD N
whether IN N
tonabersat NN N
has VBZ N
a DT N
preventive JJ N
effect NN N
in IN N
migraine NN N
with IN N
aura NN N
. . N

METHODS NNP N
In IN N
this DT N
randomised JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
crossover NN N
trial NN N
, , N
40 CD N
mg NN N
tonabersat NN N
once IN N
daily JJ N
was VBD N
compared VBN N
with IN N
matched JJ N
placebo NN N
in IN N
patients NNS N
who WP N
had VBD N
at IN N
least JJS N
one CD 4_p
aura NN 4_p
attack NN 4_p
per IN 4_p
month NN 4_p
during IN N
the DT N
past JJ N
3 CD N
months NNS N
. . N

Randomisation NN N
was VBD N
by IN N
computer-generated JJ N
list NN N
. . N

Patients NNS N
kept VBD N
a DT N
detailed JJ N
diary NN N
to TO N
enable VB N
objective JJ N
diagnosis NN N
of IN N
each DT N
attack NN N
as IN N
migraine NN N
with IN N
aura NN N
, , N
migraine NN N
without IN N
aura NN N
, , N
or CC N
other JJ N
type NN N
of IN N
headache NN N
. . N

Primary JJ N
endpoints NNS N
were VBD N
a DT N
reduction NN N
in IN N
aura NN N
attacks NNS N
with IN N
or CC N
without IN N
headache NN N
and CC N
a DT N
reduction NN N
in IN N
migraine JJ N
headache NN N
days NNS N
with IN N
or CC N
without IN N
an DT N
aura NN N
. . N

Analysis NN N
was VBD N
per IN N
protocol NN N
. . N

This DT N
trial NN N
is VBZ N
registered VBN N
, , N
number NN N
NCT00332007 NNP N
. . N

FINDINGS NNP N
39 CD 3_p
patients NNS N
were VBD N
included VBN N
in IN N
the DT N
study NN N
, , N
of IN N
whom WP N
31 CD 3_p
were VBD N
included VBN N
in IN N
the DT N
statistical JJ N
analysis NN N
of IN N
efficacy NN N
. . N

Median JJ N
( ( N
IQR NNP N
) ) N
attacks NNS N
of IN N
aura NN N
were VBD N
reduced VBN N
from IN N
3.2 CD N
( ( N
1.0-5.0 JJ N
) ) N
per IN N
12 CD N
weeks NNS N
on IN N
placebo NN N
to TO N
1.0 CD N
( ( N
0-3.0 CD N
) ) N
on IN N
tonabersat NN N
( ( N
p=0.01 NN N
) ) N
, , N
whereas VBP N
the DT N
other JJ N
primary JJ N
outcome JJ N
measure NN N
, , N
median JJ N
migraine NN N
headache NN N
days NNS N
with IN N
or CC N
without IN N
aura NN N
, , N
was VBD N
not RB N
significantly RB N
different JJ N
between IN N
placebo NN N
and CC N
tonabersat NN N
groups NNS N
( ( N
3.0 CD N
days NNS N
in IN N
each DT N
group NN N
; : N
p=0.09 NN N
) ) N
. . N

Tonabersat NNP N
was VBD N
well RB N
tolerated VBN N
but CC N
overall JJ N
had VBD N
more RBR N
side-effects NNS N
than IN N
placebo NN N
. . N

INTERPRETATION NNP N
Tonabersat NNP N
showed VBD N
a DT N
preventive JJ N
effect NN N
on IN N
attacks NNS N
of IN N
migraine NN N
aura NN N
but CC N
no DT N
efficacy NN N
on IN N
non-aura JJ N
attacks NNS N
, , N
in IN N
keeping VBG N
with IN N
its PRP$ N
known JJ N
inhibitory JJ N
effect NN N
on IN N
CSD NNP N
. . N

The DT N
results NNS N
support VBD N
the DT N
theory NN N
that IN N
auras NNS N
are VBP N
caused VBN N
by IN N
CSD NNP N
and CC N
that IN N
this DT N
phenomenon NN N
is VBZ N
not RB N
involved VBN N
in IN N
attacks NNS N
without IN N
aura NN N
. . N

FUNDING NN N
Minster NNP N
Pharmaceuticals NNP N
; : N
Lundbeck NNP N
Foundation NNP N
. . N

-DOCSTART- -X- O O

Optimization NN N
of IN N
acid JJ N
suppression NN N
for IN N
patients NNS N
with IN N
peptic JJ 4_p
ulcer NN 4_p
bleeding NN 4_p
: : N
an DT N
intragastric JJ N
pH-metry NN N
study NN N
with IN N
omeprazole NN N
. . N

OBJECTIVE UH N
To TO N
study VB N
whether IN N
an DT N
intravenous JJ N
infusion NN N
dose NN N
of IN N
omeprazole NN N
( ( N
80 CD N
mg NN N
+ VBD N
8 CD N
mg/h NN N
) ) N
during IN N
24 CD N
h NNS N
can MD N
be VB N
subsequently RB N
reduced VBN N
with IN N
maintained JJ N
effect NN N
. . N

Second NNP N
, , N
to TO N
study VB N
the DT N
effect NN N
of IN N
oral JJ N
omeprazole JJ N
20 CD N
mg NN N
given VBN N
once RB N
or CC N
twice RB N
daily RB N
up IN N
to TO N
day NN N
10 CD N
, , N
after IN N
cessation NN N
of IN N
a DT N
3-day JJ N
intravenous JJ N
infusion NN N
( ( N
80 CD N
mg NN N
+ VBD N
8 CD N
mg/h NN N
) ) N
. . N

DESIGN NNP N
Prospective NNP N
, , N
randomized VBD N
, , N
partly RB N
blinded VBD N
study NN N
. . N

METHODS NNP N
Twelve NNP 3_p
Helicobacter NNP 4_p
pylori NN 4_p
( ( 4_p
+ NNP 4_p
) ) 4_p
patients NNS 4_p
and CC N
12 CD 3_p
H. NNP 4_p
pylori NN 4_p
( ( 4_p
- : 4_p
) ) 4_p
subjects NNS N
were VBD N
included VBN N
. . N

In IN N
part NN N
I PRP N
the DT N
patients NNS N
received VBD N
omeprazole JJ N
, , N
80 CD N
mg NN N
+ VBD N
8 CD N
mg/h NN N
, , N
during IN N
24 CD N
h NN N
followed VBN N
by IN N
8 CD N
, , N
4 CD N
or CC N
2 CD N
mg/h NN N
. . N

In IN N
part NN N
II NNP N
the DT N
subjects NNS N
received VBD N
80 CD N
mg NNS N
+ VBD N
8 CD N
mg/h NN N
during IN N
3 CD N
days NNS N
followed VBN N
by IN N
20 CD N
mg NNS N
omeprazole JJ N
orally RB N
, , N
once RB N
or CC N
twice JJ N
daily JJ N
until IN N
day NN N
10 CD N
. . N

Intragastric NNP N
pH NN N
was VBD N
measured VBN N
. . N

RESULTS NNP N
All NNP N
H. NNP N
pylori FW N
( ( N
+ NN N
) ) N
patients NNS N
showed VBD N
a DT N
rapid JJ N
increase NN N
of IN N
intragastric JJ N
pH NN N
with IN N
a DT N
mean JJ N
intragastric JJ N
pH NN N
of IN N
6.7 CD N
during IN N
the DT N
second JJ N
half NN N
of IN N
the DT N
first JJ N
day NN N
. . N

After IN N
the DT N
subsequent JJ N
dose NN N
reduction NN N
, , N
the DT N
mean JJ N
pH NN N
decreased VBD N
to TO N
6.1-6.2 JJ N
. . N

Patients NNPS N
continuing VBG N
on IN N
8 CD N
mg/h NN N
showed VBD N
the DT N
best JJS N
results NNS N
. . N

Likewise NNP N
, , N
all DT N
H. NNP N
pylori NN N
( ( N
- : N
) ) N
subjects VBZ N
showed VBD N
a DT N
rapid JJ N
and CC N
sustained JJ N
reduction NN N
of IN N
intragastric JJ N
acidity NN N
during IN N
the DT N
infusion NN N
. . N

Subsequent NNP N
dose JJ N
reduction NN N
to TO N
20 CD N
mg NNS N
once RB N
daily RB N
led VBN N
to TO N
a DT N
stable JJ N
fraction NN N
of IN N
time NN N
with IN N
pH JJ N
> JJ N
3 CD N
of IN N
72 CD N
% NN N
. . N

CONCLUSIONS NNP N
Omeprazole NNP N
given VBN N
as IN N
a DT N
continuous JJ N
infusion NN N
of IN N
80 CD N
mg NNS N
+ VBD N
8 CD N
mg/h NN N
for IN N
72 CD N
h NN N
followed VBN N
by IN N
omeprazole JJ N
20 CD N
mg NN N
once RB N
daily RB N
raised VBD N
the DT N
intragastric JJ N
pH NN N
to TO N
and CC N
above JJ N
levels NNS N
alleged VBN N
to TO N
allow VB N
haemostasis NN N
in IN N
patients NNS N
with IN N
peptic JJ 4_p
ulcer NN 4_p
bleeding NN 4_p
and CC N
subsequent JJ N
healing NN N
of IN N
the DT N
ulcer NN N
. . N

-DOCSTART- -X- O O

In-hospital JJ N
costs NNS N
of IN N
self-expanding JJ N
nitinol JJ N
stent NN N
implantation NN N
versus NN N
balloon NN N
angioplasty NN N
in IN N
the DT N
femoropopliteal JJ N
artery NN N
( ( N
the DT N
VascuCoil NNP N
Trial NNP N
) ) N
. . N

PURPOSE NNP N
Although IN N
several JJ N
prospective JJ N
studies NNS N
have VBP N
examined VBN N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
stent JJ N
placement NN N
for IN N
femoropopliteal JJ 4_p
arterial JJ 4_p
disease NN 4_p
, , N
the DT N
current JJ N
cost NN N
of IN N
these DT N
procedures NNS N
is VBZ N
unknown JJ N
. . N

To TO N
estimate VB N
and CC N
compare VB N
hospital NN N
costs NNS N
associated VBN N
with IN N
conventional JJ N
balloon NN N
angioplasty NN N
( ( N
percutaneous JJ N
transluminal NN N
angioplasty NN N
[ NNP N
PTA NNP N
] NNP N
) ) N
and CC N
stent JJ N
placement NN N
for IN N
patients NNS N
with IN N
symptomatic JJ N
peripheral JJ N
arterial JJ N
disease NN N
, , N
the DT N
authors NNS N
performed VBD N
a DT N
prospective JJ N
economic JJ N
evaluation NN N
in IN N
conjunction NN N
with IN N
the DT N
Intracoil NNP N
Femoropopliteal NNP N
Stent NNP N
Trial NNP N
( ( N
VascuCoil NNP N
) ) N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
Between NNP N
May NNP N
1997 CD N
and CC N
December NNP N
1999 CD N
, , N
266 CD 3_p
patients NNS N
with IN N
stenotic JJ 4_p
or CC 4_p
occluded VBN 4_p
superficial JJ 4_p
femoral JJ 4_p
or CC 4_p
popliteal JJ 4_p
arteries NNS 4_p
were VBD N
prospectively RB N
randomized VBN N
to TO N
treatment NN N
with IN N
the DT N
IntraCoil NNP N
stent NN N
or CC N
PTA NNP N
. . N

Detailed NNP N
resource NN N
use NN N
and CC N
cost NN N
data NNS N
for IN N
each DT N
patient NN N
's POS N
initial JJ N
revascularization NN N
procedure NN N
and CC N
ensuing VBG N
hospitalization NN N
were VBD N
collected VBN N
and CC N
analyzed VBN N
on IN N
an DT N
intention-to-treat JJ N
basis NN N
. . N

RESULTS NNP N
Compared VBD N
with IN N
conventional JJ N
balloon NN N
angioplasty NN N
, , N
stent JJ N
placement NN N
did VBD N
not RB N
improve VB N
clinical JJ N
outcomes NNS N
but CC N
increased JJ N
procedure NN N
duration NN N
, , N
equipment NN N
costs NNS N
, , N
and CC N
physician JJ N
services NNS N
. . N

As IN N
a DT N
result NN N
, , N
initial JJ N
hospital NN N
costs NNS N
were VBD N
approximately RB N
3,500 CD N
dollars NNS N
higher JJR N
for IN N
patients NNS N
randomized VBN N
to TO N
the DT N
IntraCoil NNP N
stent NN N
, , N
compared VBN N
with IN N
PTA NNP N
( ( N
8,435 CD N
dollars NNS N
vs RB N
4,980 CD N
dollars NNS N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

CONCLUSIONS NNP N
As IN N
performed VBN N
in IN N
the DT N
VascuCoil NNP N
trial NN N
, , N
primary JJ N
stent NN N
placement NN N
for IN N
femoropopliteal JJ N
disease NN N
did VBD N
not RB N
improve VB N
clinical JJ N
outcomes NNS N
but CC N
increased VBD N
initial JJ N
treatment NN N
costs NNS N
by IN N
more JJR N
than IN N
3,000 CD N
dollars NNS N
. . N

Because IN N
there EX N
were VBD N
no DT N
substantial JJ N
differences NNS N
in IN N
subsequent JJ N
clinical JJ N
outcomes NNS N
between IN N
the DT N
two CD N
treatments NNS N
, , N
it PRP N
is VBZ N
unlikely JJ N
that IN N
these DT N
increased VBN N
initial JJ N
costs NNS N
would MD N
be VB N
offset VBN N
by IN N
savings NNS N
in IN N
follow-up JJ N
costs NNS N
. . N

These DT N
findings NNS N
suggest VBP N
that IN N
a DT N
strategy NN N
of IN N
routine JJ N
stent NN N
implantation NN N
for IN N
patients NNS N
undergoing VBG N
femoropopliteal JJ 4_p
PTA NNP 4_p
is VBZ N
not RB N
optimal JJ N
on IN N
economic JJ N
grounds NNS N
and CC N
that DT N
PTA NNP N
with IN N
provisional JJ N
stent JJ N
implantation NN N
is VBZ N
preferred VBN N
. . N

-DOCSTART- -X- O O

Treatment NN N
of IN N
adults NNS 1_p
with IN N
acute JJ 4_p
lymphoblastic JJ 4_p
leukemia NN 4_p
: : N
do VB N
the DT N
specifics NNS N
of IN N
the DT N
regimen NNS N
matter NN N
? . N
: : N
Results NNS N
from IN N
a DT N
prospective JJ N
randomized VBN N
trial NN N
. . N

BACKGROUND NNP N
Induction NNP N
therapy NN N
for IN N
adults NNS 1_p
with IN N
acute JJ 4_p
lymphoblastic JJ 4_p
leukemia NN 4_p
( ( N
ALL DT 4_p
) ) N
is VBZ N
similar JJ N
across IN N
essentially RB N
all DT N
regimens NNS N
, , N
comprised VBN N
of IN N
vincristine NN N
, , N
corticosteroids NNS N
, , N
and CC N
anthracyclines NNS N
intensified VBN N
with IN N
cyclophosphamide NN N
, , N
asparaginase NN N
, , N
or CC N
both DT N
. . N

Given VBN N
the DT N
lack NN N
of IN N
randomized VBN N
data NNS N
, , N
to TO N
date NN N
, , N
no DT N
regimen NN N
has VBZ N
emerged VBN N
as IN N
standard NN N
. . N

The DT N
authors NNS N
previously RB N
evaluated VBD N
cytarabine JJ N
3 CD N
g/m NN N
( ( N
2 CD N
) ) N
daily RB N
for IN N
5 CD N
days NNS N
with IN N
mitoxantrone NN N
80 CD N
mg/m NN N
( ( N
2 CD N
) ) N
( ( N
the DT N
ALL-2 NNP N
regimen NNS N
) ) N
as IN N
a DT N
novel JJ N
induction NN N
regimen NNS N
. . N

Compared VBN N
with IN N
historic JJ N
controls NNS N
, , N
the DT N
ALL-2 NNP N
regimen NN N
was VBD N
superior JJ N
in IN N
terms NNS N
of IN N
incidence NN N
of IN N
complete JJ N
remission NN N
, , N
failure NN N
with IN N
resistant JJ N
disease NN N
, , N
and CC N
activity NN N
in IN N
patients NNS N
with IN N
Philadelphia NNP 4_p
chromosome NN 4_p
( ( 4_p
Ph NNP 4_p
) ) 4_p
-positive VBP 4_p
ALL NNP N
. . N

METHODS NNP N
The DT N
authors NNS N
conducted VBD N
a DT N
multicenter NN N
, , N
prospective JJ N
, , N
randomized JJ N
trial NN N
of IN N
the DT N
ALL-2 NNP N
regimen NNS N
compared VBN N
with IN N
a DT N
standard JJ N
4-drug JJ N
induction NN N
( ( N
the DT N
L-20 NNP N
regimen NNS N
) ) N
. . N

Patients NNS N
also RB N
received VBD N
consolidation NN N
, , N
maintenance NN N
therapy NN N
, , N
and CC N
central JJ N
nervous JJ N
system NN N
prophylaxis NN N
. . N

The DT N
trial NN N
accrued VBD N
patients NNS N
from IN N
August NNP N
1996 CD N
to TO N
October NNP N
2004 CD N
. . N

RESULTS VB N
The DT N
median JJ N
follow-up NN N
for IN N
survivors NNS N
was VBD N
7 CD N
years NNS N
, , N
and CC N
the DT N
median JJ N
patient NN N
age NN N
was VBD N
43 CD 1_p
years NNS N
. . N

Responses NNS N
were VBD N
evaluated VBN N
in IN N
164 CD 3_p
patients NNS N
. . N

The DT N
treatment NN N
arms NNS N
were VBD N
balanced VBN N
in IN N
terms NNS N
of IN N
pretreatment NN N
characteristics NNS N
. . N

The DT N
frequency NN N
of IN N
complete JJ N
remission NN N
for IN N
the DT N
ALL-2 NNP N
regimen NNS N
versus IN N
the DT N
L-20 JJ N
regimen NN N
was VBD N
83 CD N
% NN N
versus IN N
71 CD N
% NN N
( ( N
P NNP N
= NNP N
.06 NNP N
) ) N
. . N

More JJR N
patients NNS N
on IN N
the DT N
L-20 NNP N
arm NN N
failed VBD N
with IN N
resistant JJ N
disease NN N
( ( N
21 CD N
% NN N
vs JJ N
8 CD N
% NN N
; : N
P NNP N
= NNP N
.02 NNP N
) ) N
. . N

Induction NNP N
deaths NNS N
were VBD N
comparable JJ N
at IN N
9 CD N
% NN N
( ( N
ALL-2 NNP N
) ) N
versus VBD N
7 CD N
% NN N
( ( N
L-20 NNP N
) ) N
. . N

The DT N
median JJ N
survival NN N
was VBD N
similar JJ N
; : N
and CC N
, , N
at IN N
5 CD N
years NNS N
, , N
the DT N
survival NN N
rate NN N
was VBD N
33 CD N
% NN N
alive JJ N
on IN N
the DT N
ALL-2 NNP N
arm NN N
versus NN N
27 CD N
% NN N
on IN N
the DT N
L-20 NNP N
. . N

CONCLUSIONS NNP N
Despite IN N
superior JJ N
results NNS N
of IN N
induction NN N
therapy NN N
with IN N
the DT N
ALL-2 NNP N
regimen NNS N
, , N
this DT N
treatment NN N
did VBD N
not RB N
improve VB N
long-term JJ N
outcomes NNS N
. . N

When WRB N
coupled VBN N
to TO N
the DT N
reported VBN N
experience NN N
of IN N
other JJ N
studies NNS N
in IN N
adults NNS N
with IN N
ALL NNP N
, , N
the DT N
results NNS N
of IN N
this DT N
randomized VBN N
trial NN N
raise NN N
the DT N
possibility NN N
that WDT N
ultimate JJ N
outcomes NNS N
in IN N
adult NN N
ALL NNP N
may MD N
be VB N
independent JJ N
of IN N
the DT N
specific JJ N
regimen NNS N
chosen VBN N
. . N

Cancer NN N
2013 CD N
. . N

? . N
2012 CD N
American JJ N
Cancer NNP N
Society NNP N
. . N

-DOCSTART- -X- O O

Short-term JJ N
studies NNS N
on IN N
the DT N
use NN N
of IN N
glycerol NN N
as IN N
an DT N
osmotic JJ N
agent NN N
in IN N
continuous JJ 4_p
ambulatory JJ 4_p
peritoneal JJ 4_p
dialysis NN 4_p
( ( N
CAPD NNP 4_p
) ) N
. . N

The DT N
use NN N
of IN N
glycerol NN N
as IN N
an DT N
osmotic JJ N
agent NN N
in IN N
two CD N
different JJ N
concentrations NNS N
( ( N
92 CD N
mmol/l NN N
and CC N
272 CD N
mmol/l NN N
) ) N
in IN N
peritoneal JJ N
dialysis NN N
fluid NN N
was VBD N
investigated VBN N
over IN N
3 CD N
days NNS N
in IN N
six CD 3_p
patients NNS N
on IN N
continuous JJ 4_p
ambulatory JJ 4_p
peritoneal JJ 4_p
dialysis NN 4_p
and CC N
compared VBN N
with IN N
two CD N
concentrations NNS N
of IN N
glucose NN N
( ( N
76 CD N
mmol/l NN N
and CC N
215 CD N
mmol/l NN N
) ) N
in IN N
the DT N
same JJ N
patients NNS N
. . N

The DT N
calorific JJ N
value NN N
of IN N
the DT N
absorbed JJ N
osmotic JJ N
agent NN N
was VBD N
lower JJR N
, , N
by IN N
19 CD N
% NN N
with IN N
isotonic JJ N
and CC N
22 CD N
% NN N
with IN N
hypertonic JJ N
solutions NNS N
, , N
when WRB N
glycerol NN N
was VBD N
used VBN N
in IN N
place NN N
of IN N
glucose NN N
. . N

However RB N
, , N
glycerol NN N
provided VBD N
significantly RB N
lower JJR N
total JJ N
ultrafiltration NN N
than IN N
glucose NN N
at IN N
each DT N
concentration NN N
, , N
despite IN N
a DT N
higher JJR N
initial JJ N
osmotic JJ N
pressure NN N
of IN N
the DT N
glycerol-based JJ N
solutions NNS N
. . N

Thus RB N
, , N
the DT N
higher JJR N
concentration NN N
of IN N
glycerol NN N
required VBN N
to TO N
provide VB N
equal JJ N
ultrafiltration NN N
may MD N
offset VB N
any DT N
calorific JJ N
advantage NN N
. . N

Equilibration NN N
of IN N
creatinine NN N
and CC N
urea NN N
was VBD N
slower JJR N
and CC N
creatinine JJ N
clearance NN N
lower RBR N
with IN N
glycerol NN N
. . N

Solutions NNS N
containing VBG N
glycerol NN N
were VBD N
initially RB N
less JJR N
acid JJ N
( ( N
pH JJ N
6.5 CD N
) ) N
than IN N
those DT N
containing VBG N
glucose NN N
( ( N
pH JJ N
5.1 CD N
) ) N
. . N

Blood NNP N
glycerol NN N
levels NNS N
, , N
which WDT N
were VBD N
in IN N
the DT N
physiological JJ N
range NN N
with IN N
glucose NN N
as IN N
the DT N
osmotic JJ N
agent NN N
, , N
reached VBD N
a DT N
peak JJ N
80-fold JJ N
greater JJR N
at IN N
4.3 CD N
+/- JJ N
0.8 CD N
mmol/l NN N
during IN N
dialysis NN N
with IN N
fluid NN N
containing VBG N
glycerol NN N
at IN N
272 CD N
mmol/l NN N
and CC N
eightfold VB N
higher JJR N
at IN N
0.42 CD N
+/- JJ N
0.09 CD N
mmol/l NN N
with IN N
glycerol NN N
at IN N
92 CD N
mmol/l NN N
. . N

There EX N
was VBD N
no DT N
evidence NN N
of IN N
haemolysis NN N
or CC N
other JJ N
toxic JJ N
effect NN N
despite IN N
these DT N
levels NNS N
. . N

The DT N
rise NN N
in IN N
blood NN N
glucose NN N
and CC N
insulin NN N
noted VBD N
during IN N
the DT N
use NN N
of IN N
glucose-based JJ N
solutions NNS N
was VBD N
not RB N
found VBN N
with IN N
glycerol NN N
. . N

Circulating NNP N
levels NNS N
of IN N
lactate NN N
, , N
pyruvate NN N
, , N
alanine NN N
, , N
non-esterified JJ N
fatty JJ N
acids NNS N
and CC N
the DT N
ketone NN N
bodies NNS N
were VBD N
similar JJ N
with IN N
the DT N
two CD N
agents NNS N
. . N

Although IN N
these DT N
short-term JJ N
studies NNS N
have VBP N
shown VBN N
no DT N
conclusive JJ N
advantage NN N
of IN N
glycerol NN N
over IN N
glucose JJ N
, , N
long-term JJ N
effects NNS N
of IN N
glycerol NN N
, , N
particularly RB N
on IN N
circulating VBG N
lipid JJ N
levels NNS N
, , N
will MD N
determine VB N
its PRP$ N
future JJ N
role NN N
as IN N
an DT N
osmotic JJ N
agent NN N
in IN N
continuous JJ N
ambulatory JJ 4_p
peritoneal JJ 4_p
dialysis NN 4_p
. . N

-DOCSTART- -X- O O

A DT N
description NN N
of IN N
the DT N
clinical JJ N
characteristics NNS N
at IN N
baseline NN N
of IN N
patients NNS N
recruited VBN N
into IN N
the DT N
Carvedilol NNP N
or CC N
Metoprolol NNP N
European JJ N
Trial NNP N
( ( N
COMET NNP N
) ) N
. . N

BACKGROUND NNP N
& CC N
AIMS NNP N
The DT N
COMET NNP N
trial NN N
was VBD N
a DT N
prospective JJ N
, , N
double-blind JJ N
, , N
randomised JJ N
trial NN N
comparing VBG N
carvedilol NN N
, , N
a DT N
comprehensive JJ N
adrenergic NN N
receptor NN N
antagonist NN N
, , N
with IN N
metoprolol NN N
, , N
a DT N
beta-1-selective JJ N
agent NN N
in IN N
patients NNS N
with IN N
heart NN 4_p
failure NN 4_p
and CC N
left VBD 4_p
ventricular JJ 4_p
systolic JJ 4_p
dysfunction NN 4_p
. . N

The DT N
trial NN N
showed VBD N
a DT N
reduction NN N
in IN N
mortality NN N
with IN N
carvedilol NN N
that WDT N
was VBD N
consistent JJ N
across IN N
subgroups NNS N
. . N

The DT N
purpose NN N
of IN N
this DT N
report NN N
is VBZ N
to TO N
describe VB N
in IN N
greater JJR N
detail NN N
the DT N
heterogeneity NN N
of IN N
this DT N
population NN N
at IN N
baseline NN N
with IN N
particular JJ N
reference NN N
to TO N
the DT N
impact NN N
of IN N
symptomatic JJ N
severity NN N
, , N
age NN N
and CC N
gender NN N
on IN N
patient JJ N
characteristics NNS N
. . N

METHODS NNP N
A NNP N
descriptive JJ N
report NN N
using VBG N
data NNS N
entered VBN N
in IN N
the DT N
COMET NNP N
study NN N
data-base NN N
. . N

RESULTS VB N
The DT N
characteristics NNS N
of IN N
the DT N
population NN N
studied VBN N
were VBD N
similar JJ N
to TO N
those DT N
reported VBN N
in IN N
previous JJ N
trials NNS N
of IN N
beta-blockers NNS N
. . N

Almost NNP N
all DT N
patients NNS N
were VBD N
receiving VBG N
diuretics NNS N
and CC N
ACE NNP N
inhibitors NNS N
with IN N
few JJ N
patients NNS N
taking VBG N
angiotensin JJ N
receptor NN N
blockers NNS N
. . N

As IN N
expected VBN N
, , N
older JJR N
patients NNS N
had VBD N
more RBR N
co-morbidity JJ N
. . N

Older JJR N
patients NNS N
and CC N
women NNS N
reported VBD N
worse JJR N
symptoms NNS N
and CC N
poorer JJR N
well-being JJ N
despite IN N
similar JJ N
ventricular JJ N
dimensions NNS N
and CC N
systolic JJ N
dysfunction NN N
. . N

NT-proBNP NNP N
was VBD N
higher RBR N
in IN N
patients NNS N
with IN N
more RBR N
severe JJ N
symptoms NNS N
and CC N
older JJR N
patients NNS N
but CC N
not RB N
in IN N
women NNS N
, , N
although IN N
differences NNS N
in IN N
NT-proBNP NNP N
may MD N
have VB N
been VBN N
confounded VBN N
by IN N
differences NNS N
in IN N
renal JJ N
function NN N
. . N

CONCLUSION NNP N
Age NNP N
and CC N
gender NN N
, , N
as RB N
well RB N
as IN N
the DT N
severity NN N
of IN N
cardiac JJ N
dysfunction NN N
, , N
appear VBP N
to TO N
have VB N
an DT N
important JJ N
effect NN N
on IN N
the DT N
severity NN N
of IN N
heart NN N
failure NN N
symptoms NNS N
and CC N
patient JJ N
'well-being NN N
' POS N
. . N

This DT N
could MD N
have VB N
important JJ N
implications NNS N
for IN N
the DT N
relationship NN N
between IN N
symptoms NNS N
and CC N
prognosis NN N
and CC N
therefore RB N
the DT N
way NN N
in IN N
which WDT N
patients NNS N
are VBP N
selected VBN N
for IN N
clinical JJ N
trials NNS N
and CC N
the DT N
goals NNS N
of IN N
treatment NN N
. . N

This DT N
will MD N
be VB N
the DT N
subject NN N
of IN N
further JJ N
analyses NNS N
. . N

-DOCSTART- -X- O O

Codeine/acetaminophen NNP N
and CC N
hydrocodone/acetaminophen JJ N
combination NN N
tablets NNS N
for IN N
the DT N
management NN N
of IN N
chronic JJ 4_p
cancer NN 4_p
pain NN 4_p
in IN N
adults NNS 1_p
: : N
a DT N
23-day JJ N
, , N
prospective JJ N
, , N
double-blind JJ N
, , N
randomized VBN N
, , N
parallel-group JJ N
study NN N
. . N

BACKGROUND NNP N
Analgesics NNPS N
are VBP N
an DT N
essential JJ N
component NN N
of IN N
the DT N
treatment NN N
of IN N
cancer-associated JJ N
pain NN N
. . N

Pharmacologic NNP N
treatment NN N
is VBZ N
usually RB N
begun VBN N
with IN N
nonopioid JJ N
analgesics NNS N
, , N
most JJS N
frequently RB N
acetaminophen VBP N
. . N

If IN N
pain JJ N
relief NN N
is VBZ N
not RB N
achieved VBN N
, , N
the DT N
so-called JJ N
weak JJ N
opioids NNS N
, , N
such JJ N
as IN N
codeine NN N
and CC N
hydrocodone NN N
, , N
may MD N
be VB N
used VBN N
in IN N
combination NN N
with IN N
acetaminophen NN N
. . N

Adverse JJ N
effects NNS N
( ( N
AEs NNP N
) ) N
of IN N
the DT N
opioids NNS N
include VBP N
constipation NN N
, , N
somnolence NN N
, , N
nausea NN N
, , N
and CC N
vomiting VBG N
. . N

Based VBN N
on IN N
the DT N
results NNS N
of IN N
a DT N
literature NN N
search NN N
, , N
data NNS N
comparing VBG N
the DT N
effects NNS N
of IN N
the DT N
opioids NNS N
are VBP N
lacking VBG N
. . N

OBJECTIVE CC N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
analgesic JJ N
efficacy NN N
and CC N
tolerability NN N
of IN N
codeine NN N
phosphate NN N
versus IN N
hydrocodone NN N
bitartrate NN N
in IN N
combination NN N
with IN N
acetaminophen NN N
in IN N
the DT N
relief NN N
of IN N
cancer-related JJ N
pain NN N
. . N

METHODS NNP N
This DT N
23-day JJ N
, , N
prospective JJ N
, , N
double-blind JJ N
, , N
randomized VBN N
, , N
parallel-group JJ N
study NN N
was VBD N
conducted VBN N
at IN N
3 CD N
Colombian JJ N
centers NNS N
: : N
University NNP N
Libre NNP N
, , N
Social NNP N
Security NNP N
Institute NNP N
, , N
and CC N
General NNP N
Hospital NNP N
of IN N
Medell?n NNP N
, , N
Cali NNP N
, , N
Colombia NNP N
. . N

Outpatients NNS N
with IN N
cancer NN N
were VBD N
eligible JJ N
for IN N
the DT N
study NN N
if IN N
they PRP N
were VBD N
aged VBN N
> JJ N
-18 CD N
years NNS N
and CC N
had VBD N
chronic VBN N
( ( N
duration NN N
, , N
> NNP N
/= VBZ N
3 CD N
months NNS N
) ) N
moderate VBP N
to TO N
severe VB N
cancer-related JJ N
pain NN N
( ( N
score NN N
on IN N
10-cm JJ N
visual JJ N
analog NN N
scale NN N
[ NNP N
VAS NNP N
] NNP N
, , N
> VBD N
3 CD N
cm NN N
[ NN N
moderate JJ N
] NN N
; : N
score NN N
on IN N
a DT N
4-point JJ N
verbal JJ N
pain-intensity NN N
scale NN N
, , N
> VBZ N
1 CD N
[ NN N
moderate JJ N
] NN N
) ) N
. . N

Eligible JJ N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
1 CD N
tablet NN N
of IN N
codeine/acetaminophen NN N
( ( N
C/A NNP N
) ) N
30/500 CD N
mg NN N
or CC N
hydrocodone/acetaminophen NN N
( ( N
H/A NNP N
) ) N
5/500 CD N
mg NN N
PO NNP N
q4h NN N
( ( N
total JJ N
daily JJ N
doses NNS N
, , N
150/2500 CD N
and CC N
25/2500 CD N
mg NN N
, , N
respectively RB N
) ) N
for IN N
23 CD N
days NNS N
. . N

In IN N
both DT N
groups NNS N
, , N
if IN N
pain JJ N
intensity NN N
was VBD N
rated VBN N
as IN N
> JJ N
3 CD N
on IN N
the DT N
VAS NNP N
at IN N
week NN N
1 CD N
or CC N
2 CD N
, , N
the DT N
dosage NN N
was VBD N
doubled VBN N
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
the DT N
proportion NN N
of IN N
patients NNS N
who WP N
achieved VBD N
pain NN N
relief NN N
( ( N
defined VBN N
as IN N
a DT N
score NN N
of IN N
> $ N
1 CD N
on IN N
a DT N
5-point JJ N
verbal NN N
rating NN N
scale NN N
[ NNP N
VRS NNP N
] NNP N
( ( N
0 CD N
= NNP N
none NN N
; : N
1 CD N
= IN N
a DT N
little JJ N
; : N
2 CD N
= IN N
some DT N
; : N
3 CD N
= IN N
a DT N
lot NN N
; : N
and CC N
4 CD N
= NNP N
complete JJ N
) ) N
on IN N
study NN N
days NNS N
1 CD N
and CC N
2 CD N
and CC N
weeks NNS N
1 CD N
, , N
2 CD N
, , N
and CC N
3 CD N
. . N

The DT N
secondary JJ N
end NN N
point NN N
was VBD N
the DT N
proportion NN N
of IN N
patients NNS N
in IN N
whom WP N
pain NN N
was VBD N
decreased VBN N
( ( N
VAS NNP N
score RB N
, , N
< NNP N
- : N
3 CD N
cm NN N
) ) N
. . N

AEs $ N
were VBD N
self-reported VBN N
on IN N
a DT N
4-point JJ N
VRS NNP N
( ( N
0 CD N
= NNP N
absent NN N
; : N
1 CD N
= NNP N
mild NN N
; : N
2 CD N
= NN N
moderate NN N
; : N
and CC N
3 CD N
= NNP N
severe RB N
) ) N
. . N

RESULTS NNP N
Of IN N
the DT N
121 CD N
patients NNS N
who WP N
participated VBD N
, , N
59 CD N
received VBD N
C/A NNP N
and CC N
62 CD N
received VBD N
H/A NNP N
. . N

Of IN N
the DT N
total JJ N
number NN N
of IN N
cases NNS N
, , N
59 CD N
% NN N
were VBD N
aged VBN N
60 CD N
to TO N
89 CD N
years NNS N
, , N
and CC N
55 CD N
% NN N
were VBD N
men NNS N
. . N

At IN N
baseline NN N
, , N
88 CD N
% NN N
of IN N
the DT N
patients NNS N
described VBD N
their PRP$ N
pain NN N
intensity NN N
as IN N
moderate JJ N
; : N
12 CD N
% NN N
, , N
severe JJ N
. . N

Of IN N
the DT N
patients NNS N
who WP N
received VBD N
C/A NNP N
, , N
58 CD N
% NN N
responded VBD N
to TO N
the DT N
initial JJ N
dosage NN N
of IN N
150/2500 CD N
mg/d NN N
, , N
and CC N
8 CD N
% NN N
of IN N
the DT N
patients NNS N
responded VBD N
to TO N
the DT N
double JJ N
dosage NN N
; : N
34 CD N
% NN N
did VBD N
not RB N
experience VB N
pain NN N
relief NN N
. . N

In IN N
patients NNS N
with IN N
H/A NNP N
, , N
pain NN N
was VBD N
reported VBN N
as IN N
absent NN N
or CC N
mild NN N
in IN N
56 CD N
% NN N
of IN N
patients NNS N
at IN N
the DT N
starting VBG N
dosage NN N
of IN N
25/2500 CD N
mg/d NN N
; : N
an DT N
additional JJ N
15 CD N
% NN N
of IN N
the DT N
patients NNS N
responded VBD N
to TO N
the DT N
double JJ N
dosage NN N
; : N
the DT N
remaining VBG N
29 CD N
% NN N
of IN N
patients NNS N
did VBD N
not RB N
experience VB N
any DT N
pain NN N
relief NN N
. . N

None NN N
of IN N
the DT N
between-group JJ N
differences NNS N
in IN N
response NN N
rates NNS N
were VBD N
significant JJ N
. . N

The DT N
most RBS N
common JJ N
AEs NNP N
in IN N
the DT N
C/A NNP N
and CC N
H/A NNP N
groups NNS N
were VBD N
constipation NN N
( ( N
36 CD N
% NN N
and CC N
29 CD N
% NN N
, , N
respectively RB N
) ) N
, , N
dizziness NN N
( ( N
24 CD N
% NN N
and CC N
19 CD N
% NN N
) ) N
, , N
vomiting VBG N
( ( N
24 CD N
% NN N
and CC N
16 CD N
% NN N
) ) N
, , N
and CC N
dry JJ N
mouth NN N
( ( N
15 CD N
% NN N
and CC N
18 CD N
% NN N
) ) N
, , N
with IN N
no DT N
significant JJ N
differences NNS N
between IN N
groups NNS N
. . N

CONCLUSION NNP N
In IN N
this DT N
study NN N
, , N
efficacy NN N
and CC N
tolerability NN N
were VBD N
comparable JJ N
between IN N
C/A NNP N
and CC N
H/A NNP N
over IN N
23 CD N
days NNS N
of IN N
treatment NN N
in IN N
these DT N
patients NNS N
with IN N
moderate JJ N
or CC N
severe JJ N
, , N
chronic JJ N
, , N
cancer-related JJ N
pain NN N
. . N

-DOCSTART- -X- O O

Late JJ N
patient-reported JJ N
toxicity NN N
after IN N
preoperative JJ N
radiotherapy NN N
or CC N
chemoradiotherapy NN N
in IN N
nonresectable JJ 4_p
rectal JJ 4_p
cancer NN 4_p
: : N
results NNS N
from IN N
a DT N
randomized JJ N
Phase NNP N
III NNP N
study NN N
. . N

PURPOSE NNP N
Preoperative NNP N
chemoradiotherapy NN N
( ( N
CRT NNP N
) ) N
is VBZ N
superior JJ N
to TO N
radiotherapy VB N
( ( N
RT NNP N
) ) N
in IN N
locally RB 4_p
advanced JJ 4_p
rectal JJ 4_p
cancer NN 4_p
, , N
but CC N
the DT N
survival JJ N
gain NN N
is VBZ N
limited JJ N
. . N

Late JJ N
toxicity NN N
is VBZ N
, , N
therefore RB N
, , N
important JJ N
. . N

The DT N
aim NN N
was VBD N
to TO N
compare VB N
late JJ N
bowel NN N
, , N
urinary JJ N
, , N
and CC N
sexual JJ N
functions NNS N
after IN N
CRT NNP N
or CC N
RT NNP N
. . N

METHODS NNP N
AND CC N
MATERIALS NNP N
Patients NNP N
( ( N
N NNP N
= NNP N
207 CD N
) ) N
with IN N
nonresectable JJ N
rectal JJ N
cancer NN N
were VBD N
randomized VBN N
to TO N
preoperative VB N
CRT NNP N
or CC N
RT NNP N
( ( N
2 CD N
Gy NNP N
? . N
25 CD N
? . N
5-fluorouracil/leucovorin JJ N
) ) N
. . N

Extended VBN N
surgery NN N
was VBD N
often RB N
required VBN N
. . N

Self-reported JJ N
late JJ N
toxicity NN N
was VBD N
scored VBN N
according VBG N
to TO N
the DT N
LENT NNP N
SOMA NNP N
criteria NNS N
in IN N
a DT N
structured JJ N
telephone NN N
interview NN N
and CC N
with IN N
questionnaires NNS N
European JJ N
Organisation NNP N
for IN N
Research NNP N
and CC N
Treatment NNP N
of IN N
Cancer NNP N
( ( N
EORTC NNP N
) ) N
Quality NN N
of IN N
Life NNP N
Questionnaire NNP N
( ( N
QLQ-C30 NNP N
) ) N
, , N
International NNP N
Index NNP N
of IN N
Erectile NNP N
Function NNP N
( ( N
IIEF NNP N
) ) N
, , N
and CC N
sexual JJ N
function-vaginal JJ N
changes NNS N
questionnaire VBP N
( ( N
SVQ NNP N
) ) N
. . N

RESULTS NNP N
Of IN N
the DT N
105 CD N
patients NNS N
alive JJ N
in IN N
Norway NNP N
and CC N
Sweden NNP N
after IN N
4 CD N
to TO N
12 CD N
years NNS N
of IN N
follow-up NN N
, , N
78 CD N
( ( N
74 CD N
% NN N
) ) N
responded VBD N
. . N

More JJR N
patients NNS N
in IN N
the DT N
CRT NNP N
group NN N
had VBD N
received VBN N
a DT N
stoma NN N
( ( N
73 CD N
% NN N
vs. FW N
52 CD N
% NN N
, , N
p NN N
= NNP N
0.09 CD N
) ) N
. . N

Most JJS N
patients NNS N
without IN N
a DT N
stoma NN N
( ( N
7 CD N
of IN N
12 CD N
in IN N
CRT NNP N
group NN N
and CC N
9 CD N
of IN N
16 CD N
in IN N
RT NNP N
group NN N
) ) N
had VBD N
incontinence NN N
for IN N
liquid NN N
stools NNS N
or CC N
gas NN N
. . N

No DT N
stoma NN N
and CC N
good JJ N
anal JJ N
function NN N
were VBD N
seen VBN N
in IN N
5 CD N
patients NNS N
( ( N
11 CD N
% NN N
) ) N
in IN N
the DT N
CRT NNP N
group NN N
and CC N
in IN N
11 CD N
( ( N
30 CD N
% NN N
) ) N
in IN N
the DT N
RT NNP N
group NN N
( ( N
p JJ N
= NNP N
0.046 CD N
) ) N
. . N

Of IN N
44 CD N
patients NNS N
in IN N
the DT N
CRT NNP N
group NN N
, , N
12 CD N
( ( N
28 CD N
% NN N
) ) N
had VBD N
had VBN N
bowel VBN N
obstruction NN N
compared VBN N
with IN N
5 CD N
of IN N
33 CD N
( ( N
15 CD N
% NN N
) ) N
in IN N
the DT N
RT NNP N
group NN N
( ( N
p JJ N
= NNP N
0.27 CD N
) ) N
. . N

One-quarter NN N
of IN N
the DT N
patients NNS N
reported VBD N
urinary JJ N
incontinence NN N
. . N

The DT N
majority NN N
of IN N
men NNS N
had VBD N
severe JJ N
erectile JJ N
dysfunction NN N
. . N

Few JJ N
women NNS N
reported VBD N
sexual JJ N
activity NN N
during IN N
the DT N
previous JJ N
month NN N
. . N

However RB N
, , N
the DT N
majority NN N
did VBD N
not RB N
have VB N
concerns NNS N
about IN N
their PRP$ N
sex NN N
life NN N
. . N

CONCLUSIONS NNP N
Fecal NNP N
incontinence NN N
and CC N
erectile JJ N
dysfunction NN N
are VBP N
frequent JJ N
after IN N
combined JJ N
treatment NN N
for IN N
locally RB N
advanced JJ N
rectal JJ N
cancer NN N
. . N

There EX N
was VBD N
a DT N
clear JJ N
tendency NN N
for IN N
the DT N
problems NNS N
to TO N
be VB N
more JJR N
common JJ N
after IN N
CRT NNP N
than IN N
after IN N
RT NNP N
. . N

-DOCSTART- -X- O O

Niacin NNP N
revisited VBD N
. . N

A DT N
randomized JJ N
, , N
controlled JJ N
trial NN N
of IN N
wax-matrix JJ N
sustained-release JJ N
niacin NN N
in IN N
hypercholesterolemia NN 4_p
. . N

Two CD 3_p
hundred VBD 3_p
one CD 3_p
male NN 2_p
and CC 2_p
female JJ 2_p
subjects NNS N
, , N
aged VBD N
20 CD 1_p
to TO 1_p
70 CD 1_p
years NNS N
, , N
with IN N
elevated VBN 4_p
low-density NN 4_p
lipoprotein NN 4_p
cholesterol NN N
values NNS N
( ( N
in IN N
the DT N
75th CD 4_p
to TO 4_p
95th CD 4_p
percentiles NNS 4_p
) ) N
, , N
participated VBN N
in IN N
a DT N
randomized NN N
, , N
controlled VBN N
, , N
double-blind NN N
study NN N
using VBG N
a DT N
new JJ N
form NN N
of IN N
niacin NN N
( ( N
Enduracin NNP N
) ) N
, , N
which WDT N
employs VBZ N
a DT N
wax-matrix JJ N
vehicle NN N
for IN N
sustained JJ N
release NN N
. . N

Four CD N
niacin JJ N
treatment NN N
groups NNS N
( ( N
daily JJ N
doses NNS N
of IN N
2000 CD N
, , N
1500 CD N
, , N
1250 CD N
, , N
and CC N
1000 CD N
mg NN N
) ) N
were VBD N
compared VBN N
with IN N
placebo- JJ N
and CC N
diet-treated JJ N
controls NNS N
to TO N
determine VB N
side-effect JJ N
profile NN N
and CC N
optimal JJ N
range NN N
of IN N
efficacy NN N
. . N

The DT N
groups NNS N
given VBN N
2000 CD N
and CC N
1500 CD N
mg NN N
demonstrated VBD N
significant JJ N
reductions NNS N
in IN N
values NNS N
of IN N
low-density NN N
lipoprotein NN N
cholesterol NN N
( ( N
-26 CD N
% NN N
and CC N
-19.3 CD N
% NN N
, , N
respectively RB N
) ) N
, , N
total JJ N
cholesterol NN N
( ( N
-18.4 CD N
% NN N
and CC N
-13.3 NNP N
% NN N
) ) N
, , N
and CC N
total JJ N
cholesterol-high-density NN N
lipoprotein NN N
cholesterol NN N
ratio NN N
( ( N
-20.4 CD N
% NN N
and CC N
-19.4 CD N
% NN N
) ) N
when WRB N
compared VBN N
with IN N
diet- JJ N
and CC N
placebo-treated JJ N
controls NNS N
. . N

Smaller NN N
improvements NNS N
were VBD N
seen VBN N
in IN N
high-density NN N
lipoprotein NN N
cholesterol NN N
and CC N
triglyceride NN N
levels NNS N
. . N

Blood NNP N
chemistry NN N
monitoring NN N
indicated VBD N
that DT N
reduction NN N
in IN N
low-density NN N
lipoprotein NN N
cholesterol NN N
level NN N
strongly RB N
correlated VBN N
with IN N
an DT N
increase NN N
in IN N
baseline JJ N
levels NNS N
of IN N
some DT N
enzymes NNS N
for IN N
niacin-treated JJ N
subjects NNS N
. . N

The DT N
improved JJ N
side-effect JJ N
profile NN N
of IN N
the DT N
wax-matrix JJ N
form NN N
of IN N
niacin NN N
was VBD N
particularly RB N
notable JJ N
. . N

The DT N
dropout NN N
rate NN N
due JJ N
to TO N
side VB N
effects NNS N
was VBD N
only RB N
3.4 CD N
% NN N
and CC N
was VBD N
coupled VBN N
with IN N
good JJ N
medication NN N
compliance NN N
. . N

-DOCSTART- -X- O O

Ilioinguinal-iliohypogastric JJ N
nerve NN N
block NN N
within IN N
travenous JJ N
dexketoprofen NN N
improves VBZ N
postoperative JJ N
analgesia NN N
in IN N
abdominal JJ 4_p
hysterectomies NNS 4_p
. . N

BACKGROUND NNP N
AND NNP N
OBJECTIVE NNP N
In IN N
this DT N
study NN N
, , N
our PRP$ N
aim NN N
was VBD N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
intravenous JJ N
dexketoprofen NNS N
trometamol VBP N
with IN N
ilioinguinal JJ N
and CC N
iliohypogastric JJ N
nerve NN N
block NN N
on IN N
analgesic JJ N
quality NN N
and CC N
morphine NN N
consumption NN N
after IN N
total JJ 4_p
abdominal JJ 4_p
hysterectomy NN 4_p
operations NNS N
. . N

METHODS NNP N
We PRP N
conducted VBD N
this DT N
randomized VBN N
controlled VBD N
clinical JJ N
study NN N
on IN N
61 CD 3_p
patients NNS N
. . N

The DT N
study NN N
was VBD N
conducted VBN N
in IN N
the DT N
operation NN N
room NN N
, , N
post-anesthesia JJ N
care NN N
unit NN N
, , N
and CC N
inpatient JJ N
clinic NN N
. . N

We PRP N
randomly RB N
grouped VBD N
the DT N
61 CD N
patients NNS N
into IN N
control NN N
group NN N
( ( N
group NN N
C NNP N
) ) N
, , N
block NN N
group NN N
( ( N
group NN N
B NNP N
) ) N
and CC N
dexketoprofen-block JJ N
group NN N
( ( N
group NN N
DB NNP N
) ) N
. . N

Before IN N
the DT N
skin NN N
incision NN N
performed VBD N
after IN N
anesthesia JJ N
induction NN N
, , N
we PRP N
performed VBD N
ilioinguinal JJ N
iliohypogastric JJ N
block NN N
( ( N
group NN N
C NNP N
given VBN N
saline NN N
and CC N
group NN N
P NNP N
and CC N
DB NNP N
given VBN N
levobupivacaine NN N
) ) N
. . N

In IN N
contrast NN N
to TO N
group NN N
C NNP N
and CC N
B NNP N
, , N
group NN N
DB NNP N
was VBD N
given VBN N
dexketoprofen RB N
. . N

We PRP N
administered VBD N
morphine JJ N
analgesia NN N
to TO N
all DT N
patients NNS N
by IN N
patient-controlled JJ N
analgesia NN N
( ( N
PCA NNP N
) ) N
during IN N
the DT N
postoperative JJ N
24 CD N
hours NNS N
. . N

We PRP N
recorded VBD N
Visual NNP N
Analogue NNP N
Scale NNP N
( ( N
VAS NNP N
) ) N
, , N
satisfaction NN N
scores NNS N
, , N
morphine NN N
consumption NN N
and CC N
side NN N
effects NNS N
during IN N
postoperative JJ N
24 CD N
hours NNS N
. . N

RESULTS NNP N
We PRP N
found VBD N
the DT N
DB NNP N
group?s NN N
VAS NNP N
scores VBZ N
to TO N
be VB N
lower JJR N
than IN N
the DT N
control NN N
group NN N
and CC N
block NN N
group?s NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
values NNS N
at IN N
postoperative JJ N
1st CD N
, , N
2nd CD N
, , N
6th CD N
and CC N
12th CD N
hours NNS N
. . N

VAS NNP N
scores NNS N
of IN N
group NN N
C NNP N
were VBD N
higher JJR N
than IN N
of IN N
group NN N
B NNP N
at IN N
postoperative JJ N
fi NN N
rst VBD N
2 CD N
hours NNS N
. . N

Time NNP N
to TO N
fi VB N
rst JJ N
PCA NNP N
demand NN N
was VBD N
longer RBR N
, , N
morphine JJ N
consumption NN N
values NNS N
were VBD N
lower JJR N
and CC N
satisfaction NN N
scores NNS N
were VBD N
higher JJR N
in IN N
group NN N
DB NNP N
than IN N
in IN N
the DT N
other JJ N
two CD N
groups NNS N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS NNP N
Ilioinguinal-iliohypogastric JJ N
nerve NN N
block NN N
with IN N
IV NNP N
dexketoprofen NN N
increases NNS N
patient JJ N
satisfaction NN N
by IN N
decreasing VBG N
opioid JJ N
consumption NN N
, , N
increasing VBG N
patient JJ N
satisfaction NN N
, , N
which WDT N
suggests VBZ N
that IN N
dexketoprofen NN N
trometamol NN N
is VBZ N
an DT N
effective JJ N
non-steroidal JJ N
anti-inflammatory JJ N
analgesic NN N
in IN N
postoperative JJ N
analgesia NN N
. . N

-DOCSTART- -X- O O

Perioperative JJ N
myocardial JJ N
infarctions NNS N
are VBP N
common JJ N
and CC N
often RB N
unrecognized JJ N
in IN N
patients NNS N
undergoing VBG N
hip JJ 4_p
fracture NN 4_p
surgery NN 4_p
. . N

BACKGROUND IN N
The DT N
aim NN N
of IN N
this DT N
prospective JJ N
cohort NN N
study NN N
was VBD N
to TO N
assess VB N
the DT N
incidence NN N
and CC N
characteristics NNS N
of IN N
acute JJ N
myocardial JJ N
infarction NN N
in IN N
patients NNS N
undergoing JJ N
surgery NN 4_p
for IN N
acute JJ 4_p
hip NN 4_p
fracture NN 4_p
. . N

METHODS NNP N
A NNP N
consecutive JJ N
cohort NN N
of IN N
patients NNS N
( ( N
n JJ N
= NN N
200 CD 3_p
, , N
68 CD 3_p
men NNS 2_p
) ) N
referred VBD N
to TO N
acute VB 4_p
surgical JJ 4_p
correction NN N
of IN N
hip NN 4_p
fracture NN 4_p
was VBD N
studied VBN N
. . N

Troponin NNP N
T NNP N
( ( N
TnT NNP N
) ) N
measurements NNS N
and CC N
electrocardiographic JJ N
( ( N
ECG NNP N
) ) N
recordings NNS N
were VBD N
performed VBN N
at IN N
admission NN N
, , N
before IN N
operation NN N
, , N
and CC N
on IN N
the DT N
first JJ N
and CC N
2nd CD N
postoperative JJ N
days NNS N
, , N
which WDT N
were VBD N
used VBN N
for IN N
diagnosis NN N
. . N

RESULTS VB N
The DT N
age NN N
of IN N
the DT N
patients NNS N
ranged VBD N
from IN N
32 CD 1_p
to TO 1_p
98 CD 1_p
years NNS N
( ( N
mean NN N
, , N
80.8 CD 1_p
years NNS 1_p
) ) N
, , N
and CC N
65 CD 3_p
patients NNS N
had VBD N
a DT N
history NN N
of IN N
coronary JJ 4_p
artery NN 4_p
disease NN 4_p
. . N

A DT N
significant JJ N
rise NN N
in IN N
TnT NNP N
as IN N
a DT N
sign NN N
of IN N
myocardial JJ N
infarction NN N
was VBD N
observed VBN N
in IN N
71 CD N
patients NNS N
( ( N
35.5 CD N
% NN N
) ) N
, , N
and CC N
25 CD N
of IN N
them PRP N
had VBD N
a DT N
TnT NNP N
elevation NN N
exceeding VBG N
five CD N
times NNS N
the DT N
upper JJ N
normal JJ N
limit NN N
. . N

TnT NNP N
elevation NN N
was VBD N
observed VBN N
in IN N
36 CD N
patients NNS N
( ( N
51 CD N
% NN N
) ) N
already RB N
before RB N
surgery NN N
. . N

Seven CD N
patients NNS N
( ( N
10 CD N
% NN N
) ) N
had VBD N
ST NNP N
elevation NN N
myocardial JJ N
infarction NN N
, , N
23 CD N
patients NNS N
( ( N
32 CD N
% NN N
) ) N
had VBD N
new JJ N
ST NNP N
depressions NNS N
, , N
and CC N
21 CD N
patients NNS N
( ( N
30 CD N
% NN N
) ) N
had VBD N
no DT N
new JJ N
ST NNP N
segment NN N
changes NNS N
in IN N
the DT N
serial JJ N
electrocardiographic JJ N
recordings NNS N
. . N

In IN N
40 CD N
patients NNS N
( ( N
56 CD N
% NN N
) ) N
, , N
the DT N
perioperative JJ N
myocardial JJ N
infarction NN N
was VBD N
the DT N
first JJ N
manifestation NN N
of IN N
coronary JJ N
artery NN N
disease NN N
. . N

Multivariate NNP N
logistic JJ N
regression NN N
revealed VBD N
that IN N
old JJ N
age NN N
( ( N
odds NNS N
ratio VBP N
[ CD N
OR NNP N
] NNP N
, , N
1.06 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
1.02-1.10 JJ N
; : N
p VB N
= $ N
0.002 CD N
) ) N
, , N
earlier JJR N
revascularization NN N
( ( N
OR NNP N
, , N
3.29 CD N
; : N
95 CD N
% NN N
CI NNP N
1.12-9.73 CD N
; : N
p CC N
= VB N
0.03 CD N
) ) N
, , N
and CC N
heart NN N
failure NN N
( ( N
OR NNP N
, , N
2.42 CD N
; : N
95 CD N
% NN N
CI NNP N
1.04-5.61 CD N
; : N
p CC N
= VB N
0.04 CD N
) ) N
were VBD N
independent JJ N
predictors NNS N
of IN N
TnT NNP N
elevation NN N
. . N

Majority NNP N
of IN N
myocardial JJ N
infarctions NNS N
were VBD N
asymptomatic JJ N
or CC N
unrecognized JJ N
. . N

Evidence-based JJ N
medications NNS N
of IN N
myocardial JJ N
infarction NN N
were VBD N
seldom RB N
started VBN N
and CC N
cardiologist NN N
was VBD N
consulted VBN N
in IN N
12 CD N
patients NNS N
( ( N
16.9 CD N
% NN N
) ) N
. . N

CONCLUSION JJ N
Patients NNS N
with IN N
hip JJ N
fracture NN N
often RB N
develop VBZ N
asymptomatic JJ N
and CC N
clinically RB N
unrecognized JJ N
perioperative JJ N
myocardial JJ N
infarctions NNS N
. . N

Earlier JJR N
diagnosis NN N
and CC N
appropriate JJ N
treatment NN N
of IN N
cardiac JJ N
infarction NN N
may MD N
improve VB N
survival NN N
of IN N
hip NN N
fracture NN N
patients NNS N
. . N

LEVEL NNP N
OF IN N
EVIDENCE NNP N
Epidemiologic NNP N
study NN N
, , N
level NN N
III NNP N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
aliskiren NN N
on IN N
proteinuria NNS N
in IN N
non-diabetic JJ 4_p
chronic JJ 4_p
kidney NN 4_p
disease NN 4_p
: : N
a DT N
double-blind NN N
, , N
crossover NN N
, , N
randomised VBN N
, , N
controlled VBN N
trial NN N
. . N

AIM NNP N
To TO N
evaluate VB N
the DT N
proteinuria-lowering JJ N
effect NN N
of IN N
a DT N
renin NN N
inhibitor NN N
( ( N
aliskiren NN N
) ) N
, , N
compared VBN N
to TO N
placebo VB N
and CC N
to TO N
an DT N
angiotensin-converting JJ N
enzyme NN N
inhibitor NN N
( ( N
perindopril NN N
) ) N
, , N
in IN N
patients NNS N
with IN N
non-diabetic JJ N
chronic JJ N
kidney NN N
disease NN N
. . N

METHODS NNP N
A DT N
randomised JJ N
, , N
double-blind JJ N
, , N
crossover JJ N
trial NN N
was VBD N
performed VBN N
in IN N
14 CD N
patients NNS N
with IN N
nondiabetic JJ N
chronic JJ N
kidney NN N
disease NN N
with IN N
24-h JJ N
mean JJ N
proteinuria NN N
of IN N
2.01 CD N
g NN N
( ( N
95 CD N
% NN N
CI NNP N
, , N
1.36?2.66 CD N
) ) N
and CC N
estimated VBN N
creatinine JJ N
clearance NN N
of IN N
93?6.8 CD N
ml/min NN N
. . N

The DT N
study NN N
consisted VBD N
of IN N
five CD N
treatment NN N
periods NNS N
. . N

The DT N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
aliskiren NNS N
( ( N
150 CD N
mg NN N
) ) N
, , N
aliskiren RB N
( ( N
300 CD N
mg NN N
) ) N
, , N
perindopril NN N
( ( N
5 CD N
mg NN N
) ) N
, , N
perindopril NN N
( ( N
10 CD N
mg NN N
) ) N
or CC N
placebo NN N
. . N

RESULTS NNP N
Aliskiren NNP N
and CC N
perindopril NN N
reduced VBN N
proteinuria NN N
. . N

These DT N
effects NNS N
were VBD N
dose-dependent JJ N
. . N

Furthermore CD N
, , N
24-h JJ N
proteinuria NN N
was VBD N
reduced VBN N
by IN N
23 CD N
% NN N
( ( N
mean JJ N
95 CD N
% NN N
CI NNP N
; : N
2?44 CD N
) ) N
by IN N
treatment NN N
with IN N
aliskiren NNS N
( ( N
150 CD N
mg NN N
) ) N
, , N
by IN N
36 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
, , N
17?55 CD N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
with IN N
aliskiren NN N
( ( N
300 CD N
mg NN N
) ) N
, , N
by IN N
7.1 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
, , N
11?26 CD N
) ) N
with IN N
perindopril NN N
( ( N
5 CD N
mg NN N
) ) N
and CC N
by IN N
25 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
, , N
11?39 CD N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
with IN N
perindopril NN N
( ( N
10 CD N
mg NN N
) ) N
, , N
compared VBN N
to TO N
placebo VB N
. . N

No DT N
significant JJ N
difference NN N
was VBD N
found VBN N
between IN N
the DT N
effects NNS N
of IN N
aliskiren NNS N
and CC N
perindopril NN N
. . N

CONCLUSIONS NNP N
Aliskiren NNP N
significantly RB N
reduced VBD N
proteinuria NNS N
. . N

The DT N
antiproteinuric JJ N
effect NN N
is VBZ N
probably RB N
similar JJ N
to TO N
that DT N
of IN N
perindopril NN N
, , N
for IN N
equivalent JJ N
hypotensive JJ N
dosages NNS N
. . N

The DT N
renin JJ N
inhibitor NN N
provides VBZ N
a DT N
promising JJ N
alternative JJ N
approach NN N
for IN N
the DT N
treatment NN N
of IN N
patients NNS N
with IN N
chronic JJ N
proteinuric JJ N
non-diabetic JJ N
kidney NN N
disease NN N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
acute NN N
exercise NN N
on IN N
executive NN N
function NN N
in IN N
children NNS 1_p
with IN N
attention NN 4_p
deficit NN 4_p
hyperactivity NN 4_p
disorder NN 4_p
. . N

This DT N
study NN N
was VBD N
conducted VBN N
to TO N
determine VB N
the DT N
effect NN N
of IN N
acute NN N
aerobic JJ N
exercise NN N
on IN N
executive NN N
function NN N
in IN N
children NNS 1_p
with IN N
attention NN 4_p
deficit NN 4_p
hyperactivity NN 4_p
disorder NN 4_p
( ( N
ADHD NNP 4_p
) ) N
. . N

Forty NNP 3_p
children NNS 1_p
with IN N
ADHD NNP 4_p
were VBD N
randomly RB N
assigned VBN N
into IN N
exercise NN N
or CC N
control NN N
groups NNS N
. . N

Participants NNS N
in IN N
the DT N
exercise NN N
group NN N
performed VBD N
a DT N
moderate JJ N
intensity NN N
aerobic JJ N
exercise NN N
for IN N
30 CD N
min NN N
, , N
whereas IN N
the DT N
control NN N
group NN N
watched VBD N
a DT N
running/exercise-related JJ N
video NN N
. . N

Neuropsychological JJ N
tasks NNS N
, , N
the DT N
Stroop NNP N
Test NNP N
and CC N
the DT N
Wisconsin NNP N
Card NNP N
Sorting NNP N
Test NNP N
( ( N
WCST NNP N
) ) N
, , N
were VBD N
assessed VBN N
before IN N
and CC N
after IN N
each DT N
treatment NN N
. . N

The DT N
results NNS N
indicated VBD N
that IN N
acute JJ N
exercise NN N
facilitated VBN N
performance NN N
in IN N
the DT N
Stroop NNP N
Test NNP N
, , N
particularly RB N
in IN N
the DT N
Stroop NNP N
Color-Word NNP N
condition NN N
. . N

Additionally RB N
, , N
children NNS N
in IN N
the DT N
exercise NN N
group NN N
demonstrated VBD N
improvement NN N
in IN N
specific JJ N
WCST NNP N
performances NNS N
in IN N
Non-perseverative JJ N
Errors NNS N
and CC N
Categories NNP N
Completed NNP N
, , N
whereas VBZ N
no DT N
influences NNS N
were VBD N
found VBN N
in IN N
those DT N
performances NNS N
in IN N
the DT N
control NN N
group NN N
. . N

Tentative JJ N
explanations NNS N
for IN N
the DT N
exercise NN N
effect NN N
postulate NN N
that WDT N
exercise NN N
allocates VBZ N
attention NN N
resources NNS N
, , N
influences VBZ N
the DT N
dorsolateral JJ N
prefrontal NN N
cortex NN N
, , N
and CC N
is VBZ N
implicated VBN N
in IN N
exercise-induced JJ N
dopamine NN N
release NN N
. . N

These DT N
findings NNS N
are VBP N
promising VBG N
and CC N
additional JJ N
investigations NNS N
to TO N
explore VB N
the DT N
efficacy NN N
of IN N
exercise NN N
on IN N
executive NN N
function NN N
in IN N
children NNS N
with IN N
ADHD NNP N
are VBP N
encouraged VBN N
. . N

-DOCSTART- -X- O O

[ JJ N
Clinical NNP N
observation NN N
on IN N
different JJ N
acupuncture NN N
and CC N
moxibustion NN N
therapies NNS N
for IN N
treatment NN N
of IN N
postsurgical JJ 4_p
gastroparesis NN 4_p
syndrome NN 4_p
] NNP N
. . N

OBJECTIVE NNP N
To TO N
optimize VB N
therapy NN N
of IN N
acupuncture NN N
and CC N
moxibustion NN N
for IN N
postsurgical JJ N
gastroparesis NN N
syndrome NN N
( ( N
PGS NNP 4_p
) ) N
. . N

METHODS NNP N
Forty-one JJ 3_p
cases NNS N
of IN N
PGS NNP N
were VBD N
randomly RB N
divided VBN N
into IN N
3 CD N
groups NNS N
in IN N
order NN N
of IN N
visiting VBG N
. . N

Group NNP N
A NNP N
( ( N
n JJ N
= NNP N
17 CD 3_p
) ) N
were VBD N
treated VBN N
by IN N
warming VBG N
needle JJ N
moxibustion NN N
, , N
group NN N
B NNP N
( ( N
n JJ N
= NNP N
12 CD 3_p
) ) N
by IN N
acupuncture NN N
plus CC N
auricular JJ N
point NN N
sticking NN N
, , N
and CC N
group NN N
C NNP N
( ( N
n JJ N
= NNP N
12 CD 3_p
) ) N
by IN N
routine JJ N
acupuncture NN N
. . N

Changes NNS N
of IN N
gastric JJ N
drainage NN N
volume NN N
, , N
therapeutic JJ N
times NNS N
and CC N
cured JJ N
rate NN N
were VBD N
investigated VBN N
in IN N
the DT N
3 CD N
groups NNS N
. . N

RESULTS NNP N
All PDT N
the DT N
3 CD N
therapeutic JJ N
methods NNS N
could MD N
significantly RB N
decrease VB N
gastric JJ N
drainage NN N
volume NN N
. . N

The DT N
cured JJ N
rate NN N
was VBD N
100.0 CD N
% NN N
and CC N
the DT N
therapeutic JJ N
times NNS N
was VBD N
( ( N
7.24 CD N
+/- JJ N
3.87 CD N
) ) N
in IN N
the DT N
group NN N
A NNP N
, , N
66.7 CD N
% NN N
, , N
( ( N
9.83 CD N
+/- JJ N
4.60 CD N
) ) N
times NNS N
in IN N
the DT N
group NN N
B NNP N
and CC N
75.0 CD N
% NN N
, , N
( ( N
15.25 CD N
+/- JJ N
3.81 CD N
) ) N
times NNS N
in IN N
the DT N
group NN N
C NNP N
, , N
with IN N
significant JJ N
differences NNS N
in IN N
the DT N
cured JJ N
rate NN N
and CC N
the DT N
therapeutic JJ N
times NNS N
among IN N
the DT N
3 CD N
groups NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

CONCLUSION NNP N
The DT N
warming VBG N
needle JJ N
moxibustion NN N
is VBZ N
the DT N
best JJS N
method NN N
for IN N
PGS NNP N
, , N
with IN N
less RBR N
therapeutic JJ N
times NNS N
, , N
high JJ N
cured VBN N
rate NN N
and CC N
rapid JJ N
effect NN N
. . N

-DOCSTART- -X- O O

Pilot NNP N
study NN N
of IN N
imiquimod JJ N
5 CD N
% NN N
cream NN N
as IN N
adjunctive JJ N
therapy NN N
to TO N
curettage VB N
and CC N
electrodesiccation NN N
for IN N
nodular JJ 4_p
basal NN 4_p
cell NN 4_p
carcinoma NN 4_p
. . N

BACKGROUND NNP N
Curettage NNP N
and CC N
electrodesiccation NN N
( ( N
C NNP N
& CC N
D NNP N
) ) N
is VBZ N
a DT N
widely RB N
used VBN N
method NN N
to TO N
treat VB N
nodular JJ 4_p
basal NN 4_p
cell NN 4_p
carcinoma NN 4_p
( ( N
BCC NNP 4_p
) ) N
. . N

However RB N
, , N
residual JJ N
tumor NN N
is VBZ N
present JJ N
immediately RB N
after IN N
the DT N
procedure NN N
in IN N
approximately RB N
20 CD N
to TO N
40 CD N
% NN N
of IN N
cases NNS N
. . N

Imiquimod NNP N
, , N
a DT N
topical JJ N
immune NN N
response NN N
modifier NN N
that WDT N
targets VBZ N
Toll-like NNP N
receptor NN N
7 CD N
, , N
is VBZ N
currently RB N
approved VBN N
for IN N
superficial JJ N
BCC NNP N
. . N

OBJECTIVE NNP N
In IN N
a DT N
double-blind JJ N
, , N
vehicle-controlled JJ N
study NN N
, , N
the DT N
administration NN N
of IN N
imiquimod NN N
after IN N
C NNP N
& CC N
D NNP N
was VBD N
investigated VBN N
to TO N
determine VB N
if IN N
the DT N
combination NN N
regimen NNS N
would MD N
reduce VB N
the DT N
frequency NN N
of IN N
residual JJ N
tumor NN N
compared VBN N
with IN N
C NNP N
& CC N
D NNP N
alone RB N
in IN N
patients NNS N
with IN N
nodular JJ 4_p
BCC NNP 4_p
. . N

METHODS NNP N
Twenty NNP 3_p
patients NNS N
received VBD N
three CD N
cycles NNS N
of IN N
C NNP N
& CC N
D NNP N
followed VBN N
by IN N
imiquimod JJ N
5 CD N
% NN N
or CC N
vehicle NN N
cream NN N
once RB N
daily JJ N
for IN N
1 CD N
month NN N
as IN N
adjunctive JJ N
therapy NN N
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
the DT N
frequency NN N
of IN N
residual JJ N
tumor NN N
. . N

The DT N
secondary JJ N
end NN N
points NNS N
included VBD N
the DT N
time NN N
to TO N
heal VB N
and CC N
cosmetic JJ N
appearance NN N
. . N

RESULTS NNP N
Twenty NNP 3_p
patients NNS N
were VBD N
randomized VBN N
to TO N
the DT N
imiquimod NN N
( ( N
n JJ N
= NNP N
10 CD 3_p
) ) N
or CC N
vehicle NN N
( ( N
n JJ N
= NNP N
10 CD 3_p
) ) N
treatment NN N
group NN N
. . N

At IN N
8 CD N
weeks NNS N
, , N
the DT N
proportion NN N
of IN N
patients NNS N
with IN N
residual JJ N
tumor NN N
was VBD N
substantially RB N
decreased VBN N
with IN N
imiquimod JJ N
therapy NN N
( ( N
10 CD N
% NN N
) ) N
compared VBN N
with IN N
vehicle NN N
( ( N
40 CD N
% NN N
) ) N
. . N

Wounds VBZ N
in IN N
the DT N
vehicle NN N
group NN N
healed VBD N
more RBR N
quickly RB N
than IN N
those DT N
in IN N
the DT N
imiquimod NN N
group NN N
, , N
although IN N
by IN N
8 CD N
weeks NNS N
, , N
all DT N
excision NN N
sites NNS N
were VBD N
healed VBN N
. . N

The DT N
majority NN N
of IN N
scars NNS N
in IN N
the DT N
control NN N
group NN N
were VBD N
atrophic JJ N
and CC N
hypopigmented VBD N
, , N
whereas IN N
most JJS N
scars NNS N
in IN N
the DT N
imiquimod NN N
group NN N
were VBD N
flat JJ N
and CC N
slightly RB N
pink VBP N
. . N

CONCLUSION NNP N
Imiquimod NNP N
5 CD N
% NN N
cream NN N
once RB N
daily JJ N
for IN N
1 CD N
month NN N
as IN N
adjunctive JJ N
therapy NN N
after IN N
C NNP N
& CC N
D NNP N
substantially RB N
reduced VBD N
the DT N
frequency NN N
of IN N
residual JJ N
tumor NN N
and CC N
improved VBD N
the DT N
cosmetic JJ N
appearance NN N
compared VBN N
with IN N
C NNP N
& CC N
D NNP N
alone RB N
. . N

These DT N
preliminary JJ N
results NNS N
suggest VBP N
that IN N
further JJ N
studies NNS N
to TO N
investigate VB N
imiquimod JJ N
adjunctive JJ N
therapy NN N
are VBP N
warranted VBN N
. . N

-DOCSTART- -X- O O

Induction NNP N
chemotherapy NN N
in IN N
head NN 4_p
and CC 4_p
neck NN 4_p
cancer NN 4_p
: : N
results NNS N
of IN N
a DT N
phase NN N
III NNP N
trial NN N
. . N

Between IN N
December NNP N
1982 CD N
and CC N
October NNP N
1986 CD N
, , N
131 CD 3_p
patients NNS N
with IN N
stage JJ 4_p
II-III-IV NNP 4_p
squamous JJ 4_p
cell NN 4_p
carcinoma NN 4_p
of IN N
the DT N
oropharynx NN 4_p
or CC N
oral JJ 4_p
cavity NN 4_p
were VBD N
randomized VBN N
to TO N
induction VB N
chemotherapy NN N
, , N
consisting VBG N
of IN N
bleomycin NN N
( ( N
10 CD N
mg/m2/day NN N
in IN N
continuous JJ N
infusion NN N
from IN N
day NN N
1 CD N
to TO N
day NN N
5 CD N
) ) N
, , N
methotrexate NN N
( ( N
120 CD N
mg/m2 NN N
on IN N
day NN N
2 CD N
) ) N
followed VBN N
by IN N
folinic JJ N
acid NN N
, , N
5-fluorouracil JJ N
( ( N
5 CD N
FU NNP N
) ) N
( ( N
600 CD N
mg/m2 NN N
on IN N
day NN N
2 CD N
) ) N
, , N
and CC N
cisplatin NN N
( ( N
120 CD N
mg/m2 NN N
on IN N
day NN N
4 CD N
) ) N
every DT N
4 CD N
weeks NNS N
for IN N
a DT N
total NN N
of IN N
three CD N
cycles NNS N
followed VBN N
by IN N
definitive JJ N
locoregional JJ N
treatment NN N
versus IN N
locoregional JJ N
treatment NN N
alone RB N
. . N

The DT N
modalities NNS N
of IN N
definitive JJ N
treatment NN N
( ( N
radiotherapy JJ N
+/- JJ N
surgery NN N
) ) N
were VBD N
chosen VBN N
prior RB N
to TO N
randomization NN N
. . N

A DT N
total NN N
of IN N
116 CD 3_p
patients NNS N
were VBD N
evaluable JJ N
. . N

Of IN N
55 CD N
patients NNS N
in IN N
the DT N
chemotherapy NN N
arm NN N
, , N
four CD N
( ( N
7 CD N
% NN N
) ) N
had VBD N
a DT N
complete JJ N
response NN N
( ( N
CR NNP N
) ) N
and CC N
23 CD N
( ( N
42 CD N
% NN N
) ) N
a DT N
partial JJ N
response NN N
( ( N
PR NNP N
) ) N
following VBG N
the DT N
induction NN N
regimen NNS N
. . N

At IN N
the DT N
completion NN N
of IN N
locoregional JJ N
treatment NN N
, , N
76 CD N
% NN N
( ( N
42 CD N
of IN N
55 CD N
) ) N
of IN N
patients NNS N
in IN N
the DT N
experimental JJ N
group NN N
were VBD N
in IN N
CR NNP N
compared VBN N
to TO N
89 CD N
% NN N
( ( N
54 CD N
of IN N
61 CD N
) ) N
in IN N
the DT N
control NN N
group NN N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
survival NN N
, , N
cause-specific JJ N
survival NN N
, , N
and CC N
pattern NN N
of IN N
relapse NN N
between IN N
both DT N
groups NNS N
. . N

The DT N
median JJ N
survival NN N
was VBD N
22 CD N
months NNS N
in IN N
the DT N
chemotherapy NN N
group NN N
and CC N
29 CD N
months NNS N
in IN N
the DT N
control NN N
group NN N
. . N

Responders NNS N
to TO N
chemotherapy VB N
did VBD N
not RB N
fare VB N
better JJR N
than IN N
nonresponders NNS N
. . N

Chemotherapy-related JJ N
toxicities NNS N
were VBD N
few JJ N
and CC N
most JJS N
of IN N
them PRP N
related VBN N
to TO N
cisplatin VB N
which WDT N
was VBD N
reduced VBN N
to TO N
100 CD N
mg/m2 NN N
for IN N
35 CD N
patients NNS N
. . N

There EX N
were VBD N
no DT N
treatment-related JJ N
deaths NNS N
and CC N
, , N
in IN N
the DT N
experimental JJ N
arm NN N
of IN N
the DT N
trial NN N
, , N
no DT N
increased VBN N
morbidity NN N
from IN N
locoregional JJ N
treatment NN N
. . N

This DT N
induction NN N
regimen NN N
does VBZ N
not RB N
offer VB N
any DT N
advantages NNS N
over IN N
standard JJ N
treatment NN N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
self-directed JJ N
stress NN N
management NN N
training NN N
and CC N
home-based JJ N
exercise NN N
on IN N
stress NN N
management NN N
skills NNS N
in IN N
cancer NN 4_p
patients NNS N
receiving VBG N
chemotherapy NN 4_p
. . N

Although IN N
exercise NN N
may MD N
be VB N
used VBN N
by IN N
some DT N
to TO N
decrease VB N
distress NN N
, , N
little JJ N
is VBZ N
known VBN N
about IN N
how WRB N
it PRP N
may MD N
contribute VB N
to TO N
stress VB N
management NN N
( ( N
SM NNP N
) ) N
among IN N
patients NNS N
receiving VBG N
chemotherapy NN N
. . N

We PRP N
evaluated VBD N
whether IN N
exercise NN N
separately RB N
or CC N
in IN N
combination NN N
with IN N
SM NNP N
training NN N
is VBZ N
effective JJ N
at IN N
increasing VBG N
perceived JJ N
ability NN N
to TO N
manage VB N
stress NN N
. . N

Patients NNS N
receiving VBG N
chemotherapy NN N
( ( N
N NNP N
= NNP N
391 CD 3_p
) ) N
were VBD N
randomized VBN N
to TO N
receive VB N
usual JJ N
care NN N
only RB N
( ( N
UCO NNP N
) ) N
, , N
SM NNP N
, , N
exercise NN N
( ( N
EX NNP N
) ) N
, , N
or CC N
stress JJ N
management NN N
and CC N
exercise NN N
( ( N
SMEX NNP N
) ) N
. . N

They PRP N
completed VBD N
the DT N
Measure NN N
of IN N
Current NNP N
Status NNP N
prior RB N
to TO N
receiving VBG N
chemotherapy NN N
and CC N
12 CD N
weeks NNS N
after IN N
the DT N
first JJ N
infusion NN N
. . N

We PRP N
hypothesized VBD N
that IN N
participants NNS N
randomized VBN N
to TO N
an DT N
intervention NN N
condition NN N
would MD N
report VB N
improvements NNS N
in IN N
relaxation NN N
, , N
awareness NN N
of IN N
tension NN N
, , N
getting VBG N
needs NNS N
met VBD N
and CC N
coping VBG N
confidence NN N
compared VBN N
with IN N
those DT N
receiving VBG N
UCO NNP N
. . N

Results NNP N
indicated VBD N
significant JJ N
group-by-time JJ N
interactions NNS N
for IN N
the DT N
following NN N
: : N
relaxation NN N
( ( N
UCO NNP N
versus NN N
SM NNP N
, , N
p NN N
= NNP N
0.008 CD N
) ) N
, , N
awareness NN N
of IN N
tension NN N
( ( N
UCO NNP N
versus NN N
SMEX NNP N
, , N
p NN N
= VBD N
0.029 CD N
and CC N
UCO NNP N
versus NN N
EX NNP N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
, , N
getting VBG N
needs NNS N
met VBD N
( ( N
UCO NNP N
versus NN N
SMEX NNP N
, , N
p NN N
= NNP N
0.020 CD N
) ) N
and CC N
Measure NN N
of IN N
Current NNP N
Status NNP N
total NN N
score NN N
( ( N
UCO NNP N
versus NN N
SMEX NNP N
, , N
p NN N
= VBD N
0.007 CD N
and CC N
UCO NNP N
versus NN N
EX NNP N
, , N
p NN N
= NNP N
0.016 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
group-by-time JJ N
interactions NNS N
for IN N
coping VBG N
confidence NN N
( ( N
p-values JJ N
> NNP N
0.05 CD N
) ) N
. . N

This DT N
study NN N
provides VBZ N
support NN N
for IN N
including VBG N
an DT N
exercise NN N
component NN N
in IN N
SM NNP N
interventions NNS N
for IN N
cancer NN N
patients NNS N
receiving VBG N
chemotherapy NN N
( ( N
clinicaltrials.gov JJ N
identifier NN N
: : N
NCT00740038 NNP N
) ) N
. . N

-DOCSTART- -X- O O

Timing VBG N
for IN N
delivering VBG N
individualized JJ N
patient JJ N
education NN N
intervention NN N
to TO N
Coronary NNP 4_p
Artery NNP 4_p
Bypass NNP 4_p
Graft NNP 4_p
patients NNS N
: : N
An DT N
RCT NNP N
. . N

BACKGROUND NNP N
The DT N
primary JJ N
focus NN N
of IN N
this DT N
study NN N
is VBZ N
on IN N
the DT N
timing NN N
of IN N
the DT N
delivery NN N
of IN N
education NN N
to TO N
patients NNS N
who WP N
had VBD N
CABG NNP 4_p
surgery NN 4_p
. . N

AIM NNP N
To TO N
determine VB N
the DT N
efficacy NN N
of IN N
an DT N
individualized JJ N
telephone NN N
patient JJ N
education NN N
intervention NN N
, , N
delivered VBN N
at IN N
two CD N
different JJ N
points NNS N
in IN N
time NN N
( ( N
1-2 JJ N
days NNS N
pre-discharge JJ N
versus JJ N
1-2 JJ N
days NNS N
post-discharge NN N
) ) N
in IN N
enhancing VBG N
the DT N
CABG NNP 4_p
patient NN N
's POS N
knowledge NN N
of IN N
self-care JJ N
behaviours NNS N
, , N
performance NN N
of IN N
self-care JJ N
behaviours NNS N
, , N
and CC N
symptom JJ N
frequency NN N
. . N

METHOD NNP N
A NNP N
randomized VBD N
clinical JJ N
trial NN N
that WDT N
included VBD N
a DT N
convenience NN N
sample NN N
of IN N
first JJ N
time NN N
CABG NNP 4_p
patients NNS N
. . N

Individuals NNS N
who WP N
received VBD N
education NN N
pre-discharge NN N
were VBD N
compared VBN N
to TO N
individuals NNS N
who WP N
received VBD N
education NN N
post-discharge NN N
on IN N
the DT N
outcomes NNS N
. . N

RESULTS NNP N
Results NNP N
indicated VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
in IN N
outcomes NNS N
between IN N
the DT N
two CD N
time NN N
points NNS N
. . N

As NNP N
well RB N
, , N
anxiety NN N
levels NNS N
were VBD N
found VBN N
to TO N
be VB N
significantly RB N
higher JJR N
in IN N
the DT N
pre-discharge NN N
group NN N
than IN N
the DT N
post-discharge JJ N
group NN N
. . N

CONCLUSIONS VB N
The DT N
individualized JJ N
nature NN N
of IN N
the DT N
educational JJ N
intervention NN N
may MD N
have VB N
accounted VBN N
for IN N
non-significant JJ N
findings NNS N
reported VBN N
in IN N
outcomes NNS N
between IN N
the DT N
two CD N
time NN N
points NNS N
. . N

PRACTICE NNP N
IMPLICATIONS NNP N
Nurses NNP N
may MD N
consider VB N
assessing VBG N
anxiety NN N
levels NNS N
prior RB N
to TO N
delivery NN N
of IN N
educational JJ N
interventions NNS N
, , N
implement JJ N
interventions NNS N
aimed VBN N
at IN N
reducing VBG N
anxiety NN N
levels NNS N
, , N
and CC N
provide VB N
individualized JJ N
teaching NN N
. . N

-DOCSTART- -X- O O

Pegfilgrastim NN N
for IN N
peripheral JJ N
CD34+ NNP N
mobilization NN N
in IN N
patients NNS N
with IN N
solid JJ 4_p
tumours NNS 4_p
. . N

The DT N
efficacy NN N
of IN N
pegfilgrastim+/-chemotherapy NN N
for IN N
mobilizing VBG N
stem NN N
cells NNS N
in IN N
patients NNS N
with IN N
solid JJ 4_p
tumours NN 4_p
was VBD N
assessed VBN N
. . N

In IN N
cycle NN N
0 CD N
, , N
a DT N
14-day JJ N
prechemotherapy NN N
cycle NN N
, , N
patients NNS N
( ( N
N=61 NNP 3_p
) ) N
were VBD N
randomized VBN N
open-label NN N
to TO N
single JJ N
doses NNS N
of IN N
pegfilgrastim NN N
( ( N
6 CD N
, , N
12 CD N
or CC N
18 CD N
mg NN N
) ) N
on IN N
day NN N
1 CD N
, , N
or CC N
daily RB N
filgrastim NNS N
( ( N
10 CD N
microg/kg NN N
) ) N
for IN N
< NN N
or CC N
=7 JJ N
days NNS N
. . N

Mean JJ N
peak JJ N
peripheral JJ N
CD34+ NNP N
cell NN N
counts NNS N
increased VBD N
with IN N
pegfilgrastim NN N
dose NN N
, , N
but CC N
were VBD N
significantly RB N
higher JJR N
than IN N
filgrastim JJR N
only RB N
at IN N
the DT N
18 CD N
mg NN N
dose NN N
( ( N
10.17 CD N
vs RB N
4.96 CD N
x JJ N
10 CD N
( ( N
4 CD N
) ) N
/ml NN N
; : N
P=0.014 NNP N
) ) N
. . N

In IN N
the DT N
clinically NN N
relevant JJ N
period NN N
of IN N
days NNS N
3-7 CD N
, , N
both DT N
12 CD N
and CC N
18 CD N
mg NN N
pegfilgrastim NN N
doses NNS N
produced VBD N
significantly RB N
higher JJR N
peak NN N
CD34+ NNP N
counts VBZ N
( ( N
8.18 CD N
and CC N
9.96 CD N
vs NN N
4.51 CD N
x NN N
10 CD N
( ( N
4 CD N
) ) N
/ml NN N
for IN N
filgrastim NN N
; : N
P=0.034 NNP N
and CC N
0.006 CD N
) ) N
. . N

In IN N
cycle NN N
1 CD N
, , N
patients NNS N
received VBD N
carboplatin/paclitaxel NNS N
on IN N
day NN N
1 CD N
, , N
followed VBD N
from IN N
day NN N
2 CD N
by IN N
pegfilgrastim JJ N
6-18 JJ N
mg NN N
or CC N
daily JJ N
filgrastim NN N
( ( N
5 CD N
microg/kg/day NN N
for IN N
< NN N
or CC N
=14 NNP N
days NNS N
) ) N
as IN N
per IN N
randomization NN N
in IN N
cycle NN N
0 CD N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
mean JJ N
peak NN N
CD34+ NNP N
count NN N
between IN N
pegfilgrastim NN N
and CC N
filgrastim NN N
, , N
but CC N
there EX N
was VBD N
an DT N
advantage NN N
for IN N
pegfilgrastim NN N
18 CD N
mg NN N
in IN N
the DT N
relevant JJ N
period NN N
of IN N
days NNS N
7-12 NNP N
( ( N
3.14 CD N
vs RB N
1.19 CD N
x JJ N
10 CD N
( ( N
4 CD N
) ) N
/ml NN N
; : N
P=0.043 NNP N
) ) N
. . N

A DT N
single JJ N
pegfilgrastim NN N
dose NN N
( ( N
> CD N
or CC N
=6 VB N
mg NN N
) ) N
could MD N
be VB N
substituted VBN N
for IN N
daily JJ N
filgrastim NN N
in IN N
cytokine-only JJ N
peripheral JJ N
CD34+ NNP N
cell NN N
mobilization NN N
. . N

-DOCSTART- -X- O O

Gamma-hydroxybutyric JJ N
acid NN N
versus NN N
clomethiazole NN N
for IN N
the DT N
treatment NN N
of IN N
alcohol NN 4_p
withdrawal NN 4_p
syndrome NN 4_p
in IN N
a DT N
medical JJ N
intensive JJ N
care NN N
unit NN N
: : N
an DT N
open JJ N
, , N
single-center JJ N
randomized VBN N
study NN N
. . N

BACKGROUND NNP N
Clomethiazole NNP N
( ( N
CLO NNP N
) ) N
has VBZ N
been VBN N
shown VBN N
to TO N
be VB N
effective JJ N
in IN N
treating VBG N
alcohol NN 4_p
withdrawal NN 4_p
syndrome NN 4_p
( ( N
AWS NNP 4_p
) ) N
. . N

Gamma-Hydroxybutyric JJ N
acid NN N
( ( N
GHB NNP N
) ) N
has VBZ N
also RB N
been VBN N
introduced VBN N
in IN N
the DT N
treatment NN N
of IN N
alcoholic JJ N
patients NNS N
and CC N
is VBZ N
effective JJ N
in IN N
surgical JJ N
intensive JJ N
care NN N
unit NN N
( ( N
ICU NNP N
) ) N
patients NNS N
in IN N
preventing VBG N
and CC N
treating VBG N
AWS NNP N
. . N

There EX N
are VBP N
no DT N
comparative JJ N
studies NNS N
between IN N
CLO NNP N
and CC N
GHB NNP N
in IN N
a DT N
medical JJ N
ICU NNP N
setting NN N
. . N

METHODS NNP N
Twenty-six NNP 3_p
alcoholic JJ N
patients NNS N
with IN N
severe JJ N
AWS NNP N
and CC N
concomitant JJ N
medical JJ N
diseases NNS N
were VBD N
randomally RB N
enrolled VBN N
in IN N
the DT N
study NN N
. . N

CLO NNP N
was VBD N
given VBN N
orally RB N
to TO N
12 CD N
patients NNS N
in IN N
a DT N
dosage NN N
of IN N
250 CD N
mg NN N
every DT N
4 CD N
hours NNS N
as IN N
a DT N
liquid NN N
; : N
GHB NNP N
( ( N
initially RB N
30 CD N
mg/kg NNS N
body NN N
weight NN N
( ( N
BW NNP N
) ) N
followed VBN N
by IN N
15 CD N
mg/kg NNS N
BW NNP N
) ) N
was VBD N
administered VBN N
intravenously RB N
to TO N
14 CD N
patients NNS N
. . N

Four CD N
major JJ N
AWS NNP N
symptoms NNS N
( ( N
tremor NN N
, , N
sweating VBG N
, , N
nausea NN N
, , N
restlessness NN N
) ) N
were VBD N
scored VBN N
, , N
and CC N
the DT N
administration NN N
of IN N
additional JJ N
medication NN N
was VBD N
registered VBN N
. . N

RESULTS NNP N
GHB NNP N
was VBD N
more RBR N
effective JJ N
in IN N
treating VBG N
AWS NNP N
symptoms NNS N
. . N

In IN N
the DT N
GHB NNP N
group NN N
, , N
AWS NNP N
score NN N
dropped VBD N
from IN N
6.6 CD N
+/- JJ N
2.6 CD N
to TO N
1.8 CD N
+/- JJ N
2.1 CD N
( ( N
p JJ N
< NNP N
.01 NNP N
) ) N
, , N
while IN N
in IN N
the DT N
CLO NNP N
group NN N
, , N
the DT N
score NN N
dropped VBD N
from IN N
6 CD N
+/- JJ N
2.5 CD N
to TO N
4.1 CD N
+/- JJ N
2.4 CD N
( ( N
n. JJ N
s. NN N
) ) N
. . N

Differences NNS N
between IN N
groups NNS N
were VBD N
significant JJ N
( ( N
p JJ N
=.021 NN N
, , N
two-way JJ N
ANOVA NNP N
) ) N
. . N

The DT N
treatment NN N
did VBD N
not RB N
alter VB N
outcome NN N
or CC N
the DT N
duration NN N
of IN N
ICU NNP N
stay NN N
. . N

No DT N
serious JJ N
side NN N
effects NNS N
were VBD N
detected VBN N
. . N

CONCLUSION NNP N
GHB NNP N
effectively RB N
controls VBZ N
AWS NNP N
symptoms NNS N
in IN N
medical JJ N
ICU NNP N
patients NNS N
. . N

The DT N
rapid JJ N
initial JJ N
treatment NN N
response NN N
of IN N
GHB NNP N
in IN N
contrast NN N
to TO N
CLO NNP N
has VBZ N
no DT N
influence NN N
on IN N
duration NN N
of IN N
patient NN N
withdrawal NN N
. . N

-DOCSTART- -X- O O

Randomized VBN N
controlled VBD N
trial NN N
to TO N
compare VB N
the DT N
early JJ N
and CC N
mid-term JJ N
results NNS N
of IN N
stapled JJ N
versus NN N
open JJ N
hemorrhoidectomy NN 4_p
. . N

BACKGROUND VB N
The DT N
new JJ N
technique NN N
of IN N
circular JJ N
stapler NN N
for IN N
the DT N
treatment NN N
of IN N
hemorrhoids NNS 4_p
has VBZ N
shown VBN N
early JJ N
promise NN N
in IN N
terms NNS N
of IN N
minimal NN N
or CC N
no DT N
postoperative JJ N
pain NN N
, , N
early JJ N
discharge NN N
from IN N
hospital NN N
, , N
and CC N
quick JJ N
return NN N
to TO N
work VB N
. . N

This DT N
study NN N
was VBD N
designed VBN N
to TO N
compare VB N
stapled VBN N
technique NN N
with IN N
the DT N
well-accepted JJ N
conventional JJ N
Milligan NNP N
Morgan NNP N
hemorrhoidectomy NN N
. . N

METHODS NNP N
After IN N
fulfilling VBG N
the DT N
selection NN N
criteria NNS N
, , N
84 CD 3_p
patients NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
the DT N
stapled VBN N
( ( N
n JJ N
= NNP N
42 CD 3_p
) ) N
or CC N
open JJ N
group NN N
( ( N
n JJ N
= NNP N
42 CD 3_p
) ) N
. . N

All DT N
patients NNS N
were VBD N
operated VBN N
on IN N
under IN N
spinal JJ N
anesthesia NN N
. . N

The DT N
2 CD N
techniques NNS N
were VBD N
evaluated VBN N
with IN N
respect NN N
to TO N
the DT N
operative JJ N
time NN N
, , N
pain NN N
scores NNS N
, , N
complications NNS N
, , N
day NN N
of IN N
discharge NN N
, , N
return NN N
to TO N
work VB N
, , N
and CC N
level NN N
of IN N
satisfaction NN N
. . N

RESULTS VB N
The DT N
mean JJ N
age NN N
of IN N
patients NNS N
was VBD N
46.02 CD 1_p
years NNS N
( ( N
SD NNP N
, , N
12.33 CD N
) ) N
in IN N
the DT N
stapled JJ N
group NN N
and CC N
48.64 CD 1_p
years NNS N
( ( N
14.57 CD N
) ) N
in IN N
the DT N
open JJ N
group NN N
. . N

Grade NNP 4_p
III NNP 4_p
or CC 4_p
IV NNP 4_p
hemorrhoids NNS 4_p
were VBD N
more JJR N
common JJ N
in IN N
men NNS N
( ( N
ie NN N
, , N
80.9 CD N
% NN N
and CC N
85.7 CD N
% NN N
in IN N
the DT N
stapled JJ N
and CC N
open JJ N
group NN N
, , N
respectively RB N
) ) N
. . N

The DT N
mean JJ N
operative JJ N
time NN N
was VBD N
shorter RBR N
in IN N
the DT N
stapled JJ N
group NN N
24.28 CD N
minutes NNS N
( ( N
4.25 CD N
) ) N
versus NN N
45.21 CD N
minutes NNS N
( ( N
5.36 CD N
) ) N
in IN N
the DT N
Milligan-Morgan NNP N
group NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

The DT N
blood NN N
loss NN N
, , N
pain NN N
scores NNS N
and CC N
requirement NN N
of IN N
analgesics NNS N
was VBD N
significantly RB N
less RBR N
in IN N
the DT N
stapled JJ N
group NN N
. . N

Mean NNP N
hospital NN N
stay NN N
was VBD N
1.24 CD N
days NNS N
( ( N
0.62 CD N
) ) N
and CC N
2.76 CD N
days NNS N
( ( N
1.01 CD N
) ) N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
in IN N
the DT N
stapled JJ N
and CC N
open JJ N
group NN N
, , N
respectively RB N
. . N

The DT N
patients NNS N
in IN N
the DT N
stapled JJ N
group NN N
returned VBD N
to TO N
work VB N
or CC N
routine VB N
activities NNS N
earlier RBR N
( ( N
ie NN N
, , N
within IN N
8.12 CD N
days NNS N
[ RB N
2.48 CD N
] NN N
) ) N
as IN N
compared VBN N
with IN N
17.62 CD N
( ( N
5.59 CD N
) ) N
in IN N
the DT N
open JJ N
group NN N
. . N

Only RB N
88.1 CD N
% NN N
of IN N
patients NNS N
were VBD N
satisfied VBN N
by IN N
the DT N
open JJ N
method NN N
compared VBN N
with IN N
97.6 CD N
% NN N
after IN N
the DT N
stapled JJ N
technique NN N
. . N

The DT N
median JJ N
follow-up JJ N
period NN N
was VBD N
11 CD N
months NNS N
with IN N
a DT N
maximum JJ N
follow-up NN N
of IN N
19 CD N
months NNS N
( ( N
range VB N
2-19 JJ N
months NNS N
) ) N
. . N

CONCLUSIONS NNP N
Stapled NNP N
hemorrhoidectomy NN N
is VBZ N
a DT N
safe JJ N
and CC N
effective JJ N
day-care JJ N
procedure NN N
for IN N
the DT N
treatment NN N
of IN N
grade NN 4_p
III NNP 4_p
and CC 4_p
grade VBD 4_p
IV NNP 4_p
hemorrhoids NNS 4_p
. . N

It PRP N
ensures VBZ N
lesser RBR N
postoperative JJ N
pain NN N
, , N
early JJ N
discharge NN N
, , N
less JJR N
time NN N
off IN N
work NN N
, , N
complications NNS N
similar JJ N
to TO N
the DT N
open JJ N
technique NN N
, , N
and CC N
in IN N
the DT N
end NN N
a DT N
more RBR N
satisfied JJ N
patient NN N
with IN N
no DT N
perianal JJ N
wound NN N
. . N

However RB N
, , N
more RBR N
such JJ N
randomized JJ N
trials NNS N
are VBP N
essential JJ N
to TO N
deny VB N
any DT N
long-term JJ N
complication NN N
. . N

-DOCSTART- -X- O O

Hyperbaric NNP N
oxygen NN N
attenuation NN N
of IN N
lipopolysaccharide-induced JJ 4_p
acute NN 4_p
lung NN 4_p
injury NN 4_p
involves VBZ N
heme JJ N
oxygenase-1 NN N
. . N

BACKGROUND NNP N
Hyperbaric NNP N
oxygen NN N
( ( N
HBO NNP N
) ) N
attenuates VBZ N
lipopolysaccharide JJ N
( ( N
LPS NNP N
) ) N
-induced VBD N
acute JJ 4_p
lung NN 4_p
injury NN 4_p
. . N

This DT N
beneficial JJ N
effect NN N
of IN N
HBO NNP N
involves VBZ N
inhibition NN N
of IN N
inducible JJ N
nitric JJ N
oxide NN N
synthase NN N
( ( N
iNOS NN N
) ) N
expression NN N
and CC N
subsequent JJ N
nitric JJ N
oxide NN N
( ( N
NO NNP N
) ) N
biosynthesis NN N
. . N

We PRP N
sought VBD N
to TO N
investigate VB N
the DT N
role NN N
of IN N
heme JJ N
oxygenase-1 JJ N
( ( N
HO-1 NNP N
) ) N
on IN N
this DT N
HBO NNP N
inhibition NN N
of IN N
iNOS JJ N
induction NN N
and CC N
acute NN N
lung NN N
injury NN N
in IN N
septic JJ N
rat NN N
lungs NNS N
. . N

METHODS NNP N
Before IN N
the DT N
experiment NN N
, , N
72 CD 3_p
rats NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
receive VB N
HBO NNP N
or CC N
air NN N
treatment NN N
. . N

With IN N
or CC N
without IN N
HBO NNP N
pre-treatment NN N
, , N
the DT N
rats NNS N
were VBD N
further RB N
divided VBN N
into IN N
the DT N
following JJ N
subgroups NNS N
( ( N
n JJ N
= NNP N
6 CD N
) ) N
: : N
( ( N
i NN N
) ) N
LPS NNP N
injection NN N
, , N
( ( N
ii NN N
) ) N
normal JJ N
saline NN N
( ( N
N/S NNP N
) ) N
injection NN N
, , N
( ( N
iii NN N
) ) N
hemin NN N
( ( N
a DT N
HO-1 NNP N
inducer NN N
) ) N
plus CC N
LPS NNP N
, , N
( ( N
iv NN N
) ) N
hemin NN N
alone RB N
, , N
( ( N
v NN N
) ) N
tin NN N
protoporphyrin NN N
( ( N
SnPP NNP N
; : N
a DT N
HO-1 NNP N
inhibitor NN N
) ) N
plus CC N
LPS NNP N
, , N
and CC N
( ( N
vi NN N
) ) N
SnPP NNP N
alone RB N
. . N

All DT N
rats NNS N
were VBD N
maintained VBN N
for IN N
6 CD N
h NN N
and CC N
then RB N
sacrificed VBD N
with IN N
a DT N
high-dose JJ N
pentobarbital JJ N
injection NN N
. . N

Lung NNP N
injuries NNS N
and CC N
relevant JJ N
enzymes NNS N
expression NN N
were VBD N
thus RB N
assayed VBN N
. . N

RESULTS NNP N
Histological NNP N
analysis NN N
, , N
PMNs/alveoli NNP N
ratio NN N
, , N
and CC N
wet/dry JJ N
weight NN N
ratio NN N
measurements NNS N
demonstrated VBD N
that IN N
LPS NNP N
caused VBD N
significant JJ N
lung JJ N
injury NN N
and CC N
HBO NNP N
and/or VBP N
hemin NN N
significantly RB N
attenuated VBD N
this DT N
LPS-induced JJ N
lung NN N
injury NN N
. . N

Increased VBD N
pulmonary JJ N
iNOS NN N
expression NN N
and CC N
NO DT N
production NN N
were VBD N
associated VBN N
with IN N
lung JJ N
injury NN N
. . N

Induction NN N
of IN N
HO-1 NNP N
, , N
by IN N
HBO NNP N
and/or NN N
hemin NN N
, , N
significantly RB N
attenuated VBD N
this DT N
LPS-induced JJ N
iNOS NN N
expression NN N
and CC N
acute NN N
lung NN N
injury NN N
. . N

SnPP NNP N
, , N
on IN N
the DT N
contrary JJ N
, , N
offset VB N
the DT N
effects NNS N
of IN N
HBO NNP N
and CC N
worsened VBD N
the DT N
LPS-induced NNP N
lung NN N
injury NN N
. . N

CONCLUSIONS NNP N
HBO NNP N
may MD N
act VB N
through IN N
inhibiting VBG N
pulmonary JJ N
iNOS NN N
expression NN N
to TO N
attenuate VB N
LPS-induced NNP N
acute NN N
lung NN N
injury NN N
in IN N
septic JJ 4_p
rats NNS 4_p
. . N

Furthermore RB N
, , N
this DT N
HBO NNP N
attenuation NN N
of IN N
iNOS JJ N
expression NN N
involves VBZ N
HO-1 NNP N
induction NN N
. . N

-DOCSTART- -X- O O

Comparison NNP N
of IN N
rectal JJ N
midazolam NN N
and CC N
diazepam NN N
for IN N
premedication NN N
in IN N
pediatric JJ 1_p
dental JJ 4_p
patients NNS 4_p
. . N

Rectally RB N
administered VBN N
midazolam NN N
( ( N
0.35 CD N
mg/kg NN N
) ) N
and CC N
diazepam NN N
( ( N
0.70 CD N
mg/kg NN N
) ) N
were VBD N
compared VBN N
with IN N
each DT N
other JJ N
and CC N
with IN N
placebo NN N
for IN N
preanesthetic JJ N
medication NN N
in IN N
children NNS 1_p
undergoing VBG N
dental JJ 4_p
extractions NNS 4_p
. . N

All DT N
rectal JJ N
medications NNS N
were VBD N
very RB N
well RB N
accepted VBN N
, , N
but CC N
mask JJ N
acceptance NN N
, , N
improvement NN N
in IN N
anxiety NN N
, , N
and CC N
sedation NN N
were VBD N
best RBS N
in IN N
the DT N
midazolam NN N
group NN N
. . N

Improvement NNP N
in IN N
anxiety NN N
and CC N
sedation NN N
were VBD N
significantly RB N
better RBR N
in IN N
the DT N
two CD N
drug NN N
groups NNS N
than IN N
in IN N
those DT N
patients NNS N
who WP N
had VBD N
received VBN N
placebo NN N
. . N

Thirty NNP N
minutes NNS N
after IN N
rectal JJ N
administration NN N
of IN N
midazolam NNS N
, , N
patients NNS N
showed VBD N
a DT N
decrease NN N
in IN N
both DT N
systolic JJ N
and CC N
diastolic JJ N
blood NN N
pressure NN N
and CC N
heart NN N
rate NN N
. . N

Although IN N
these DT N
decreases NNS N
differed VBD N
significantly RB N
from IN N
the DT N
premedication NN N
values NNS N
, , N
they PRP N
were VBD N
probably RB N
of IN N
little JJ N
clinical JJ N
importance NN N
. . N

Only RB N
minor JJ N
adverse JJ N
effects NNS N
were VBD N
observed VBN N
in IN N
this DT N
study NN N
. . N

Overall NNP N
rectally RB N
administered VBD N
midazolam NNS N
appeared VBD N
to TO N
be VB N
somewhat RB N
more RBR N
efficacious JJ N
than IN N
diazepam NN N
. . N

-DOCSTART- -X- O O

Once-daily RB N
MMX NNP N
( ( N
? . N
) ) N
mesalamine NN N
for IN N
endoscopic JJ N
maintenance NN N
of IN N
remission NN N
of IN N
ulcerative JJ N
colitis NN N
. . N

OBJECTIVES NNP N
Treatment NNP N
with IN N
mesalamine NN N
to TO N
maintain VB N
endoscopic JJ N
remission NN N
( ( N
mucosal JJ N
healing VBG N
) ) N
of IN N
ulcerative JJ N
colitis NN N
( ( N
UC NNP N
) ) N
has VBZ N
been VBN N
shown VBN N
to TO N
reduce VB N
the DT N
risk NN N
of IN N
relapse NN N
and CC N
is VBZ N
the DT N
recommended JJ N
first-line JJ N
maintenance NN N
therapy NN N
. . N

To TO N
improve VB N
treatment NN N
adherence NN N
, , N
a DT N
mesalamine NN N
formulation NN N
that WDT N
can MD N
be VB N
administered VBN N
once-daily RB N
, , N
MMX NNP N
( ( N
? . N
) ) N
mesalamine NN N
( ( N
Lialda NNP N
; : N
Shire NNP N
Pharmaceuticals NNP N
LLC NNP N
, , N
Wayne NNP N
, , N
PA NNP N
) ) N
, , N
was VBD N
developed VBN N
. . N

This DT N
study NN N
was VBD N
conducted VBN N
to TO N
determine VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
once-daily JJ N
MMX NNP N
mesalamine NN N
compared VBN N
with IN N
twice-daily JJ N
delayed-release JJ N
mesalamine NN N
( ( N
Asacol NNP N
; : N
Warner NNP N
Chilcott NNP N
, , N
Dublin NNP N
, , N
Ireland NNP N
) ) N
for IN N
maintaining VBG N
endoscopic JJ N
remission NN N
in IN N
patients NNS N
with IN N
UC NNP N
. . N

METHODS NNP N
A NNP N
multicenter NN N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
6-month JJ N
, , N
active-control JJ N
trial NN N
was VBD N
conducted VBN N
to TO N
assess VB N
the DT N
non-inferiority NN N
of IN N
once-daily JJ N
MMX NNP N
mesalamine NN N
2.4 CD N
g/day NN N
compared VBN N
with IN N
twice-daily JJ N
delayed-release JJ N
mesalamine NN N
at IN N
a DT N
total JJ N
daily JJ N
dose NN N
of IN N
1.6 CD N
g/day NN N
in IN N
patients NNS N
with IN N
UC NNP N
in IN N
endoscopic JJ N
remission NN N
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
maintenance NN N
of IN N
endoscopic JJ N
remission NN N
at IN N
month NN N
6 CD N
in IN N
the DT N
per-protocol NN N
( ( N
PP NNP N
) ) N
population NN N
. . N

RESULTS NNP N
Overall NNP N
, , N
826 CD N
patients NNS N
were VBD N
randomized VBN N
and CC N
dosed VBN N
. . N

The DT N
primary JJ N
objective JJ N
( ( N
non-inferiority NN N
) ) N
was VBD N
met VBN N
. . N

At IN N
month NN N
6 CD N
, , N
83.7 CD N
and CC N
77.8 CD N
% NN N
of IN N
patients NNS N
receiving VBG N
MMX NNP N
mesalamine NN N
in IN N
the DT N
PP NNP N
and CC N
intent-to-treat NN N
( ( N
ITT NNP N
) ) N
populations NNS N
, , N
respectively RB N
, , N
had VBD N
maintained VBN N
endoscopic JJ N
remission NN N
compared VBN N
with IN N
81.5 CD N
% NN N
( ( N
PP NNP N
) ) N
and CC N
76.9 CD N
% NN N
( ( N
ITT NNP N
) ) N
of IN N
patients NNS N
receiving VBG N
delayed-release JJ N
mesalamine NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
for IN N
difference NN N
: : N
-3.9 CD N
% NN N
, , N
8.1 CD N
% NN N
( ( N
PP NNP N
) ) N
; : N
-5.0 CD N
% NN N
, , N
6.9 CD N
% NN N
( ( N
ITT NNP N
) ) N
) ) N
. . N

Time NN N
to TO N
relapse VB N
was VBD N
not RB N
significantly RB N
different JJ N
between IN N
the DT N
two CD N
treatment NN N
groups NNS N
( ( N
log-rank JJ N
test NN N
, , N
P=0.5116 NNP N
( ( N
PP NNP N
) ) N
; : N
P=0.5455 NNP N
( ( N
ITT NNP N
) ) N
) ) N
. . N

The DT N
proportion NN N
of IN N
patients NNS N
with IN N
adverse JJ N
events NNS N
was VBD N
37.1 CD N
and CC N
36.0 CD N
% NN N
in IN N
patients NNS N
receiving VBG N
MMX NNP N
mesalamine NN N
and CC N
delayed-release JJ N
mesalamine NN N
, , N
respectively RB N
. . N

CONCLUSIONS NNP N
Once-daily JJ N
dosing NN N
of IN N
MMX NNP N
mesalamine NN N
2.4 CD N
g/day NN N
was VBD N
shown VBN N
to TO N
be VB N
well RB N
tolerated VBN N
and CC N
non-inferior JJ N
to TO N
twice-daily JJ N
dosing VBG N
with IN N
delayed-release JJ N
mesalamine NN N
1.6 CD N
g/day NN N
for IN N
maintenance NN N
of IN N
endoscopic JJ N
remission NN N
in IN N
patients NNS N
with IN N
UC NNP N
. . N

-DOCSTART- -X- O O

Ten-year JJ N
incidence NN N
of IN N
myocardial JJ N
infarction NN N
and CC N
prognosis NN N
after IN N
infarction NN N
. . N

Department NNP N
of IN N
Veterans NNP N
Affairs NNP N
Cooperative NNP N
Study NNP N
of IN N
Coronary NNP N
Artery NNP N
Bypass NNP N
Surgery NNP N
. . N

BACKGROUND NNP N
The DT N
10-year JJ N
incidence NN N
of IN N
myocardial JJ N
infarction NN N
( ( N
fatal JJ N
and CC N
nonfatal JJ N
) ) N
and CC N
the DT N
prognosis NN N
after IN N
infarction NN N
were VBD N
evaluated VBN N
in IN N
686 CD 3_p
patients NNS N
with IN N
stable JJ 4_p
angina NNS 4_p
who WP N
were VBD N
randomly RB N
assigned VBN N
to TO N
medical JJ N
or CC N
surgical JJ N
treatment NN N
in IN N
the DT N
Veterans NNPS N
Administration NNP N
Cooperative NNP N
Study NNP N
of IN N
Coronary NNP N
Artery NNP N
Bypass NNP N
Surgery NNP N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
Myocardial NNP N
infarction NN N
was VBD N
defined VBN N
by IN N
either DT N
new JJ N
Q NNP N
wave VBP N
findings NNS N
or CC N
clinical JJ N
symptoms NNS N
compatible JJ N
with IN N
myocardial JJ 4_p
infarction NN 4_p
accompanied VBN N
by IN N
serum NN N
enzyme NN N
elevations NNS N
with IN N
or CC N
without IN N
electrocardiographic JJ N
findings NNS N
. . N

Treatment JJ N
comparisons NNS N
were VBD N
made VBN N
according VBG N
to TO N
original JJ N
treatment NN N
assignment NN N
; : N
35 CD N
% NN N
of IN N
the DT N
medical JJ N
cohort NN N
had VBD N
bypass NN N
surgery NN N
during IN N
the DT N
10-year JJ N
follow-up JJ N
period NN N
. . N

The DT N
overall JJ N
cumulative JJ N
infarction NN N
rate NN N
was VBD N
somewhat RB N
higher JJR N
in IN N
patients NNS N
assigned VBN N
to TO N
surgery VB N
( ( N
36 CD N
% NN N
) ) N
than IN N
in IN N
medical JJ N
patients NNS N
( ( N
31 CD N
% NN N
) ) N
( ( N
p JJ N
= NNP N
0.13 CD N
) ) N
due JJ N
to TO N
perioperative JJ N
infarctions NNS N
( ( N
13 CD N
% NN N
) ) N
and CC N
an DT N
accelerated JJ N
infarction NN N
rate NN N
after IN N
the DT N
fifth JJ N
year NN N
of IN N
follow-up NN N
( ( N
average JJ N
, , N
2.4 CD N
% NN N
/yr NN N
in IN N
the DT N
surgical JJ N
group NN N
versus VBD N
1.4 CD N
% NN N
/yr NN N
in IN N
the DT N
medical JJ N
group NN N
) ) N
. . N

The DT N
10-year JJ N
cumulative JJ N
incidence NN N
of IN N
death NN N
or CC N
myocardial JJ N
infarction NN N
was VBD N
also RB N
higher JJR N
in IN N
surgical JJ N
( ( N
54 CD N
% NN N
) ) N
than IN N
in IN N
medical JJ N
( ( N
49 CD N
% NN N
) ) N
patients NNS N
( ( N
p JJ N
= NNP N
0.20 CD N
) ) N
. . N

According VBG N
to TO N
the DT N
Cox NNP N
model NN N
, , N
the DT N
estimated VBN N
risk NN N
of IN N
death NN N
after IN N
infarction NN N
was VBD N
59 CD N
% NN N
lower JJR N
in IN N
surgical JJ N
than IN N
in IN N
medical JJ N
patients NNS N
( ( N
p NN N
less JJR N
than IN N
0.0001 CD N
) ) N
. . N

The DT N
reduction NN N
in IN N
postinfarction NN N
mortality NN N
with IN N
surgery NN N
was VBD N
most RBS N
striking JJ N
in IN N
the DT N
first JJ N
month NN N
after IN N
the DT N
event NN N
: : N
99 CD N
% NN N
in IN N
the DT N
first JJ N
month NN N
( ( N
p NN N
less JJR N
than IN N
0.0001 CD N
) ) N
and CC N
49 CD N
% NN N
subsequently RB N
( ( N
p NN N
less JJR N
than IN N
0.0001 CD N
) ) N
. . N

The DT N
estimated VBN N
risk NN N
of IN N
death NN N
in IN N
the DT N
absence NN N
of IN N
infarction NN N
was VBD N
nearly RB N
identical JJ N
regardless NN N
of IN N
treatment NN N
( ( N
p JJ N
= NNP N
0.75 CD N
) ) N
. . N

Exclusion NN N
of IN N
perioperative JJ N
infarctions NNS N
did VBD N
not RB N
alter VB N
the DT N
findings NNS N
. . N

CONCLUSIONS NNP N
Although IN N
surgery NN N
does VBZ N
not RB N
reduce VB N
the DT N
incidence NN N
of IN N
myocardial JJ N
infarction NN N
overall RB N
, , N
it PRP N
does VBZ N
reduce VB N
the DT N
risk NN N
of IN N
mortality NN N
after IN N
infarction NN N
, , N
particularly RB N
in IN N
the DT N
first JJ N
30 CD N
days NNS N
after IN N
the DT N
event NN N
( ( N
fatal JJ N
infarctions NNS N
) ) N
. . N

-DOCSTART- -X- O O

Transcutaneous JJ N
electrical JJ N
nerve NN N
stimulation NN N
following VBG N
appendicectomy NN 4_p
: : N
the DT N
placebo NN N
effect NN N
. . N

A DT N
controlled JJ N
trial NN N
was VBD N
undertaken VBN N
to TO N
compare VB N
the DT N
efficacy NN N
of IN N
transcutaneous JJ N
electrical JJ N
nerve NN N
stimulation NN N
( ( N
TENS NNP N
) ) N
with IN N
standard JJ N
intramuscular JJ N
opiate NN N
analgesia NN N
in IN N
the DT N
management NN N
of IN N
postoperative JJ N
pain NN N
following VBG N
appendicectomy NN 4_p
. . N

Consecutive JJ N
patients NNS N
undergoing VBG N
emergency NN N
appendicectomy NN 4_p
were VBD N
randomised VBN N
into IN N
control NN N
, , N
sham NN N
TENS NNP N
and CC N
active JJ N
TENS NNP N
groups NNS N
. . N

There EX N
was VBD N
a DT N
significant JJ N
decrease NN N
in IN N
pain NN N
severity NN N
and CC N
analgesic JJ N
intake NN N
in IN N
both DT N
active JJ N
and CC N
sham JJ N
TENS NNP N
groups NNS N
when WRB N
compared VBN N
with IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

No DT N
difference NN N
was VBD N
demonstrated VBN N
in IN N
pain NN N
severity NN N
between IN N
active JJ N
and CC N
sham JJ N
TENS NNP N
groups NNS N
but CC N
the DT N
active JJ N
TENS NNP N
group NN N
required VBD N
slightly RB N
less JJR N
analgesia NN N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
the DT N
major JJ N
benefit NN N
of IN N
TENS NNP N
in IN N
the DT N
postappendicectomy NN 4_p
patient NN N
is VBZ N
due JJ N
to TO N
its PRP$ N
'placebo JJ N
effect NN N
' POS N
and CC N
its PRP$ N
use NN N
in IN N
this DT N
situation NN N
can MD N
not RB N
be VB N
recommended VBN N
. . N

-DOCSTART- -X- O O

Dissociation NN N
between IN N
cortical JJ N
activation NN N
and CC N
cognitive JJ N
performance NN N
under IN N
pharmacological JJ N
blood NN N
pressure NN N
elevation NN N
in IN N
chronic JJ N
hypotension NN N
. . N

The DT N
present JJ N
study NN N
explored VBD N
the DT N
impact NN N
of IN N
pharmacological JJ N
blood NN N
pressure NN N
elevation NN N
on IN N
cortical JJ N
activation NN N
and CC N
reaction NN N
time NN N
in IN N
chronic JJ 4_p
hypotension NN 4_p
. . N

Effects NNS N
of IN N
the DT N
sympathomimetic JJ N
etilefrine NN N
were VBD N
investigated VBN N
in IN N
50 CD 3_p
hypotensive JJ 4_p
persons NNS N
based VBN N
on IN N
a DT N
randomized VBN N
, , N
placebo-controlled JJ N
double JJ N
blind NN N
design NN N
. . N

As IN N
an DT N
indicator NN N
of IN N
cortical JJ N
excitability NN N
, , N
the DT N
contingent NN N
negative JJ N
variation NN N
( ( N
CNV NNP N
) ) N
, , N
induced VBN N
by IN N
a DT N
constant JJ N
foreperiod NN N
reaction NN N
time NN N
task NN N
, , N
was VBD N
assessed VBN N
at IN N
frontal JJ N
( ( N
F3 NNP N
, , N
Fz NNP N
, , N
F4 NNP N
) ) N
and CC N
central JJ N
( ( N
C3 NNP N
, , N
Cz NNP N
, , N
C4 NNP N
) ) N
scalp NN N
sites NNS N
. . N

Etilefrine NNP N
provoked VBD N
a DT N
decrease NN N
in IN N
the DT N
frontal NN N
and CC N
central JJ N
CNV NNP N
. . N

In IN N
contrast NN N
, , N
shorter JJR N
reaction NN N
times NNS N
were VBD N
observed JJ N
following JJ N
drug NN N
administration NN N
. . N

The DT N
degree NN N
of IN N
pharmacologically RB N
induced VBN N
blood NN N
pressure NN N
elevation NN N
was VBD N
correlated VBN N
to TO N
CNV NNP N
attrition NN N
as RB N
well RB N
as IN N
to TO N
performance NN N
enhancement NN N
. . N

Inhibitory JJ N
effects NNS N
of IN N
baroreceptor NN N
activation NN N
on IN N
cortical JJ N
excitability NN N
and CC N
enhanced VBD N
cerebral JJ N
blood NN N
flow NN N
are VBP N
considered VBN N
to TO N
be VB N
involved VBN N
in IN N
mediating VBG N
the DT N
effects NNS N
of IN N
blood NN N
pressure NN N
elevation NN N
on IN N
cerebral JJ N
functioning NN N
. . N

Implications NNS N
for IN N
the DT N
treatment NN N
of IN N
chronic JJ N
hypotension NN N
are VBP N
discussed VBN N
. . N

-DOCSTART- -X- O O

White NNP N
coat NN N
effect NN N
detected VBD N
using VBG N
self-monitoring NN N
of IN N
blood NN N
pressure NN N
at IN N
home NN N
: : N
comparison NN N
with IN N
ambulatory JJ N
blood NN N
pressure NN N
. . N

The DT N
objective NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
investigate VB N
whether IN N
home NN N
blood NN N
pressure NN N
( ( N
HBP NNP N
) ) N
is VBZ N
a DT N
reliable JJ N
alternative NN N
to TO N
ambulatory VB N
blood NN N
pressure NN N
( ( N
ABP NNP N
) ) N
for IN N
the DT N
detection NN N
of IN N
the DT N
white JJ N
coat NN N
effect NN N
( ( N
WCE NNP N
) ) N
. . N

Hypertensive JJ 4_p
patients NNS N
were VBD N
randomized VBN N
to TO N
measure VB N
HBP NNP N
for IN N
2 CD N
weeks NNS N
or CC N
ABP NNP N
for IN N
24 CD N
h. PDT N
The DT N
alternative JJ N
measurement NN N
was VBD N
then RB N
performed VBN N
. . N

Clinic NNP N
blood NN N
pressure NN N
( ( N
CBP NNP N
) ) N
was VBD N
measured VBN N
in IN N
the DT N
beginning NN N
and CC N
end NN N
of IN N
the DT N
study NN N
. . N

Subjects NNS N
with IN N
a DT N
difference NN N
of IN N
> NN N
or CC N
= $ N
20 CD N
mm NN N
Hg NNP N
systolic NN N
or CC N
> NN N
or CC N
= $ N
10 CD N
mm NN N
Hg NNP N
diastolic VBZ N
BP NNP N
between IN N
CBP NNP N
and CC N
awake VB N
ABP NNP N
or CC N
CBP NNP N
and CC N
HBP NNP N
, , N
were VBD N
classified VBN N
as IN N
clinic JJ N
reactors NNS N
. . N

A DT N
total NN N
of IN N
189 CD 3_p
patients NNS N
completed VBD N
the DT N
study NN N
( ( N
79 CD 3_p
on IN N
stable JJ N
antihypertensive JJ N
treatment NN N
) ) N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
magnitude NN N
of IN N
WCE NNP N
assessed VBD N
using VBG N
the DT N
ABP NNP N
or CC N
the DT N
HBP NNP N
method NN N
( ( N
mean JJ N
discrepancy NN N
, , N
systolic JJ N
BP NNP N
: : N
-1.5 JJ N
+/- JJ N
11.7 CD N
mm NN N
Hg NNP N
, , N
95 CD N
% NN N
CI NNP N
-3.2 NNP N
, , N
0.2 CD N
; : N
diastolic JJ N
BP NNP N
: : N
0.9 CD N
+/- JJ N
7.0 CD N
, , N
95 CD N
% NN N
CI NNP N
-0.1 NNP N
, , N
1.9 CD N
) ) N
. . N

A NNP N
strong JJ N
association NN N
existed VBD N
between IN N
WCE NNP N
calculated VBD N
using VBG N
the DT N
HBP NNP N
or CC N
the DT N
ABP NNP N
method NN N
( ( N
r VB N
= RB N
0.64/0.59 CD N
systolic/diastolic JJ N
, , N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

The DT N
proportion NN N
of IN N
patients NNS N
classified VBN N
as IN N
clinic JJ N
reactors NNS N
was VBD N
identical JJ N
using VBG N
the DT N
HBP NNP N
or CC N
the DT N
ABP NNP N
method NN N
( ( N
25.9 CD N
% NN N
) ) N
. . N

Agreement NN N
between IN N
methods NNS N
in IN N
the DT N
classification NN N
of IN N
clinic JJ N
reactors NNS N
was VBD N
found VBN N
in IN N
147 CD N
patients NNS N
( ( N
78 CD N
% NN N
) ) N
. . N

The DT N
sensitivity NN N
and CC N
specificity NN N
of IN N
the DT N
HBP NNP N
method NN N
to TO N
classify VB N
correctly RB N
clinic JJ N
reactors NNS N
( ( N
ABP NNP N
method RB N
used VBD N
as IN N
the DT N
standard NN N
) ) N
were VBD N
57 CD N
% NN N
and CC N
85 CD N
% NN N
, , N
respectively RB N
, , N
whereas VBD N
its PRP$ N
positive JJ N
and CC N
negative JJ N
predictive JJ N
value NN N
were VBD N
57 CD N
% NN N
and CC N
85 CD N
% NN N
. . N

These DT N
results NNS N
indicate VBP N
that IN N
HBP NNP N
is VBZ N
not RB N
appropriate JJ N
as IN N
an DT N
alternative NN N
to TO N
ABP NNP N
diagnostic JJ N
testing NN N
in IN N
the DT N
detection NN N
of IN N
WCE NNP N
. . N

Nevertheless NNP N
, , N
HBP NNP N
appears VBZ N
useful JJ N
as IN N
a DT N
screening JJ N
test NN N
for IN N
the DT N
detection NN N
of IN N
this DT N
phenomenon NN N
. . N

-DOCSTART- -X- O O

Cytokine NN N
levels NNS N
and CC N
systemic JJ N
toxicity NN N
in IN N
patients NNS N
undergoing VBG N
isolated JJ 4_p
limb NN 4_p
perfusion NN 4_p
with IN N
high-dose JJ N
tumor NN N
necrosis NN N
factor NN N
, , N
interferon NN N
gamma NN N
, , N
and CC N
melphalan NN N
. . N

PURPOSE NNP N
Isolated NNP N
limb NN N
perfusion NN N
( ( N
ILP NNP N
) ) N
with IN N
tumor NN N
necrosis NN N
factor NN N
( ( N
TNF NNP N
) ) N
, , N
interferon JJ N
gamma NN N
, , N
and CC N
melphalan NN N
( ( N
M NNP N
) ) N
has VBZ N
been VBN N
reported VBN N
to TO N
result VB N
in IN N
high JJ N
response NN N
rates NNS N
for IN N
extremity NN N
melanoma NN N
and CC N
sarcoma NN N
. . N

We PRP N
have VBP N
evaluated VBN N
the DT N
relationship NN N
of IN N
systemic JJ N
TNF NNP N
exposure NN N
to TO N
induction NN N
of IN N
several JJ N
secondary JJ N
mediators NNS N
and CC N
incidence NN N
of IN N
systemic JJ N
toxicity NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Nineteen NNP 3_p
patients NNS N
with IN N
extremity NN 4_p
melanoma NN 4_p
( ( N
n JJ N
= NNP N
16 CD 3_p
) ) N
or CC N
sarcoma NN 4_p
( ( N
n JJ N
= NNP N
3 CD 3_p
) ) N
, , N
underwent JJ N
90-minute JJ N
ILP NNP N
with IN N
TNF-alpha NNP N
, , N
interferon NN N
gamma NN N
( ( N
0.2 CD N
mg NN N
) ) N
, , N
and CC N
M NNP N
( ( N
10 CD N
to TO N
13 CD N
mg/L NN N
of IN N
limb NN N
volume NN N
) ) N
( ( N
TNF/IFN/M NNP N
) ) N
( ( N
n JJ N
= NNP N
12 CD N
) ) N
, , N
or CC N
M NNP N
alone RB N
( ( N
n JJ N
= NNP N
7 CD N
) ) N
. . N

Continuous JJ N
intraoperative JJ N
monitoring NN N
( ( N
CIM NNP N
) ) N
for IN N
systemic JJ N
leak NN N
from IN N
the DT N
perfusion NN N
circuit NN N
was VBD N
performed VBN N
using VBG N
radioactive JJ N
iodine-131 JJ N
albumin NN N
. . N

Cytokine NN N
levels NNS N
in IN N
the DT N
perfusate NN N
and CC N
systemic JJ N
circulation NN N
during IN N
and CC N
after IN N
ILP NNP N
were VBD N
measured VBN N
by IN N
enzyme-linked JJ N
immunosorbent NN N
assay NN N
. . N

RESULTS NNP N
Systemic NNP N
leaks VBZ N
> CD N
or CC N
= VB N
1 CD N
% NN N
from IN N
the DT N
perfusion NN N
circuit NN N
occurred VBD N
in IN N
six CD N
patients NNS N
who WP N
received VBD N
TNF/IFN/M NNP N
and CC N
in IN N
four CD N
who WP N
received VBD N
M NNP N
alone RB N
. . N

Hypotension NNP N
that IN N
required VBD N
vasopressor NN N
support NN N
occurred VBD N
in IN N
six CD N
of IN N
six CD N
patients NNS N
with IN N
evidence NN N
of IN N
a DT N
leak NN N
( ( N
> CD N
or CC N
= VB N
1 CD N
% NN N
) ) N
and CC N
zero CD N
of IN N
six CD N
patients NNS N
without IN N
a DT N
leak NN N
( ( N
< JJ N
1 CD N
% NN N
) ) N
. . N

These DT N
six CD N
patients NNS N
had VBD N
significantly RB N
higher JJR N
peak JJ N
systemic JJ N
TNF NNP N
levels NNS N
during IN N
and CC N
after IN N
perfusion NN N
than IN N
patients NNS N
without IN N
a DT N
leak NN N
( ( N
2.8 CD N
and CC N
8.2 CD N
ng/mL JJ N
v NN N
0.7 CD N
and CC N
2.0 CD N
ng/mL NN N
, , N
respectively RB N
; : N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

All PDT N
patients NNS N
who WP N
received VBD N
TNF/IFN/M NNP N
had VBD N
significantly RB N
greater JJR N
increases NNS N
in IN N
systemic JJ N
interleukin-6 JJ N
( ( N
IL-6 NNP N
) ) N
levels NNS N
than IN N
in IN N
patients NNS N
with IN N
M NNP N
alone RB N
( ( N
12,395 CD N
+/- JJ N
10,374 CD N
pg/mL NN N
v NN N
79.4 CD N
+/- JJ N
7.2 CD N
pg/mL NN N
, , N
respectively RB N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

Intracellular JJ N
adhesion NN N
molecule NN N
( ( N
ICAM NNP N
) ) N
, , N
IL-8 NNP N
, , N
and CC N
TNF-R JJ N
levels NNS N
were VBD N
also RB N
increased VBN N
after IN N
ILP NNP N
with IN N
TNF/IFN/M NNP N
. . N

CONCLUSION NNP N
ILP NNP N
with IN N
TNF/IFN/M NNP N
can MD N
be VB N
safely RB N
performed VBN N
, , N
as IN N
I131 NNP N
albumin VBP N
provides VBZ N
a DT N
sensitive JJ N
measure NN N
of IN N
systemic JJ N
leakage NN N
from IN N
the DT N
perfusion NN N
circuit NN N
. . N

Patients NNS N
with IN N
a DT N
measured JJ N
leak NN N
of IN N
> NN N
or CC N
= VB N
1 CD N
% NN N
develop NN N
mild NN N
and CC N
transient JJ N
postoperative JJ N
hypotension NN N
with IN N
significantly RB N
higher JJR N
systemic JJ N
TNF NNP N
levels NNS N
and CC N
lower JJR N
perfusate NN N
TNF NNP N
levels NNS N
than IN N
in IN N
patients NNS N
without IN N
leaks NNS N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
long-term JJ N
vitamin NN N
E NNP N
supplementation NN N
on IN N
cardiovascular JJ 4_p
events NNS 4_p
and CC N
cancer NN 4_p
: : N
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

CONTEXT NNP N
Experimental NNP N
and CC N
epidemiological JJ N
data NNS N
suggest VBP N
that IN N
vitamin NN N
E NNP N
supplementation NN N
may MD N
prevent VB N
cancer NN 4_p
and CC N
cardiovascular JJ 4_p
events NNS 4_p
. . N

Clinical JJ N
trials NNS N
have VBP N
generally RB N
failed VBN N
to TO N
confirm VB N
benefits NNS N
, , N
possibly RB N
due JJ N
to TO N
their PRP$ N
relatively RB N
short JJ N
duration NN N
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
whether IN N
long-term JJ N
supplementation NN N
with IN N
vitamin JJ N
E NN N
decreases VBZ N
the DT N
risk NN N
of IN N
cancer NN N
, , N
cancer NN N
death NN N
, , N
and CC N
major JJ N
cardiovascular JJ N
events NNS N
. . N

DESIGN NNP N
, , N
SETTING NNP N
, , N
AND NNP N
PATIENTS NNP N
A NNP N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
international JJ N
trial NN N
( ( N
the DT N
initial JJ N
Heart NNP N
Outcomes NNP N
Prevention NNP N
Evaluation NNP N
[ NNP N
HOPE NNP N
] NNP N
trial NN N
conducted VBD N
between IN N
December NNP N
21 CD N
, , N
1993 CD N
, , N
and CC N
April NNP N
15 CD N
, , N
1999 CD N
) ) N
of IN N
patients NNS N
at IN N
least JJS N
55 CD 1_p
years NNS N
old JJ N
with IN N
vascular JJ 4_p
disease NN 4_p
or CC N
diabetes VBZ 4_p
mellitus NN 4_p
was VBD N
extended VBN N
( ( N
HOPE-The NNP N
Ongoing NNP N
Outcomes NNP N
[ NNP N
HOPE-TOO NNP N
] NNP N
) ) N
between IN N
April NNP N
16 CD N
, , N
1999 CD N
, , N
and CC N
May NNP N
26 CD N
, , N
2003 CD N
. . N

Of IN N
the DT N
initial JJ N
267 CD N
HOPE NNP N
centers NNS N
that WDT N
had VBD N
enrolled VBN N
9541 CD 3_p
patients NNS N
, , N
174 CD N
centers NNS N
participated VBN N
in IN N
the DT N
HOPE-TOO NNP N
trial NN N
. . N

Of IN N
7030 CD 3_p
patients NNS N
enrolled VBN N
at IN N
these DT N
centers NNS N
, , N
916 CD N
were VBD N
deceased VBN N
at IN N
the DT N
beginning NN N
of IN N
the DT N
extension NN N
, , N
1382 CD N
refused VBD N
participation NN N
, , N
3994 CD N
continued VBD N
to TO N
take VB N
the DT N
study NN N
intervention NN N
, , N
and CC N
738 CD N
agreed VBD N
to TO N
passive VB N
follow-up NN N
. . N

Median JJ N
duration NN N
of IN N
follow-up NN N
was VBD N
7.0 CD N
years NNS N
. . N

INTERVENTION NNP N
Daily NNP N
dose NN N
of IN N
natural JJ N
source NN N
vitamin NN N
E NNP N
( ( N
400 CD N
IU NNP N
) ) N
or CC N
matching VBG N
placebo NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Primary NNP N
outcomes NNS N
included VBD N
cancer NN N
incidence NN N
, , N
cancer NN N
deaths NNS N
, , N
and CC N
major JJ N
cardiovascular JJ N
events NNS N
( ( N
myocardial JJ N
infarction NN N
, , N
stroke NN N
, , N
and CC N
cardiovascular JJ N
death NN N
) ) N
. . N

Secondary JJ N
outcomes NNS N
included VBD N
heart NN N
failure NN N
, , N
unstable JJ N
angina NN N
, , N
and CC N
revascularizations NNS N
. . N

RESULTS NNP N
Among IN N
all DT N
HOPE NNP N
patients NNS N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
primary JJ N
analysis NN N
: : N
for IN N
cancer NN N
incidence NN N
, , N
there EX N
were VBD N
552 CD N
patients NNS N
( ( N
11.6 CD N
% NN N
) ) N
in IN N
the DT N
vitamin NN N
E NNP N
group NN N
vs VBD N
586 CD N
( ( N
12.3 CD N
% NN N
) ) N
in IN N
the DT N
placebo NN N
group NN N
( ( N
relative JJ N
risk NN N
[ NNP N
RR NNP N
] NNP N
, , N
0.94 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
0.84-1.06 NNP N
; : N
P NNP N
= NNP N
.30 NNP N
) ) N
; : N
for IN N
cancer NN N
deaths NNS N
, , N
156 CD N
( ( N
3.3 CD N
% NN N
) ) N
vs NN N
178 CD N
( ( N
3.7 CD N
% NN N
) ) N
, , N
respectively RB N
( ( N
RR NNP N
, , N
0.88 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.71-1.09 NNP N
; : N
P NNP N
= NNP N
.24 NNP N
) ) N
; : N
and CC N
for IN N
major JJ N
cardiovascular JJ N
events NNS N
, , N
1022 CD N
( ( N
21.5 CD N
% NN N
) ) N
vs NN N
985 CD N
( ( N
20.6 CD N
% NN N
) ) N
, , N
respectively RB N
( ( N
RR NNP N
, , N
1.04 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.96-1.14 NNP N
; : N
P NNP N
= NNP N
.34 NNP N
) ) N
. . N

Patients NNS N
in IN N
the DT N
vitamin NN N
E NNP N
group NN N
had VBD N
a DT N
higher JJR N
risk NN N
of IN N
heart NN N
failure NN N
( ( N
RR NNP N
, , N
1.13 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
1.01-1.26 JJ N
; : N
P NNP N
= NNP N
.03 NNP N
) ) N
and CC N
hospitalization NN N
for IN N
heart NN N
failure NN N
( ( N
RR NNP N
, , N
1.21 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
1.00-1.47 JJ N
; : N
P NNP N
= NNP N
.045 NNP N
) ) N
. . N

Similarly RB N
, , N
among IN N
patients NNS N
enrolled VBN N
at IN N
the DT N
centers NNS N
participating VBG N
in IN N
the DT N
HOPE-TOO NNP N
trial NN N
, , N
there EX N
were VBD N
no DT N
differences NNS N
in IN N
cancer NN N
incidence NN N
, , N
cancer NN N
deaths NNS N
, , N
and CC N
major JJ N
cardiovascular JJ N
events NNS N
, , N
but CC N
higher JJR N
rates NNS N
of IN N
heart NN N
failure NN N
and CC N
hospitalizations NNS N
for IN N
heart NN N
failure NN N
. . N

CONCLUSION NNP N
In IN N
patients NNS N
with IN N
vascular JJ N
disease NN N
or CC N
diabetes VBZ N
mellitus NNS N
, , N
long-term JJ N
vitamin NN N
E NNP N
supplementation NN N
does VBZ N
not RB N
prevent VB N
cancer NN N
or CC N
major JJ N
cardiovascular JJ N
events NNS N
and CC N
may MD N
increase VB N
the DT N
risk NN N
for IN N
heart NN N
failure NN N
. . N

-DOCSTART- -X- O O

Sex NN N
risk NN N
behavior NN N
among IN N
adolescent JJ 1_p
and CC N
young JJ 1_p
adult NN 1_p
children NNS 1_p
of IN N
opiate JJ 4_p
addicts NNS 4_p
: : N
outcomes NNS N
from IN N
the DT N
focus NN N
on IN N
families NNS N
prevention VBP N
trial NN N
and CC N
an DT N
examination NN N
of IN N
childhood NN N
and CC N
concurrent JJ N
predictors NNS N
of IN N
sex NN N
risk NN N
behavior NN N
. . N

This DT N
study NN N
reports VBZ N
on IN N
rates NNS N
and CC N
predictors NNS N
of IN N
sex NN N
risk NN N
behavior NN N
among IN N
a DT N
sample NN N
of IN N
adolescent NN 1_p
and CC N
young JJ 1_p
adult NN 1_p
children NNS 1_p
of IN N
parents NNS N
enrolled VBN N
in IN N
methadone NN N
treatment NN N
for IN N
opiate JJ 4_p
addiction NN 4_p
. . N

Data NNS N
are VBP N
from IN N
151 CD 3_p
participants NNS N
( ( N
80 CD 3_p
males NNS 2_p
, , N
71 CD 3_p
females NNS 2_p
) ) N
in IN N
the DT N
Focus NNP N
on IN N
Families NNP N
( ( N
FOF NNP N
) ) N
project NN N
, , N
a DT N
randomized JJ N
trial NN N
of IN N
a DT N
family NN N
intervention NN N
and CC N
a DT N
study NN N
of IN N
the DT N
development NN N
of IN N
at-risk JJ N
children NNS N
. . N

The DT N
study NN N
participants NNS N
are VBP N
children NNS N
of IN N
parents NNS N
enrolled VBN N
in IN N
methadone NN N
treatment NN N
between IN N
1990 CD N
and CC N
1993 CD N
. . N

Participants NNS N
were VBD N
interviewed VBN N
in IN N
2005 CD N
when WRB N
they PRP N
ranged VBD N
in IN N
age NN N
from IN N
15 CD 1_p
to TO 1_p
29 CD 1_p
years NNS N
. . N

In IN N
the DT N
year NN N
prior RB N
to TO N
the DT N
follow-up NN N
, , N
79 CD N
% NN N
of IN N
the DT N
males NNS N
and CC N
83 CD N
% NN N
of IN N
females NNS N
were VBD N
sexually RB N
active JJ N
, , N
26 CD N
% NN N
of IN N
males NNS N
and CC N
10 CD N
% NN N
of IN N
females NNS N
had VBD N
more JJR N
than IN N
one CD N
partner NN N
in IN N
the DT N
prior JJ N
year NN N
, , N
and CC N
34 CD N
% NN N
of IN N
males NNS N
and CC N
24 CD N
% NN N
of IN N
females NNS N
reported VBN N
having VBG N
sex NN N
outside IN N
of IN N
a DT N
committed JJ N
relationship NN N
. . N

Twenty-four CD N
percent NN N
of IN N
males NNS N
and CC N
17 CD N
% NN N
of IN N
females NNS N
met VBD N
criteria NNS N
for IN N
high-risk JJ N
sexual JJ N
behavior NN N
, , N
reporting VBG N
casual JJ N
or CC N
multiple JJ N
partners NNS N
in IN N
the DT N
prior JJ N
year NN N
and CC N
inconsistent NN N
condom NN N
use NN N
. . N

Participants NNS N
in IN N
the DT N
intervention NN N
and CC N
control NN N
conditions NNS N
did VBD N
not RB N
differ VB N
significantly RB N
in IN N
terms NNS N
of IN N
any DT N
measure NN N
of IN N
sex NN N
risk NN N
behavior NN N
examined VBN N
. . N

None NN N
of IN N
the DT N
measures NNS N
of IN N
parent NN N
behavior NN N
and CC N
family NN N
processes NNS N
derived VBN N
from IN N
data NNS N
at IN N
baseline NN N
of IN N
the DT N
FOF NNP N
study NN N
predicted VBD N
whether IN N
participants NNS N
engaged VBN N
in IN N
high-risk JJ N
sex NN N
. . N

Among IN N
measures NNS N
derived VBN N
from IN N
data NNS N
collected VBN N
at IN N
long-term JJ N
follow-up NN N
, , N
however RB N
, , N
having VBG N
ever RB N
met VBN N
criteria NNS N
for IN N
substance NN N
abuse NN N
or CC N
dependence NN N
predicted VBN N
greater JJR N
likelihood NN N
of IN N
high-risk JJ N
sexual JJ N
behavior NN N
, , N
and CC N
being VBG N
married VBD N
or CC N
being VBG N
in IN N
a DT N
romantic JJ N
relationship NN N
was VBD N
associated VBN N
with IN N
lower JJR N
likelihood NN N
of IN N
high-risk JJ N
sexual JJ N
behavior NN N
. . N

The DT N
findings NNS N
point NN N
to TO N
the DT N
important JJ N
role NN N
of IN N
committed JJ N
relationships NNS N
in IN N
regulating VBG N
sex NN N
risk NN N
behavior NN N
among IN N
this DT N
population NN N
, , N
as RB N
well RB N
as IN N
heightened VBN N
levels NNS N
of IN N
sex NN N
risk NN N
behavior NN N
associated VBN N
with IN N
substance NN N
abuse NN N
or CC N
dependence NN N
. . N

-DOCSTART- -X- O O

A DT N
prospective JJ N
, , N
double-blind JJ N
, , N
randomized VBN N
, , N
controlled VBD N
clinical JJ N
trial NN N
comparing VBG N
standard NN N
wound NN N
care NN N
with IN N
adjunctive JJ N
hyperbaric JJ N
oxygen NN N
therapy NN N
( ( N
HBOT NNP N
) ) N
to TO N
standard VB N
wound NN N
care NN N
only RB N
for IN N
the DT N
treatment NN N
of IN N
chronic JJ 4_p
, , N
non-healing JJ 4_p
ulcers NNS 4_p
of IN N
the DT N
lower JJR 4_p
limb NN 4_p
in IN N
patients NNS N
with IN N
diabetes NNS 4_p
mellitus NNS 4_p
: : N
a DT N
study NN N
protocol NN N
. . N

BACKGROUND NNP N
It PRP N
has VBZ N
been VBN N
suggested VBN N
that IN N
the DT N
use NN N
of IN N
adjunctive JJ N
hyperbaric JJ N
oxygen NN N
therapy NN N
improves VBZ N
the DT N
healing NN N
of IN N
diabetic JJ N
foot NN N
ulcers NNS N
, , N
and CC N
decreases VBZ N
the DT N
risk NN N
of IN N
lower JJR N
extremity NN N
amputations NNS N
. . N

A DT N
limited JJ N
number NN N
of IN N
studies NNS N
have VBP N
used VBN N
a DT N
double JJ N
blind NN N
approach NN N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
hyperbaric JJ N
oxygen NN N
therapy NN N
in IN N
the DT N
treatment NN N
of IN N
diabetic JJ 4_p
ulcers NNS 4_p
. . N

The DT N
primary JJ N
aim NN N
of IN N
this DT N
study NN N
is VBZ N
to TO N
assess VB N
the DT N
efficacy NN N
of IN N
hyperbaric JJ N
oxygen NN N
therapy NN N
plus CC N
standard NN N
wound NN N
care NN N
compared VBN N
with IN N
standard NN N
wound NN N
care NN N
alone RB N
in IN N
preventing VBG N
the DT N
need NN N
for IN N
major JJ N
amputation NN N
in IN N
patients NNS N
with IN N
diabetes NNS N
mellitus NNS N
and CC N
chronic JJ 4_p
ulcers NNS 4_p
of IN N
the DT N
lower JJR 4_p
limb NN 4_p
. . N

METHODS/DESIGN NNP N
One CD 3_p
hundred CD 3_p
and CC 3_p
eighteen JJ 3_p
( ( N
59 CD 3_p
patients NNS N
per IN N
arm NN N
) ) N
patients NNS N
with IN N
non-healing JJ 4_p
diabetic JJ 4_p
ulcers NNS 4_p
of IN N
the DT N
lower JJR 4_p
limb NN 4_p
, , N
referred VBD N
to TO N
the DT N
Judy NNP N
Dan NNP N
Research NNP N
and CC N
Treatment NNP N
Centre NNP N
are VBP N
being VBG N
recruited VBN N
if IN N
they PRP N
are VBP N
at IN N
least JJS N
18 CD 1_p
years NNS N
of IN N
age NN N
, , N
have VBP N
either DT N
Type NNP 4_p
1 CD 4_p
or CC 4_p
2 CD 4_p
diabetes NNS 4_p
with IN N
a DT N
Wagner NNP N
grading NN N
of IN N
foot NN N
lesions NNS N
2 CD N
, , N
3 CD N
or CC N
4 CD N
on IN N
lower JJR N
limb NN N
not RB N
healing VBG N
for IN N
at IN N
least JJS N
4 CD N
weeks NNS N
. . N

Patients NNS N
receive JJ N
hyperbaric JJ N
oxygen NN N
therapy NN N
every DT N
day NN N
for IN N
6 CD N
weeks NNS N
during IN N
the DT N
treatment NN N
phase NN N
and CC N
are VBP N
provided VBN N
ongoing VBG N
wound NN N
care NN N
and CC N
weekly JJ N
assessments NNS N
. . N

Patients NNS N
are VBP N
required VBN N
to TO N
return VB N
to TO N
the DT N
study NN N
centre NN N
every DT N
week NN N
for IN N
an DT N
additional JJ N
6 CD N
weeks NNS N
of IN N
follow-up NN N
for IN N
wound JJ N
evaluation NN N
and CC N
management NN N
. . N

The DT N
primary JJ N
outcome NN N
is VBZ N
freedom RB N
from IN N
having VBG N
, , N
or CC N
meeting VBG N
the DT N
criteria NN N
for IN N
, , N
a DT N
major JJ N
amputation NN N
( ( N
below IN N
knee NN N
amputation NN N
, , N
or CC N
metatarsal VB N
level NN N
) ) N
up RB N
to TO N
12 CD N
weeks NNS N
after IN N
randomization NN N
. . N

The DT N
decision NN N
to TO N
amputate VB N
is VBZ N
made VBN N
by IN N
a DT N
vascular JJ N
surgeon NN N
. . N

Other JJ N
outcomes NNS N
include VBP N
wound IN N
healing NN N
, , N
effectiveness NN N
, , N
safety NN N
, , N
healthcare JJ N
resource NN N
utilization NN N
, , N
quality NN N
of IN N
life NN N
, , N
and CC N
cost-effectiveness NN N
. . N

The DT N
study NN N
will MD N
run VB N
for IN N
a DT N
total NN N
of IN N
about IN N
3 CD N
years NNS N
. . N

DISCUSSION VB N
The DT N
results NNS N
of IN N
this DT N
study NN N
will MD N
provide VB N
detailed JJ N
information NN N
on IN N
the DT N
efficacy NN N
of IN N
hyperbaric JJ N
oxygen NN N
therapy NN N
for IN N
the DT N
treatment NN N
of IN N
non-healing JJ N
ulcers NNS N
of IN N
the DT N
lower JJR N
limb NN N
. . N

This DT N
will MD N
be VB N
the DT N
first JJ N
double-blind JJ N
randomized VBN N
controlled JJ N
trial NN N
for IN N
this DT N
health NN N
technology NN N
which WDT N
evaluates VBZ N
the DT N
efficacy NN N
of IN N
hyperbaric JJ N
oxygen NN N
therapy NN N
in IN N
prevention NN N
of IN N
amputations NNS N
in IN N
diabetic JJ N
patients NNS N
. . N

TRIAL NNP N
REGISTRATION NNP N
ClinicalTrials.gov NNP N
Identifier NNP N
: : N
NCT00621608 NN N
. . N

-DOCSTART- -X- O O

Randomized VBN N
trial NN N
of IN N
tailored JJ N
skin NN 4_p
cancer NN 4_p
prevention NN N
for IN N
children NNS 1_p
: : N
the DT N
Project NNP N
SCAPE NNP N
family NN N
study NN N
. . N

This DT N
study NN N
evaluated VBD N
a DT N
tailored VBN N
intervention NN N
to TO N
promote VB N
sun NN N
protection NN N
in IN N
parents NNS 1_p
and CC N
their PRP$ N
children NNS N
, , N
hypothesizing VBG N
that IN N
the DT N
tailored VBN N
intervention NN N
would MD N
lead VB N
to TO N
improved JJ N
skin NN N
cancer NN N
prevention NN N
behaviors NNS N
compared VBN N
to TO N
generic JJ N
materials NNS N
. . N

Families NNS N
were VBD N
recruited VBN N
through IN N
schools NNS N
and CC N
community NN N
centers NNS N
and CC N
were VBD N
included VBN N
if IN N
there EX N
was VBD N
1 CD N
child NN N
in IN N
Grades NNP N
1-3 JJ N
at IN N
moderate JJ N
to TO N
high JJ N
risk NN N
for IN N
skin JJ N
cancer NN N
. . N

Participants NNS N
were VBD N
randomized VBN N
into IN N
one CD N
of IN N
two CD N
intervention NN N
groups NNS N
: : N
a DT N
tailored JJ N
intervention NN N
, , N
in IN N
which WDT N
they PRP N
received VBD N
personalized JJ N
skin NN N
cancer NN N
education NN N
through IN N
the DT N
mail NN N
; : N
or CC N
a DT N
control NN N
group NN N
who WP N
received VBD N
generic JJ N
skin NN N
cancer NN N
information NN N
materials NNS N
. . N

Before IN N
and CC N
after IN N
intervention NN N
, , N
parents NNS N
completed VBD N
questionnaires NNS N
about IN N
their PRP$ N
and CC N
their PRP$ N
children NNS N
's POS N
skin NN N
cancer NN N
risk NN N
and CC N
prevention NN N
knowledge NN N
and CC N
behaviors NNS N
. . N

Parents NNS N
also RB N
completed VBD N
4-day JJ N
sun NN N
exposure NN N
and CC N
protection NN N
diaries NNS N
for IN N
their PRP$ N
child NN N
and CC N
themselves PRP N
. . N

Tailored VBN N
group NN N
participants NNS N
demonstrated VBD N
significantly RB N
greater JJR N
positive JJ N
changes NNS N
in IN N
prevention NN N
behavior NN N
after IN N
the DT N
intervention NN N
, , N
including VBG N
children NNS N
's POS N
use NN N
of IN N
sunscreen NN N
, , N
shirts NNS N
, , N
and CC N
hats NNS N
, , N
and CC N
parents NNS N
' POS N
use NN N
of IN N
shade NN N
, , N
and CC N
skin JJ N
examinations NNS N
. . N

Effect JJ N
sizes NNS N
were VBD N
small JJ N
and CC N
perceived JJ N
benefits NNS N
and CC N
social JJ N
norms NNS N
mediated VBN N
intervention NN N
effects NNS N
. . N

Findings NNS N
from IN N
this DT N
study NN N
support VBD N
the DT N
efficacy NN N
of IN N
focusing VBG N
tailored VBN N
communications NNS N
to TO N
families NNS N
in IN N
order NN N
to TO N
change VB N
skin JJ N
cancer NN N
prevention NN N
practices NNS N
in IN N
young JJ 1_p
children NNS N
. . N

-DOCSTART- -X- O O

Allogeneic NNP N
marrow NN N
transplantation NN N
in IN N
patients NNS N
with IN N
chronic JJ 4_p
myeloid NN 4_p
leukemia NN 4_p
in IN N
the DT N
chronic JJ 4_p
phase NN 4_p
: : N
a DT N
randomized JJ N
trial NN N
of IN N
two CD N
irradiation NN N
regimens NNS N
. . N

A DT N
randomized JJ N
trial NN N
was VBD N
performed VBN N
to TO N
compare VB N
two CD N
regimens NNS N
of IN N
total JJ N
body NN N
irradiation NN N
in IN N
patients NNS N
with IN N
chronic JJ 4_p
myeloid NN 4_p
leukemia NN 4_p
treated VBN N
by IN N
allogeneic JJ 4_p
marrow NN 4_p
transplantation NN 4_p
while IN N
in IN N
the DT N
chronic JJ 4_p
phase NN 4_p
. . N

All DT N
patients NNS N
received VBD N
cyclophosphamide JJ N
120 CD N
mg/kg NN N
followed VBN N
by IN N
total JJ N
body NN N
irradiation NN N
and CC N
marrow NN N
from IN N
HLA-identical JJ N
siblings NNS N
. . N

Cyclosporine NNP N
and CC N
methotrexate NN N
were VBD N
used VBN N
for IN N
prophylaxis NN N
against IN N
acute JJ N
graft-versus-host JJ N
disease NN N
. . N

Fifty-seven JJ 3_p
patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
2.0 CD N
Gy NNP N
fractions NNS N
of IN N
irradiation NN N
daily NN N
for IN N
6 CD N
days NNS N
and CC N
59 CD N
were VBD N
randomized VBN N
to TO N
receive VB N
2.25 CD N
Gy NNP N
fractions NNS N
daily RB N
for IN N
7 CD N
days NNS N
. . N

The DT N
probabilities NNS N
of IN N
relapse NN N
at IN N
4 CD N
years NNS N
were VBD N
0.25 CD N
for IN N
the DT N
12.0 CD N
Gy NNP N
group NN N
and CC N
0.00 CD N
for IN N
the DT N
15.75 CD N
Gy NNP N
group NN N
( ( N
P NNP N
= NNP N
.008 NNP N
) ) N
. . N

The DT N
actuarial JJ N
probabilities NNS N
of IN N
survival NN N
and CC N
relapse-free JJ N
survival NN N
at IN N
4 CD N
years NNS N
were VBD N
0.60 CD N
and CC N
0.58 CD N
among IN N
the DT N
patients NNS N
who WP N
received VBD N
12.0 CD N
Gy NNP N
compared VBN N
with IN N
0.66 CD N
and CC N
0.66 CD N
for IN N
those DT N
who WP N
received VBD N
15.75 CD N
Gy NNP N
. . N

The DT N
4-year JJ N
probabilities NNS N
of IN N
transplant-related JJ N
mortality NN N
were VBD N
0.24 CD N
and CC N
0.34 CD N
respectively RB N
( ( N
P NNP N
= NNP N
.13 NNP N
) ) N
while IN N
the DT N
probability NN N
of IN N
moderate JJ N
to TO N
severe VB N
acute JJ N
graft-versus-host JJ N
disease NN N
was VBD N
0.33 CD N
for IN N
the DT N
12.0 CD N
Gy NNP N
group NN N
and CC N
0.44 CD N
for IN N
the DT N
15.75 CD N
Gy NNP N
group NN N
( ( N
P NNP N
= NNP N
.15 NNP N
) ) N
. . N

The DT N
lower JJR N
relapse NN N
probability NN N
in IN N
the DT N
patients NNS N
receiving VBG N
the DT N
higher JJR N
dose NN N
of IN N
total JJ N
body NN N
irradiation NN N
did VBD N
not RB N
result VB N
in IN N
improved JJ N
survival NN N
because IN N
mortality NN N
from IN N
causes VBZ N
other JJ N
than IN N
relapse NN N
was VBD N
increased VBN N
. . N

-DOCSTART- -X- O O

Pedantic JJ N
speaking NN N
style NN N
differentiates VBZ N
Asperger NNP N
syndrome NN N
from IN N
high-functioning JJ N
autism NN N
. . N

Asperger NNP N
syndrome NN N
( ( N
AS IN N
) ) N
is VBZ N
a DT N
pervasive JJ N
developmental NN N
disorder NN N
recently RB N
introduced VBD N
as IN N
a DT N
new JJ N
diagnostic JJ N
category NN N
in IN N
the DT N
ICD-10 NNP N
and CC N
the DT N
DSM-IV NNP N
. . N

Along IN N
with IN N
motor NN N
clumsiness NN N
, , N
pedantic JJ N
speech NN N
has VBZ N
been VBN N
proposed VBN N
as IN N
a DT N
clinical JJ N
feature NN N
of IN N
AS NNP N
. . N

However RB N
, , N
few JJ N
attempts NNS N
have VBP N
been VBN N
made VBN N
to TO N
define VB N
and CC N
measure VB N
this DT N
symptom NN N
. . N

We PRP N
studied VBD N
17 CD 3_p
patients NNS N
with IN N
AS NNP 4_p
( ( N
ICD-10 NNP N
; : N
14 CD 3_p
male NN 2_p
, , N
3 CD 3_p
female NN 2_p
; : N
mean JJ N
age NN N
16.4 CD 1_p
years NNS N
, , N
mean JJ N
full-scale JJ N
IQ NNP N
97 CD N
) ) N
and CC N
compared VBN N
them PRP N
with IN N
a DT N
control NN N
group NN N
of IN N
13 CD 3_p
patients NNS N
with IN N
normal-intelligence JJ 4_p
autism NN 4_p
or CC N
high-functioning JJ 4_p
autism NN 4_p
( ( N
HFA NNP 4_p
) ) N
( ( N
ICD-10/DSM-III-R NNP N
; : N
12 CD 3_p
male NN 2_p
, , N
1 CD 3_p
female NN 2_p
; : N
mean JJ N
age NN N
15.5 CD 1_p
years NNS N
, , N
mean JJ N
full-scale JJ N
IQ NNP N
81.2 CD N
) ) N
. . N

An DT N
operational JJ N
definition NN N
of IN N
pedantic JJ N
speech NN N
was VBD N
formulated VBN N
and CC N
a DT N
rating NN N
scale NN N
devised VBD N
. . N

13 CD N
( ( N
76 CD N
% NN N
) ) N
of IN N
the DT N
AS NNP 4_p
patients NNS N
were VBD N
rated VBN N
as IN N
pedantic JJ N
compared VBN N
to TO N
4 CD N
( ( N
31 CD N
% NN N
) ) N
of IN N
the DT N
HFA NNP 4_p
group NN N
( ( N
chi JJ N
2 CD N
= JJ N
6.3 CD N
; : N
p NN N
= NNP N
.01 NNP N
) ) N
. . N

Results VB N
suggest JJS N
that IN N
pedantic JJ N
speech NN N
is VBZ N
common JJ N
in IN N
AS NNP N
and CC N
may MD N
help VB N
differentiate VB N
AS IN N
from IN N
high-functioning JJ N
autism NN N
. . N

-DOCSTART- -X- O O

Chemotherapy NN N
of IN N
large JJ 4_p
bowel NN 4_p
carcinoma NN 4_p
-- : N
fluorouracil NN N
( ( N
FU NNP N
) ) N
+ VBP N
hydroxyurea NN N
( ( N
HU NNP N
) ) N
vs. FW N
methyl-CCNU NN N
, , N
oncovin NN N
, , N
fluorouracil NN N
, , N
and CC N
streptozotocin NN N
( ( N
MOF-Strep NNP N
) ) N
. . N

An DT N
Eastern JJ N
Cooperative NNP N
Oncology NNP N
Group NNP N
study NN N
. . N

In IN N
this DT N
prospective JJ N
randomized NN N
study NN N
of IN N
initial JJ N
chemotherapy NN N
for IN N
advanced JJ 4_p
measurable JJ 4_p
metastatic JJ 4_p
large JJ 4_p
bowel NN 4_p
carcinoma NN 4_p
, , N
the DT N
response NN N
rate NN N
was VBD N
6/32 CD N
( ( N
19 CD N
% NN N
) ) N
for IN N
FU NNP N
+ NNP N
HU NNP N
and CC N
5/32 CD N
( ( N
16 CD N
% NN N
) ) N
for IN N
MOF-Strep NNP N
; : N
the DT N
estimated JJ N
median JJ N
survival NN N
is VBZ N
43 CD N
weeks NNS N
for IN N
both DT N
treatments NNS N
. . N

Patients NNS N
who WP N
received VBD N
MOF-Strep NNP N
experienced VBD N
substantially RB N
greater JJR N
vomiting VBG N
and CC N
hematologic JJ N
toxicity NN N
than IN N
patients NNS N
who WP N
received VBD N
FU NNP N
+ NNP N
HU NNP N
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
. . N

-DOCSTART- -X- O O

Attenuation NN N
of IN N
hemodynamic JJ N
responses NNS N
to TO N
laryngoscopy VB N
and CC N
tracheal VB N
intubation NN N
during IN N
rapid JJ N
sequence NN N
induction NN N
: : N
remifentanil NN N
vs. FW N
lidocaine NN N
with IN N
esmolol NN N
. . N

AIM NNP N
This DT N
study NN N
was VBD N
designed VBN N
to TO N
compare VB N
the DT N
effectiveness NN N
of IN N
remifentanil NN N
vs. FW N
a DT N
lidocaine-esmolol JJ N
combination NN N
in IN N
blunting VBG N
the DT N
hemodynamic JJ N
response NN N
to TO N
laryngoscopy VB N
and CC N
intubation NN N
during IN N
rapid JJ N
sequence NN N
induction NN N
using VBG N
thiopental JJ N
and CC N
rocuronium NN N
in IN N
normotensive JJ 4_p
patients NNS N
. . N

METHODS NNP N
Sixty-six JJ 3_p
patients NNS N
with IN N
American JJ N
Society NNP N
of IN N
Anesthesiologists NNP N
( ( 4_p
ASA NNP 4_p
) ) 4_p
physical JJ 4_p
status NN 4_p
class NN 4_p
I PRP 4_p
who WP N
required VBD N
tracheal JJ 4_p
intubation NN 4_p
for IN N
elective JJ N
surgery NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
two CD N
groups NNS N
. . N

Group NNP N
R NNP N
received VBD N
0.9 CD N
% NN N
saline NN N
10 CD N
ml NN N
and CC N
remifentanil VB N
1 CD N
microg/kg NN N
. . N

Group NNP N
LE NNP N
received VBD N
lidocaine JJ N
1.5 CD N
mg/kg NN N
and CC N
esmolol $ N
1.0 CD N
mg/kg NN N
. . N

Anesthesia NNP N
was VBD N
induced VBN N
with IN N
thiopental JJ N
sodium NN N
5 CD N
mg/kg NN N
, , N
followed VBN N
by IN N
rocuronium NN N
1.0 CD N
mg/kg NN N
. . N

Mean NNP N
arterial JJ N
pressure NN N
and CC N
heart NN N
rate NN N
were VBD N
recorded VBN N
at IN N
baseline NN N
, , N
after IN N
induction NN N
, , N
immediately RB N
after IN N
intubation NN N
and CC N
every DT N
minute NN N
for IN N
five CD N
minutes NNS N
after IN N
intubation NN N
. . N

RESULTS NNP N
Changes NNP N
in IN N
mean JJ N
arterial JJ N
pressure NN N
over IN N
time NN N
between IN N
the DT N
two CD N
groups NNS N
were VBD N
significantly RB N
different JJ N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

The DT N
maximum JJ N
pressor NN N
response NN N
was VBD N
observed VBN N
immediately RB N
after IN N
intubation NN N
, , N
at IN N
which WDT N
time NN N
the DT N
mean JJ N
arterial JJ N
pressure NN N
change NN N
from IN N
baseline NN N
in IN N
group NN N
LE NNP N
( ( N
29.7 CD N
% NN N
) ) N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NN N
: : N
116.1 CD N
, , N
121.9 CD N
) ) N
was VBD N
higher JJR N
than IN N
that DT N
in IN N
group NN N
R NNP N
( ( N
4.4 CD N
% NN N
) ) N
( ( N
95 CD N
% NN N
CI NNP N
: : N
92.9 CD N
, , N
98.5 CD N
) ) N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

Two CD N
patients NNS N
in IN N
group NN N
R NNP N
and CC N
15 CD N
patients NNS N
in IN N
group NN N
LE NNP N
developed VBD N
hypertension NN N
( ( N
odds NNS N
ratio VBP N
[ CD N
OR NNP N
] NN N
: : N
0.064 CD N
) ) N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Changes NNS N
in IN N
heart NN N
rate NN N
over IN N
time NN N
between IN N
the DT N
two CD N
groups NNS N
were VBD N
not RB N
significantly RB N
different JJ N
( ( N
P=0.465 NNP N
) ) N
. . N

CONCLUSION VB N
The DT N
results NNS N
of IN N
this DT N
study NN N
show NN N
that IN N
remifentanil VBZ N
1 CD N
mg/kg NN N
is VBZ N
more RBR N
effective JJ N
than IN N
the DT N
combination NN N
of IN N
lidocaine JJ N
1.5 CD N
mg/kg NN N
and CC N
esmolol $ N
1 CD N
mg/kg NN N
for IN N
attenuating VBG N
the DT N
hemodynamic JJ N
responses NNS N
to TO N
rapid JJ N
sequence NN N
intubation NN N
. . N

-DOCSTART- -X- O O

[ JJ N
Usage NN N
of IN N
titanoreine NN N
after IN N
procedure NN 4_p
for IN 4_p
prolapse NN 4_p
and CC 4_p
hemorrhoids NNS 4_p
] NNP N
. . N

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
effect NN N
of IN N
titanoreine NN N
on IN N
early JJ N
postoperative NN N
symptoms NNS N
after IN N
procedure NN N
for IN N
prolapse NN N
and CC N
hemorrhoids NNS N
( ( N
PPH NNP N
) ) N
. . N

METHODS NNP N
From IN N
November NNP N
2002 CD N
to TO N
July NNP N
2003 CD N
, , N
80 CD 3_p
patients NNS N
who WP N
received VBD N
PPH NNP N
were VBD N
randomly RB N
divided VBN N
in IN N
to TO N
titanoreine VB N
group NN N
( ( N
n=42 CC N
) ) N
and CC N
control VB N
group NN N
without IN N
titanoreine NN N
( ( N
n=38 JJ N
) ) N
. . N

Symptom JJ N
relief NN N
was VBD N
recorded VBN N
24 CD N
hours NNS N
, , N
6 CD N
days NNS N
and CC N
12 CD N
days NNS N
after IN N
PPH NNP N
, , N
urine JJ N
retention NN N
24h CD N
after IN N
PPH NNP N
, , N
first RB N
stool JJ N
time NN N
, , N
wound IN N
healing VBG N
time NN N
, , N
mean JJ N
hospital NN N
stay NN N
were VBD N
also RB N
recorded VBN N
. . N

RESULTS VB N
The DT N
score NN N
of IN N
symptom NN N
was VBD N
lower JJR N
in IN N
titanoreine NN N
group NN N
( ( N
4.4 CD N
) ) N
than IN N
that DT N
in IN N
the DT N
control NN N
group NN N
( ( N
6.1 CD N
) ) N
24 CD N
hours NNS N
after IN N
PPH NNP N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
but CC N
no DT N
significant JJ N
difference NN N
in IN N
symptom NN N
grade NN N
was VBD N
found VBN N
between IN N
the DT N
two CD N
groups NNS N
6 CD N
days NNS N
and CC N
12 CD N
days NNS N
after IN N
PPH NNP N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

Decrements NNS N
of IN N
symptom NN N
grade NN N
were VBD N
lower JJR N
in IN N
titanoreine NN N
group NN N
than IN N
those DT N
of IN N
control NN N
group NN N
at IN N
any DT N
point NN N
after IN N
PPH NNP N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
urine JJ N
retention NN N
rate NN N
and CC N
mean JJ N
hospital NN N
stay NN N
between IN N
two CD N
groups NNS N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS NNP N
Titanoreine NNP N
can MD N
effectively RB N
relieve VB N
the DT N
early JJ N
postoperative NN N
symptoms NNS N
after IN N
PPH NNP N
. . N

-DOCSTART- -X- O O

Cognitive-behavioural JJ N
stress NN N
management NN N
with IN N
HIV-positive JJ 4_p
homosexual JJ N
men NNS 2_p
: : N
mechanisms NNS N
of IN N
sustained JJ N
reductions NNS N
in IN N
depressive JJ N
symptoms NNS N
. . N

BACKGROUND IN N
We PRP N
examined VBD N
the DT N
sustained JJ N
efficacy NN N
of IN N
a DT N
group-based JJ N
cognitive-behavioural JJ N
stress NN N
management NN N
( ( N
CBSM NNP N
) ) N
intervention NN N
in IN N
comparison NN N
to TO N
a DT N
modified VBN N
wait-list NN N
control NN N
condition NN N
on IN N
measures NNS N
of IN N
mood NN N
, , N
coping VBG N
and CC N
social JJ N
support NN N
in IN N
mildly RB N
symptomatic JJ N
HIV-positive JJ 4_p
homosexual JJ 4_p
and CC N
bisexual JJ 4_p
men NNS 2_p
. . N

Participants NNS N
were VBD N
recruited VBN N
largely RB N
during IN N
the DT N
era NN N
prior RB N
to TO N
highly RB N
active JJ N
antiretroviral JJ N
therapy NN N
( ( N
HAART NNP N
; : N
1992-1997 JJ N
) ) N
. . N

METHODS NNP N
Men NNPS N
were VBD N
randomized VBN N
to TO N
either VB N
a DT N
10-week JJ N
, , N
group-based JJ N
CBSM NNP N
intervention NN N
( ( N
n JJ N
= NNP N
83 CD N
) ) N
or CC N
a DT N
psychoeducational JJ N
seminar NN N
group NN N
( ( N
n JJ N
= NNP N
46 CD 3_p
) ) N
. . N

All DT N
participants NNS N
completed VBD N
a DT N
battery NN N
of IN N
psychosocial JJ N
questionnaires NNS N
administered VBN N
by IN N
a DT N
research NN N
assistant NN N
at IN N
baseline NN N
, , N
immediately RB N
following VBG N
the DT N
10-week JJ N
CBSM NNP N
intervention NN N
period NN N
, , N
and CC N
at IN N
a DT N
6-month JJ N
follow-up NN N
. . N

RESULTS NNP N
Men NNP N
in IN N
the DT N
CBSM NNP N
group NN N
maintained VBD N
previously RB N
observed VBN N
effects NNS N
on IN N
depressive NN N
symptoms NNS N
and CC N
perceived VBD N
social JJ N
support NN N
. . N

These DT N
sustained JJ N
effects NNS N
of IN N
CBSM NNP N
on IN N
depressive JJ N
symptoms NNS N
were VBD N
mediated VBN N
by IN N
10-week JJ N
increases NNS N
in IN N
cognitive JJ N
coping NN N
( ( N
i.e JJ N
. . N

positive JJ N
reframing NN N
) ) N
. . N

DISCUSSION NNP N
CBSM NNP N
appears VBZ N
to TO N
be VB N
a DT N
potentially RB N
efficacious JJ N
treatment NN N
that WDT N
reduces VBZ N
and CC N
maintains NNS N
lower JJR N
levels NNS N
of IN N
depressive NN N
symptoms NNS N
and CC N
enhances VBZ N
social JJ N
support NN N
in IN N
HIV-positive JJ N
homosexual JJ N
and CC N
bisexual JJ N
men NNS N
. . N

In IN N
particular JJ N
, , N
changes NNS N
in IN N
positive JJ N
reframing NN N
during IN N
the DT N
10-week JJ N
intervention NN N
period NN N
remain VBP N
a DT N
crucial JJ N
factor NN N
contributing VBG N
to TO N
sustained VBN N
reductions NNS N
in IN N
depressive JJ N
symptoms NNS N
. . N

-DOCSTART- -X- O O

Parent-mediated JJ N
communication-focused JJ N
treatment NN N
in IN N
children NNS 1_p
with IN N
autism NN 4_p
( ( N
PACT NNP N
) ) N
: : N
a DT N
randomised JJ N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Results NNP N
of IN N
small JJ N
trials NNS N
suggest VBP N
that IN N
early JJ N
interventions NNS N
for IN N
social JJ N
communication NN N
are VBP N
effective JJ N
for IN N
the DT N
treatment NN N
of IN N
autism NN N
in IN N
children NNS N
. . N

We PRP N
therefore RB N
investigated VBD N
the DT N
efficacy NN N
of IN N
such JJ N
an DT N
intervention NN N
in IN N
a DT N
larger JJR N
trial NN N
. . N

METHODS NNP N
Children NNP N
with IN N
core NN 4_p
autism NN 4_p
( ( N
aged VBN N
2 CD 1_p
years NNS 1_p
to TO 1_p
4 CD 1_p
years NNS 1_p
and CC 1_p
11 CD 1_p
months NNS 1_p
) ) N
were VBD N
randomly RB N
assigned VBN N
in IN N
a DT N
one-to-one JJ N
ratio NN N
to TO N
a DT N
parent-mediated JJ N
communication-focused JJ N
( ( N
Preschool NNP N
Autism NNP N
Communication NNP N
Trial NNP N
[ NNP N
PACT NNP N
] NNP N
) ) N
intervention NN N
or CC N
treatment NN N
as IN N
usual JJ N
at IN N
three CD N
specialist NN N
centres NNS N
in IN N
the DT N
UK NNP N
. . N

Those DT N
assigned VBN N
to TO N
PACT NNP N
were VBD N
also RB N
given VBN N
treatment NN N
as IN N
usual JJ N
. . N

Randomisation NN N
was VBD N
by IN N
use NN N
of IN N
minimisation NN N
of IN N
probability NN N
in IN N
the DT N
marginal JJ N
distribution NN N
of IN N
treatment NN N
centre NN N
, , N
age NN N
( ( N
< JJ N
/=42 NNP N
months NNS N
or CC N
> $ N
42 CD N
months NNS N
) ) N
, , N
and CC N
autism NN N
severity NN N
( ( N
Autism NNP N
Diagnostic NNP N
Observation NNP N
Schedule-Generic NNP N
[ NNP N
ADOS-G NNP N
] NNP N
algorithm VBZ N
score RB N
12-17 JJ N
or CC N
18-24 JJ N
) ) N
. . N

Primary JJ N
outcome NN N
was VBD N
severity NN N
of IN N
autism NN N
symptoms NNS N
( ( N
a DT N
total NN N
score NN N
of IN N
social JJ N
communication NN N
algorithm NNS N
items NNS N
from IN N
ADOS-G NNP N
, , N
higher JJR N
score NN N
indicating VBG N
greater JJR N
severity NN N
) ) N
at IN N
13 CD N
months NNS N
. . N

Complementary NNP N
secondary JJ N
outcomes NNS N
were VBD N
measures NNS N
of IN N
parent-child JJ N
interaction NN N
, , N
child JJ N
language NN N
, , N
and CC N
adaptive JJ N
functioning NN N
in IN N
school NN N
. . N

Analysis NN N
was VBD N
by IN N
intention NN N
to TO N
treat VB N
. . N

This DT N
study NN N
is VBZ N
registered VBN N
as IN N
an DT N
International NNP N
Standard NNP N
Randomised VBD N
Controlled NNP N
Trial NNP N
, , N
number NN N
ISRCTN58133827 NNP N
. . N

RESULTS NNP N
152 CD 3_p
children NNS N
were VBD N
recruited VBN N
. . N

77 CD 3_p
were VBD N
assigned VBN N
to TO N
PACT NNP N
( ( N
London NNP N
[ NNP N
n=26 MD N
] VB N
, , N
Manchester NNP N
[ NNP N
n=26 MD N
] VB N
, , N
and CC N
Newcastle NNP N
[ NNP N
n=25 FW N
] NNP N
) ) N
; : N
and CC N
75 CD 3_p
to TO N
treatment NN N
as IN N
usual JJ N
( ( N
London NNP N
[ NNP N
n=26 MD N
] VB N
, , N
Manchester NNP N
[ NNP N
n=26 MD N
] VB N
, , N
and CC N
Newcastle NNP N
[ NNP N
n=23 FW N
] NNP N
) ) N
. . N

At IN N
the DT N
13-month JJ N
endpoint NN N
, , N
the DT N
severity NN N
of IN N
symptoms NNS N
was VBD N
reduced VBN N
by IN N
3.9 CD N
points NNS N
( ( N
SD NNP N
4.7 CD N
) ) N
on IN N
the DT N
ADOS-G NNP N
algorithm NN N
in IN N
the DT N
group NN N
assigned VBD N
to TO N
PACT NNP N
, , N
and CC N
2.9 CD N
( ( N
3.9 CD N
) ) N
in IN N
the DT N
group NN N
assigned VBD N
to TO N
treatment NN N
as IN N
usual JJ N
, , N
representing VBG N
a DT N
between-group JJ N
effect NN N
size NN N
of IN N
-0.24 NNP N
( ( N
95 CD N
% NN N
CI NNP N
-0.59 NNP N
to TO N
0.11 CD N
) ) N
, , N
after IN N
adjustment NN N
for IN N
centre NN N
, , N
sex NN N
, , N
socioeconomic JJ N
status NN N
, , N
age NN N
, , N
and CC N
verbal JJ N
and CC N
non-verbal JJ N
abilities NNS N
. . N

Treatment NNP N
effect NN N
was VBD N
positive JJ N
for IN N
parental JJ N
synchronous JJ N
response NN N
to TO N
child VB N
( ( N
1.22 CD N
, , N
0.85 CD N
to TO N
1.59 CD N
) ) N
, , N
child JJ N
initiations NNS N
with IN N
parent NN N
( ( N
0.41 CD N
, , N
0.08 CD N
to TO N
0.74 CD N
) ) N
, , N
and CC N
for IN N
parent-child JJ N
shared VBN N
attention NN N
( ( N
0.33 CD N
, , N
-0.02 NN N
to TO N
0.68 CD N
) ) N
. . N

Effects NNS N
on IN N
directly RB N
assessed VBN N
language NN N
and CC N
adaptive JJ N
functioning NN N
in IN N
school NN N
were VBD N
small JJ N
. . N

INTERPRETATION NN N
On IN N
the DT N
basis NN N
of IN N
our PRP$ N
findings NNS N
, , N
we PRP N
can MD N
not RB N
recommend VB N
the DT N
addition NN N
of IN N
the DT N
PACT NNP N
intervention NN N
to TO N
treatment NN N
as IN N
usual JJ N
for IN N
the DT N
reduction NN N
of IN N
autism NN N
symptoms NNS N
; : N
however RB N
, , N
a DT N
clear JJ N
benefit NN N
was VBD N
noted VBN N
for IN N
parent-child JJ N
dyadic JJ N
social JJ N
communication NN N
. . N

FUNDING NN N
UK NNP N
Medical NNP N
Research NNP N
Council NNP N
, , N
and CC N
UK NNP N
Department NNP N
for IN N
Children NNP N
, , N
Schools NNP N
and CC N
Families NNP N
. . N

-DOCSTART- -X- O O

Comparative JJ N
drug NN N
effects NNS N
and CC N
abuse NN N
liability NN N
of IN N
lorazepam NN N
, , N
buspirone NN N
, , N
and CC N
secobarbital NN N
in IN N
nondependent JJ 4_p
subjects NNS N
. . N

The DT N
pharmacologic JJ N
effects NNS N
of IN N
lorazepam NN N
( ( N
2 CD N
mg NN N
) ) N
, , N
buspirone NN N
( ( N
20 CD N
mg NN N
, , N
10 CD N
mg NN N
) ) N
, , N
secobarbital JJ N
( ( N
100 CD N
mg NN N
) ) N
, , N
and CC N
placebo NN N
were VBD N
compared VBN N
in IN N
15 CD 3_p
male NN 2_p
, , N
experienced VBD N
, , N
intermittent JJ N
nontherapeutic JJ N
drug NN 4_p
users NNS 4_p
. . N

All DT N
drugs NNS N
produced VBD N
a DT N
drug NN N
effect NN N
, , N
however RB N
, , N
buspirone RB N
20 CD N
mg NN N
was VBD N
significantly RB N
less JJR N
liked JJ N
than IN N
were VBD N
lorazepam JJ N
, , N
secobarbital JJ N
, , N
or CC N
buspirone RB N
10 CD N
mg NN N
( ( N
p NN N
less JJR N
than IN N
.05 NN N
) ) N
but CC N
not RB N
placebo VB N
. . N

Lorazepam NNP N
was VBD N
liked VBN N
better RBR N
than IN N
were VBD N
other JJ N
drugs NNS N
only RB N
at IN N
1 CD N
hour NN N
and CC N
only RB N
compared VBN N
with IN N
buspirone NN N
20 CD N
and CC N
placebo NN N
. . N

Compared VBN N
with IN N
other JJ N
drugs NNS N
, , N
lorazepam JJ N
drug NN N
effects NNS N
were VBD N
greater JJR N
and CC N
resulted VBD N
in IN N
more RBR N
prolonged JJ N
impairment NN N
of IN N
a DT N
motor NN N
tracking VBG N
task NN N
, , N
standing VBG N
steadiness NN N
, , N
and CC N
memory NN N
. . N

Buspirone CD N
20 CD N
mg NNS N
significantly RB N
impaired JJ N
memory NN N
at IN N
1 CD N
hour NN N
compared VBN N
with IN N
placebo NN N
. . N

Subjects NNS N
were VBD N
more RBR N
likely JJ N
to TO N
identify VB N
buspirone NN N
as IN N
unfamiliar JJ N
. . N

Because IN N
buspirone NN N
20 CD N
mg NN N
was VBD N
less JJR N
liked JJ N
than IN N
were VBD N
other JJ N
drugs NNS N
, , N
dose JJ N
escalation NN N
as IN N
part NN N
of IN N
drug NN N
abuse NN N
is VBZ N
not RB N
likely JJ N
to TO N
occur VB N
. . N

Lorazepam NNP N
also RB N
was VBD N
not RB N
particularly RB N
liked VBN N
and CC N
was VBD N
not RB N
different JJ N
from IN N
placebo NN N
on IN N
most JJS N
subjective JJ N
abuse-relevant JJ N
measures NNS N
. . N

-DOCSTART- -X- O O

The DT N
development NN N
of IN N
a DT N
web- JJ N
and CC N
a DT N
print-based JJ N
decision NN N
aid NN N
for IN N
prostate NN 4_p
cancer NN 4_p
screening VBG N
. . N

BACKGROUND NNP N
Whether NNP N
early JJ N
detection NN N
and CC N
treatment NN N
of IN N
prostate NN N
cancer NN N
( ( N
PCa NNP N
) ) N
will MD N
reduce VB N
disease-related JJ N
mortality NN N
remains VBZ N
uncertain JJ N
. . N

As IN N
a DT N
result NN N
, , N
tools NNS N
are VBP N
needed VBN N
to TO N
facilitate VB N
informed JJ N
decision NN N
making NN N
. . N

While IN N
there EX N
have VBP N
been VBN N
several JJ N
decision NN N
aids NNS N
( ( N
DAs NNP N
) ) N
developed VBD N
and CC N
tested VBD N
, , N
very RB N
few JJ N
have VBP N
included VBN N
an DT N
exercise NN N
to TO N
help VB N
men NNS N
clarify VB N
their PRP$ N
values NNS N
and CC N
preferences NNS N
about IN N
PCa NNP N
screening NN N
. . N

Further NNP N
, , N
only RB N
one CD N
DA NNP N
has VBZ N
utilized VBN N
an DT N
interactive JJ N
web-based JJ N
format NN N
, , N
which WDT N
allows VBZ N
for IN N
an DT N
expansion NN N
and CC N
customization NN N
of IN N
the DT N
material NN N
. . N

We PRP N
describe VBP N
the DT N
development NN N
of IN N
two CD N
DAs NNP N
, , N
a DT N
booklet NN N
and CC N
an DT N
interactive JJ N
website NN N
, , N
each DT N
with IN N
a DT N
values NNS N
clarification NN N
component NN N
and CC N
designed VBN N
for IN N
use NN N
in IN N
diverse JJ N
settings NNS N
. . N

METHODS NNP N
We PRP N
conducted VBD N
two CD N
feasibility NN N
studies NNS N
to TO N
assess VB N
men NNS 2_p
's POS 2_p
( ( N
45-70 CD 1_p
years NNS N
) ) N
Internet NNP N
access NN N
and CC N
their PRP$ N
willingness NN N
to TO N
use VB N
a DT N
web- JJ N
vs. FW N
a DT N
print-based JJ N
tool NN N
. . N

The DT N
booklet NN N
was VBD N
adapted VBN N
from IN N
two CD N
previous JJ N
versions NNS N
evaluated VBN N
in IN N
randomized VBN N
controlled JJ N
trials NNS N
( ( N
RCTs NNP N
) ) N
and CC N
the DT N
website NN N
was VBD N
created VBN N
to TO N
closely RB N
match VB N
the DT N
content NN N
of IN N
the DT N
revised JJ N
booklet NN N
. . N

Usability NNP N
testing NN N
was VBD N
conducted VBN N
to TO N
obtain VB N
feedback NN N
regarding VBG N
draft JJ N
versions NNS N
of IN N
the DT N
materials NNS N
. . N

The DT N
tools NNS N
were VBD N
also RB N
reviewed VBN N
by IN N
a DT N
plain NN N
language NN N
expert NN N
and CC N
the DT N
interdisciplinary JJ N
research NN N
team NN N
. . N

Feedback NN N
on IN N
the DT N
content NN N
and CC N
presentation NN N
led VBD N
to TO N
iterative JJ N
modifications NNS N
of IN N
the DT N
tools NNS N
. . N

RESULTS VB N
The DT N
feasibility NN N
studies NNS N
confirmed VBD N
that IN N
the DT N
Internet NNP N
was VBD N
a DT N
viable JJ N
medium NN N
, , N
as IN N
the DT N
majority NN N
of IN N
men NNS N
used VBN N
a DT N
computer NN N
, , N
had VBD N
access NN N
to TO N
the DT N
Internet NNP N
, , N
and CC N
Internet NNP N
use NN N
increased VBD N
over IN N
time NN N
. . N

Feedback NN N
from IN N
the DT N
usability NN N
testing VBG N
on IN N
the DT N
length NN N
, , N
presentation NN N
, , N
and CC N
content NN N
of IN N
the DT N
materials NNS N
was VBD N
incorporated VBN N
into IN N
the DT N
final JJ N
versions NNS N
of IN N
the DT N
booklet NN N
and CC N
website NN N
. . N

Both CC N
the DT N
feasibility NN N
studies NNS N
and CC N
the DT N
usability NN N
testing VBG N
highlighted VBD N
the DT N
need NN N
to TO N
address VB N
men NNS N
's POS N
informed VBN N
decision NN N
making VBG N
regarding VBG N
screening NN N
. . N

CONCLUSIONS NNP N
Informed NNP N
decision NN N
making VBG N
for IN N
PCa NNP N
screening NN N
is VBZ N
crucial JJ N
at IN N
present JJ N
and CC N
may MD N
be VB N
important JJ N
for IN N
some DT N
time NN N
, , N
particularly RB N
if IN N
a DT N
definitive JJ N
recommendation NN N
either DT N
for IN N
or CC N
against IN N
screening VBG N
does VBZ N
not RB N
emerge VB N
from IN N
ongoing VBG N
prostate NN N
cancer NN N
screening VBG N
trials NNS N
. . N

We PRP N
have VBP N
detailed VBN N
our PRP$ N
efforts NNS N
at IN N
developing VBG N
print- JJ N
and CC N
web-based JJ N
DAs NNP N
to TO N
assist VB N
men NNS N
in IN N
determining VBG N
how WRB N
to TO N
best VB N
meet VB N
their PRP$ N
PCa NNP N
screening NN N
preferences NNS N
. . N

Following VBG N
completion NN N
of IN N
our PRP$ N
ongoing JJ N
RCT NNP N
designed VBN N
to TO N
test VB N
these DT N
materials NNS N
, , N
our PRP$ N
goal NN N
will MD N
be VB N
to TO N
develop VB N
a DT N
dissemination NN N
project NN N
for IN N
the DT N
more RBR N
effective JJ N
tool NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
NCT00623090 NNP N
. . N

-DOCSTART- -X- O O

Learning VBG N
about IN N
the DT N
equal JJ N
sign NN N
: : N
does VBZ N
comparing VBG N
with IN N
inequality NN N
symbols NNS N
help VB N
? . N
This DT N
study NN N
investigated VBD N
whether IN N
instruction NN N
that WDT N
involves VBZ N
comparing VBG N
the DT N
equal JJ N
sign NN N
with IN N
other JJ N
relational JJ N
symbols NNS N
is VBZ N
more RBR N
effective JJ N
at IN N
imparting VBG N
a DT N
relational JJ N
interpretation NN N
of IN N
the DT N
equal JJ N
sign NN N
than IN N
instruction NN N
about IN N
the DT N
equal JJ N
sign NN N
alone RB N
. . N

Third- JJ 1_p
and CC 1_p
fourth-grade JJ 1_p
students NNS 1_p
in IN N
a DT N
comparing NN N
symbols NNS N
group NN N
learned VBD N
about IN N
the DT N
greater JJR N
than IN N
, , N
less JJR N
than IN N
, , N
and CC N
equal JJ N
signs NNS N
and CC N
had VBD N
the DT N
opportunity NN N
to TO N
compare VB N
the DT N
inequality NN N
symbols VBZ N
with IN N
the DT N
equal JJ N
sign NN N
. . N

Students NNS N
in IN N
an DT N
equal JJ N
sign NN N
group NN N
learned VBD N
about IN N
the DT N
equal JJ N
sign NN N
only RB N
. . N

A NNP N
third JJ N
group NN N
of IN N
students NNS N
served VBD N
as IN N
a DT N
control NN N
group NN N
. . N

Three CD N
aspects NNS N
of IN N
students NNS N
' POS N
knowledge NN N
were VBD N
assessed VBN N
before IN N
and CC N
after IN N
the DT N
lesson NN N
: : N
( ( N
a DT N
) ) N
conceptual JJ N
understanding NN N
of IN N
the DT N
equal JJ N
sign NN N
, , N
( ( N
b NN N
) ) N
equation NN N
encoding NN N
, , N
and CC N
( ( N
c NN N
) ) N
problem NN N
solving VBG N
. . N

Students NNS N
in IN N
the DT N
comparing NN N
symbols NNS N
group NN N
showed VBD N
greater JJR N
gains NNS N
in IN N
conceptual JJ N
understanding NN N
from IN N
pretest NN N
to TO N
posttest VB N
than IN N
students NNS N
in IN N
the DT N
other JJ N
two CD N
groups NNS N
, , N
and CC N
students NNS N
in IN N
the DT N
comparing NN N
symbols NNS N
group NN N
also RB N
scored VBD N
higher JJR N
on IN N
a DT N
posttest NN N
that WDT N
assessed VBD N
knowledge NN N
about IN N
inequality NN N
symbols NNS N
and CC N
inequality NN N
problem NN N
solving VBG N
. . N

Thus RB N
, , N
they PRP N
learned VBD N
about IN N
three CD N
symbols NNS N
in IN N
the DT N
same JJ N
amount NN N
of IN N
time NN N
as IN N
other JJ N
students NNS N
learned VBD N
about IN N
the DT N
equal JJ N
sign NN N
alone RB N
or CC N
not RB N
at IN N
all DT N
. . N

Therefore NNP N
, , N
an DT N
instructional JJ N
approach NN N
involving VBG N
comparison NN N
can MD N
be VB N
an DT N
effective JJ N
tool NN N
for IN N
learning VBG N
about IN N
concepts NNS N
in IN N
mathematics NNS N
. . N

-DOCSTART- -X- O O

Albendazole JJ N
trial NN N
at IN N
15 CD N
or CC N
30 CD N
mg/kg/day NN N
for IN N
subarachnoid NN 4_p
and CC N
intraventricular JJ 4_p
cysticercosis NN 4_p
. . N

Thirty-six JJ 3_p
patients NNS N
with IN N
subarachnoid JJ 4_p
and CC N
intraventricular JJ 4_p
cysticercosis NN 4_p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
albendazole NN N
at IN N
15 CD N
or CC N
30 CD N
mg/kg/day JJ N
plus CC N
dexamethasone NN N
for IN N
8 CD N
days NNS N
. . N

Results NNS N
favored VBD N
a DT N
higher JJR N
dose NN N
, , N
with IN N
larger JJR N
cyst NN N
reduction NN N
on IN N
MRI NNP N
at IN N
90 CD N
and CC N
180 CD N
days NNS N
and CC N
higher JJR N
albendazole JJ N
sulfoxide NN N
levels NNS N
in IN N
plasma NN N
. . N

An DT N
albendazole JJ N
course NN N
at IN N
30 CD N
mg/kg/day NN N
combined VBN N
with IN N
corticosteroids NNS N
is VBZ N
safe JJ N
and CC N
more RBR N
effective JJ N
than IN N
the DT N
usual JJ N
dose NN N
. . N

A DT N
single JJ N
treatment NN N
was VBD N
insufficient JJ N
in IN N
intraventricular JJ N
and CC N
giant JJ N
cysts NNS N
. . N

-DOCSTART- -X- O O

Oral NNP N
health NN N
impacts NNS N
on IN N
daily JJ N
living NN N
related VBN N
to TO N
four CD N
different JJ N
treatment NN N
protocols NNS N
for IN N
chronic JJ 4_p
periodontitis NN 4_p
. . N

BACKGROUND IN N
The DT N
aims NNS N
of IN N
this DT N
study NN N
were VBD N
to TO N
evaluate VB N
the DT N
oral JJ N
health NN N
impacts NNS N
perceived VBN N
by IN N
patients NNS N
submitted VBN N
to TO N
different JJ N
treatments NNS N
of IN N
chronic JJ 4_p
periodontitis NN 4_p
and CC N
their PRP$ N
association NN N
with IN N
clinical JJ N
parameters NNS N
. . N

METHODS NNP N
Sixty NNP 3_p
patients NNS N
were VBD N
assigned VBN N
to TO N
one CD N
of IN N
the DT N
following JJ N
therapeutic JJ N
groups NNS N
: : N
control NN N
, , N
treated VBN N
with IN N
full-mouth JJ N
scaling NN N
and CC N
root NN N
planing NN N
( ( N
SRP NNP N
) ) N
; : N
test $ N
1 CD N
, , N
treated VBN N
with IN N
SRP NNP N
and CC N
400 CD N
mg NNS N
systemically RB N
administered VBN N
metronidazole NN N
( ( N
MET NNP N
) ) N
three CD N
times NNS N
per IN N
day NN N
for IN N
10 CD N
days NNS N
; : N
test JJS N
2 CD N
, , N
treated VBN N
with IN N
SRP NNP N
and CC N
professional JJ N
supragingival NN N
plaque NN N
removal NN N
( ( N
PP NNP N
) ) N
every DT N
week NN N
for IN N
3 CD N
months NNS N
; : N
and CC N
test VB N
3 CD N
, , N
treated VBN N
with IN N
SRP NNP N
and CC N
MET NNP N
plus CC N
PP NNP N
. . N

Clinical NNP N
periodontal JJ N
measurements NNS N
and CC N
data NNS N
regarding VBG N
patients NNS N
' POS N
oral JJ N
health NN N
impacts NNS N
( ( N
perceived VBN N
impacts NNS N
on IN N
bleeding VBG N
gums NNS N
, , N
gingival JJ N
recession NN N
, , N
sensitivity NN N
to TO N
cold VB N
, , N
packing VBG N
foods NNS N
, , N
aesthetics NNS N
, , N
bad JJ N
breath NN N
, , N
and CC N
tooth DT N
mobility NN N
) ) N
were VBD N
collected VBN N
at IN N
baseline NN N
and CC N
3 CD N
months NNS N
after IN N
therapy NN N
. . N

RESULTS NNP N
All NNP N
groups NNS N
presented VBD N
significant JJ N
improvement NN N
in IN N
oral JJ N
health NN N
perceived VBD N
impacts NNS N
. . N

There EX N
was VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
in IN N
the DT N
improvement NN N
of IN N
oral JJ N
health NN N
impacts NNS N
among IN N
groups NNS N
subjected VBN N
to TO N
different JJ N
treatments NNS N
. . N

The DT N
clinical JJ N
data NNS N
of IN N
percentage NN N
of IN N
deep JJ N
probing VBG N
depth NN N
, , N
deep JJ N
clinical JJ N
attachment NN N
level NN N
, , N
and CC N
bleeding VBG N
on IN N
probing VBG N
were VBD N
found VBN N
to TO N
be VB N
correlated VBN N
significantly RB N
with IN N
oral JJ N
health NN N
impacts NNS N
. . N

CONCLUSIONS NNP N
Periodontal NNP N
treatment NN N
leads VBZ N
to TO N
a DT N
significant JJ N
reduction NN N
of IN N
self-perceived JJ N
impacts NNS N
regardless RB N
of IN N
the DT N
non-surgical JJ N
treatment NN N
protocol NN N
employed VBN N
. . N

Most JJS N
of IN N
the DT N
clinical JJ N
data NNS N
were VBD N
associated VBN N
with IN N
oral JJ N
health NN N
impacts NNS N
. . N

-DOCSTART- -X- O O

Efficacy NN N
and CC N
long-term JJ N
tolerability NN N
of IN N
sublingual JJ N
fentanyl NN N
orally RB N
disintegrating VBG N
tablet NN N
in IN N
the DT N
treatment NN N
of IN N
breakthrough NN N
cancer NN N
pain NN N
. . N

BACKGROUND NNP N
AND NNP N
OBJECTIVES NNP N
Breakthrough NNP N
cancer NN N
pain NN N
( ( N
BTcP NNP N
) ) N
represents VBZ N
an DT N
important JJ N
clinical JJ N
challenge NN N
in IN N
the DT N
care NN N
of IN N
patients NNS N
with IN N
cancer NN 4_p
. . N

This DT N
trial NN N
evaluated VBD N
the DT N
efficacy NN N
and CC N
long-term JJ N
tolerability NN N
of IN N
a DT N
sublingual JJ N
formulation NN N
of IN N
the DT N
fast-acting JJ N
opioid NN N
fentanyl NN N
, , N
for IN N
the DT N
treatment NN N
of IN N
BTcP NNP N
in IN N
opioid-tolerant JJ N
patients NNS N
with IN N
cancer NN N
. . N

RESEARCH NNP N
DESIGN NNP N
AND NNP N
METHODS NNP N
This DT N
was VBD N
a DT N
randomized JJ N
, , N
placebo-controlled JJ N
, , N
multi-center JJ N
, , N
phase JJ N
III NNP N
trial NN N
, , N
conducted VBN N
in IN N
opioid-tolerant JJ N
male NN 2_p
and CC 2_p
female JJ 2_p
patients NNS N
( ( N
aged VBN N
> NN 1_p
or CC 1_p
=17 CD 1_p
years NNS N
) ) N
with IN N
BTcP NNP N
. . N

The DT N
study NN N
was VBD N
conducted VBN N
at IN N
36 CD N
centers NNS N
across IN N
the DT N
USA NNP N
. . N

The DT N
study NN N
comprised VBD N
a DT N
2-week JJ N
open-label JJ N
titration NN N
phase NN N
, , N
followed VBN N
by IN N
a DT N
double-blind JJ N
efficacy NN N
phase NN N
, , N
during IN N
which WDT N
patients NNS N
received VBD N
sublingual JJ N
fentanyl NN N
citrate NN N
orally RB N
disintegrating VBG N
tablet NN N
( ( N
sublingual JJ N
fentanyl NN N
ODT NNP N
) ) N
or CC N
placebo NN N
, , N
in IN N
a DT N
random JJ N
order NN N
. . N

The DT N
primary JJ N
efficacy NN N
endpoint NN N
was VBD N
the DT N
sum NN N
of IN N
pain NN N
intensity NN N
difference NN N
( ( N
SPID NNP N
) ) N
over IN N
30 CD N
min JJ N
post-administration NN N
. . N

Secondary JJ N
efficacy NN N
endpoints NNS N
included VBD N
pain NN N
intensity NN N
difference NN N
( ( N
PID NNP N
) ) N
and CC N
pain NN N
relief NN N
( ( N
PR NNP N
) ) N
throughout IN N
the DT N
60-min JJ N
post-dose JJ N
assessment NN N
period NN N
. . N

Following VBG N
efficacy NN N
evaluation NN N
, , N
patients NNS N
entered VBD N
a DT N
long-term JJ N
safety NN N
phase NN N
of IN N
up IN N
to TO N
12 CD N
months NNS N
. . N

Adverse JJ N
events NNS N
were VBD N
recorded VBN N
throughout IN N
the DT N
study NN N
. . N

[ VB N
CLINICAL NNP N
TRIAL NNP N
REGISTRATION NNP N
NCT00262678 NNP N
] NNP N
RESULTS NNP N
A NNP N
total NN N
of IN N
131 CD 3_p
patients NNS N
entered VBD N
the DT N
titration NN N
phase NN N
, , N
of IN N
whom WP N
61 CD 3_p
were VBD N
included VBN N
in IN N
the DT N
primary JJ N
efficacy NN N
analysis NN N
. . N

Sublingual JJ N
fentanyl NN N
ODT NNP N
provided VBD N
significant JJ N
improvements NNS N
in IN N
SPID NNP N
relative VBP N
to TO N
placebo VB N
at IN N
30 CD N
min NN N
( ( N
49.5 CD N
vs. FW N
36.6 CD N
, , N
p NN N
= NNP N
0.0004 CD N
) ) N
and CC N
60 CD N
min NNS N
post-administration NN N
( ( N
143.0 CD N
vs. FW N
104.5 CD N
, , N
p NN N
= NNP N
0.0002 CD N
) ) N
. . N

Furthermore UH N
, , N
sublingual JJ N
fentanyl NN N
ODT NNP N
provided VBD N
significant JJ N
improvements NNS N
in IN N
PID NNP N
and CC N
PR NNP N
compared VBN N
to TO N
placebo VB N
, , N
from IN N
10 CD N
min NNS N
post-dose JJ N
( ( N
p JJ N
= NN N
0.0055 CD N
and CC N
p VB N
= $ N
0.049 CD N
for IN N
PID NNP N
and CC N
PR NNP N
, , N
respectively RB N
) ) N
. . N

Patient JJ N
recruitment NN N
was VBD N
stopped VBN N
early RB N
, , N
due JJ N
to TO N
positive JJ N
interim JJ N
analysis NN N
results NNS N
( ( N
significant JJ N
at IN N
prespecified JJ N
level NN N
, , N
p JJ N
< NN N
or CC N
= VB N
0.0414 CD N
) ) N
. . N

Overall JJ N
, , N
sublingual JJ N
fentanyl NN N
ODT NNP N
was VBD N
well-tolerated JJ N
both DT N
systemically RB N
and CC N
sublingually RB N
, , N
with IN N
41 CD N
patients NNS N
experiencing VBG N
> NN N
or CC N
=1 NN N
study NN N
drug-related JJ N
adverse JJ N
event NN N
( ( N
AE NNP N
) ) N
. . N

The DT N
most RBS N
common JJ N
AEs NNP N
included VBD N
nausea NN N
( ( N
12.2 CD N
% NN N
) ) N
, , N
vomiting VBG N
( ( N
5.3 CD N
% NN N
) ) N
and CC N
somnolence NN N
( ( N
4.6 CD N
% NN N
) ) N
. . N

One CD N
serious JJ N
AE NNP N
( ( N
mild JJ N
affect VBP N
lability NN N
) ) N
was VBD N
considered VBN N
possibly RB N
related VBN N
to TO N
study VB N
medication NN N
. . N

The DT N
observed JJ N
pattern NN N
of IN N
AEs NNP N
was VBD N
consistent JJ N
with IN N
that DT N
previously RB N
observed VBN N
with IN N
fentanyl NN N
. . N

CONCLUSIONS NNP N
Sublingual NNP N
fentanyl NN N
ODT NNP N
was VBD N
efficacious JJ N
and CC N
well-tolerated JJ N
for IN N
the DT N
treatment NN N
of IN N
BTcP NNP N
in IN N
opioid-tolerant JJ N
patients NNS N
with IN N
cancer NN N
. . N

Sublingual JJ N
fentanyl NN N
ODT NNP N
provided VBD N
significant JJ N
improvements NNS N
in IN N
pain NN N
intensity NN N
compared VBN N
to TO N
placebo VB N
, , N
from IN N
10 CD N
min JJ N
post-administration NN N
and CC N
throughout IN N
the DT N
60-min JJ N
post-dose JJ N
assessment NN N
period NN N
. . N

Sublingual JJ N
fentanyl NN N
ODT NNP N
was VBD N
well RB N
tolerated VBN N
over IN N
12 CD N
months NNS N
of IN N
treatment NN N
. . N

-DOCSTART- -X- O O

Short- JJ N
and CC N
long-term JJ N
effects NNS N
of IN N
tactile JJ N
massage NN N
on IN N
salivary JJ N
cortisol NN N
concentrations NNS N
in IN N
Parkinson NNP 4_p
's POS 4_p
disease NN 4_p
: : N
a DT N
randomised JJ N
controlled VBN N
pilot NN N
study NN N
. . N

BACKGROUND NNP N
Parkinson NNP N
's POS N
disease NN N
( ( N
PD NNP N
) ) N
is VBZ N
a DT N
chronic JJ N
neurodegenerative JJ N
disorder NN N
with IN N
limited JJ N
knowledge NN N
about IN N
the DT N
normal JJ N
function NN N
and CC N
effects NNS N
of IN N
non-pharmacological JJ N
therapies NNS N
on IN N
the DT N
hypothalamic-pituitary-adrenal JJ N
( ( N
HPA NNP N
) ) N
axis NN N
. . N

The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
analyse VB N
the DT N
basal NN N
diurnal JJ N
and CC N
total JJ N
secretion NN N
of IN N
salivary JJ N
cortisol NN N
in IN N
short- JJ N
and CC N
long-term JJ N
aspects NNS N
of IN N
tactile JJ N
massage NN N
( ( N
TM NNP N
) ) N
. . N

METHODS NNP N
DESIGN NNP N
Prospective NNP N
, , N
Controlled NNP N
and CC N
Randomised VBD N
Multicentre NNP N
Trial NNP N
. . N

SETTING NN N
AND JJ N
INTERVENTIONS NNP N
Forty-five NNP 3_p
women NNS 2_p
and CC 2_p
men NNS 2_p
, , N
aged VBN N
50-79 CD 1_p
years NNS N
, , N
were VBD N
recruited VBN N
. . N

Twenty-nine NN 3_p
of IN N
them PRP N
were VBD N
blindly RB N
randomised VBN N
to TO N
tactile VB N
massage NN N
( ( N
TM NNP N
) ) N
and CC N
16 CD 3_p
of IN N
them PRP N
to TO N
the DT N
control NN N
group NN N
, , N
rest NN N
to TO N
music NN N
( ( N
RTM NNP N
) ) N
. . N

Ten CD N
interventions NNS N
were VBD N
given VBN N
during IN N
8 CD N
weeks NNS N
followed VBN N
by IN N
a DT N
26 CD N
weeks NNS N
of IN N
follow JJ N
up RB N
. . N

Salivary JJ N
cortisol NN N
was VBD N
collected VBN N
at IN N
8 CD N
am VBP N
, , N
1 CD N
pm NN N
, , N
8 CD N
pm NN N
, , N
and CC N
8 CD N
am VBP N
the DT N
next JJ N
day NN N
, , N
on IN N
five CD N
occasions NNS N
. . N

With IN N
the DT N
first JJ N
and CC N
eighth JJ N
interventions NNS N
, , N
it PRP N
was VBD N
collected VBN N
immediately RB N
before IN N
and CC N
after IN N
intervention NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
The DT N
primary JJ N
aim NN N
was VBD N
to TO N
assess VB N
and CC N
compare VB N
cortisol JJ N
concentrations NNS N
before IN N
and CC N
immediately RB N
after IN N
intervention NN N
and CC N
also RB N
during IN N
the DT N
follow-up JJ N
period NN N
. . N

The DT N
secondary JJ N
aim NN N
was VBD N
to TO N
assess VB N
the DT N
impact NN N
of IN N
age NN N
, , N
gender NN N
, , N
body NN N
mass NN N
index NN N
( ( N
BMI NNP N
) ) N
, , N
duration NN N
and CC N
severity NN N
of IN N
PD NNP N
, , N
effects NNS N
of IN N
interventional JJ N
time-point NN N
of IN N
the DT N
day NN N
, , N
and CC N
levodopa JJ N
doses NNS N
on IN N
cortisol JJ N
concentration NN N
. . N

RESULTS VB N
The DT N
median JJ N
cortisol NN N
concentrations NNS N
for IN N
all DT N
participants NNS N
were VBD N
16.0 CD N
, , N
5.8 CD N
, , N
2.8 CD N
, , N
and CC N
14.0 CD N
nmol/L NN N
at IN N
baseline NN N
, , N
later RB N
reproduced VBD N
four CD N
times NNS N
without IN N
significant JJ N
differences NNS N
. . N

Cortisol NNP N
concentrations NNS N
decreased VBD N
significantly RB N
after IN N
TM NNP N
intervention NN N
but CC N
no DT N
change NN N
in IN N
diurnal JJ N
salivary JJ N
cortisol NN N
pattern NN N
was VBD N
found VBN N
. . N

The DT N
findings NNS N
of IN N
reduced JJ N
salivary JJ N
cortisol NN N
concentrations NNS N
immediately RB N
after IN N
the DT N
interventions NNS N
are VBP N
in IN N
agreement NN N
with IN N
previous JJ N
studies NNS N
. . N

However RB N
, , N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
TM NNP N
and CC N
control NN N
groups NNS N
. . N

There EX N
were VBD N
no DT N
significant JJ N
correlations NNS N
between IN N
cortisol JJ N
concentrations NNS N
and CC N
age NN N
, , N
gender NN N
, , N
BMI NNP N
, , N
time-point NN N
for IN N
intervention NN N
, , N
time NN N
interval NN N
between IN N
anti-parkinson JJ N
pharmacy NN N
intake NN N
and CC N
sampling NN N
, , N
levodopa NN N
doses NNS N
, , N
duration NN N
, , N
or CC N
severity NN N
of IN N
PD NNP N
. . N

CONCLUSIONS NNP N
Diurnal NNP N
salivary JJ N
cortisol NN N
rhythm NN N
was VBD N
normal JJ N
. . N

Salivary JJ N
cortisol NN N
concentrations NNS N
were VBD N
significantly RB N
reduced VBN N
after IN N
the DT N
TM NNP N
intervention NN N
and CC N
after IN N
RTM NNP N
, , N
but CC N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
groups NNS N
and CC N
no DT N
sustained JJ N
long-term JJ N
effect NN N
. . N

No CC N
associations NNS N
were VBD N
seen VBN N
between IN N
salivary JJ N
cortisol NN N
concentration NN N
and CC N
clinical JJ N
and/or NN N
pharmacological JJ N
characteristics NNS N
. . N

TRIAL NNP N
REGISTRATION NNP N
ClinicalTrial.gov NNP N
, , N
NCT01734876 NNP N
and CC N
FoU NNP N
Sweden NNP N
108881 CD N
. . N

-DOCSTART- -X- O O

Penetration NN N
and CC N
accumulation NN N
of IN N
moxifloxacin NN N
in IN N
uterine JJ N
tissue NN N
. . N

OBJECTIVE NN N
To TO N
determine VB N
whether IN N
moxifloxacin NN N
penetrates VBZ N
the DT N
uterine JJ N
tissue NN N
and CC N
accumulates NNS N
at IN N
levels NNS N
sufficient JJ N
to TO N
eradicate VB N
the DT N
major JJ N
pathogens NNS N
causing VBG N
pelvic JJ 4_p
inflammatory JJ 4_p
disease NN 4_p
( ( N
PID NNP 4_p
) ) N
. . N

METHOD NNP N
In IN N
a DT N
prospective JJ N
, , N
multicenter NN N
, , N
open-label JJ N
, , N
parallel-group JJ N
study NN N
we PRP N
determined VBD N
the DT N
concentration NN N
of IN N
moxifloxacin NN N
in IN N
plasma NN N
and CC N
uterine JJ N
tissue NN N
after IN N
a DT N
single JJ N
, , N
400-mg JJ N
intravenous JJ N
dose NN N
of IN N
moxifloxacin NN N
. . N

Study NN N
participants NNS N
were VBD N
randomized VBN N
for IN N
time NN N
of IN N
tissue NN N
sampling NN N
, , N
which WDT N
was VBD N
performed VBN N
1 CD N
, , N
2 CD N
, , N
4 CD N
, , N
7 CD N
, , N
or CC N
24 CD N
hours NNS N
following VBG N
the DT N
moxifloxacin JJ N
infusion NN N
. . N

RESULTS NNP N
Of IN N
43 CD 3_p
participants NNS N
, , N
40 CD 3_p
were VBD N
randomized VBN N
to TO N
tissue VB N
sampling VBG N
. . N

Moxifloxacin NNP N
accumulated VBD N
in IN N
uterine JJ N
tissue NN N
and CC N
concentrations NNS N
were VBD N
highest JJS N
1 CD N
hour NN N
after IN N
infusion NN N
in IN N
both DT N
plasma NN N
and CC N
tissue NN N
. . N

Tissue NN N
to TO N
plasma VB N
ratios NNS N
remained VBD N
between IN N
1.7 CD N
and CC N
2.1 CD N
for IN N
24 CD N
hours NNS N
. . N

Moxifloxacin NNP N
was VBD N
found VBN N
to TO N
be VB N
safe JJ N
and CC N
well RB N
tolerated VBN N
. . N

CONCLUSION NNP N
Based VBD N
on IN N
known VBN N
minimum JJ N
inhibitory JJ N
concentration NN N
data NNS N
, , N
the DT N
uterine JJ N
tissue NN N
concentrations NNS N
of IN N
moxifloxacin NN N
achieved VBN N
over IN N
24 CD N
hours NNS N
would MD N
be VB N
sufficient JJ N
to TO N
eradicate VB N
the DT N
range NN N
of IN N
bacterial JJ N
pathogens NNS N
responsible JJ N
for IN N
PID NNP N
. . N

-DOCSTART- -X- O O

Shorter NNP N
treatment NN N
for IN N
vaginal JJ 4_p
candidosis NN 4_p
: : N
comparison NN N
between IN N
single-dose JJ N
oral JJ N
fluconazole NN N
and CC N
three-day JJ N
treatment NN N
with IN N
local JJ N
miconazole NN N
. . N

Fluconazole NNP N
is VBZ N
an DT N
effective JJ N
, , N
simple JJ N
and CC N
safe JJ N
, , N
although IN N
slightly RB N
expensive JJ N
, , N
agent NN N
for IN N
the DT N
treatment NN N
of IN N
vaginal JJ 4_p
candidosis NN 4_p
. . N

Single-dose JJ N
fluconazole NN N
( ( N
150 CD N
mg NN N
) ) N
administered VBD N
orally RB N
in IN N
capsule NN N
form NN N
was VBD N
compared VBN N
with IN N
three-day JJ N
local JJ N
treatment NN N
with IN N
miconazole JJ N
pessaries NNS N
in IN N
the DT N
treatment NN N
of IN N
vaginal JJ 4_p
candidosis NN 4_p
in IN N
a DT N
randomized JJ N
study NN N
in IN N
Finland NNP N
. . N

Cure NN N
rates NNS N
were VBD N
good JJ N
( ( N
> JJ N
80 CD N
% NN N
) ) N
in IN N
randomized VBN N
patient NN N
groups NNS N
assessed VBD N
both DT N
clinically RB N
and CC N
by IN N
the DT N
results NNS N
of IN N
yeast JJ N
cultures NNS N
. . N

Oral JJ N
administration NN N
was VBD N
preferred VBN N
to TO N
local JJ N
therapy NN N
by IN N
patients NNS N
in IN N
both DT N
the DT N
miconazole NN N
and CC N
fluconazole JJ N
groups NNS N
. . N

For IN N
the DT N
time NN N
being VBG N
, , N
fluconazole NN N
is VBZ N
not RB N
recommended VBN N
for IN N
use NN N
during IN N
pregnancy NN N
or CC N
lactation NN N
. . N

-DOCSTART- -X- O O

Clinically RB N
relevant JJ N
improvement NN N
of IN N
recurrence-free JJ N
survival NN N
with IN N
5-aminolevulinic JJ N
acid NN N
induced VBD N
fluorescence NN N
diagnosis NN N
in IN N
patients NNS N
with IN N
superficial JJ 4_p
bladder NN 4_p
tumors NNS 4_p
. . N

PURPOSES NNP N
Fluorescence NNP N
diagnosis NN N
induced VBN N
by IN N
5-aminolevulinic JJ N
acid NN N
enables VBZ N
more RBR N
thorough JJ N
transurethral JJ N
resection NN N
of IN N
superficial JJ 4_p
bladder NN 4_p
carcinoma NNS 4_p
compared VBN N
with IN N
conventional JJ N
white JJ N
light NN N
. . N

We PRP N
performed VBD N
a DT N
prospective JJ N
, , N
single JJ N
institution NN N
, , N
randomized VBN N
trial NN N
to TO N
investigate VB N
whether IN N
the DT N
residual JJ N
tumor NN N
rate NN N
and CC N
long-term JJ N
tumor NN N
recurrence NN N
can MD N
be VB N
decreased VBN N
by IN N
fluorescence NN N
diagnosis NN N
. . N

MATERIALS NNP N
AND NNP N
METHODS NNP N
A NNP N
total NN N
of IN N
301 CD 3_p
patients NNS N
underwent JJ N
transurethral JJ 4_p
resection NN 4_p
of IN N
bladder NN 4_p
tumors NNS 4_p
with IN N
white JJ N
light NN N
or CC N
fluorescence NN N
diagnosis NN N
. . N

Transurethral JJ N
resection NN N
was VBD N
repeated VBN N
5 CD N
to TO N
6 CD N
weeks NNS N
later RB N
to TO N
evaluate VB N
the DT N
residual JJ N
tumor NN N
rate NN N
. . N

To TO N
determine VB N
recurrence-free JJ N
survival JJ N
patient NN N
followup NN N
was VBD N
performed VBN N
every DT N
3 CD N
months NNS N
by IN N
white JJ N
light JJ N
cystoscopy NN N
and CC N
urine JJ N
cytology NN N
. . N

Recurrence-free JJ N
survival NN N
was VBD N
analyzed VBN N
via IN N
Kaplan-Meier NNP N
methods NNS N
and CC N
multivariable JJ N
Cox NNP N
regression NN N
analysis NN N
. . N

RESULTS VB N
A DT N
total NN N
of IN N
191 CD 3_p
patients NNS N
with IN N
superficial JJ 4_p
bladder NN 4_p
carcinoma NN 4_p
were VBD N
available JJ N
for IN N
efficacy NN N
analysis NN N
. . N

The DT N
residual JJ N
tumor NN N
rate NN N
was VBD N
25.2 CD N
% NN N
in IN N
the DT N
white JJ N
light JJ N
arm NN N
versus NN N
4.5 CD N
% NN N
in IN N
the DT N
fluorescence NN N
diagnosis NN N
arm NN N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
. . N

Median JJ N
followup NN N
in IN N
the DT N
white JJ N
light JJ N
arm NN N
in IN N
103 CD N
cases NNS N
was VBD N
21.2 CD N
months NNS N
( ( N
range VB N
4 CD N
to TO N
40 CD N
) ) N
compared VBN N
with IN N
20.5 CD N
( ( N
range NN N
3 CD N
to TO N
40 CD N
) ) N
in IN N
the DT N
88 CD N
in IN N
the DT N
fluorescence NN N
diagnosis NN N
arm NN N
. . N

Recurrence-free JJ N
survival NN N
in IN N
the DT N
fluorescence NN N
diagnosis NN N
group NN N
was VBD N
89.6 CD N
% NN N
after IN N
12 CD N
and CC N
24 CD N
months NNS N
compared VBN N
with IN N
73.8 CD N
% NN N
and CC N
65.9 CD N
% NN N
, , N
respectively RB N
, , N
in IN N
the DT N
white JJ N
light NN N
group NN N
( ( N
p JJ N
= NNP N
0.004 CD N
) ) N
. . N

This DT N
superiority NN N
proved VBD N
to TO N
be VB N
independent JJ N
of IN N
risk NN N
group NN N
. . N

The DT N
adjusted JJ N
hazard NN N
ratio NN N
of IN N
fluorescence NN N
diagnosis NN N
versus IN N
white JJ N
light JJ N
transurethral JJ N
resection NN N
was VBD N
0.33 CD N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
0.16 CD N
to TO N
0.67 CD N
) ) N
. . N

CONCLUSIONS NNP N
Fluorescence NNP N
diagnosis NN N
is VBZ N
significantly RB N
superior JJ N
to TO N
conventional JJ N
white JJ N
light JJ N
transurethral JJ N
resection NN N
with IN N
respect NN N
to TO N
the DT N
residual JJ N
tumor NN N
rate NN N
and CC N
recurrence-free JJ N
survival NN N
. . N

The DT N
differences NNS N
in IN N
recurrence-free JJ N
survival NN N
imply NN N
that WDT N
fluorescence NN N
diagnosis NN N
is VBZ N
a DT N
clinically RB N
relevant JJ N
procedure NN N
for IN N
decreasing VBG N
the DT N
number NN N
of IN N
tumor NN N
recurrences NNS N
. . N

-DOCSTART- -X- O O

Three-year JJ N
clinical JJ N
outcome NN N
after IN N
primary JJ N
stenting NN N
of IN N
totally RB N
occluded JJ N
native JJ N
coronary JJ N
arteries NNS N
: : N
a DT N
randomized JJ N
comparison NN N
of IN N
bare-metal JJ N
stent JJ N
implantation NN N
with IN N
sirolimus-eluting JJ N
stent NN N
implantation NN N
for IN N
the DT N
treatment NN N
of IN N
total JJ 4_p
coronary JJ 4_p
occlusions NNS 4_p
( ( N
Primary JJ N
Stenting NNP N
of IN N
Totally NNP N
Occluded NNP N
Native NNP N
Coronary NNP N
Arteries NNP N
[ NNP N
PRISON NNP N
] NNP N
II NNP N
study NN N
) ) N
. . N

BACKGROUND IN N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
examine VB N
the DT N
3-year JJ N
clinical JJ N
outcome NN N
in IN N
patients NNS N
enrolled VBN N
in IN N
the DT N
Primary NNP N
Stenting NNP N
of IN N
Totally NNP N
Occluded NNP N
Native NNP N
Coronary NNP N
Arteries NNP N
II NNP N
study NN N
. . N

METHODS NNP N
Patients NNPS N
with IN N
totally RB 4_p
occluded JJ 4_p
coronary JJ 4_p
arteries NNS 4_p
randomized VBN N
to TO N
either DT N
sirolimus-eluting JJ N
Cypher NNP N
stents NNS N
( ( N
SESs NNP N
) ) N
( ( N
Cordis NNP N
, , N
a DT N
Johnson NNP N
& CC N
Joshson NNP N
Company NNP N
, , N
Miami NNP N
Lakes NNP N
, , N
FL NNP N
) ) N
( ( N
100 CD 3_p
patients NNS N
) ) N
or CC N
bare-metal JJ N
BxVelocity NNP N
stents NNS N
( ( N
BMSs NNP N
) ) N
( ( N
Cordis NNP N
) ) N
( ( N
100 CD 3_p
patients NNS N
) ) N
were VBD N
followed VBN N
clinically RB N
for IN N
3 CD N
years NNS N
. . N

RESULTS NNP N
Between NNP N
1 CD N
and CC N
3 CD N
years NNS N
, , N
there EX N
were VBD N
infrequent JJ N
additional JJ N
clinical JJ N
events NNS N
that WDT N
were VBD N
equally RB N
distributed VBN N
between IN N
the DT N
SES NNP N
and CC N
the DT N
BMS NNP N
group NN N
. . N

After IN N
3 CD N
years NNS N
, , N
target NN N
lesion NN N
revascularization NN N
was VBD N
7 CD N
% NN N
in IN N
the DT N
SES NNP N
group NN N
versus VBD N
27 CD N
% NN N
in IN N
the DT N
BMS NNP N
group NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
; : N
and CC N
target VB N
vessel JJ N
revascularization NN N
was VBD N
seen VBN N
in IN N
11 CD N
% NN N
in IN N
the DT N
SES NNP N
group NN N
versus VBD N
30 CD N
% NN N
in IN N
the DT N
BMS NNP N
group NN N
( ( N
P NNP N
= NNP N
.002 NNP N
) ) N
. . N

Major JJ N
adverse JJ N
cardiac NN N
events NNS N
were VBD N
noted VBN N
in IN N
10 CD N
% NN N
of IN N
the DT N
SES NNP N
group NN N
versus VBD N
34 CD N
% NN N
in IN N
the DT N
BMS NNP N
group NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
in IN N
death NN N
, , N
myocardial JJ N
infarction NN N
, , N
and CC N
stent JJ N
thrombosis NN N
according VBG N
to TO N
the DT N
Academic NNP N
Research NNP N
Consortium NNP N
criteria NNS N
between IN N
the DT N
2 CD N
groups NNS N
. . N

CONCLUSIONS NNP N
Clinical NNP N
outcome VBD N
up RB N
to TO N
3 CD N
years NNS N
after IN N
implantation NN N
of IN N
SESs NNP N
for IN N
total JJ N
coronary JJ N
occlusions NNS N
continues VBZ N
to TO N
demonstrate VB N
a DT N
significant JJ N
reduction NN N
in IN N
adverse JJ N
clinical JJ N
events NNS N
compared VBN N
with IN N
BMSs NNP N
without IN N
the DT N
evidence NN N
for IN N
either DT N
disproportionate NN N
late JJ N
restenosis NN N
or CC N
late JJ N
stent JJ N
thrombosis NN N
. . N

-DOCSTART- -X- O O

Relationship NN N
between IN N
baseline NN N
blood NN N
pressure NN N
parameters NNS N
( ( N
including VBG N
mean JJ N
pressure NN N
, , N
pulse JJ N
pressure NN N
, , N
and CC N
variability NN N
) ) N
and CC N
early JJ N
outcome NN N
after IN N
stroke NN 4_p
: : N
data NN N
from IN N
the DT N
Tinzaparin NNP N
in IN N
Acute NNP 4_p
Ischaemic NNP 4_p
Stroke NNP 4_p
Trial NNP N
( ( N
TAIST NNP N
) ) N
. . N

BACKGROUND NNP N
AND NNP N
PURPOSE NNP N
High NNP 4_p
blood NN 4_p
pressure NN 4_p
( ( N
BP NNP N
) ) N
in IN N
acute JJ 4_p
stroke NN 4_p
is VBZ N
associated VBN N
independently RB N
with IN N
a DT N
poor JJ N
outcome NN N
. . N

Recent JJ N
evidence NN N
suggests VBZ N
that IN N
other JJ N
hemodynamic JJ N
parameters NNS N
may MD N
also RB N
be VB N
associated VBN N
with IN N
outcomes NNS N
following VBG N
stroke NN N
. . N

METHODS NNP N
The DT N
relationship NN N
between IN N
baseline NN N
BP NNP N
, , N
heart NN N
rate NN N
, , N
and CC N
other JJ N
hemodynamic JJ N
parameters NNS N
, , N
and CC N
early RB N
outcomes NNS N
were VBD N
assessed VBN N
using VBG N
data NNS N
from IN N
TAIST NNP N
trial NN N
. . N

RESULTS NNP N
Death NNP N
or CC N
neurological JJ N
deterioration NN N
at IN N
day NN N
10 CD N
was VBD N
associated VBN N
, , N
both DT N
in IN N
unadjusted JJ N
and CC N
adjusted JJ N
analyses NNS N
, , N
with IN N
systolic JJ N
BP NNP N
( ( N
adjusted VBN N
OR NNP N
, , N
1.02 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
1.01-1.03 JJ N
) ) N
, , N
mean JJ N
arterial JJ N
pressure NN N
( ( N
OR NNP N
, , N
1.02 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
1.01-1.04 JJ N
) ) N
, , N
pulse JJ N
pressure NN N
( ( N
OR NNP N
, , N
1.02 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
1.01-1.03 JJ N
) ) N
, , N
and CC N
BP NNP N
variability NN N
( ( N
OR NNP N
, , N
1.03 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
1.01-1.05 JJ N
) ) N
. . N

Similar JJ N
relationships NNS N
were VBD N
noted VBN N
for IN N
deterioration NN N
alone RB N
, , N
and CC N
recurrent JJ N
stroke NN N
. . N

CONCLUSIONS NNP N
Early JJ N
death NN N
or CC N
neurologic JJ N
deterioration NN N
, , N
deterioration NN N
, , N
and CC N
recurrent JJ N
stroke NN N
are VBP N
associated VBN N
independently RB N
with IN N
high JJ N
systolic JJ N
BP NNP N
, , N
mean JJ N
arterial JJ N
pressure NN N
, , N
pulse JJ N
pressure NN N
, , N
and CC N
BP NNP N
variability NN N
. . N

These DT N
measures NNS N
offer VBP N
potential JJ N
therapeutic JJ N
targets NNS N
for IN N
improving VBG N
early JJ N
outcome NN N
after IN N
acute JJ 4_p
ischemic JJ 4_p
stroke NN 4_p
. . N

-DOCSTART- -X- O O

0.1 CD N
% NN N
bupivacaine NN N
does VBZ N
not RB N
reduce VB N
the DT N
requirement NN N
for IN N
epidural JJ N
fentanyl NN N
infusion NN N
after IN N
major JJ 4_p
abdominal JJ 4_p
surgery NN 4_p
. . N

BACKGROUND NNP N
AND NNP N
OBJECTIVES NNP N
Although IN N
local JJ N
anesthesia NN N
has VBZ N
been VBN N
demonstrated VBN N
to TO N
potentiate VB N
spinal JJ N
morphine NN N
analgesia NN N
in IN N
animal JJ N
studies NNS N
, , N
results NNS N
comparing VBG N
epidural JJ N
local JJ N
anesthesia/opioid NN N
mixtures NNS N
with IN N
opioid JJ N
alone NN N
are VBP N
contradictory JJ N
in IN N
clinical JJ N
studies NNS N
. . N

The DT N
hypothesis NN N
was VBD N
that IN N
, , N
although IN N
the DT N
concentration NN N
of IN N
bupivacaine NN N
( ( N
0.1 CD N
% NN N
) ) N
was VBD N
low JJ N
to TO N
minimize VB N
its PRP$ N
adverse JJ N
effects NNS N
, , N
if IN N
the DT N
infusion NN N
rate NN N
of IN N
a DT N
fentanyl/bupivacaine JJ N
solution NN N
was VBD N
closely RB N
adjusted VBN N
according VBG N
to TO N
need NN N
, , N
the DT N
presence NN N
bupivacaine NN N
would MD N
reduce VB N
the DT N
requirement NN N
for IN N
epidural JJ N
fentanyl NN N
. . N

METHODS NNP N
Forty NNP 3_p
patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either DT N
fentanyl NN N
( ( N
10 CD N
micrograms/mL NN N
) ) N
or CC N
a DT N
fentanyl/bupivacaine NN N
( ( N
0.1 CD N
% NN N
) ) N
mixture NN N
epidurally RB N
corresponding VBG N
to TO N
the DT N
dermatome NN N
of IN N
the DT N
surgical JJ N
incision NN N
in IN N
a DT N
double-blind JJ N
fashion NN N
for IN N
the DT N
first JJ N
18 CD N
hours NNS N
after IN N
major JJ 4_p
abdominal JJ 4_p
surgery NN 4_p
. . N

The DT N
infusion NN N
was VBD N
titrated VBN N
for IN N
each DT N
patient NN N
to TO N
the DT N
rate NN N
required VBN N
for IN N
pain NN N
relief NN N
during IN N
forced VBN N
inspiration NN N
( ( N
pain NN N
score NN N
< NN N
or CC N
= $ N
2 CD N
, , N
maximum JJ N
10 CD N
) ) N
. . N

Pain NN N
scores NNS N
, , N
the DT N
fentanyl JJ N
doses NNS N
required VBN N
, , N
plasma JJ N
concentrations NNS N
of IN N
fentanyl NN N
at IN N
18 CD N
hours NNS N
, , N
and CC N
the DT N
incidence NN N
and CC N
severity NN N
of IN N
adverse JJ N
effects NNS N
were VBD N
recorded VBN N
. . N

RESULTS JJ N
Patients NNPS N
reported VBD N
similar JJ N
median JJ N
pain NN N
scores NNS N
and CC N
were VBD N
equally RB N
satisfied VBN N
with IN N
pain NN N
relief NN N
in IN N
both DT N
groups NNS N
. . N

The DT N
mean NN N
required VBN N
post-operative JJ N
fentanyl JJ N
infusion NN N
rate NN N
( ( N
57.7 CD N
+/- JJ N
19.5 CD N
micrograms/h NN N
) ) N
and CC N
the DT N
plasma NN N
concentrations NNS N
( ( N
0.84 CD N
+/- JJ N
0.36 CD N
ng/mL NN N
) ) N
in IN N
the DT N
fentanyl NN N
group NN N
were VBD N
comparable JJ N
to TO N
the DT N
infusion NN N
rate NN N
( ( N
54.4 CD N
+/- JJ N
19.2 CD N
micrograms/h NN N
) ) N
and CC N
the DT N
plasma NN N
concentrations NNS N
( ( N
0.86 CD N
+/- JJ N
0.36 CD N
ng/mL NN N
) ) N
in IN N
the DT N
fentanyl/bupivacaine NN N
group NN N
. . N

Respiratory NNP N
and CC N
cardiovascular JJ N
functions NNS N
were VBD N
preserved VBN N
, , N
and CC N
the DT N
incidence NN N
of IN N
nausea NN N
, , N
pruritus NN N
, , N
and CC N
periods NNS N
of IN N
drowsiness NN N
or CC N
sleep NN N
were VBD N
similar JJ N
in IN N
both DT N
groups NNS N
. . N

CONCLUSIONS NNP N
In IN N
low JJ N
concentrations NNS N
( ( N
0.1 CD N
% NN N
) ) N
, , N
bupivacaine NN N
did VBD N
not RB N
reduce VB N
the DT N
titrated JJ N
dose NN N
of IN N
epidural JJ N
fentanyl NN N
required VBN N
for IN N
adequate JJ N
pain NN N
relief NN N
during IN N
forced VBN N
inspiration NN N
after IN N
major JJ N
abdominal JJ N
surgery NN N
. . N

The DT N
incidence NN N
and CC N
severity NN N
of IN N
adverse JJ N
effects NNS N
were VBD N
also RB N
comparable JJ N
whether IN N
or CC N
not RB N
low-dose JJ N
bupivacaine NN N
infusion NN N
was VBD N
used VBN N
. . N

-DOCSTART- -X- O O

Immunologic NNP N
response NN N
after IN N
laparoscopic NN N
colon NN 4_p
cancer NN 4_p
operation NN N
within IN N
an DT N
enhanced JJ N
recovery NN N
program NN N
. . N

OBJECTIVE NN N
It PRP N
has VBZ N
been VBN N
demonstrated VBN N
that IN N
colon NN N
operation NN N
combined VBN N
with IN N
fast-track NN N
( ( N
FT NNP N
) ) N
surgery NN N
and CC N
laparoscopic NN N
technique NN N
can MD N
shorten VB N
the DT N
length NN N
of IN N
hospital NN N
stay NN N
, , N
accelerate JJ N
recovery NN N
of IN N
intestinal JJ N
function NN N
, , N
and CC N
reduce VB N
the DT N
occurrence NN N
of IN N
post-operative JJ N
complications NNS N
. . N

However RB N
, , N
there EX N
are VBP N
no DT N
reports NNS N
regarding VBG N
the DT N
combined JJ N
effects NNS N
of IN N
FT NNP N
colon NN N
operation NN N
and CC N
laparoscopic NN N
technique NN N
on IN N
humoral JJ N
inflammatory NN N
cellular JJ N
immunity NN N
. . N

METHODS NNP N
This DT N
was VBD N
a DT N
prospective JJ N
, , N
controlled VBD N
study NN N
. . N

One CD 3_p
hundred VBD 3_p
sixty-three JJ 3_p
colon NN 4_p
cancer NN 4_p
patients NNS N
underwent VBD N
the DT N
traditional JJ N
protocol NN N
and CC N
open JJ N
operation NN N
( ( N
traditional JJ N
open JJ N
group NN N
, , N
n=42 RB 3_p
) ) N
, , N
the DT N
traditional JJ N
protocol NN N
and CC N
laparoscopic NN N
operation NN N
( ( N
traditional JJ N
laparoscopic NN N
group NN N
, , N
n=40 RB 3_p
) ) N
, , N
the DT N
FT NNP N
protocol NN N
and CC N
open JJ N
operation NN N
( ( N
FT NNP N
open JJ N
group NN N
, , N
n=41 RB 3_p
) ) N
, , N
or CC N
the DT N
FT NNP N
protocol NN N
and CC N
laparoscopic NN N
operation NN N
( ( N
FT NNP N
laparoscopic NN N
group NN N
, , N
n=40 RB 3_p
) ) N
. . N

Blood NN N
samples NNS N
were VBD N
taken VBN N
prior RB N
to TO N
operation NN N
as RB N
well RB N
as IN N
on IN N
days NNS N
1 CD N
, , N
3 CD N
, , N
and CC N
5 CD N
after IN N
operation NN N
. . N

The DT N
number NN N
of IN N
lymphocyte JJ N
subpopulations NNS N
was VBD N
determined VBN N
by IN N
flow JJ N
cytometry NN N
, , N
and CC N
serum VB N
interleukin-6 JJ N
and CC N
C-reactive JJ N
protein NN N
levels NNS N
were VBD N
measured VBN N
. . N

Post-operative JJ N
hospital NN N
stay NN N
, , N
post-operative JJ N
morbidity NN N
, , N
readmission NN N
rate NN N
, , N
and CC N
in-hospital JJ N
mortality NN N
were VBD N
recorded VBN N
. . N

RESULTS NNP N
Compared VBD N
with IN N
open JJ N
operation NN N
, , N
laparoscopic JJ N
colon NN N
operation NN N
effectively RB N
inhibited VBD N
the DT N
release NN N
of IN N
post-operative JJ N
inflammatory JJ N
factors NNS N
and CC N
yielded VBD N
good JJ N
protection NN N
via IN N
post-operative JJ N
cell NN N
immunity NN N
. . N

FT NNP N
surgery NN N
had VBD N
a DT N
better RBR N
protective JJ N
role NN N
with IN N
respect NN N
to TO N
the DT N
post-operative JJ N
immune NN N
system NN N
compared VBN N
with IN N
traditional JJ N
peri-operative JJ N
care NN N
. . N

Inflammatory JJ N
reactions NNS N
, , N
based VBN N
on IN N
interleukin-6 JJ N
and CC N
C-reactive JJ N
protein NN N
levels NNS N
, , N
were VBD N
less JJR N
intense JJ N
following VBG N
FT NNP N
laparoscopic NN N
operation NN N
compared VBN N
to TO N
FT NNP N
open JJ N
operation NN N
; : N
however RB N
, , N
there EX N
were VBD N
no DT N
differences NNS N
in IN N
specific JJ N
immunity NN N
( ( N
CD3+ NNP N
and CC N
CD4+ NNP N
counts NNS N
, , N
and CC N
the DT N
CD4+/CD8+ NNP N
ratio NN N
) ) N
during IN N
these DT N
two CD N
types NNS N
of IN N
surgical JJ N
procedures NNS N
. . N

Post-operative JJ N
hospital NN N
stay NN N
in IN N
patients NNS N
randomized VBN N
to TO N
the DT N
FT NNP N
laparoscopic NN N
group NN N
was VBD N
significantly RB N
shorter JJR N
than IN N
in IN N
the DT N
other JJ N
three CD N
treatment NN N
groups NNS N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Post-operative JJ N
complications NNS N
in IN N
patients NNS N
who WP N
underwent VBP N
FT NNP N
laparoscopic NN N
treatment NN N
were VBD N
less JJR N
than IN N
in IN N
the DT N
other JJ N
three CD N
treatment NN N
groups NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
four CD N
treatment NN N
groups NNS N
regarding VBG N
readmission NN N
rate NN N
and CC N
in-hospital JJ N
mortality NN N
. . N

CONCLUSIONS VB N
The DT N
laparoscopic NN N
technique NN N
and CC N
FT NNP N
surgery NN N
rehabilitation NN N
program NN N
effectively RB N
inhibited VBD N
release NN N
of IN N
post-operative JJ N
inflammatory JJ N
factors NNS N
with IN N
a DT N
reduction NN N
in IN N
peri-operative JJ N
trauma NN N
and CC N
stress NN N
, , N
which WDT N
together RB N
played VBD N
a DT N
protective JJ N
role NN N
on IN N
the DT N
post-operative JJ N
immune NN N
system NN N
. . N

Combining VBG N
two CD N
treatment NN N
measures NNS N
during IN N
colon NN N
operation NN N
produced VBD N
better RBR N
protective JJ N
effects NNS N
via IN N
the DT N
immune JJ N
system NN N
. . N

The DT N
beneficial JJ N
clinical JJ N
effects NNS N
support NN N
that IN N
the DT N
better-preserved JJ N
post-operative JJ N
immune NN N
system NN N
may MD N
also RB N
contribute VB N
to TO N
the DT N
improvement NN N
of IN N
post-operative JJ N
results NNS N
in IN N
FT NNP N
laparoscopic NN N
patients NNS N
. . N

-DOCSTART- -X- O O

The DT N
problem NN N
of IN N
measurement NN N
error NN N
in IN N
multisite JJ N
clinical JJ N
trials NNS N
. . N

The DT N
implementation NN N
of IN N
a DT N
multisite NN N
, , N
randomized VBN N
, , N
clinical JJ N
psychopharmacologic JJ N
trial NN N
involves VBZ N
a DT N
substantial JJ N
investment NN N
of IN N
time NN N
and CC N
effort NN N
on IN N
the DT N
part NN N
of IN N
all DT N
participants NNS N
. . N

Because IN N
of IN N
their PRP$ N
complexity NN N
, , N
such JJ N
clinical JJ N
trials NNS N
present JJ N
unique JJ N
methodological JJ N
and CC N
design NN N
challenges NNS N
. . N

Indeed RB N
, , N
it PRP N
is VBZ N
not RB N
uncommon JJ N
for IN N
such JJ N
studies NNS N
to TO N
conclude VB N
with IN N
uninterpretable JJ N
results NNS N
, , N
due JJ N
in IN N
part NN N
to TO N
such JJ N
methodological JJ N
pitfalls NNS N
. . N

It PRP N
has VBZ N
been VBN N
suggested VBN N
that IN N
clarification NN N
of IN N
such JJ N
methodologic JJ N
dilemmas NN N
is VBZ N
one CD N
of IN N
the DT N
most RBS N
important JJ N
challenges NNS N
facing VBG N
the DT N
future NN N
of IN N
industry-sponsored JJ N
psychopharmacologic JJ N
drug NN N
development NN N
. . N

Among IN N
the DT N
many JJ N
factors NNS N
that WDT N
may MD N
contribute VB N
to TO N
problematic JJ N
clinical JJ N
trial NN N
results NNS N
, , N
error NN N
in IN N
measuring VBG N
the DT N
phenomena NN N
being VBG N
studied VBN N
is VBZ N
of IN N
particular JJ N
concern NN N
. . N

In IN N
this DT N
article NN N
, , N
we PRP N
describe VBP N
the DT N
outcome NN N
of IN N
an DT N
intensive JJ N
series NN N
of IN N
interrater JJ N
reliability NN N
training NN N
sessions NNS N
for IN N
the DT N
17-item JJ N
Hamilton NNP N
Depression NNP N
Rating NNP N
Scale NNP N
conducted VBD N
at IN N
the DT N
start NN N
of IN N
a DT N
Phase NNP N
II NNP N
multisite RB N
clinical JJ N
drug NN N
trial NN N
. . N

The DT N
data NN N
underscore IN N
the DT N
magnitude NN N
of IN N
error NN N
present NN N
in IN N
such JJ N
a DT N
test NN N
setting NN N
and CC N
provide VB N
preliminary JJ N
evidence NN N
for IN N
the DT N
potential JJ N
effect NN N
of IN N
this DT N
problem NN N
on IN N
the DT N
detection NN N
of IN N
clinical JJ N
change NN N
. . N

-DOCSTART- -X- O O

The DT N
effect NN N
of IN N
body NN N
positioning VBG N
upon IN N
maximal JJ N
oxygenation NN N
of IN N
patients NNS N
with IN N
unilateral JJ 4_p
lung NN 4_p
pathology NN 4_p
. . N

A DT N
quasi-experimental JJ N
, , N
repeated-measures JJ N
cross-over NN N
design NN N
study NN N
on IN N
the DT N
effect NN N
of IN N
body NN N
position NN N
on IN N
oxygenation NN N
( ( N
SaO2 NNP N
) ) N
blood NN N
pressure NN N
, , N
respiration NN N
and CC N
pulse NN N
in IN N
patients NNS N
with IN N
unilateral JJ 4_p
lung NN 4_p
pathology NN 4_p
was VBD N
conducted VBN N
. . N

Previous JJ N
research NN N
strongly RB N
suggests VBZ N
that IN N
positioning VBG N
with IN N
the DT N
healthy JJ N
( ( N
unaffected JJ N
) ) N
lung NN N
in IN N
the DT N
dependent JJ N
lateral NN N
( ( N
down RP N
) ) N
position NN N
is VBZ N
related VBN N
to TO N
improved VBN N
oxygenation NN N
, , N
but CC N
knowledge VBP N
about IN N
whether IN N
this DT N
effect NN N
is VBZ N
maintained VBN N
over IN N
time NN N
is VBZ N
lacking VBG N
. . N

The DT N
purpose NN N
of IN N
this DT N
investigation NN N
was VBD N
to TO N
determine VB N
: : N
( ( N
1 CD N
) ) N
Is VBZ N
positioning VBG N
with IN N
the DT N
unaffected JJ N
lung NN N
in IN N
the DT N
dependent JJ N
lateral JJ N
position NN N
related VBN N
to TO N
increased VBN N
arterial JJ N
blood NN N
saturation NN N
levels NNS N
and CC N
decreased VBD N
blood NN N
pressure NN N
, , N
pulse NN N
and CC N
respiration NN N
? . N
( ( N
2 CD N
) ) N
What WP N
is VBZ N
the DT N
relationship NN N
between IN N
the DT N
dependent JJ N
variables NNS N
-- : N
oxygenation NN N
saturation NN N
levels NNS N
, , N
blood NN N
pressure NN N
, , N
pulse NN N
and CC N
respiration NN N
-- : N
and CC N
the DT N
independent JJ N
variables NNS N
-- : N
body NN N
position NN N
and CC N
time NN N
in IN N
the DT N
position NN N
? . N
Thirty-nine JJ 3_p
patients NNS N
with IN N
unilateral JJ 4_p
lung NN 4_p
pathology NN 4_p
were VBD N
positioned VBN N
on IN N
their PRP$ N
sides NNS N
with IN N
the DT N
unaffected JJ N
lung NN N
down RP N
, , N
on IN N
their PRP$ N
sides NNS N
with IN N
the DT N
affected JJ N
lung NN N
down RB N
, , N
and CC N
also RB N
in IN N
semi-Fowler NN N
's POS N
position NN N
. . N

Arterial NNP N
( ( N
SaO2 NNP N
) ) N
blood NN N
saturation NN N
and CC N
vital JJ N
signs NNS N
were VBD N
measured VBN N
at IN N
baseline NN N
0 CD N
, , N
15 CD N
and CC N
30 CD N
minutes NNS N
. . N

There EX N
was VBD N
no DT N
statistically RB N
significant JJ N
relationship NN N
between IN N
oxygenation NN N
level NN N
or CC N
systolic JJ N
blood NN N
pressure NN N
. . N

Diastolic NNP N
blood NN N
pressure NN N
, , N
respiration NN N
and CC N
pulse NN N
did VBD N
vary JJ N
significantly RB N
with IN N
position NN N
. . N

-DOCSTART- -X- O O

Randomized NNP N
comparison NN N
of IN N
interferon NN N
alpha NN N
and CC N
hydroxyurea NN N
with IN N
hydroxyurea JJ N
monotherapy NN N
in IN N
chronic JJ N
myeloid NN N
leukemia NN N
( ( N
CML-study NNP N
II NNP N
) ) N
: : N
prolongation NN N
of IN N
survival NN N
by IN N
the DT N
combination NN N
of IN N
interferon NN N
alpha NN N
and CC N
hydroxyurea NN N
. . N

The DT N
optimum JJ N
treatment NN N
conditions NNS N
of IN N
interferon NN N
( ( N
IFN NNP N
) ) N
alpha VBP N
therapy NN N
in IN N
chronic JJ N
myeloid NN N
leukemia NN N
( ( N
CML NNP N
) ) N
are VBP N
still RB N
controversial JJ N
. . N

To TO N
evaluate VB N
the DT N
role NN N
of IN N
hydroxyurea NN N
( ( N
HU NNP N
) ) N
for IN N
the DT N
outcome NN N
of IN N
IFN NNP N
therapy NN N
, , N
we PRP N
conducted VBD N
a DT N
randomized JJ N
trial NN N
to TO N
compare VB N
the DT N
combination NN N
of IN N
IFN NNP N
and CC N
HU NNP N
vs VBP N
HU NNP N
monotherapy NN N
( ( N
CML-study NNP N
II NNP N
) ) N
. . N

From IN N
February NNP N
1991 CD N
to TO N
December NNP N
1994 CD N
, , N
376 CD 3_p
patients NNS N
with IN N
newly RB N
diagnosed VBN N
CML NNP 4_p
in IN N
chronic JJ 4_p
phase NN 4_p
were VBD N
randomized VBN N
. . N

In IN N
all DT N
, , N
340 CD 3_p
patients NNS N
were VBD N
Ph/BCR-ABL NNP 4_p
positive JJ N
and CC N
evaluable JJ N
. . N

Randomization NN N
was VBD N
unbalanced JJ N
1:2 CD N
in IN N
favor NN N
of IN N
the DT N
combination NN N
therapy NN N
, , N
since IN N
study NN N
conditions NNS N
were VBD N
identical JJ N
to TO N
the DT N
previous JJ N
CML-study NNP N
I PRP N
and CC N
it PRP N
had VBD N
been VBN N
planned VBN N
in IN N
advance NN N
to TO N
add VB N
the DT N
HU NNP N
patients NNS N
of IN N
study NN N
I PRP N
( ( N
n=194 RB N
) ) N
to TO N
the DT N
HU NNP N
control NN N
group NN N
. . N

Therefore RB N
, , N
a DT N
total NN N
of IN N
534 CD 3_p
patients NNS N
were VBD N
evaluable JJ N
( ( N
226 CD 3_p
patients NNS N
with IN N
IFN/HU NNP N
and CC N
308 CD 3_p
patients NNS N
with IN N
HU NNP N
) ) N
. . N

Analyses NNS N
were VBD N
according VBG N
to TO N
intention-to-treat NN N
. . N

Median JJ N
observation NN N
time NN N
of IN N
nontransplanted JJ N
living NN N
patients NNS N
was VBD N
7.6 CD N
years NNS N
( ( N
7.9 CD N
years NNS N
for IN N
IFN/HU NNP N
and CC N
7.3 CD N
years NNS N
for IN N
HU NNP N
) ) N
. . N

The DT N
risk NN N
profile NN N
( ( N
new JJ N
CML NNP N
score NN N
) ) N
was VBD N
available JJ N
for IN N
532 CD N
patients NNS N
: : N
200 CD N
patients NNS N
( ( N
38 CD N
% NN N
) ) N
were VBD N
low JJ N
, , N
239 CD N
patients NNS N
( ( N
45 CD N
% NN N
) ) N
intermediate NN N
, , N
and CC N
93 CD N
patients NNS N
( ( N
17 CD N
% NN N
) ) N
high JJ N
risk NN N
. . N

Complete NNP N
hematologic JJ N
response NN N
rates NNS N
were VBD N
higher JJR N
in IN N
IFN/HU-treated JJ N
patients NNS N
( ( N
59 CD N
vs RB N
32 CD N
% NN N
) ) N
. . N

Of IN N
169 CD N
evaluable JJ N
IFN/HU-treated JJ N
patients NNS N
( ( N
75 CD N
% NN N
) ) N
, , N
104 CD N
patients NNS N
( ( N
62 CD N
% NN N
) ) N
achieved VBD N
a DT N
cytogenetic JJ N
response NN N
that WDT N
was VBD N
complete JJ N
in IN N
12 CD N
% NN N
( ( N
n=21 JJ N
) ) N
, , N
major JJ N
in IN N
14 CD N
% NN N
( ( N
n=24 JJ N
) ) N
, , N
and CC N
at IN N
least JJS N
minimal JJ N
in IN N
35 CD N
% NN N
( ( N
n=59 JJ N
) ) N
. . N

Of IN N
the DT N
534 CD 3_p
patients NNS N
, , N
105 CD N
( ( N
20 CD N
% NN N
) ) N
underwent NN N
allogeneic JJ N
stem NN N
cell NN N
transplantation NN N
in IN N
first JJ N
chronic JJ N
phase NN N
. . N

In IN N
the DT N
low-risk JJ N
group NN N
, , N
65 CD N
of IN N
200 CD N
patients NNS N
were VBD N
transplanted VBN N
( ( N
33 CD N
% NN N
) ) N
, , N
30 CD N
( ( N
13 CD N
% NN N
) ) N
in IN N
the DT N
intermediate-risk JJ N
group NN N
, , N
and CC N
nine CD N
( ( N
10 CD N
% NN N
) ) N
in IN N
the DT N
high-risk JJ N
group NN N
. . N

Duration NN N
of IN N
chronic JJ N
phase NN N
was VBD N
55 CD N
months NNS N
for IN N
IFN/HU NNP N
and CC N
41 CD N
months NNS N
for IN N
HU NNP N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

Median JJ N
survival NN N
was VBD N
64 CD N
months NNS N
for IN N
IFN/HU NNP N
and CC N
53 CD N
months NNS N
for IN N
HU-treated JJ N
patients NNS N
( ( N
P=0.0063 NNP N
) ) N
. . N

We PRP N
conclude VBP N
that DT N
IFN NNP N
in IN N
combination NN N
with IN N
HU NNP N
achieves VBZ N
a DT N
significant JJ N
long-term JJ N
survival NN N
advantage NN N
over IN N
HU NNP N
monotherapy NN N
. . N

In IN N
view NN N
of IN N
the DT N
data NNS N
of IN N
CML-study NNP N
I PRP N
, , N
these DT N
results NNS N
suggest VBP N
that IN N
IFN/HU NNP N
is VBZ N
also RB N
superior JJ N
to TO N
IFN NNP N
alone RB N
. . N

HU NNP N
should MD N
be VB N
combined VBN N
with IN N
IFN NNP N
in IN N
IFN-based JJ N
therapies NNS N
and CC N
for IN N
comparisons NNS N
with IN N
new JJ N
therapies NNS N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
entacapone NN N
, , N
a DT N
peripherally RB N
acting VBG N
catechol-O-methyltransferase NN N
inhibitor NN N
, , N
on IN N
the DT N
motor NN N
response NN N
to TO N
acute VB N
treatment NN N
with IN N
levodopa NN N
in IN N
patients NNS N
with IN N
Parkinson NNP 4_p
's POS 4_p
disease NN 4_p
. . N

Catechol-O-methyltransferase NNP N
( ( N
COMT NNP N
) ) N
inhibitors NNS N
may MD N
be VB N
useful JJ N
in IN N
the DT N
treatment NN N
of IN N
Parkinson NNP N
's POS N
disease NN N
by IN N
improving VBG N
the DT N
bioavailability NN N
of IN N
levodopa NN N
and CC N
by IN N
prolonging VBG N
its PRP$ N
effects NNS N
. . N

Entacapone NNP N
( ( N
OR-611 NNP N
) ) N
, , N
a DT N
novel JJ N
COMT NNP N
inhibitor NN N
, , N
which WDT N
does VBZ N
not RB N
cross VB N
the DT N
blood NN N
brain NN N
barrier NN N
, , N
was VBD N
assessed VBN N
in IN N
12 CD 3_p
patients NNS N
with IN N
Parkinson NNP 4_p
's POS 4_p
disease NN 4_p
and CC N
motor NN 4_p
fluctuations NNS 4_p
in IN N
a DT N
randomised JJ N
, , N
double-blind JJ N
, , N
cross-over JJ N
, , N
single JJ N
dose NN N
study NN N
. . N

The DT N
magnitude NN N
and CC N
duration NN N
of IN N
the DT N
therapeutic JJ N
response NN N
to TO N
a DT N
single JJ N
dose NN N
of IN N
200 CD N
mg NNS N
levodopa/50 JJ N
mg FW N
carbidopa NN N
was VBD N
evaluated VBN N
after IN N
concomitant JJ N
placebo NN N
, , N
or CC N
200 CD N
or CC N
800 CD N
mg NN N
entacapone NN N
. . N

A DT N
significant JJ N
increase NN N
in IN N
the DT N
duration NN N
of IN N
the DT N
motor NN N
response NN N
to TO N
levodopa NN N
was VBD N
seen VBN N
when WRB N
200 CD N
mg NN N
entacapone NN N
was VBD N
given VBN N
with IN N
levodopa/carbidopa NN N
. . N

Plasma NNP N
levodopa JJ N
concentrations NNS N
were VBD N
increased VBN N
with IN N
both DT N
doses NNS N
of IN N
the DT N
COMT NNP N
inhibitor NN N
. . N

The DT N
latency NN N
to TO N
onset VB N
of IN N
motor NN N
response NN N
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
active JJ N
drug NN N
and CC N
placebo NN N
. . N

Entacapone NN N
may MD N
prove VB N
useful JJ N
in IN N
prolonging VBG N
the DT N
duration NN N
of IN N
the DT N
benefit NN N
obtained VBN N
from IN N
individual JJ N
doses NNS N
of IN N
levodopa NN N
. . N

-DOCSTART- -X- O O

1999 CD N
WHO/ISH NNP N
Guidelines NNP N
applied VBD N
to TO N
a DT N
1999 CD N
MONICA NNP N
sample NN N
from IN N
northern JJ N
Sweden NNP N
. . N

BACKGROUND NNP N
Treating NNP N
hypertension NN N
with IN N
drugs NNS N
is VBZ N
so RB N
far RB N
the DT N
most RBS N
cost-effective JJ N
way NN N
to TO N
reduce VB N
this DT N
important JJ N
risk NN N
factor NN N
for IN N
cardiovascular JJ N
disease NN N
( ( N
CVD NNP N
) ) N
. . N

It PRP N
is VBZ N
, , N
however RB N
, , N
important JJ N
to TO N
determine VB N
absolute NN N
risk NN N
, , N
and CC N
thereby RB N
estimate VB N
indication NN N
for IN N
drug NN N
treatment NN N
, , N
in IN N
order NN N
to TO N
maintain VB N
a DT N
cost-effective JJ N
drug NN N
treatment NN N
. . N

WHO/ISH NNP N
Hypertension NNP N
Guidelines NNP N
from IN N
1999 CD N
propose NN N
a DT N
risk NN N
stratification NN N
for IN N
estimating VBG N
absolute NN N
risk NN N
for IN N
CVD NNP N
based VBN N
on IN N
blood NN N
pressure NN N
and CC N
additional JJ N
risk NN N
factors NNS N
, , N
target NN N
organ JJ N
damage NN N
( ( N
TOD NNP N
) ) N
and CC N
CVD NNP N
. . N

OBJECTIVES NNP N
We PRP N
studied VBD N
the DT N
consequences NNS N
of IN N
applying VBG N
the DT N
recent JJ N
WHO/ISH NNP N
risk NN N
stratification NN N
scheme NN N
to TO N
a DT N
MONICA NNP N
sample NN N
of IN N
6000 CD 3_p
subjects NNS N
from IN N
a DT N
geographically RB N
defined VBN N
population NN N
in IN N
northern JJ N
Sweden NNP N
, , N
regarding VBG N
indications NNS N
for IN N
treatment NN N
, , N
target VB N
blood NN N
pressure NN N
and CC N
risk NN N
distribution NN N
. . N

METHODS NNP N
We PRP N
have VBP N
risk-classified JJ N
each DT N
of IN N
these DT N
patients NNS N
using VBG N
a DT N
computer NN N
program NN N
, , N
according VBG N
to TO N
the DT N
WHO/ISH NNP N
scheme NN N
. . N

Data NNP N
on IN N
TOD NNP N
were VBD N
not RB N
available JJ N
. . N

RESULTS NNP N
In IN N
all DT N
, , N
917 CD N
( ( N
15 CD N
% NN N
) ) N
had VBD N
drug-treated JJ 4_p
hypertension NN 4_p
. . N

Three-quarters NNS N
( ( N
n JJ N
= NNP N
737 CD N
) ) N
were VBD N
inadequately RB N
treated VBN N
, , N
with IN N
blood NN N
pressure NN N
levels NNS N
at IN N
or CC N
above VB N
140 CD N
or CC N
90 CD N
mmHg NN N
. . N

1773 CD N
( ( N
30 CD N
% NN N
of IN N
5997 CD N
) ) N
untreated JJ 4_p
subjects NNS N
had VBD N
a DT N
blood NN N
pressure NN N
of IN N
140/90 CD N
or CC N
above RB N
; : N
16 CD N
% NN N
in IN N
the DT N
low- JJ N
, , N
62 CD N
% NN N
in IN N
the DT N
medium- NN N
, , N
8 CD N
% NN N
in IN N
the DT N
high- NN N
, , N
and CC N
14 CD N
% NN N
in IN N
the DT N
very-high-risk JJ N
group NN N
. . N

The DT N
corresponding JJ N
risk-group JJ N
pattern NN N
for IN N
the DT N
inadequately RB N
treated JJ N
hypertensives NNS N
( ( N
n JJ N
= NNP N
737 CD N
) ) N
was VBD N
5.5 CD N
, , N
48.3 CD N
, , N
11.1 CD N
and CC N
35.2 CD N
% NN N
, , N
respectively RB N
. . N

If IN N
we PRP N
shifted VBD N
the DT N
target NN N
blood NN N
pressure NN N
from IN N
below IN N
140/90 CD N
to TO N
below VB N
130/85 CD N
for IN N
drug-treated JJ N
subjects NNS N
under IN N
60 CD N
( ( N
n JJ N
= NNP N
278 CD N
) ) N
the DT N
number NN N
of IN N
inadequately RB N
treated JJ N
subjects NNS N
increased VBN N
by IN N
34 CD N
( ( N
12.2 CD N
% NN N
of IN N
278 CD N
) ) N
; : N
14 CD N
in IN N
the DT N
low-risk JJ N
group NN N
, , N
15 CD N
in IN N
the DT N
medium-risk JJ N
group NN N
, , N
and CC N
only RB N
five CD N
in IN N
the DT N
high- JJ N
or CC N
very-high-risk JJ N
groups NNS N
. . N

CONCLUSIONS NNP N
Only RB N
one-fifth NN N
of IN N
the DT N
drug-treated JJ N
hypertensives NNS N
were VBD N
well RB N
controlled VBN N
. . N

Moreover RB N
, , N
the DT N
incidence NN N
of IN N
newly RB N
detected VBN N
blood NN N
pressure NN N
elevation NN N
was VBD N
high JJ N
. . N

The DT N
majority NN N
of IN N
younger JJR N
subjects NNS N
with IN N
high JJ N
blood NN N
pressure NN N
had VBD N
low JJ N
risk NN N
, , N
but CC N
in IN N
those DT N
aged VBN N
45-54 CD 1_p
this DT N
had VBD N
already RB N
risen VBN N
to TO N
a DT N
medium NN N
risk NN N
. . N

Changing VBG N
the DT N
target NN N
blood NN N
pressure NN N
to TO N
below IN N
130/85 CD N
, , N
for IN N
subjects NNS N
aged VBN 1_p
below IN 1_p
60 CD 1_p
, , N
as IN N
recommended VBN N
by IN N
WHO/ISH NNP N
, , N
affects VBZ N
predominantly RB N
low- JJ N
and CC N
medium-risk JJ N
groups NNS N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
testosterone NN N
and CC N
a DT N
nutritional JJ N
supplement NN N
, , N
alone RB N
and CC N
in IN N
combination NN N
, , N
on IN N
hospital JJ N
admissions NNS N
in IN N
undernourished JJ 4_p
older JJR 1_p
men NNS 2_p
and CC 2_p
women NNS 2_p
. . N

BACKGROUND NNP N
In IN N
older JJR 1_p
people NNS 1_p
, , N
undernutrition NN N
is VBZ N
associated VBN N
with IN N
increased JJ N
hospitalization NN N
rates NNS N
and CC N
mortality NN N
. . N

Because IN N
weight JJ N
loss NN N
in IN N
older JJR N
people NNS N
often RB N
reflects VBZ N
a DT N
disproportionate JJ N
reduction NN N
of IN N
skeletal JJ N
muscle NN N
, , N
anabolic JJ N
treatments NNS N
may MD N
be VB N
beneficial JJ N
. . N

OBJECTIVE NNP N
Our PRP$ N
aim NN N
was VBD N
to TO N
evaluate VB N
the DT N
hypothesis NN N
that WDT N
testosterone NN N
treatment NN N
and CC N
a DT N
nutritional JJ N
supplement NN N
have VBP N
additive JJ N
benefits NNS N
. . N

DESIGN NNP N
Oral NNP N
testosterone NN N
undecanoate NN N
( ( N
40 CD N
mg NNS N
daily RB N
for IN N
women NNS N
, , N
80 CD N
mg NN N
twice RB N
daily RB N
for IN N
men NNS N
) ) N
and CC N
an DT N
oral JJ N
nutritional JJ N
supplement NN N
( ( N
475 CD N
kcal/d NN N
) ) N
were VBD N
administered VBN N
, , N
alone RB N
or CC N
combined VBN N
, , N
for IN N
1 CD N
y NNS N
to TO N
49 CD 3_p
community-dwelling NN N
, , N
undernourished JJ 4_p
people NNS N
[ VBP N
Mini NNP 4_p
Nutritional NNP 4_p
Assessment NNP 4_p
score VBD 4_p
< JJ 4_p
24 CD 4_p
and CC N
low JJ 4_p
body NN 4_p
weight NN 4_p
( ( N
body JJ 4_p
mass NN 4_p
index NN 4_p
, , 4_p
in IN 4_p
kg/m NN 4_p
( ( 4_p
2 CD 4_p
) ) 4_p
: : 4_p
< $ 4_p
22 CD 4_p
) ) N
or CC N
recent JJ 4_p
weight JJ 4_p
loss NN 4_p
( ( N
> JJ N
7.5 CD N
% NN N
over IN N
3 CD N
mo NNS N
) ) N
] VBP N
aged VBN 1_p
> $ 1_p
65 CD 1_p
y NN N
( ( N
mean JJ N
age NN N
: : N
77 CD 1_p
y NN N
; : N
26 CD 3_p
women NNS 2_p
and CC N
23 CD 3_p
men NNS 2_p
) ) N
. . N

Hospital JJ N
admissions NNS N
and CC N
other JJ N
variables NNS N
were VBD N
assessed VBN N
. . N

RESULTS NNP N
In IN N
subjects NNS N
receiving VBG N
combined VBN N
testosterone NN N
and CC N
nutritional JJ N
supplements NNS N
( ( N
n JJ N
= NNP N
11 CD N
) ) N
, , N
there EX N
were VBD N
no DT N
hospital NN N
admissions NNS N
, , N
whereas IN N
there EX N
were VBD N
9 CD N
admissions NNS N
( ( N
2 CD N
elective NN N
) ) N
in IN N
13 CD N
subjects NNS N
in IN N
the DT N
no-treatment JJ N
group NN N
, , N
4 CD N
in IN N
the DT N
testosterone-treated JJ N
group NN N
( ( N
n JJ N
= NNP N
12 CD N
) ) N
, , N
and CC N
5 CD N
in IN N
the DT N
supplement-treated JJ N
group NN N
( ( N
n JJ N
= NNP N
13 CD N
) ) N
; : N
P NNP N
= VBD N
0.06 CD N
with IN N
no-treatment JJ N
compared VBN N
with IN N
combined JJ N
treatment NN N
. . N

When WRB N
compared VBN N
with IN N
the DT N
no-treatment JJ N
group NN N
, , N
the DT N
combined-treatment JJ N
group NN N
had VBD N
significantly RB N
fewer JJR N
subjects NNS N
admitted VBN N
to TO N
hospital VB N
( ( N
0 CD N
compared VBN N
with IN N
5 CD N
, , N
P NNP N
= NNP N
0.03 CD N
) ) N
, , N
fewer JJR N
days NNS N
in IN N
hospital NN N
( ( N
0 CD N
compared VBN N
with IN N
74 CD N
, , N
P NNP N
= NNP N
0.041 CD N
) ) N
, , N
and CC N
a DT N
longer JJR N
time NN N
to TO N
hospital VB N
admission NN N
( ( N
P NNP N
= NNP N
0.017 CD N
) ) N
. . N

CONCLUSIONS NNP N
In IN N
undernourished JJ 4_p
older JJR 1_p
people NNS N
, , N
combined VBN N
treatment NN N
with IN N
testosterone NN N
and CC N
nutritional JJ N
supplementation NN N
reduced VBD N
the DT N
number NN N
of IN N
people NNS N
hospitalized VBN N
and CC N
the DT N
duration NN N
of IN N
hospital NN N
admissions NNS N
, , N
which WDT N
are VBP N
important JJ N
endpoints NNS N
in IN N
this DT N
group NN N
. . N

Larger NNP N
, , N
confirmatory NN N
studies NNS N
are VBP N
now RB N
needed VBN N
. . N

This DT N
trial NN N
was VBD N
registered VBN N
before IN N
commencement NN N
at IN N
clinical JJ N
trials.gov NN N
as IN N
NCT00117000 NNP N
. . N

-DOCSTART- -X- O O

Somatostatin NNP N
and CC N
ranitidine NN N
in IN N
the DT N
treatment NN N
of IN N
non-variceal JJ 4_p
upper JJ 4_p
gastrointestinal JJ 4_p
bleeding NN 4_p
: : N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-blind NN N
, , N
controlled VBN N
study NN N
. . N

BACKGROUND/AIMS IN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
efficacy NN N
of IN N
somatostatin NN N
vs. FW N
ranitidine NN N
in IN N
controlling VBG N
acute JJ 4_p
non-variceal JJ 4_p
gastrointestinal JJ 4_p
bleeding NN 4_p
. . N

METHODOLOGY NNP N
A NNP N
total NN N
of IN N
48 CD 3_p
patients NNS N
with IN N
acute JJ 4_p
upper JJ 4_p
gastrointestinal NN 4_p
bleeding NN 4_p
due JJ N
to TO N
duodenal JJ 4_p
or CC 4_p
gastric JJ 4_p
ulcer NN 4_p
were VBD N
divided VBN N
into IN N
2 CD N
groups NNS N
. . N

Group NNP N
I PRP N
consisted VBD N
of IN N
15 CD 3_p
patients NNS N
with IN N
Forrest NNP N
IB NNP N
and CC N
Group NNP N
II NNP N
consisted VBD N
of IN N
30 CD 3_p
patients NNS N
with IN N
Forrest NNP N
II NNP N
. . N

Two CD N
regimens NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
all DT N
patients NNS N
within IN N
half PDT N
an DT N
hour NN N
after IN N
the DT N
endoscopic JJ N
procedure NN N
: : N
1 CD N
) ) N
somatostatin-UCB NN N
250 CD N
mcg NN N
i.v NN N
. . N

bolus CC N
followed VBN N
by IN N
continuous JJ N
i.v NN N
. . N

infusion NN N
at IN N
a DT N
rate NN N
of IN N
6 CD N
mg/d NN N
for IN N
72 CD N
h NN N
, , N
or CC N
2 CD N
) ) N
ranitidine NN N
300 CD N
mg/d NN N
by IN N
continuous JJ N
i.v NN N
. . N

infusion NN N
for IN N
72 CD N
h. JJ N
RESULTS NNP N
In IN N
Group NNP N
I PRP N
, , N
although IN N
mean JJ N
blood NN N
transfusion NN N
requirements NNS N
( ( N
no DT N
. . N

of IN N
units NNS N
) ) N
were VBD N
lower JJR N
in IN N
patients NNS N
treated VBN N
with IN N
somatostatin NN N
than IN N
in IN N
those DT N
treated VBN N
with IN N
ranitidine NN N
, , N
this DT N
was VBD N
not RB N
statistically RB N
significant JJ N
( ( N
mean JJ N
+/- JJ N
SD NN N
: : N
2.56 CD N
+/- JJ N
3.05 CD N
vs. FW N
5.17 CD N
+/- JJ N
4.96 CD N
, , N
respectively RB N
; : N
P NNP N
> NNP N
0.05 CD N
) ) N
; : N
the DT N
time NN N
of IN N
bleeding VBG N
stop NN N
was VBD N
shorter RBR N
in IN N
the DT N
somatostatin NN N
group NN N
than IN N
in IN N
the DT N
ranitidine NN N
group NN N
( ( N
mean JJ N
+/- JJ N
SD NN N
: : N
3.24 CD N
+/- JJ N
2.45 CD N
vs. FW N
11.25 CD N
+/- JJ N
11.63 CD N
, , N
respectively RB N
; : N
P NNP N
= NNP N
0.0383 CD N
) ) N
. . N

The DT N
rebleeding NN N
and CC N
the DT N
mortality NN N
rates NNS N
did VBD N
not RB N
differ VB N
between IN N
the DT N
treatment NN N
groups NNS N
in IN N
both DT N
Group NNP N
I PRP N
and CC N
Group NNP N
II NNP N
. . N

CONCLUSIONS NNP N
Somatostatin NNP N
is VBZ N
more RBR N
effective JJ N
than IN N
ranitidine NN N
in IN N
controlling VBG N
acute JJ N
non-variceal JJ N
gastrointestinal JJ N
bleeding NN N
in IN N
patients NNS N
with IN N
Forrest NNP N
IB NNP N
bleeding NN N
activity NN N
. . N

Somatostatin NNP N
has VBZ N
no DT N
additional JJ N
benefit NN N
in IN N
those DT N
with IN N
Forrest NNP N
II NNP N
bleeding NN N
activity NN N
. . N

-DOCSTART- -X- O O

Treatment NN N
of IN N
stable JJ 4_p
angina NN 4_p
of IN 4_p
effort NN 4_p
with IN N
verapamil NN N
: : N
a DT N
double-blind NN N
, , N
placebo-controlled JJ N
randomized VBN N
crossover NN N
study NN N
. . N

The DT N
effects NNS N
of IN N
verapamil NN N
were VBD N
assessed VBN N
in IN N
26 CD 3_p
patients NNS N
with IN N
stable JJ 4_p
exertional JJ 4_p
angina NN 4_p
pectoris NN 4_p
in IN N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
randomized VBN N
crossover NN N
protocol NN N
using VBG N
serial JJ N
treadmill NN N
tests NNS N
. . N

Verapamil NNP N
, , N
480 CD N
mg/day NN N
, , N
reduced VBD N
anginal JJ N
frequency NN N
from IN N
5.6 CD N
+/- JJ N
7.3 CD N
to TO N
2.2 CD N
+/- JJ N
3.9 CD N
attacks NNS N
per IN N
week NN N
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
and CC N
nitroglycerin JJ N
consumption NN N
from IN N
3.4 CD N
+/- JJ N
4.9 CD N
to TO N
1.2 CD N
+/- JJ N
2.5 CD N
tablets NNS N
per IN N
week NN N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
compared VBN N
with IN N
placebo NN N
. . N

Treadmill NNP N
time NN N
increased VBD N
from IN N
6.4 CD N
+/- JJ N
2.1 CD N
minutes NNS N
during IN N
the DT N
placebo NN N
phase NN N
to TO N
7.5 CD N
+/- JJ N
1.8 CD N
minutes NNS N
during IN N
the DT N
verapamil JJ N
phase NN N
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
. . N

Verapamil NNP N
's POS N
beneficial JJ N
effect NN N
appeared VBD N
to TO N
be VB N
related VBN N
, , N
in IN N
part NN N
, , N
to TO N
a DT N
10 CD N
% NN N
reduction NN N
of IN N
the DT N
rate-pressure JJ N
product NN N
at IN N
rest NN N
( ( N
p IN N
less JJR N
than IN N
0.05 CD N
) ) N
and CC N
a DT N
12 CD N
% NN N
reduction NN N
during IN N
submaximal JJ N
exercise NN N
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
. . N

Verapamil NNP N
also RB N
caused VBD N
less JJR N
marked JJ N
ST-segment JJ N
depressions NNS N
at IN N
peak NN N
exercise NN N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
at IN N
a DT N
similar JJ N
rate-pressure NN N
product NN N
, , N
suggesting VBG N
a DT N
favorable JJ N
redistribution NN N
of IN N
coronary JJ N
blood NN N
flow NN N
to TO N
the DT N
ischemic JJ N
zone NN N
. . N

Side JJ N
effects NNS N
from IN N
verapamil NN N
were VBD N
minimal JJ N
, , N
consisting VBG N
mainly RB N
of IN N
constipation NN N
( ( N
six CD N
patients NNS N
) ) N
. . N

Verapamil NNP N
appears VBZ N
to TO N
be VB N
a DT N
safe JJ N
and CC N
effective JJ N
drug NN N
for IN N
treating VBG N
angina NN 4_p
of IN N
effort NN N
. . N

-DOCSTART- -X- O O

Outcomes NNS N
in IN N
a DT N
nursing NN N
home NN N
transition NN N
case-management JJ N
program NN N
targeting VBG N
new JJ N
admissions NNS N
. . N

PURPOSE VB N
The DT N
Providing VBG N
Assistance NNP N
to TO N
Caregivers NNPS N
in IN N
Transition NNP N
( ( N
PACT NNP N
) ) N
program NN N
offers NNS N
nursing VBG N
home NN N
discharge NN N
planning NN N
and CC N
case NN N
management NN N
for IN N
individuals NNS N
in IN N
the DT N
transitional JJ N
period NN N
following VBG N
a DT N
return NN N
to TO N
the DT N
community NN N
. . N

The DT N
PACT NNP N
program NN N
targeted VBN N
individuals NNS N
newly RB N
admitted VBN N
to TO N
nursing VBG 4_p
homes NNS 4_p
and CC N
worked VBD N
with IN N
a DT N
family NN N
caregiver NN N
to TO N
develop VB N
and CC N
implement VB N
a DT N
nursing NN N
home NN N
discharge NN N
plan NN N
. . N

DESIGN NNP N
AND CC N
METHOD NNP N
Reported NNP N
are VBP N
the DT N
results NNS N
of IN N
a DT N
randomized JJ N
control NN N
design NN N
evaluating VBG N
the DT N
program NN N
's POS N
effectiveness NN N
. . N

Those DT N
individuals NNS N
randomly RB N
assigned VBN N
to TO N
the DT N
intervention NN N
group NN N
( ( N
n JJ N
= NNP N
33 CD 3_p
) ) N
received VBN N
PACT NNP N
case NN N
management NN N
in IN N
addition NN N
to TO N
their PRP$ N
usual JJ N
medical JJ N
and CC N
nursing NN N
home NN N
care NN N
. . N

The DT N
individuals NNS N
in IN N
the DT N
control NN N
group NN N
( ( N
n JJ N
= NNP N
29 CD 3_p
) ) N
continued VBD N
their PRP$ N
usual JJ N
care NN N
. . N

RESULT CC N
There EX N
were VBD N
no DT N
statistical JJ N
differences NNS N
in IN N
the DT N
discharge NN N
rate NN N
( ( N
84 CD N
% NN N
treatment NN N
vs RB N
76 CD N
% NN N
controls NNS N
) ) N
or CC N
in IN N
the DT N
median JJ N
length NN N
of IN N
stay NN N
( ( N
42 CD N
days NNS N
vs RB N
55 CD N
days NNS N
) ) N
between IN N
the DT N
two CD N
groups NNS N
of IN N
individuals NNS N
. . N

IMPLICATIONS NNP N
Replications NNPS N
or CC N
extensions NNS N
of IN N
a DT N
PACT-type JJ N
intervention NN N
might MD N
consider VB N
a DT N
broader JJR N
mix NN N
of IN N
nursing NN N
homes NNS N
, , N
working VBG N
directly RB N
with IN N
the DT N
nursing NN N
home NN N
's POS N
admission NN N
Minimum NNP N
Data NNP N
Set NNP N
coordinator NN N
in IN N
patient JJ N
selection NN N
, , N
or CC N
working VBG N
with IN N
Medicare NNP N
or CC N
Medicaid NNP N
HMO NNP N
plans VBZ N
. . N

-DOCSTART- -X- O O

Comparison NNP N
of IN N
antihypertensives NNS N
after IN N
coronary JJ N
artery NN N
surgery NN N
. . N

Hypertension NN N
following VBG N
coronary JJ 4_p
artery JJ 4_p
bypass NN 4_p
grafting NN 4_p
is VBZ N
a DT N
common JJ N
problem NN N
that WDT N
may MD N
result VB N
in IN N
postoperative JJ N
myocardial JJ N
infraction NN N
or CC N
bleeding NN N
, , N
Hemodynamic NNP N
effects NNS N
were VBD N
compared VBN N
in IN N
45 CD 3_p
hypertensive JJ 4_p
coronary JJ 4_p
bypass NN 4_p
patients NNS N
randomized VBN N
to TO N
receive VB N
either DT N
diltiazem NN N
, , N
nitroglycerin NN N
, , N
or CC N
sodium NN N
nitroprusside RB N
. . N

Diltiazem NNP N
was VBD N
administered VBN N
as IN N
an DT N
intravenous JJ N
bolus NN N
of IN N
0.3 CD N
mg.kg-1 NN N
within IN N
5 CD N
min NN N
, , N
followed VBN N
by IN N
infusion NN N
of IN N
0.1-0.8 JJ N
mg.kg-1.h-1 NN N
in IN N
group NN N
1 CD N
. . N

Nitroglycerin NNP N
was VBD N
infused VBN N
at IN N
a DT N
rate NN N
of IN N
1-3 JJ N
microg.kg.h-1 NN N
in IN N
group NN N
2 CD N
, , N
and CC N
sodium NN N
nitroprusside NN N
was VBD N
given VBN N
at IN N
a DT N
rate NN N
of IN N
1-3 JJ N
microg.kg-1.min-1 NN N
in IN N
group NN N
3 CD N
. . N

Hemodynamic JJ N
measurements NNS N
were VBD N
carried VBN N
out RP N
before IN N
infusion NN N
( ( N
T1 NNP N
) ) N
and CC N
at IN N
30 CD N
min NN N
( ( N
T2 NNP N
) ) N
, , N
2 CD N
h NN N
( ( N
T3 NNP N
) ) N
, , N
and CC N
12 CD N
h NN N
( ( N
T4 NNP N
) ) N
after IN N
initiation NN N
of IN N
treatment NN N
in IN N
the DT N
intensive JJ N
care NN N
unit NN N
. . N

Mean NNP N
arterial JJ N
pressure NN N
decreased VBN N
significantly RB N
in IN N
all DT N
groups NNS N
. . N

There EX N
were VBD N
no DT N
differences NNS N
among IN N
groups NNS N
at IN N
T1 NNP N
and CC N
T2 NNP N
. . N

At IN N
T3 NNP N
, , N
heart NN N
rate NN N
in IN N
group NN N
2 CD N
was VBD N
significantly RB N
higher JJR N
than IN N
group NN N
1 CD N
. . N

At IN N
T3 NNP N
and CC N
T4 NNP N
, , N
the DT N
double JJ N
product NN N
was VBD N
highest JJS N
in IN N
group NN N
3 CD N
( ( N
group NN N
1 CD N
vs. NN N
3 CD N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
the DT N
hemodynamic JJ N
effects NNS N
of IN N
the DT N
3 CD N
drugs NNS N
are VBP N
similar JJ N
within IN N
the DT N
first JJ N
30 CD N
min NN N
. . N

However RB N
, , N
after IN N
30 CD N
min NN N
, , N
diltiazem NN N
affords NNS N
better RBR N
myocardial JJ N
performance NN N
and CC N
more RBR N
effective JJ N
control NN N
of IN N
hypertension NN N
. . N

-DOCSTART- -X- O O

Efficacy NN N
of IN N
patient JJ N
education NN N
and CC N
supervised VBD N
exercise NN N
vs NN N
patient JJ N
education NN N
alone RB N
in IN N
patients NNS N
with IN N
hip JJ 4_p
osteoarthritis NN 4_p
: : N
a DT N
single JJ N
blind NN N
randomized VBD N
clinical JJ N
trial NN N
. . N

OBJECTIVE UH N
To TO N
compare VB N
the DT N
efficacy NN N
of IN N
patient JJ N
education NN N
and CC N
supervised VBD N
exercise NN N
with IN N
that DT N
of IN N
patient JJ N
education NN N
alone RB N
for IN N
the DT N
management NN N
of IN N
pain NN N
in IN N
patients NNS N
with IN N
hip NN N
osteoarthritis NN N
( ( N
OA NNP 4_p
) ) N
. . N

DESIGN NNP N
Single NNP N
blind IN N
randomized JJ N
clinical JJ N
trial NN N
. . N

SETTING NNP N
Recruitment NNP N
of IN N
patients NNS N
from IN N
hospitals NNS N
, , N
primary JJ N
health NN N
care NN N
and CC N
advertisement NN N
, , N
Oslo NNP N
, , N
Norway NNP N
. . N

PARTICIPANTS NNP N
109 CD 3_p
patients NNS N
with IN N
radiographic JJ N
and CC N
symptomatic JJ N
hip NN N
OA NNP N
with IN N
mild NN N
to TO N
moderate VB N
symptoms NNS N
. . N

INTERVENTIONS NNP N
Patient NNP N
education NN N
( ( N
PE NNP N
) ) N
. . N

Patient JJ N
education NN N
and CC N
supervised VBN N
exercise NN N
( ( N
PE+SE NNP N
) ) N
. . N

PRIMARY NNP N
OUTCOME NNP N
MEASURE NNP N
The DT N
pain NN N
subscale NN N
of IN N
the DT N
Western NNP N
Ontario NNP N
and CC N
McMaster NNP N
Universities NNP N
Osteoarthritis NNP N
Index NNP N
( ( N
WOMAC NNP N
pain NN N
) ) N
. . N

RESULTS NNP N
No NNP N
significant JJ N
between IN N
group NN N
differences NNS N
were VBD N
found VBN N
for IN N
WOMAC NNP N
pain NN N
over IN N
the DT N
16-month JJ N
follow-up NN N
. . N

Significant JJ N
improvements NNS N
were VBD N
found VBN N
for IN N
the DT N
secondary JJ N
outcome NN N
WOMAC NNP N
physical JJ N
function NN N
( ( N
P=0.011 NNP N
) ) N
in IN N
the DT N
group NN N
receiving VBG N
PE+SE NNP N
compared VBN N
to TO N
the DT N
group NN N
receiving VBG N
PE NNP N
only RB N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
for IN N
WOMAC NNP N
stiffness NN N
, , N
the DT N
SF-36 JJ N
subscales NNS N
or CC N
the DT N
activity NN N
scale NN N
. . N

The DT N
effect NN N
sizes VBZ N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
) ) N
for IN N
WOMAC NNP N
pain NN N
were VBD N
-0.26 NNP N
( ( N
0.11 CD N
, , N
-0.64 NN N
) ) N
, , N
-0.35 NNP N
( ( N
0.07 CD N
, , N
-0.77 NN N
) ) N
, , N
and CC N
-0.30 NNP N
( ( N
0.15 CD N
, , N
-0.75 NN N
) ) N
, , N
and CC N
for IN N
WOMAC NNP N
physical JJ N
function NN N
-0.29 NNP N
( ( N
0.09 CD N
, , N
-0.67 NN N
) ) N
, , N
-0.48 NNP N
( ( N
-0.06 NNP N
, , N
-0.91 NNP N
) ) N
, , N
and CC N
-0.47 NNP N
( ( N
-0.02 NNP N
, , N
-0.93 NNP N
) ) N
at IN N
4 CD N
, , N
10 CD N
and CC N
16 CD N
months NNS N
, , N
respectively RB N
, , N
in IN N
favor NN N
of IN N
the DT N
group NN N
receiving VBG N
both DT N
PE NNP N
and CC N
SE NNP N
. . N

All DT N
patients NNS N
attended VBD N
the DT N
three-session JJ N
PE NNP N
program NN N
, , N
and CC N
75 CD N
% NN N
performed VBN N
?16 JJ N
sessions NNS N
of IN N
the DT N
12-week JJ N
SE NNP N
program NN N
. . N

CONCLUSION NNP N
The DT N
study NN N
could MD N
not RB N
demonstrate VB N
a DT N
significant JJ N
difference NN N
in IN N
pain NN N
reduction NN N
over IN N
time NN N
between IN N
PE+SE NNP N
vs NNP N
PE NNP N
alone RB N
. . N

Adding VBG N
SE NNP N
to TO N
PE NNP N
may MD N
improve VB N
physical JJ N
function NN N
, , N
but CC N
the DT N
magnitude NN N
of IN N
possible JJ N
benefit NN N
is VBZ N
unknown JJ N
as IN N
the DT N
95 CD N
% NN N
confidence NN N
intervals NNS N
around IN N
the DT N
mean JJ N
difference NN N
were VBD N
wide JJ N
. . N

TRIAL NNP N
REGISTRATION NNP N
Clinical NNP N
Trials NNP N
NCT00319423 NNP N
. . N

-DOCSTART- -X- O O

Memantine NNP N
add-on JJ N
to TO N
risperidone VB N
for IN N
treatment NN N
of IN N
negative JJ N
symptoms NNS N
in IN N
patients NNS N
with IN N
stable JJ 4_p
schizophrenia NN 4_p
: : N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
. . N

We PRP N
aimed VBD N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
memantine JJ N
add-on JJ N
in IN N
the DT N
treatment NN N
of IN N
primary JJ N
negative JJ N
symptoms NNS N
of IN N
patients NNS N
with IN N
stable JJ N
schizophrenia NN N
. . N

In IN N
a DT N
double-blind JJ N
placebo-controlled JJ N
clinical JJ N
trial NN N
, , N
40 CD 3_p
patients NNS N
with IN N
schizophrenia NN 4_p
( ( N
Diagnostic NNP N
and CC N
Statistical NNP N
Manual NNP N
of IN N
Mental NNP N
Disorders NNP N
, , N
Fourth NNP N
Edition NNP N
) ) N
who WP N
were VBD N
stabilized VBN N
on IN N
risperidone NN N
for IN N
a DT N
minimum NN N
of IN N
8 CD N
weeks NNS N
were VBD N
randomized VBN N
to TO N
either DT N
memantine NN N
( ( N
20 CD N
mg NN N
) ) N
or CC N
placebo NN N
in IN N
addition NN N
to TO N
risperidone VB N
, , N
6 CD N
mg/d NN N
, , N
for IN N
eight CD N
weeks NNS N
. . N

Assessment NNP N
was VBD N
done VBN N
using VBG N
the DT N
Positive NNP N
and CC N
Negative NNP N
Syndrome NNP N
Scale NNP N
at IN N
baseline NN N
, , N
week NN N
4 CD N
, , N
and CC N
week NN N
8 CD N
. . N

The DT N
Hamilton NNP N
Depression NNP N
Rating NNP N
Scale NNP N
and CC N
the DT N
Extrapyramidal NNP N
Symptom NNP N
Rating NNP N
Scale NNP N
at IN N
baseline NN N
and CC N
week NN N
8 CD N
were VBD N
used VBN N
to TO N
assess VB N
depression NN N
and CC N
extrapyramidal NN N
symptoms NNS N
, , N
respectively RB N
. . N

All DT N
40 CD N
patients NNS N
had VBD N
at IN N
least JJS N
one CD N
postbaseline NN N
measurement NN N
, , N
and CC N
38 CD 3_p
patients NNS N
completed VBD N
the DT N
trial NN N
. . N

Patients NNS N
in IN N
the DT N
memantine NN N
group NN N
showed VBD N
a DT N
significantly RB N
greater JJR N
improvement NN N
on IN N
negative JJ N
subscale NN N
than IN N
the DT N
placebo NN N
group NN N
at IN N
end NN N
point NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
same JJ N
effect NN N
was VBD N
observed VBN N
for IN N
the DT N
total JJ N
score NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
the DT N
general JJ N
psychopathology NN N
subscale NN N
score NN N
( ( N
P NNP N
= NNP N
0.002 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
reduction NN N
of IN N
positive JJ N
symptoms NNS N
score VBP N
between IN N
the DT N
2 CD N
groups NNS N
( ( N
P NNP N
= NNP N
0.757 CD N
) ) N
. . N

Changes NNS N
in IN N
the DT N
Hamilton NNP N
Depression NNP N
Rating NNP N
Scale NNP N
and CC N
the DT N
Extrapyramidal NNP N
Symptom NNP N
Rating NNP N
Scale NNP N
scores NNS N
and CC N
frequency NN N
of IN N
adverse JJ N
effects NNS N
did VBD N
not RB N
differ VB N
between IN N
the DT N
2 CD N
groups NNS N
. . N

Our PRP$ N
study NN N
showed VBD N
that IN N
memantine NN N
is VBZ N
a DT N
tolerable JJ N
and CC N
efficacious JJ N
add-on JJ N
treatment NN N
for IN N
primary JJ N
negative JJ N
symptoms NNS N
of IN N
schizophrenia NN N
. . N

-DOCSTART- -X- O O

Enhancing VBG N
attitudes NNS N
and CC N
intentions NNS N
in IN N
prospective JJ 4_p
blood NN 4_p
donors NNS 4_p
: : N
evaluation NN N
of IN N
a DT N
new JJ N
donor NN N
recruitment NN N
brochure NN N
. . N

BACKGROUND NNP N
Although IN N
little JJ N
empiric JJ N
evidence NN N
has VBZ N
been VBN N
published VBN N
concerning VBG N
the DT N
efficacy NN N
of IN N
blood NN N
donor NN N
recruitment NN N
materials NNS N
, , N
research NN N
suggests VBZ N
that IN N
simple JJ N
attempts NNS N
to TO N
enhance VB N
knowledge NN N
may MD N
not RB N
be VB N
sufficient JJ N
to TO N
motivate VB N
donation NN N
. . N

In IN N
contrast NN N
, , N
recent JJ N
donor NN N
motivation NN N
studies NNS N
highlight VBD N
the DT N
importance NN N
of IN N
anxiety NN N
, , N
attitudes NNS N
, , N
and CC N
perceived VBD N
ability NN N
to TO N
cope VB N
with IN N
donation NN N
( ( N
i.e. JJ N
, , N
self-efficacy NN N
) ) N
as IN N
crucial JJ N
determinants NNS N
of IN N
donation NN N
intention NN N
. . N

Therefore RB N
, , N
recruitment JJ N
materials NNS N
that WDT N
specifically RB N
address VBP N
these DT N
constructs NNS N
have VBP N
the DT N
potential JJ N
to TO N
outperform VB N
traditional JJ N
educational JJ N
brochures NNS N
. . N

STUDY NNP N
DESIGN NNP N
AND NNP N
METHODS NNP N
Participants NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
read VB N
one CD N
of IN N
three CD N
brochures NNS N
: : N
1 CD N
) ) N
a DT N
new JJ N
brochure NN N
addressing VBG N
common JJ N
donor NN N
concerns NNS N
and CC N
suggesting VBG N
specific JJ N
coping VBG N
strategies NNS N
, , N
2 CD N
) ) N
a DT N
standard JJ N
blood NN N
center NN N
brochure NN N
, , N
or CC N
3 CD N
) ) N
a DT N
control JJ N
brochure NN N
on IN N
healthy JJ N
eating NN N
and CC N
exercise NN N
. . N

Standardized JJ N
questionnaires NNS N
were VBD N
completed VBN N
before IN N
and CC N
after IN N
the DT N
brochures NNS N
to TO N
assess VB N
change NN N
in IN N
blood NN N
donation NN N
anxiety NN N
, , N
attitude NN N
, , N
self-efficacy NN N
, , N
and CC N
intention NN N
. . N

RESULTS NNP N
Although IN N
no DT N
significant JJ N
changes NNS N
were VBD N
noted VBN N
for IN N
the DT N
control NN N
brochure NN N
, , N
after IN N
reading VBG N
the DT N
new JJ N
brochure NN N
participants NNS N
reported VBD N
significant JJ N
improvements NNS N
in IN N
attitude NN N
, , N
anxiety NN N
, , N
self-efficacy NN N
, , N
and CC N
donation NN N
intention NN N
. . N

The DT N
standard JJ N
donation NN N
brochure NN N
had VBD N
an DT N
intermediate JJ N
effect NN N
. . N

CONCLUSION NNP N
Efforts NNPS N
to TO N
address VB N
common JJ N
donor NN N
fears NNS N
and CC N
to TO N
provide VB N
useful JJ N
coping VBG N
suggestions NNS N
may MD N
improve VB N
the DT N
effectiveness NN N
of IN N
blood NN N
donation NN N
recruitment NN N
materials NNS N
. . N

-DOCSTART- -X- O O

Fine NNP N
needle JJ N
aspiration NN N
coupled VBN N
with IN N
real-time JJ N
PCR NNP N
: : N
a DT N
painless JJ N
methodology NN N
to TO N
study VB N
adaptive JJ N
functional JJ N
changes NNS N
in IN N
skeletal JJ N
muscle NN N
. . N

BACKGROUND NNP N
AND NNP N
AIM NNP N
In IN N
this DT N
study NN N
we PRP N
developed VBD N
a DT N
new JJ N
methodology NN N
for IN N
obtaining VBG N
human JJ N
skeletal JJ N
muscle NN N
samples NNS N
to TO N
evaluate VB N
gene NN N
expression NN N
. . N

This DT N
approach NN N
is VBZ N
based VBN N
on IN N
a DT N
fine JJ N
needle JJ N
aspiration NN N
technique NN N
, , N
which WDT N
allows VBZ N
us PRP N
to TO N
extract VB N
a DT N
small JJ N
tissue NN N
sample NN N
in IN N
a DT N
significantly RB N
less RBR N
invasive JJ N
manner NN N
than IN N
with IN N
classic JJ N
biopsy NN N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
Multiplex NNP N
tandem VBD N
RT-PCR NNP N
was VBD N
used VBN N
to TO N
determine VB N
the DT N
mRNA NN N
levels NNS N
of IN N
genes NNS N
involved VBN N
in IN N
ATP NNP N
production NN N
and CC N
mitochondrial JJ N
biogenesis NN N
in IN N
muscle NN N
tissue NN N
. . N

Samples NNS N
of IN N
vastus NN N
lateralis NNS N
muscle NN N
were VBD N
obtained VBN N
from IN N
21 CD 3_p
healthy JJ 4_p
subjects NNS 4_p
with IN N
different JJ N
fitness NN 4_p
levels NNS 4_p
. . N

The DT N
principal JJ N
findings NNS N
in IN N
our PRP$ N
study NN N
show VB N
a DT N
strong JJ N
correlation NN N
between IN N
PGC-1alpha NNP N
and CC N
COX5B NNP N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
and CC N
between IN N
PGC-1alpha NNP N
and CC N
MT-CO2 NNP N
( ( N
p=0.017 NN N
) ) N
expression NN N
. . N

Furthermore NNP N
, , N
a DT N
significant JJ N
positive JJ N
correlation NN N
between IN N
mtDNA NN N
content NN N
and CC N
the DT N
percentage NN N
of IN N
MHCI NNP N
present NN N
in IN N
the DT N
aspired JJ N
samples NNS N
were VBD N
found VBN N
( ( N
p=0.028 NN N
) ) N
. . N

These DT N
data NNS N
are VBP N
in IN N
agreement NN N
with IN N
current JJ N
knowledge NN N
on IN N
skeletal JJ N
muscle NN N
physiology NN N
and CC N
show VB N
the DT N
reliability NN N
of IN N
the DT N
proposed VBN N
method NN N
. . N

CONCLUSION VB N
This DT N
painless JJ N
methodology NN N
can MD N
be VB N
used VBN N
to TO N
investigate VB N
, , N
in IN N
vivo NN N
, , N
human JJ N
muscle NN N
RNA NNP N
and CC N
DNA NNP N
adaptations NNS N
in IN N
response NN N
to TO N
either DT N
physiological JJ N
and/or NN N
pharmacological JJ N
stimuli NN N
. . N

This DT N
method NN N
has VBZ N
major JJ N
clinical JJ N
relevance NN N
, , N
such JJ N
as IN N
its PRP$ N
application NN N
in IN N
clarifying VBG N
the DT N
mechanisms NN N
underling VBG N
metabolic JJ N
and CC N
systemic JJ N
disorders NNS N
. . N

-DOCSTART- -X- O O

International NNP N
Czech NNP N
and CC N
Slovak NNP N
cooperation NN N
in IN N
the DT N
treatment NN N
of IN N
patients NNS N
with IN N
differentiated JJ 4_p
thyroid NN 4_p
cancer NN 4_p
. . N

BACKGROUND IN N
The DT N
aim NN N
of IN N
this DT N
paper NN N
is VBZ N
to TO N
present VB N
our PRP$ N
experience NN N
concerning VBG N
cooperation NN N
in IN N
the DT N
treatment NN N
of IN N
Slovak NNP N
patients NNS N
with IN N
differentiated JJ N
thyroid NN N
cancer NN N
in IN N
Slovak NNP N
and CC N
Czech NNP N
hospitals NNS N
. . N

The DT N
objectives NNS N
of IN N
this DT N
study NN N
were VBD N
to TO N
demonstrate VB N
the DT N
means NNS N
of IN N
this DT N
cooperation NN N
and CC N
the DT N
results NNS N
of IN N
therapy NN N
. . N

MATERIAL NNP N
AND CC N
METHODS NNP N
From NNP N
September NNP N
1991 CD N
to TO N
October NNP N
2005 CD N
in IN N
the DT N
Department NNP N
of IN N
Nuclear NNP N
Medicine NNP N
in IN N
Ostrava NNP N
357 CD 3_p
patients NNS N
from IN N
the DT N
Slovak NNP N
Republic NNP N
with IN N
differentiated VBN 4_p
thyroid NN 4_p
cancers NNS 4_p
( ( N
follicular JJ 4_p
and CC 4_p
papillary JJ 4_p
) ) N
underwent NN N
complex JJ N
therapy NN N
. . N

They PRP N
were VBD N
diagnosed VBN N
and CC N
operated VBN N
due JJ N
to TO N
the DT N
cancer NN N
( ( N
near-total JJ 4_p
thyroidectomy NN 4_p
and CC N
removal NN 4_p
of IN 4_p
lymph JJ 4_p
node JJ 4_p
metastases NNS 4_p
) ) N
in IN N
Slovak NNP N
hospitals NNS N
. . N

Then RB N
they PRP N
were VBD N
sent VBN N
to TO N
the DT N
Department NNP N
of IN N
Nuclear NNP N
Medicine NNP N
in IN N
Ostrava NNP N
in IN N
the DT N
Czech NNP N
Republic NNP N
. . N

In IN N
this DT N
department NN N
a DT N
radioiodine JJ N
ablation NN N
of IN N
thyroid JJ N
remnants NNS N
, , N
by IN N
means NNS N
of IN N
the DT N
treatment NN N
amount NN N
of IN N
radioiodine NN N
of IN N
a DT N
standard JJ N
activity NN N
of IN N
3.7 CD N
GBq NNP N
, , N
was VBD N
performed VBN N
, , N
and CC N
then RB N
a DT N
suppression NN N
and CC N
substitution NN N
therapy NN N
of IN N
thyroid JJ N
hormones NNS N
was VBD N
started VBN N
. . N

After IN N
3-6 JJ N
months NNS N
some DT N
patients NNS N
were VBD N
examined VBN N
by IN N
means NNS N
of IN N
diagnostic JJ N
whole JJ N
body NN N
scintigraphy NN N
after IN N
application NN N
of IN N
300 CD N
MBq NNP N
131I CD N
. . N

Some DT N
patients NNS N
were VBD N
treated VBN N
by IN N
means NNS N
of IN N
a DT N
standard JJ N
activity NN N
of IN N
7.4 CD N
GBq NNP N
131I CD N
and CC N
after IN N
5 CD N
days NNS N
whole JJ N
body NN N
scintigraphy NN N
( ( N
WBS NNP N
) ) N
was VBD N
performed VBN N
. . N

In IN N
both DT N
of IN N
these DT N
groups NNS N
of IN N
patients NNS N
the DT N
diagnostic JJ N
or CC N
therapeutic JJ N
radioiodine NN N
application NN N
was VBD N
done VBN N
after IN N
withdrawal NN N
of IN N
thyroid JJ N
hormone NN N
treatment NN N
. . N

If IN N
thyroglobulin JJ N
levels NNS N
were VBD N
low JJ N
and CC N
WBSs NNP N
were VBD N
negative JJ N
, , N
patients NNS N
were VBD N
followed VBN N
up RP N
in IN N
the DT N
Department NNP N
of IN N
Nuclear NNP N
Medicine NNP N
in IN N
Martin NNP N
. . N

Patients NNS N
with IN N
radioiodine NN N
accumulated VBN N
metastases NNS N
were VBD N
again RB N
treated VBN N
with IN N
radioiodine NN N
in IN N
Ostrava NNP N
. . N

If IN N
indicated VBN N
, , N
external JJ N
radiation NN N
therapy NN N
targeted VBN N
on IN N
the DT N
neck NN N
and CC N
upper JJ N
mediastinum NN N
was VBD N
performed VBN N
in IN N
the DT N
Slovak NNP N
Republic NNP N
, , N
in IN N
the DT N
University NNP N
Hospital NNP N
in IN N
Martin NNP N
. . N

Newly RB N
formed VBN N
lymph JJ N
node NN N
metastases NNS N
were VBD N
surgically RB N
treated VBN N
in IN N
Slovakia NNP N
, , N
too RB N
. . N

Generally RB N
we PRP N
have VBP N
very RB N
good JJ N
treatment NN N
results NNS N
. . N

Also RB N
, , N
economically RB N
our PRP$ N
partnership NN N
is VBZ N
cost VBN N
effective JJ N
. . N

Our PRP$ N
collaboration NN N
also RB N
successfully RB N
continues VBZ N
after IN N
entrance NN N
of IN N
the DT N
Slovak NNP N
Republic NNP N
and CC N
the DT N
Czech NNP N
Republic NNP N
to TO N
the DT N
European NNP N
Union NNP N
in IN N
2004 CD N
. . N

CONCLUSIONS VB N
The DT N
results NNS N
of IN N
this DT N
multi-centre JJ N
study NN N
show NN N
that IN N
international JJ N
Czech NNP N
and CC N
Slovak NNP N
cooperation NN N
in IN N
the DT N
complex JJ N
therapy NN N
of IN N
patients NNS N
with IN N
differentiated JJ N
thyroid NN N
cancers NNS N
is VBZ N
successful JJ N
, , N
with IN N
high JJ N
efficacy NN N
. . N

The DT N
treatment NN N
results NNS N
were VBD N
very RB N
similar JJ N
to TO N
therapeutic JJ N
results NNS N
in IN N
our PRP$ N
patients NNS N
from IN N
the DT N
Czech NNP N
Republic NNP N
. . N

-DOCSTART- -X- O O

Are NNP N
tyrosine JJ N
kinase NN N
inhibitors NNS N
still RB N
active JJ N
in IN N
patients NNS N
with IN N
metastatic JJ 4_p
renal NN 4_p
cell NN 4_p
carcinoma VBZ 4_p
previously RB N
treated VBN N
with IN N
a DT N
tyrosine JJ N
kinase NN N
inhibitor NN N
and CC N
everolimus VB N
? . N
Experience NNP N
of IN N
36 CD 3_p
patients NNS N
treated VBN N
in IN N
France NNP N
in IN N
the DT N
RECORD-1 JJ N
Trial NNP N
. . N

BACKGROUND NNP N
Because IN N
the DT N
response NN N
to TO N
treatment NN N
is VBZ N
limited JJ N
, , N
patients NNS N
with IN N
metastatic JJ N
renal NN N
cell NN N
carcinoma NN N
( ( N
mRCC NN 4_p
) ) N
typically RB N
receive JJ N
multiple NN N
treatments NNS N
. . N

Guidelines NNS N
recommend VBP N
everolimus NN N
for IN N
patients NNS N
previously RB N
treated VBN N
with IN N
tyrosine JJ N
kinase NN N
inhibitors NNS N
( ( N
TKI NNP N
) ) N
sunitinib NN N
or CC N
sorafenib NN N
. . N

This DT N
study NN N
evaluated VBD N
the DT N
efficacy NN N
of IN N
TKI NNP N
re-treatment NN N
in IN N
patients NNS N
with IN N
disease JJ N
progression NN N
after IN N
a DT N
TKI-everolimus JJ N
sequence NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Data NNP N
were VBD N
reviewed VBN N
for IN N
patients NNS N
enrolled VBN N
in IN N
RECORD-1 NNP N
( ( N
Renal NNP 4_p
Cell NNP 4_p
Cancer NNP 4_p
Treatment NNP N
With IN N
Oral NNP N
RAD001 NNP N
Given NNP N
Daily NNP N
) ) N
at IN N
French JJ N
sites NNS N
. . N

Response NNP N
, , N
progression-free JJ N
survival NN N
( ( N
PFS NNP N
) ) N
, , N
and CC N
overall JJ N
survival NN N
were VBD N
evaluated VBN N
in IN N
patients NNS N
treated VBN N
with IN N
a DT N
TKI-everolimus-TKI JJ N
sequence NN N
. . N

RESULTS NNP N
Thirty-six JJ N
patients NNS N
received VBD N
a DT N
TKI NNP N
after IN N
everolimus NN N
: : N
sunitinib NN N
in IN N
17 CD N
patients NNS N
, , N
sorafenib NN N
in IN N
15 CD N
, , N
and CC N
dovitinib NN N
( ( N
TKI258 NNP N
) ) N
in IN N
4 CD N
. . N

The DT N
response NN N
rate NN N
with IN N
TKI NNP N
re-treatment NN N
was VBD N
8 CD N
% NN N
, , N
and CC N
the DT N
disease-control JJ N
rate NN N
( ( N
response NN N
plus CC N
stable JJ N
disease NN N
) ) N
was VBD N
75 CD N
% NN N
. . N

The DT N
median JJ N
PFS NNP N
with IN N
each DT N
component NN N
of IN N
the DT N
TKI-everolimus-TKI NNP N
sequence NN N
was VBD N
10.7 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
, , N
1.8-28.5 JJ N
months NNS N
) ) N
, , N
8.9 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
, , N
1.7-34.6 JJ N
months NNS N
) ) N
, , N
and CC N
8.2 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
, , N
5.2-11.9 JJ N
months NNS N
) ) N
, , N
respectively RB N
. . N

The DT N
median JJ N
overall JJ N
survival NN N
from IN N
the DT N
start NN N
of IN N
everolimus NN N
was VBD N
29.1 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
21.1 CD N
to TO N
not RB N
reached VB N
months NNS N
) ) N
, , N
which WDT N
suggests VBZ N
a DT N
benefit NN N
in IN N
using VBG N
TKI NNP N
in IN N
this DT N
setting NN N
. . N

CONCLUSIONS NNP N
Administration NNP N
of IN N
a DT N
TKI-everolimus-TKI JJ N
sequence NN N
may MD N
be VB N
associated VBN N
with IN N
clinical JJ N
benefit NN N
and CC N
should MD N
be VB N
prospectively RB N
investigated VBN N
. . N

-DOCSTART- -X- O O

Paricalcitol NNP N
capsule NN N
for IN N
the DT N
treatment NN N
of IN N
secondary JJ 4_p
hyperparathyroidism NN 4_p
in IN N
stages NNS 4_p
3 CD 4_p
and CC 4_p
4 CD 4_p
CKD NNP 4_p
. . N

BACKGROUND NNP N
The DT N
safety NN N
and CC N
efficacy NN N
of IN N
paricalcitol NN N
injection NN N
have VBP N
been VBN N
well RB N
established VBN N
for IN N
the DT N
prevention NN N
and CC N
treatment NN N
of IN N
secondary JJ N
hyperparathyroidism NN N
( ( N
SHPT NNP 4_p
) ) N
in IN N
patients NNS N
with IN N
chronic JJ 4_p
kidney NN 4_p
disease NN 4_p
( ( N
CKD NNP 4_p
) ) N
stage NN 4_p
5 CD 4_p
. . N

The DT N
capsule JJ N
form NN N
of IN N
paricalcitol NN N
was VBD N
developed VBN N
to TO N
provide VB N
a DT N
convenient JJ N
dosage NN N
form NN N
for IN N
patients NNS N
with IN N
stages NNS N
3 CD N
and CC N
4 CD N
CKD NNP N
. . N

METHODS NNP N
Three NNP N
randomized VBD N
, , N
placebo-controlled JJ N
, , N
phase-3 JJ N
trials NNS N
were VBD N
conducted VBN N
in IN N
patients NNS N
with IN N
stages NNS N
3 CD N
and CC N
4 CD N
CKD NNP N
with IN N
SHPT NNP N
. . N

Enrollment NNP N
criteria NNS N
included VBD N
an DT N
estimated VBN N
glomerular JJ N
filtration NN N
rate NN N
between IN N
15 CD N
and CC N
60 CD N
mL/min/1.73 NN N
m2 NN N
( ( N
0.25 CD N
and CC N
1.00 CD N
mL/s/1.73 NNS N
m2 NN N
) ) N
, , N
an DT N
average NN N
of IN N
2 CD N
consecutive JJ N
intact JJ N
parathyroid NN N
hormone NN N
( ( N
iPTH NN N
) ) N
levels NNS N
greater JJR N
than IN N
150 CD N
pg/mL NN N
( ( N
ng/L JJ N
) ) N
, , N
2 CD N
consecutive JJ N
serum NN N
calcium NN N
levels NNS N
between IN N
8.0 CD N
and CC N
10.0 CD N
mg/dL NN N
( ( N
2.00 CD N
and CC N
2.50 CD N
mmol/L NN N
) ) N
, , N
and CC N
2 CD N
consecutive JJ N
serum NN N
phosphorus NN N
levels NNS N
of IN N
5.2 CD N
mg/dL NN N
or CC N
less JJR N
( ( N
< NN N
or CC N
= $ N
1.68 CD N
mmol/L NN N
) ) N
. . N

Two CD N
studies NNS N
used VBD N
a DT N
thrice-weekly JJ N
dosing NN N
regimen NNS N
and CC N
1 CD N
study NN N
used VBD N
a DT N
once-daily JJ N
dosing NN N
regimen NNS N
for IN N
24 CD N
weeks NNS N
. . N

Dosing NNP N
was VBD N
based VBN N
on IN N
serum NN N
iPTH NN N
, , N
calcium NN N
, , N
and CC N
phosphorus NN N
levels NNS N
. . N

The DT N
primary JJ N
efficacy JJ N
end NN N
point NN N
is VBZ N
2 CD N
consecutive JJ N
decreases NNS N
in IN N
iPTH NN N
levels NNS N
greater JJR N
than IN N
30 CD N
% NN N
from IN N
baseline NN N
. . N

RESULTS NNP N
Two CD 3_p
hundred VBD 3_p
twenty NN 3_p
patients NNS N
participated VBD N
( ( N
n JJ N
= NN N
107 CD 3_p
, , N
paricalcitol NN N
; : N
n CC N
= $ N
113 CD 3_p
, , N
placebo NN N
) ) N
. . N

At IN N
least JJS N
2 CD N
consecutive JJ N
decreases NNS N
in IN N
iPTH JJ N
levels NNS N
of IN N
30 CD N
% NN N
or CC N
greater JJR N
from IN N
baseline NN N
occurred VBN N
in IN N
91 CD N
% NN N
of IN N
paricalcitol JJ N
versus FW N
13 CD N
% NN N
of IN N
placebo NN N
patients NNS N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Incidences NNS N
of IN N
hypercalcemia NN N
, , N
hyperphosphatemia NN N
, , N
and CC N
elevated VBD N
calcium-phosphorus JJ N
product NN N
levels NNS N
were VBD N
not RB N
significantly RB N
different JJ N
between IN N
groups NNS N
. . N

Similarly RB N
, , N
no DT N
significant JJ N
differences NNS N
in IN N
urinary JJ N
calcium NN N
and CC N
phosphorus JJ N
excretion NN N
or CC N
deterioration NN N
in IN N
kidney NN N
function NN N
were VBD N
detected VBN N
in IN N
patients NNS N
administered VBN N
paricalcitol NNS N
compared VBN N
with IN N
placebo NN N
. . N

CONCLUSION NNP N
Paricalcitol NNP N
capsule NN N
was VBD N
well RB N
tolerated VBN N
and CC N
effectively RB N
decreased VBN N
iPTH NN N
levels NNS N
with IN N
minimal JJ N
or CC N
no DT N
impact NN N
on IN N
calcium NN N
levels NNS N
, , N
phosphorus NN N
balance NN N
, , N
and CC N
kidney NN N
function NN N
in IN N
patients NNS N
with IN N
stages NNS N
3 CD N
and CC N
4 CD N
CKD NNP N
. . N

-DOCSTART- -X- O O

Influence NN N
of IN N
occlusal JJ N
access NN N
on IN N
demineralized JJ N
dentin NN N
removal NN N
in IN N
the DT N
atraumatic JJ N
restorative JJ N
treatment NN N
( ( N
ART NNP N
) ) N
approach NN N
. . N

PURPOSE NNP N
To TO N
verify VB N
the DT N
influence NN N
of IN N
cavity NN N
access NN N
diameter NN N
on IN N
demineralized JJ N
dentin NN N
removal NN N
in IN N
the DT N
ART NNP N
approach NN N
. . N

METHODS $ N
40 CD 3_p
non-carious JJ 4_p
human JJ 4_p
premolars NNS 4_p
were VBD N
randomly RB N
divided VBN N
into IN N
four CD N
groups NNS N
. . N

The DT N
occlusal JJ N
surface NN N
was VBD N
ground NN N
flat JJ N
and CC N
the DT N
teeth NNS N
were VBD N
sectioned VBN N
mesio-distally RB N
. . N

The DT N
hemi-sections NNS N
were VBD N
reassembled VBN N
and CC N
occlusal JJ N
access NN N
preparations NNS N
were VBD N
carried VBN N
out RP N
using VBG N
ball-shaped JJ N
diamonds NNS N
. . N

The DT N
resulting VBG N
size NN N
of IN N
the DT N
occlusal NN N
opening NN N
was VBD N
1.0 CD N
mm NN N
, , N
1.4 CD N
mm NN N
, , N
1.6 CD N
mm NN N
and CC N
1.8 CD N
mm NN N
for IN N
Groups NNP N
A NNP N
, , N
B NNP N
, , N
C NNP N
, , N
and CC N
D NNP N
, , N
respectively RB N
. . N

Standardized VBN N
artificial JJ N
carious JJ N
lesions NNS N
were VBD N
created VBN N
and CC N
demineralized VBN N
dentin NN N
was VBD N
excavated VBN N
. . N

After IN N
excavation NN N
, , N
the DT N
cavities NNS N
were VBD N
analyzed VBN N
using VBG N
: : N
( ( N
a DT N
) ) N
the DT N
tactile NN N
method NN N
, , N
( ( N
b NN N
) ) N
caries-detection NN N
dye NN N
to TO N
stain VB N
demineralized JJ N
dentin NN N
, , N
as IN N
proposed VBN N
by IN N
Smales NNP N
& CC N
Fang NNP N
, , N
and CC N
( ( N
c NN N
) ) N
Demineralized NNP N
Tissue NNP N
Removal NNP N
index NN N
, , N
as IN N
proposed VBN N
in IN N
this DT N
study NN N
. . N

Statistical JJ N
analysis NN N
was VBD N
performed VBN N
using VBG N
Fisher NNP N
, , N
Spearman NNP N
correlation NN N
coefficient NN N
, , N
kappa NN N
, , N
Kruskal-Wallis NNP N
and CC N
Miller NNP N
tests NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

RESULTS VB N
The DT N
three CD N
methods NNS N
of IN N
evaluation NN N
showed VBD N
no DT N
significant JJ N
difference NN N
between IN N
Groups NNP N
A NNP N
vs. NN N
B NNP N
, , N
and CC N
C NNP N
vs. FW N
D NNP N
, , N
while IN N
statistically RB N
significant JJ N
differences NNS N
were VBD N
observed VBN N
between IN N
Groups NNP N
A NNP N
vs. FW N
C NNP N
, , N
A NNP N
vs. NN N
D NNP N
, , N
B NNP N
vs. FW N
C NNP N
and CC N
B NNP N
vs. FW N
D. NNP N
Based VBD N
on IN N
the DT N
results NNS N
of IN N
this DT N
study NN N
, , N
the DT N
size NN N
of IN N
occlusal JJ N
access NN N
significantly RB N
affected VBD N
the DT N
efficacy NN N
of IN N
demineralized JJ N
tissue NN N
removal NN N
. . N

-DOCSTART- -X- O O

A DT N
pilot NN N
study NN N
of IN N
a DT N
low-tilt JJ N
biphasic JJ N
waveform NN N
for IN N
transvenous JJ N
cardioversion NN N
of IN N
atrial JJ 4_p
fibrillation NN 4_p
: : N
improved VBN N
efficacy NN N
compared VBN N
with IN N
conventional JJ N
capacitor-based JJ N
waveforms NNS N
in IN N
patients NNS N
. . N

BACKGROUND NNP N
The DT N
optimal JJ N
waveform NN N
tilt NN N
for IN N
defibrillation NN N
is VBZ N
not RB N
known VBN N
. . N

Most JJS N
modern JJ N
defibrillators NNS N
used VBN N
for IN N
the DT N
cardioversion NN N
of IN N
atrial JJ N
fibrillation NN N
( ( N
AF NNP N
) ) N
employ VBD N
high-tilt JJ N
, , N
capacitor-based JJ N
biphasic JJ N
waveforms NNS N
. . N

METHODS NNP N
We PRP N
have VBP N
developed VBN N
a DT N
low-tilt JJ N
biphasic JJ N
waveform NN N
for IN N
defibrillation NN N
. . N

This DT N
low-tilt JJ N
waveform NN N
was VBD N
compared VBN N
with IN N
a DT N
conventional JJ N
waveform NN N
of IN N
equivalent JJ N
duration NN N
and CC N
voltage NN N
in IN N
patients NNS N
with IN N
AF NNP N
. . N

Patients NNS N
with IN N
persistent JJ 4_p
AF NNP 4_p
or CC N
AF NNP 4_p
induced VBD 4_p
during IN N
a DT N
routine JJ N
electrophysiology NN 4_p
study NN 4_p
( ( N
EPS NNP N
) ) N
were VBD N
randomized VBN N
to TO N
receive VB N
either RB N
the DT N
low-tilt JJ N
waveform NN N
or CC N
a DT N
conventional JJ N
waveform NN N
. . N

Defibrillation NNP N
electrodes NNS N
were VBD N
positioned VBN N
in IN N
the DT N
right JJ N
atrial JJ N
appendage NN N
and CC N
distal JJ N
coronary JJ N
sinus NN N
. . N

Phase VB N
1 CD N
peak JJ N
voltage NN N
was VBD N
increased VBN N
in IN N
a DT N
stepwise NN N
progression NN N
from IN N
50 CD N
V NNP N
to TO N
300V CD N
. . N

Shock NNP N
success NN N
was VBD N
defined VBN N
as IN N
return NN N
of IN N
sinus NN N
rhythm NN N
for IN N
> NNP N
/=30 NNP N
seconds NNS N
. . N

RESULTS VB N
The DT N
low-tilt JJ N
waveform NN N
produced VBN N
successful JJ N
termination NN N
of IN N
persistent JJ N
AF NNP N
at IN N
a DT N
mean JJ N
voltage NN N
of IN N
223 CD N
V NNP N
( ( N
8.2 CD N
J NNP N
) ) N
versus VBD N
270 CD N
V NNP N
( ( N
6.7 CD N
J NNP N
) ) N
with IN N
the DT N
conventional JJ N
waveform NN N
( ( N
P NNP N
= VBZ N
0.002 CD N
for IN N
voltage NN N
, , N
P NNP N
= NNP N
ns NN N
for IN N
energy NN N
) ) N
. . N

In IN N
patients NNS N
with IN N
induced JJ N
AF NNP N
the DT N
mean JJ N
voltage NN N
for IN N
the DT N
low-tilt JJ N
waveform NN N
was VBD N
91V CD N
( ( N
1.6 CD N
J NNP N
) ) N
and CC N
for IN N
the DT N
conventional JJ N
waveform NN N
was VBD N
158 CD N
V NNP N
( ( N
2.0 CD N
J NNP N
) ) N
( ( N
P NNP N
= VBZ N
0.005 CD N
for IN N
voltage NN N
, , N
P NNP N
= NNP N
ns NN N
for IN N
energy NN N
) ) N
. . N

The DT N
waveform NN N
was VBD N
much RB N
more RBR N
successful JJ N
at IN N
very RB N
low JJ N
voltages NNS N
( ( N
less JJR N
than IN N
or CC N
equal JJ N
to TO N
100 CD N
V NNP N
) ) N
compared VBN N
with IN N
the DT N
conventional JJ N
waveform NN N
( ( N
Novel NNP N
: : N
82 CD N
% NN N
vs JJ N
Conventional NNP N
22 CD N
% NN N
, , N
P NNP N
= NNP N
0.008 CD N
) ) N
. . N

CONCLUSION VB N
The DT N
low-tilt JJ N
biphasic JJ N
waveform NN N
was VBD N
more RBR N
successful JJ N
for IN N
the DT N
internal JJ N
cardioversion NN N
of IN N
both DT N
persistent JJ N
and CC N
induced JJ N
AF NNP N
in IN N
patients NNS N
( ( N
in IN N
terms NNS N
of IN N
leading VBG N
edge NN N
voltage NN N
) ) N
. . N

-DOCSTART- -X- O O

Arthroscopic NNP N
rotator NN N
cuff NN N
repair NN N
with IN N
and CC N
without IN N
acromioplasty NN N
in IN N
the DT N
treatment NN N
of IN N
full-thickness JJ 4_p
rotator NN 4_p
cuff NN 4_p
tears NNS 4_p
: : N
a DT N
multicenter NN N
, , N
randomized VBN N
controlled VBN N
trial NN N
. . N

BACKGROUND VB N
The DT N
primary JJ N
objective NN N
of IN N
this DT N
prospective JJ N
randomized NN N
controlled VBD N
trial NN N
was VBD N
to TO N
compare VB N
functional JJ N
and CC N
quality-of-life JJ N
indices NNS N
and CC N
rates NNS N
of IN N
revision NN N
surgery NN N
in IN N
arthroscopic NN N
rotator NN N
cuff NN N
repair NN N
with IN N
and CC N
without IN N
acromioplasty JJ N
. . N

METHODS NNP N
Eighty-six JJ 3_p
patients NNS N
consented VBN N
and CC N
were VBD N
randomly RB N
assigned VBN N
intraoperatively RB N
to TO N
one CD N
of IN N
two CD N
study NN N
groups NNS N
, , N
and CC N
sixty-eight NN 3_p
of IN N
them PRP N
completed VBD N
the DT N
study NN N
. . N

The DT N
primary JJ N
outcome NN N
was VBD N
the DT N
Western JJ N
Ontario NNP N
Rotator NNP N
Cuff NNP N
( ( N
WORC NNP N
) ) N
index NN N
. . N

Secondary JJ N
outcome NN N
measures NNS N
included VBD N
the DT N
American JJ N
Shoulder NNP N
and CC N
Elbow NNP N
Surgeons NNP N
( ( N
ASES NNP N
) ) N
shoulder NN N
assessment JJ N
form NN N
and CC N
a DT N
count NN N
of IN N
revisions NNS N
required VBN N
in IN N
each DT N
group NN N
. . N

Outcome NNP N
measures NNS N
were VBD N
completed VBN N
preoperatively RB N
and CC N
at IN N
three CD N
, , N
six CD N
, , N
twelve NN N
, , N
eighteen NN N
, , N
and CC N
twenty-four JJ N
months NNS N
after IN N
surgery NN N
. . N

RESULTS NNP N
WORC NNP N
and CC N
ASES NNP N
scores VBZ N
improved VBN N
significantly RB N
in IN N
each DT N
group NN N
over IN N
time NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
WORC NNP N
or CC N
ASES NNP N
scores NNS N
between IN N
the DT N
groups NNS N
that WDT N
had VBD N
arthroscopic VBN N
cuff JJ N
repair NN N
with IN N
or CC N
without IN N
acromioplasty JJ N
at IN N
any DT N
time NN N
point NN N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
scores NNS N
on IN N
the DT N
basis NN N
of IN N
acromion NN N
type NN N
, , N
nor CC N
were VBD N
any DT N
interaction NN N
effects NNS N
identified VBN N
between IN N
group NN N
and CC N
acromion NN N
type NN N
. . N

Four CD N
participants NNS N
( ( N
9 CD N
% NN N
) ) N
in IN N
the DT N
group NN N
that WDT N
had VBD N
arthroscopic VBN N
cuff JJ N
repair NN N
alone RB N
, , N
one CD N
with IN N
a DT N
Type-2 JJ N
and CC N
three CD N
with IN N
a DT N
Type-3 JJ N
acromion NN N
, , N
required VBN N
additional JJ N
surgery NN N
by IN N
the DT N
twenty-four-month JJ N
time NN N
point NN N
. . N

The DT N
number NN N
of IN N
patients NNS N
who WP N
required VBD N
additional JJ N
surgery NN N
was VBD N
greater JJR N
( ( N
p JJ N
= NNP N
0.05 CD N
) ) N
in IN N
the DT N
group NN N
that WDT N
had VBD N
arthroscopic VBN N
cuff JJ N
repair NN N
alone RB N
than IN N
in IN N
the DT N
group NN N
that WDT N
had VBD N
arthroscopic VBN N
cuff JJ N
repair NN N
and CC N
acromioplasty NN N
. . N

CONCLUSIONS NNP N
Our PRP$ N
findings NNS N
are VBP N
consistent JJ N
with IN N
previous JJ N
research NN N
reports NNS N
in IN N
which WDT N
there EX N
was VBD N
no DT N
difference NN N
in IN N
functional JJ N
and CC N
quality-of-life JJ N
indices NNS N
for IN N
patients NNS N
who WP N
had VBD N
rotator NN N
cuff NN N
repair NN N
with IN N
or CC N
without IN N
acromioplasty JJ N
. . N

The DT N
higher JJR N
reoperation NN N
rate NN N
was VBD N
found VBN N
in IN N
the DT N
group NN N
without IN N
acromioplasty NN N
. . N

Further CC N
study NN N
that WDT N
includes VBZ N
follow-up JJ N
imaging NN N
and CC N
patient-reported JJ N
outcomes NNS N
over IN N
a DT N
greater JJR N
follow-up JJ N
period NN N
is VBZ N
needed VBN N
. . N

-DOCSTART- -X- O O

Cyclosporin NNP N
versus NN N
cyclophosphamide NN N
for IN N
patients NNS N
with IN N
steroid-dependent JJ 4_p
and CC N
frequently RB 4_p
relapsing VBG 4_p
idiopathic JJ 4_p
nephrotic JJ 4_p
syndrome NN 4_p
: : N
a DT N
multicentre NN N
randomized VBN N
controlled VBN N
trial NN N
. . N

OBJECTIVE UH N
To TO N
compare VB N
the DT N
efficacy NN N
( ( N
maintenance NN N
of IN N
remission NN N
) ) N
, , N
safety NN N
and CC N
tolerability NN N
of IN N
cyclosporin NN N
( ( N
CsA NNP N
) ) N
with IN N
those DT N
of IN N
cyclophosphamide NN N
in IN N
patients NNS N
with IN N
steroid-dependent JJ 4_p
or CC N
frequently RB 4_p
relapsing VBG 4_p
nephrotic JJ 4_p
syndrome NN 4_p
( ( N
NS NNP 4_p
) ) N
. . N

DESIGN NNP N
Open NNP N
, , N
prospective JJ N
, , N
randomized VBN N
, , N
multicentre FW N
, , N
controlled VBD N
study NN N
for IN N
parallel JJ N
groups NNS N
, , N
stratified VBN N
for IN N
adults NNS 1_p
and CC N
children NNS 1_p
. . N

The DT N
setting NN N
was VBD N
in IN N
nephrological JJ N
departments NNS N
in IN N
Italy NNP N
. . N

SUBJECTS NNP N
AND CC N
INTERVENTIONS NNP N
Seventy-three JJ 3_p
patients NNS N
with IN N
steroid-sensitive JJ 4_p
idiopathic JJ 4_p
NS NNP 4_p
admitted VBD N
to TO N
the DT N
study NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
cyclophosphamide VB N
( ( N
2.5 CD N
mg/kg/day NN N
) ) N
for IN N
8 CD N
weeks NNS N
or CC N
CsA NNP N
( ( N
5 CD N
mg/kg/day NN N
in IN N
adults NNS N
, , N
6 CD N
mg/kg/day NN N
in IN N
children NNS N
) ) N
for IN N
9 CD N
months NNS N
, , N
tapered VBD N
off RP N
by IN N
25 CD N
% NN N
every DT N
month NN N
until IN N
complete JJ N
discontinuation NN N
at IN N
month NN N
12 CD N
. . N

Seven CD N
patients NNS N
lost VBN N
to TO N
follow VB N
up RP N
were VBD N
not RB N
considered VBN N
in IN N
the DT N
analysis NN N
. . N

The DT N
remaining VBG N
66 CD N
patients NNS N
were VBD N
followed VBN N
up RP N
for IN N
3-24 JJ N
months NNS N
after IN N
randomization NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Relapse-free NNP N
survival NN N
; : N
number NN N
of IN N
N.S NNP N
. . N

relapses/patient/year NN N
; : N
cumulative JJ N
dose NN N
of IN N
prednisone/patient NN N
; : N
laboratory JJ N
investigations NNS N
( ( N
kidney NN N
and CC N
liver NN N
functions NNS N
, , N
haematological JJ N
parameters NNS N
) ) N
; : N
incidence NN N
of IN N
adverse JJ N
events NNS N
. . N

RESULTS NNP N
At IN N
month NN N
9 CD N
, , N
26 CD N
of IN N
35 CD N
CsA-treated JJ N
patients NNS N
were VBD N
still RB N
in IN N
complete JJ N
remission NN N
and CC N
a DT N
further JJ N
five CD N
patients NNS N
were VBD N
in IN N
partial JJ N
remission NN N
; : N
18 CD N
of IN N
28 CD N
cyclophosphamide-treated JJ N
patients NNS N
were VBD N
in IN N
complete JJ N
remission NN N
, , N
and CC N
one CD N
in IN N
partial JJ N
remission NN N
( ( N
P NNP N
= NNP N
NS NNP N
) ) N
. . N

No DT N
difference NN N
between IN N
adults NNS N
and CC N
children NNS N
was VBD N
seen VBN N
with IN N
either DT N
treatment NN N
. . N

The DT N
risk NN N
of IN N
relapse NN N
was VBD N
similar JJ N
between IN N
frequent JJ N
relapsers NNS N
( ( N
19 CD N
of IN N
22 CD N
) ) N
and CC N
steroid-dependent JJ N
patients NNS N
( ( N
8 CD N
of IN N
14 CD N
) ) N
given VBN N
CsA NNP N
, , N
and CC N
those DT N
given VBN N
cyclophosphamide NN N
( ( N
5 CD N
of IN N
15 CD N
and CC N
6 CD N
of IN N
15 CD N
) ) N
. . N

The DT N
mean JJ N
number NN N
of IN N
relapses NNS N
per IN N
year NN N
and CC N
the DT N
mean NN N
dose NN N
of IN N
prednisone NN N
per IN N
year NN N
were VBD N
significantly RB N
less JJR N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
in IN N
both DT N
groups NNS N
for IN N
the DT N
experimental JJ N
year NN N
than IN N
for IN N
the DT N
year NN N
before IN N
randomization NN N
. . N

At IN N
2 CD N
years NNS N
, , N
25 CD N
% NN N
of IN N
the DT N
patients NNS N
given VBN N
CsA NNP N
( ( N
50 CD N
% NN N
adults NNS N
and CC N
20 CD N
% NN N
children NNS N
) ) N
and CC N
63 CD N
% NN N
of IN N
those DT N
given VBN N
cyclophosphamide NN N
( ( N
40 CD N
% NN N
adults NNS N
and CC N
68 CD N
% NN N
children NNS N
) ) N
had VBD N
not RB N
had VBN N
any DT N
relapse NN N
of IN N
NS NNP N
. . N

Tolerance NN N
to TO N
the DT N
two CD N
drugs NNS N
was VBD N
generally RB N
good JJ N
. . N

The DT N
CsA-related JJ N
side-effects NNS N
were VBD N
mild JJ N
and CC N
disappeared VBD N
after IN N
drug NN N
discontinuation NN N
. . N

CONCLUSIONS VB N
This DT N
study NN N
shows VBZ N
that IN N
both DT N
treatments NNS N
are VBP N
effective JJ N
and CC N
well RB N
tolerated VBD N
; : N
more RBR N
patients NNS N
given VBN N
cyclophosphamide JJ N
had VBD N
stable JJ N
remissions NNS N
. . N

-DOCSTART- -X- O O

Genotyping VBG N
of IN N
CYP21 NNP N
, , N
linked VBD N
chromosome NN N
6p CD N
markers NNS N
, , N
and CC N
a DT N
sex-specific JJ N
gene NN N
in IN N
neonatal JJ 1_p
screening NN N
for IN N
congenital JJ 4_p
adrenal JJ 4_p
hyperplasia NN 4_p
. . N

We PRP N
investigated VBD N
the DT N
feasibility NN N
and CC N
diagnostic JJ N
utility NN N
of IN N
genotyping VBG N
9 CD N
CYP21 NNP N
mutations NNS N
, , N
linked VBD N
chromosome NN N
6p CD N
markers NNS N
, , N
and CC N
a DT N
dimorphic JJ N
X-Y JJ N
marker NN N
from IN N
neonatal JJ 1_p
screening NN N
samples NNS N
. . N

Blood-impregnated JJ N
filter NN N
papers NNS N
( ( N
Guthrie NNP N
cards NNS N
) ) N
from IN N
603 CD 3_p
randomly RB N
chosen VBN N
New NNP N
Zealand NNP N
neonates NNS 1_p
were VBD N
genotyped VBN N
blind IN N
to TO N
17-hydroxyprogesterone CD N
( ( N
17-OHP CD N
) ) N
levels NNS N
. . N

Another DT N
50 CD 3_p
samples NNS N
from IN N
Swiss NNP N
and CC N
North NNP N
American JJ N
infants NNS N
with IN N
correlative JJ N
hormonal JJ N
data NNS N
were VBD N
also RB N
genotyped VBN N
. . N

DNA NN N
was VBD N
extracted VBN N
, , N
and CC N
gene-specific JJ N
PCR NNP N
was VBD N
performed VBN N
. . N

CYP21 NNP N
PCR NNP N
products NNS N
were VBD N
subjected VBN N
to TO N
ligase VB N
detection NN N
reaction NN N
, , N
simultaneously RB N
analyzing VBG N
9 CD N
CYP21 NNP N
mutations NNS N
; : N
PCR NNP N
products NNS N
of IN N
other JJ N
genes NNS N
were VBD N
subjected VBN N
to TO N
direct VB N
gel JJ N
analysis NN N
. . N

CYP21 NNP N
genotyping VBG N
indicated VBD N
a DT N
heterozygote NN N
rate NN N
of IN N
2.8 CD N
% NN N
for IN N
classic JJ N
mutations NNS N
( ( N
excluding VBG N
CYP21 NNP N
deletions NNS N
) ) N
, , N
and CC N
2.0 CD N
% NN N
for IN N
nonclassic JJ N
mutations NNS N
in IN N
New NNP N
Zealanders NNP N
. . N

Ten CD N
full-term JJ N
affected JJ N
neonates NNS N
showed VBD N
a DT N
wide JJ N
range NN N
of IN N
17-OHP JJ N
levels NNS N
( ( N
15-1400 JJ N
nmol/L NN N
) ) N
. . N

Sick NNP N
or CC N
preterm JJ N
infants NNS N
or CC N
infants NNS N
screened VBN N
on IN N
the DT N
first JJ N
day NN N
of IN N
life NN N
with IN N
high JJ N
17-OHP JJ N
proved VBN N
genetically RB N
unaffected JJ N
. . N

Genetic JJ N
linkage NN N
disequilibrium NN N
was VBD N
found VBN N
between IN N
two CD N
CYP21 NNP N
mutations NNS N
and CC N
chromosome NN N
6p CD N
markers NNS N
. . N

Guthrie NNP N
cards NNS N
can MD N
be VB N
used VBN N
to TO N
accurately RB N
genotype VB N
CYP21 NNP N
and CC N
other JJ N
relevant JJ N
markers NNS N
, , N
potentially RB N
enhancing VBG N
the DT N
specificity NN N
and CC N
sensitivity NN N
of IN N
congenital JJ N
adrenal JJ N
hyperplasia NN N
screening NN N
. . N

CYP21 NNP N
heterozygote JJ N
frequency NN N
for IN N
classic JJ N
mutations NNS N
is VBZ N
higher JJR N
than IN N
expected VBN N
based VBN N
on IN N
genotype NN N
compared VBN N
with IN N
that DT N
predicted VBN N
by IN N
hormonal JJ N
newborn JJ 1_p
screening NN N
. . N

-DOCSTART- -X- O O

Lack NN N
of IN N
effect NN N
of IN N
food NN N
on IN N
the DT N
steady JJ N
state NN N
pharmacokinetics NNS N
of IN N
BMS-181101 NNP N
, , N
an DT N
antidepressant NN N
, , N
in IN N
healthy JJ 4_p
subjects NNS N
. . N

The DT N
effect NN N
of IN N
food NN N
on IN N
the DT N
pharmacokinetics NNS N
of IN N
BMS-181101 NNP N
, , N
a DT N
new JJ N
anti-depressant JJ N
under IN N
development NN N
, , N
was VBD N
investigated VBN N
in IN N
12 CD 3_p
healthy JJ 4_p
male NN 2_p
volunteers NNS N
at IN N
steady JJ N
state NN N
. . N

Each DT N
subject NN N
received VBD N
a DT N
15 CD N
mg JJ N
oral JJ N
dose NN N
of IN N
BMS-181101 NNP N
twice NN N
a DT N
day NN N
( ( N
q JJ N
12 CD N
h NN N
) ) N
for IN N
11 CD N
days NNS N
and CC N
a DT N
morning NN N
dose NN N
of IN N
BMS-181101 NNP N
on IN N
day NN N
12 CD N
. . N

Six CD 3_p
subjects NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
BMS-181101 NNP N
under IN N
fasted VBN N
conditions NNS N
from IN N
days NNS N
1 CD N
to TO N
6 CD N
and CC N
then RB N
crossed VBD N
over IN N
to TO N
fed VB N
conditions NNS N
from IN N
days NNS N
7 CD N
to TO N
12 CD N
. . N

The DT N
other JJ N
six CD 3_p
subjects NNS N
received VBD N
the DT N
reverse NN N
conditions NNS N
, , N
fed VBN N
for IN N
days NNS N
1-6 CD N
and CC N
fasted VBN N
for IN N
days NNS N
7-12 CD N
. . N

Serial JJ N
blood NN N
samples NNS N
were VBD N
collected VBN N
up RB N
to TO N
12 CD N
h NNS N
on IN N
days NNS N
6 CD N
and CC N
12 CD N
following VBG N
the DT N
administration NN N
of IN N
the DT N
morning NN N
dose NN N
. . N

In IN N
addition NN N
, , N
trough IN N
blood NN N
samples NNS N
were VBD N
collected VBN N
on IN N
days NNS N
4 CD N
, , N
5 CD N
, , N
10 CD N
, , N
and CC N
11 CD N
prior RB N
to TO N
the DT N
morning NN N
dose NN N
. . N

Plasma NNP N
samples NNS N
were VBD N
analyzed VBN N
for IN N
intact JJ N
BMS-181101 NNP N
using VBG N
a DT N
validated JJ N
high-performance NN N
liquid NN N
chromatography NN N
method NN N
with IN N
an DT N
electrochemical JJ N
detector NN N
. . N

BMS-181101 NNP N
was VBD N
well RB N
tolerated VBN N
both DT N
with IN N
and CC N
without IN N
ingestion NN N
of IN N
food NN N
. . N

The DT N
statistical JJ N
evaluation NN N
of IN N
the DT N
Cmin NNP N
values NNS N
indicated VBD N
that IN N
steady JJ N
state NN N
of IN N
BMS-181101 NNP N
was VBD N
achieved VBN N
by IN N
the DT N
fourth JJ N
day NN N
of IN N
dosing VBG N
regardless NN N
of IN N
whether IN N
the DT N
subject NN N
was VBD N
fasted VBN N
or CC N
fed VBN N
. . N

When WRB N
BMS-181101 NNP N
was VBD N
administered VBN N
with IN N
food NN N
, , N
Cmax NNP N
was VBD N
reduced VBN N
by IN N
about IN N
25 CD N
% NN N
and CC N
tmax NN N
was VBD N
prolonged VBN N
by IN N
1 CD N
h. NN N
However RB N
, , N
AUCtau NNP N
, , N
t1/2 NN N
, , N
and CC N
time NN N
to TO N
attain VB N
steady JJ N
state NN N
of IN N
BMS-181101 NNP N
were VBD N
not RB N
altered VBN N
by IN N
ingestion NN N
of IN N
food NN N
. . N

In IN N
summary JJ N
, , N
BMS-181101 NNP N
can MD N
be VB N
given VBN N
with IN N
food NN N
without IN N
adversely RB N
impacting VBG N
the DT N
safety NN N
or CC N
pharmacokinetic JJ N
profiles NNS N
of IN N
the DT N
drug NN N
. . N

-DOCSTART- -X- O O

Midazolam NNP N
vs NN N
ondansetron NN N
for IN N
preventing VBG N
postoperative JJ N
nausea NN N
and CC N
vomiting NN N
: : N
a DT N
randomised JJ N
controlled VBN N
trial NN N
. . N

We PRP N
compared VBN N
the DT N
prophylactic JJ N
anti-emetic JJ N
efficacy NN N
of IN N
midazolam NN N
and CC N
ondansetron NN N
in IN N
90 CD 3_p
patients NNS N
scheduled VBN N
for IN N
minor JJ 4_p
gynaecological JJ 4_p
( ( N
hysteroscopy NN 4_p
) ) N
or CC N
urological JJ 4_p
( ( N
ureteroscopy JJ 4_p
) ) N
procedures NNS N
planned VBN N
to TO N
last JJ N
1-2 JJ N
h NN N
under IN N
sevoflurane NN N
anaesthesia NN N
with IN N
spontaneous JJ N
ventilation NN N
of IN N
the DT N
lungs NNS N
via IN N
a DT N
laryngeal JJ N
mask NN N
airway NN N
. . N

Midazolam NNP N
2 CD N
mg NN N
or CC N
ondansetron $ N
4 CD N
mg NN N
were VBD N
administered VBN N
intravenously RB N
30 CD N
min NN N
before IN N
the DT N
end NN N
of IN N
surgery NN N
. . N

The DT N
proportions NNS N
of IN N
patients NNS N
who WP N
experienced VBD N
postoperative JJ 4_p
nausea NN 4_p
and CC N
vomiting NN 4_p
in IN N
the DT N
first JJ N
24 CD N
h NN N
( ( N
30 CD N
% NN N
and CC N
27 CD N
% NN N
for IN N
the DT N
midazolam NN N
and CC N
ondansetron NN N
groups NNS N
, , N
respectively RB N
) ) N
were VBD N
similar JJ N
in IN N
the DT N
two CD N
groups NNS N
. . N

The DT N
incidence NN N
of IN N
postoperative JJ N
nausea NN N
and CC N
vomiting NN N
was VBD N
significantly RB N
smaller JJR N
in IN N
both DT N
groups NNS N
than IN N
predicted VBN N
according VBG N
to TO N
the DT N
patients NNS N
' POS N
underlying JJ N
risks NNS N
( ( N
midazolam JJ N
group NN N
: : N
p NN N
= VBZ N
0.018 CD N
; : N
ondansetron VBN N
group NN N
: : N
p NN N
= VBZ N
0.017 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
average JJ N
sedation NN N
scores NNS N
or CC N
pain NN N
scores NNS N
. . N

Treatment NNP N
using VBG N
ondansetron NN N
for IN N
anti-emetic JJ N
prophylaxis NN N
did VBD N
not RB N
provide VB N
a DT N
superior JJ N
benefit NN N
compared VBN N
to TO N
midazolam VB N
in IN N
the DT N
present JJ N
study NN N
. . N

-DOCSTART- -X- O O

A DT N
randomized VBN N
controlled VBN N
trial NN N
to TO N
improve VB N
colon NN N
cancer NN N
screening VBG N
in IN N
rural JJ 4_p
family NN 4_p
medicine NN N
: : N
an DT N
Iowa NNP N
Research NNP N
Network NNP N
( ( N
IRENE NNP N
) ) N
study NN N
. . N

BACKGROUND NNP N
Many JJ N
adults NNS N
have VBP N
not RB N
been VBN N
screened VBN N
for IN N
colon NN N
cancer NN N
, , N
a DT N
potentially RB N
preventable JJ N
cause NN N
of IN N
death NN N
. . N

METHODS NNP N
This DT N
was VBD N
a DT N
randomized VBN N
controlled VBN N
trial NN N
conducted VBN N
between IN N
December NNP N
2008 CD N
and CC N
April NNP N
2011 CD N
to TO N
improve VB N
CRC NNP N
screening VBG N
in IN N
16 CD N
rural JJ N
family NN N
physician NN N
offices NNS N
. . N

Subjects NNS 4_p
due JJ N
for IN N
CRC NNP 4_p
screening VBG 4_p
were VBD N
randomized VBN N
within IN N
each DT N
practice NN N
to TO N
1 CD N
of IN N
4 CD N
groups NNS N
: : N
( ( N
1 CD N
) ) N
usual JJ N
care NN N
; : N
( ( N
2 CD N
) ) N
physician JJ N
chart NN N
reminder NN N
; : N
( ( N
3 CD N
) ) N
physician JJ N
chart NN N
reminder NN N
, , N
mailed VBN N
education NN N
, , N
CRC NNP N
reminder NN N
magnet NN N
, , N
and CC N
fecal JJ N
immunochemical JJ N
test NN N
( ( N
FIT NNP N
) ) N
( ( N
mailed JJ N
education/FIT NN N
) ) N
; : N
or CC N
( ( N
4 CD N
) ) N
all PDT N
the DT N
preceding VBG N
plus CC N
a DT N
structured JJ N
telephone NN N
call NN N
to TO N
the DT N
patient NN N
from IN N
project JJ N
staff NN N
to TO N
provide VB N
education NN N
, , N
assess JJ N
interest NN N
in IN N
screening VBG N
, , N
explain VB N
the DT N
screening NN N
tests NNS N
, , N
and CC N
address JJ N
barriers NNS N
( ( N
mailed VBN N
education/FIT RB N
plus CC N
phone NN N
call NN N
) ) N
. . N

The DT N
main JJ N
outcome NN N
was VBD N
completion NN N
of IN N
any DT N
CRC NNP N
screening NN N
. . N

RESULTS VB N
This DT N
study NN N
enrolled VBD N
743 CD 3_p
patients NNS N
. . N

CRC NNP N
screening NN N
was VBD N
completed VBN N
by IN N
17.8 CD N
% NN N
in IN N
the DT N
usual JJ N
care NN N
group NN N
, , N
20.5 CD N
% NN N
in IN N
the DT N
chart NN N
reminder NN N
group NN N
, , N
56.5 CD N
% NN N
in IN N
the DT N
mailed JJ N
education/FIT NN N
group NN N
, , N
and CC N
57.2 CD N
% NN N
in IN N
the DT N
mailed JJ N
education/FIT NN N
plus CC N
phone NN N
call NN N
group NN N
. . N

We PRP N
found VBD N
no DT N
effect NN N
from IN N
the DT N
chart NN N
reminder NN N
compared VBN N
with IN N
usual JJ N
care NN N
( ( N
odds NNS N
ratio VBP N
[ CD N
OR NNP N
] NNP N
, , N
1.2 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
0.7-2.0 NNP N
) ) N
; : N
and CC N
a DT N
beneficial JJ N
effect NN N
from IN N
the DT N
mailed VBN N
education/FIT NN N
( ( N
OR NNP N
, , N
6.0 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
3.7-9.6 JJ N
) ) N
and CC N
the DT N
mailed JJ N
education/FIT NN N
plus CC N
phone NN N
call NN N
( ( N
OR NNP N
, , N
6.2 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
3.8-9.9 JJ N
) ) N
. . N

Both DT N
FIT NNP N
and CC N
colonoscopy JJ N
rates NNS N
increased VBD N
significantly RB N
in IN N
both DT N
mailed JJ N
education NN N
groups NNS N
. . N

CONCLUSION NNP N
CRC NNP N
screening VBG N
rates NNS N
increased VBD N
significantly RB N
among IN N
patients NNS N
who WP N
were VBD N
overdue JJ N
for IN N
screening VBG N
after IN N
they PRP N
received VBD N
mailed VBD N
educational JJ N
materials NNS N
and CC N
a DT N
FIT NNP N
. . N

The DT N
addition NN N
of IN N
a DT N
phone NN N
call NN N
did VBD N
not RB N
further JJ N
increase NN N
screening VBG N
rates NNS N
. . N

-DOCSTART- -X- O O

Direct JJ N
trocar NN N
insertion NN N
vs. FW N
Verres NNP N
needle FW N
use NN N
for IN N
laparoscopic JJ 4_p
sterilization NN 4_p
. . N

A DT N
randomized JJ N
, , N
prospective JJ N
trial NN N
was VBD N
designed VBN N
to TO N
compare VB N
direct JJ N
trocar NN N
insertion NN N
with IN N
prior JJ N
peritoneal JJ N
insufflation NN N
with IN N
a DT N
Verres NNP N
needle NN N
for IN N
laparoscopic NN 4_p
tubal JJ 4_p
sterilization NN 4_p
. . N

Direct JJ N
trocar NN N
insertion NN N
resulted VBD N
in IN N
fewer JJR N
instrument NN N
insertions NNS N
( ( N
21.8 CD N
% NN N
vs. FW N
7.8 CD N
% NN N
) ) N
and CC N
use NN N
of IN N
smaller JJR N
volumes NNS N
of IN N
CO2 NNP N
( ( N
2.67 CD N
vs. FW N
2.32 CD N
L NNP N
) ) N
. . N

Direct JJ N
trocar NN N
use NN N
resulted VBD N
in IN N
a DT N
decrease NN N
in IN N
operating NN N
time NN N
from IN N
9 CD N
minutes NNS N
, , N
40 CD N
seconds NNS N
in IN N
the DT N
needle JJ N
group NN N
to TO N
7 CD N
minutes NNS N
, , N
30 CD N
seconds NNS N
in IN N
the DT N
trocar NN N
group NN N
. . N

Minor NNP N
omental JJ 4_p
injuries NNS 4_p
occurred VBD N
in IN N
a DT N
small JJ N
percentage NN N
of IN N
each DT N
group NN N
, , N
while IN N
serious JJ N
complications NNS N
occurred VBD N
once RB N
in IN N
each DT N
group NN N
. . N

-DOCSTART- -X- O O

Is VBZ N
a DT N
calculated JJ N
total JJ N
hip NN N
BMD NNP N
of IN N
clinical JJ N
use NN N
? . N
The DT N
diagnosis NN N
of IN N
osteoporosis NN N
is VBZ N
based VBN N
on IN N
bone NN N
mass NN N
measurement NN N
. . N

To TO N
avoid VB N
the DT N
errors NNS N
associated VBN N
with IN N
the DT N
measurement NN N
of IN N
spinal JJ N
bone NN N
density NN N
the DT N
total JJ N
hip NN N
has VBZ N
been VBN N
accepted VBN N
as IN N
the DT N
standard JJ N
measurement NN N
site NN N
. . N

This DT N
information NN N
is VBZ N
not RB N
available JJ N
for IN N
many JJ N
early JJ N
measurements NNS N
. . N

We PRP N
have VBP N
assessed VBN N
whether IN N
it PRP N
is VBZ N
possible JJ N
to TO N
derive VB N
clinically RB N
useful JJ N
information NN N
about IN N
total JJ N
hip NN N
bone NN N
mineral JJ N
density NN N
( ( N
BMD NNP N
) ) N
from IN N
measurements NNS N
at IN N
other JJ N
hip NN N
sites NNS N
. . N

The DT N
bone NN N
mass NN N
measurements NNS N
of IN N
46 CD 3_p
patients NNS N
participating VBG N
in IN N
a DT N
current JJ N
trial NN N
of IN N
therapy NN N
for IN N
osteoporosis NN 4_p
were VBD N
reviewed VBN N
. . N

The DT N
total JJ N
hip NN N
BMD NNP N
as IN N
directly RB N
measured VBN N
was VBD N
compared VBN N
with IN N
that DT N
obtained VBN N
from IN N
the DT N
formula NN N
: : N
Total JJ N
hip NN N
BMD NNP N
= VBZ N
0.48 CD N
x NN N
Neck NNP N
BMD NNP N
+ VBD N
0.62 CD N
x NNP N
Trochanteric NNP N
BMD NNP N
+ VBD N
0.03 CD N
. . N

In IN N
30 CD 3_p
patients NNS N
with IN N
follow-up JJ N
data NNS N
the DT N
rate NN N
of IN N
change NN N
in IN N
hip NN N
BMD NNP N
over IN N
a DT N
year NN N
was VBD N
also RB N
determined VBN N
by IN N
both DT N
methods NNS N
. . N

In IN N
the DT N
pretreatment NN N
state NN N
there EX N
was VBD N
good JJ N
agreement NN N
between IN N
the DT N
two CD N
measures NNS N
( ( N
r2 VB N
= RB N
0.96 CD N
, , N
SEE NNP N
0.012 CD N
g/cm2 NN N
) ) N
. . N

If IN N
the DT N
formula NN N
was VBD N
used VBN N
to TO N
compute VB N
a DT N
change NN N
in IN N
total JJ N
hip NN N
BMD NNP N
, , N
the DT N
agreement NN N
between IN N
both DT N
methods NNS N
remained VBD N
good JJ N
. . N

However RB N
, , N
the DT N
standard JJ N
error NN N
of IN N
the DT N
estimate NN N
of IN N
the DT N
change NN N
represented VBD N
59 CD N
% NN N
of IN N
the DT N
observed JJ N
change NN N
. . N

This DT N
indicates VBZ N
that IN N
the DT N
error NN N
associated VBN N
with IN N
this DT N
estimate NN N
is VBZ N
too RB N
great JJ N
to TO N
allow VB N
clinically RB N
meaningful JJ N
conclusions NNS N
to TO N
be VB N
drawn VBN N
from IN N
calculated VBN N
total JJ N
hip NN N
BMD NNP N
. . N

We PRP N
conclude VBP N
that IN N
, , N
whilst VB N
it PRP N
may MD N
be VB N
possible JJ N
to TO N
obtain VB N
reasonable JJ N
point NN N
estimates NNS N
of IN N
total JJ N
hip NN N
BMD NNP N
from IN N
other JJ N
measures NNS N
in IN N
the DT N
hip NN N
, , N
these DT N
estimates NNS N
are VBP N
too RB N
imprecise JJ N
to TO N
allow VB N
conclusions NNS N
about IN N
change NN N
in IN N
BMD NNP N
to TO N
be VB N
made VBN N
. . N

-DOCSTART- -X- O O

Predictors NNS N
of IN N
postdischarge NN N
outcomes NNS N
from IN N
information NN N
acquired VBN N
shortly RB N
after IN N
admission NN N
for IN N
acute JJ 4_p
heart NN 4_p
failure NN 4_p
: : N
a DT N
report NN N
from IN N
the DT N
Placebo-Controlled NNP N
Randomized NNP N
Study NNP N
of IN N
the DT N
Selective NNP N
A1 NNP N
Adenosine NNP N
Receptor NNP N
Antagonist NNP N
Rolofylline NNP N
for IN N
Patients NNP N
Hospitalized NNP N
With IN N
Acute NNP 4_p
Decompensated NNP 4_p
Heart NNP 4_p
Failure NNP 4_p
and CC N
Volume NN 4_p
Overload NNP 4_p
to TO N
Assess NNP N
Treatment NNP N
Effect NNP N
on IN N
Congestion NNP N
and CC N
Renal NNP N
Function NNP N
( ( N
PROTECT NNP N
) ) N
Study NNP N
. . N

BACKGROUND NNP N
Acute NNP 4_p
heart NN 4_p
failure NN 4_p
is VBZ N
a DT N
common JJ N
reason NN N
for IN N
admission NN N
, , N
and CC N
outcome NN N
is VBZ N
often RB N
poor JJ N
. . N

Improved VBN N
prognostic JJ N
risk NN N
stratification NN N
may MD N
assist VB N
in IN N
the DT N
design NN N
of IN N
future JJ N
trials NNS N
and CC N
in IN N
patient JJ N
management NN N
. . N

Using VBG N
data NNS N
from IN N
a DT N
large JJ N
randomized JJ N
trial NN N
, , N
we PRP N
explored VBD N
the DT N
prognostic JJ N
value NN N
of IN N
clinical JJ N
variables NNS N
, , N
measured VBN N
at IN N
hospital JJ N
admission NN N
for IN N
acute JJ N
heart NN N
failure NN N
, , N
to TO N
determine VB N
whether IN N
a DT N
few JJ N
selected VBN N
variables NNS N
were VBD N
inferior JJ N
to TO N
an DT N
extended VBN N
data NN N
set NN N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
The DT N
prognostic JJ N
model NN N
included VBD N
37 CD N
clinical JJ N
characteristics NNS N
collected VBN N
at IN N
baseline NN N
in IN N
PROTECT NNP N
, , N
a DT N
study NN N
comparing VBG N
rolofylline NN N
and CC N
placebo NN N
in IN N
2033 CD 3_p
patients NNS N
admitted VBN N
with IN N
acute JJ 4_p
heart NN 4_p
failure NN 4_p
. . N

Prespecified VBN N
outcomes NNS N
at IN N
30 CD N
days NNS N
were VBD N
death NN N
or CC N
rehospitalization NN N
for IN N
any DT N
reason NN N
; : N
death NN N
or CC N
rehospitalization NN N
for IN N
cardiovascular NN N
or CC N
renal JJ N
reasons NNS N
; : N
and CC N
, , N
at IN N
both DT N
30 CD N
and CC N
180 CD N
days NNS N
, , N
all-cause JJ N
mortality NN N
. . N

No DT N
variable JJ N
had VBD N
a DT N
c-index NN N
> NN N
0.70 CD N
, , N
and CC N
few JJ N
had VBD N
values NNS N
> $ N
0.60 CD N
; : N
c-indices NNS N
were VBD N
lower JJR N
for IN N
composite JJ N
outcomes NNS N
than IN N
for IN N
mortality NN N
. . N

Blood NNP N
urea NN N
was VBD N
generally RB N
the DT N
strongest JJS N
single JJ N
predictor NN N
. . N

Eighteen NNP N
variables NNS N
contributed VBD N
independent JJ N
prognostic JJ N
information NN N
, , N
but CC N
a DT N
reduced JJ N
model NN N
using VBG N
only RB N
8 CD N
items NNS N
( ( N
age NN N
, , N
previous JJ N
heart NN N
failure NN N
hospitalization NN N
, , N
peripheral JJ N
edema NN N
, , N
systolic JJ N
blood NN N
pressure NN N
, , N
serum NN N
sodium NN N
, , N
urea JJ N
, , N
creatinine NN N
, , N
and CC N
albumin NN N
) ) N
performed VBD N
similarly RB N
. . N

For IN N
prediction NN N
of IN N
all-cause JJ N
mortality NN N
at IN N
180 CD N
days NNS N
, , N
the DT N
model NN N
c-index NN N
using VBG N
all DT N
variables NNS N
was VBD N
0.72 CD N
and CC N
for IN N
the DT N
simplified JJ N
model NN N
, , N
also RB N
0.72 CD N
. . N

CONCLUSIONS VB N
A NNP N
few JJ N
simple JJ N
clinical JJ N
variables NNS N
measured VBN N
on IN N
admission NN N
in IN N
patients NNS N
with IN N
acute JJ 4_p
heart NN 4_p
failure NN 4_p
predict VBP N
a DT N
variety NN N
of IN N
adverse JJ N
outcomes NNS N
with IN N
accuracy NN N
similar JJ N
to TO N
more RBR N
complex JJ N
models NNS N
. . N

However RB N
, , N
predictive JJ N
models NNS N
were VBD N
of IN N
only RB N
moderate JJ N
accuracy NN N
, , N
especially RB N
for IN N
outcomes NNS N
that WDT N
included VBD N
nonfatal JJ N
events NNS N
. . N

Better NNP N
methods NNS N
of IN N
risk NN N
stratification NN N
are VBP N
required VBN N
. . N

CLINICAL JJ N
TRIAL NNP N
REGISTRATION NNP N
URL NNP N
: : N
http NN N
: : N
//www.clinicaltrials.gov NN N
. . N

Unique JJ N
identifiers NNS N
: : N
NCT00328692 NNP N
and CC N
NCT00354458 NNP N
. . N

-DOCSTART- -X- O O

Study NN N
of IN N
the DT N
therapeutic JJ N
effects NNS N
of IN N
a DT N
hippotherapy NN N
simulator NN N
in IN N
children NNS 1_p
with IN N
cerebral JJ 4_p
palsy NN 4_p
: : N
a DT N
stratified JJ N
single-blind NN N
randomized VBD N
controlled JJ N
trial NN N
. . N

OBJECTIVE UH N
To TO N
investigate VB N
whether IN N
hippotherapy NN N
( ( N
when WRB N
applied VBN N
by IN N
a DT N
simulator NN N
) ) N
improves VBZ N
postural JJ N
control NN N
and CC N
balance NN N
in IN N
children NNS 1_p
with IN N
cerebral JJ 4_p
palsy NN 4_p
. . N

DESIGN NNP N
Stratified VBD N
single-blind JJ N
randomized NN N
controlled VBD N
trial NN N
with IN N
an DT N
independent JJ N
assessor NN N
. . N

Stratification NN N
was VBD N
made VBN N
by IN N
gross JJ N
motor NN N
function NN N
classification NN N
system NN N
levels NNS N
, , N
and CC N
allocation NN N
was VBD N
concealed VBN N
. . N

SUBJECTS NNP N
Children NNP 1_p
between IN N
4 CD 1_p
and CC 1_p
18 CD 1_p
years NNS N
old JJ N
with IN N
cerebral JJ 4_p
palsy NN 4_p
. . N

INTERVENTIONS JJ N
Participants NNS N
were VBD N
randomized VBN N
to TO N
an DT N
intervention NN N
( ( N
simulator NN N
ON NNP N
) ) N
or CC N
control NN N
( ( N
simulator VB N
OFF NNP N
) ) N
group NN N
after IN N
getting VBG N
informed JJ N
consent NN N
. . N

Treatment NNP N
was VBD N
provided VBN N
once RB N
a DT N
week NN N
( ( N
15 CD N
minutes NNS N
) ) N
for IN N
10 CD N
weeks NNS N
. . N

MAIN NNP N
MEASURES NNP N
Gross NNP N
Motor NNP N
Function NNP N
Measure NNP N
( ( N
dimension NN N
B NNP N
for IN N
balance NN N
and CC N
the DT N
Total NNP N
Score NNP N
) ) N
and CC N
Sitting VBG N
Assessment NNP N
Scale NNP N
were VBD N
carried VBN N
out RP N
at IN N
baseline NN N
( ( N
prior JJ N
to TO N
randomization NN N
) ) N
, , N
end NN N
of IN N
intervention NN N
and CC N
12 CD N
weeks NNS N
after IN N
completing VBG N
the DT N
intervention NN N
. . N

RESULTS NNP N
Thirty-eight JJ 3_p
children NNS 1_p
participated VBN N
. . N

The DT N
groups NNS N
were VBD N
balanced VBN N
at IN N
baseline NN N
. . N

Sitting VBG N
balance NN N
( ( N
measured VBN N
by IN N
dimension NN N
B NNP N
of IN N
the DT N
Gross NNP N
Motor NNP N
Function NNP N
Measure NNP N
) ) N
improved VBD N
significantly RB N
in IN N
the DT N
treatment NN N
group NN N
( ( N
effect NN N
size NN N
= $ N
0.36 CD N
; : N
95 CD N
% NN N
CI NNP N
0.01-0.71 NN N
) ) N
and CC N
the DT N
effect NN N
size NN N
was VBD N
greater JJR N
in IN N
the DT N
severely RB N
disabled JJ N
group NN N
( ( N
effect NN N
size NN N
= $ N
0.80 CD N
; : N
95 CD N
% NN N
CI NNP N
0.13-1.47 NN N
) ) N
. . N

The DT N
improvements NNS N
in IN N
sitting VBG N
balance NN N
were VBD N
not RB N
maintained VBN N
over IN N
the DT N
follow-up JJ N
period NN N
. . N

Changes NNS N
in IN N
the DT N
total JJ N
score NN N
of IN N
the DT N
Gross NNP N
Motor NNP N
Function NNP N
Measure NNP N
and CC N
the DT N
Sitting NNP N
Assessment NNP N
Scale NNP N
were VBD N
not RB N
significant JJ N
. . N

CONCLUSION NNP N
Hippotherapy NNP N
with IN N
a DT N
simulator NN N
can MD N
improve VB N
sitting VBG N
balance NN N
in IN N
cerebral JJ 4_p
palsy NN 4_p
children NNS 1_p
who WP N
have VBP N
higher JJR N
levels NNS N
of IN N
disability NN N
. . N

However RB N
, , N
this DT N
did VBD N
not RB N
lead VB N
to TO N
a DT N
change NN N
in IN N
the DT N
overall JJ N
function NN N
of IN N
these DT N
children NNS N
( ( N
Gross NNP N
Motor NNP N
Function NNP N
Classification NNP N
System NNP N
level JJ N
V NNP N
) ) N
. . N

-DOCSTART- -X- O O

Comparison NNP N
of IN N
intravenous JJ N
and CC N
intra-arterial JJ N
urokinase JJ N
thrombolysis NN N
for IN N
acute JJ 4_p
ischaemic JJ 4_p
stroke NN 4_p
. . N

Intravenous JJ N
fibrinolysis NN N
( ( N
IVF NNP N
) ) N
with IN N
rt-PA NN N
( ( N
alteplase NN N
) ) N
provides VBZ N
significant JJ N
benefits NNS N
in IN N
acute JJ N
ischaemic JJ N
stroke NN N
when WRB N
it PRP N
is VBZ N
given VBN N
within IN N
the DT N
first JJ N
three CD N
hours NNS N
following VBG N
stroke NN N
onset VBN N
. . N

Intra-arterial JJ N
fibrinolysis NN N
( ( N
IAF NNP N
) ) N
with IN N
pro-urokinase NN N
in IN N
PROACT NNP N
II NNP N
study NN N
provides VBZ N
quite RB N
the DT N
same JJ N
benefit NN N
in IN N
the DT N
first JJ N
6 CD N
hours NNS N
. . N

IVF NNP N
and CC N
IAF NNP N
have VBP N
never RB N
been VBN N
compared VBN N
. . N

To TO N
compare VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
IVF NNP N
and CC N
IAF NNP N
with IN N
urokinase JJ N
given VBN N
within IN N
the DT N
first JJ N
6 CD N
hours NNS N
of IN N
acute JJ 4_p
ischaemic JJ 4_p
stroke NN 4_p
. . N

Patients NNS N
fulfilling VBG N
the DT N
selection NN N
criteria NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
urokinase JJ N
900,000 CD N
units NNS N
via IN N
intravenous JJ N
or CC N
intra-arterial JJ N
routes NNS N
. . N

This DT N
randomised VBD N
monocentre NN N
study NN N
was VBD N
done VBN N
between IN N
December NNP N
1995 CD N
and CC N
August NNP N
1997 CD N
. . N

The DT N
primary JJ N
outcome NN N
was VBD N
defined VBN N
as IN N
the DT N
number NN N
of IN N
patients NNS N
with IN N
a DT N
modified JJ N
Rankin NNP N
score NN N
of IN N
2 CD N
or CC N
less JJR N
. . N

Secondary JJ N
outcomes NNS N
included VBD N
mortality NN N
, , N
frequency NN N
of IN N
symptomatic JJ N
intracranial JJ N
haemorrhage NN N
( ( N
SIH NNP N
) ) N
, , N
neurological JJ N
and CC N
functional JJ N
scores NNS N
. . N

Fourteen CD 3_p
patients NNS N
were VBD N
given VBN N
IVF NNP N
and CC N
13 CD 3_p
IAF NNP N
. . N

The DT N
study NN N
was VBD N
terminated VBN N
by IN N
the DT N
National NNP N
Health NNP N
Authorities NNP N
when WRB N
27 CD 3_p
patients NNS N
had VBD N
been VBN N
included VBN N
because IN N
of IN N
the DT N
mortality NN N
rate NN N
. . N

Seven CD N
patients NNS N
( ( N
26 CD N
% NN N
) ) N
died VBD N
, , N
4 CD N
in IN N
the DT N
IV NNP N
group NN N
( ( N
oedematous JJ N
infarct NN N
in IN N
3 CD N
and CC N
recurrence NN N
in IN N
1 CD N
) ) N
, , N
3 CD N
in IN N
the DT N
IA NNP N
group NN N
( ( N
SIH NNP N
in IN N
2 CD N
, , N
and CC N
oedematous JJ N
infarct NN N
in IN N
1 CD N
) ) N
. . N

Patients NNS N
given VBN N
IVF NNP N
were VBD N
treated VBN N
significantly RB N
earlier RBR N
( ( N
4:16 CD N
h NN N
vs NN N
5:24 CD N
h NN N
; : N
p=.007 NN N
) ) N
. . N

Although IN N
IA NNP N
patients NNS N
showed VBD N
greater JJR N
and CC N
earlier RBR N
improvement NN N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
primary JJ N
and CC N
secondary JJ N
outcomes NNS N
. . N

Because IN N
of IN N
premature NN N
termination NN N
, , N
the DT N
trial NN N
was VBD N
too RB N
small JJ N
to TO N
provide VB N
any DT N
reliable JJ N
and CC N
conclusive JJ N
results NNS N
. . N

Intra-arterial JJ N
fibrinolysis NN N
began VBD N
significantly RB N
later RBR N
than IN N
IV NNP N
fibrinolysis NN N
but CC N
it PRP N
gave VBD N
non-significantly RB N
better JJ N
results NNS N
in IN N
this DT N
prematurely RB N
terminated VBN N
study NN N
. . N

-DOCSTART- -X- O O

No DT N
effect NN N
of IN N
acetylsalicylic JJ N
acid NN N
on IN N
B-thromboglobulin NNP N
and CC N
platelet VB N
factor NN N
4 CD N
plasma NN N
levels NNS N
in IN N
patients NNS N
with IN N
transient JJ 4_p
ischaemic JJ 4_p
attacks NNS 4_p
. . N

We PRP N
studied VBD N
the DT N
effect NN N
of IN N
acetylsalicylic JJ N
acid NN N
( ( N
ASA NNP N
) ) N
versus NN N
placebo NN N
on IN N
B-thromboglobulin NNP N
( ( N
B-TG NNP N
) ) N
and CC N
platelet JJ N
factor NN N
4 CD N
( ( N
PF4 NNP N
) ) N
plasma NN N
levels NNS N
and CC N
ADP-induced NNP N
platelet NN N
aggregation NN N
in IN N
25 CD 3_p
male JJ 2_p
patients NNS N
with IN N
transient JJ 4_p
ischaemic JJ 4_p
attacks NNS 4_p
( ( N
TIA NNP 4_p
) ) N
. . N

The DT N
patients NNS N
were VBD N
allocated VBN N
randomly RB N
to TO N
two CD N
groups NNS N
: : N
14 CD N
patients NNS N
received JJ N
oral JJ N
treatment NN N
with IN N
ASA NNP N
500 CD N
mg NN N
b.i.d NN N
. . N

for IN N
14 CD N
days NNS N
, , N
11 CD N
patients NNS N
placebo JJ N
b.i.d NN N
. . N

for IN N
the DT N
same JJ N
period NN N
. . N

B-TG NNP N
and CC N
PF4 NNP N
plasma NN N
levels NNS N
and CC N
ADP-induced NNP N
platelet NN N
aggregation NN N
were VBD N
determined VBN N
in IN N
basal NN N
conditions NNS N
, , N
and CC N
two CD N
hours NNS N
, , N
and CC N
seven CD N
and CC N
fourteen JJ N
days NNS N
after IN N
starting VBG N
with IN N
ASA NNP N
or CC N
placebo NN N
. . N

In IN N
addition NN N
, , N
the DT N
same JJ N
parameters NNS N
were VBD N
studied VBN N
in IN N
a DT N
group NN N
of IN N
20 CD 3_p
healthy JJ 4_p
males NNS 2_p
of IN N
matched JJ N
age NN N
. . N

Basal NNP N
levels NNS N
of IN N
plasma JJ N
B-TG NNP N
and CC N
PF4 NNP N
and CC N
the DT N
maximal JJ N
amplitude NN N
of IN N
ADP-induced NNP N
platelet NN N
aggregation NN N
were VBD N
abnormally RB N
high JJ N
in IN N
TIA NNP N
patients NNS N
. . N

ASA NNP N
caused VBD N
a DT N
significant JJ N
reduction NN N
of IN N
B-TG NNP N
plasma NN N
levels NNS N
in IN N
TIA NNP N
patients NNS N
2 CD N
hours NNS N
after IN N
the DT N
first JJ N
administration NN N
, , N
but CC N
no DT N
effect NN N
was VBD N
observed VBN N
at IN N
the DT N
7th CD N
and CC N
14th CD N
day NN N
of IN N
treatment NN N
. . N

PF4 NNP N
plasma NN N
levels NNS N
were VBD N
unaffected VBN N
by IN N
ASA NNP N
treatment NN N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
ASA NNP N
, , N
at IN N
the DT N
dose NN N
conventionally RB N
used VBN N
in IN N
clinical JJ N
trials NNS N
, , N
does VBZ N
not RB N
affect VB N
the DT N
release NN N
of IN N
two CD N
alpha-granule JJ N
proteins NNS N
. . N

-DOCSTART- -X- O O

Effect NNP N
of IN N
four CD N
intermediate JJ N
layer NN N
treatments NNS N
on IN N
microleakage NN 4_p
of IN N
Class NNP 4_p
II NNP 4_p
composite JJ 4_p
restorations NNS 4_p
. . N

This DT N
in IN N
vitro NN N
study NN N
examines VBZ N
the DT N
marginal JJ N
sealing NN N
ability NN N
of IN N
four CD N
different JJ N
intermediate JJ N
materials NNS N
applied VBN N
before IN N
placement NN N
of IN N
a DT N
condensable JJ N
composite NN N
. . N

Class NNP 4_p
II NNP 4_p
preparations NNS 4_p
were VBD N
made VBN N
with IN N
gingival JJ N
margins NNS N
placed VBD N
1.0 CD N
mm JJ N
apical JJ N
to TO N
the DT N
cementoenamel JJ N
junction NN N
of IN N
60 CD 3_p
extracted JJ 4_p
teeth NNS 4_p
, , N
randomly RB N
assigned VBN N
to TO N
five CD N
groups NNS N
of IN N
12 CD 3_p
. . N

Following VBG N
restoration NN N
, , N
teeth EX N
were VBD N
thermocycled VBN N
, , N
soaked VBN N
in IN N
0.5 CD N
% NN N
basic JJ N
fuchsin NN N
, , N
and CC N
sectioned VBD N
longitudinally RB N
. . N

The DT N
resin-modified JJ N
glass NN N
ionomer NN N
cement NN N
demonstrated VBD N
significantly RB N
less JJR N
microleakage NN N
than IN N
the DT N
use NN N
of IN N
a DT N
dentin NN N
bonding NN N
agent NN N
alone RB N
or CC N
in IN N
combination NN N
with IN N
flowable JJ N
composite JJ N
, , N
flowable JJ N
compomer NN N
, , N
or CC N
autoploymerizing VBG N
composite JJ N
( ( N
p JJ N
< NN N
0.05 CD N
, , N
Dunn NNP N
's POS N
test NN N
) ) N
. . N

This DT N
study NN N
supports VBZ N
the DT N
use NN N
of IN N
the DT N
glass NN N
ionomer NN N
open JJ N
sandwich NN N
technique NN N
in IN N
deep JJ 4_p
Class NNP 4_p
II NNP 4_p
direct JJ 4_p
composite JJ 4_p
restorations NNS 4_p
. . N

-DOCSTART- -X- O O

The DT N
influence NN N
of IN N
dietary JJ N
fibre NN N
source NN N
and CC N
gender NN N
on IN N
the DT N
postprandial JJ N
glucose NN N
and CC N
lipid JJ N
response NN N
in IN N
healthy JJ 4_p
subjects NNS N
. . N

BACKGROUND NNP N
Consumption NNP N
of IN N
soluble JJ N
dietary JJ N
fibre NN N
is VBZ N
correlated VBN N
with IN N
decreased JJ N
postprandial JJ N
glucose NN N
and CC N
insulin NN N
responses NNS N
and CC N
hence NN N
has VBZ N
beneficial JJ N
effects NNS N
on IN N
the DT N
metabolic JJ N
syndrome NN N
. . N

AIM NNP N
OF IN N
THE NNP N
STUDY NNP N
To TO N
investigate VB N
the DT N
effects NNS N
on IN N
postprandial JJ N
glucose NN N
, , N
insulin NN N
and CC N
triglyceride JJ N
concentrations NNS N
of IN N
meals NNS N
enriched VBN N
with IN N
soluble JJ N
dietary JJ N
fibres NNS N
from IN N
oats NNS N
, , N
rye NN N
bran NN N
, , N
sugar JJ N
beet NN N
fibre NN N
or CC N
a DT N
mixture NN N
of IN N
these DT N
three CD N
fibres NNS N
. . N

METHODS NNP N
Thirteen NNP 3_p
healthy JJ N
human JJ N
volunteers NNS N
( ( N
6 CD 2_p
men NNS 2_p
and CC 2_p
7 CD 2_p
women NNS 2_p
, , N
aged VBN N
20-28 CD 1_p
years NNS N
) ) N
were VBD N
included VBN N
in IN N
the DT N
study NN N
. . N

The DT N
subjects NNS N
came VBD N
to TO N
the DT N
study NN N
centre NN N
once RB N
a DT N
week NN N
after IN N
an DT N
overnight JJ N
fast NN N
to TO N
ingest VB N
test NN N
meals NNS N
and CC N
a DT N
control NN N
meal NN N
in IN N
random JJ N
order NN N
. . N

The DT N
meals NNS N
contained VBD N
either CC N
oat JJ N
powder NN N
( ( N
62 CD N
g NN N
, , N
of IN N
which WDT N
2.7 CD N
soluble JJ N
fibre NN N
) ) N
, , N
rye NN N
bran NN N
( ( N
31 CD N
g NN N
, , N
of IN N
which WDT N
1.7 CD N
g NN N
soluble JJ N
fibre NN N
) ) N
, , N
sugar JJ N
beet NN N
fibre NN N
( ( N
19 CD N
g NN N
, , N
of IN N
which WDT N
5 CD N
g NN N
soluble JJ N
fibre NN N
) ) N
, , N
a DT N
mixture NN N
of IN N
these DT N
three CD N
fibres NNS N
( ( N
74 CD N
g NN N
, , N
of IN N
which WDT N
1.7 CD N
g NN N
soluble JJ N
fibre NN N
from IN N
each DT N
source NN N
, , N
giving VBG N
5 CD N
g NN N
soluble JJ N
fibre NN N
) ) N
or CC N
no DT N
added JJ N
fibre NN N
( ( N
control NN N
) ) N
and CC N
were VBD N
all DT N
adjusted VBN N
to TO N
contain VB N
the DT N
same JJ N
total JJ N
amount NN N
of IN N
available JJ N
carbohydrates NNS N
. . N

Blood NN N
samples NNS N
were VBD N
drawn VBN N
before RB N
and CC N
every DT N
30 CD N
min NN N
up RB N
to TO N
180 CD N
min NN N
after IN N
the DT N
meals NNS N
. . N

RESULTS NNP N
Meals NNP N
with IN N
rye NN N
bran NN N
gave VBD N
a DT N
lower JJR N
postprandial JJ N
glucose NN N
peak NN N
when WRB N
compared VBN N
with IN N
the DT N
control NN N
meal NN N
, , N
and CC N
this DT N
effect NN N
was VBD N
more RBR N
pronounced JJ N
in IN N
women NNS N
compared VBN N
to TO N
men NNS N
. . N

Oat NNP N
powder NN N
, , N
containing VBG N
a DT N
low JJ N
amount NN N
of IN N
total JJ N
fibre NN N
and CC N
a DT N
high JJ N
amount NN N
of IN N
carbohydrates NNS N
in IN N
liquid NN N
matrix NN N
, , N
gave VBD N
a DT N
higher JJR N
incremental JJ N
glucose JJ N
peak NN N
concentration NN N
compared VBN N
to TO N
rye VB N
bran NN N
and CC N
sugar NN N
beet NN N
fibre NN N
and CC N
higher JJR N
insulin NN N
incremental JJ N
area NN N
under IN N
curve NN N
compared VBN N
to TO N
control VB N
. . N

The DT N
oat NN N
powder NN N
also RB N
influenced VBD N
the DT N
effects NNS N
of IN N
the DT N
mixed JJ N
meal NN N
, , N
diminishing VBG N
the DT N
glucose-lowering JJ N
effects NNS N
. . N

Postprandial NNP N
triglyceride NN N
levels NNS N
tended VBD N
to TO N
be VB N
higher JJR N
after IN N
all DT N
fibre-rich JJ N
meals NNS N
, , N
but CC N
only RB N
significant JJ N
for IN N
oat NN N
powder NN N
and CC N
the DT N
mixed JJ N
meal NN N
when WRB N
compared VBN N
with IN N
the DT N
control NN N
meal NN N
. . N

CONCLUSIONS NNP N
Postprandial NNP N
glucose NN N
, , N
insulin NN N
and CC N
triglyceride JJ N
concentrations NNS N
are VBP N
influenced VBN N
by IN N
dietary JJ N
fibre-rich JJ N
meals NNS N
, , N
depending VBG N
on IN N
fibre NN N
source NN N
, , N
dose NN N
of IN N
soluble JJ N
and CC N
total JJ N
fibre NN N
and CC N
possibly RB N
gender NN N
. . N

-DOCSTART- -X- O O

Nitrous JJ N
oxide JJ N
diffusion NN N
into IN N
tracheal JJ N
tube JJ N
cuffs NNS N
-- : N
efficacy NN N
of IN N
a DT N
new JJ N
prototype NN N
cuff NN N
pressure NN N
release NN N
valve NN N
. . N

BACKGROUND IN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
performance NN N
of IN N
a DT N
new JJ N
cuff NN N
pressure NN N
release NN N
valve NN N
( ( N
CPRV NNP N
) ) N
, , N
in IN N
which WDT N
the DT N
release NN N
pressure NN N
can MD N
be VB N
adjusted VBN N
from IN N
10 CD N
to TO N
25 CD N
cmH2O NNS N
, , N
particularly RB N
intended VBN N
to TO N
control VB N
pressure NN N
in IN N
paediatric JJ 1_p
cuffed NN 4_p
tracheal NN 4_p
tubes NNS 4_p
and CC N
to TO N
avoid VB N
cuff NN N
hyperinflation NN N
caused VBN N
by IN N
N2O NNP N
diffusion NN N
. . N

METHODS NNP N
In IN N
vitro NN N
: : N
the DT N
PRV NNP N
was VBD N
set VBN N
to TO N
10 CD N
, , N
15 CD N
, , N
20 CD N
or CC N
25 CD N
cmH2O JJ N
release NN N
pressure NN N
and CC N
connected VBN N
to TO N
a DT N
cuffed NN N
tube NN N
placed VBD N
into IN N
a DT N
box NN N
flushed VBN N
with IN N
66 CD N
% NN N
N2O NNP N
in IN N
O2 NNP N
. . N

The DT N
cuff NN N
pressure NN N
was VBD N
monitored VBN N
with IN N
and CC N
without IN N
CPRV NNP N
for IN N
60 CD N
min NN N
. . N

Experiments NNS N
were VBD N
performed VBN N
four CD N
times NNS N
using VBG N
two CD N
different JJ N
CPRVs NNP N
. . N

In IN N
vivo NN N
: : N
with IN N
Institutional NNP N
Review NNP N
Board NNP N
approval NN N
, , N
CPRV NNP N
was VBD N
studied VBN N
in IN N
50 CD 3_p
children NNS 1_p
undergoing VBG N
general JJ 4_p
anaesthesia NN 4_p
with IN 4_p
tracheal JJ 4_p
intubation NN 4_p
and CC N
standardized JJ 4_p
anaesthesia NN 4_p
technique NN 4_p
( ( N
including VBG N
66 CD N
% NN N
N2O NNP N
in IN N
O2 NNP N
) ) N
and CC N
ventilator JJ 4_p
settings NNS 4_p
. . N

Patients NNS N
were VBD N
randomized VBN N
into IN N
two CD N
groups NNS N
( ( N
with IN N
and CC N
without IN N
CPRV NNP N
) ) N
. . N

The DT N
cuff JJ N
pressure NN N
baseline NN N
was VBD N
20 CD N
cmH2O NN N
and CC N
CPRV NNP N
was VBD N
set VBN N
to TO N
25 CD N
cmH2O NN N
. . N

If IN N
the DT N
cuff NN N
pressure NN N
exceeded VBD N
25 CD N
cmH2O NN N
, , N
it PRP N
was VBD N
manually RB N
released VBN N
to TO N
20 CD N
cmH2O NN N
. . N

The DT N
numbers NNS N
of IN N
deflations NNS N
in IN N
both DT N
groups NNS N
were VBD N
noted VBN N
and CC N
compared VBN N
by IN N
Mann-Whitney NNP N
U-test NNP N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

RESULTS NNP N
In IN N
vitro NN N
: : N
the DT N
cuff NN N
pressure NN N
exceeded VBD N
50 CD N
cmH2O NN N
after IN N
60 CD N
min NN N
without IN N
CPRV NNP N
, , N
but CC N
did VBD N
not RB N
exceed VB N
the DT N
settings NNS N
with IN N
CPRV NNP N
. . N

In IN N
vivo NN N
: : N
there EX N
was VBD N
no DT N
need NN N
to TO N
manually RB N
deflate VB N
the DT N
cuff NN N
in IN N
the DT N
CPRV NNP N
group NN N
but CC N
, , N
in IN N
every DT N
patient NN N
in IN N
the DT N
control NN N
group NN N
, , N
three CD N
( ( N
two CD N
to TO N
seven CD N
) ) N
deflating VBG N
manoeuvres NNS N
were VBD N
required VBN N
within IN N
the DT N
first JJ N
hour NN N
of IN N
anaesthesia NN N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

CONCLUSION VB N
The DT N
CPRV NNP N
allows VBZ N
reliable JJ N
cuff NN N
pressure NN N
release NN N
at IN N
various JJ N
pressure NN N
levels NNS N
and CC N
reliably RB N
prevents NNS N
cuff JJ N
pressure NN N
increases NNS N
caused VBN N
by IN N
N2O NNP N
. . N

-DOCSTART- -X- O O

Rationale NNP N
and CC N
design NN N
of IN N
RE-LY NNP N
: : N
randomized JJ N
evaluation NN N
of IN N
long-term JJ N
anticoagulant JJ N
therapy NN N
, , N
warfarin NN N
, , N
compared VBN N
with IN N
dabigatran NN N
. . N

Vitamin NNP N
K NNP N
antagonists NNS N
( ( N
VKAs NNP N
) ) N
are VBP N
effective JJ N
for IN N
stroke NN N
prevention NN N
in IN N
patients NNS N
with IN N
atrial JJ 4_p
fibrillation NN 4_p
( ( N
AF NNP 4_p
) ) N
but CC N
are VBP N
difficult JJ N
to TO N
use VB N
. . N

Dabigatran NNP N
etexilate NN N
is VBZ N
a DT N
prodrug NN N
that WDT N
is VBZ N
rapidly RB N
converted VBN N
to TO N
the DT N
active JJ N
direct JJ N
thrombin NN N
inhibitor NN N
dabigatran NN N
. . N

It PRP N
is VBZ N
administered VBN N
in IN N
a DT N
fixed JJ N
dose NN N
without IN N
laboratory JJ N
monitoring NN N
and CC N
is VBZ N
being VBG N
compared VBN N
with IN N
warfarin NN N
( ( N
international JJ N
normalized VBN N
ratio JJ N
2-3 JJ N
) ) N
in IN N
the DT N
RE-LY JJ N
trial NN N
. . N

Two CD N
doses NNS N
of IN N
dabigatran NN N
( ( N
110 CD N
and CC N
150 CD N
mg NNS N
BID NNP N
) ) N
are VBP N
being VBG N
evaluated VBN N
. . N

RE-LY NNP N
is VBZ N
a DT N
phase NN N
3 CD N
, , N
prospective JJ N
, , N
randomized VBN N
, , N
open-label JJ N
multinational NN N
( ( N
44 CD N
countries NNS N
) ) N
trial NN N
of IN N
patients NNS N
with IN N
nonvalvular JJ 4_p
AF NNP 4_p
and CC N
at IN N
least JJS N
1 CD N
risk NN N
factor NN N
for IN N
stroke NN N
. . N

Recruitment NNP N
concluded VBD N
with IN N
a DT N
total NN N
of IN N
18,113 CD 3_p
patients NNS N
. . N

Patients NNS N
who WP N
were VBD N
VKA-naive NNP N
and CC N
experienced VBN N
are VBP N
included VBN N
in IN N
balanced JJ N
proportions NNS N
. . N

The DT N
primary JJ N
outcome NN N
is VBZ N
stroke VBN N
( ( N
including VBG N
hemorrhagic NN N
) ) N
or CC N
systemic JJ N
embolism NN N
. . N

Safety NNP N
outcomes NNS N
are VBP N
bleeding VBG N
, , N
liver JJ N
function NN N
abnormalities NNS N
, , N
and CC N
other JJ N
adverse JJ N
events NNS N
. . N

Adjudication NN N
of IN N
end NN N
points NNS N
is VBZ N
blinded VBN N
to TO N
drug NN N
assignment NN N
. . N

The DT N
trial NN N
is VBZ N
expected VBN N
to TO N
accrue VB N
a DT N
minimum NN N
of IN N
450 CD N
events NNS N
with IN N
a DT N
minimum JJ N
1-year JJ N
of IN N
follow-up JJ N
. . N

RE-LY NN N
is VBZ N
the DT N
largest JJS N
AF NNP N
stroke VBD N
prevention NN N
trial NN N
yet RB N
undertaken VBN N
. . N

It PRP N
is VBZ N
unique JJ N
because IN N
it PRP N
includes VBZ N
equal JJ N
numbers NNS N
of IN N
VKA-experienced NNP N
and CC N
naive JJ N
patients NNS N
and CC N
evaluates VBZ N
2 CD N
different JJ N
dosages NNS N
of IN N
dabigatran NN N
, , N
which WDT N
may MD N
allow VB N
tailoring NN N
of IN N
dosing VBG N
to TO N
individual JJ N
patient NN N
needs NNS N
. . N

The DT N
worldwide JJ N
site NN N
distribution NN N
and CC N
broad JJ N
range NN N
of IN N
stroke NN N
risk NN N
further RBR N
increase VB N
the DT N
general JJ N
applicability NN N
of IN N
the DT N
trial NN N
. . N

Results NNS N
are VBP N
expected VBN N
in IN N
2009 CD N
. . N

-DOCSTART- -X- O O

How WRB N
to TO N
establish VB N
equivalence NN N
when WRB N
data NNS N
are VBP N
censored VBN N
: : N
a DT N
randomized JJ N
trial NN N
of IN N
treatments NNS N
for IN N
B NNP 4_p
non-Hodgkin JJ 4_p
lymphoma NN 4_p
. . N

Interest NN N
in IN N
equivalence NN N
trials NNS N
has VBZ N
been VBN N
increasing VBG N
for IN N
many JJ N
years NNS N
, , N
though IN N
the DT N
methodology NN N
which WDT N
has VBZ N
been VBN N
developed VBN N
for IN N
such JJ N
trials NNS N
is VBZ N
mainly RB N
for IN N
uncensored JJ N
data NNS N
. . N

In IN N
cancer NN N
research NN N
we PRP N
are VBP N
more RBR N
often RB N
concerned VBN N
with IN N
survival NN N
. . N

In IN N
an DT N
efficacy NN N
trial NN N
, , N
the DT N
null JJ N
hypothesis NN N
specifies NNS N
equality NN N
of IN N
the DT N
two CD N
survival JJ N
distributions NNS N
, , N
but CC N
in IN N
an DT N
equivalence NN N
trial NN N
, , N
a DT N
null JJ N
hypothesis NN N
of IN N
inequivalence NN N
H0 NNP N
has VBZ N
to TO N
be VB N
tested VBN N
. . N

The DT N
usual JJ N
logrank NN N
test NN N
has VBZ N
to TO N
be VB N
modified VBN N
to TO N
test VB N
whether IN N
the DT N
true JJ N
value NN N
r NN N
of IN N
the DT N
ratio NN N
of IN N
hazard NN N
rates NNS N
in IN N
two CD N
treatment NN N
groups NNS N
is VBZ N
at IN N
least JJS N
equal JJ N
to TO N
a DT N
limit NN N
value NN N
r0 NN N
. . N

If IN N
prognostic JJ N
factors NNS N
have VBP N
to TO N
be VB N
taken VBN N
into IN N
account NN N
, , N
the DT N
Cox NNP N
model NN N
provides VBZ N
tests NNS N
of IN N
Ho NNP N
, , N
and CC N
a DT N
useful JJ N
confidence NN N
interval NN N
for IN N
the DT N
adjusted JJ N
relative JJ N
derived VBN N
from IN N
the DT N
regression NN N
parameter NN N
for IN N
the DT N
treatment NN N
indicator NN N
. . N

An DT N
equivalence NN N
trial NN N
of IN N
maintenance NN N
therapy NN N
was VBD N
carried VBN N
out RP N
in IN N
children NNS 1_p
with IN N
B NNP 4_p
non-Hodgkin JJ 4_p
lymphoma NN 4_p
, , N
and CC N
serves VBZ N
as IN N
an DT N
illustration NN N
. . N

-DOCSTART- -X- O O

Intranasal NNP N
nicotine NN N
for IN N
postoperative JJ 4_p
pain NN 4_p
treatment NN N
. . N

BACKGROUND NNP N
Despite IN N
pharmacological JJ N
treatment NN N
, , N
70-80 CD N
% NN N
of IN N
patients NNS N
report NN N
moderate VBP N
to TO N
severe VB N
pain NN N
after IN N
surgery NN N
. . N

Because IN N
nicotine NN N
has VBZ N
been VBN N
reported VBN N
to TO N
have VB N
analgesic JJ N
properties NNS N
in IN N
animal NN N
and CC N
human JJ N
volunteer NN N
studies NNS N
, , N
the DT N
authors NNS N
assessed VBD N
the DT N
analgesic JJ N
efficacy NN N
of IN N
a DT N
single JJ N
3 CD N
mg NN N
dose NN N
of IN N
nicotine JJ N
nasal NN N
spray NN N
administered VBD N
before IN N
emergence NN N
from IN N
general JJ N
anesthesia NN N
. . N

METHODS NNP N
The DT N
authors NNS N
conducted VBD N
a DT N
randomized VBN N
, , N
double JJ N
blind NN N
, , N
placebo NN N
controlled VBD N
trial NN N
of IN N
20 CD 3_p
healthy JJ 4_p
women NNS 2_p
( ( N
mean JJ N
age NN N
45 CD 1_p
( ( N
SD NNP N
8 CD N
) ) N
yr NN N
) ) N
who WP N
were VBD N
to TO N
undergo VB N
uterine JJ 4_p
surgery NN 4_p
through IN N
a DT N
low JJ 4_p
transverse NN 4_p
incision NN 4_p
. . N

After IN N
the DT N
conclusion NN N
of IN N
surgery NN N
but CC N
before IN N
emergence NN N
from IN N
general JJ N
anesthesia NN N
, , N
the DT N
anesthesiologist NN N
administered VBD N
either CC N
nicotine JJ N
nasal NN N
spray NN N
or CC N
a DT N
placebo NN N
. . N

Numerical JJ N
analog NN N
pain NN N
score NN N
and CC N
morphine JJ N
utilization NN N
and CC N
hemodynamic JJ N
values NNS N
were VBD N
measured VBN N
for IN N
24 CD N
h. NN N
RESULTS NNP N
The DT N
patients NNS N
treated VBN N
with IN N
nicotine NN N
reported VBN N
lower JJR N
pain NN N
scores NNS N
during IN N
the DT N
first JJ N
hour NN N
after IN N
surgery NN N
( ( N
peak JJ N
numerical JJ N
analog NN N
score NN N
, , N
7.6 CD N
( ( N
SD NNP N
1.4 CD N
) ) N
versus NN N
5.3 CD N
( ( N
SD NNP N
1.6 CD N
) ) N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
used VBN N
half PDT N
the DT N
amount NN N
of IN N
morphine NN N
as IN N
the DT N
control NN N
group NN N
( ( N
12 CD N
( ( N
SD NNP N
6 CD N
) ) N
versus NN N
6 CD N
( ( N
SD NNP N
5 CD N
) ) N
mg NN N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Patients NNPS N
who WP N
received VBD N
nicotine NN N
still RB N
reported VBD N
less RBR N
pain NN N
than IN N
those DT N
in IN N
the DT N
control NN N
group NN N
24 CD N
h NN N
after IN N
surgery NN N
( ( N
1.5 CD N
( ( N
SD NNP N
0.5 CD N
) ) N
versus NN N
4.9 CD N
( ( N
SD NNP N
1.4 CD N
) ) N
; : N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Systolic JJ N
blood NN N
pressure NN N
was VBD N
lower JJR N
in IN N
the DT N
group NN N
that WDT N
received VBD N
nicotine JJ N
( ( N
105 CD N
( ( N
SD NNP N
3 CD N
) ) N
versus NN N
122 CD N
( ( N
SD NNP N
3 CD N
) ) N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
but CC N
there EX N
was VBD N
no DT N
difference NN N
in IN N
diastolic JJ N
blood NN N
pressure NN N
or CC N
heart NN N
rate NN N
. . N

CONCLUSIONS NNP N
Treatment NNP N
with IN N
a DT N
single JJ N
dose NN N
of IN N
nicotine JJ N
immediately RB N
before IN N
emergence NN N
from IN N
anesthesia NN N
was VBD N
associated VBN N
with IN N
significantly RB N
lower JJR N
reported VBD N
pain JJ N
scores NNS N
during IN N
the DT N
first JJ N
day NN N
after IN N
surgery NN N
. . N

The DT N
decreased JJ N
pain NN N
was VBD N
associated VBN N
with IN N
a DT N
reduction NN N
in IN N
morphine JJ N
utilization NN N
and CC N
the DT N
analgesic JJ N
effect NN N
of IN N
nicotine NN N
was VBD N
not RB N
associated VBN N
with IN N
hypertension NN N
or CC N
tachycardia NN N
. . N

-DOCSTART- -X- O O

Is VBZ N
chronic JJ N
sildenafil NN N
therapy NN N
safe JJ N
and CC N
clinically RB N
beneficial JJ N
in IN N
patients NNS N
with IN N
systolic JJ 4_p
heart NN 4_p
failure NN 4_p
? . N
Sildenafil NNP N
is VBZ N
a DT N
selective JJ N
phosphodiesterase-5 JJ N
inhibitor NN N
and CC N
causes VBZ N
vasodilatation NN N
, , N
particularly RB N
in IN N
pulmonary JJ N
circulation NN N
. . N

Since IN N
left JJ 4_p
heart NN 4_p
failure NN 4_p
may MD N
be VB N
associated VBN N
with IN N
pulmonary JJ N
hypertension NN N
out IN N
of IN N
proportion NN N
to TO N
left VB N
heart NN N
disease NN N
, , N
sildenafil NN N
may MD N
have VB N
beneficial JJ N
effect NN N
in IN N
such JJ N
patients NNS N
. . N

The DT N
present JJ N
investigation NN N
was VBD N
designed VBN N
as IN N
a DT N
12-week JJ N
, , N
single-center JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
evaluating VBG N
the DT N
effects NNS N
of IN N
sildenafil NN N
on IN N
mean JJ N
blood NN N
pressure NN N
( ( N
primary JJ N
endpoint NN N
) ) N
in IN N
patients NNS N
with IN N
left JJ 4_p
systolic JJ 4_p
heart NN 4_p
failure NN 4_p
. . N

Secondary JJ N
endpoints NNS N
included VBD N
exercise NN N
capacity NN N
assessed VBN N
by IN N
6-minute JJ N
walk NN N
test NN N
. . N

A DT N
total NN N
of IN N
106 CD 3_p
patients NNS N
were VBD N
randomized VBN N
1:1 CD N
to TO N
sildenafil VB N
( ( N
n=53 NN 3_p
) ) N
or CC N
placebo NN N
( ( N
n=53 JJ 3_p
) ) N
. . N

Patients NNS N
received VBD N
sildenafil JJ N
25 CD N
mg NN N
twice RB N
a DT N
day NN N
or CC N
matching VBG N
placebo NN N
for IN N
the DT N
first JJ N
2 CD N
weeks NNS N
and CC N
50 CD N
mg NN N
3 CD N
times NNS N
a DT N
week NN N
for IN N
the DT N
remainder NN N
of IN N
the DT N
trial NN N
. . N

The DT N
placebo-corrected JJ N
effect NN N
on IN N
mean JJ N
blood NN N
pressure NN N
was VBD N
1.16 CD N
mm NN N
Hg NNP N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
-1.6 VBP N
to TO N
5.1 CD N
, , N
P NNP N
> NNP N
.05 NNP N
) ) N
, , N
demonstrating VBG N
that IN N
sildenafil NN N
did VBD N
not RB N
decrease VB N
mean JJ N
blood NN N
pressure NN N
. . N

Compared VBN N
with IN N
placebo NN N
, , N
sildenafil NN N
increased VBD N
the DT N
6-minute JJ N
walk NN N
test NN N
by IN N
a DT N
nonsignificant JJ N
treatment NN N
effect NN N
of IN N
14 CD N
m NN N
( ( N
P=.67 NNP N
) ) N
. . N

Adverse JJ N
effects NNS N
occurred VBD N
in IN N
a DT N
comparable JJ N
proportion NN N
of IN N
patients NNS N
taking VBG N
sildenafil JJ N
and CC N
placebo NN N
, , N
and CC N
none NN N
of IN N
the DT N
patients NNS N
needed VBN N
to TO N
discontinue VB N
therapy NN N
. . N

Sildenafil NNP N
is VBZ N
well RB N
tolerated VBN N
in IN N
left JJ N
heart NN N
failure NN N
patients NNS N
and CC N
does VBZ N
not RB N
decrease VB N
blood NN N
pressure NN N
. . N

It PRP N
can MD N
be VB N
safely RB N
added VBN N
to TO N
standard VB N
heart NN N
failure NN N
therapy NN N
. . N

-DOCSTART- -X- O O

Long RB N
pediatric JJ N
colonoscope NN N
versus NN N
intermediate JJ N
length NN N
adult NN N
colonoscope NN N
for IN N
colonoscopy NN N
. . N

BACKGROUND NNP N
Controversy NNP N
exists VBZ N
on IN N
how WRB N
the DT N
length NN N
and CC N
diameter NN N
of IN N
colonoscopes NNS N
affect VBP N
the DT N
quality NN N
of IN N
colonoscopy NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
a DT N
long JJ N
pediatric JJ N
colonoscope NN N
with IN N
an DT N
intermediate JJ N
length NN N
adult NN N
colonoscope NN N
with IN N
regards NNS N
to TO N
completion NN N
rate NN N
and CC N
cecal JJ N
intubation NN N
time NN N
. . N

Whether CC N
either DT N
scope NN N
may MD N
be VB N
more RBR N
efficient JJ N
in IN N
any DT N
subgroups NN N
was VBD N
also RB N
investigated VBN N
. . N

METHODS NNP N
Asymptomatic JJ 4_p
patients NNS N
admitted VBN N
to TO N
the DT N
physical JJ N
check-up JJ N
department NN N
of IN N
Buddhist NNP N
Dalin NNP N
Tzu NNP N
Chi NNP N
General NNP N
Hospital NNP N
were VBD N
included VBN N
. . N

A DT N
single JJ N
endoscopist NN N
performed VBD N
all DT N
of IN N
the DT N
colonoscopic NN N
examinations NNS N
under IN N
sedation NN N
. . N

Consecutive JJ N
patients NNS N
were VBD N
randomized VBN N
to TO N
undergo VB N
colonoscopy NN N
with IN N
either DT N
intermediate JJ N
length NN N
adult NN N
colonoscope NN N
( ( N
CF-240I NNP N
) ) N
or CC N
long JJ N
pediatric JJ N
colonoscope NN N
( ( N
PCF-240L NNP N
) ) N
. . N

The DT N
success NN N
rate NN N
and CC N
time NN N
required VBN N
to TO N
reach VB N
cecum NN N
were VBD N
compared VBN N
between IN N
the DT N
two CD N
groups NNS N
. . N

RESULTS NNP N
Between NNP N
April NNP N
2005 CD N
and CC N
February NNP N
2006 CD N
, , N
a DT N
total NN N
of IN N
918 CD 3_p
patients NNS N
were VBD N
enrolled VBN N
. . N

Incomplete NNP N
colonoscopy NN N
occurred VBD N
in IN N
21 CD N
( ( N
2.3 CD N
% NN N
) ) N
cases NNS N
( ( N
14 CD N
in IN N
the DT N
CF-240I NNP N
group NN N
and CC N
seven CD N
in IN N
the DT N
PCF-240L NNP N
group NN N
, , N
P NNP N
> NNP N
0.1 CD N
) ) N
. . N

The DT N
overall JJ N
cecal JJ N
mean NN N
insertion NN N
time NN N
was VBD N
6.00 CD N
+/- JJ N
3.66 CD N
min NN N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
CF-240I NNP N
and CC N
PCF NNP N
240L CD N
groups NNS N
with IN N
regard NN N
to TO N
the DT N
cecal JJ N
intubation NN N
rate NN N
( ( N
96.9 CD N
% NN N
vs JJ N
98.5 CD N
% NN N
, , N
P NNP N
= NNP N
0.18 CD N
) ) N
, , N
the DT N
need NN N
for IN N
abdominal JJ N
pressure NN N
( ( N
71.7 CD N
% NN N
vs JJ N
73.4 CD N
% NN N
, , N
P NNP N
= NNP N
0.55 CD N
) ) N
and CC N
change NN N
of IN N
position NN N
( ( N
13.5 CD N
% NN N
vs JJ N
11.5 CD N
% NN N
, , N
P NNP N
= NNP N
0.37 CD N
) ) N
. . N

However RB N
, , N
the DT N
cecal JJ N
intubation NN N
time NN N
was VBD N
shorter RBR N
in IN N
the DT N
CF-240I NNP N
group NN N
( ( N
5.75 CD N
+/- JJ N
3.18 CD N
vs JJ N
6.26 CD N
+/- JJ N
3.30 CD N
min NN N
, , N
P NNP N
= NNP N
0.02 CD N
) ) N
. . N

Subgroup NNP N
analysis NN N
by IN N
sex NN N
, , N
age NN N
, , N
and CC N
body NN N
mass NN N
index NN N
showed VBD N
comparable JJ N
outcomes NNS N
between IN N
the DT N
two CD N
groups NNS N
except IN N
that IN N
the DT N
cecal JJ N
intubation NN N
times NNS N
were VBD N
significantly RB N
shorter JJR N
in IN N
the DT N
CF-240I NNP N
group NN N
when WRB N
only RB N
men NNS N
( ( N
4.78 CD N
+/- JJ N
2.57 CD N
vs JJ N
5.50 CD N
+/- JJ N
2.93 CD N
min NN N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
or CC N
those DT N
younger JJR N
than IN N
50 CD N
years NNS N
( ( N
5.50 CD N
+/- JJ N
2.90 CD N
vs JJ N
6.25 CD N
+/- JJ N
3.68 CD N
min NN N
, , N
P NNP N
= NNP N
0.02 CD N
) ) N
were VBD N
considered VBN N
. . N

CONCLUSION NNP N
Cecal NNP N
intubation NN N
time NN N
is VBZ N
shorter RBR N
in IN N
patients NNS N
examined VBN N
with IN N
an DT N
intermediate JJ N
length NN N
adult NN N
colonoscope NN N
, , N
mainly RB N
in IN N
the DT N
subgroups NNS N
of IN N
men NNS N
and CC N
those DT N
younger JJR N
than IN N
50 CD N
years NNS N
of IN N
age NN N
. . N

-DOCSTART- -X- O O

Docosahexaenoic NNP N
acid-rich JJ N
fish JJ N
oil NN N
modulates VBZ N
the DT N
cerebral JJ N
hemodynamic JJ N
response NN N
to TO N
cognitive JJ N
tasks NNS N
in IN N
healthy JJ 4_p
young JJ 1_p
adults NNS 1_p
. . N

A DT N
number NN N
of IN N
recent JJ N
studies NNS N
have VBP N
assessed VBN N
the DT N
impact NN N
of IN N
dietary JJ N
omega-3 JJ N
polyunsaturated VBN N
fatty JJ N
acids NNS N
( ( N
n-3 JJ N
PUFAs NNP N
) ) N
on IN N
behavioral JJ N
outcomes NNS N
; : N
however RB N
, , N
very RB N
little JJ N
attention NN N
has VBZ N
been VBN N
given VBN N
to TO N
their PRP$ N
impact NN N
upon IN N
brain NN N
function NN N
in IN N
physiological JJ N
terms NNS N
. . N

Sixty-five JJ 3_p
healthy JJ 4_p
adults NNS 1_p
aged VBD N
18-29yrs JJ 1_p
took VBD N
part NN N
in IN N
this DT N
double-blind NN N
, , N
placebo-controlled JJ N
study NN N
assessing VBG N
the DT N
effects NNS N
of IN N
12 CD N
weeks NNS N
daily RB N
dietary JJ N
supplementation NN N
with IN N
docosahexaenoic JJ N
acid-rich JJ N
fish JJ N
oil NN N
( ( N
1g CD N
, , N
2g CD N
) ) N
or CC N
placebo NN N
( ( N
olive JJ N
oil NN N
) ) N
. . N

Relative JJ N
changes NNS N
in IN N
the DT N
concentration NN N
of IN N
oxyhemoglobin NN N
and CC N
deoxyhemoglobin NN N
were VBD N
assessed VBN N
in IN N
the DT N
prefrontal JJ N
cortex NN N
using VBG N
near-infrared JJ N
spectroscopy NN N
during IN N
performance NN N
of IN N
nine CD N
computerized JJ N
cognitive JJ N
tasks NNS N
. . N

Supplementation NN N
with IN N
both DT N
doses NNS N
of IN N
fish JJ N
oil NN N
, , N
in IN N
comparison NN N
with IN N
placebo NN N
, , N
resulted VBD N
in IN N
significantly RB N
increased JJ N
concentrations NNS N
of IN N
oxyhemoglobin NN N
and CC N
total JJ N
levels NNS N
of IN N
hemoglobin NN N
, , N
indicative JJ N
of IN N
increased JJ N
cerebral JJ N
blood NN N
flow NN N
, , N
during IN N
the DT N
cognitive JJ N
tasks NNS N
. . N

Changes NNS N
in IN N
hemodynamic JJ N
response NN N
to TO N
tasks NNS N
were VBD N
not RB N
accompanied VBN N
by IN N
consistent JJ N
changes NNS N
in IN N
cognitive JJ N
performance NN N
. . N

-DOCSTART- -X- O O

The DT N
prophylactic JJ N
effect NN N
of IN N
valproate NN N
on IN N
glyceryltrinitrate NN N
induced VBN N
migraine NN 4_p
. . N

In IN N
this DT N
study NN N
the DT N
human JJ N
glyceryltrinitrate NN N
( ( N
GTN NNP N
) ) N
model NN N
of IN N
migraine NN N
was VBD N
for IN N
the DT N
first JJ N
time NN N
used VBN N
to TO N
test VB N
the DT N
effect NN N
of IN N
a DT N
prophylactic JJ N
drug NN N
. . N

We PRP N
chose VBD N
to TO N
test VB N
valproate NN N
due JJ N
to TO N
its PRP$ N
well RB N
documented JJ N
effect NN N
as IN N
a DT N
migraine JJ N
prophylactic JJ N
drug NN N
. . N

Efficacy NN N
of IN N
this DT N
compound NN N
would MD N
support VB N
the DT N
usefulness NN N
of IN N
the DT N
model NN N
in IN N
prophylactic JJ N
antimigraine JJ N
drug NN N
development NN N
. . N

Twelve CD 3_p
patients NNS N
with IN N
migraine NN 4_p
without IN 4_p
aura NN 4_p
were VBD N
included VBN N
in IN N
a DT N
randomized JJ N
double JJ N
blind NN N
crossover NN N
study NN N
. . N

Valproate VB N
1000 CD N
mg NN N
or CC N
placebo NN N
was VBD N
given VBN N
daily RB N
, , N
each DT N
for IN N
a DT N
minimum NN N
of IN N
13 CD N
days NNS N
. . N

On IN N
the DT N
last JJ N
treatment NN N
day NN N
of IN N
each DT N
arm NN N
a DT N
20 CD N
min NN N
intravenous JJ N
infusion NN N
of IN N
GTN NNP N
( ( N
0.25 CD N
microg/kg/min NN N
) ) N
was VBD N
given VBN N
. . N

Headache NNP N
was VBD N
registered VBN N
for IN N
12 CD N
h NN N
after IN N
the DT N
infusion NN N
and CC N
headache NN N
intensity NN N
was VBD N
scored VBN N
on IN N
a DT N
scale NN N
from IN N
0 CD N
to TO N
10 CD N
. . N

Fulfillment NN N
of IN N
IHS NNP N
criteria NNS N
was VBD N
recorded VBN N
for IN N
24 CD N
h. PDT N
The DT N
middle JJ N
cerebral JJ N
arteries NNS N
were VBD N
evaluated VBN N
by IN N
transcranial JJ N
Doppler NNP N
and CC N
the DT N
diameter NN N
of IN N
the DT N
superficial JJ N
temporal JJ N
and CC N
radial JJ N
arteries NNS N
were VBD N
measured VBN N
with IN N
high JJ N
frequency NN N
ultrasound NN N
. . N

GTN NNP N
evoked VBD N
migraine JJ N
fulfilling NN N
IHS NNP N
criteria NNS N
1.1 CD N
in IN N
6 CD N
patients NNS N
after IN N
placebo NN N
and CC N
in IN N
2 CD N
patients NNS N
after IN N
valproate NN N
( ( N
P NNP N
= NNP N
0.125 CD N
) ) N
. . N

Including VBG N
additionally RB N
3 CD N
patients NNS N
on IN N
placebo NN N
and CC N
1 CD N
patient NN N
on IN N
valproate NN N
who WP N
felt VBD N
they PRP N
had VBD N
suffered VBN N
a DT N
migraine JJ N
attack NN N
, , N
but CC N
who WP N
had VBD N
as IN N
associated VBN N
symptoms NNS N
only RB N
photophobia VBP N
or CC N
phonophobia VBP N
, , N
a DT N
significant JJ N
reduction NN N
in IN N
the DT N
number NN N
of IN N
patients NNS N
with IN N
induced JJ N
migraine NN N
after IN N
valproate NN N
was VBD N
seen VBN N
( ( N
P NNP N
= NNP N
0.031 CD N
) ) N
. . N

Median JJ N
peak NN N
headache NN N
intensity NN N
was VBD N
1 CD N
( ( N
range VB N
0-9 NN N
) ) N
after IN N
valproate NN N
compared VBN N
to TO N
4.5 CD N
( ( N
range VB N
0-8 NN N
) ) N
after IN N
placebo NN N
( ( N
P NNP N
= NNP N
0.120 CD N
) ) N
. . N

Pretreatment NN N
with IN N
valproate NN N
as IN N
compared VBN N
to TO N
placebo VB N
reduced VBN N
the DT N
velocity NN N
in IN N
both DT N
middle JJ N
cerebral NN N
arteries NNS N
after IN N
GTN NNP N
( ( N
left VBN N
P NNP N
= NNP N
0.021 CD N
, , N
right JJ N
P NNP N
= NNP N
0.031 CD N
) ) N
. . N

No DT N
effect NN N
of IN N
valproate NN N
was VBD N
seen VBN N
in IN N
the DT N
diameter NN N
of IN N
the DT N
superficial JJ N
temporal JJ N
artery NN N
( ( N
P NNP N
= NNP N
0.781 CD N
) ) N
or CC N
the DT N
radial JJ N
artery NN N
( ( N
P NNP N
= NNP N
0.367 CD N
) ) N
before IN N
or CC N
after IN N
GTN NNP N
. . N

The DT N
study NN N
indicates VBZ N
that IN N
a DT N
prophylactic JJ N
effect NN N
of IN N
valproate NN N
may MD N
be VB N
demonstrated VBN N
using VBG N
the DT N
GTN NNP N
human JJ N
migraine NN N
model NN N
. . N

Although IN N
, , N
all DT N
headache NN N
parameters NNS N
were VBD N
reduced VBN N
after IN N
valproate NN N
compared VBN N
to TO N
placebo VB N
, , N
only RB N
one CD N
parameter NN N
was VBD N
statistically RB N
significantly RB N
reduced VBN N
probably RB N
because IN N
of IN N
the DT N
small JJ N
number NN N
of IN N
patients NNS N
. . N

The DT N
size NN N
of IN N
the DT N
effect NN N
was VBD N
similar JJ N
to TO N
that DT N
of IN N
valproate NN N
in IN N
clinical JJ N
trials NNS N
. . N

The DT N
GTN NNP N
model NN N
may MD N
therefore RB N
be VB N
a DT N
valid JJ N
tool NN N
for IN N
testing VBG N
new JJ N
prophylactic JJ N
antimigraine NN N
drugs NNS N
. . N

-DOCSTART- -X- O O

Using VBG N
baby NN N
books NNS N
to TO N
increase VB N
new JJ 4_p
mothers NNS 4_p
' POS N
safety NN N
practices NNS N
. . N

OBJECTIVE NN N
To TO N
determine VB N
whether IN N
educational JJ N
baby NN N
books NNS N
are VBP N
an DT N
effective JJ N
method NN N
for IN N
increasing VBG N
low-income JJ N
, , N
first-time JJ N
mothers NNS N
' POS N
safety NN N
practices NNS N
during IN N
their PRP$ N
child NN N
's POS N
first JJ N
18 CD N
months NNS N
. . N

METHODS NNP N
Primiparous JJ 4_p
women NNS 2_p
( ( N
n JJ N
= NNP N
167 CD 3_p
) ) N
were VBD N
randomly RB N
assigned VBN N
to TO N
1 CD N
of IN N
3 CD N
groups NNS N
: : N
an DT N
educational JJ N
book NN N
group NN N
, , N
a DT N
noneducational JJ N
book NN N
group NN N
, , N
or CC N
a DT N
no-book JJ N
group NN N
. . N

Home NNP N
visits NNS N
and CC N
interviews NNS N
measured VBN N
safety NN N
practices NNS N
when WRB N
women NNS N
were VBD N
in IN N
their PRP$ N
third JJ N
trimester NN N
of IN N
pregnancy NN N
( ( N
baseline NN N
) ) N
and CC N
when WRB N
their PRP$ N
children NNS N
were VBD N
2 CD N
, , N
4 CD N
, , N
6 CD N
, , N
9 CD N
, , N
12 CD N
, , N
and CC N
18 CD N
months NNS N
of IN N
age NN N
. . N

RESULTS NNP N
Women NNP N
in IN N
the DT N
educational JJ N
book NN N
group NN N
had VBD N
fewer JJR N
risks NNS N
in IN N
their PRP$ N
homes NNS N
and CC N
exercised VBD N
more JJR N
safety NN N
practices NNS N
than IN N
the DT N
no-book JJ N
group NN N
( ( N
- : N
20 CD N
% NN N
risk NN N
reduction NN N
; : N
effect NN N
size NN N
= NNP N
-.30 NNP N
) ) N
. . N

When WRB N
the DT N
safety NN N
practices NNS N
involved VBN N
little JJ N
time NN N
or CC N
expense NN N
( ( N
eg UH N
, , N
putting VBG N
away RB N
sharp JJ N
objects NNS N
) ) N
, , N
the DT N
educational JJ N
book NN N
group NN N
was VBD N
significantly RB N
more RBR N
likely JJ N
to TO N
engage VB N
in IN N
these DT N
behaviors NNS N
than IN N
the DT N
no-book JJ N
group NN N
( ( N
40 CD N
% NN N
higher JJR N
practices NNS N
; : N
effect NN N
size NN N
= NNP N
0.19 CD N
) ) N
or CC N
noneducational JJ N
book NN N
group NN N
( ( N
27 CD N
% NN N
higher JJR N
practices NNS N
; : N
effect NN N
size NN N
= NNP N
0.13 CD N
) ) N
. . N

However RB N
, , N
no DT N
differences NNS N
were VBD N
found VBN N
between IN N
groups NNS N
for IN N
behaviors NNS N
that WDT N
required VBD N
high JJ N
effort NN N
in IN N
time NN N
, , N
money NN N
, , N
or CC N
hassle NN N
( ( N
eg JJ N
, , N
installing VBG N
latches NNS N
on IN N
cabinets NNS N
) ) N
. . N

CONCLUSIONS NNP N
Educational NNP N
baby NN N
books NNS N
appear VBP N
to TO N
be VB N
an DT N
easy JJ N
and CC N
low-cost JJ N
way NN N
to TO N
increase VB N
the DT N
safety NN N
practices NNS N
of IN N
new JJ N
mothers NNS N
, , N
especially RB N
if IN N
the DT N
practices NNS N
involve VBP N
little JJ N
to TO N
no DT N
time NN N
, , N
money NN N
, , N
or CC N
hassle NN N
. . N

-DOCSTART- -X- O O

Can MD N
a DT N
home-visit JJ N
invitation NN N
increase NN N
Pap NNP N
smear JJ N
screening NN N
in IN N
Samliem NNP N
, , N
Khon NNP N
Kaen NNP N
, , N
Thailand NNP N
? . N
Our PRP$ N
objective NN N
was VBD N
to TO N
assess VB N
the DT N
efficiency NN N
of IN N
a DT N
home-visit JJ N
invitation NN N
aimed VBN N
to TO N
increase VB N
uptake NN N
of IN N
cervical JJ 4_p
cancer NN 4_p
screening VBG 4_p
in IN N
women NNS 2_p
between IN N
35 CD 1_p
and CC 1_p
60 CD 1_p
years NNS N
of IN N
age NN N
. . N

From NN N
May NNP N
, , N
2006 CD N
, , N
we PRP N
conducted VBD N
a DT N
quasi-randomized JJ N
trial NN N
to TO N
determine VB N
if IN N
an DT N
in-home JJ N
education NN N
and CC N
invitation NN N
intervention NN N
would MD N
increase VB N
uptake NN N
of IN N
cervical JJ N
cancer NN N
screening VBG N
. . N

We PRP N
randomly RB N
recruited VBD N
304 CD 3_p
women NNS N
from IN N
the DT N
Samliem NNP N
inner-city NN N
community NN N
, , N
Khon NNP N
Kaen NNP N
, , N
Northeast NNP N
Thailand NNP N
, , N
and CC N
assigned VBD N
participants NNS N
to TO N
either VB N
the DT N
intervention NN N
or CC N
control VB N
zone NN N
. . N

Baseline NNP N
screening VBG N
coverage NN N
interviews NNS N
were VBD N
then RB N
performed VBN N
: : N
58 CD N
of IN N
158 CD 3_p
women NNS N
in IN N
the DT N
intervention NN N
zone NN N
and CC N
46 CD N
of IN N
146 CD 3_p
in IN N
the DT N
control NN N
zone NN N
were VBD N
excluded VBN N
from IN N
the DT N
study NN N
because IN N
of IN N
having VBG N
had VBD N
a DT N
Pap NNP N
smear NN N
within IN N
5 CD N
years NNS N
, , N
but CC N
these DT N
were VBD N
included VBN N
in IN N
the DT N
final JJ N
analysis NN N
. . N

First NNP N
, , N
100 CD N
women NNS N
in IN N
the DT N
intervention NN N
group NN N
were VBD N
visited VBN N
in IN N
their PRP$ N
homes NNS N
by IN N
one CD N
of IN N
the DT N
researchers NNS N
, , N
who WP N
provided VBD N
culturally-sensitive JJ N
health NN N
education NN N
that WDT N
emphasized VBD N
the DT N
need NN N
for IN N
screening VBG N
. . N

Four CD N
months NNS N
later RB N
, , N
post-intervention NN N
, , N
screening-coverage JJ N
interviews NNS N
were VBD N
again RB N
performed VBN N
in IN N
both DT N
groups NNS N
, , N
in IN N
combination NN N
with IN N
the DT N
same JJ N
health NN N
education NN N
for IN N
100 CD N
women NNS N
in IN N
the DT N
control NN N
group NN N
for IN N
a DT N
comparison NN N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
baseline NN N
Pap NNP N
smear JJ N
screening-coverage NN N
rate NN N
in IN N
the DT N
intervention NN N
vs. FW N
control NN N
zones NNS N
( ( N
36.7 CD N
vs. FW N
31.5 CD N
% NN N
, , N
p=0.339 NN N
) ) N
. . N

One CD N
hundred JJ N
women NNS N
in IN N
the DT N
intervention NN N
group NN N
completed VBD N
the DT N
intervention NN N
interviews NNS N
and CC N
after IN N
four CD N
months NNS N
, , N
100 CD N
women NNS N
in IN N
the DT N
intervention NN N
group NN N
and CC N
100 CD N
in IN N
the DT N
control NN N
group NN N
also RB N
completed VBD N
the DT N
post-intervention NN N
interviews NNS N
. . N

The DT N
increased JJ N
screening-coverage NN N
rate NN N
in IN N
the DT N
intervention NN N
zone NN N
was VBD N
similar JJ N
to TO N
that DT N
of IN N
the DT N
control NN N
zone NN N
( ( N
43.6 CD N
vs. FW N
34.9 CD N
% NN N
, , N
p=0.119 NN N
) ) N
; : N
however RB N
, , N
there EX N
was VBD N
a DT N
borderline NN N
significant JJ N
increase NN N
in IN N
the DT N
intervention NN N
zone NN N
compared VBN N
with IN N
baseline NN N
( ( N
36.7 CD N
to TO N
43.6 CD N
% NN N
, , N
p=0.070 NN N
) ) N
. . N

Therefore NNP N
, , N
home NN N
visit NN N
education NN N
and CC N
invitation NN N
intervention NN N
produced VBD N
only RB N
a DT N
nominal JJ N
effect NN N
on IN N
increasing VBG N
Pap NNP N
smear JJ N
coverage NN N
within IN N
a DT N
4-month JJ N
study NN N
period NN N
. . N

-DOCSTART- -X- O O

Observer NNP N
variation NN N
in IN N
the DT N
assessment NN N
of IN N
outcome NN N
in IN N
traumatic JJ N
brain NN N
injury NN N
: : N
experience NN N
from IN N
a DT N
multicenter NN N
, , N
international JJ N
randomized VBD N
clinical JJ N
trial NN N
. . N

OBJECTIVE NNP N
Accurate NNP N
and CC N
consistent JJ N
outcome NN N
assessment NN N
is VBZ N
essential JJ N
to TO N
randomized VB N
clinical JJ N
trials NNS N
. . N

We PRP N
aimed VBD N
to TO N
explore VB N
observer JJ N
variation NN N
in IN N
the DT N
assessment NN N
of IN N
outcome NN N
in IN N
a DT N
recently RB N
completed VBN N
trial NN N
of IN N
dexanabinol NN N
in IN N
head JJ 4_p
injury NN 4_p
and CC N
to TO N
consider VB N
steps NNS N
to TO N
reduce VB N
such JJ N
variation NN N
. . N

METHODS NNP N
Eight NNP 3_p
hundred VBD 3_p
sixty-one JJ 3_p
patients NNS N
with IN N
severe JJ 4_p
traumatic JJ 4_p
brain NN 4_p
injury NN 4_p
who WP N
were VBD N
admitted VBN N
to TO N
86 CD N
centers NNS N
were VBD N
included VBN N
in IN N
a DT N
multicenter NN N
, , N
placebo-controlled JJ N
, , N
Phase NNP N
III NNP N
trial NN N
. . N

Outcome NNP N
was VBD N
assessed VBN N
at IN N
3 CD N
and CC N
6 CD N
months NNS N
postinjury NN N
using VBG N
the DT N
extended JJ N
Glasgow NNP N
Outcome NNP N
Scale NNP N
; : N
standardized VBD N
assessment NN N
was VBD N
facilitated VBN N
by IN N
the DT N
use NN N
of IN N
a DT N
structured JJ N
interview NN N
. . N

Before IN N
initiation NN N
of IN N
trial NN N
centers NNS N
, , N
outcome JJ N
ratings NNS N
were VBD N
obtained VBN N
for IN N
sample JJ N
cases NNS N
to TO N
establish VB N
initial JJ N
levels NNS N
of IN N
agreement NN N
. . N

Training NN N
sessions NNS N
in IN N
outcome JJ N
assessment NN N
were VBD N
held VBN N
, , N
and CC N
problems NNS N
in IN N
assigning VBG N
outcome NN N
were VBD N
investigated VBN N
. . N

During IN N
the DT N
trial NN N
, , N
a DT N
process NN N
of IN N
central JJ N
review NN N
was VBD N
established VBN N
to TO N
monitor VB N
performance NN N
. . N

Interobserver NNP N
variation NN N
was VBD N
analyzed VBN N
using VBG N
the DT N
kappa NN N
statistic JJ N
. . N

RESULTS NNP N
Substantial NNP N
observer JJ N
variation NN N
was VBD N
found VBN N
in IN N
the DT N
rating NN N
of IN N
sample JJ N
cases NNS N
( ( N
weighted JJ N
kappa NN N
, , N
0.72 CD N
; : N
confidence NN N
interval NN N
, , N
0.68-0.75 JJ N
) ) N
and CC N
in IN N
assigning VBG N
outcome NN N
based VBN N
on IN N
completed VBN N
structured JJ N
interviews NNS N
( ( N
weighted JJ N
kappa NN N
, , N
0.61 CD N
; : N
confidence NN N
interval NN N
, , N
0.57-0.64 JJ N
) ) N
. . N

In IN N
the DT N
early JJ N
stages NNS N
of IN N
the DT N
trial NN N
, , N
a DT N
relatively RB N
large JJ N
number NN N
of IN N
discrepancies NNS N
( ( N
29-37 CD N
% NN N
) ) N
were VBD N
identified VBN N
on IN N
central JJ N
review NN N
. . N

This DT N
number NN N
declined VBD N
as IN N
the DT N
trial NN N
progressed VBD N
and CC N
coincided VBD N
with IN N
investigator NN N
training NN N
and CC N
feedback NN N
from IN N
central JJ N
review NN N
. . N

Centers NNS N
with IN N
higher JJR N
enrollment NN N
rates NNS N
showed VBD N
better JJR N
performance NN N
. . N

CONCLUSION NNP N
Observer NNP N
variation NN N
in IN N
outcome JJ N
assessment NN N
is VBZ N
a DT N
significant JJ N
problem NN N
for IN N
head NN N
injury NN N
trials NNS N
. . N

Consistency NN N
can MD N
be VB N
improved VBN N
by IN N
standardizing VBG N
procedures NNS N
, , N
training VBG N
assessors NNS N
, , N
and CC N
monitoring VBG N
the DT N
quality NN N
of IN N
assessments NNS N
and CC N
providing VBG N
feedback NN N
to TO N
interviewers NNS N
. . N

-DOCSTART- -X- O O

Iron NNP N
in IN N
relation NN N
to TO N
gastric JJ 4_p
cancer NN 4_p
in IN N
the DT N
Alpha-tocopherol NNP N
, , N
Beta-carotene NNP N
Cancer NNP N
Prevention NNP N
Study NNP N
. . N

BACKGROUND NNP N
Iron NNP N
is VBZ N
an DT N
essential JJ N
micronutrient NN N
that WDT N
can MD N
have VB N
carcinogenic JJ N
effects NNS N
when WRB N
at IN N
high JJ N
or CC N
low JJ N
concentrations NNS N
. . N

Previous JJ N
studies NNS N
of IN N
iron NN N
in IN N
relation NN N
to TO N
gastric JJ N
cancer NN N
have VBP N
not RB N
assessed VBN N
subtype-specific JJ N
relationships NNS N
. . N

We PRP N
used VBD N
the DT N
prospective JJ N
Alpha-Tocopherol NNP N
, , N
Beta-Carotene NNP N
( ( N
ATBC NNP N
) ) N
Cancer NNP N
Prevention NNP N
Study NNP N
to TO N
assess VB N
whether IN N
iron NN N
metrics NNS N
were VBD N
associated VBN N
with IN N
gastric JJ 4_p
cardia NN 4_p
cancer NN 4_p
( ( N
GCC NNP 4_p
) ) N
and CC N
gastric JJ 4_p
noncardia NN 4_p
cancer NN 4_p
( ( N
GNCC NNP 4_p
) ) N
. . N

METHODS NNP N
We PRP N
selected VBD N
341 CD 3_p
incident JJ N
gastric JJ N
cancer NN N
cases NNS N
( ( N
86 CD N
cardia NN N
, , N
172 CD N
noncardia NN N
, , N
and CC N
83 CD N
nonspecified VBN N
) ) N
, , N
accrued VBN N
during IN N
22 CD N
years NNS N
of IN N
follow-up NN N
, , N
and CC N
341 CD 3_p
individually RB N
matched VBN N
controls NNS N
. . N

We PRP N
measured VBD N
prediagnostic JJ N
serum NN N
iron NN N
, , N
ferritin NN N
, , N
unsaturated JJ N
iron NN N
binding NN N
capacity NN N
, , N
and CC N
C-reactive JJ N
protein NN N
. . N

Total JJ N
iron-binding JJ N
capacity NN N
( ( N
TIBC NNP N
) ) N
and CC N
transferrin JJ N
saturation NN N
were VBD N
estimated VBN N
from IN N
these DT N
metrics NNS N
. . N

Dietary NNP N
iron NN N
exposures NNS N
were VBD N
estimated VBN N
from IN N
a DT N
food NN N
frequency NN N
questionnaire NN N
. . N

Multivariable JJ N
logistic JJ N
regression NN N
was VBD N
used VBN N
for IN N
analysis NN N
. . N

RESULTS NNP N
Serum NNP N
iron NN N
metrics NNS N
were VBD N
not RB N
associated VBN N
with IN N
GCC NNP N
, , N
except IN N
for IN N
a DT N
potential JJ N
n NN N
-shaped VBD N
relationship NN N
with IN N
TIBC NNP N
( ( N
global JJ N
P NNP N
= NNP N
0.038 CD N
) ) N
. . N

GNCC NNP N
was VBD N
inversely RB N
associated VBN N
with IN N
serum NN N
ferritin NN N
( ( N
global JJ N
P NNP N
= NNP N
0.024 CD N
) ) N
, , N
serum JJ N
iron NN N
( ( N
global JJ N
P NNP N
= NNP N
0.060 CD N
) ) N
and CC N
, , N
possibly RB N
, , N
transferrin JJ N
saturation NN N
. . N

TIBC NNP N
appeared VBD N
to TO N
share NN N
a DT N
u NN N
-shaped VBD N
relationship NN N
with IN N
GNCC NNP N
( ( N
global JJ N
P NNP N
= NNP N
0.033 CD N
) ) N
. . N

Dietary NNP N
iron NN N
exposures NNS N
were VBD N
not RB N
associated VBN N
with IN N
either DT N
subsite NN N
. . N

Adjustment NN N
for IN N
Helicobacter NNP N
pylori NN N
and CC N
gastric JJ N
atrophy NN N
had VBD N
little JJ N
effect NN N
on IN N
observed JJ N
associations NNS N
. . N

CONCLUSIONS NNP N
We PRP N
found VBD N
little JJ N
evidence NN N
for IN N
the DT N
involvement NN N
of IN N
iron NN N
exposure NN N
in IN N
the DT N
pathogenesis NN N
of IN N
GCC NNP N
. . N

GNCC NNP N
was VBD N
associated VBN N
with IN N
an DT N
iron NN N
profile NN N
similar JJ N
to TO N
that DT N
of IN N
iron NN N
deficiency NN N
. . N

IMPACT NNP N
Our PRP$ N
findings NNS N
indicate VBP N
that IN N
inverse JJ N
associations NNS N
between IN N
iron NN N
metrics NNS N
and CC N
gastric JJ N
cancer NN N
are VBP N
driven VBN N
by IN N
associations NNS N
with IN N
GNCC NNP N
. . N

Further NNP N
elucidation NN N
of IN N
potential JJ N
mechanisms NN N
is VBZ N
warranted VBN N
. . N

-DOCSTART- -X- O O

Longitudinal JJ N
follow-up NN N
of IN N
children NNS 1_p
with IN N
autism NN 4_p
receiving VBG N
targeted VBN N
interventions NNS N
on IN N
joint JJ N
attention NN N
and CC N
play NN N
. . N

OBJECTIVE CC N
This DT N
study NN N
examines VBZ N
the DT N
cognitive NN N
and CC N
language NN N
outcomes NNS N
of IN N
children NNS N
with IN N
an DT N
autism NN 4_p
spectrum NN 4_p
disorder NN 4_p
( ( N
ASD NNP 4_p
) ) N
over IN N
a DT N
5-year JJ N
period NN N
after IN N
receiving VBG N
targeted VBD N
early JJ N
interventions NNS N
that WDT N
focused VBD N
on IN N
joint JJ N
attention NN N
and CC N
play NN N
skills NNS N
. . N

METHOD NNP N
Forty NNP 3_p
children NNS N
from IN N
the DT N
original JJ N
study NN N
( ( N
n JJ N
= NNP N
58 CD 3_p
) ) N
had VBD N
complete JJ N
data NNS N
at IN N
the DT N
5-year JJ N
follow-up NN N
. . N

RESULTS NNP N
In IN N
all DT N
, , N
80 CD N
% NN N
of IN N
children NNS N
had VBD N
achieved VBN N
functional JJ N
use NN N
of IN N
spoken JJ N
language NN N
with IN N
baseline JJ N
play NN N
level NN N
predicting VBG N
spoken JJ N
language NN N
at IN N
the DT N
5-year JJ N
follow-up NN N
. . N

Of IN N
children NNS N
who WP N
were VBD N
using VBG N
spoken JJ N
language NN N
at IN N
age NN N
8 CD N
years NNS N
, , N
several JJ N
baseline NN N
behaviors NNS N
predicted VBD N
their PRP$ N
later JJ N
ability NN N
, , N
including VBG N
earlier JJR N
age NN N
of IN N
entry NN N
into IN N
the DT N
study NN N
, , N
initiating VBG N
joint JJ N
attention NN N
skill NN N
, , N
play VB N
level NN N
, , N
and CC N
assignment NN N
to TO N
either VB N
the DT N
joint JJ N
attention NN N
or CC N
symbolic JJ N
play NN N
intervention NN N
group NN N
. . N

Only RB N
baseline JJ N
play NN N
diversity NN N
predicted VBD N
cognitive JJ N
scores NNS N
at IN N
age NN N
8 CD N
years NNS N
. . N

CONCLUSIONS VB N
This DT N
study NN N
is VBZ N
one CD N
of IN N
the DT N
only JJ N
long-term JJ N
follow-up JJ N
studies NNS N
of IN N
children NNS 1_p
who WP N
participated VBD N
in IN N
preschool NN N
early JJ N
interventions NNS N
aimed VBN N
at IN N
targeting VBG N
core NN 4_p
developmental NN 4_p
difficulties NNS 4_p
. . N

The DT N
study NN N
findings NNS N
suggest VBP N
that IN N
focusing VBG N
on IN N
joint JJ N
attention NN N
and CC N
play NN N
skills NNS N
in IN N
comprehensive JJ N
treatment NN N
models NNS N
is VBZ N
important JJ N
for IN N
long-term JJ N
spoken JJ N
language NN N
outcomes NNS N
. . N

-DOCSTART- -X- O O

Rehabilitation NN N
of IN N
therapy-related JJ N
cognitive JJ N
deficits NNS N
in IN N
patients NNS N
after IN N
hematopoietic JJ 4_p
stem NN 4_p
cell NN 4_p
transplantation NN 4_p
. . N

Neuropsychological JJ N
deficits NNS N
are VBP N
potential JJ N
side NN N
effects NNS N
of IN N
hematopoietic JJ N
stem NN N
cell NN N
therapy NN N
( ( N
HSCT NNP N
) ) N
. . N

Systematic JJ N
data NNS N
on IN N
the DT N
long-term JJ N
course NN N
of IN N
and CC N
therapeutic JJ N
options NNS N
for IN N
these DT N
consequences NNS N
are VBP N
limited VBN N
. . N

One CD 3_p
hundred VBD 3_p
fifty-seven JJ 3_p
patients NNS N
were VBD N
screened VBN N
for IN N
cognitive JJ 4_p
deficits NNS 4_p
following VBG N
HSCT NNP N
for IN N
malignant JJ 4_p
diseases NNS 4_p
at IN N
an DT N
in-patient JJ N
oncologic NN N
rehabilitation NN N
clinic NN N
. . N

Patients NNS N
showing VBG N
evidence NN N
of IN N
impairment NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
two CD N
training VBG N
groups NNS N
: : N
individualized VBN N
PC-supported JJ N
training NN N
or CC N
neuropsychological JJ N
group NN N
therapy NN N
. . N

The DT N
control NN N
group NN N
consisted VBD N
of IN N
patients NNS N
who WP N
received VBD N
no DT N
specific JJ N
training NN N
. . N

During IN N
in-patient JJ N
rehabilitation NN N
, , N
the DT N
results NNS N
of IN N
a DT N
comprehensive JJ N
neuropsychological JJ N
test NN N
battery NN N
improved VBD N
significantly RB N
in IN N
all DT N
three CD N
groups NNS N
, , N
and CC N
no DT N
specific JJ N
intervention NN N
effects NNS N
were VBD N
identified VBN N
. . N

Neuropsychological JJ N
deficits NNS N
were VBD N
still RB N
evident JJ N
in IN N
a DT N
subgroup NN N
of IN N
patients NNS N
6 CD N
months NNS N
later RB N
. . N

Correlation NN N
between IN N
neuropsychological JJ N
testing NN N
and CC N
patients NNS N
' POS N
self-evaluation NN N
of IN N
cognitive JJ N
functioning NN N
in IN N
daily JJ N
life NN N
was VBD N
generally RB N
low JJ N
. . N

Sustained VBN N
attention NN N
and CC N
verbal-semantic JJ N
memory NN N
played VBD N
the DT N
main JJ N
role NN N
for IN N
self-appraisal JJ N
and CC N
in IN N
the DT N
designation NN N
as IN N
'neuropsychologically RB N
impaired VBN N
' '' N
. . N

In IN N
conclusion NN N
, , N
a DT N
substantial JJ N
number NN N
of IN N
patients NNS N
revealed JJ N
evidence NN N
of IN N
cognitive JJ N
deficits NNS N
a DT N
long JJ N
time NN N
after IN N
HSCT NNP N
. . N

There EX N
is VBZ N
a DT N
need NN N
for IN N
more JJR N
studies NNS N
and CC N
for IN N
the DT N
development NN N
of IN N
differentiated JJ N
rehabilitative JJ N
measures NNS N
for IN N
such JJ N
therapeutic JJ N
consequences NNS N
. . N

-DOCSTART- -X- O O

In IN N
school-aged JJ 1_p
children NNS 1_p
a DT N
combination NN N
of IN N
galacto-oligosaccharides NNS N
and CC N
Lactobacillus NNP N
GG NNP N
increases VBZ N
bifidobacteria RB N
more JJR N
than IN N
Lactobacillus NNP N
GG NNP N
on IN N
its PRP$ N
own JJ N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
a DT N
combination NN N
of IN N
Lactobacillus NNP N
GG NNP N
( ( N
LGG NNP N
) ) N
and CC N
galacto-oligosaccharides NNS N
( ( N
GOS NNP N
) ) N
with IN N
LGG NNP N
on IN N
its PRP$ N
own JJ N
, , N
and CC N
their PRP$ N
effects NNS N
on IN N
the DT N
intestinal JJ N
microbiota NN N
in IN N
school-aged JJ N
children NNS N
. . N

The DT N
randomized JJ N
, , N
double-blinded JJ N
, , N
crossover NN N
study NN N
comprised VBD N
30 CD 3_p
healthy JJ 4_p
children NNS N
. . N

There EX N
were VBD N
two CD N
3-week JJ N
study NN N
periods NNS N
with IN N
a DT N
4-week JJ N
wash-out JJ N
period NN N
in IN N
between IN N
. . N

The DT N
children NNS N
ingested VBD N
daily RB N
65 CD N
ml NN N
of IN N
milk-based JJ N
fruit NN N
juice NN N
containing VBG N
either CC N
LGG NNP N
alone RB N
( ( N
6.5 CD N
x RB N
10 CD N
( ( N
9 CD N
) ) N
CFU NNP N
) ) N
or CC N
LGG NNP N
plus CC N
2 CD N
g NN N
of IN N
GOS NNP N
. . N

Symptom NNP N
diaries NNS N
were VBD N
filled VBN N
during IN N
the DT N
study NN N
periods NNS N
. . N

Fecal JJ N
samples NNS N
were VBD N
collected VBN N
at IN N
the DT N
beginning NN N
and CC N
end NN N
of IN N
both DT N
study NN N
periods NNS N
. . N

At IN N
the DT N
end NN N
of IN N
both DT N
study NN N
periods NNS N
, , N
the DT N
amount NN N
of IN N
bifidobacteria NN N
was VBD N
significantly RB N
greater JJR N
after IN N
the DT N
ingestion NN N
of IN N
LGG NNP N
+ NNP N
GOS NNP N
compared VBN N
with IN N
LGG NNP N
alone RB N
( ( N
geometric JJ N
mean VBP N
9.33 CD N
x $ N
10 CD N
( ( N
9 CD N
) ) N
vs. FW N
4.28 CD N
x $ N
10 CD N
( ( N
9 CD N
) ) N
CFU/g NNP N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
seen VBN N
in IN N
the DT N
amount NN N
of IN N
lactobacilli NN N
or CC N
LGG NNP N
, , N
nor CC N
did VBD N
gastrointestinal JJ N
symptoms NNS N
, , N
defecation NN N
frequency NN N
, , N
consistency NN N
of IN N
stools NNS N
or CC N
ease NN N
of IN N
defecation NN N
differ NN N
between IN N
the DT N
two CD N
study NN N
periods NNS N
. . N

Ingestion NN N
of IN N
LGG NNP N
combined VBD N
with IN N
2 CD N
g NN N
of IN N
GOS NNP N
increased VBD N
the DT N
bifidobacteria NN N
more JJR N
than IN N
LGG NNP N
on IN N
its PRP$ N
own JJ N
and CC N
thus RB N
GOS NNP N
clearly RB N
has VBZ N
a DT N
prebiotic JJ N
effect NN N
in IN N
children NNS 1_p
. . N

The DT N
children NNS N
tolerated VBN N
well RB N
a DT N
daily JJ N
intake NN N
of IN N
2 CD N
g NN N
of IN N
GOS NNP N
. . N

